
<html lang="en"     class="pb-page"  data-request-id="d53bb768-eb9d-4584-94f2-950e3db4e91b"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2020.63.issue-23;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;article:article:10.1021/acs.jmedchem.0c01357;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Cannabinoid Receptor Subtype 2 (CB2R) in a Multitarget Approach: Perspective of an Innovative Strategy in Cancer and Neurodegeneration" /></meta><meta name="dc.Creator" content="Giuseppe Felice  Mangiatordi" /></meta><meta name="dc.Creator" content="Francesca  Intranuovo" /></meta><meta name="dc.Creator" content="Pietro  Delre" /></meta><meta name="dc.Creator" content="Francesca Serena  Abatematteo" /></meta><meta name="dc.Creator" content="Carmen  Abate" /></meta><meta name="dc.Creator" content="Mauro  Niso" /></meta><meta name="dc.Creator" content="Teresa Maria  Creanza" /></meta><meta name="dc.Creator" content="Nicola  Ancona" /></meta><meta name="dc.Creator" content="Angela  Stefanachi" /></meta><meta name="dc.Creator" content="Marialessandra  Contino" /></meta><meta name="dc.Description" content="The cannabinoid receptor subtype 2 (CB2R) represents an interesting and new therapeutic target for its involvement in the first steps of neurodegeneration as well as in cancer onset and progression..." /></meta><meta name="Description" content="The cannabinoid receptor subtype 2 (CB2R) represents an interesting and new therapeutic target for its involvement in the first steps of neurodegeneration as well as in cancer onset and progression..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 23, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c01357" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01357" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c01357" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c01357" /></link>
        
    
    

<title>Cannabinoid Receptor Subtype 2 (CB2R) in a Multitarget Approach: Perspective of an Innovative Strategy in Cancer and Neurodegeneration | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c01357" /></meta><meta property="og:title" content="Cannabinoid Receptor Subtype 2 (CB2R) in a Multitarget Approach: Perspective of an Innovative Strategy in Cancer and Neurodegeneration" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0016.jpeg" /></meta><meta property="og:description" content="The cannabinoid receptor subtype 2 (CB2R) represents an interesting and new therapeutic target for its involvement in the first steps of neurodegeneration as well as in cancer onset and progression. Several studies, focused on different types of tumors, report a promising anticancer activity induced by CB2R agonists due to their ability to reduce inflammation and cell proliferation. Moreover, in neuroinflammation, the stimulation of CB2R, overexpressed in microglial cells, exerts beneficial effects in neurodegenerative disorders. With the aim to overcome current treatment limitations, new drugs can be developed by specifically modulating, together with CB2R, other targets involved in such multifactorial disorders. Building on successful case studies of already developed multitarget strategies involving CB2R, in this Perspective we aim at prompting the scientific community to consider new promising target associations involving HDACs (histone deacetylases) and σ receptors by employing modern approaches based on molecular hybridization, computational polypharmacology, and machine learning algorithms." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c01357"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01357">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c01357&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c01357&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c01357&amp;href=/doi/10.1021/acs.jmedchem.0c01357" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 23</span><span class="cit-fg-pageRange">, 14448-14469</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/23" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01332" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c01480" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Cannabinoid Receptor Subtype 2 (CB2R) in a Multitarget Approach: Perspective of an Innovative Strategy in Cancer and Neurodegeneration</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Giuseppe Felice Mangiatordi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Giuseppe Felice Mangiatordi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">CNR—Institute of Crystallography, Via Amendola 122/o, 70126 Bari, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Giuseppe+Felice++Mangiatordi">Giuseppe Felice Mangiatordi</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4042-2841" title="Orcid link">http://orcid.org/0000-0003-4042-2841</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Francesca Intranuovo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Francesca Intranuovo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari Aldo Moro, Via Orabona 4, 70125 Bari, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Francesca++Intranuovo">Francesca Intranuovo</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Pietro Delre</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Pietro Delre</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">CNR—Institute of Crystallography, Via Amendola 122/o, 70126 Bari, Italy</div><div class="loa-info-affiliations-info">Dipartimento di Chimica, Università degli Studi di Bari Aldo Moro, 70125 Bari, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Pietro++Delre">Pietro Delre</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Francesca Serena Abatematteo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Francesca Serena Abatematteo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari Aldo Moro, Via Orabona 4, 70125 Bari, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Francesca+Serena++Abatematteo">Francesca Serena Abatematteo</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Carmen Abate</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Carmen Abate</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari Aldo Moro, Via Orabona 4, 70125 Bari, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Carmen++Abate">Carmen Abate</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9292-884X" title="Orcid link">http://orcid.org/0000-0001-9292-884X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mauro Niso</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mauro Niso</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari Aldo Moro, Via Orabona 4, 70125 Bari, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mauro++Niso">Mauro Niso</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath6">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Teresa Maria Creanza</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Teresa Maria Creanza</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">CNR—Institute of Intelligent Industrial Technologies and Systems for Advanced Manufacturing, Via Amendola 122/o, 70126 Bari, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Teresa+Maria++Creanza">Teresa Maria Creanza</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath7">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nicola Ancona</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nicola Ancona</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">CNR—Institute of Intelligent Industrial Technologies and Systems for Advanced Manufacturing, Via Amendola 122/o, 70126 Bari, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nicola++Ancona">Nicola Ancona</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath8">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0065-0321" title="Orcid link">http://orcid.org/0000-0003-0065-0321</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Angela Stefanachi</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Angela Stefanachi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari Aldo Moro, Via Orabona 4, 70125 Bari, Italy</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: +0390805442783. Email: <a href="/cdn-cgi/l/email-protection#fb9a959c9e979ad5888f9e9d9a959a989392bb8e9592999ad5928f"><span class="__cf_email__" data-cfemail="4c2d222b29202d623f38292a2d222d2f24250c3922252e2d622538">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Angela++Stefanachi">Angela Stefanachi</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath9">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9430-7972" title="Orcid link">http://orcid.org/0000-0002-9430-7972</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Marialessandra Contino</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marialessandra Contino</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari Aldo Moro, Via Orabona 4, 70125 Bari, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marialessandra++Contino">Marialessandra Contino</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath10">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0713-3151" title="Orcid link">http://orcid.org/0000-0002-0713-3151</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01357&amp;href=/doi/10.1021%2Facs.jmedchem.0c01357" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 23</span><span class="cit-pageRange">, 14448–14469</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 23, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>3 August 2020</li><li><span class="item_label"><b>Published</b> online</span>23 October 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 December 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c01357" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01357</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D14448%26pageCount%3D22%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DGiuseppe%2BFelice%2BMangiatordi%252C%2BFrancesca%2BIntranuovo%252C%2BPietro%2BDelre%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D23%26contentID%3Dacs.jmedchem.0c01357%26title%3DCannabinoid%2BReceptor%2BSubtype%2B2%2B%2528CB2R%2529%2Bin%2Ba%2BMultitarget%2BApproach%253A%2BPerspective%2Bof%2Ban%2BInnovative%2BStrategy%2Bin%2BCancer%2Band%2BNeurodegeneration%26numPages%3D22%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D14469%26publicationDate%3DDecember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c01357"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1079</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">3</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c01357" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Cannabinoid Receptor Subtype 2 (CB2R) in a Multitarget Approach: Perspective of an Innovative Strategy in Cancer and Neurodegeneration&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Giuseppe&quot;,&quot;last_name&quot;:&quot;Felice Mangiatordi&quot;},{&quot;first_name&quot;:&quot;Francesca&quot;,&quot;last_name&quot;:&quot;Intranuovo&quot;},{&quot;first_name&quot;:&quot;Pietro&quot;,&quot;last_name&quot;:&quot;Delre&quot;},{&quot;first_name&quot;:&quot;Francesca&quot;,&quot;last_name&quot;:&quot;Serena Abatematteo&quot;},{&quot;first_name&quot;:&quot;Carmen&quot;,&quot;last_name&quot;:&quot;Abate&quot;},{&quot;first_name&quot;:&quot;Mauro&quot;,&quot;last_name&quot;:&quot;Niso&quot;},{&quot;first_name&quot;:&quot;Teresa&quot;,&quot;last_name&quot;:&quot;Maria Creanza&quot;},{&quot;first_name&quot;:&quot;Nicola&quot;,&quot;last_name&quot;:&quot;Ancona&quot;},{&quot;first_name&quot;:&quot;Angela&quot;,&quot;last_name&quot;:&quot;Stefanachi&quot;},{&quot;first_name&quot;:&quot;Marialessandra&quot;,&quot;last_name&quot;:&quot;Contino&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;23&quot;,&quot;issue&quot;:&quot;23&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;14448-14469&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c01357&quot;},&quot;abstract&quot;:&quot;The cannabinoid receptor subtype 2 (CB2R) represents an interesting and new therapeutic target for its involvement in the first steps of neurodegeneration as well as in cancer onset and progression. Several studies, focused on different types of tumors, report a promising anticancer activity induced by CB2R agonists due to their ability to reduce inflammation and cell proliferation. Moreover, in neuroinflammation, the stimulation of CB2R, overexpressed in microglial cells, exerts beneficial effects in neurodegenerative disorders. With the aim to overcome current treatment limitations, new drugs can be developed by specifically modulating, together with CB2R, other targets involved in such multifactorial disorders. Building on successful case studies of already developed multitarget strategies involving CB2R, in this Perspective we aim at prompting the scientific community to consider new promising target associations involving HDACs (histone deacetylases) and σ receptors by employing modern approaches based o&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01357&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01357" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01357&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01357" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c01357&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01357" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c01357&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c01357&amp;href=/doi/10.1021/acs.jmedchem.0c01357" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c01357" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c01357" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c01357%26sid%3Dliteratum%253Aachs%26pmid%3D33094613%26genre%3Darticle%26aulast%3DMangiatordi%26date%3D2020%26atitle%3DCannabinoid%2BReceptor%2BSubtype%2B2%2B%2528CB2R%2529%2Bin%2Ba%2BMultitarget%2BApproach%253A%2BPerspective%2Bof%2Ban%2BInnovative%2BStrategy%2Bin%2BCancer%2Band%2BNeurodegeneration%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D23%26spage%3D14448%26epage%3D14469%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=292366" title="Ligands">Ligands</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/23" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/jmcmar.2020.63.issue-23/20201210/jmcmar.2020.63.issue-23.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/medium/jm0c01357_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The cannabinoid receptor subtype 2 (CB2R) represents an interesting and new therapeutic target for its involvement in the first steps of neurodegeneration as well as in cancer onset and progression. Several studies, focused on different types of tumors, report a promising anticancer activity induced by CB2R agonists due to their ability to reduce inflammation and cell proliferation. Moreover, in neuroinflammation, the stimulation of CB2R, overexpressed in microglial cells, exerts beneficial effects in neurodegenerative disorders. With the aim to overcome current treatment limitations, new drugs can be developed by specifically modulating, together with CB2R, other targets involved in such multifactorial disorders. Building on successful case studies of already developed multitarget strategies involving CB2R, in this Perspective we aim at prompting the scientific community to consider new promising target associations involving HDACs (histone deacetylases) and σ receptors by employing modern approaches based on molecular hybridization, computational polypharmacology, and machine learning algorithms.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20262" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20262" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The cannabinoid receptor subtype 2 (CB2R), together with the subtype 1 (CB1R), belongs to the endocannabinoid system, widely explored because of its physiological functions and more importantly because of its involvement in a wide range of conditions, such as cancer and neurodegeneration.<a onclick="showRef(event, 'ref1 ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3">(1−3)</a></div><div class="NLM_p">Different from the CB1R subtype, mainly localized at the central nervous system (CNS), where its activation leads to unwanted psychotropic effects,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> CB2R is physiologically expressed at the peripheral level, mainly in the immune system (tonsils, spleen, thymus, lymphocytes, monocytes, macrophages, eosinophils, etc.).<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> In pathological conditions, this receptor is overexpressed in the activated microglia at the CNS<a onclick="showRef(event, 'ref6 ref7 ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8 ref9 ref10">(6−10)</a> and in several types of cancer.<a onclick="showRef(event, 'ref11 ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13 ref14">(11−14)</a> Importantly, its activation is responsible for the restoration of normal microglial function as a result of the inhibition of neuroinflammatory signaling pathways.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div><div class="NLM_p">In the Alzheimer disease (AD) onset, for instance, CB2R counteracts microglia-mediated neurotoxicity by inhibiting the production of proinflammatory mediators and by modulating the migration of macrophages.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> High levels of CB2R were found in postmortem AD patients brain, in particular in the microglial cells surrounding the β-amyloid plaques.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Interestingly, in vitro and in vivo studies demonstrated the ability of CB2R agonists to reduce both the levels of pre-existing β-amyloid (Aβ) plaques and their formation, leading to a general improvement of memory,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> as well as promoting intrinsic brain repair mechanisms.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Moreover, CB2R activation, together with the decrease in the production, aggregation, and clearance of Aβ plaques, reduces the hyperphosphorylation of the tau protein, another pathological AD hallmark.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a></div><div class="NLM_p">The neuroprotective effects exerted by CB2R activation in AD were also observed in other neurodegenerative disorders such as Parkinson,<a onclick="showRef(event, 'ref2 ref18'); return false;" href="javascript:void(0);" class="ref ref2 ref18">(2,18)</a> Huntington’s disease, and amyotrophic lateral sclerosis.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> In the oncologic field, a high CB2R expression has been found in several types of cancer (breast, lung, prostate, pancreas, and resistant cancers)<a onclick="showRef(event, 'ref20 ref21 ref22 ref12 ref23'); return false;" href="javascript:void(0);" class="ref ref20 ref21 ref22 ref12 ref23">(20−22,12,23)</a> and a correlation between CB2R expression and the histological grade and prognosis has been demonstrated in breast cancer, colon–rectal carcinoma, glioblastoma, and glioma,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> with different suggested mechanisms.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> All of these pieces of evidence make CB2R modulators potential therapeutics in different types of pathologic conditions where inflammation is involved such as cancer and neurodegeneration. Furthermore, properly functionalized CB2R ligands can be considered useful molecular probes.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Given the multifactorial nature of these diseases, it is today evident that therapies acting on multiple mechanisms are highly desirable. On the basis of this evidence, multitarget approaches combining CB2R activation with the ability of modulating other targets (e.g., acetylcholinesterase (AChE) and butyrylcholinesterase (BChE))<a onclick="showRef(event, 'ref26 ref27 ref28 ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref26 ref27 ref28 ref29 ref30 ref31">(26−31)</a> have been recently proposed to improve AD therapy. As extensively reviewed in the past years,<a onclick="showRef(event, 'ref32 ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref32 ref33 ref34">(32−34)</a> the so-called multitarget directed ligands (MTDLs) have several advantages over combination approaches where two or more drugs are administered at the same time.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Achieving an optimized activity toward multiple targets, however, is still considered one of the most difficult challenges facing contemporary medicinal chemistry. This is mostly due to the difficulty in preserving drug-like properties while, at the same time, finding a balance between the “wanted polypharmacology” and the “dangerous promiscuity” of the designed drugs. Obviously, this task becomes even more challenging when the targets of interest belong to different protein families.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div><div class="NLM_p">This issue can be properly approached by integrating different medicinal chemistry strategies, including those based on knowledge-based framework combination (e.g., molecular hybridization), computational polypharmacology, and machine learning algorithms.<a onclick="showRef(event, 'ref36 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref36 ref37 ref38">(36−38)</a></div><div class="NLM_p">Aim of this Perspective is to propose a new multitarget approach where CB2R is associated with other important targets involved both in cancer and in neurodegenerative diseases such as histone deacetylases (HDAC) and σ receptors.</div><div class="NLM_p">Noteworthy, these targets were selected being overexpressed<a onclick="showRef(event, 'ref39 ref40 ref41 ref42 ref43 ref44 ref45 ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref39 ref40 ref41 ref42 ref43 ref44 ref45 ref46 ref47">(39−47)</a> and linked to inflammation modulation.<a onclick="showRef(event, 'ref48 ref49 ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref48 ref49 ref50 ref51">(48−51)</a> In detail, HDAC inhibitors have been successfully employed as cytotoxic agents in breast cancer,<a onclick="showRef(event, 'ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref41 ref42">(41,42)</a> triple negative breast cancer,<a onclick="showRef(event, 'ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref43 ref44">(43,44)</a> and lung,<a onclick="showRef(event, 'ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref46 ref47">(46,47)</a> pancreatic, and prostate cancers<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> where CB2R involvement has been demonstrated.<a onclick="showRef(event, 'ref20 ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref20 ref21 ref22 ref23">(20−23)</a> More importantly, CB2R agonists and HDAC inhibitors share the same effect not only as antiproliferative agents but also as anti-inflammatory modulators, being able to modulate microglia/macrophages polarization from the M1 state (proinflammatory and detrimental) to the M2 state (anti-inflammatory or proresolving).<a onclick="showRef(event, 'ref52 ref53 ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref52 ref53 ref54 ref55">(52−55)</a> The influence on the polarization of microglia/macrophages may be considered as a useful approach to treat some microglia/macrophage-mediated chronic inflammatory diseases as cancer and neurodegeneration.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a></div><div class="NLM_p">As for σ receptors, they are involved in the same types of cancer.<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39,40)</a> More specifically, σ<sub>2</sub> agonists and σ<sub>1</sub> antagonists display cytotoxic effects similar to those resulting from CB2R activation. Moreover, the involvement of both σ receptors on inflammation is widely reported,<a onclick="showRef(event, 'ref48 ref49 ref50 ref51 ref57'); return false;" href="javascript:void(0);" class="ref ref48 ref49 ref50 ref51 ref57">(48−51,57)</a> and interestingly the effect of σ<sub>1</sub> on microglia polarization has been suggested.<a onclick="showRef(event, 'ref58 ref59'); return false;" href="javascript:void(0);" class="ref ref58 ref59">(58,59)</a></div><div class="NLM_p last">Inspired by successful case studies of already developed multitarget strategies for AD treatment (i.e., compounds acting as CB2R agonists and AChE/BChE  inhibitors, in this paper we propose different strategies for designing dual CB2R agonists/HDAC inhibitors (hereinafter referred to as dual CB2R/HDAC) and dual CB2R agonists/σ modulators (dual CB2R/σ) based on (i) the evidence of common pharmacophoric elements (molecular hybridization), (ii) the presence of valuable structural information concerning the targets of interest (structure-based drug design), and (iii) the knowledge, based on preliminary data, of active ligands sharing a common chemical space (ligand-based drug design and machine-learning-assisted de novo design).</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">CB2R Agonists: The Proposed Pharmacophore</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85611" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85611" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Several classes of compounds acting as CB2R agonists have been developed in the past years, bearing different scaffolds: dibenzopyran,<a onclick="showRef(event, 'ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref60 ref61">(60,61)</a> oxoquinoline,<a onclick="showRef(event, 'ref62 ref63 ref64 ref65'); return false;" href="javascript:void(0);" class="ref ref62 ref63 ref64 ref65">(62−65)</a> naphthyridinone,<a onclick="showRef(event, 'ref66 ref67 ref68'); return false;" href="javascript:void(0);" class="ref ref66 ref67 ref68">(66−68)</a> quinolinedione<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> alkyloxy-coumarin<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> indole,<a onclick="showRef(event, 'ref71 ref72 ref73 ref74 ref75'); return false;" href="javascript:void(0);" class="ref ref71 ref72 ref73 ref74 ref75">(71−75)</a> indazole<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> imidazopyridine,<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> imidazopyrazine,<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> benzimidazole,<a onclick="showRef(event, 'ref79 ref80'); return false;" href="javascript:void(0);" class="ref ref79 ref80">(79,80)</a> purine,<a onclick="showRef(event, 'ref81 ref82'); return false;" href="javascript:void(0);" class="ref ref81 ref82">(81,82)</a> thiophene,<a onclick="showRef(event, 'ref83 ref84'); return false;" href="javascript:void(0);" class="ref ref83 ref84">(83,84)</a> triazine,<a onclick="showRef(event, 'ref85 ref86'); return false;" href="javascript:void(0);" class="ref ref85 ref86">(85,86)</a> pyridinone,<a onclick="showRef(event, 'ref87 ref88 ref89'); return false;" href="javascript:void(0);" class="ref ref87 ref88 ref89">(87−89)</a> biphenyl,<a onclick="showRef(event, 'ref90 ref91'); return false;" href="javascript:void(0);" class="ref ref90 ref91">(90,91)</a> proline,<a onclick="showRef(event, 'ref92 ref93'); return false;" href="javascript:void(0);" class="ref ref92 ref93">(92,93)</a> and piperidine.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> In <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> the most representative and selective known CB2R ligands are reported along with their <i>K</i><sub>i</sub> values on CB1R and CB2R.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/medium/jm0c01357_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative CB2R ligands bearing different scaffolds.<a onclick="showRef(event, 'ref62 ref95 ref96 ref97 ref98 ref99 ref100 ref101 ref102'); return false;" href="javascript:void(0);" class="ref ref62 ref95 ref96 ref97 ref98 ref99 ref100 ref101 ref102">(62,95−102)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">On the basis of the available literature, we recently proposed a CB2R pharmacophore reported in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/medium/jm0c01357_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Proposed CB2R pharmacophore.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The first structural requirement is represented by a monocyclic or bicyclic core carrying heteroatoms (N, S, O): a nitrogen in the heterocycle leads to an improved affinity but it is not essential for the activity.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> The presence of OH or C═O groups in the 2- or 4-position of the core increases the affinity vs the target via H-bonds formation.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> On the core scaffold, R<sub>1</sub> can be (i) a linear alkyl chain (four to six carbon atoms) often formed by five methylene units (that proved to be optimal for receptor affinity<a onclick="showRef(event, 'ref62 ref63 ref64 ref65 ref66 ref67 ref68 ref69 ref70 ref71 ref72 ref73 ref74 ref75 ref76 ref77 ref78 ref79 ref80 ref81 ref82 ref83 ref84 ref85 ref86 ref87 ref88 ref89 ref90 ref91 ref92 ref93 ref94 ref95 ref96 ref97 ref98 ref99 ref100 ref101 ref102 ref103 ref104'); return false;" href="javascript:void(0);" class="ref ref62 ref63 ref64 ref65 ref66 ref67 ref68 ref69 ref70 ref71 ref72 ref73 ref74 ref75 ref76 ref77 ref78 ref79 ref80 ref81 ref82 ref83 ref84 ref85 ref86 ref87 ref88 ref89 ref90 ref91 ref92 ref93 ref94 ref95 ref96 ref97 ref98 ref99 ref100 ref101 ref102 ref103 ref104">(62−104)</a> due to their ability to maximize the interactions with a hydrophobic region of the receptor), (ii) cycloalkyl or aromatic alkyl groups, (iii) heterocycloalkyl ring such as alkylmorpholine or piperidine.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a></div><div class="NLM_p">To meet selectivity toward CB1R, in order to avoid the unwanted psychotropic effects due to the interaction with the CB1R subtype and to increase binding affinity, an aliphatic (cycloalkyl rings) or aromatic (naphthalene, phenyl) carboxamide (R<sub>2</sub>) is usually inserted on the core. Noteworthy, the carboxamide portion can be replaced by bioisosters (e.g., a carbonyl). R<sub>2</sub> is a bulky and lipophilic group that confers great selectivity and potency. Examples of used R<sub>2</sub> groups are represented by the adamantane (strong increase in selectivity), lipophilic cycloalkyls (cyclohexyl, cycloheptyl), branched aliphatic chains (<i>i</i>-Pr, <i>t</i>-Bu).<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a></div><div class="NLM_p last">In R<sub>3</sub>, the presence of aromatic groups that allow the formation of π–π stacking interactions with the aromatic amino acids located in a deep hydrophobic pocket of the receptor may be favorable to the affinity vs CB2R. The substitutions on the bicycle may lead to discrimination between agonist and antagonist activity.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">A Successful Case Study: Molecular Hybridization Based on CB2R Agonists and AChE/BChE Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88024" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88024" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The molecular hybridization strategy is based on the combination of two molecules endowed with different pharmacological activities in a single chemical entity, able to hit different targets involved in the same multifactorial pathology. The adopted strategies can be based on the connection (through a linker) or the integration (by merging or fusing) of pharmacophoric frameworks. Although very promising to combat the multifactorial nature of complex diseases, the development of molecular hybrids faces the critical issues of selecting the right target combination and the achievement of a balanced activity toward them while maintaining drug-like properties for the diverse targets.<a onclick="showRef(event, 'ref107 ref108 ref109'); return false;" href="javascript:void(0);" class="ref ref107 ref108 ref109">(107−109)</a></div><div class="NLM_p">As suggested by Bolognesi, early ADME studies should be included at the early stage to overcome all the pharmacokinetic issues.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a></div><div class="NLM_p">As mentioned above, CB2R activation is widely reported to improve cognitive impairment in animal models of AD, as CB2R agonists may reduce the release of proinflammatory molecules, facilitate the clearance of Aβ, promote the phagocytic phenotype of microglia, reduce the Aβ neurotoxicity, and reduce the oxidative stress damage produced by reactive oxidative species (ROS) and tau hyperphosphorylation.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Cannabinoids are potentially excellent multitarget candidate drugs for their interesting pharmacological profiles. Notable is the double ability to act as CB2R agonist and cholinesterase inhibitors (AChE/BChE) reported for some of them.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The AChE and BChE enzymes are identified as critical targets for the effective management of AD.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> Together with memantine (a <i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate (NMDA) receptor antagonist), three cholinesterase inhibitors (AChE/BChE) (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) were approved in the past years by FDA for AD treatment. Indeed, a progressive loss of cholinergic innervation in different CNS areas occurs in the pathology,<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> and thus a decreased cholinergic transmission is observed (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Therefore, the inhibition of these enzymes allows an increased acetylcholine availability in the brain regions and a decreased deposition of Aβ.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> Since the AChE levels in the brain areas are associated with progression of the AD disease, likely limiting the therapeutic utility of this class of drugs, BChE levels in the disease are markedly high compared to the levels recorded in the healthy subjects. Thus, the inhibition of BChE represents an innovative therapeutic approach for AD.<a onclick="showRef(event, 'ref114 ref115 ref116'); return false;" href="javascript:void(0);" class="ref ref114 ref115 ref116">(114−116)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/medium/jm0c01357_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. AChE inhibitors approved by FDA for AD treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although a wide structural heterogenicity can be observed among the AChE/BChE inhibitors, there are some specific molecular determinants that allow the identification of the basic requirements for inhibiting the two enzymes isoforms: a H-bond acceptor, an aromatic ring, a positive ionizable group, a hydrophobic portion, and the presence of tertiary amino groups, which can be protonated under physiological conditions.</div><div class="NLM_p">The idea of developing multitarget agents useful in AD treatment starting from CB2R agonists relied on the observation that some cannabinoids, such as JWH-015 (<b>8</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), were able to induce the removal of β-amyloid plaques<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> and that THC<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> and some cannabinoid agonists, such as JWH-015 (<b>8</b>) and WIN 55,212-2 (<b>10</b>), were able to inhibit AChE in vitro.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> With this in mind, Paez and colleagues proposed the first multitarget strategy for AD treatment based on the design of dual compounds with mixed CB2R/cholinesterase profiles.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> They tested several cannabinoid ligands for their activity as AChE/BChE inhibitors and<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> performed rational structural modifications starting from the core of the CB2R agonist JWH-015 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). In particular, by applying the concept of bioisosterism and by adding an aromatic ether suitable for CB2R interaction (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>),<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> they developed a series of indazoles, and the best results were shown by compounds <b>14</b> and <b>15</b>, whose 2D structures are reported in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/medium/jm0c01357_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. 2D sketch of the JWH-015 structural modifications proposed by Paez and colleagues<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> for designing dual CB2R/ChE indazole compounds ligands <b>14</b> and <b>15</b> and the CB2R/ChE/BACE-1 indazolyl ketone <b>16</b>.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">More recently, the same authors designed a series of new compounds having an indazolyl ketone as scaffold and showing a multitarget profile vs CB2R and cholinesterase. They started from 1-(2-diisopropylaminoethyl)-3-(4-methoxybenzyloxy)indazole <b>14</b><a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> that could be considered an interesting starting point for the hit-to-lead development of BChE inhibitors and CB2R agonists. Structural modifications on the indazole led to obtaining of a family of dual CB2R agonists/BChE inhibitors with high selectivity, potency, and good biological profile. In this study, the multitarget effect was also evaluated against β secretase 1 (BACE-1), the cleavage enzyme of β-site amyloid precursor proteins (a key enzyme in the abnormal production of amyloid-β protein which leads to fibrillary aggregation toxic to neurons). On the basis of pharmacological studies conducted in vitro and ex vivo, it was observed that two of these compounds showed a CB2R agonist profile (isolated tissue assay) as well as a BChE and BACE-1 inhibitory profile.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Replacing the alkyl chain with an amide moiety maximizes the CB2R binding affinity by allowing the formation of new interactions. These indazolyl ketone derivatives can be considered as two- or three-target cannabinoids: compound <b>16</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>), indeed, acts as selective CB2R full agonist in an isolated tissue assay and, at the same time, as BChE and BACE-1 inhibitor. Its effect was also tested on Alzheimer’s cell models, and the obtained results put forward this compound as a promising agent for AD treatment.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></div><div class="NLM_p">Very recently, 2-benzofuran-derived compounds, whose general scaffold is presented in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, were evaluated as potential cholinesterase inhibitors and CB2R ligands.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> Montanari and colleagues<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a> identified some benzofuran analogues endowed with promising anti-BChE activity and antiaggregation properties toward β amyloid plaques but an undesired CB1R affinity. Starting from this promising scaffold and in order to direct the multitarget spectrum of action toward CB2R, they designed an original class of compounds as a result of different modifications on the central skeleton. In the most active compounds, the alkoxy <i>N</i>-methyl-<i>N</i>-benzylamine side chain was removed and substituted by a methoxy group, and the amines were directly linked to the benzophenone ring. Compound <b>17</b> showed inhibitory activity on BChE in the micromolar range and CB2R selectivity over CB1R. Compound <b>18</b> is the most powerful CB2R ligand of the class, probably as a consequence of the nitrogen methylation. Compound <b>17</b> presents a broad spectrum of action; in fact it inhibits BChE, acts on CB2R with high selectivity over CB1R, shows a neuroprotective action, and could be considered a promising MTDL, while compound <b>18</b>, despite the lack of BChE inhibitory activity, proved to be a potent CB2R inverse agonist and exerts an interesting multifunctional action by combining anti-inflammatory and neuroprotective effects.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/medium/jm0c01357_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Dual CB2R/BChE benzofuran derivatives proposed by Montanari and collegues.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2008, Astra Zeneca developed a very interesting and selective CB2R agonist (compound <b>19</b>, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> On the basis of the pharmacophoric model of BChE inhibitors and of the results showed by the already reported indazole <b>14</b>, Dolles and colleagues in 2016 measured the ability of compound <b>19</b> to inhibit choline esterases, finding interesting pharmacodynamic properties toward human CB2R (<i>h</i>CB2R) and equine BChE (<i>eq</i>BChE) (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).<named-content content-type="anchor" rid="fig7" type="simple"></named-content></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/medium/jm0c01357_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Pharmacophore model of BChE inhibitors and CB2R compound <b>14</b> (top). Benzimidazole derivative <b>19</b> proposed by Astra Zeneca<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> as <i>h</i>CB2R agonist and studied by Dolles and co-workers as BchE/AchE inhibitor (bottom).<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/medium/jm0c01357_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Dual CB2R/BChE benzimidazole derivatives proposed by Dolles and colleagues: second generation.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29,30)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Starting from compound <b>19</b>, Dolles and co-workers proposed a second generation of dual CB2R/BChE benzimidazole derivatives by performing four structural changes: (i) the replacement of the diethylamide function with a hydrogen atom to confirm the need of this fragment for the interactions with CB2R and BChE; (ii) the introduction of a basic center on the hydrophobic alkyl chain; (iii) the modifications of the linker connecting the imidazole moiety and the phenyl ring; (iv) the modification of the heterocycle core (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The results clearly indicated that the presence of the diethylamide function is pivotal to ensure both the affinity vs <i>h</i>CB2R and the inhibition of <i>eq</i>BChE.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> For this reason, the authors focused their attention on substitutions in other portions of the molecule. The performed changes aimed to increase the basicity of the final compound through the insertion of amino groups to improve the interactions with the <i>eq</i>BChE active site. Interesting results came from the introduction of a piperidine ring on the alkyl chain obtaining compound <b>21</b>. Compounds <b>19</b>, <b>20</b>, and <b>21</b> presented moderate affinity towards <i>h</i>CB2R but an interesting <i>eq</i>BChE inhibition (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). Other modifications led to 2-aminobenzimidazole compound <b>22</b> that showed a moderate affinity vs <i>h</i>CB2R but, also in this case, a good inhibitory effect on <i>eq</i>BChE.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/medium/jm0c01357_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Dual CB2R/BChE benzimidazole derivatives proposed by Dolles and collegues, third generation.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">However, the excellent results were not recapitulated in a later study in human BChE.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> A third generation of analogues of compound <b>19</b> was studied by performing additional structural changes such as the (i) diethylamide substitution in position 5 of the main scaffold, (ii) substituent modification in position 5 (reverse amide, nitro group, and primary amine), and (iii) merging between the most interesting CB2R and BChE pharmacophoric fragments (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).</div><div class="NLM_p">Starting from compound <b>19</b>, the introduction in 5-position of different amides determined a decrease of <i>h</i>CB2R affinity but an interesting increase in <i>h</i>BChE inhibition. The 1-piperidinyl amide (<b>25)</b> determines an inhibitory activity on <i>h</i>BChE and higher CB2R affinity compared to the linear analogues. The anilineamide <b>24</b> showed the lowest CB2R affinity of this series (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).</div><div class="NLM_p">In <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>, modifications in the 5-position of compounds <b>19</b> were also evaluated. The introduction of electron-withdrawing/donating substituents, in place of the diethyl amide group, determined a complete loss of the activity/affinity vs both targets. Interestingly, compound <b>28</b>, with an inverse anilineamide, maintained CB2R affinity but lost the <i>h</i>BChE inhibition.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> By merging structures <b>20</b>, <b>21</b>, and <b>22</b>, Dolles and colleagues developed the compounds illustrated in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>. The introduction in compound <b>21</b> of an additional methylene between the amino group and the phenyl ring (compound <b>29</b>) determined an increase of CB2R affinity but no <i>h</i>BChE inhibition. Compound <b>30</b> derives from merging compounds <b>21</b> (<i>p</i>-ethoxyphenyl core) and <b>22</b> (ethylene piperidinyl core), while compound <b>31</b> results from <b>22</b> (<i>p</i>-phenoxyphenyl core) and <b>23</b>, but an improvement in terms of pharmacological profile was not observed.</div><div class="NLM_p">The authors also explored changes of the length of ethylene pyridinyl moiety of compound <b>21</b> without obtaining interesting results in terms of <i>h</i>CB2R affinity, selectivity toward <i>h</i>CB1R, and selective BChE/AChE inhibition.</div><div class="NLM_p">In conclusion the strategy followed by the authors could be considered as very representative for a MTDL design. Indeed, the developed compounds showed balanced affinities/activities toward the selected targets and were proved to improve cognition in vivo.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div><div class="NLM_p">In a more recent paper, Scheiner and colleagues reported the synthesis of a series of hybrid compounds derived from the combination of tacrine (a cholinesterase inhibitor (ChE)) and compound <b>19</b> through different spacers.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div><div class="NLM_p">The amide group and the N1 of the imidazole core are the most appropriate groups to be connected by the linker, hence obtaining two series of ligands. The hybrids of both series resulted in CB2R agonists and AChE/BChE inhibitors (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>).</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/medium/jm0c01357_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. General structures of hybrid compounds derived from the combination of tacrine and compound <b>20</b><a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> reported by Scheiner and collegues.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">An additional strategy consisted in the insertion of an additional linker such as a disulfide bridge with the aim to improve the pharmacokinetic profile (<b>34</b>). All these hybrids have maintained their behavior as CB2R agonist and the related immunomodulatory effect shown by compound <b>19</b>. Compounds <b>33</b> and <b>34</b> were able to reduce the β-amyloid plaques concentration with neuroprotective effect despite a not so high potency as ChE inhibitors and CB2R agonists.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Dual CB2R/HDAC for Cancer and Neurodegeneration Therapy</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_57124" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_57124" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Histone acetylation is crucial for the transcriptional activity.<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> The balance between acetylation and deacetylation is the principal epigenetic control of genetic transcription, and it is mediated by two important classes of enzymes: histone acetyl transferase (HAT) and histone deacetylase (HDAC).<a onclick="showRef(event, 'ref122'); return false;" href="javascript:void(0);" class="ref ref122">(122)</a> The loss of acetylating agents in combination with increased HDAC activities is one of the most frequent epigenetic anomalies occurring in cancer. It was reported<a onclick="showRef(event, 'ref123'); return false;" href="javascript:void(0);" class="ref ref123">(123)</a> that the repression of onco-suppressor genes is one of the principal causes of carcinogenesis and tumor progression, and among all the epigenetic modulators, HDAC enzymes have a pivotal role in this context. At the beginning of this process, HDAC enzymes restrain genes devoted to the check of cells growth, and this determines an uncontrolled cellular proliferation, loss of differentiation, and apoptosis inhibition. Moreover, in the cancer progression, HDAC enzymes silence genes appointed to check cellular adhesion, migration, and invasion.<a onclick="showRef(event, 'ref124'); return false;" href="javascript:void(0);" class="ref ref124">(124)</a> Recently, HDAC involvement in neurodegenerative disease was also reported and reviewed.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a></div><div class="NLM_p">For all these reasons, HDAC inhibitors (HDACi) represent an interesting option in cancer research. They are able to activate pathways involved in apoptosis and also to modulate the expression of non-histone proteins such as DNA repair enzymes, transcription factors, and nuclear regulators.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> Each HDAC enzyme presents a common deacetylation domain constituted by 390 amino acids. The catalytic pocket is strict and cylindrical presenting a central Zn<sup>2+</sup> atom that, coordinated by a network of histidines and aspartates, performs its catalytic activity.<a onclick="showRef(event, 'ref125 ref126 ref127 ref128 ref129'); return false;" href="javascript:void(0);" class="ref ref125 ref126 ref127 ref128 ref129">(125−129)</a></div><div class="NLM_p">Some representative HDACi are illustrated in <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>. As expected, all of them present a typical Zn<sup>2+</sup> binding group (ZBG), which is usually a hydroxamic acid or a 2-aminoanilide, a linker, and a hydrophobic cap group able to interact with the enzyme surface.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/medium/jm0c01357_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Representative HDAC inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The combination of HDACi with other drugs, able to hit other antitumoral targets, can induce a synergic positive effect in the therapy of cancer, as recently reported.<a onclick="showRef(event, 'ref130 ref131'); return false;" href="javascript:void(0);" class="ref ref130 ref131">(130,131)</a></div><div class="NLM_p">The successful use of HDACi in the same cancer cell lines where CB2R are overexpressed as well as their anti-inflammatory properties in the same pathologies where CB2R is involved<a onclick="showRef(event, 'ref132 ref133 ref134 ref135 ref136 ref137 ref138 ref139'); return false;" href="javascript:void(0);" class="ref ref132 ref133 ref134 ref135 ref136 ref137 ref138 ref139">(132−139)</a> suggests the development of dual CB2R/HDAC as a valuable strategy for cancer and neurodegeneration therapy. Our idea is also supported by many recent works proposing chimeric HDACi as a winning strategy for cancer.<a onclick="showRef(event, 'ref140 ref141'); return false;" href="javascript:void(0);" class="ref ref140 ref141">(140,141)</a></div><div class="NLM_p">On the basis of this evidence and inspired by Stazi et al.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a> reporting HDACi hybrids obtained through a molecular hybridization approach, herein we propose that linking a known CB2R scaffold to a proper ZBG group might be a valuable strategy to design compounds acting as dual CB2R/HDAC.</div><div class="NLM_p">For example, panobinostat (<b>36</b>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>), a well-known HDACi, and many CB2R agonists (e.g., compound JWH-015, <b>8</b>, <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>) share an indole group and could be considered an interesting starting point. Noteworthy, it was already evidenced the versatile ability of the indole group to interact with diverse targets and to confer drug-like properties.<a onclick="showRef(event, 'ref142'); return false;" href="javascript:void(0);" class="ref ref142">(142)</a></div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/medium/jm0c01357_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Proposed dual CB2R/HDACi obtained by merging compound <b>8</b> and panobinostat.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Another strategy may consist of the introduction of CB2R pharmacophoric fragments on HDACi scaffolds (merging approach). In this fashion, a problem could arise from the introduction on HDACi structure of the bulky cycloalifatic carboxamide group (usually an adamantyl carboxamide) very useful to recover CB2R affinity. Mercifully, the work of Cincinelli and co-workers<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> very recently reported the synthesis of HDACi presenting the large hydrofobic adamantyl group and showing a good efficacy as antiproliferative and proapoptotic agents.</div><div class="NLM_p">Interestingly, also Gopalan and colleagues reported the discovery of adamantane based highly potent HDACi,<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> thus confirming that the presence of the adamantyl core, although very bulky, is compatible with an inhibitory activity toward HDAC.</div><div class="NLM_p">On this basis, 2-aminoanilide represents another HDAC scaffold that can be proposed as a starting point for satisfying CB2R pharmacophore needs.</div><div class="NLM_p">In particular, the structure of entinostat (<b>38</b>, <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>) could represent a suitable starting scaffold for the introduction of CB2R pharmacophoric substituents such as a cycloaliphatic (also the adamantyl) carboxamide and the essential aliphatic chain.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/medium/jm0c01357_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Proposed strategy to design dual CB2R/HDACi: merging approach involving the structure of entinostat and the CB2R pharmacophore.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">As reported in the following sections, all these suggestions, based on the inspection of the available literature, may represent a promising starting point for setting up rational strategies based on an effective interplay between experimental and computational approaches.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Dual CB2R/σ for Cancer and Neurodegeneration Therapy</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83048" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83048" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The σ<sub>1</sub> and σ<sub>2</sub> receptors are other targets that we propose as promising for the development of dual drugs, both being involved in cancer and neurodegeneration. The σ<sub>1</sub> receptor is a chaperone protein expressed in the central nervous system (CNS),<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> where it plays a role in neurodegeneration, and in peripheral organs and in immune and endocrine tissues<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> where the protein is mainly studied for its involvement in cancer disease. Because of its chaperone nature, σ<sub>1</sub> receptor is usually associated with binding immunoglobulin protein (BiP) in a resting state on the surface of endoplasmic reticulum (ER), in an area known as the mitochondrial associated ER membrane (MAM). After activation by ligands or Ca<sup>2+</sup> depletion from ER, σ<sub>1</sub> receptor dissociates from BiP and binds to inositol 1,4,5-trisphosphate receptor type 3 (IP3R3) in order to increase Ca<sup>2+</sup> fluxes from ER to mitochondria and to regulate the IRE1-dependent pathway, which neutralizes ER stress. Among the activities associated with σ<sub>1</sub> receptor, worthy of note are also the antiapoptotic and antioxidant ones resulting from the interaction with Bcl-2, and Nrf2.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> Several ligands have been developed as modulators of σ<sub>1</sub> receptor, allowing the identification of a commonly accepted pharmacophoric model that works well irrespective of the ligand activity (antagonism and agonism): an amine site flanked by two hydrophobic regions.<a onclick="showRef(event, 'ref147'); return false;" href="javascript:void(0);" class="ref ref147">(147)</a></div><div class="NLM_p">σ<sub>2</sub> receptor is less known and understood. Through the years, diverse identities have been attributed to this still little-known receptor. After the histone hypothesis<a onclick="showRef(event, 'ref148 ref149'); return false;" href="javascript:void(0);" class="ref ref148 ref149">(148,149)</a> the σ<sub>2</sub> receptor was proposed as the progesterone receptor membrane component 1 (PGRMC1)<a onclick="showRef(event, 'ref150'); return false;" href="javascript:void(0);" class="ref ref150">(150)</a> and recently as TMEM97.<a onclick="showRef(event, 'ref151'); return false;" href="javascript:void(0);" class="ref ref151">(151)</a> The σ<sub>1</sub> subtype is strictly connected to several neurodegenerative diseases (such as amyotrophic lateral sclerosis (ALS),<a onclick="showRef(event, 'ref152 ref153 ref154 ref155 ref156'); return false;" href="javascript:void(0);" class="ref ref152 ref153 ref154 ref155 ref156">(152−156)</a> Parkinson’s disease (PD),<a onclick="showRef(event, 'ref157 ref158 ref159 ref160 ref161'); return false;" href="javascript:void(0);" class="ref ref157 ref158 ref159 ref160 ref161">(157−161)</a> Huntington’s disease (HD),<a onclick="showRef(event, 'ref162 ref163'); return false;" href="javascript:void(0);" class="ref ref162 ref163">(162,163)</a> Alzheimer’s disease (AD)<a onclick="showRef(event, 'ref164 ref165'); return false;" href="javascript:void(0);" class="ref ref164 ref165">(164,165)</a>) with σ<sub>1</sub> receptor agonists that improve neurotransmission and exert antineurodegenerative effects.<a onclick="showRef(event, 'ref156 ref161 ref162 ref163 ref165 ref166 ref167'); return false;" href="javascript:void(0);" class="ref ref156 ref161 ref162 ref163 ref165 ref166 ref167">(156,161−163,165−167)</a> The σ<sub>2</sub> subtype has only recently been associated with AD, as a class of σ<sub>2</sub> receptor antagonists inhibit the binding of Aβ oligomers to their neuronal binding sites, reducing the neurotoxic effects.<a onclick="showRef(event, 'ref168 ref169'); return false;" href="javascript:void(0);" class="ref ref168 ref169">(168,169)</a> Importantly, one of these molecules CT1812 (Elayta) has entered phase 2 clinical trials for early AD treatment.</div><div class="NLM_p">As for its involvement in cancer, σ<sub>1</sub> receptor is expressed in many human tumor cell lines<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> where it influences ion channels (highly expressed in cancer cells)<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> and regulates essential processes for tumor expansion and cell survival such as mitosis and apoptosis.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a> Therefore, σ<sub>1</sub> receptor antagonists such as rimcazole, IPAG, reduced haloperidol, BD-1047, BD-1063,<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> and PB212<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> can inhibit tumor cell survival.</div><div class="NLM_p">The σ<sub>2</sub> receptor has been widely studied in the oncology field, where the effect on cell proliferation of its modulators, through diverse mechanisms, mainly relies on the modulation of ER stress through the control of Ca<sup>2+</sup> release,<a onclick="showRef(event, 'ref174 ref175 ref176'); return false;" href="javascript:void(0);" class="ref ref174 ref175 ref176">(174−176)</a> the increase in ROS,<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a> and the mitochondrial superoxide production.<a onclick="showRef(event, 'ref178'); return false;" href="javascript:void(0);" class="ref ref178">(178)</a></div><div class="NLM_p">According to the MTDL strategy, these pieces of evidence prompt us to connect the antineurodegenerative and anticancer activities of CB2Rs with the properties of σ receptors. We believe that hitting these targets at the same time could provide a successful strategy to modulate, in a synergistic manner, diverse biological pathways underlying cancer and neurodegeneration. Dual CB2R/σ have never been synthesized, but the exploitation of scaffolds with proven affinity for both the receptors classes, according to the corresponding pharmacophores, could represent a valuable starting point.</div><div class="NLM_p">As an example, the herein reported 4-quinolone class (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>), which is proved to have high CB2R affinity, was used by Estrada-Valencia and colleagues to design MTDLs able to bind σ<sub>1</sub> and other targets involved in AD, such as AChE, MAOs, BACE-1, and LOX-5.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a></div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/medium/jm0c01357_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. General structure of Estrada-Valencia et al.’s ligands.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Another example is represented by the 2-quinolone class, which has been explored by Mugnaini and colleagues to develop CB2R ligands with anticancer activity,<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> while Weber and colleagues produced 3,4-dihydro-2-quinolones as σ<sub>1</sub> receptor antagonists with antinociceptive action (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>).<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a> These studies provide evidence of the common scaffolds that can be employed in order to obtain dual CB2R/σ ligands. Modification of these scaffolds with the insertion of a basic moiety on the quinolinone nucleus for the Mugnaini’s ligand <b>39</b> or with a bulky alkylamide for the Weber’s ligand <b>40</b> could correspond to an overlap of the CB2R and σ<sub>1</sub> receptor pharmacophore leading to the desired dual ligands. On the basis of this evidence, structure-based and ligand-based approaches, as reported in the following section, can be employed to select the appropriate positions for convenient structural changes, guiding also the selection of other scaffolds different from those herein proposed.</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/medium/jm0c01357_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Mugnaini’s ligand <b>39</b> on the left, Weber’s ligand <b>40</b> on the right, and proposed strategy to design dual CB2R/σ, where an outline of possible modifications is reported at the bottom.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The same strategy could also be applied for the development of dual CB2R agonists and σ<sub>2</sub> receptor ligands, with similar therapeutic perspectives outlined for the σ<sub>1</sub> subtype. However, despite the fact that the two σ subtypes share similar pharmacophoric elements, the lack of the σ<sub>2</sub> receptor crystal structure makes this task more difficult, hampering the application of in silico structure-based approaches.</div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">In Silico Approaches for the Identification of Dual CB2R/HDAC and CB2R/σ Compounds</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05435" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05435" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Although the first chemicals able to act on multiple targets were discovered by serendipity, MTDLs are today designed by means of rational approaches. As extensively reviewed in the past years,<a onclick="showRef(event, 'ref33 ref109 ref182'); return false;" href="javascript:void(0);" class="ref ref33 ref109 ref182">(33,109,182)</a> employing state-of-the-art computational strategies is mandatory to properly approach such a difficult issue, saving money and time. More specifically, molecular modeling (MM) is in the spotlight (i) to select promising target combinations at the early stages of a multitarget drug discovery project, (ii) to identify initial hits acting on multiple targets, and (iii) to optimize the multitarget activity during the “hit-to-lead” and “lead-optimization” phases. A fundamental prerequisite for employing MM approaches is the knowledge of molecules acting on the targets of interest (i.e., ligand-based rational design, LBRD) or of the three-dimensional information on the target structures (i.e., structure-based rational design, SBRD). As described below, such conditions are totally met when CB2R, HDAC, and σ<sub>1</sub> receptor are taken into account while, on the contrary, the available information regarding σ<sub>2</sub> receptor is still too poor to apply reliable MM approaches, although we are confident that this limit will be overcome in the future due to the increasing importance of this target. In this section, we will outline viable computational approaches to guide the identification and design of dual CB2R/HDAC and CB2R/σ<sub>1</sub>, with the aim of providing valuable preliminary information for medicinal chemists interested in the field. In particular, special attention will be devoted to emerging strategies based on the application of machine learning techniques.</div><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Structure- and Ligand-Based Rational Design</h3><div class="NLM_p">CB2R/HDAC and CB2R/σ<sub>1</sub> represent promising target associations not only from a therapeutic but also from a methodological point of view. The high amount of data, today available in freely accessible data resources such as Protein Data Bank<a onclick="showRef(event, 'ref183'); return false;" href="javascript:void(0);" class="ref ref183">(183)</a> containing information about experimentally determined structures of proteins, and CHEMBL<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a> containing a curated database of bioactive molecules, constitutes an ideal playground for planning reliable SBRD and LBRD strategies. Noteworthy, in the past years the absence of an atomic-resolution structure of CB2R has represented the main hindrance to the application of SBRD strategies on this target, although examples of research efforts in this direction, based on the development and employment of homology models, are available in the literature.<a onclick="showRef(event, 'ref185 ref186 ref187'); return false;" href="javascript:void(0);" class="ref ref185 ref186 ref187">(185−187)</a> Such a limitation has been overcome only in 2019 when Li et al. deposited the first X-ray structure of human CB2R in the Protein Data Bank (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZTY">5ZTY</a><a onclick="showRef(event, 'ref188'); return false;" href="javascript:void(0);" class="ref ref188">(188)</a>), thus making reliable the application of SBRD approaches, as we showed in a recently published paper.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Even more interestingly, Hua et al. published in 2020 the first crystal structure of an agonist bound human CB2R (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6KPC">6KPC</a><a onclick="showRef(event, 'ref189'); return false;" href="javascript:void(0);" class="ref ref189">(189)</a>), thus providing unprecedented structural information for rationally designing CB2R agonists. As far as HDACs are concerned, several 3D structures of different human isoforms are available in the Protein Data Bank. Examples are given by several X-ray structures, in complex with inhibitors, of HDAC2 (PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3MAX">3MAX</a>,<a onclick="showRef(event, 'ref190'); return false;" href="javascript:void(0);" class="ref ref190">(190)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5IX0">5IX0</a>,<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5IWG">5IWG</a>,<a onclick="showRef(event, 'ref191'); return false;" href="javascript:void(0);" class="ref ref191">(191)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WBZ">6WBZ</a>,<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WBW">6WBW</a>,<a onclick="showRef(event, 'ref192'); return false;" href="javascript:void(0);" class="ref ref192">(192)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6G3O">6G3O</a>,<a onclick="showRef(event, 'ref193'); return false;" href="javascript:void(0);" class="ref ref193">(193)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LXZ">4LXZ</a>,<a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LY1">4LY1</a><a onclick="showRef(event, 'ref194'); return false;" href="javascript:void(0);" class="ref ref194">(194)</a>), HDAC4 (PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VQQ">2VQQ</a>,<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VQM">2VQM</a>,<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VQJ">2VQJ</a>,<a onclick="showRef(event, 'ref195'); return false;" href="javascript:void(0);" class="ref ref195">(195)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5A2S">5A2S</a>,<a onclick="showRef(event, 'ref196'); return false;" href="javascript:void(0);" class="ref ref196">(196)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CBY">4CBY</a>,<a onclick="showRef(event, 'ref196'); return false;" href="javascript:void(0);" class="ref ref196">(196)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CBT">4CBT</a>,<a onclick="showRef(event, 'ref196'); return false;" href="javascript:void(0);" class="ref ref196">(196)</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FYZ">6FYZ</a><a onclick="showRef(event, 'ref197'); return false;" href="javascript:void(0);" class="ref ref197">(197)</a>), HDAC7 (PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZNR">3ZNR</a>,<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZNS">3ZNS</a>,<a onclick="showRef(event, 'ref198'); return false;" href="javascript:void(0);" class="ref ref198">(198)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3C0Z">3C0Z</a>,<a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3C10">3C10</a><a onclick="showRef(event, 'ref199'); return false;" href="javascript:void(0);" class="ref ref199">(199)</a>), and HDAC8 (PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1VKG">1VKG</a>,<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T64">1T64</a>,<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5D1B">5D1B</a>,<a onclick="showRef(event, 'ref201'); return false;" href="javascript:void(0);" class="ref ref201">(201)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T69">1T69</a>,<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a><a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T67">1T67</a>,<a onclick="showRef(event, 'ref200'); return false;" href="javascript:void(0);" class="ref ref200">(200)</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2V5X">2V5X</a><a onclick="showRef(event, 'ref202'); return false;" href="javascript:void(0);" class="ref ref202">(202)</a>). Some of these structures have been successfully employed in the past years to identify, for instance, HDAC4,<a onclick="showRef(event, 'ref203'); return false;" href="javascript:void(0);" class="ref ref203">(203)</a> HDAC8,<a onclick="showRef(event, 'ref204'); return false;" href="javascript:void(0);" class="ref ref204">(204)</a> dual MMP-2/HDAC-8,<a onclick="showRef(event, 'ref205'); return false;" href="javascript:void(0);" class="ref ref205">(205)</a> and dual MMP2/HDAC-6<a onclick="showRef(event, 'ref206'); return false;" href="javascript:void(0);" class="ref ref206">(206)</a> inhibitors by means of SBRD strategies. Valuable structural information is today available also for σ<sub>1</sub> receptor. In 2016 Schmidt et al. published on <i>Nature</i> the first crystal structures of its human form in complex with PD144418 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HK1">5HK1</a><a onclick="showRef(event, 'ref207'); return false;" href="javascript:void(0);" class="ref ref207">(207)</a>) and 4-IBP (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HK2">5HK2</a><a onclick="showRef(event, 'ref207'); return false;" href="javascript:void(0);" class="ref ref207">(207)</a>), while 2 years later, the same research group made available the crystal structures of human σ<sub>1</sub> in complex with haloperidol (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DJZ">6DJZ</a><a onclick="showRef(event, 'ref208'); return false;" href="javascript:void(0);" class="ref ref208">(208)</a>), NE-100 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DK0">6DK0</a><a onclick="showRef(event, 'ref208'); return false;" href="javascript:void(0);" class="ref ref208">(208)</a>), and (+)pentazocine (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DK1">6DK1</a><a onclick="showRef(event, 'ref208'); return false;" href="javascript:void(0);" class="ref ref208">(208)</a>). All these receptor–ligand complexes show a common ligand binding mode where an interaction between a basic amine and Glu172 seems to be crucial for molecular recognition. Importantly, Greeenfield et al. have recently identified high affinity σ<sub>1</sub> receptor ligands by employing a docking based virtual screening (VS).<a onclick="showRef(event, 'ref209'); return false;" href="javascript:void(0);" class="ref ref209">(209)</a> These results allowed them to suggest this receptor as an ideal candidate for SBRD strategies. All these pieces of evidence, taken as whole, provide a breeding ground to guide the identification and design of CB2R/HDAC and CB2R/σ<sub>1</sub> MTDLs by means of SBRD strategies. Binding site similarity analysis can be performed in order to select, for instance, which HDAC structure (and therefore isoform) is better suited for designing dual CB2R/HDAC compounds by comparing the available CB2R and HDAC pockets. Cavities can be characterized by means of several methodologies<a onclick="showRef(event, 'ref210'); return false;" href="javascript:void(0);" class="ref ref210">(210)</a> based, for instance, on quadruplet fingerprints applied to molecular interaction fields<a onclick="showRef(event, 'ref211'); return false;" href="javascript:void(0);" class="ref ref211">(211)</a> or principal component analysis (PCA) applied on properties such as size, polarity, and charge.<a onclick="showRef(event, 'ref212'); return false;" href="javascript:void(0);" class="ref ref212">(212)</a> Hierarchical computational platforms for multilayer VS of large chemical libraries can be developed based on molecular shape similarity, structure-based pharmacophore models, and molecular docking simulations.<a onclick="showRef(event, 'ref213'); return false;" href="javascript:void(0);" class="ref ref213">(213)</a> VS campaigns can be independently performed on CB2R, HDAC, and σ<sub>1</sub>, and promising hits can be identified from those compounds located at the top of the ranked lists. Molecular docking simulations can also be employed to investigate the proposed scaffolds based on molecular hybridization (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>, <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a>, and <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a>) and suggest the most promising structural changes to be considered for designing the first MTDLs acting on these targets. Due to the currently available data, CB2R/HDAC and CB2R/σ<sub>1</sub> MTDLs might be also identified by means of LBDD approaches based, for instance, on the development and application of quantitative structure–activity relationship (QSAR) models or similarity-based algorithms for target prediction.<a onclick="showRef(event, 'ref214'); return false;" href="javascript:void(0);" class="ref ref214">(214)</a> Examples of successful application of the so-called “multitarget QSAR” are available in the literature<a onclick="showRef(event, 'ref215 ref216 ref217'); return false;" href="javascript:void(0);" class="ref ref215 ref216 ref217">(215−217)</a> and have been recently reviewed by Abdolmaleki et al.<a onclick="showRef(event, 'ref218'); return false;" href="javascript:void(0);" class="ref ref218">(218)</a> Noteworthy, ChEMBL (version 27.1) contains curated experimental data concerning 3989, 1678, and 2274 compounds provided with high affinity (IC<sub>50</sub> or <i>K</i><sub>i</sub> values of ≤1 μM) toward human CB2R, HDAC, and σ<sub>1</sub> receptor, respectively. <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a> shows the projection of these compounds into the top two principal components (PCs) obtained from 11 topological and 323 physicochemical descriptors computed for each ligand using Canvas<a onclick="showRef(event, 'ref219'); return false;" href="javascript:void(0);" class="ref ref219">(219)</a> available in the Schrodinger suite, as software. The plot clearly indicates the presence of a common chemical space covered by CB2R and HDAC (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>A) as well as CB2R and σ<sub>1</sub> (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>B) binders, thus supporting the idea, based on the inspection of the proposed pharmacophores, that these target combinations are promising for designing MTDLs. Note that in a chemical space representation the closeness of the represented points reflects the structural and/or property similarity of the corresponding compounds.</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/medium/jm0c01357_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Projection of (A) CB2R (black points) and HDAC (red points) and (B) CB2R (black points) and σ<sub>1</sub> (red points) high affinity (IC<sub>50</sub> or <i>K</i><sub>i</sub> of ≤1 μM) compounds into the top two PCs obtained from 11 topological and 323 physicochemical descriptors. Note that PC1 and PC2 are plotted accounting for (A) 90% and (B) 87% of the total variance.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Last but not least, the available public data can be implemented to identify CB2R/HDAC and CB2R/σ<sub>1</sub> MTDLs by integrating SBDD and LBDD approaches in a single technique.<a onclick="showRef(event, 'ref220'); return false;" href="javascript:void(0);" class="ref ref220">(220)</a> Indeed, combining the information on the protein structures with that on the physicochemical and biological properties of bound ligands can strongly enhance the success rate in multitarget drug discovery programs. Noteworthy, this strategy proved effective for the identification of a first dual compound acting on heat shock protein 90 (Hsp90) and tubulin,<a onclick="showRef(event, 'ref221'); return false;" href="javascript:void(0);" class="ref ref221">(221)</a> two important anticancer targets.</div></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Machine-Learning-Assisted de Novo Design</h3><div class="NLM_p">Due to the available knowledge of ligands acting on CB2R, HDAC, and σ<sub>1</sub>, machine learning can also be employed to design CB2R/HDAC and CB2R/σ<sub>1</sub> MTDLs. Such approaches, widely used in several application domains such as image understanding, signal processing, and matter engineering, are today emerging as particularly effective for de novo design of compounds having desired properties, including biological activities toward specific targets of interest.<a onclick="showRef(event, 'ref222'); return false;" href="javascript:void(0);" class="ref ref222">(222)</a></div><div class="NLM_p last">The main aspect of these techniques is that they are capable of learning a representation of a given physical or abstract phenomenon described by a functional relation <i>y</i> = <i>f</i>(<i>x</i>), i.e., a mapping function between the input variables or observations (for example, fingerprint representations of molecules) and an output variable that can be discrete or continuous such as an active/inactive label or the bioactivity value. The data take the form of input/output pairs (<i>x</i>,<i>y</i>) called examples and collected during the observation of the phenomenon. In mathematical terms, de novo design aims to find an element <i>x</i> that is related to the value <i>y</i>: <i>y</i> = <i>f</i>(<i>x</i>). In molecular terms, <i>x</i> is a molecular structure from the chemical space and <i>y</i> is the descriptor of <i>x</i> computed by function <i>f</i>. The problem becomes learning a representation of <i>f</i> by using a training set composed of <i>N</i> examples (<i>x</i>,<i>y</i>). This form of learning is known as supervised learning, as there is a teacher providing the value <i>y</i> for each input <i>x</i> in the training phase. There is another form of learning that is unsupervised and relevant for de novo drug design called density estimation.<a onclick="showRef(event, 'ref223'); return false;" href="javascript:void(0);" class="ref ref223">(223)</a> We can imagine the chemical space of compounds as a compact continuous space that includes a probability density <i>p</i>; the goal is to learn this probability density in order to sample from it new observations. Recently, this difficult problem has been tackled under a different and appealing perspective. Instead of estimating the density <i>p</i> and then sampling <i>p</i> for obtaining new observations, we can directly generate new observations. This class of techniques, known as generative models, uses deep neural networks for representing the probability density functions. Probabilistic models based on neural networks are computationally scalable since they use stochastic gradient-based optimization which allows scaling to large models and large data sets.<a onclick="showRef(event, 'ref224 ref225'); return false;" href="javascript:void(0);" class="ref ref224 ref225">(224,225)</a> The simplest form of the generative model for de novo drug design is described in Gupta et al., 2018.<a onclick="showRef(event, 'ref225'); return false;" href="javascript:void(0);" class="ref ref225">(225)</a> The authors explore the vast chemical space for compounds that may not have been synthesized before by using a generative deep learning model based on recurrent neural networks (RNNs), the network of choice for tasks involving sequential inputs. Indeed, the authors used simplified molecular input line entry specification (SMILE) representation. RNNs process an input sequence one element at a time, maintaining in their hidden units a state vector that implicitly contains information about the history of all the past elements of the sequence. Their recurrent network is composed of two layers of long short-term memory (LSTM) cells first introduced by Hochreiter and Schmidhuber in 1997<a onclick="showRef(event, 'ref226'); return false;" href="javascript:void(0);" class="ref ref226">(226)</a> for solving the gradient vanishing problem affecting the vanilla RNNs. Trained with back-propagation through time, their model was able to generate valid SMILE strings with high accuracy, structurally similar to drugs with known activities against particular targets. In other words, by training RNNs on data sets containing compounds with high affinity toward human CB2R, HDAC, and σ<sub>1</sub> receptor, one could generate compounds that can be considered as ideal MTDLs candidates. More sophisticated deep generative models, well suited for multitarget drug de novo design, make use of autoencoders for converting molecular discrete representations of variable length to continuous, fixed length vectors belonging to a latent space in which to generate novel chemical compounds by performing simple algebraic operations such as interpolating between molecules. Variational autoencoders (VAEs)<a onclick="showRef(event, 'ref227'); return false;" href="javascript:void(0);" class="ref ref227">(227)</a> are generative models composed of an encoder that maps SMILES representations of molecules into a latent space and of a decoder that converts latent vectors to the original input SMILES. Both encoder and decoder are implemented by using multilayer RNNs with LSTM units. The main aspect of VAE consists of learning the parameters of probability distribution of the latent space and of using these parameters for generating new latent vectors corresponding to novel compounds with given properties. In other terms, generating chemical structures by optimizing with respect to selected properties (such as activity toward more targets of interest) can be performed by optimizing a reward function in the continuous latent space. Gómez-Bombarelli et al. utilized Bayesian optimization<a onclick="showRef(event, 'ref227'); return false;" href="javascript:void(0);" class="ref ref227">(227)</a> to find points in the space corresponding to molecules with a desired property. Another approach for fine-tuning a generative model in order to design molecules with a specific property is reinforcement learning. In the case of de novo design, reinforcement learning aims at learning how it is possible to optimize a reward in a given space. Olivecrone et al.<a onclick="showRef(event, 'ref222'); return false;" href="javascript:void(0);" class="ref ref222">(222)</a> utilized this concept to modify the generative process of a pretrained RNN to generate a set of molecules enriched of compounds with desirable properties. An appealing alternative to VAE are the generative adversarial networks (GAN) adopted by Kudurin et al.<a onclick="showRef(event, 'ref228'); return false;" href="javascript:void(0);" class="ref ref228">(228)</a> to identify new molecular fingerprints with predefined anticancer properties. GANs are based on a minimax game. A generative model G (generator) is opposed to a discriminative model D (discriminator) that learns to determine whether a sample is drawn from the data distribution or from the distribution generated by G (model distribution). This model G is analogous to a group of counterfeiters, trying to produce counterfeit money, while the model D is analogous to the police, trying to detect the fake currency. During the competition, both the counterfeiters and the police try to improve their strategies until the counterfeits are indistinguishable from the true articles. So D has to minimize the error rate in discriminating true from fake samples, and G has to maximize its ability to generate samples similar to the real data. Both D and G are described through multilayer perceptron and optimized through back-propagation. A characteristic of such generative models is that they do not explicitly represent the likelihood, yet they are able to generate samples from the desired distribution. GANs differ in how they generate molecules, but they all apply reinforcement learning to generate more molecules with structures that are active on both targets of interest. Successful generative models for the de novo design of multitarget compounds are available in the literature. Of note is the paper by Winter et al.<a onclick="showRef(event, 'ref229'); return false;" href="javascript:void(0);" class="ref ref229">(229)</a> By using a lighter weight heuristic optimization method termed particle swarm optimization (PSO), the authors designed de novo compounds with predicted multitarget activity toward the epidermal growth factor receptor (EGFR) and aspartyl protease β-site APP cleaving enzyme-1 (BACE-1). Noteworthy, they applied PSO in a continuous chemical representation and used it to optimize molecules with respect to a multiobjective value function defined as a combination of multiple molecular properties. The model was able to generate compounds with optimized metabolic stability, predicted solubility, cell permeability, druglikeness as well as a good synthetic accessibility. Another meaningful example is represented by a paper published while writing this Perspective. In particular, Tan et al.<a onclick="showRef(event, 'ref230'); return false;" href="javascript:void(0);" class="ref ref230">(230)</a> reported an automated deep learning workflow for the automatic design of MTDLs. The developed model was able to generate molecules with potent activities toward dopamine D2 and serotonin 5-HT1A and 5-HT2A receptors, a polypharmacology profile highly desirable for developing drugs with antipsychotic effects.</div></div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32635" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32635" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">CB2R plays a crucial role in neurodegeneration and several types of tumors due to its involvement in the (neuro)inflammatory process, and recently, it has been successfully associated with other targets such as AChE and BchE for developing MTDLs with beneficial polypharmacology effects for the AD treatment. Starting from this evidence, in this paper we prompt the scientific community to consider new target associations, namely, CB2R/HDAC and CB2R/σ receptors, for developing new and promising MTDLs for cancer and neurodegeneration therapy. Such a suggestion is based on (i) an in-depth inspection of the available literature indicating the presence of common pharmacophoric elements and (ii) the available public information concerning the 3D target structures as well as several known high affinity ligands. The paper is discussed in the Perspective to provide a guide for medicinal chemists interested in this attractive opportunity and having experience in the fields of molecular hybridization, molecular modeling, and/or machine learning guided de novo design.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c01357" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60037" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60037" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Angela Stefanachi</span> - <span class="hlFld-Affiliation affiliation">Dipartimento
di Farmacia-Scienze del Farmaco, Università
degli Studi di Bari Aldo Moro, Via Orabona 4, 70125 Bari, Italy</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9430-7972" title="Orcid link">http://orcid.org/0000-0002-9430-7972</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#6c0d020b09000d421f18090a0d020d0f04052c1902050e0d420518"><span class="__cf_email__" data-cfemail="45242b222029246b36312023242b24262d2c05302b2c27246b2c31">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Giuseppe Felice Mangiatordi</span> - <span class="hlFld-Affiliation affiliation">CNR—Institute
of Crystallography, Via
Amendola 122/o, 70126 Bari, Italy</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-4042-2841" title="Orcid link">http://orcid.org/0000-0003-4042-2841</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Francesca Intranuovo</span> - <span class="hlFld-Affiliation affiliation">Dipartimento
di Farmacia-Scienze del Farmaco, Università
degli Studi di Bari Aldo Moro, Via Orabona 4, 70125 Bari, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Pietro Delre</span> - <span class="hlFld-Affiliation affiliation">CNR—Institute
of Crystallography, Via
Amendola 122/o, 70126 Bari, Italy</span>; 
    <span class="hlFld-Affiliation affiliation">Dipartimento
di Chimica, Università degli Studi
di Bari Aldo Moro, 70125 Bari, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Francesca Serena Abatematteo</span> - <span class="hlFld-Affiliation affiliation">Dipartimento
di Farmacia-Scienze del Farmaco, Università
degli Studi di Bari Aldo Moro, Via Orabona 4, 70125 Bari, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carmen Abate</span> - <span class="hlFld-Affiliation affiliation">Dipartimento
di Farmacia-Scienze del Farmaco, Università
degli Studi di Bari Aldo Moro, Via Orabona 4, 70125 Bari, Italy</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9292-884X" title="Orcid link">http://orcid.org/0000-0001-9292-884X</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mauro Niso</span> - <span class="hlFld-Affiliation affiliation">Dipartimento
di Farmacia-Scienze del Farmaco, Università
degli Studi di Bari Aldo Moro, Via Orabona 4, 70125 Bari, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Teresa Maria Creanza</span> - <span class="hlFld-Affiliation affiliation">CNR—Institute
of Intelligent Industrial Technologies and Systems for Advanced Manufacturing, Via Amendola 122/o, 70126 Bari, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicola Ancona</span> - <span class="hlFld-Affiliation affiliation">CNR—Institute
of Intelligent Industrial Technologies and Systems for Advanced Manufacturing, Via Amendola 122/o, 70126 Bari, Italy</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-0065-0321" title="Orcid link">http://orcid.org/0000-0003-0065-0321</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marialessandra Contino</span> - <span class="hlFld-Affiliation affiliation">Dipartimento
di Farmacia-Scienze del Farmaco, Università
degli Studi di Bari Aldo Moro, Via Orabona 4, 70125 Bari, Italy</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-0713-3151" title="Orcid link">http://orcid.org/0000-0002-0713-3151</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>G.F.M. and F.I. contributed equally to the work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80570" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80570" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Giuseppe Felice Mangiatordi</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=BIO-d7e2300-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Giuseppe Felice Mangiatordi</b> obtained his M.Sc. degree in Chemistry and Pharmaceutical Technology cum laude at the University of Bari in 2008 and a Ph.D. in Theoretical Chemistry at the École Nationale Supérieure de Chimie de Paris (ENSCP, Paris) in 2012. From 2013 to 2017 he was a postdoctoral researcher at the University of Bari (Dipartimento di Farmacia, Scienze del Farmaco). Since December 2018 he has a permanent position as researcher of the National Research Council (CNR) where he is head of the in silico design laboratory (<a href="/cdn-cgi/l/email-protection" class="__cf_email__" data-cfemail="733a3d203a37363f3311">[email protected]</a>). He has major expertise in structure- and ligand-based drug design, molecular dynamics (MD) simulations, and predictive toxicology. He is an author of 64 papers in international peer-reviewed journals and 11 lectures at international meetings.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Francesca Intranuovo</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=BIO-d7e2305-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Francesca Intranuovo</b> is a Ph.D. student in Drug Sciences at University of Bari (Italy), currently under the supervision of Assistant Professor Marialessandra Contino. She graduated (cum laude) in 2018 in Medicinal Chemistry at the University of Bari, dealing with the synthesis development of fluorescent tracers towards CB2 receptor for the early diagnosis of Alzheimer’s disease. In 2020 she obtained a second level University Master’s degree in Sciences of Cosmetic Products, dealing with a specific cosmetic line for cancer patients. Today her Ph.D. project focused on the design, synthesis, and biological evaluation of new cannabinoid receptor 2 ligands as therapeutic and diagnostic compounds in cancer and neurodegenerative diseases.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Pietro Delre</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=BIO-d7e2310-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Pietro Delre</b> obtained his M.Sc. degree in Chemistry and Pharmaceutical Technology at the University of Bari in 2017. Since January 2019, he is a Ph.D. student at the University of Bari (Chemistry Department) working at the Institute of Crystallography of the National Research Council (IC-CNR). He gained experience in the application of structure- and ligand-based drug design, molecular dynamics (MD) simulations, and predictive toxicology.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Francesca Serena Abatematteo</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=BIO-d7e2315-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Francesca Serena Abatematteo</b> is a Ph.D. student in Biomolecular, Pharmaceutical, and Medical Sciences at University of Bari (Italy), currently under the supervision of Assistant Professor Carmen Abate. She graduated in 2018 in Medicinal Chemistry at the University of Bari, dealing with the synthesis and biological evaluation of fluorescent probes of cyclooxygenase-1 as a diagnostic tool for ovarian cancer. Actually, she is involved with the development of σ and CB2 receptors’ ligands as astherapeutic and diagnostic tools in neurodegenerative diseases and in cancer.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Carmen Abate</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=BIO-d7e2320-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Carmen Abate</b> is an Assistant Professor at the University of Bari since 2009 in the Department of Pharmacy. She graduated in 1998 in Medicinal Chemistry and got her Ph.D. in 2002 developing σ receptors ligands. From 2002 to 2003 and from 2005 to 2009 she worked as Associate Researcher at the Department of Pharmacy, University of Bari, to develop EBP and σ receptor ligands and MTDLs antitumor agents. From 2003 to 2005 she developed serotonergic ligands as a postdoctoral fellow at the Virginia Commonwealth University (VCU), Richmond, VA (USA). From January to July 2008, as “Fulbright Research Scholar”, she worked at VCU on the identification of a σ<sub>2</sub> receptor pharmacophore. She is author of more than 50 papers in international peer-reviewed journals.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Mauro Niso</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=BIO-d7e2328-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Mauro Niso</b> is Assistant Professor at the Department of Pharmacy, University of Bari (Italy), since 2015. He graduated in 2002 in Medicinal Chemistry and took his Ph.D. in 2006 with a thesis about the identification of σ receptors in tumour cell lines and tumour tissue. He was Associate Researcher from 2006 to 2015 dealing with the development of ligands active towards MDR proteins and σ receptors. He is now dealing with the development of metal chelators useful in neurodegeneration and cancer. He is an author of 70 papers in international peer-reviewed journals and 1 patent.</p></figure></div><div class="bio" rid="ath7"><figure id="ath7" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Teresa Maria Creanza</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=BIO-d7e2333-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Teresa Maria Creanza</b> is a researcher at the Institute of Intelligent Industrial Technologies and Systems for Advanced Manufacturing of the National Research Council of Italy. She graduated in Physics and obtained a Ph.D. in the “Complex Systems for Life Sciences” program at the University of Turin. Her research focuses on statistical inference, theory, and algorithms for machine learning and graphical models for high-dimensional data. She has been involved in projects including the development of statistical methods and software for the analysis of high-throughput gene expression data and modeling and analysis of gene networks for the study of the molecular mechanisms underlying complex diseases.</p></figure></div><div class="bio" rid="ath8"><figure id="ath8" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Nicola Ancona</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=BIO-d7e2338-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Nicola Ancona</b> received the degree in Computer Science (summa cum laude) from the University of Bari in 1986. He was researcher at Istituto per la Ricerca Scientifica e Tecnologica (I.R.S.T.) in Trento (1988–1990) and at Centro Tecnopolis CSATA Novus Ortus, Valenzano, in Bari (1990–1997) working in the fields of machine vision and robotics. In December 1997, he joined the Istituto di Sistemi e Tecnologie Industriali Intelligenti per il Manifatturiero Avanzato of the CNR where he leads the Bioinformatics and Systems Biology Laboratory. The main scientific interests of Dr. Ancona include applied statistics, statistical learning theory, algorithms for machine learning, and computational methods for the assessment of learning machines.</p></figure></div><div class="bio" rid="ath9"><figure id="ath9" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Angela Stefanachi</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=BIO-d7e2343-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Angela Stefanachi</b> is an Assistant Professor at the University of Bari from 2009 in the Department of Pharmacy. She graduated in 1998 summa cum laude in Medicinal Chemistry and she got her Ph.D. in Medicinal Chemistry in 2004 at the University of Bari. She worked as postdoc in the Department of Pharmacy at the University of Bari until November 2008. Her research is focused on the design and synthesis of small molecules with potential pharmacological activity toward pathologies such as cancer (aromatase, protein kinases, MDR and HDAC inhibitors, CB2R ligands), neurodegenerative diseases (AChE-BChE and Aβ1-40 aggregation inhibitors), and asthma (selective adenosine 2B receptor antagonists). She is author of more than 40 papers in international peer-reviewed journals.</p></figure></div><div class="bio" rid="ath10"><figure id="ath10" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Marialessandra Contino</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=BIO-d7e2348-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Marialessandra Contino</b> is Assistant Professor at the Department of Pharmacy, University of Bari (Italy). She was Associate Researcher from 2004 to 2015 dealing with the development of (i) arylpiperazine derivatives active toward CNS receptors, (ii) new PET tracers for the early diagnosis of Alzheimer’s disease, and (iii) MDR ligands. She is now dealing with the development of CB2R ligands useful for the diagnosis and therapy of neurodegenerative diseases and cancers. She obtained her Ph.D. in Medicinal Chemistry in 2004, having worked on the biological evaluation of σ receptors ligands. In 2019, she won an EMBO fellowship at the CIMUS of Santiago de Compostela (Spain). She is author of more than 80 papers in international peer-reviewed journals and 2 patents.</p></figure></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">5-HT<sub>1A</sub></td><td class="NLM_def"><p class="first last">serotonin receptor subtype 1A</p></td></tr><tr><td class="NLM_term">5-HT<sub>2A</sub></td><td class="NLM_def"><p class="first last">serotonin receptor subtype 2A</p></td></tr><tr><td class="NLM_term">μM</td><td class="NLM_def"><p class="first last">micromolar</p></td></tr><tr><td class="NLM_term">Aβ</td><td class="NLM_def"><p class="first last">amyloid β-protein</p></td></tr><tr><td class="NLM_term">AChE</td><td class="NLM_def"><p class="first last">acetylcholine esterase</p></td></tr><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">Alzheimer’s disease</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, and excretion</p></td></tr><tr><td class="NLM_term">ALS</td><td class="NLM_def"><p class="first last">amyotrophic lateral sclerosis</p></td></tr><tr><td class="NLM_term">APP</td><td class="NLM_def"><p class="first last">amyloid-β precursor protein</p></td></tr><tr><td class="NLM_term">BACE-1</td><td class="NLM_def"><p class="first last">β-secretase</p></td></tr><tr><td class="NLM_term">BChE</td><td class="NLM_def"><p class="first last">butyrylcholinesterase</p></td></tr><tr><td class="NLM_term">Bcl-2</td><td class="NLM_def"><p class="first last">B-cell lymphoma 2</p></td></tr><tr><td class="NLM_term">BiP</td><td class="NLM_def"><p class="first last">binding immunoglobulin protein</p></td></tr><tr><td class="NLM_term">CB1R</td><td class="NLM_def"><p class="first last">cannabinoid receptor subtype 1</p></td></tr><tr><td class="NLM_term">CB2R</td><td class="NLM_def"><p class="first last">cannabinoid receptor subtype 2</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">D<sub>2</sub></td><td class="NLM_def"><p class="first last">dopamine receptor subtype 2</p></td></tr><tr><td class="NLM_term">D</td><td class="NLM_def"><p class="first last">discriminator</p></td></tr><tr><td class="NLM_term">DNA</td><td class="NLM_def"><p class="first last">deoxyribonucleic acid</p></td></tr><tr><td class="NLM_term">EC<sub>50</sub></td><td class="NLM_def"><p class="first last">half maximal effective concentration</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">endoplasmic reticulum</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">G</td><td class="NLM_def"><p class="first last">generator</p></td></tr><tr><td class="NLM_term">GAN</td><td class="NLM_def"><p class="first last">generative adversarial networks</p></td></tr><tr><td class="NLM_term">HAT</td><td class="NLM_def"><p class="first last">histone acetyl transferase</p></td></tr><tr><td class="NLM_term">HD</td><td class="NLM_def"><p class="first last">Huntington’s disease</p></td></tr><tr><td class="NLM_term">HDAC</td><td class="NLM_def"><p class="first last">histone deacetylase</p></td></tr><tr><td class="NLM_term">HDACi</td><td class="NLM_def"><p class="first last">HDAC inhibitors</p></td></tr><tr><td class="NLM_term">Hsp90</td><td class="NLM_def"><p class="first last">heat shock protein 90</p></td></tr><tr><td class="NLM_term"><i>i</i>-Pr</td><td class="NLM_def"><p class="first last">isopropyl</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">half-maximum inhibitory concentration</p></td></tr><tr><td class="NLM_term">IP3R3</td><td class="NLM_def"><p class="first last">inositol 1,4,5-triphosphate receptor type 3</p></td></tr><tr><td class="NLM_term">IRE1</td><td class="NLM_def"><p class="first last">inositol-requiring enzyme 1</p></td></tr><tr><td class="NLM_term"><i>K</i><sub>i</sub></td><td class="NLM_def"><p class="first last">inhibition constant</p></td></tr><tr><td class="NLM_term">LBDD</td><td class="NLM_def"><p class="first last">ligand-based drug design</p></td></tr><tr><td class="NLM_term">LBRD</td><td class="NLM_def"><p class="first last">ligand-based rational design</p></td></tr><tr><td class="NLM_term">LOX-5</td><td class="NLM_def"><p class="first last">arachidonate 5-lipoxygenase</p></td></tr><tr><td class="NLM_term">LSTM</td><td class="NLM_def"><p class="first last">long short–term memory</p></td></tr><tr><td class="NLM_term">MAM</td><td class="NLM_def"><p class="first last">mitochondrial associated ER membrane</p></td></tr><tr><td class="NLM_term">MAO</td><td class="NLM_def"><p class="first last">monoamine oxidase</p></td></tr><tr><td class="NLM_term">MM</td><td class="NLM_def"><p class="first last">molecular modeling</p></td></tr><tr><td class="NLM_term">MTDL</td><td class="NLM_def"><p class="first last">multitarget directed ligand</p></td></tr><tr><td class="NLM_term">nM</td><td class="NLM_def"><p class="first last">nanomolar</p></td></tr><tr><td class="NLM_term">Nrf2</td><td class="NLM_def"><p class="first last">nuclear factor erythroid 2-related factor 2</p></td></tr><tr><td class="NLM_term">PCA</td><td class="NLM_def"><p class="first last">principal component analysis</p></td></tr><tr><td class="NLM_term">PC</td><td class="NLM_def"><p class="first last">principal component</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">Parkinson’s disease</p></td></tr><tr><td class="NLM_term">PDB</td><td class="NLM_def"><p class="first last">Protein Data Bank</p></td></tr><tr><td class="NLM_term">PGRMC1</td><td class="NLM_def"><p class="first last">progesterone receptor membrane component 1</p></td></tr><tr><td class="NLM_term">PSO</td><td class="NLM_def"><p class="first last">particle swarm optimization</p></td></tr><tr><td class="NLM_term">QSAR</td><td class="NLM_def"><p class="first last">quantitative structure–activity relationship</p></td></tr><tr><td class="NLM_term">ROS</td><td class="NLM_def"><p class="first last">reactive oxygen species</p></td></tr><tr><td class="NLM_term">RNN</td><td class="NLM_def"><p class="first last">recurrent neural networks</p></td></tr><tr><td class="NLM_term">SBDD</td><td class="NLM_def"><p class="first last">structure-based drug design</p></td></tr><tr><td class="NLM_term">SBRD</td><td class="NLM_def"><p class="first last">structure-based rational design</p></td></tr><tr><td class="NLM_term">SMILES</td><td class="NLM_def"><p class="first last">simplified molecular input line entry specification</p></td></tr><tr><td class="NLM_term"><i>t</i>-Bu</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyl</p></td></tr><tr><td class="NLM_term">THC</td><td class="NLM_def"><p class="first last">tetrahydrocannabinol</p></td></tr><tr><td class="NLM_term">TMEM97</td><td class="NLM_def"><p class="first last">transmembrane protein 97</p></td></tr><tr><td class="NLM_term">VAE</td><td class="NLM_def"><p class="first last">variational autoencoder</p></td></tr><tr><td class="NLM_term">VS</td><td class="NLM_def"><p class="first last">virtual screening</p></td></tr><tr><td class="NLM_term">ZBG</td><td class="NLM_def"><p class="first last">zinc binding group</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52825" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52825" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 230 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capparelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bush, A. I.</span></span> <span> </span><span class="NLM_article-title">Editorial: The CB2 Cannabinoid System: A New Strategy in Neurodegenerative Disorder and Neuroinflammation</span>. <i>Front. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">196</span>, <span class="refDoi"> DOI: 10.3389/fnins.2017.00196</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3389%2Ffnins.2017.00196" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=28428743" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BC1cvpslCgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=196&author=M.+Continoauthor=E.+Capparelliauthor=N.+A.+Colabufoauthor=A.+I.+Bush&title=Editorial%3A+The+CB2+Cannabinoid+System%3A+A+New+Strategy+in+Neurodegenerative+Disorder+and+Neuroinflammation&doi=10.3389%2Ffnins.2017.00196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Editorial: The CB2 Cannabinoid System: A New Strategy in Neurodegenerative Disorder and Neuroinflammation</span></div><div class="casAuthors">Contino Marialessandra; Capparelli Elena; Colabufo Nicola A; Bush Ashley I</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">196</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSeo9MkHaT4STMsgLhIoICsfW6udTcc2eY2Zmax9WHY_rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvpslCgsg%253D%253D&md5=e7885fa8e8ab93b3d78c87bfbead1f63</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2017.00196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2017.00196%26sid%3Dliteratum%253Aachs%26aulast%3DContino%26aufirst%3DM.%26aulast%3DCapparelli%26aufirst%3DE.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DBush%26aufirst%3DA.%2BI.%26atitle%3DEditorial%253A%2520The%2520CB2%2520Cannabinoid%2520System%253A%2520A%2520New%2520Strategy%2520in%2520Neurodegenerative%2520Disorder%2520and%2520Neuroinflammation%26jtitle%3DFront.%2520Neurosci.%26date%3D2017%26volume%3D11%26spage%3D196%26doi%3D10.3389%2Ffnins.2017.00196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spinelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capparelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span> <span> </span><span class="NLM_article-title">Perspectives of Cannabinoid Type 2 Receptor (CB2R) Ligands in Neurodegenerative Disorders: Structure-Affinity Relationship (SAfiR) and Structure-Activity Relationship (SAR) Studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">9913</span>– <span class="NLM_lpage">9931</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00155</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00155" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpvFeisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9913-9931&author=F.+Spinelliauthor=E.+Capparelliauthor=C.+Abateauthor=N.+A.+Colabufoauthor=M.+Contino&title=Perspectives+of+Cannabinoid+Type+2+Receptor+%28CB2R%29+Ligands+in+Neurodegenerative+Disorders%3A+Structure-Affinity+Relationship+%28SAfiR%29+and+Structure-Activity+Relationship+%28SAR%29+Studies&doi=10.1021%2Facs.jmedchem.7b00155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Perspectives of Cannabinoid Type 2 Receptor (CB2R) Ligands in Neurodegenerative Disorders: Structure-Affinity Relationship (SAfiR) and Structure-Activity Relationship (SAR) Studies</span></div><div class="casAuthors">Spinelli, Francesco; Capparelli, Elena; Abate, Carmen; Colabufo, Nicola A.; Contino, Marialessandra</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9913-9931</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Up-regulation of CB2R on activated microglial cells, the first step in neurodegeneration, has been widely demonstrated, and this finding makes the receptor a promising target in the early diagnosis and treatment of several neurodegenerative disorders such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and multiple sclerosis (MS).  The development of CB2R PET ligands could help demonstrate the neurodegenerative pathogenesis, thus providing useful tools for characterizing the role of neuroinflammation in the progression of these disorders.  CB2R agonists and inverse agonists have emerged as neuroprotective agents and CB2R agonists have entered several clin. trials.  CB2R ligands have therefore received great attention and different mol. scaffolds have been selected to target CB2R subtypes.  This perspective is focused on structure-activity relationship (SAR) and structure-affinity relationship (SAfiR) studies performed on different scaffolds with the aim to identify the mol. features useful for the design of both therapeutic and diagnostic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy3g8MJz6QjbVg90H21EOLACvtfcHk0ljvHAT5yjpWZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpvFeisbY%253D&md5=e4dfd58a0cb94a9d00203a8f32de43f8</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00155%26sid%3Dliteratum%253Aachs%26aulast%3DSpinelli%26aufirst%3DF.%26aulast%3DCapparelli%26aufirst%3DE.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DContino%26aufirst%3DM.%26atitle%3DPerspectives%2520of%2520Cannabinoid%2520Type%25202%2520Receptor%2520%2528CB2R%2529%2520Ligands%2520in%2520Neurodegenerative%2520Disorders%253A%2520Structure-Affinity%2520Relationship%2520%2528SAfiR%2529%2520and%2520Structure-Activity%2520Relationship%2520%2528SAR%2529%2520Studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D9913%26epage%3D9931%26doi%3D10.1021%2Facs.jmedchem.7b00155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, P. J.</span></span> <span> </span><span class="NLM_article-title">Editorial: The Canonical and Non-Canonical Endocannabinoid System as a Target in Cancer and Acute and Chronic Pain</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">312</span>, <span class="refDoi"> DOI: 10.3389/fphar.2020.00312</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3389%2Ffphar.2020.00312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=32218737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BB383otVygtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=312&author=M.+Continoauthor=P.+J.+McCormick&title=Editorial%3A+The+Canonical+and+Non-Canonical+Endocannabinoid+System+as+a+Target+in+Cancer+and+Acute+and+Chronic+Pain&doi=10.3389%2Ffphar.2020.00312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Editorial: The Canonical and Non-Canonical Endocannabinoid System as a Target in Cancer and Acute and Chronic Pain</span></div><div class="casAuthors">Contino Marialessandra; McCormick Peter J</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">312</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5mM0MqNbBQdts4TFFB11gfW6udTcc2ebeOV8pyFecFbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB383otVygtg%253D%253D&md5=c8e019c9707eb6449c76c17d87ff4e21</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2020.00312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2020.00312%26sid%3Dliteratum%253Aachs%26aulast%3DContino%26aufirst%3DM.%26aulast%3DMcCormick%26aufirst%3DP.%2BJ.%26atitle%3DEditorial%253A%2520The%2520Canonical%2520and%2520Non-Canonical%2520Endocannabinoid%2520System%2520as%2520a%2520Target%2520in%2520Cancer%2520and%2520Acute%2520and%2520Chronic%2520Pain%26jtitle%3DFront.%2520Pharmacol.%26date%3D2020%26volume%3D11%26spage%3D312%26doi%3D10.3389%2Ffphar.2020.00312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Howlett, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breivogel, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Childers, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deadwyler, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hampson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porrino, L. J.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid Physiology and Pharmacology: 30 Years of Progress</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">358</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2004.07.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.neuropharm.2004.07.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=15464149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotF2htLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=345-358&author=A.+C.+Howlettauthor=C.+S.+Breivogelauthor=S.+R.+Childersauthor=S.+A.+Deadwylerauthor=R.+E.+Hampsonauthor=L.+J.+Porrino&title=Cannabinoid+Physiology+and+Pharmacology%3A+30+Years+of+Progress&doi=10.1016%2Fj.neuropharm.2004.07.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid physiology and pharmacology: 30 years of progress</span></div><div class="casAuthors">Howlett, Allyn C.; Breivogel, Christopher S.; Childers, Steven R.; Deadwyler, Samuel A.; Hampson, Robert E.; Porrino, Linda J.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">345-358</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Δ9-Tetrahydrocannabinol from Cannabis sativa is mimicked by cannabimimetic analogs such as CP55940 and WIN55212-2, and antagonized by rimonabant and SR144528, through G-protein-coupled receptors, CB1 in the brain, and CB2 in the immune system.  Eicosanoids anandamide and 2-arachidonoylglycerol are the "endocannabinoid" agonists for these receptors.  CB1 receptors are abundant in basal ganglia, hippocampus and cerebellum, and their functional activity can be mapped during behaviors using cerebral metab. as the neuroimaging tool.  CB1 receptors couple to Gi/o to inhibit cAMP prodn., decrease Ca2+ conductance, increase K+ conductance, and increase mitogen-activated protein kinase activity.  Functional activation of G-proteins can be imaged by [35S]GTPγS autoradiog.  Post-synaptically generated endocannabinoids form the basis of a retrograde signaling mechanism referred to as depolarization-induced suppression of inhibition (DSI) or excitation (DSE).  Under circumstances of sufficient intracellular Ca2+ (e.g., burst activity in seizures), synthesis of endocannabinoids releases a diffusible retrograde messenger to stimulate presynaptic CB1 receptors.  This results in suppression of γ-aminobutyric acid (GABA) release, thereby relieving the post-synaptic inhibition.  Tolerance develops as neurons adjust both receptor no. and cellular signal transduction to the chronic administration of cannabinoid drugs.  Future therapeutic drug design can progress based upon our current understanding of the physiol. and pharmacol. of CB1, CB2 and related receptors.  One very important role for CB1 antagonists will be in the treatment of craving in the disease of substance abuse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK3XofJxHGFrVg90H21EOLACvtfcHk0lgzE4VaaTXFDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotF2htLw%253D&md5=33ee30df65c515d46caf49203ab885e9</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2004.07.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2004.07.030%26sid%3Dliteratum%253Aachs%26aulast%3DHowlett%26aufirst%3DA.%2BC.%26aulast%3DBreivogel%26aufirst%3DC.%2BS.%26aulast%3DChilders%26aufirst%3DS.%2BR.%26aulast%3DDeadwyler%26aufirst%3DS.%2BA.%26aulast%3DHampson%26aufirst%3DR.%2BE.%26aulast%3DPorrino%26aufirst%3DL.%2BJ.%26atitle%3DCannabinoid%2520Physiology%2520and%2520Pharmacology%253A%252030%2520Years%2520of%2520Progress%26jtitle%3DNeuropharmacology%26date%3D2004%26volume%3D47%26spage%3D345%26epage%3D358%26doi%3D10.1016%2Fj.neuropharm.2004.07.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turcotte, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchet, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laviolette, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flamand, N.</span></span> <span> </span><span class="NLM_article-title">The CB2 receptor and Its Role as a Regulator of Inflammation</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">4449</span>– <span class="NLM_lpage">4470</span>, <span class="refDoi"> DOI: 10.1007/s00018-016-2300-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1007%2Fs00018-016-2300-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=27402121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFCrtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2016&pages=4449-4470&author=C.+Turcotteauthor=M.+R.+Blanchetauthor=M.+Lavioletteauthor=N.+Flamand&title=The+CB2+receptor+and+Its+Role+as+a+Regulator+of+Inflammation&doi=10.1007%2Fs00018-016-2300-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The CB2 receptor and its role as a regulator of inflammation</span></div><div class="casAuthors">Turcotte, Caroline; Blanchet, Marie-Renee; Laviolette, Michel; Flamand, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4449-4470</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">The CB2 receptor is the peripheral receptor for cannabinoids.  It is mainly expressed in immune tissues, highlighting the possibility that the endocannabinoid system has an immunomodulatory role.  In this respect, the CB2 receptor was shown to modulate immune cell functions, both in cellulo and in animal models of inflammatory diseases.  In this regard, numerous studies have reported that mice lacking the CB2 receptor have an exacerbated inflammatory phenotype.  This suggests that therapeutic strategies aiming at modulating CB2 signaling could be promising for the treatment of various inflammatory conditions.  Herein, we review the pharmacol. of the CB2 receptor, its expression pattern, and the signaling pathways induced by its activation.  We next examine the regulation of immune cell functions by the CB2 receptor and the evidence obtained from primary human cells, immortalized cell lines, and animal models of inflammation.  Finally, we discuss the possible therapies targeting the CB2 receptor and the questions that remain to be addressed to det. whether this receptor could be a potential target to treat inflammatory disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqa70FJsUK5IbVg90H21EOLACvtfcHk0lgzE4VaaTXFDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFCrtLrN&md5=572eaca44428863b1c69dde0bca87662</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1007%2Fs00018-016-2300-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-016-2300-4%26sid%3Dliteratum%253Aachs%26aulast%3DTurcotte%26aufirst%3DC.%26aulast%3DBlanchet%26aufirst%3DM.%2BR.%26aulast%3DLaviolette%26aufirst%3DM.%26aulast%3DFlamand%26aufirst%3DN.%26atitle%3DThe%2520CB2%2520receptor%2520and%2520Its%2520Role%2520as%2520a%2520Regulator%2520of%2520Inflammation%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2016%26volume%3D73%26spage%3D4449%26epage%3D4470%26doi%3D10.1007%2Fs00018-016-2300-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cabral, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raborn, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marciano-Cabral, F.</span></span> <span> </span><span class="NLM_article-title">CB2 Receptors in the Brain: Role in Central Immune Function</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>153</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">251</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0707584</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fsj.bjp.0707584" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=18037916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovFCltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=153&publication_year=2008&pages=240-251&author=G.+A.+Cabralauthor=E.+S.+Rabornauthor=L.+Griffinauthor=J.+Dennisauthor=F.+Marciano-Cabral&title=CB2+Receptors+in+the+Brain%3A+Role+in+Central+Immune+Function&doi=10.1038%2Fsj.bjp.0707584"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">CB2 receptors in the brain: role in central immune function</span></div><div class="casAuthors">Cabral, G. A.; Raborn, E. S.; Griffin, L.; Dennis, J.; Marciano-Cabral, F.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">153</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">240-251</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Recently, it has been recognized that the cannabinoid receptor CB2 may play a functionally relevant role in the central nervous system (CNS).  This role is mediated primarily through microglia, a resident population of cells in the CNS that is morphol., phenotypically, and functionally related to macrophages.  These cells also express the cannabinoid receptor CB1.  The CB1 receptor (CB1R) is constitutively expressed at low levels while the CB2 receptor (CB2R) is expressed at higher levels and is modulated in relation to cell activation state.  The relatively high levels of the CB2R correspond with microglia being in responsive' and primed' states, suggesting the existence of a window' of functional relevance during which activation of the CB2R modulates microglial activities.  Signature activities of responsive' and primed' microglia are chemotaxis and antigen processing, resp.  The endocannabinoid 2-arachidonylglycerol has been reported to stimulate a chemotactic response from these cells through the CB2R.  In contrast, we have shown in vivo and in vitro that the exogenous cannabinoids delta-9-tetrahydrocannabinol and CP55940 inhibit the chemotactic response of microglia to Acanthamoeba culbertsoni, an opportunistic pathogen that is the causative agent of Granulomatous Amoebic Encephalitis, through activation of the CB2R.  It is postulated that these exogenous cannabinoids superimpose an inhibitory effect on pro-chemotactic endocannabinoids that are elicited in response to Acanthamoeba.  Furthermore, the collective results suggest that the CB2R plays a crit. immune functional role in the CNS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtGbYSu3oih7Vg90H21EOLACvtfcHk0lgzE4VaaTXFDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovFCltw%253D%253D&md5=c6b41ff809a36b2b29b327cd9e9f0e68</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0707584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0707584%26sid%3Dliteratum%253Aachs%26aulast%3DCabral%26aufirst%3DG.%2BA.%26aulast%3DRaborn%26aufirst%3DE.%2BS.%26aulast%3DGriffin%26aufirst%3DL.%26aulast%3DDennis%26aufirst%3DJ.%26aulast%3DMarciano-Cabral%26aufirst%3DF.%26atitle%3DCB2%2520Receptors%2520in%2520the%2520Brain%253A%2520Role%2520in%2520Central%2520Immune%2520Function%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D153%26spage%3D240%26epage%3D251%26doi%3D10.1038%2Fsj.bjp.0707584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heneka, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kummer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latz, E.</span></span> <span> </span><span class="NLM_article-title">Innate Immune Activation in Neurodegenerative Disease</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">463</span>– <span class="NLM_lpage">477</span>, <span class="refDoi"> DOI: 10.1038/nri3705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fnri3705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=24962261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVemu7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=463-477&author=M.+T.+Henekaauthor=M.+P.+Kummerauthor=E.+Latz&title=Innate+Immune+Activation+in+Neurodegenerative+Disease&doi=10.1038%2Fnri3705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Innate immune activation in neurodegenerative disease</span></div><div class="casAuthors">Heneka, Michael T.; Kummer, Markus P.; Latz, Eicke</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">463-477</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The triggering of innate immune mechanisms is emerging as a crucial component of major neurodegenerative diseases.  Microglia and other cell types in the brain can be activated in response to misfolded proteins or aberrantly localized nucleic acids.  This diverts microglia from their physiol. and beneficial functions, and leads to their sustained release of pro-inflammatory mediators.  In this Review, we discuss how the activation of innate immune signalling pathways - in particular, the NOD-, LRR- and pyrin domain-contg. 3 (NLRP3) inflammasome - by aberrant host proteins may be a common step in the development of diverse neurodegenerative disorders.  During chronic activation of microglia, the sustained exposure of neurons to pro-inflammatory mediators can cause neuronal dysfunction and contribute to cell death.  As chronic neuroinflammation is obsd. at relatively early stages of neurodegenerative disease, targeting the mechanisms that drive this process may be useful for diagnostic and therapeutic purposes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3f5cVxCKo5bVg90H21EOLACvtfcHk0lgzE4VaaTXFDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVemu7zJ&md5=9050d14e40248997e8c9dd567a1c59b8</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnri3705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri3705%26sid%3Dliteratum%253Aachs%26aulast%3DHeneka%26aufirst%3DM.%2BT.%26aulast%3DKummer%26aufirst%3DM.%2BP.%26aulast%3DLatz%26aufirst%3DE.%26atitle%3DInnate%2520Immune%2520Activation%2520in%2520Neurodegenerative%2520Disease%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2014%26volume%3D14%26spage%3D463%26epage%3D477%26doi%3D10.1038%2Fnri3705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGeer, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGeer, E.</span></span> <span> </span><span class="NLM_article-title">Conquering Alzheimer’s Disease by Self Treatment</span>. <i>J. Alzheimer's Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">S361</span>– <span class="NLM_lpage">S363</span>, <span class="refDoi"> DOI: 10.3233/JAD-179913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3233%2FJAD-179913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=29562519" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2018&pages=S361-S363&author=P.+L.+McGeerauthor=E.+McGeer&title=Conquering+Alzheimer%E2%80%99s+Disease+by+Self+Treatment&doi=10.3233%2FJAD-179913"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.3233%2FJAD-179913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-179913%26sid%3Dliteratum%253Aachs%26aulast%3DMcGeer%26aufirst%3DP.%2BL.%26aulast%3DMcGeer%26aufirst%3DE.%26atitle%3DConquering%2520Alzheimer%25E2%2580%2599s%2520Disease%2520by%2520Self%2520Treatment%26jtitle%3DJ.%2520Alzheimer%2527s%2520Dis.%26date%3D2018%26volume%3D64%26spage%3DS361%26epage%3DS363%26doi%3D10.3233%2FJAD-179913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cassano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calcagnini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pace, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Marco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaetani, S.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target</span>. <i>Front. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">30</span>, <span class="refDoi"> DOI: 10.3389/fnins.2017.00030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3389%2Ffnins.2017.00030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=28210207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BC1c3nvV2msA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=30&author=T.+Cassanoauthor=S.+Calcagniniauthor=L.+Paceauthor=F.+De+Marcoauthor=A.+Romanoauthor=S.+Gaetani&title=Cannabinoid+Receptor+2+Signaling+in+Neurodegenerative+Disorders%3A+From+Pathogenesis+to+a+Promising+Therapeutic+Target&doi=10.3389%2Ffnins.2017.00030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target</span></div><div class="casAuthors">Cassano Tommaso; Pace Lorenzo; Calcagnini Silvio; Romano Adele; Gaetani Silvana; De Marco Federico</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">30</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">As a consequence of an increasingly aging population, the number of people affected by neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease and Huntington's disease, is rapidly increasing.  Although the etiology of these diseases has not been completely defined, common molecular mechanisms including neuroinflammation, excitotoxicity and mitochondrial dysfunction have been confirmed and can be targeted therapeutically.  Moreover, recent studies have shown that endogenous cannabinoid signaling plays a number of modulatory roles throughout the central nervous system (CNS), including the neuroinflammation and neurogenesis.  In particular, the up-regulation of type-2 cannabinoid (CB2) receptors has been found in a number of neurodegenerative disorders.  Thus, the modulation of CB2 receptor signaling may represent a promising therapeutic target with minimal psychotropic effects that can be used to modulate endocannabinoid-based therapeutic approaches and to reduce neuronal degeneration.  For these reasons this review will focus on the CB2 receptor as a promising pharmacological target in a number of neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT1_cRDLQozygqdek-gHSrIfW6udTcc2eZmgeuDEmA7fLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3nvV2msA%253D%253D&md5=138c88d7d465474f6f6a067fd6d0ffe9</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2017.00030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2017.00030%26sid%3Dliteratum%253Aachs%26aulast%3DCassano%26aufirst%3DT.%26aulast%3DCalcagnini%26aufirst%3DS.%26aulast%3DPace%26aufirst%3DL.%26aulast%3DDe%2BMarco%26aufirst%3DF.%26aulast%3DRomano%26aufirst%3DA.%26aulast%3DGaetani%26aufirst%3DS.%26atitle%3DCannabinoid%2520Receptor%25202%2520Signaling%2520in%2520Neurodegenerative%2520Disorders%253A%2520From%2520Pathogenesis%2520to%2520a%2520Promising%2520Therapeutic%2520Target%26jtitle%3DFront.%2520Neurosci.%26date%3D2017%26volume%3D11%26spage%3D30%26doi%3D10.3389%2Ffnins.2017.00030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cabral, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin-Thomas, L.</span></span> <span> </span><span class="NLM_article-title">Emerging Role of the Cannabinoid Receptor CB2 in Immune Regulation: Therapeutic Prospects for Neuroinflammation</span>. <i>Expert Rev. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">e3</span> <span class="refDoi"> DOI: 10.1017/S1462399409000957</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1017%2FS1462399409000957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=19152719" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&author=G.+A.+Cabralauthor=L.+Griffin-Thomas&title=Emerging+Role+of+the+Cannabinoid+Receptor+CB2+in+Immune+Regulation%3A+Therapeutic+Prospects+for+Neuroinflammation&doi=10.1017%2FS1462399409000957"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1017%2FS1462399409000957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1462399409000957%26sid%3Dliteratum%253Aachs%26aulast%3DCabral%26aufirst%3DG.%2BA.%26aulast%3DGriffin-Thomas%26aufirst%3DL.%26atitle%3DEmerging%2520Role%2520of%2520the%2520Cannabinoid%2520Receptor%2520CB2%2520in%2520Immune%2520Regulation%253A%2520Therapeutic%2520Prospects%2520for%2520Neuroinflammation%26jtitle%3DExpert%2520Rev.%2520Mol.%2520Med.%26date%3D2009%26volume%3D11%26doi%3D10.1017%2FS1462399409000957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krivokuca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casado, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canela, E.</span></span> <span> </span><span class="NLM_article-title">The Endocannabinoid System as a Target in Cancer Diseases: Are We There Yet?</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">339</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.00339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3389%2Ffphar.2019.00339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=31024307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVGlsLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=339&author=E.+Morenoauthor=M.+Cavicauthor=A.+Krivokucaauthor=V.+Casadoauthor=E.+Canela&title=The+Endocannabinoid+System+as+a+Target+in+Cancer+Diseases%3A+Are+We+There+Yet%3F&doi=10.3389%2Ffphar.2019.00339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The endocannabinoid system as a target in cancer diseases: are we there yet?</span></div><div class="casAuthors">Moreno, Estefania; Cavic, Milena; Krivokuca, Ana; Casado, Vicent; Canela, Enric</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">339</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  The endocannabinoid system (ECS) has been placed in the anti-cancer spotlight in the last decade.  The immense data load published on its dual role in both tumorigenesis and inhibition of tumor growth and metastatic spread has transformed the cannabinoid receptors CB1 (CB1R) and CB2 (CB2R), and other members of the endocannabinoid-like system, into attractive new targets for the treatment of various cancer subtypes.  Although the clin. use of cannabinoids has been extensively documented in the palliative setting, clin. trials on their application as anti-cancer drugs are still ongoing.  As drug repurposing is significantly faster and more economical than de novo introduction of a new drug into the clinic, there is hope that the existing pharmacokinetic and safety data on the ECS ligands will contribute to their successful translation into oncol. healthcare.  CB1R and CB2R are members of a large family of membrane proteins called G protein-coupled receptors (GPCR).  GPCRs can form homodimers, heterodimers and higher order oligomers with other GPCRs or non-GPCRs.  Currently, several CB1R and CB2R-contg. heteromers have been reported and, in cancer cells, CB2R form heteromers with the G protein-coupled chemokine receptor CXCR4, the G protein-coupled receptor 55 (GPR55) and the tyrosine kinase receptor (TKR) human V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2).  These protein complexes possess unique pharmacol. and signaling properties, and their modulation might affect the antitumoral activity of the ECS.  This review will explore the potential of the endocannabinoid network in the anti-cancer setting as well as the clin. and ethical pitfalls behind it, and will develop on the value of cannabinoid receptor heteromers as potential new targets for anti-cancer therapies and as prognostic biomarkers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLnxgEkYRlV7Vg90H21EOLACvtfcHk0lgczlWsqoekiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVGlsLfO&md5=799d02287d5c179eba3e7cd79857667a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.00339%26sid%3Dliteratum%253Aachs%26aulast%3DMoreno%26aufirst%3DE.%26aulast%3DCavic%26aufirst%3DM.%26aulast%3DKrivokuca%26aufirst%3DA.%26aulast%3DCasado%26aufirst%3DV.%26aulast%3DCanela%26aufirst%3DE.%26atitle%3DThe%2520Endocannabinoid%2520System%2520as%2520a%2520Target%2520in%2520Cancer%2520Diseases%253A%2520Are%2520We%2520There%2520Yet%253F%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D339%26doi%3D10.3389%2Ffphar.2019.00339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Capozzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattei, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martellucci, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manganelli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccomanni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garofalo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorice, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misasi, R.</span></span> <span> </span><span class="NLM_article-title">Anti-Proliferative Properties and Proapoptotic Function of New CB2 Selective Cannabinoid Receptor Agonist in Jurkat Leukemia Cells</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1958</span>, <span class="refDoi"> DOI: 10.3390/ijms19071958</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3390%2Fijms19071958" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFKlt7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=1958&author=A.+Capozziauthor=V.+Matteiauthor=S.+Martellucciauthor=V.+Manganelliauthor=G.+Saccomanniauthor=T.+Garofaloauthor=M.+Soriceauthor=C.+Maneraauthor=R.+Misasi&title=Anti-Proliferative+Properties+and+Proapoptotic+Function+of+New+CB2+Selective+Cannabinoid+Receptor+Agonist+in+Jurkat+Leukemia+Cells&doi=10.3390%2Fijms19071958"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-proliferative properties and proapoptotic function of new CB2 selective cannabinoid receptor agonist in Jurkat leukemia cells</span></div><div class="casAuthors">Capozzi, Antonella; Mattei, Vincenzo; Martellucci, Stefano; Manganelli, Valeria; Saccomanni, Giuseppe; Garofalo, Tina; Sorice, Maurizio; Manera, Clementina; Misasi, Roberta</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1958/1-1958/20</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Several studies demonstrated that cannabinoids reduce tumor growth, inhibit angiogenesis, and decrease cancer cell migration.  As these mols. are well tolerated, it would be interesting to investigate the potential benefit of newly synthesized compds., binding cannabinoid receptors (CBRs).  In this study, we describe the synthesis and biol. effect of 2-oxo-1,8-naphthyridine-3-carboxamide deriv. LV50, a new compd. with high CB2 receptor (CB2R) affinity.  We demonstrated that it decreases viability of Jurkat leukemia cells, evaluated by Trypan Blue and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), but mainly induces a proapoptotic effect.  We obsd. an increase of a hypodiploid peak by propidium iodide staining and changes in nuclear morphol. by Hoechst 33258.  These data were confirmed by a significant increase of Annexin V staining, cleavage of the nuclear enzyme poly(ADP-ribose)-polymerase (PARP), and caspases activation.  In addn., in order to exclude that LV50 non-specifically triggers death of all normal leukocytes, we tested the new compd. on normal peripheral blood lymphocytes, excluding the idea of general cytotoxicity.  To characterize the involvement of CB2R in the anti-proliferative and proapoptotic effect of LV50, cells were pretreated with a specific CB2R antagonist and the obtained data showed reverse results.  Thus, we suggest a link between inhibition of cell survival and proapoptotic activity of the new compd. that elicits this effect as selective CB2R agonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1FtJUxLHRiLVg90H21EOLACvtfcHk0lgczlWsqoekiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFKlt7rM&md5=48bdbd3800b0a643fabb36f62178eaf0</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.3390%2Fijms19071958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms19071958%26sid%3Dliteratum%253Aachs%26aulast%3DCapozzi%26aufirst%3DA.%26aulast%3DMattei%26aufirst%3DV.%26aulast%3DMartellucci%26aufirst%3DS.%26aulast%3DManganelli%26aufirst%3DV.%26aulast%3DSaccomanni%26aufirst%3DG.%26aulast%3DGarofalo%26aufirst%3DT.%26aulast%3DSorice%26aufirst%3DM.%26aulast%3DManera%26aufirst%3DC.%26aulast%3DMisasi%26aufirst%3DR.%26atitle%3DAnti-Proliferative%2520Properties%2520and%2520Proapoptotic%2520Function%2520of%2520New%2520CB2%2520Selective%2520Cannabinoid%2520Receptor%2520Agonist%2520in%2520Jurkat%2520Leukemia%2520Cells%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2018%26volume%3D19%26spage%3D1958%26doi%3D10.3390%2Fijms19071958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guindon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohmann, A. G.</span></span> <span> </span><span class="NLM_article-title">The Endocannabinoid System and Cancer: Therapeutic Implication</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">1447</span>– <span class="NLM_lpage">1463</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01327.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1111%2Fj.1476-5381.2011.01327.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=21410463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3MXps1Sju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2011&pages=1447-1463&author=J.+Guindonauthor=A.+G.+Hohmann&title=The+Endocannabinoid+System+and+Cancer%3A+Therapeutic+Implication&doi=10.1111%2Fj.1476-5381.2011.01327.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The endocannabinoid system and cancer: therapeutic implication</span></div><div class="casAuthors">Guindon, Josee; Hohmann, Andrea G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1447-1463</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The endocannabinoid system is implicated in a variety of physiol. and pathol. conditions (inflammation, immunomodulation, analgesia, cancer and others).  The main active ingredient of cannabis, Δ9-tetrahydrocannabinol (Δ9-THC), produces its effects through activation of CB1 and CB2 receptors.  CB1 receptors are expressed at high levels in the central nervous system (CNS), whereas CB2 receptors are concd. predominantly, although not exclusively, in cells of the immune system.  Endocannabinoids are endogenous lipid-signaling mols. that are generated in the cell membrane from phospholipid precursors.  The 2 best characterized endocannabinoids identified to date are anandamide (AEA) and 2-arachidonoylglycerol (2-AG).  Here we review the relationship between the endocannabinoid system and anti-tumor actions (inhibition of cell proliferation and migration, induction of apoptosis, redn. of tumor growth) of the cannabinoids in different types of cancer.  This review will focus on examg. how activation of the endocannabinoid system impacts breast, prostate and bone cancers in both in vitro and in vivo systems.  The therapeutic potential of cannabinoids for cancer, as identified in clin. trials, is also discussed.  Identification of safe and effective treatments to manage and improve cancer therapy is crit. to improve quality of life and reduce unnecessary suffering in cancer patients.  In this regard, cannabis-like compds. offer therapeutic potential for the treatment of breast, prostate and bone cancer in patients.  Further basic research on anti-cancer properties of cannabinoids as well as clin. trials of cannabinoid therapeutic efficacy in breast, prostate and bone cancer is therefore warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_omB4D6NVN7Vg90H21EOLACvtfcHk0lgczlWsqoekiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXps1Sju7g%253D&md5=fb5ec332b401d12e51c229d291c1909d</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01327.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01327.x%26sid%3Dliteratum%253Aachs%26aulast%3DGuindon%26aufirst%3DJ.%26aulast%3DHohmann%26aufirst%3DA.%2BG.%26atitle%3DThe%2520Endocannabinoid%2520System%2520and%2520Cancer%253A%2520Therapeutic%2520Implication%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D163%26spage%3D1447%26epage%3D1463%26doi%3D10.1111%2Fj.1476-5381.2011.01327.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman, M.</span></span> <span> </span><span class="NLM_article-title">Anticancer Mechanisms of Cannabinoids</span>. <i>Curr. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">S23</span>– <span class="NLM_lpage">S32</span>, <span class="refDoi"> DOI: 10.3747/co.23.3080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3747%2Fco.23.3080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=27022311" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=S23-S32&author=G.+Velascoauthor=C.+Sanchezauthor=M.+Guzman&title=Anticancer+Mechanisms+of+Cannabinoids&doi=10.3747%2Fco.23.3080"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.3747%2Fco.23.3080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3747%252Fco.23.3080%26sid%3Dliteratum%253Aachs%26aulast%3DVelasco%26aufirst%3DG.%26aulast%3DSanchez%26aufirst%3DC.%26aulast%3DGuzman%26aufirst%3DM.%26atitle%3DAnticancer%2520Mechanisms%2520of%2520Cannabinoids%26jtitle%3DCurr.%2520Oncol.%26date%3D2016%26volume%3D23%26spage%3DS23%26epage%3DS32%26doi%3D10.3747%2Fco.23.3080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aso, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, I.</span></span> <span> </span><span class="NLM_article-title">CB2 Cannabinoid Receptor As Potential Target against Alzheimer’s Disease</span>. <i>Front. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">243</span>, <span class="refDoi"> DOI: 10.3389/fnins.2016.00243</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3389%2Ffnins.2016.00243" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=27303261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BC2s7gtlGktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=243&author=E.+Asoauthor=I.+Ferrer&title=CB2+Cannabinoid+Receptor+As+Potential+Target+against+Alzheimer%E2%80%99s+Disease&doi=10.3389%2Ffnins.2016.00243"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">CB2 Cannabinoid Receptor As Potential Target against Alzheimer's Disease</span></div><div class="casAuthors">Aso Ester; Ferrer Isidro</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">243</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">The CB2 receptor is one of the components of the endogenous cannabinoid system, a complex network of signaling molecules and receptors involved in the homeostatic control of several physiological functions.  Accumulated evidence suggests a role for CB2 receptors in Alzheimer's disease (AD) and indicates their potential as a therapeutic target against this neurodegenerative disease.  Levels of CB2 receptors are significantly increased in post-mortem AD brains, mainly in microglia surrounding senile plaques, and their expression levels correlate with the amounts of Aβ42 and β-amyloid plaque deposition.  Moreover, several studies on animal models of AD have demonstrated that specific CB2 receptor agonists, which are devoid of psychoactive effects, reduce AD-like pathology, resulting in attenuation of the inflammation associated with the disease but also modulating Aβ and tau aberrant processing, among other effects.  CB2 receptor activation also improves cognitive impairment in animal models of AD.  This review discusses available data regarding the role of CB2 receptors in AD and the potential usefulness of specific agonists of these receptors against AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQFAQnNocm8nuWhZTslLrfffW6udTcc2eaQ0N96YlmRgLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7gtlGktA%253D%253D&md5=b3065b406c0d13c0f6493ddf33f3018a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2016.00243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2016.00243%26sid%3Dliteratum%253Aachs%26aulast%3DAso%26aufirst%3DE.%26aulast%3DFerrer%26aufirst%3DI.%26atitle%3DCB2%2520Cannabinoid%2520Receptor%2520As%2520Potential%2520Target%2520against%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DFront.%2520Neurosci.%26date%3D2016%26volume%3D10%26spage%3D243%26doi%3D10.3389%2Ffnins.2016.00243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aso, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, I.</span></span> <span> </span><span class="NLM_article-title">Cannabinoids for Treatment of Alzheimer’s Disease: Moving toward the Clinic</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">37</span>, <span class="refDoi"> DOI: 10.3389/fphar.2014.00037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3389%2Ffphar.2014.00037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=24634659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BC2cflslSltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=37&author=E.+Asoauthor=I.+Ferrer&title=Cannabinoids+for+Treatment+of+Alzheimer%E2%80%99s+Disease%3A+Moving+toward+the+Clinic&doi=10.3389%2Ffphar.2014.00037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic</span></div><div class="casAuthors">Aso Ester; Ferrer Isidre</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">37</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">The limited effectiveness of current therapies against Alzheimer's disease (AD) highlights the need for intensifying research efforts devoted to developing new agents for preventing or retarding the disease process.  During the last few years, targeting the endogenous cannabinoid system has emerged as a potential therapeutic approach to treat Alzheimer.  The endocannabinoid system is composed by a number of cannabinoid receptors, including the well-characterized CB1 and CB2 receptors, with their endogenous ligands and the enzymes related to the synthesis and degradation of these endocannabinoid compounds.  Several findings indicate that the activation of both CB1 and CB2 receptors by natural or synthetic agonists, at non-psychoactive doses, have beneficial effects in Alzheimer experimental models by reducing the harmful β-amyloid peptide action and tau phosphorylation, as well as by promoting the brain's intrinsic repair mechanisms.  Moreover, endocannabinoid signaling has been demonstrated to modulate numerous concomitant pathological processes, including neuroinflammation, excitotoxicity, mitochondrial dysfunction, and oxidative stress.  The present paper summarizes the main experimental studies demonstrating the polyvalent properties of cannabinoid compounds for the treatment of AD, which together encourage progress toward a clinical trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQCYty_MiAZP50d-O_J5C0AfW6udTcc2eaQ0N96YlmRgLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflslSltg%253D%253D&md5=18ab4f10157b9f6be7cf343ed9c3bde5</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2014.00037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2014.00037%26sid%3Dliteratum%253Aachs%26aulast%3DAso%26aufirst%3DE.%26aulast%3DFerrer%26aufirst%3DI.%26atitle%3DCannabinoids%2520for%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%253A%2520Moving%2520toward%2520the%2520Clinic%26jtitle%3DFront.%2520Pharmacol.%26date%3D2014%26volume%3D5%26spage%3D37%26doi%3D10.3389%2Ffphar.2014.00037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bie, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naguib, M.</span></span> <span> </span><span class="NLM_article-title">Activation of the CB2 Receptor System Reverses Amyloid-Induced Memory Deficiency</span>. <i>Neurobiol. Aging</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">791</span>– <span class="NLM_lpage">804</span>, <span class="refDoi"> DOI: 10.1016/j.neurobiolaging.2012.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.neurobiolaging.2012.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=22795792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVektLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=791-804&author=J.+Wuauthor=B.+Bieauthor=H.+Yangauthor=J.+J.+Xuauthor=D.+L.+Brownauthor=M.+Naguib&title=Activation+of+the+CB2+Receptor+System+Reverses+Amyloid-Induced+Memory+Deficiency&doi=10.1016%2Fj.neurobiolaging.2012.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the CB2 receptor system reverses amyloid-induced memory deficiency</span></div><div class="casAuthors">Wu, Jiang; Bie, Bihua; Yang, Hui; Xu, Jijun J.; Brown, David L.; Naguib, Mohamed</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Aging</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">791-804</span>CODEN:
                <span class="NLM_cas:coden">NEAGDO</span>;
        ISSN:<span class="NLM_cas:issn">0197-4580</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Cannabinoid type 2 (CB2) agonists are neuroprotective and appear to play modulatory roles in neurodegenerative processes in Alzheimer's disease.  We have studied the effect of 1-((3-benzyl-3-methyl-2,3-dihydro-1-benzofuran-6-yl) carbonyl) piperidine (MDA7)-a novel selective CB2 agonist that lacks psychoactivity-on ameliorating the neuroinflammatory process, synaptic dysfunction, and cognitive impairment induced by bilateral microinjection of amyloid-β (Aβ)1-40 fibrils into the hippocampal CA1 area of rats.  In rats injected with Aβ1-40 fibrils, compared with the administration of i.p. saline for 14 days, treatment with 15 mg/kg of i.p. MDA7 daily for 14 days (1) ameliorated the expression of CD11b (microglia marker) and glial fibrillary acidic protein (astrocyte marker), (2) decreased the secretion of interleukin-1β, (3) decreased the upsurge of CB2 receptors, (4) promoted Aβ clearance, and (5) restored synaptic plasticity, cognition, and memory.  Our findings suggest that MDA7 is an innovative therapeutic approach for the treatment of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqekBBhIM0ej7Vg90H21EOLACvtfcHk0liDn2NDMEA1xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVektLnO&md5=ee0c45a830bc6f4d2236ccfcee75b2ad</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.neurobiolaging.2012.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neurobiolaging.2012.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DBie%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DJ.%2BJ.%26aulast%3DBrown%26aufirst%3DD.%2BL.%26aulast%3DNaguib%26aufirst%3DM.%26atitle%3DActivation%2520of%2520the%2520CB2%2520Receptor%2520System%2520Reverses%2520Amyloid-Induced%2520Memory%2520Deficiency%26jtitle%3DNeurobiol.%2520Aging%26date%3D2013%26volume%3D34%26spage%3D791%26epage%3D804%26doi%3D10.1016%2Fj.neurobiolaging.2012.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Concannon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowd, E.</span></span> <span> </span><span class="NLM_article-title">Cannabinoids in Parkinson’s Disease</span>. <i>Cannabinoids Neurol. Ment. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1016/B978-0-12-417041-4.00003-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2FB978-0-12-417041-4.00003-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2015&pages=35-59&author=R.+Concannonauthor=D.+P.+Finnauthor=E.+Dowd&title=Cannabinoids+in+Parkinson%E2%80%99s+Disease&doi=10.1016%2FB978-0-12-417041-4.00003-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-417041-4.00003-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-417041-4.00003-5%26sid%3Dliteratum%253Aachs%26aulast%3DConcannon%26aufirst%3DR.%26aulast%3DFinn%26aufirst%3DD.%2BP.%26aulast%3DDowd%26aufirst%3DE.%26atitle%3DCannabinoids%2520in%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DCannabinoids%2520Neurol.%2520Ment.%2520Dis.%26date%3D2015%26volume%3D2%26spage%3D35%26epage%3D59%26doi%3D10.1016%2FB978-0-12-417041-4.00003-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seely, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crow, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prather, P. L.</span></span> <span> </span><span class="NLM_article-title">The CB2 Cannabinoid Agonist AM-1241 Prolongs Survival in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis When Initiated at Symptom Onset</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2006.04346.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1111%2Fj.1471-4159.2006.04346.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=17241118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksFSqsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2007&pages=87-98&author=J.+L.+Shoemakerauthor=K.+A.+Seelyauthor=R.+L.+Reedauthor=J.+P.+Crowauthor=P.+L.+Prather&title=The+CB2+Cannabinoid+Agonist+AM-1241+Prolongs+Survival+in+a+Transgenic+Mouse+Model+of+Amyotrophic+Lateral+Sclerosis+When+Initiated+at+Symptom+Onset&doi=10.1111%2Fj.1471-4159.2006.04346.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset</span></div><div class="casAuthors">Shoemaker, Jennifer L.; Seely, Kathryn A.; Reed, Ronald L.; Crow, John P.; Prather, Paul L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-98</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive motor neuron loss, paralysis and death within 2-5 years of diagnosis.  Currently, no effective pharmacol. agents exist for the treatment of this devastating disease.  Neuroinflammation may accelerate the progression of ALS.  Cannabinoids produce anti-inflammatory actions via cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2), and delay the progression of neuroinflammatory diseases.  Addnl., CB2 receptors, which normally exist primarily in the periphery, are dramatically up-regulated in inflamed neural tissues assocd. with CNS disorders.  In G93A-SOD1 mutant mice, the most well-characterized animal model of ALS, endogenous cannabinoids are elevated in spinal cords of symptomatic mice.  Furthermore, treatment with non-selective cannabinoid partial agonists prior to, or upon, symptom appearance minimally delays disease onset and prolongs survival through undefined mechanisms.  We demonstrate that mRNA, receptor binding and function of CB2, but not CB1, receptors are dramatically and selectively up-regulated in spinal cords of G93A-SOD1 mice in a temporal pattern paralleling disease progression.  More importantly, daily injections of the selective CB2 agonist AM-1241, initiated at symptom onset, increase the survival interval after disease onset by 56%.  Therefore, CB2 agonists may slow motor neuron degeneration and preserve motor function, and represent a novel therapeutic modality for treatment of ALS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0tTHgAMzBILVg90H21EOLACvtfcHk0lgyaxz9ZFCTzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksFSqsb4%253D&md5=3d05001d4f2eb1ae8e10e1986b1d153c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2006.04346.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2006.04346.x%26sid%3Dliteratum%253Aachs%26aulast%3DShoemaker%26aufirst%3DJ.%2BL.%26aulast%3DSeely%26aufirst%3DK.%2BA.%26aulast%3DReed%26aufirst%3DR.%2BL.%26aulast%3DCrow%26aufirst%3DJ.%2BP.%26aulast%3DPrather%26aufirst%3DP.%2BL.%26atitle%3DThe%2520CB2%2520Cannabinoid%2520Agonist%2520AM-1241%2520Prolongs%2520Survival%2520in%2520a%2520Transgenic%2520Mouse%2520Model%2520of%2520Amyotrophic%2520Lateral%2520Sclerosis%2520When%2520Initiated%2520at%2520Symptom%2520Onset%26jtitle%3DJ.%2520Neurochem.%26date%3D2007%26volume%3D101%26spage%3D87%26epage%3D98%26doi%3D10.1111%2Fj.1471-4159.2006.04346.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spinelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giampietro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanachi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riganti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopecka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abatematteo, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangiatordi, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolotti, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brea, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loza, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infantino, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Fluorescent Ligands for the Detection of Cannabinoid Type 2 Receptor (CB2R)</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>188</i></span>,  <span class="NLM_fpage">112037</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2020.112037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=31954990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFCqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2020&pages=112037&author=F.+Spinelliauthor=R.+Giampietroauthor=A.+Stefanachiauthor=C.+Rigantiauthor=J.+Kopeckaauthor=F.+S.+Abatematteoauthor=F.+Leonettiauthor=N.+A.+Colabufoauthor=G.+F.+Mangiatordiauthor=O.+Nicolottiauthor=M.+G.+Perroneauthor=J.+Breaauthor=M.+I.+Lozaauthor=V.+Infantinoauthor=C.+Abateauthor=M.+Contino&title=Design+and+Synthesis+of+Fluorescent+Ligands+for+the+Detection+of+Cannabinoid+Type+2+Receptor+%28CB2R%29&doi=10.1016%2Fj.ejmech.2020.112037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of fluorescent ligands for the detection of cannabinoid type 2 receptor (CB2R)</span></div><div class="casAuthors">Spinelli, Francesco; Giampietro, Roberta; Stefanachi, Angela; Riganti, Chiara; Kopecka, Joanna; Abatematteo, Francesca Serena; Leonetti, Francesco; Colabufo, Nicola Antonio; Mangiatordi, Giuseppe Felice; Nicolotti, Orazio; Perrone, Maria Grazia; Brea, Jose; Loza, Maria Isabel; Infantino, Vittoria; Abate, Carmen; Contino, Marialessandra</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112037</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The Cannabinoid 2 receptor, CB2R, belonging to the endocannabinoid system, ECS, is involved in the first steps of neurodegeneration and cancer evolution and progression and thus its modulation may be exploited in the therapeutic and diagnostic fields.  However, CB2Rs distribution and signaling pathways in physiol. and pathol. conditions are still controversial mainly because of the lack of reliable diagnostic tools.  With the aim to produce green and safe systems to detect CB2R, we designed a series of fluorescent ligands with three different green fluorescent moieties (4-dimethylaminophthalimide, 4-DMAP, 7-nitro-4-yl-aminobenzoxadiazole, NBD, and Fluorescein-thiourea, FTU) linked to the N1-position of the CB2R pharmacophore N-adamantyl-4-oxo-1,4-dihydroquinoline-3-carboxamide through polymethylene chains.  Compd. 28 emerged for its compromise between good pharmacodynamic properties (CB2R Ki = 130 nM and no affinity vs the other subtype CB1R) and optimal fluorescent spectroscopic properties.  Therefore, compd. 28 was studied through FACS (satn. and competitive binding studies) and fluorescence microscopy (visualization and competitive binding) in engineered cells (CB2R-HEK293 cells) and in diverse tumor cells.  The fluoligand binding assays were successfully set up, and affinity values for the two ref. compds. GW405833 and WIN55,212-2, comparable to the values obtained by radioligand binding assays, were obtained.  Fluoligand 28 also allowed the detection of the presence and quantification of the CB2R in the same cell lines.  The interactions of compd. 28 within the CB2R binding site were also investigated by mol. docking simulations, and indications for the improvement of the CB2R affinity of this class of compds. were provided.  Overall, the results obtained through these studies propose compd. 28 as a safe and green alternative to the commonly used radioligands for in vitro investigations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZMTpwQWQXdrVg90H21EOLACvtfcHk0lgyaxz9ZFCTzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFCqtbs%253D&md5=6288c692b0e56765fe08b24daadc8ee0</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112037%26sid%3Dliteratum%253Aachs%26aulast%3DSpinelli%26aufirst%3DF.%26aulast%3DGiampietro%26aufirst%3DR.%26aulast%3DStefanachi%26aufirst%3DA.%26aulast%3DRiganti%26aufirst%3DC.%26aulast%3DKopecka%26aufirst%3DJ.%26aulast%3DAbatematteo%26aufirst%3DF.%2BS.%26aulast%3DLeonetti%26aufirst%3DF.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DMangiatordi%26aufirst%3DG.%2BF.%26aulast%3DNicolotti%26aufirst%3DO.%26aulast%3DPerrone%26aufirst%3DM.%2BG.%26aulast%3DBrea%26aufirst%3DJ.%26aulast%3DLoza%26aufirst%3DM.%2BI.%26aulast%3DInfantino%26aufirst%3DV.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DContino%26aufirst%3DM.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Fluorescent%2520Ligands%2520for%2520the%2520Detection%2520of%2520Cannabinoid%2520Type%25202%2520Receptor%2520%2528CB2R%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D188%26spage%3D112037%26doi%3D10.1016%2Fj.ejmech.2020.112037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kisková, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mungenast, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suváková, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jäger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thalhammer, T.</span></span> <span> </span><span class="NLM_article-title">Future Aspects for Cannabinoids in Breast Cancer Therapy</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1673</span>, <span class="refDoi"> DOI: 10.3390/ijms20071673</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3390%2Fijms20071673" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BB3cXosVOqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1673&author=T.+Kiskov%C3%A1author=F.+Mungenastauthor=M.+Suv%C3%A1kov%C3%A1author=W.+J%C3%A4gerauthor=T.+Thalhammer&title=Future+Aspects+for+Cannabinoids+in+Breast+Cancer+Therapy&doi=10.3390%2Fijms20071673"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Future aspects for cannabinoids in breast cancer therapy</span></div><div class="casAuthors">Kiskova, Terezia; Mungenast, Felicitas; Suvakova, Maria; Jager, Walter; Thalhammer, Theresia</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1673</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Cannabinoids (CBs) from Cannabis sativa provide relief for tumor-assocd. symptoms (including nausea, anorexia, and neuropathic pain) in the palliative treatment of cancer patients.  Addnl., they may decelerate tumor progression in breast cancer patients.  Indeed, the psychoactive delta-9-tetrahydrocannabinol (THC), non-psychoactive cannabidiol (CBD) and other CBs inhibited disease progression in breast cancer models.  The effects of CBs on signaling pathways in cancer cells are conferred via G-protein coupled CB-receptors (CB-Rs), CB1-R and CB2-R, but also via other receptors, and in a receptor-independent way.  THC is a partial agonist for CB1-R and CB2-R; CBD is an inverse agonist for both.  In breast cancer, CB1-R expression is moderate, but CB2-R expression is high, which is related to tumor aggressiveness.  CBs block cell cycle progression and cell growth and induce cancer cell apoptosis by inhibiting constitutive active pro-oncogenic signaling pathways, such as the extracellular-signal-regulated kinase pathway.  They reduce angiogenesis and tumor metastasis in animal breast cancer models.  CBs are not only active against estrogen receptor-pos., but also against estrogen-resistant breast cancer cells.  In human epidermal growth factor receptor 2-pos. and triple-neg. breast cancer cells, blocking protein kinase B- and cyclooxygenase-2 signaling via CB2-R prevents tumor progression and metastasis.  Furthermore, selective estrogen receptor modulators (SERMs), including tamoxifen, bind to CB-Rs; this process may contribute to the growth inhibitory effect of SERMs in cancer cells lacking the estrogen receptor.  In summary, CBs are already administered to breast cancer patients at advanced stages of the disease, but they might also be effective at earlier stages to decelerate tumor progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplxc-IDLkQu7Vg90H21EOLACvtfcHk0lhMPjJHR9e75A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXosVOqtA%253D%253D&md5=6e3743aa394e4024de70ff4252ec4f2d</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.3390%2Fijms20071673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20071673%26sid%3Dliteratum%253Aachs%26aulast%3DKiskov%25C3%25A1%26aufirst%3DT.%26aulast%3DMungenast%26aufirst%3DF.%26aulast%3DSuv%25C3%25A1kov%25C3%25A1%26aufirst%3DM.%26aulast%3DJ%25C3%25A4ger%26aufirst%3DW.%26aulast%3DThalhammer%26aufirst%3DT.%26atitle%3DFuture%2520Aspects%2520for%2520Cannabinoids%2520in%2520Breast%2520Cancer%2520Therapy%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D1673%26doi%3D10.3390%2Fijms20071673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, M.</span></span> <span> </span><span class="NLM_article-title">Combined CB2 Receptor Agonist and Photodynamic Therapy Synergistically Inhibit Tumor Growth in Triple Negative Breast Cancer</span>. <i>Photodiagn. Photodyn. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1016/j.pdpdt.2018.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.pdpdt.2018.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=30240926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVamsLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=185-191&author=J.+Zhangauthor=S.+Zhangauthor=Y.+Liuauthor=M.+Suauthor=X.+Lingauthor=F.+Liuauthor=Y.+Geauthor=M.+Bai&title=Combined+CB2+Receptor+Agonist+and+Photodynamic+Therapy+Synergistically+Inhibit+Tumor+Growth+in+Triple+Negative+Breast+Cancer&doi=10.1016%2Fj.pdpdt.2018.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Combined CB2 receptor agonist and photodynamic therapy synergistically inhibit tumor growth in triple negative breast cancer</span></div><div class="casAuthors">Zhang, Jiliang; Zhang, Shaojuan; Liu, Yang; Su, Meng; Ling, Xiaoxi; Liu, Funan; Ge, Yinghui; Bai, Mingfeng</div><div class="citationInfo"><span class="NLM_cas:title">Photodiagnosis and Photodynamic Therapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">185-191</span>CODEN:
                <span class="NLM_cas:coden">PPTHBF</span>;
        ISSN:<span class="NLM_cas:issn">1572-1000</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Triple neg. breast cancer (TNBC) is the deadliest form of breast cancer because it is more aggressive, diagnosed at later stage and more likely to develop local and systemic recurrence.  Many patients do not experience adequate tumor control after current clin. treatments involving surgical removal, chemotherapy and/or radiotherapy, leading to disease progression and significantly decreased quality of life.  Here we report a new combinatory therapy strategy involving cannabinoid-based medicine and photodynamic therapy (PDT) for the treatment of TNBC.  This combinatory therapy targets two proteins upregulated in TNBC: the cannabinoid CB2 receptor (CB2R, a G-protein coupled receptor) and translocator protein (TSPO, a mitochondria membrane receptor).  We found that the combined CB2R agonist and TSPO-PDT treatment resulted in synergistic inhibition in TNBC cell and tumor growth.  This combinatory therapy approach provides new opportunities to treat TNBC with high efficacy.  In addn., this study provides new evidence on the therapeutic potential of CB2R agonists for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBC-J0AkR1Q7Vg90H21EOLACvtfcHk0lhMPjJHR9e75A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVamsLnK&md5=28009f9579ba604637f0f7094da65c79</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.pdpdt.2018.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pdpdt.2018.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DLing%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DGe%26aufirst%3DY.%26aulast%3DBai%26aufirst%3DM.%26atitle%3DCombined%2520CB2%2520Receptor%2520Agonist%2520and%2520Photodynamic%2520Therapy%2520Synergistically%2520Inhibit%2520Tumor%2520Growth%2520in%2520Triple%2520Negative%2520Breast%2520Cancer%26jtitle%3DPhotodiagn.%2520Photodyn.%2520Ther.%26date%3D2018%26volume%3D24%26spage%3D185%26epage%3D191%26doi%3D10.1016%2Fj.pdpdt.2018.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span> <span> </span><span class="NLM_article-title">Molecular Imaging of Pancreatic Duct Adenocarcinoma Using a Type 2 Cannabinoid Receptor-Targeted Near-Infrared Fluorescent Probe</span>. <i>Transl. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1065</span>– <span class="NLM_lpage">1073</span>, <span class="refDoi"> DOI: 10.1016/j.tranon.2018.06.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.tranon.2018.06.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=30005208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FnvFSnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=1065-1073&author=X.+Guoauthor=X.+Lingauthor=F.+Duauthor=Q.+Wangauthor=W.+Huangauthor=Z.+Wangauthor=X.+Dingauthor=M.+Baiauthor=Z.+Wu&title=Molecular+Imaging+of+Pancreatic+Duct+Adenocarcinoma+Using+a+Type+2+Cannabinoid+Receptor-Targeted+Near-Infrared+Fluorescent+Probe&doi=10.1016%2Fj.tranon.2018.06.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Imaging of Pancreatic Duct Adenocarcinoma Using a Type 2 Cannabinoid Receptor-Targeted Near-Infrared Fluorescent Probe</span></div><div class="casAuthors">Guo Xiaoxia; Wang Qingbing; Huang Wei; Wang Zhongmin; Ding Xiaoyi; Ling Xiaoxi; Du Fang; Bai Mingfeng; Wu Zhiyuan</div><div class="citationInfo"><span class="NLM_cas:title">Translational oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1065-1073</span>
        ISSN:<span class="NLM_cas:issn">1936-5233</span>.
    </div><div class="casAbstract">Imaging probes targeting type 2 cannabinoid receptor (CB2R) overexpressed in pancreatic duct adenocarcinoma (PDAC) tissue have the potential to improve early detection and surgical outcome of PDAC.  The aim of our study was to evaluate the molecular imaging potential of a CB2R-targeted near-infrared (NIR) fluorescent probe (NIR760-XLP6) for PDAC.  CB2R overexpression was observed in both PDAC patient tissues and various pancreatic cancer cell lines.  In vitro fluorescence imaging indicated specific binding of NIR760-XLP6 to CB2R in human PDAC PANC-1 cells.  In a xenograft mouse tumor model, NIR760-XLP6 showed remarkable 50- (ex vivo) and 3.2-fold (in vivo) tumor to normal contrast enhancement with minimal liver and kidney uptake.  In a PDAC lymph node metastasis model, significant signal contrast was observed in bilateral axillary lymph nodes with PDAC metastasis after injection of the probe.  In conclusion, NIR760-XLP6 exhibits promising characteristics for imaging PDAC, and CB2R appears to be an attractive target for PDAC imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRluw1KnvQw9ZdYoSR9eyvsfW6udTcc2eZNY8i0dnEnjbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FnvFSnsw%253D%253D&md5=46c5f12dc88b818cf1bbe0e5eea68dd9</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.tranon.2018.06.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tranon.2018.06.009%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DX.%26aulast%3DLing%26aufirst%3DX.%26aulast%3DDu%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DBai%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DZ.%26atitle%3DMolecular%2520Imaging%2520of%2520Pancreatic%2520Duct%2520Adenocarcinoma%2520Using%2520a%2520Type%25202%2520Cannabinoid%2520Receptor-Targeted%2520Near-Infrared%2520Fluorescent%2520Probe%26jtitle%3DTransl.%2520Oncol.%26date%3D2018%26volume%3D11%26spage%3D1065%26epage%3D1073%26doi%3D10.1016%2Fj.tranon.2018.06.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez-Tiedra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davila, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorente, M.</span></span> <span> </span><span class="NLM_article-title">The Use of Cannabinoids as Anticancer Agents</span>. <i>Prog. Neuro-Psychopharmacol. Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">259</span>– <span class="NLM_lpage">266</span>, <span class="refDoi"> DOI: 10.1016/j.pnpbp.2015.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.pnpbp.2015.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=26071989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFajsL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2016&pages=259-266&author=G.+Velascoauthor=S.+Hernandez-Tiedraauthor=D.+Davilaauthor=M.+Lorente&title=The+Use+of+Cannabinoids+as+Anticancer+Agents&doi=10.1016%2Fj.pnpbp.2015.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The use of cannabinoids as anticancer agents</span></div><div class="casAuthors">Velasco, Guillermo; Hernandez-Tiedra, Sonia; Davila, David; Lorente, Mar</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neuro-Psychopharmacology & Biological Psychiatry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">259-266</span>CODEN:
                <span class="NLM_cas:coden">PNPPD7</span>;
        ISSN:<span class="NLM_cas:issn">0278-5846</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">It is well-established that cannabinoids exert palliative effects on some cancer-assocd. symptoms.  In addn. evidences obtained during the last fifteen years support that these compds. can reduce tumor growth in animal models of cancer.  Cannabinoids have been shown to activate an ER-stress related pathway that leads to the stimulation of autophagy-mediated cancer cell death.  In addn., cannabinoids inhibit tumor angiogenesis and decrease cancer cell migration.  The mechanisms of resistance to cannabinoid anticancer action as well as the possible strategies to develop cannabinoid-based combinational therapies to fight cancer have also started to be explored.  In this review we will summarize these observations (that have already helped to set the bases for the development of the first clin. studies to investigate the potential clin. benefit of using cannabinoids in anticancer therapies) and will discuss the possible future avenues of research in this area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHl8_MWK7vUbVg90H21EOLACvtfcHk0lizJMixZqO_4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFajsL7K&md5=4e20347b10118d585add29b8ad93b31a</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.pnpbp.2015.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pnpbp.2015.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DVelasco%26aufirst%3DG.%26aulast%3DHernandez-Tiedra%26aufirst%3DS.%26aulast%3DDavila%26aufirst%3DD.%26aulast%3DLorente%26aufirst%3DM.%26atitle%3DThe%2520Use%2520of%2520Cannabinoids%2520as%2520Anticancer%2520Agents%26jtitle%3DProg.%2520Neuro-Psychopharmacol.%2520Biol.%2520Psychiatry%26date%3D2016%26volume%3D64%26spage%3D259%26epage%3D266%26doi%3D10.1016%2Fj.pnpbp.2015.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basagni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, M.</span></span> <span> </span><span class="NLM_article-title">Functionalized Cannabinoid Subtype 2 Receptor Ligands: Fluorescent, PET, Photochromic and Covalent Molecular Probes</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1374</span>– <span class="NLM_lpage">1389</span>, <span class="refDoi"> DOI: 10.1002/cmdc.202000298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1002%2Fcmdc.202000298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=32578963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1akt7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&pages=1374-1389&author=F.+Basagniauthor=M.+Rosiniauthor=M.+Decker&title=Functionalized+Cannabinoid+Subtype+2+Receptor+Ligands%3A+Fluorescent%2C+PET%2C+Photochromic+and+Covalent+Molecular+Probes&doi=10.1002%2Fcmdc.202000298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Functionalized Cannabinoid Subtype 2 Receptor Ligands: Fluorescent, PET, Photochromic and Covalent Molecular Probes</span></div><div class="casAuthors">Basagni, Filippo; Rosini, Michela; Decker, Michael</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1374-1389</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Cannabinoid subtype 2 receptors (CB2Rs) are G protein-coupled receptors (GPCRs) belonging to the endocannabinoid system, a complex network of signalling pathways leading to the regulation of key physiol. processes.  Interestingly, CB2Rs are strongly up-regulated in pathol. conditions correlated with the onset of inflammatory events like cancer and neurodegenerative diseases.  Therefore, CB2Rs represent an important biol. target for therapeutic as well as diagnostic purposes.  No CB2R-selective drugs are yet on the market, thus underlining a that deeper comprehension of CB2Rs' complex activation pathways and their role in the regulation of diseases is needed.  Herein, we report an overview of pharmacol. and imaging tools such as fluorescent, positron emission tomog. (PET), photochromic and covalent selective CB2R ligands.  These mol. probes can be used in vitro as well as in vivo to investigate and explore the unravelled role(s) of CB2Rs, and they can help to design suitable CB2R-targeted drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUlNKavII1OrVg90H21EOLACvtfcHk0lizJMixZqO_4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1akt7%252FJ&md5=64ccc6dba1fd806dfa9394017b056599</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.202000298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.202000298%26sid%3Dliteratum%253Aachs%26aulast%3DBasagni%26aufirst%3DF.%26aulast%3DRosini%26aufirst%3DM.%26aulast%3DDecker%26aufirst%3DM.%26atitle%3DFunctionalized%2520Cannabinoid%2520Subtype%25202%2520Receptor%2520Ligands%253A%2520Fluorescent%252C%2520PET%252C%2520Photochromic%2520and%2520Covalent%2520Molecular%2520Probes%26jtitle%3DChemMedChem%26date%3D2020%26volume%3D15%26spage%3D1374%26epage%3D1389%26doi%3D10.1002%2Fcmdc.202000298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Naranjo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campillo, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paez, J. A.</span></span> <span> </span><span class="NLM_article-title">Multitarget Cannabinoids as Novel Strategy for Alzheimer Disease</span>. <i>Curr. Alzheimer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">239</span>, <span class="refDoi"> DOI: 10.2174/1567205011310030002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.2174%2F1567205011310030002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=23369066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosFSmu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=229-239&author=P.+Gonzalez-Naranjoauthor=N.+E.+Campilloauthor=C.+Perezauthor=J.+A.+Paez&title=Multitarget+Cannabinoids+as+Novel+Strategy+for+Alzheimer+Disease&doi=10.2174%2F1567205011310030002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Multitarget cannabinoids as novel strategy for Alzheimer disease</span></div><div class="casAuthors">Gonzalez-Naranjo, Pedro; Campillo, Nuria E.; Perez, Concepcion; Paez, Juan A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Alzheimer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">229-239</span>CODEN:
                <span class="NLM_cas:coden">CARUBY</span>;
        ISSN:<span class="NLM_cas:issn">1567-2050</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">During the last years the development of approaches to multitarget drug design and discovery is gaining acceptance.  The cannabinoids are potentially excellent multi-target drug candidates because of their interesting pharmacol. profiles, among which stands out the dual capacity of cannabinoid ligands to act as cannabinoid agonist and cholinesterase inhibitors.  In this article, inhibition, kinetics studies and docking simulations with a representative set of cannabinoids are presented.  The results of these studies showed the inhibitory capacity of some agonist cannabinoids with selectivity at AChE or BuChE enzymes.  The kinetic and modeling studies allowed us to postulate the potential mode of action and the binding site of the cannabinoids.  In general, the studied cannabinoids showed a mixed type inhibition mode of action.  The exception to this behavior was found for the agonist CP-55,940 that showed a non-competitive inhibition, suggesting that this cannabinoid only binds to the peripheral site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJJBSiqIppQLVg90H21EOLACvtfcHk0lgpcZ0ScJMJdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosFSmu7s%253D&md5=68aaaf59f7f6c5ebb45462f67748e670</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.2174%2F1567205011310030002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1567205011310030002%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez-Naranjo%26aufirst%3DP.%26aulast%3DCampillo%26aufirst%3DN.%2BE.%26aulast%3DPerez%26aufirst%3DC.%26aulast%3DPaez%26aufirst%3DJ.%2BA.%26atitle%3DMultitarget%2520Cannabinoids%2520as%2520Novel%2520Strategy%2520for%2520Alzheimer%2520Disease%26jtitle%3DCurr.%2520Alzheimer%2520Res.%26date%3D2013%26volume%3D10%26spage%3D229%26epage%3D239%26doi%3D10.2174%2F1567205011310030002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Naranjo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Macias, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campillo, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aran, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giron, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Robles, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Canas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Arencibia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández-Ruiz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paez, J. A.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid Agonists Showing BuChE Inhibition as Potential Therapeutic Agents for Alzheimer’s Disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">56</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.11.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2013.11.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=24378710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitlSgtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2014&pages=56-72&author=P.+Gonzalez-Naranjoauthor=N.+Perez-Maciasauthor=N.+E.+Campilloauthor=C.+Perezauthor=V.+J.+Aranauthor=R.+Gironauthor=E.+Sanchez-Roblesauthor=M.+I.+Martinauthor=M.+Gomez-Canasauthor=M.+Garc%C3%ADa-Arencibiaauthor=J.+Fern%C3%A1ndez-Ruizauthor=J.+A.+Paez&title=Cannabinoid+Agonists+Showing+BuChE+Inhibition+as+Potential+Therapeutic+Agents+for+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.ejmech.2013.11.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease</span></div><div class="casAuthors">Gonzalez-Naranjo, Pedro; Perez-Macias, Natalia; Campillo, Nuria E.; Perez, Concepcion; Aran, Vicente J.; Giron, Rocio; Sanchez-Robles, Eva; Martin, Maria Isabel; Gomez-Canas, Maria; Garcia-Arencibia, Moises; Fernandez-Ruiz, Javier; Paez, Juan A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">56-72</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Designing drugs with a specific multitarget profile is a promising approach against multifactorial illnesses as Alzheimer's disease.  In this work, new indazole ethers I [R1 = H, Br, NH2, O2N; R2 = Ph, 4-MeC6H4, 1-naphthyl, etc.] that possess dual activity as both cannabinoid agonists CB2 and inhibitors of BuChE have been designed by computational methods.  On the basis of this knowledge, the synthesis, pharmacol. evaluation and docking studies of a new class of indazoles has been performed.  Pharmacol. evaluation includes radioligand binding assays with [3H]-CP55940 for CB1R and CB2R and functional activity for cannabinoid receptors on isolated tissue.  Addnl., in vitro inhibitory assays of AChE/BuChE and the corresponding competition studies have been carried out.  The results of pharmacol. tests have revealed that three of these derivs. behave as CB2 cannabinoid agonists and simultaneously show BuChE inhibition.  Two compds. have emerged as promising candidates as novel cannabinoids that inhibit BuChE by a noncompetitive or mixed mechanism, resp.  Both mols. show antioxidant properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsEZ5i6Cu4urVg90H21EOLACvtfcHk0lgpcZ0ScJMJdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitlSgtLs%253D&md5=0f4334ed1444c18bf353a34351936e5a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.11.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.11.026%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez-Naranjo%26aufirst%3DP.%26aulast%3DPerez-Macias%26aufirst%3DN.%26aulast%3DCampillo%26aufirst%3DN.%2BE.%26aulast%3DPerez%26aufirst%3DC.%26aulast%3DAran%26aufirst%3DV.%2BJ.%26aulast%3DGiron%26aufirst%3DR.%26aulast%3DSanchez-Robles%26aufirst%3DE.%26aulast%3DMartin%26aufirst%3DM.%2BI.%26aulast%3DGomez-Canas%26aufirst%3DM.%26aulast%3DGarc%25C3%25ADa-Arencibia%26aufirst%3DM.%26aulast%3DFern%25C3%25A1ndez-Ruiz%26aufirst%3DJ.%26aulast%3DPaez%26aufirst%3DJ.%2BA.%26atitle%3DCannabinoid%2520Agonists%2520Showing%2520BuChE%2520Inhibition%2520as%2520Potential%2520Therapeutic%2520Agents%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D73%26spage%3D56%26epage%3D72%26doi%3D10.1016%2Fj.ejmech.2013.11.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Naranjo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Macias, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaca, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giron, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Robles, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Fontelles, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Ceballos, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Requero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campillo, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paez, J. A.</span></span> <span> </span><span class="NLM_article-title">Indazolylketones as New Multitarget Cannabinoid Drugs</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>166</i></span>,  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.01.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2019.01.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=30685536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKks7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2019&pages=90-107&author=P.+Gonzalez-Naranjoauthor=N.+Perez-Maciasauthor=C.+Perezauthor=C.+Rocaauthor=G.+Vacaauthor=R.+Gironauthor=E.+Sanchez-Roblesauthor=M.+I.+Martin-Fontellesauthor=M.+L.+de+Ceballosauthor=A.+Martin-Requeroauthor=N.+E.+Campilloauthor=J.+A.+Paez&title=Indazolylketones+as+New+Multitarget+Cannabinoid+Drugs&doi=10.1016%2Fj.ejmech.2019.01.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Indazolylketones as new multitarget cannabinoid drugs</span></div><div class="casAuthors">Gonzalez-Naranjo, Pedro; Perez-Macias, Natalia; Perez, Concepcion; Roca, Carlos; Vaca, Gabriela; Giron, Rocio; Sanchez-Robles, Eva; Martin-Fontelles, Maria Isabel; de Ceballos, Maria L.; Martin-Requero, Angeles; Campillo, Nuria E.; Paez, Juan A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">90-107</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In this work, the synthesis and evaluation of a new class of indazolylketones I (R1 = 1-naphthyl, 2-chlorophenyl, 2-(benzyloxy)phenyl, etc.; R2 = pyrrolidinyl, piperidin-1-yl; n = 2, 3) have been performed.  Pharmacol. evaluation includes functional activity for cannabinoid receptors on isolated tissue.  In addn., in vitro inhibitory assays in AChE/BuChE enzymes and BACE-1 have been carried out.  Furthermore, studies of neuroprotective effects in human neuroblastoma SH-SY5Y cells and studies of the mechanisms of survival/death in lymphoblasts of patients with Alzheimer's disease have been achieved.  The results of pharmacol. tests have revealed that some of these derivs. I (R1 = 3-chloro-2-fluorophenyl, 2,3-dichlorophenyl; R2 = pyrrolidinyl, piperidin-1-yl; n = 2, 3) behave as CB2 cannabinoid agonists and simultaneously show BuChE and/or BACE-1 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_gzl9LX4C2bVg90H21EOLACvtfcHk0lisUDWy1ofxZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKks7k%253D&md5=bf3d193f39d132576511a4f8d96cb7e4</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.01.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.01.030%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez-Naranjo%26aufirst%3DP.%26aulast%3DPerez-Macias%26aufirst%3DN.%26aulast%3DPerez%26aufirst%3DC.%26aulast%3DRoca%26aufirst%3DC.%26aulast%3DVaca%26aufirst%3DG.%26aulast%3DGiron%26aufirst%3DR.%26aulast%3DSanchez-Robles%26aufirst%3DE.%26aulast%3DMartin-Fontelles%26aufirst%3DM.%2BI.%26aulast%3Dde%2BCeballos%26aufirst%3DM.%2BL.%26aulast%3DMartin-Requero%26aufirst%3DA.%26aulast%3DCampillo%26aufirst%3DN.%2BE.%26aulast%3DPaez%26aufirst%3DJ.%2BA.%26atitle%3DIndazolylketones%2520as%2520New%2520Multitarget%2520Cannabinoid%2520Drugs%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D166%26spage%3D90%26epage%3D107%26doi%3D10.1016%2Fj.ejmech.2019.01.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dolles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nimczick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheiner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadtmuller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawatzky, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drakopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotriffer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittmann, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, M.</span></span> <span> </span><span class="NLM_article-title">Aminobenzimidazoles and Structural Isomers as Templates for Dual-Acting Butyrylcholinesterase Inhibitors and HCB2 R Ligands To Combat Neurodegenerative Disorders</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1270</span>– <span class="NLM_lpage">1283</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1002%2Fcmdc.201500418" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=26548365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyms7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1270-1283&author=D.+Dollesauthor=M.+Nimczickauthor=M.+Scheinerauthor=J.+Ramlerauthor=P.+Stadtmullerauthor=E.+Sawatzkyauthor=A.+Drakopoulosauthor=C.+Sotrifferauthor=H.-J.+Wittmannauthor=A.+Strasserauthor=M.+Decker&title=Aminobenzimidazoles+and+Structural+Isomers+as+Templates+for+Dual-Acting+Butyrylcholinesterase+Inhibitors+and+HCB2+R+Ligands+To+Combat+Neurodegenerative+Disorders&doi=10.1002%2Fcmdc.201500418"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Aminobenzimidazoles and Structural Isomers as Templates for Dual-Acting Butyrylcholinesterase Inhibitors and hCB2R Ligands To Combat Neurodegenerative Disorders</span></div><div class="casAuthors">Dolles, Dominik; Nimczick, Martin; Scheiner, Matthias; Ramler, Jacqueline; Stadtmueller, Patricia; Sawatzky, Edgar; Drakopoulos, Antonios; Sotriffer, Christoph; Wittmann, Hans-Joachim; Strasser, Andrea; Decker, Michael</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1270-1283</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A pharmacophore model for butyrylcholinesterase (BChE) inhibitors was applied to a human cannabinoid subtype 2 receptor (hCB2R) agonist and verified it as a first-generation lead for resp. dual-acting compds.  The design, synthesis, and pharmacol. evaluation of various derivs. led to the identification of aminobenzimidazoles as second-generation leads with micro- or sub-micromolar activities at both targets and excellent selectivity over hCB1 and AChE, resp.  Computational studies of the first- and second-generation lead structures by applying mol. dynamics (MD) on the active hCB2R model, along with docking and MD on hBChE, has enabled an explanation of their binding profiles at the protein levels and opened the way for further optimization.  Dual-acting compds. with "balanced" affinities and excellent selectivities could be obtained that represent leads for treatment of both cognitive and pathophysiol. impairment occurring in neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP2lcUsRAXJ7Vg90H21EOLACvtfcHk0lisUDWy1ofxZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyms7%252FI&md5=dcd6f52f38134002413bd3d975ee9da3</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500418%26sid%3Dliteratum%253Aachs%26aulast%3DDolles%26aufirst%3DD.%26aulast%3DNimczick%26aufirst%3DM.%26aulast%3DScheiner%26aufirst%3DM.%26aulast%3DRamler%26aufirst%3DJ.%26aulast%3DStadtmuller%26aufirst%3DP.%26aulast%3DSawatzky%26aufirst%3DE.%26aulast%3DDrakopoulos%26aufirst%3DA.%26aulast%3DSotriffer%26aufirst%3DC.%26aulast%3DWittmann%26aufirst%3DH.-J.%26aulast%3DStrasser%26aufirst%3DA.%26aulast%3DDecker%26aufirst%3DM.%26atitle%3DAminobenzimidazoles%2520and%2520Structural%2520Isomers%2520as%2520Templates%2520for%2520Dual-Acting%2520Butyrylcholinesterase%2520Inhibitors%2520and%2520HCB2%2520R%2520Ligands%2520To%2520Combat%2520Neurodegenerative%2520Disorders%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D1270%26epage%3D1283%26doi%3D10.1002%2Fcmdc.201500418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dolles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunesch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinelli, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatonnet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohse, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittmann, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabissi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, M.</span></span> <span> </span><span class="NLM_article-title">Structure-Activity Relationships and Computational Investigations into the Development of Potent and Balanced Dual-Acting Butyrylcholinesterase Inhibitors and Human Cannabinoid Receptor 2 Ligands with Pro-Cognitive in Vivo Profiles</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1646</span>– <span class="NLM_lpage">1663</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01760</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Sqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1646-1663&author=D.+Dollesauthor=M.+Hoffmannauthor=S.+Guneschauthor=O.+Marinelliauthor=J.+Mollerauthor=G.+Santoniauthor=A.+Chatonnetauthor=M.+J.+Lohseauthor=H.-J.+Wittmannauthor=A.+Strasserauthor=M.+Nabissiauthor=T.+Mauriceauthor=M.+Decker&title=Structure-Activity+Relationships+and+Computational+Investigations+into+the+Development+of+Potent+and+Balanced+Dual-Acting+Butyrylcholinesterase+Inhibitors+and+Human+Cannabinoid+Receptor+2+Ligands+with+Pro-Cognitive+in+Vivo+Profiles&doi=10.1021%2Facs.jmedchem.7b01760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationships and Computational Investigations into the Development of Potent and Balanced Dual-Acting Butyrylcholinesterase Inhibitors and Human Cannabinoid Receptor 2 Ligands with Pro-Cognitive in Vivo Profiles</span></div><div class="casAuthors">Dolles, Dominik; Hoffmann, Matthias; Gunesch, Sandra; Marinelli, Oliviero; Moeller, Jan; Santoni, Giorgio; Chatonnet, Arnaud; Lohse, Martin J.; Wittmann, Hans-Joachim; Strasser, Andrea; Nabissi, Massimo; Maurice, Tangui; Decker, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1646-1663</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The enzyme butyrylcholinesterase (BChE) and the human cannabinoid receptor 2 (hCB2R) represent promising targets for pharmacotherapy in the later stages of Alzheimer's disease.  The authors merged pharmacophores for both targets into small benzimidazole-based mols., investigated SARs, and identified several dual-acting ligands with a balanced affinity/inhibitory activity and an excellent selectivity over both hCB1R and hAChE.  A homol. model for the hCB2R was developed based on the hCB1R crystal structure and used for mol. dynamics studies to investigate binding modes.  In vitro studies proved hCB2R agonism.  Unwanted μ-opioid receptor affinity could be designed out.  One well-balanced dual-acting and selective hBChE inhibitor/hCB2R agonist showed superior in vivo activity over the lead CB2 agonist with regards to cognition improvement.  The data shows the possibility to combine a small mol. with selective and balanced GPCR-activity/enzyme inhibition and in vivo activity for the therapy of AD and may help to rationalize the development of other dual-acting ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgCAoLm6nAVbVg90H21EOLACvtfcHk0lisUDWy1ofxZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Sqsbo%253D&md5=49e8e68c2c9a023b872e2522fad6e78c</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01760%26sid%3Dliteratum%253Aachs%26aulast%3DDolles%26aufirst%3DD.%26aulast%3DHoffmann%26aufirst%3DM.%26aulast%3DGunesch%26aufirst%3DS.%26aulast%3DMarinelli%26aufirst%3DO.%26aulast%3DMoller%26aufirst%3DJ.%26aulast%3DSantoni%26aufirst%3DG.%26aulast%3DChatonnet%26aufirst%3DA.%26aulast%3DLohse%26aufirst%3DM.%2BJ.%26aulast%3DWittmann%26aufirst%3DH.-J.%26aulast%3DStrasser%26aufirst%3DA.%26aulast%3DNabissi%26aufirst%3DM.%26aulast%3DMaurice%26aufirst%3DT.%26aulast%3DDecker%26aufirst%3DM.%26atitle%3DStructure-Activity%2520Relationships%2520and%2520Computational%2520Investigations%2520into%2520the%2520Development%2520of%2520Potent%2520and%2520Balanced%2520Dual-Acting%2520Butyrylcholinesterase%2520Inhibitors%2520and%2520Human%2520Cannabinoid%2520Receptor%25202%2520Ligands%2520with%2520Pro-Cognitive%2520in%2520Vivo%2520Profiles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1646%26epage%3D1663%26doi%3D10.1021%2Facs.jmedchem.7b01760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scheiner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunesch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabissi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinelli, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naldi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petralla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poeta, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falkeis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vieth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hübner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmeiner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, M.</span></span> <span> </span><span class="NLM_article-title">Dual-Acting Cholinesterase-Human Cannabinoid Receptor 2 Ligands Show Pronounced Neuroprotection in Vitro and Overadditive and Disease-Modifying Neuroprotective Effects in Vivo</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">9078</span>– <span class="NLM_lpage">9102</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00623</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00623" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFCrs7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=9078-9102&author=M.+Scheinerauthor=D.+Dollesauthor=S.+Guneschauthor=M.+Hoffmannauthor=M.+Nabissiauthor=O.+Marinelliauthor=M.+Naldiauthor=M.+Bartoliniauthor=S.+Petrallaauthor=E.+Poetaauthor=B.+Montiauthor=C.+Falkeisauthor=M.+Viethauthor=H.+H%C3%BCbnerauthor=P.+Gmeinerauthor=R.+Maitraauthor=T.+Mauriceauthor=M.+Decker&title=Dual-Acting+Cholinesterase-Human+Cannabinoid+Receptor+2+Ligands+Show+Pronounced+Neuroprotection+in+Vitro+and+Overadditive+and+Disease-Modifying+Neuroprotective+Effects+in+Vivo&doi=10.1021%2Facs.jmedchem.9b00623"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-Acting Cholinesterase-Human Cannabinoid Receptor 2 Ligands Show Pronounced Neuroprotection in Vitro and Overadditive and Disease-Modifying Neuroprotective Effects in Vivo</span></div><div class="casAuthors">Scheiner, Matthias; Dolles, Dominik; Gunesch, Sandra; Hoffmann, Matthias; Nabissi, Massimo; Marinelli, Oliviero; Naldi, Marina; Bartolini, Manuela; Petralla, Sabrina; Poeta, Eleonora; Monti, Barbara; Falkeis, Christina; Vieth, Michael; Huebner, Harald; Gmeiner, Peter; Maitra, Rangan; Maurice, Tangui; Decker, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9078-9102</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have designed and synthesized a series of 14 hybrid mols. out of the cholinesterase (ChE) inhibitor tacrine and a benzimidazole-based human cannabinoid receptor subtype 2 (hCB2R) agonist and investigated them in vitro and in vivo.  The compds. are potent ChE inhibitors, and for the most promising hybrids, the mechanism of human acetylcholinesterase (hAChE) inhibition as well as their ability to interfere with AChE-induced aggregation of β-amyloid (Aβ), and Aβ self-aggregation was assessed.  All hybrids were evaluated for affinity and selectivity for hCB1R and hCB2R.  To ensure that the hybrids retained their agonist character, the expression of cAMP-regulated genes was quantified, and potency and efficacy were detd.  Addnl., the effects of the hybrids on microglia activation and neuroprotection on HT-22 cells were investigated.  The most promising in vitro hybrids showed pronounced neuroprotection in an Alzheimer's mouse model at low dosage (0.1 mg/kg, i.p.), lacking hepatotoxicity even at high dose (3 mg/kg, i.p.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGRfz6xatTXLVg90H21EOLACvtfcHk0ljj2VgEJmB52g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFCrs7%252FM&md5=f0148c8ba51a2d0cbe83a26bb388a446</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00623%26sid%3Dliteratum%253Aachs%26aulast%3DScheiner%26aufirst%3DM.%26aulast%3DDolles%26aufirst%3DD.%26aulast%3DGunesch%26aufirst%3DS.%26aulast%3DHoffmann%26aufirst%3DM.%26aulast%3DNabissi%26aufirst%3DM.%26aulast%3DMarinelli%26aufirst%3DO.%26aulast%3DNaldi%26aufirst%3DM.%26aulast%3DBartolini%26aufirst%3DM.%26aulast%3DPetralla%26aufirst%3DS.%26aulast%3DPoeta%26aufirst%3DE.%26aulast%3DMonti%26aufirst%3DB.%26aulast%3DFalkeis%26aufirst%3DC.%26aulast%3DVieth%26aufirst%3DM.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DGmeiner%26aufirst%3DP.%26aulast%3DMaitra%26aufirst%3DR.%26aulast%3DMaurice%26aufirst%3DT.%26aulast%3DDecker%26aufirst%3DM.%26atitle%3DDual-Acting%2520Cholinesterase-Human%2520Cannabinoid%2520Receptor%25202%2520Ligands%2520Show%2520Pronounced%2520Neuroprotection%2520in%2520Vitro%2520and%2520Overadditive%2520and%2520Disease-Modifying%2520Neuroprotective%2520Effects%2520in%2520Vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D9078%26epage%3D9102%26doi%3D10.1021%2Facs.jmedchem.9b00623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span> <span> </span><span class="NLM_article-title">Multitarget Drug Discovery and Polypharmacology</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1190</span>– <span class="NLM_lpage">1192</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201600161</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1002%2Fcmdc.201600161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=27061625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC28XlslajtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1190-1192&author=M.+L.+Bolognesiauthor=A.+Cavalli&title=Multitarget+Drug+Discovery+and+Polypharmacology&doi=10.1002%2Fcmdc.201600161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Multitarget Drug Discovery and Polypharmacology</span></div><div class="casAuthors">Bolognesi, Maria Laura; Cavalli, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1190-1192</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUatZ6EoEK6LVg90H21EOLACvtfcHk0ljj2VgEJmB52g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlslajtLc%253D&md5=f120fbd9eb2c96cbe283749c95b81cb0</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600161%26sid%3Dliteratum%253Aachs%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DCavalli%26aufirst%3DA.%26atitle%3DMultitarget%2520Drug%2520Discovery%2520and%2520Polypharmacology%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D1190%26epage%3D1192%26doi%3D10.1002%2Fcmdc.201600161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anighoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastelli, G.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology: Challenges and Opportunities in Drug Discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7874</span>– <span class="NLM_lpage">7887</span>, <span class="refDoi"> DOI: 10.1021/jm5006463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7874-7887&author=A.+Anighoroauthor=J.+Bajorathauthor=G.+Rastelli&title=Polypharmacology%3A+Challenges+and+Opportunities+in+Drug+Discovery&doi=10.1021%2Fjm5006463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: Challenges and Opportunities in Drug Discovery</span></div><div class="casAuthors">Anighoro, Andrew; Bajorath, Jurgen; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7874-7887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biol. target, shares the spotlight with an emerging and alternative polypharmacol. approach.  Polypharmacol. suggests that more effective drugs can be developed by specifically modulating multiple targets.  It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches.  In this respect, a drug that "hits" multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs.  In this review, we will compare advantages and disadvantages of multitarget vs. combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOTyEu80AZrVg90H21EOLACvtfcHk0ljj2VgEJmB52g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I&md5=5ab36c961a84462d90bc25130d90a281</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm5006463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006463%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DPolypharmacology%253A%2520Challenges%2520and%2520Opportunities%2520in%2520Drug%2520Discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7874%26epage%3D7887%26doi%3D10.1021%2Fjm5006463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amelio, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisitsa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonov, A. V.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology of Approved Anticancer Drugs</span>. <i>Curr. Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">534</span>– <span class="NLM_lpage">543</span>, <span class="refDoi"> DOI: 10.2174/1389450117666160301095233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.2174%2F1389450117666160301095233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=26926468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjslSjtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=534-543&author=I.+Amelioauthor=A.+Lisitsaauthor=R.+A.+Knightauthor=G.+Melinoauthor=A.+V.+Antonov&title=Polypharmacology+of+Approved+Anticancer+Drugs&doi=10.2174%2F1389450117666160301095233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology of Approved Anticancer Drugs</span></div><div class="casAuthors">Amelio, Ivano; Lisitsa, Andrey; Knight, Richard A.; Melino, Gerry; Antonov, Alexey V.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">534-543</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">The major drug discovery efforts in oncol. have been concd. on the development of selective mols. that are supposed to act specifically on one anticancer mechanism by modulating a single or several closely related drug targets.  However, a bird's eye view on data from multiple available bioassays implies that most approved anticancer agents do, in fact, target many more proteins with different functions.  Here we will review and systematize currently available information on the targets of several anticancer drugs along with revision of their potential mechanisms of action.  Polypharmacol. of the current antineoplastic agents suggests that drug clin. efficacy in oncol. can be achieved only via modulation of multiple cellular mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZWxZCVA_iIrVg90H21EOLACvtfcHk0lhahifnZ3bn3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjslSjtrc%253D&md5=316e3ae08072b1b984523b7642b8d271</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.2174%2F1389450117666160301095233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389450117666160301095233%26sid%3Dliteratum%253Aachs%26aulast%3DAmelio%26aufirst%3DI.%26aulast%3DLisitsa%26aufirst%3DA.%26aulast%3DKnight%26aufirst%3DR.%2BA.%26aulast%3DMelino%26aufirst%3DG.%26aulast%3DAntonov%26aufirst%3DA.%2BV.%26atitle%3DPolypharmacology%2520of%2520Approved%2520Anticancer%2520Drugs%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2017%26volume%3D18%26spage%3D534%26epage%3D543%26doi%3D10.2174%2F1389450117666160301095233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology in a Single Drug: Multitarget Drugs</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1639</span>– <span class="NLM_lpage">1645</span>, <span class="refDoi"> DOI: 10.2174/0929867311320130004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.2174%2F0929867311320130004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=23410164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotl2jtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1639-1645&author=M.+L.+Bolognesi&title=Polypharmacology+in+a+Single+Drug%3A+Multitarget+Drugs&doi=10.2174%2F0929867311320130004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology in a single drug: multitarget drugs</span></div><div class="casAuthors">Bolognesi, M. L.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1639-1645</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Polypharmacol. offers a model for the way drug discovery must evolve to develop therapies most suited to treating currently incurable diseases.  It is driven by a worldwide demand for safer, more effective, and affordable medicines against the most complex diseases, and by the failures of modern drug discovery to provide these.  Polypharmacol. can involve combinations and/or multitarget drugs (MTD).  Although not mutually exclusive, my premise is that MTDs have inherent advantages over combinations.  This review article focuses on MTDs from a medicinal chem. perspective.  I will explore their use in current clin. practice, their likely application in the future, and the challenges to be overcome to achieve this goal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeSnmeFeRpMrVg90H21EOLACvtfcHk0lhahifnZ3bn3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotl2jtLk%253D&md5=0e69395566711e018db8a61b1ae0f56e</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.2174%2F0929867311320130004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867311320130004%26sid%3Dliteratum%253Aachs%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DPolypharmacology%2520in%2520a%2520Single%2520Drug%253A%2520Multitarget%2520Drugs%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26spage%3D1639%26epage%3D1645%26doi%3D10.2174%2F0929867311320130004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designing Multiple Ligands - Medicinal Chemistry Strategies and Challenges</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.2174/138161209787315594</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.2174%2F138161209787315594" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=19199984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvVSns70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=587-600&author=R.+Morphyauthor=Z.+Rankovic&title=Designing+Multiple+Ligands+-+Medicinal+Chemistry+Strategies+and+Challenges&doi=10.2174%2F138161209787315594"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Designing multiple ligands - medicinal chemistry strategies and challenges</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">587-600</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  It has been widely recognized over the recent years that parallel modulation of multiple biol. targets can be beneficial for treatment of diseases with complex etiologies such as cancer asthma, and psychiatric disease.  In this article, current strategies for the generation of ligands with a specific multi-target profile (designed multiple ligands or DMLs) are described and a no. of illustrative example are given.  Designing multiple ligands is frequently a challenging endeavor for medicinal chemists, with the need to appropriately balance affinity for 2 or more targets while obtaining physicochem. and pharmacokinetic properties that are consistent with the administration of an oral drug.  Given that the properties of DMLs are influenced to a large extent by the proteomic superfamily to which the targets belong and the lead generation strategy that is pursued, an early assessment of the feasibility of any given DML project is essential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUo6NjoK5D-LVg90H21EOLACvtfcHk0lgx-MewPMItsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvVSns70%253D&md5=fa34039be6e9c3b489f530fc74fd0346</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.2174%2F138161209787315594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161209787315594%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigning%2520Multiple%2520Ligands%2520-%2520Medicinal%2520Chemistry%2520Strategies%2520and%2520Challenges%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2009%26volume%3D15%26spage%3D587%26epage%3D600%26doi%3D10.2174%2F138161209787315594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">From Magic Bullets to Designed Multiple Ligands</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">641</span>– <span class="NLM_lpage">651</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(04)03163-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2FS1359-6446%2804%2903163-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=15279847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=641-651&author=R.+Morphyauthor=C.+Kayauthor=Z.+Rankovic&title=From+Magic+Bullets+to+Designed+Multiple+Ligands&doi=10.1016%2FS1359-6446%2804%2903163-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">From magic bullets to designed multiple ligands</span></div><div class="casAuthors">Morphy, Richard; Kay, Corinne; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">641-651</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  A major trend in medicinal chem. in the coming years will be the rational design of ligands that are capable of modulating multiple disease-relevant targets in a specific manner.  Increasingly, it is being recognized that a balanced modulation of several targets can provide a superior therapeutic effect and side effect profile compared to the action of a selective ligand.  Rational approaches in which structural features from selective ligands are combined have produced designed multiple ligands that span a wide variety of targets and target classes.  A key challenge in the design of multiple ligands is attaining a balanced activity at each target of interest while simultaneously achieving a wider selectivity and a suitable pharmacokinetic profile.  An anal. of literature examples reveals trends and insights that might help medicinal chemists discover the next generation of these types of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcsGpfzZok5rVg90H21EOLACvtfcHk0lgx-MewPMItsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D&md5=cd2491baad707043dbee4f59ccad9e1d</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903163-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903163-0%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DKay%26aufirst%3DC.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DFrom%2520Magic%2520Bullets%2520to%2520Designed%2520Multiple%2520Ligands%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D641%26epage%3D651%26doi%3D10.1016%2FS1359-6446%2804%2903163-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">The Physicochemical Challenges of Designing Multiple Ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">4961</span>– <span class="NLM_lpage">4970</span>, <span class="refDoi"> DOI: 10.1021/jm0603015</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0603015" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFejtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4961-4970&author=R.+Morphyauthor=Z.+Rankovic&title=The+Physicochemical+Challenges+of+Designing+Multiple+Ligands&doi=10.1021%2Fjm0603015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The Physicochemical Challenges of Designing Multiple Ligands</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4961-4970</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Compds. designed to bind more than one target can provide a therapeutic benefit relative to highly target-selective ligands.  The physicochem. properties of designed multiple ligands were found to be less druglike than those for preclin. compds. in general.  These properties are controlled by the superfamily to which the targets belong and the lead discovery strategy that was followed.  The properties for peptide G-protein-coupled receptor (GPCR) ligands were the least favorable for oral delivery, whereas transporter, monoamine GPCR, and oxidase ligands were the most druglike.  The lead discovery strategy, framework combination or screening, exerts a profound influence on the property values.  Combining the frameworks from two selective ligands often results in large, complex dual ligands, but druglike ligands can be achieved if the degree of framework overlap is maximized and the size of the selective ligands minimized.  For some target combinations, a screening approach may provide a route to smaller, less complex leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonGHbXyxgv4LVg90H21EOLACvtfcHk0lgx-MewPMItsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFejtL4%253D&md5=c7a227848516d0aa58ed037a582943fe</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm0603015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0603015%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DThe%2520Physicochemical%2520Challenges%2520of%2520Designing%2520Multiple%2520Ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4961%26epage%3D4970%26doi%3D10.1021%2Fjm0603015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maher, C. M.</span></span> <span> </span><span class="NLM_article-title">Sigma1 Pharmacology in the Context of Cancer</span>. <i>Handb. Exp. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>244</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1007/164_2017_38</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1007%2F164_2017_38" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=28744586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFeitbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=244&publication_year=2017&pages=237-308&author=F.+J.+Kimauthor=C.+M.+Maher&title=Sigma1+Pharmacology+in+the+Context+of+Cancer&doi=10.1007%2F164_2017_38"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma1 pharmacology in the context of cancer</span></div><div class="casAuthors">Kim, Felix J.; Maher, Christina M.</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of Experimental Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">244</span>
        (<span class="NLM_cas:issue">Sigma Proteins: Evolution of the Concept of Sigma Receptors</span>),
    <span class="NLM_cas:pages">237-308</span>CODEN:
                <span class="NLM_cas:coden">HEPHD2</span>;
        ISSN:<span class="NLM_cas:issn">1865-0325</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  Sigma1 (also known as sigma-1 receptor, Sig1R, s1 receptor) is a unique pharmacol. regulated integral membrane chaperone or scaffolding protein.  The majority of publications on the subject have focused on the neuropharmacol. of Sigma1.  However, a no. of publications have also suggested a role for Sigma1 in cancer.  Although there is currently no clin. used anti-cancer drug that targets Sigma1, a growing body of evidence supports the potential of Sigma1 ligands as therapeutic agents to treat cancer.  In preclin. models, compds. with affinity for Sigma1 have been reported to inhibit cancer cell proliferation and survival, cell adhesion and migration, tumor growth, to alleviate cancer-assocd. pain, and to have immunomodulatory properties.  This review will highlight that although the literature supports a role for Sigma1 in cancer, several fundamental questions regarding drug mechanism of action and the physiol. relevance of aberrant SIGMAR1 transcript and Sigma1 protein expression in certain cancers remain unanswered or only partially answered.  However, emerging lines of evidence suggest that Sigma1 is a component of the cancer cell support machinery, that it facilitates protein interaction networks, that it allosterically modulates the activity of its assocd. proteins, and that Sigma1 is a selectively multifunctional drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolV7ANX6gwGLVg90H21EOLACvtfcHk0lgx-MewPMItsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFeitbvI&md5=6c5d82c84dce7107d0d471a678bd6cd7</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1007%2F164_2017_38&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F164_2017_38%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DF.%2BJ.%26aulast%3DMaher%26aufirst%3DC.%2BM.%26atitle%3DSigma1%2520Pharmacology%2520in%2520the%2520Context%2520of%2520Cancer%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2017%26volume%3D244%26spage%3D237%26epage%3D308%26doi%3D10.1007%2F164_2017_38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span> <span> </span><span class="NLM_article-title">Sigma-2 Receptor Ligands and Their Perspectives in Cancer Diagnosis and Therapy</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">532</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1002/med.21297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1002%2Fmed.21297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=23922215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsl2qsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=532-566&author=Y.-S.+Huangauthor=H.-L.+Luauthor=L.-J.+Zhangauthor=Z.+Wu&title=Sigma-2+Receptor+Ligands+and+Their+Perspectives+in+Cancer+Diagnosis+and+Therapy&doi=10.1002%2Fmed.21297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-2 Receptor Ligands and Their Perspectives in Cancer Diagnosis and Therapy</span></div><div class="casAuthors">Huang, Yun-Sheng; Lu, He-Lin; Zhang, Lang-Jun; Wu, Zongwen</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">532-566</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The sigma-2 receptor is highly expressed in various rapidly proliferating cancer cells and regarded as a cancer cell biomarker.  Selective sigma-2 ligands have been shown to specifically label the tumor sites, induce cancer cells to undergo apoptosis, and inhibit tumor growth.  Sigma-2 ligands are potentially useful as cancer diagnostics, anticancer therapeutics, or adjuvant anticancer treatment agents.  However, both the cloning of this receptor and the identification of its endogenous ligand have not been successful, and the lack of structural information has severely hindered the understanding of its physiol. roles, its signaling pathways, and the development of more selective sigma-2 ligands.  Recent data have implicated that sigma-2 binding sites are within the lipid rafts and that PGRMC1 (progesterone receptor membrane component 1) complex and sigma-2 receptor may be coupled with EGFR (epidermal growth factor receptor), mTOR (mammalian target of rapamycin), caspases, and ion channels.  Due to its promising applications in cancer management, there are rapidly increasing research efforts that are being directed into this field.  This review article updates the current understanding of sigma-2 receptor and its potential physiol. roles, applications, interaction with other effectors, with special focuses on the development of sigma-2 ligands, their chem. structures, pharmacol. profiles, applications in imaging and anticancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSJIQdLSWe4LVg90H21EOLACvtfcHk0ljjoYUhfI23Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsl2qsrk%253D&md5=bce2e9be88f6cbb9e547f00b4734ce6a</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2Fmed.21297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21297%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.-S.%26aulast%3DLu%26aufirst%3DH.-L.%26aulast%3DZhang%26aufirst%3DL.-J.%26aulast%3DWu%26aufirst%3DZ.%26atitle%3DSigma-2%2520Receptor%2520Ligands%2520and%2520Their%2520Perspectives%2520in%2520Cancer%2520Diagnosis%2520and%2520Therapy%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2014%26volume%3D34%26spage%3D532%26epage%3D566%26doi%3D10.1002%2Fmed.21297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, R.</span></span> <span> </span><span class="NLM_article-title">Small Molecule HDAC Inhibitors: Promising Agents for Breast Cancer Treatment</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">103184</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2019.103184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bioorg.2019.103184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=31408831" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFyjsLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2019&pages=103184&author=M.+Huangauthor=J.+Zhangauthor=C.+Yanauthor=X.+Liauthor=J.+Zhangauthor=R.+Ling&title=Small+Molecule+HDAC+Inhibitors%3A+Promising+Agents+for+Breast+Cancer+Treatment&doi=10.1016%2Fj.bioorg.2019.103184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule HDAC inhibitors: Promising agents for breast cancer treatment</span></div><div class="casAuthors">Huang, Meiling; Zhang, Jian; Yan, Changjiao; Li, Xiaohui; Zhang, Juliang; Ling, Rui</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103184</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Breast cancer, a heterogeneous disease, is the most frequently diagnosed cancer and the second leading cause of cancer-related death among women worldwide.  Recently, epigenetic abnormalities have emerged as an important hallmark of cancer development and progression.  Given that histone deacetylases (HDACs) are crucial to chromatin remodeling and epigenetics, their inhibitors have become promising potential anticancer drugs for research.  Here we reviewed the mechanism and classification of histone deacetylases (HDACs), assocn. between HDACs and breast cancer, classification and structure-activity relationship (SAR) of HDACIs, pharmacokinetic and toxicol. properties of the HDACIs, and registered clin. studies for breast cancer treatment.  In conclusion, HDACIs have shown desirable effects on breast cancer, esp. when they are used in combination with other anticancer agents.  In the coming future, more multicenter and randomized Phase III studies are expected to be conducted pushing promising new therapies closer to the market.  In addn., the design and synthesis of novel HDACIs are also needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXhspBLLPfBrVg90H21EOLACvtfcHk0ljjoYUhfI23Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFyjsLvL&md5=f7d7d29939047fd8c74ceb489913df36</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2019.103184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2019.103184%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLing%26aufirst%3DR.%26atitle%3DSmall%2520Molecule%2520HDAC%2520Inhibitors%253A%2520Promising%2520Agents%2520for%2520Breast%2520Cancer%2520Treatment%26jtitle%3DBioorg.%2520Chem.%26date%3D2019%26volume%3D91%26spage%3D103184%26doi%3D10.1016%2Fj.bioorg.2019.103184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guerriero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotayo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponichtera, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castrillon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pourzia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrasco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobera, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letai, A.</span></span> <span> </span><span class="NLM_article-title">Class IIa HDAC Inhibition Reduces Breast Tumours and Metastases through Anti-Tumour Macrophages</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>543</i></span>,  <span class="NLM_fpage">428</span>– <span class="NLM_lpage">432</span>, <span class="refDoi"> DOI: 10.1038/nature21409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fnature21409" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=28273064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlslegtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=543&publication_year=2017&pages=428-432&author=J.+Guerrieroauthor=A.+Sotayoauthor=H.+Ponichteraauthor=J.+Castrillonauthor=A.+Pourziaauthor=S.+Schadauthor=S.+Johnsonauthor=R.+Carrascoauthor=S.+Lazoauthor=R.+T.+Bronsonauthor=S.+P.+Davisauthor=M.+Loberaauthor=M.+A.+Nolanauthor=A.+Letai&title=Class+IIa+HDAC+Inhibition+Reduces+Breast+Tumours+and+Metastases+through+Anti-Tumour+Macrophages&doi=10.1038%2Fnature21409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Class IIa HDAC inhibition reduces breast tumors and metastases through anti-tumor macrophages</span></div><div class="casAuthors">Guerriero, Jennifer L.; Sotayo, Alaba; Ponichtera, Holly E.; Castrillon, Jessica A.; Pourzia, Alexandra L.; Schad, Sara; Johnson, Shawn F.; Carrasco, Ruben D.; Lazo, Suzan; Bronson, Roderick T.; Davis, Scott P.; Lobera, Mercedes; Nolan, Michael A.; Letai, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">543</span>
        (<span class="NLM_cas:issue">7645</span>),
    <span class="NLM_cas:pages">428-432</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although the main focus of immuno-oncol. has been manipulating the adaptive immune system, harnessing both the innate and adaptive arms of the immune system might produce superior tumor redn. and elimination.  Tumor-assocd. macrophages often have net pro-tumor effects, but their embedded location and their untapped potential provide impetus to discover strategies to turn them against tumors.  Strategies that deplete (anti-CSF-1 antibodies and CSF-1R inhibition) or stimulate (agonistic anti-CD40 or inhibitory anti-CD47 antibodies) tumor-assocd. macrophages have had some success.  We hypothesized that pharmacol. modulation of macrophage phenotype could produce an anti-tumor effect.  We previously reported that a first-in-class selective class IIa histone deacetylase (HDAC) inhibitor, TMP195, influenced human monocyte responses to the colony-stimulating factors CSF-1 and CSF-2 in vitro.  Here, we utilize a macrophage-dependent autochthonous mouse model of breast cancer to demonstrate that in vivo TMP195 treatment alters the tumor microenvironment and reduces tumor burden and pulmonary metastases by modulating macrophage phenotypes.  TMP195 induces the recruitment and differentiation of highly phagocytic and stimulatory macrophages within tumors.  Furthermore, combining TMP195 with chemotherapy regimens or T-cell checkpoint blockade in this model significantly enhances the durability of tumor redn.  These data introduce class IIa HDAC inhibition as a means to harness the anti-tumor potential of macrophages to enhance cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEzcFKak-anrVg90H21EOLACvtfcHk0ljjoYUhfI23Zg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlslegtbc%253D&md5=0356d851bbeb834038527f5190d0e4b8</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fnature21409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature21409%26sid%3Dliteratum%253Aachs%26aulast%3DGuerriero%26aufirst%3DJ.%26aulast%3DSotayo%26aufirst%3DA.%26aulast%3DPonichtera%26aufirst%3DH.%26aulast%3DCastrillon%26aufirst%3DJ.%26aulast%3DPourzia%26aufirst%3DA.%26aulast%3DSchad%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DS.%26aulast%3DCarrasco%26aufirst%3DR.%26aulast%3DLazo%26aufirst%3DS.%26aulast%3DBronson%26aufirst%3DR.%2BT.%26aulast%3DDavis%26aufirst%3DS.%2BP.%26aulast%3DLobera%26aufirst%3DM.%26aulast%3DNolan%26aufirst%3DM.%2BA.%26aulast%3DLetai%26aufirst%3DA.%26atitle%3DClass%2520IIa%2520HDAC%2520Inhibition%2520Reduces%2520Breast%2520Tumours%2520and%2520Metastases%2520through%2520Anti-Tumour%2520Macrophages%26jtitle%3DNature%26date%3D2017%26volume%3D543%26spage%3D428%26epage%3D432%26doi%3D10.1038%2Fnature21409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span> <span> </span><span class="NLM_article-title">HDAC Inhibitors Induce Proline Dehydrogenase (POX) Transcription and Anti-Apoptotic Autophagy in Triple Negative Breast Cancer</span>. <i>Acta Biochim. Biophys. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1064</span>– <span class="NLM_lpage">1070</span>, <span class="refDoi"> DOI: 10.1093/abbs/gmz097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1093%2Fabbs%2Fgmz097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=31559416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVehtrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2019&pages=1064-1070&author=H.+Fangauthor=G.+Duauthor=Q.+Wuauthor=R.+Liuauthor=C.+Chenauthor=J.+Feng&title=HDAC+Inhibitors+Induce+Proline+Dehydrogenase+%28POX%29+Transcription+and+Anti-Apoptotic+Autophagy+in+Triple+Negative+Breast+Cancer&doi=10.1093%2Fabbs%2Fgmz097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibitors induce proline dehydrogenase (POX) transcription and anti-apoptotic autophagy in triple negative breast cancer</span></div><div class="casAuthors">Fang, Huan; Du, Guangshi; Wu, Qiuju; Liu, Rong; Chen, Ceshi; Feng, Jing</div><div class="citationInfo"><span class="NLM_cas:title">Acta Biochimica et Biophysica Sinica</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1064-1070</span>CODEN:
                <span class="NLM_cas:coden">ABBSC2</span>;
        ISSN:<span class="NLM_cas:issn">1745-7270</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is the most aggressive subtype of breast cancer with poor clin. outcomes and without effective targeted therapies.  Numerous studies have suggested that HDAC inhibitors (TSA/SAHA) may be effective in TNBCs.  Proline oxidase, also known as proline dehydrogenase (POX/PRODH), is a key enzyme in the proline metab. pathway and plays a vital role in tumorigenesis.  In this study, we found that HDAC inhibitors (TSA/SAHA) significantly increased POX expression and autophagy through activating AMPK.  Depletion of POX decreased autophagy and increased apoptosis induced by HDAC inhibitors in TNBC cells.  These results suggest that POX contributes to cell survival under chemotherapeutic stresses and might serve as a potential target for treatment of TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqva87oFArx5LVg90H21EOLACvtfcHk0lj-tD9cIRMi0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVehtrrJ&md5=338c0a2db77c2a704d48c63da2e834c6</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1093%2Fabbs%2Fgmz097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fabbs%252Fgmz097%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DH.%26aulast%3DDu%26aufirst%3DG.%26aulast%3DWu%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DJ.%26atitle%3DHDAC%2520Inhibitors%2520Induce%2520Proline%2520Dehydrogenase%2520%2528POX%2529%2520Transcription%2520and%2520Anti-Apoptotic%2520Autophagy%2520in%2520Triple%2520Negative%2520Breast%2520Cancer%26jtitle%3DActa%2520Biochim.%2520Biophys.%2520Sin.%26date%3D2019%26volume%3D51%26spage%3D1064%26epage%3D1070%26doi%3D10.1093%2Fabbs%2Fgmz097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fedele, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlando, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cinieri, S.</span></span> <span> </span><span class="NLM_article-title">Targeting Triple Negative Breast Cancer with Histone Deacetylase Inhibitors</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1199</span>– <span class="NLM_lpage">1206</span>, <span class="refDoi"> DOI: 10.1080/13543784.2017.1386172</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1080%2F13543784.2017.1386172" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=28952409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1alsbbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2017&pages=1199-1206&author=P.+Fedeleauthor=L.+Orlandoauthor=S.+Cinieri&title=Targeting+Triple+Negative+Breast+Cancer+with+Histone+Deacetylase+Inhibitors&doi=10.1080%2F13543784.2017.1386172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting triple negative breast cancer with histone deacetylase inhibitors</span></div><div class="casAuthors">Fedele, Palma; Orlando, Laura; Cinieri, Saverio</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1199-1206</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : Triple neg. breast cancer (TNBC) is a heterogeneous disease characterized by poor outcomes, higher rates of relapse, lack of biomarkers for rational use of targeted treatments and insensitivity to current available treatments.  Histone deacetylase inhibitors (HDACis) perform multiple cytotoxic actions and are emerging as promising multifunctional agents in TNBC.: This review focuses on the challenges so far addressed in the targeted treatment of TNBC and explores the various mechanisms by which HDACis control cancer cell growth, tumor progression and metastases.  Pivotal preclin. trials on HDACis like panobinostat, vorinostat, and entinostat show that these epigenetic agents exert an anti-proliferative effect on TNBC cells and control tumor growth by multiple mechanisms of action, including apoptosis and regulation of the epithelial to mesenchimal transition (EMT).  Combination studies have reported the synergism of HDACis with other anticancer agents.: In recent years, treatment of TNBC has recorded a high no. of failures in the development of targeted agents.  HDACis alone or in combination strategies show promising activity in TNBC and could have implications for the future targeted treatment of TNBC patients.  Future research should identify which agent synergizes better with HDACis and which patient will benefit more from these epigenetic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOqveSSSKwsbVg90H21EOLACvtfcHk0lj-tD9cIRMi0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1alsbbF&md5=c6df0d54d99bdbd171ce10f6431817df</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1080%2F13543784.2017.1386172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2017.1386172%26sid%3Dliteratum%253Aachs%26aulast%3DFedele%26aufirst%3DP.%26aulast%3DOrlando%26aufirst%3DL.%26aulast%3DCinieri%26aufirst%3DS.%26atitle%3DTargeting%2520Triple%2520Negative%2520Breast%2520Cancer%2520with%2520Histone%2520Deacetylase%2520Inhibitors%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2017%26volume%3D26%26spage%3D1199%26epage%3D1206%26doi%3D10.1080%2F13543784.2017.1386172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cubitt, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiappori, A.</span></span> <span> </span><span class="NLM_article-title">Combination of HDAC and Topoisomerase Inhibitors in Small Cell Lung Cancer</span>. <i>Cancer Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">614</span>– <span class="NLM_lpage">622</span>, <span class="refDoi"> DOI: 10.4161/cbt.19848</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.4161%2Fcbt.19848" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=22441819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ensLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=614-622&author=J.+Grayauthor=C.+L.+Cubittauthor=S.+Zhangauthor=A.+Chiappori&title=Combination+of+HDAC+and+Topoisomerase+Inhibitors+in+Small+Cell+Lung+Cancer&doi=10.4161%2Fcbt.19848"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of HDAC and topoisomerase inhibitors in small cell lung cancer</span></div><div class="casAuthors">Gray, Jhanelle; Cubitt, Christopher L.; Zhang, Shumin; Chiappori, Alberto</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">614-622</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors, including MGCD0103 and vorinostat, have led to tumor growth inhibition and apoptosis in vivo.  However, with limited single-agent activity demonstrated in solid tumor trials, we examd. the potential for enhanced effects in combination with topoisomerase I and II inhibitors, a staple for treatment in refractory small cell lung cancer (SCLC).  SCLC cell lines were exposed to increasing concns. of single-agent HDAC inhibitors and topoisomerase inhibitors, in various combinations, to assess for cell viability, additivity or synergy and apoptosis.  We found that MGCD0103 and vorinostat decreased cell viability by at least 60 and 80%, resp.  In the majority of cell lines, the strongest synergism was seen when vorinostat was followed by either etoposide or topotecan; concurrent therapy led to antagonism in most cell lines.  Synergistic effects were seen when MGCD0103 was given concurrently or sequentially with both amrubicin and epirubicin.  Enhanced additive effects leading to caspase activation were noted for the combination of MGCD0103 or vorinostat with a topoisomerase inhibitor vs. either agent alone.  Thus, the combination of HDAC inhibitors and topoisomerase inhibitors showed enhanced cytotoxic effects in SCLC cell lines.  Further evaluation in a clin. setting may be warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB97O3PJ6oa7Vg90H21EOLACvtfcHk0lj-tD9cIRMi0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ensLfJ&md5=55bf2ec649674011b2b0bb98ae8dd6a7</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.4161%2Fcbt.19848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.19848%26sid%3Dliteratum%253Aachs%26aulast%3DGray%26aufirst%3DJ.%26aulast%3DCubitt%26aufirst%3DC.%2BL.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DChiappori%26aufirst%3DA.%26atitle%3DCombination%2520of%2520HDAC%2520and%2520Topoisomerase%2520Inhibitors%2520in%2520Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2012%26volume%3D13%26spage%3D614%26epage%3D622%26doi%3D10.4161%2Fcbt.19848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Edderkaoui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chheda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soufi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zayou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujan, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boros, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tajbakhsh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhav, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhowmick, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habtezion, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murali, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandol, S. J.</span></span> <span> </span><span class="NLM_article-title">An Inhibitor of GSK3B and HDACs Kills Pancreatic Cancer Cells and Slows Pancreatic Tumor Growth and Metastasis in Mice</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">1985</span>– <span class="NLM_lpage">1998</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2018.08.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1053%2Fj.gastro.2018.08.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=30144430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVSgtb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2018&pages=1985-1998&author=M.+Edderkaouiauthor=C.+Chhedaauthor=B.+Soufiauthor=F.+Zayouauthor=R.+W.+Huauthor=V.+K.+Ramanujanauthor=X.+Panauthor=L.+G.+Borosauthor=J.+Tajbakhshauthor=A.+Madhavauthor=N.+A.+Bhowmickauthor=Q.+Wangauthor=M.+Lewisauthor=R.+Tuliauthor=A.+Habtezionauthor=R.+Muraliauthor=S.+J.+Pandol&title=An+Inhibitor+of+GSK3B+and+HDACs+Kills+Pancreatic+Cancer+Cells+and+Slows+Pancreatic+Tumor+Growth+and+Metastasis+in+Mice&doi=10.1053%2Fj.gastro.2018.08.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">An Inhibitor of GSK3B and HDACs Kills Pancreatic Cancer Cells and Slows Pancreatic Tumor Growth and Metastasis in Mice</span></div><div class="casAuthors">Edderkaoui, Mouad; Chheda, Chintan; Soufi, Badr; Zayou, Fouzia; Hu, Robert W.; Ramanujan, V. Krishnan; Pan, Xinlei; Boros, Laszlo G.; Tajbakhsh, Jian; Madhav, Anisha; Bhowmick, Neil A.; Wang, Qiang; Lewis, Michael; Tuli, Richard; Habtezion, Aida; Murali, Ramachandran; Pandol, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1985-1998.e5</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Growth, progression, and drug resistance of pancreatic ductal adenocarcinomas (PDACs) have been assocd. with increased levels and activity of glycogen synthase kinase 3 beta (GSK3B) and histone deacetylases (HDACs).  We designed and synthesized mols. that simultaneously inhibit the activities of both enzymes.  We tested the effects of one of these mols., Metavert, in pancreatic cancer cells and mice with pancreatic tumors.  We tested the ability of Metavert to bind GSK3B and HDACs using surface plasmon resonance.  MIA PaCa-2, Bx-PC3, HPAF-II, and HPDE6 cell lines were incubated with different concns. of Metavert, with or without paclitaxel or gemcitabine, or with other inhibitors of GSK3B and HDACs; cells were analyzed for apoptosis and migration and by immunoblotting, immunofluorescence, and real-time polymerase chain reaction.  Kras[symbol omitted]/LSLG12D;Trp53[symbol omitted]/LSLR172H;Pdx-1-Cre (KPC) mice (2 mo old) were given injections of Metavert (5 mg/kg, 3 times/wk) or vehicle (control).  B6.129J mice with tumors grown from UN-KPC961-Luc cells were given injections of Metavert or vehicle.  Tumors and metastases were counted and pancreata were analyzed by immunohistochem.  Glucose metab. was measured using 13C-glucose tracer and mass spectroscopy and flow cytometry.  Cytokine levels in blood samples were measured using multiplexing ELISA.  Metavert significantly reduced survival of PDAC cells but not nontransformed cells; the agent reduced markers of the epithelial-to-mesenchymal transition and stem cells in PDAC cell lines.  Cells incubated with Metavert in combination with irradn. and paclitaxel or gemcitabine had reduced survival compared with cells incubated with either agent alone; Metavert increased killing of drug-resistant PDAC cells by paclitaxel and gemcitabine.  PDAC cells incubated with Metavert acquired normalized glucose metab.  Administration of Metavert (alone or in combination with gemcitibine) to KPC mice or mice with syngeneic tumors significantly increased their survival times, slowed tumor growth, prevented tumor metastasis, decreased tumor infiltration by tumor-assocd. macrophages, and decreased blood levels of cytokines.  In studies of PDAC cells and 2 mouse models of PDAC, we found a dual inhibitor of GSK3B and HDACs (Metavert) to induce cancer cell apoptosis, reduce migration and expression of stem cell markers, and slow growth of tumors and metastases.  Metavert had synergistic effects with gemcitabine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfpL9zAQLf7rVg90H21EOLACvtfcHk0lhiVIeH5obanA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVSgtb3J&md5=aa8b71bf074275487b3f7b0d87729538</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2018.08.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2018.08.028%26sid%3Dliteratum%253Aachs%26aulast%3DEdderkaoui%26aufirst%3DM.%26aulast%3DChheda%26aufirst%3DC.%26aulast%3DSoufi%26aufirst%3DB.%26aulast%3DZayou%26aufirst%3DF.%26aulast%3DHu%26aufirst%3DR.%2BW.%26aulast%3DRamanujan%26aufirst%3DV.%2BK.%26aulast%3DPan%26aufirst%3DX.%26aulast%3DBoros%26aufirst%3DL.%2BG.%26aulast%3DTajbakhsh%26aufirst%3DJ.%26aulast%3DMadhav%26aufirst%3DA.%26aulast%3DBhowmick%26aufirst%3DN.%2BA.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLewis%26aufirst%3DM.%26aulast%3DTuli%26aufirst%3DR.%26aulast%3DHabtezion%26aufirst%3DA.%26aulast%3DMurali%26aufirst%3DR.%26aulast%3DPandol%26aufirst%3DS.%2BJ.%26atitle%3DAn%2520Inhibitor%2520of%2520GSK3B%2520and%2520HDACs%2520Kills%2520Pancreatic%2520Cancer%2520Cells%2520and%2520Slows%2520Pancreatic%2520Tumor%2520Growth%2520and%2520Metastasis%2520in%2520Mice%26jtitle%3DGastroenterology%26date%3D2018%26volume%3D155%26spage%3D1985%26epage%3D1998%26doi%3D10.1053%2Fj.gastro.2018.08.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rana, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diermeier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanif, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosengren, R. J.</span></span> <span> </span><span class="NLM_article-title">Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer</span>. <i>Biomedicines</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">22</span>, <span class="refDoi"> DOI: 10.3390/biomedicines8020022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3390%2Fbiomedicines8020022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlant7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=22&author=Z.+Ranaauthor=S.+Diermeierauthor=M.+Hanifauthor=R.+J.+Rosengren&title=Understanding+Failure+and+Improving+Treatment+Using+HDAC+Inhibitors+for+Prostate+Cancer&doi=10.3390%2Fbiomedicines8020022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding failure and improving treatment using HDAC inhibitors for prostate cancer</span></div><div class="casAuthors">Rana, Zohaib; Diermeier, Sarah; Hanif, Muhammad; Rosengren, Rhonda J.</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicines</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">22</span>CODEN:
                <span class="NLM_cas:coden">BIOMID</span>;
        ISSN:<span class="NLM_cas:issn">2227-9059</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Novel treatment regimens are required for castration-resistant prostate cancers (CRPCs) that become unresponsive to std. treatments, such as docetaxel and enzalutamide.  Histone deacetylase (HDAC) inhibitors showed promising results in hematol. malignancies, but they failed in solid tumors such as prostate cancer, despite the overexpression of HDACs in CRPC.  Four HDAC inhibitors, vorinostat, pracinostat, panobinostat and romidepsin, underwent phase II clin. trials for prostate cancers; however, phase III trials were not recommended due to a majority of patients exhibiting either toxicity or disease progression.  In this review, the pharmacodynamic reasons for the failure of HDAC inhibitors were assessed and placed in the context of the advancements in the understanding of CRPCs, HDACs and resistance mechanisms.  The review focuses on three themes: evolution of androgen receptor-neg. prostate cancers, development of resistance mechanisms and differential effects of HDACs.  In conclusion, advancements can be made in this field by characterizing HDACs in prostate tumors more extensively, as this will allow more specific drugs catering to the specific HDAC subtypes to be designed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPlgfpRIlu5rVg90H21EOLACvtfcHk0lhiVIeH5obanA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlant7nK&md5=ab6f27899dded24a2679b3497a9d1524</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.3390%2Fbiomedicines8020022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fbiomedicines8020022%26sid%3Dliteratum%253Aachs%26aulast%3DRana%26aufirst%3DZ.%26aulast%3DDiermeier%26aufirst%3DS.%26aulast%3DHanif%26aufirst%3DM.%26aulast%3DRosengren%26aufirst%3DR.%2BJ.%26atitle%3DUnderstanding%2520Failure%2520and%2520Improving%2520Treatment%2520Using%2520HDAC%2520Inhibitors%2520for%2520Prostate%2520Cancer%26jtitle%3DBiomedicines%26date%3D2020%26volume%3D8%26spage%3D22%26doi%3D10.3390%2Fbiomedicines8020022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tejada, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montilla-García, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cikes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Fernández, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-Cano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Cantero, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penninger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobos, E. J.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 Receptors Control Immune-Driven Peripheral Opioid Analgesia during Inflammation in Mice</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">8396</span>– <span class="NLM_lpage">8401</span>, <span class="refDoi"> DOI: 10.1073/pnas.1620068114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1073%2Fpnas.1620068114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=28716934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFOru73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=8396-8401&author=M.+A.+Tejadaauthor=A.+Montilla-Garc%C3%ADaauthor=S.+J.+Croninauthor=D.+Cikesauthor=C.+S%C3%A1nchez-Fern%C3%A1ndezauthor=R.+Gonz%C3%A1lez-Canoauthor=M.+C.+Ruiz-Canteroauthor=J.+M.+Penningerauthor=J.+M.+Velaauthor=J.+Baeyensauthor=E.+J.+Cobos&title=Sigma-1+Receptors+Control+Immune-Driven+Peripheral+Opioid+Analgesia+during+Inflammation+in+Mice&doi=10.1073%2Fpnas.1620068114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptors control immune-driven peripheral opioid analgesia during inflammation in mice</span></div><div class="casAuthors">Tejada, Miguel A.; Montilla-Garcia, Angeles; Cronin, Shane J.; Cikes, Domagoj; Sanchez-Fernandez, Cristina; Gonzalez-Cano, Rafael; Ruiz-Cantero, M. Carmen; Penninger, Josef M.; Vela, Jose M.; Baeyens, Jose M.; Cobos, Enrique J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">8396-8401</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Sigma-1 antagonism potentiates the antinociceptive effects of opioid drugs, so sigma-1 receptors constitute a biol. brake to opioid drug-induced analgesia.  The pathophysiol. role of this process is unknown.  We aimed to investigate whether sigma-1 antagonism reduces inflammatory pain through the disinhibition of the endogenous opioidergic system in mice.  The selective sigma-1 antagonists BD-1063 and S1RA abolished mech. and thermal hyperalgesia in mice with carrageenan-induced acute (3 h) inflammation.  Sigma-1-mediated antihyperalgesia was reversed by the opioid antagonists naloxone and naloxone methiodide (a peripherally restricted naloxone analog) and by local administration at the inflamed site of monoclonal antibody 3-E7, which recognizes the pan-opioid sequence Tyr-Gly-Gly-Phe at the N terminus of most endogenous opioid peptides (EOPs).  Neutrophils expressed pro-opiomelanocortin, the precursor of β-endorphin (a known EOP), and constituted the majority of the acute immune infiltrate. β-endorphin levels increased in the inflamed paw, and this increase and the antihyperalgesic effects of sigma-1 antagonism were abolished by reducing the neutrophil load with in vivo administration of an anti-Ly6G antibody.  The opioid-dependent sigma-1 antihyperalgesic effects were preserved 5 d after carrageenan administration, where macrophages/monocytes were found to express pro-opiomelanocortin and to now constitute the majority of the immune infiltrate.  These results suggest that immune cells harboring EOPs are needed for the antihyperalgesic effects of sigma-1 antagonism during inflammation.  In conclusion, sigma-1 receptors curtail immune-driven peripheral opioid analgesia, and sigma-1 antagonism produces local opioid analgesia by enhancing the action of EOPs of immune origin, maximizing the analgesic potential of immune cells that naturally accumulate in painful inflamed areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqktSX7oMTPDrVg90H21EOLACvtfcHk0lhiVIeH5obanA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFOru73P&md5=ede5abe4e1e51845e9bd46960a39d54a</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1620068114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1620068114%26sid%3Dliteratum%253Aachs%26aulast%3DTejada%26aufirst%3DM.%2BA.%26aulast%3DMontilla-Garc%25C3%25ADa%26aufirst%3DA.%26aulast%3DCronin%26aufirst%3DS.%2BJ.%26aulast%3DCikes%26aufirst%3DD.%26aulast%3DS%25C3%25A1nchez-Fern%25C3%25A1ndez%26aufirst%3DC.%26aulast%3DGonz%25C3%25A1lez-Cano%26aufirst%3DR.%26aulast%3DRuiz-Cantero%26aufirst%3DM.%2BC.%26aulast%3DPenninger%26aufirst%3DJ.%2BM.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26aulast%3DBaeyens%26aufirst%3DJ.%26aulast%3DCobos%26aufirst%3DE.%2BJ.%26atitle%3DSigma-1%2520Receptors%2520Control%2520Immune-Driven%2520Peripheral%2520Opioid%2520Analgesia%2520during%2520Inflammation%2520in%2520Mice%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26spage%3D8396%26epage%3D8401%26doi%3D10.1073%2Fpnas.1620068114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, X.</span></span> <span> </span><span class="NLM_article-title">Allosteric Modulation of Sigma-1 Receptors by SKF83959 Inhibits Microglia-Mediated Inflammation</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">904</span>– <span class="NLM_lpage">914</span>, <span class="refDoi"> DOI: 10.1111/jnc.13182</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1111%2Fjnc.13182" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=26031312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWqtrfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2015&pages=904-914&author=Z.+Wuauthor=L.+Liauthor=L.-T.+Zhengauthor=Z.+Xuauthor=L.+Guoauthor=X.+Zhen&title=Allosteric+Modulation+of+Sigma-1+Receptors+by+SKF83959+Inhibits+Microglia-Mediated+Inflammation&doi=10.1111%2Fjnc.13182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric modulation of sigma-1 receptors by SKF83959 inhibits microglia-mediated inflammation</span></div><div class="casAuthors">Wu, Zhuang; Li, Linlang; Zheng, Long-Tai; Xu, Zhihong; Guo, Lin; Zhen, Xuechu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">904-914</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Recent studies have shown that sigma-1 receptor orthodox agonists can inhibit neuroinflammation.  SKF83959 (3-methyl-6-chloro-7,8-hydroxy-1-[3-methylphenyl]-2,3,4,5-tetrahydro-1H-3-benzazepine), an atypical dopamine receptor-1 agonist, has been recently identified as a potent allosteric modulator of sigma-1 receptor.  Here, the authors investigated the anti-inflammatory effects of SKF83959 in lipopolysaccharide (LPS)-stimulated BV2 microglia.  The authors' results indicated that SKF83959 significantly suppressed the expression/release of the pro-inflammatory mediators, such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), inducible nitric oxide synthase (iNOS), and inhibited the generation of reactive oxygen species.  All of these responses were blocked by selective sigma-1 receptor antagonists (BD1047 or BD1063) and by ketoconazole (an inhibitor of enzyme cytochrome c17 to inhibit the synthesis of endogenous dehydroepiandrosterone, DHEA).  Addnl., the authors found that SKF83959 promoted the binding activity of DHEA with sigma-1 receptors, and enhanced the inhibitory effects of DHEA on LPS-induced microglia activation in a synergic manner.  Furthermore, in a microglia-conditioned media system, SKF83959 inhibited the cytotoxicity of conditioned medium generated by LPS-activated microglia toward HT-22 neuroblastoma cells.  Taken together, the authors' study provides the first evidence that allosteric modulation of sigma-1 receptors by SKF83959 inhibits microglia-mediated inflammation.  SKF83959 is a potent allosteric modulator of sigma-1 receptor.  The authors' results indicated that SKF83959 enhanced the activity of endogenous dehydroepiandrosterone (DHEA) in a synergic manner, and inhibited the activation of BV2 microglia and the expression/release of the pro-inflammatory mediators, such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), inducible nitric oxide synthase (iNOS).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn8L1hvvxV_LVg90H21EOLACvtfcHk0lhGul6XW760Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWqtrfM&md5=e065dcdcf61b88a93eae9799d1af230a</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1111%2Fjnc.13182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjnc.13182%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DL.-T.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DZhen%26aufirst%3DX.%26atitle%3DAllosteric%2520Modulation%2520of%2520Sigma-1%2520Receptors%2520by%2520SKF83959%2520Inhibits%2520Microglia-Mediated%2520Inflammation%26jtitle%3DJ.%2520Neurochem.%26date%3D2015%26volume%3D134%26spage%3D904%26epage%3D914%26doi%3D10.1111%2Fjnc.13182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruscher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inácio, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valind, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowshan Ravan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuric, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieloch, T.</span></span> <span> </span><span class="NLM_article-title">Effects of the Sigma-1 Receptor Agonist 1-(3,4-Dimethoxyphenethyl)-4-(3-Phenylpropyl)-Piperazine Dihydro-Chloride on Inflammation after Stroke</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">e45118</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0045118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1371%2Fjournal.pone.0045118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=23028794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVWlsb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&author=K.+Ruscherauthor=A.+R.+In%C3%A1cioauthor=K.+Valindauthor=A.+Rowshan+Ravanauthor=E.+Kuricauthor=T.+Wieloch&title=Effects+of+the+Sigma-1+Receptor+Agonist+1-%283%2C4-Dimethoxyphenethyl%29-4-%283-Phenylpropyl%29-Piperazine+Dihydro-Chloride+on+Inflammation+after+Stroke&doi=10.1371%2Fjournal.pone.0045118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of the sigma-1 receptor agonist 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)-piperazine dihydro-chloride on inflammation after stroke</span></div><div class="casAuthors">Ruscher, Karsten; Inacio, Ana R.; Valind, Kristian; Ravan, Arman Rowshan; Kuric, Enida; Wieloch, Tadeusz</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e45118</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Activation of the sigma-1 receptor (Sig-1R) improves functional recovery in models of exptl. stroke and is known to modulate microglia function.  The present study was conducted to investigate if Sig-1R activation after exptl. stroke affects mediators of the inflammatory response in the ischemic hemisphere.  Male Wistar rats were subjected to transient occlusion of the middle cerebral artery (MCAO) and injected with the specific Sig-1R agonist 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride (SA4503) or saline for 5 days starting on day 2 after MCAO.  Treatment did not affect the increased levels of the pro-inflammatory cytokines interleukin 1 beta (IL-1β), tumor necrosis factor alpha (TNF-α), interferon gamma (IFN-γ), interleukin 4 (IL-4), interleukin 5 (IL-5) and interleukin 13 (IL-13) in the infarct core and peri-infarct area after MCAO.  In addn., treatment with SA4503 did not affect elevated levels of nitrite, TNF-α and IL-1β obsd. in primary cultures of microglia exposed to combined Hypoxia/Aglycemia, while the unspecific sigma receptor ligand 1,3-di-o-tolylguanidine (DTG) significantly decreased the prodn. of nitrite and levels of TNF-α.  Anal. of the ischemic hemisphere also revealed increased levels of ionized calcium binding adaptor mol. 1 (Iba1) levels in the infarct core of SA4503 treated animals.  However, no difference in Iba1 immunoreactivity was detected in the infarct core.  Also, levels of the proliferation marker proliferating cell nuclear antigen (PCNA) and OX-42 were not increased in the infarct core in rats treated with SA4503.  Together, our results suggest that sigma-1 receptor activation affects Iba1 expression in microglia/macrophages of the ischemic hemisphere after exptl. stroke but does not affect post-stroke inflammatory mediators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAvyBGCVtvQ7Vg90H21EOLACvtfcHk0lhGul6XW760Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVWlsb7F&md5=838dcf5e3cf3d68402f0f51c8fdb5a37</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0045118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0045118%26sid%3Dliteratum%253Aachs%26aulast%3DRuscher%26aufirst%3DK.%26aulast%3DIn%25C3%25A1cio%26aufirst%3DA.%2BR.%26aulast%3DValind%26aufirst%3DK.%26aulast%3DRowshan%2BRavan%26aufirst%3DA.%26aulast%3DKuric%26aufirst%3DE.%26aulast%3DWieloch%26aufirst%3DT.%26atitle%3DEffects%2520of%2520the%2520Sigma-1%2520Receptor%2520Agonist%25201-%25283%252C4-Dimethoxyphenethyl%2529-4-%25283-Phenylpropyl%2529-Piperazine%2520Dihydro-Chloride%2520on%2520Inflammation%2520after%2520Stroke%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26doi%3D10.1371%2Fjournal.pone.0045118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández-Castañeda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beiter, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodfolk, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaultier, A.</span></span> <span> </span><span class="NLM_article-title">Modulation of the Sigma-1 Receptor-IRE1 Pathway Is Beneficial in Preclinical Models of Inflammation and Sepsis</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">eaau5266</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.aau5266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1126%2Fscitranslmed.aau5266" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=30728287" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&author=D.+A.+Rosenauthor=S.+M.+Sekiauthor=A.+Fern%C3%A1ndez-Casta%C3%B1edaauthor=R.+M.+Beiterauthor=J.+D.+Ecclesauthor=J.+A.+Woodfolkauthor=A.+Gaultier&title=Modulation+of+the+Sigma-1+Receptor-IRE1+Pathway+Is+Beneficial+in+Preclinical+Models+of+Inflammation+and+Sepsis&doi=10.1126%2Fscitranslmed.aau5266"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aau5266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aau5266%26sid%3Dliteratum%253Aachs%26aulast%3DRosen%26aufirst%3DD.%2BA.%26aulast%3DSeki%26aufirst%3DS.%2BM.%26aulast%3DFern%25C3%25A1ndez-Casta%25C3%25B1eda%26aufirst%3DA.%26aulast%3DBeiter%26aufirst%3DR.%2BM.%26aulast%3DEccles%26aufirst%3DJ.%2BD.%26aulast%3DWoodfolk%26aufirst%3DJ.%2BA.%26aulast%3DGaultier%26aufirst%3DA.%26atitle%3DModulation%2520of%2520the%2520Sigma-1%2520Receptor-IRE1%2520Pathway%2520Is%2520Beneficial%2520in%2520Preclinical%2520Models%2520of%2520Inflammation%2520and%2520Sepsis%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2019%26volume%3D11%26doi%3D10.1126%2Fscitranslmed.aau5266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dou, X.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z.</span></span> <span> </span><span class="NLM_article-title">Paeoniflorin Exerts Neuroprotective Effects by Modulating the M1/M2 Subset Polarization of Microglia/Macrophages in the Hippocampal CA1 Region of Vascular Dementia Rats via Cannabinoid Receptor 2</span>. <i>Chin. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">14</span>, <span class="refDoi"> DOI: 10.1186/s13020-018-0173-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1186%2Fs13020-018-0173-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=29560022" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisV2ms7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=14&author=X.-Q.+Luoauthor=A.+Liauthor=X.+Yangauthor=X.+Xiaoauthor=R.+Huauthor=T.-W.+Wangauthor=X.-Y.+Douauthor=D.-J.+Yangauthor=Z.+Dong&title=Paeoniflorin+Exerts+Neuroprotective+Effects+by+Modulating+the+M1%2FM2+Subset+Polarization+of+Microglia%2FMacrophages+in+the+Hippocampal+CA1+Region+of+Vascular+Dementia+Rats+via+Cannabinoid+Receptor+2&doi=10.1186%2Fs13020-018-0173-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Paeoniflorin exerts neuroprotective effects by modulating the M1/M2 subset polarization of microglia/macrophages in the hippocampal CA1 region of vascular dementia rats via cannabinoid receptor 2</span></div><div class="casAuthors">Luo, Xian-Qin; Li, Ao; Yang, Xue; Xiao, Xiao; Hu, Rong; Wang, Tian-Wen; Dou, Xiao-Yun; Yang, Da-Jian; Dong, Zhi</div><div class="citationInfo"><span class="NLM_cas:title">Chinese Medicine (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14/1-14/17</span>CODEN:
                <span class="NLM_cas:coden">CMHEBK</span>;
        ISSN:<span class="NLM_cas:issn">1749-8546</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Cerebral hypoperfusion is a pivotal risk factor for vascular dementia (VD), for which effective therapy remains inadequate.  Persistent inflammatory responses and excessive chemotaxis of microglia/macrophages in the brain may accelerate the progression of VD.  Endocannabinoids are involved in neuronal protection against inflammation-induced neuronal injury.  Cannabinoids acting at cannabinoid receptor 2 (CB2R) can decrease inflammation.  Based on the identification of paeoniflorin (PF) as a CB2R agonist, we investigated the neuroprotective and microglia/macrophages M1 to M2 polarization promoting effects of PF in a permanent four-vessel occlusion rat model.  Methods: One week after surgery, PF was i.p. administered at a dose of 40 mg/kg once a day for 28 successive days.  The effects of PF on memory deficit were investigated by a Morris water maze test, and the effects of PF on hippocampal neuronal damage were evaluated by light microscope and electron microscope.  The mRNA and protein expression levels of key mols. related to the M1/M2 polarization of microglia/macrophages were assessed by RT-qPCR and Western blotting, resp.  Results: Administration of PF could significantly attenuate cerebral hypoperfusion-induced impairment of learning and memory and reduce the morphol. and ultrastructural changes in the hippocampal CA1 region of rats.  Moreover, PF promoted an M1 to M2 phenotype transition in microglia/macrophages in the hippocampus of rats.  In addn. to its inhibitory property against proinflammatory M1 mediator expression, such as IL-1β, IL-6, TNF-α and NO, PF dramatically up-regulated expression of anti-inflammatory cytokines IL-10 and TGF-β1.  Importantly, CB2R antagonist AM630 abolished these beneficial effects produced by PF on learning, memory and hippocampus structure in rats, as well as the polarization of microglia/macrophages to the M2 phenotype.  Addnl., PF treatment significantly inhibited cerebral hypoperfusion-induced mTOR/NF-κB proinflammatory pathway and enhanced PI3K/Akt anti-inflammatory pathway.  Effects of PF on these signaling pathways were effectively attenuated when rats were co-treated with PF and AM630, indicating that the mTOR/NF-κB and PI3K/Akt signaling pathways were involved in the PF effects through CB2R activation.  Conclusion: These findings demonstrated PF exerts its neuroprotective effect and shifts the inflammatory milieu toward resoln. by modulation of microglia/macrophage polarization via CB2R activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_ktU0wl5Y4rVg90H21EOLACvtfcHk0lj3l4vGFan63g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisV2ms7jJ&md5=130f2a1ec848eb6a3f18a133fa2fea8c</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1186%2Fs13020-018-0173-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13020-018-0173-1%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DX.-Q.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DXiao%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DT.-W.%26aulast%3DDou%26aufirst%3DX.-Y.%26aulast%3DYang%26aufirst%3DD.-J.%26aulast%3DDong%26aufirst%3DZ.%26atitle%3DPaeoniflorin%2520Exerts%2520Neuroprotective%2520Effects%2520by%2520Modulating%2520the%2520M1%252FM2%2520Subset%2520Polarization%2520of%2520Microglia%252FMacrophages%2520in%2520the%2520Hippocampal%2520CA1%2520Region%2520of%2520Vascular%2520Dementia%2520Rats%2520via%2520Cannabinoid%2520Receptor%25202%26jtitle%3DChin.%2520Med.%26date%3D2018%26volume%3D13%26spage%3D14%26doi%3D10.1186%2Fs13020-018-0173-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, G.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid Receptor-2 Stimulation Suppresses Neuroinflammation by Regulating Microglial M1/M2 Polarization through the CAMP/PKA Pathway in an Experimental GMH Rat Model</span>. <i>Brain, Behav., Immun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">118</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1016/j.bbi.2016.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bbi.2016.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=27261088" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC28XpvFamsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2016&pages=118-129&author=Y.+Taoauthor=L.+Liauthor=B.+Jiangauthor=Z.+Fengauthor=L.+Yangauthor=J.+Tangauthor=Q.+Chenauthor=J.+Zhangauthor=Q.+Tanauthor=H.+Fengauthor=Z.+Chenauthor=G.+Zhu&title=Cannabinoid+Receptor-2+Stimulation+Suppresses+Neuroinflammation+by+Regulating+Microglial+M1%2FM2+Polarization+through+the+CAMP%2FPKA+Pathway+in+an+Experimental+GMH+Rat+Model&doi=10.1016%2Fj.bbi.2016.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid receptor-2 stimulation suppresses neuroinflammation by regulating microglial M1/M2 polarization through the cAMP/PKA pathway in an experimental GMH rat model</span></div><div class="casAuthors">Tao, Yihao; Li, Lin; Jiang, Bing; Feng, Zhou; Yang, Liming; Tang, Jun; Chen, Qianwei; Zhang, Jianbo; Tan, Qiang; Feng, Hua; Chen, Zhi; Zhu, Gang</div><div class="citationInfo"><span class="NLM_cas:title">Brain, Behavior, and Immunity</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">118-129</span>CODEN:
                <span class="NLM_cas:coden">BBIMEW</span>;
        ISSN:<span class="NLM_cas:issn">0889-1591</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Excessive inflammatory responses are involved in secondary brain injury during germinal matrix hemorrhage (GMH).  The process of microglial polarization to the pro-inflammatory M1 or anti-inflammatory M2 phenotypes is considered to occur in a major immunomodulatory manner during brain inflammation.  We previously found that cannabinoid receptor-2 (CB2R) stimulation attenuated microglial accumulation and brain injury following exptl. GMH.  However, whether CB2R has effects on microglial polarization after GMH remains unclear.  Herein, we investigated the effects of CB2R stimulation on neuroinflammation after exptl. GMH and the potential mechanisms that mediate M1/M2 microglial phenotype regulation.  The results indicated that during the GMH acute phase, microglia primarily polarized to the M1 phenotype and induced an overwhelming release of pro-inflammatory cytokines.  However, JWH133, a selective CB2R agonist, significantly prevented the pro-inflammatory cytokine release while promoting an M1 to M2 phenotype transformation in microglia, resulting in an increased anti-inflammatory cytokine release.  Moreover, in thrombin-induced rat primary microglial cells, JWH133 reduced the pro-inflammatory cytokine levels and M1 phenotype by enhancing the acquisition of the M2 phenotype.  Addnl., JWH133 facilitated synthesis of cAMP (cAMP) and its downstream effectors, phosphorylated cAMP-dependent protein kinase (p-PKA) and exchange protein activated by cyclic-AMP 1 (Epac1).  The promoting effects of JWH133 on M2 polarization were attenuated with a specific PKA inhibitor but not with an Epac inhibitor, indicating that the cAMP/PKA signaling pathway was involved in the JWH133 effects.  This is the first study to propose that promotion of microglial M2 polarization through the cAMP/PKA pathway participates in the CB2R-mediated anti-inflammatory effects after GMH induction.  The results will help to further understand the mechanisms that underlie neuroprotection by CB2R in GMH and promote clin. translational research for CB2R agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4Cj43phmm1bVg90H21EOLACvtfcHk0lj3l4vGFan63g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpvFamsr8%253D&md5=9fd6079a5ec6c68346109201d2a92124</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.bbi.2016.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbi.2016.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DTao%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DFeng%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DQ.%26aulast%3DFeng%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DG.%26atitle%3DCannabinoid%2520Receptor-2%2520Stimulation%2520Suppresses%2520Neuroinflammation%2520by%2520Regulating%2520Microglial%2520M1%252FM2%2520Polarization%2520through%2520the%2520CAMP%252FPKA%2520Pathway%2520in%2520an%2520Experimental%2520GMH%2520Rat%2520Model%26jtitle%3DBrain%252C%2520Behav.%252C%2520Immun.%26date%3D2016%26volume%3D58%26spage%3D118%26epage%3D129%26doi%3D10.1016%2Fj.bbi.2016.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sackett, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Endocannabinoid Modulation of Microglial Phenotypes in Neuropathology</span>. <i>Front. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">87</span>, <span class="refDoi"> DOI: 10.3389/fneur.2020.00087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3389%2Ffneur.2020.00087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=32117037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BB387nvFOmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=87&author=M.+Tanakaauthor=S.+Sackettauthor=Y.+Zhang&title=Endocannabinoid+Modulation+of+Microglial+Phenotypes+in+Neuropathology&doi=10.3389%2Ffneur.2020.00087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Endocannabinoid Modulation of Microglial Phenotypes in Neuropathology</span></div><div class="casAuthors">Tanaka Mikiei; Sackett Scott; Zhang Yumin</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neurology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">87</span>
        ISSN:<span class="NLM_cas:issn">1664-2295</span>.
    </div><div class="casAbstract">Microglia, the resident immune cells of the central nervous system, mediate brain homeostasis by controlling neuronal proliferation/differentiation and synaptic activity.  In response to external signals from neuropathological conditions, homeostatic (M0) microglia can adopt one of two activation states: the classical (M1) activation state, which secretes mediators of the proinflammatory response, and the alternative (M2) activation state, which presumably mediates the resolution of neuroinflammation and tissue repair/remodeling.  Since chronic inflammatory activation of microglia is correlated with several neurodegenerative diseases, functional modulation of microglial phenotypes has been considered as a potential therapeutic strategy.  The endocannabinoid (eCB) system, composed of cannabinoid receptors and ligands and their metabolic/biosynthetic enzymes, has been shown to activate anti-inflammatory signaling pathways that modulate immune cell functions.  Growing evidence has demonstrated that endogenous, synthetic, and plant-derived eCB agonists possess therapeutic effects on several neuropathologies; however, the molecular mechanisms that mediate the anti-inflammatory effects have not yet been identified.  Over the last decade, it has been revealed that the eCB system modulates microglial activation and population.  In this review, we thoroughly examine recent studies on microglial phenotype modulation by eCB in neuroinflammatory and neurodegenerative disease conditions.  We hypothesize that cannabinoid 2 receptor (CB2R) signaling shifts the balance of expression between neuroinflammatory (M1-type) genes, neuroprotective (M2-type) genes, and homeostatic (M0-type) genes toward the latter two gene expressions, by which microglia acquire therapeutic functionality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQr8TVfT8vUqWmbXvSEQle5fW6udTcc2eaSWJ8lqx9MBrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387nvFOmsQ%253D%253D&md5=ae51dd20a721dbc2fb5271359756ff49</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.3389%2Ffneur.2020.00087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffneur.2020.00087%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DM.%26aulast%3DSackett%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DEndocannabinoid%2520Modulation%2520of%2520Microglial%2520Phenotypes%2520in%2520Neuropathology%26jtitle%3DFront.%2520Neurol.%26date%3D2020%26volume%3D11%26spage%3D87%26doi%3D10.3389%2Ffneur.2020.00087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharifi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pourpaknia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahebkar, A.</span></span> <span> </span><span class="NLM_article-title">Manipulating Macrophage Polarization and Function Using Classical HDAC Inhibitors: Implications for Autoimmunity and Inflammation</span>. <i>Crit. Rev. Oncol. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1016/j.critrevonc.2018.05.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.critrevonc.2018.05.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=29958625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252Fjtl2qtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2018&pages=1-18&author=A.+Mohammadiauthor=A.+Sharifiauthor=R.+Pourpakniaauthor=S.+Mohammadianauthor=A.+Sahebkar&title=Manipulating+Macrophage+Polarization+and+Function+Using+Classical+HDAC+Inhibitors%3A+Implications+for+Autoimmunity+and+Inflammation&doi=10.1016%2Fj.critrevonc.2018.05.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Manipulating macrophage polarization and function using classical HDAC inhibitors: Implications for autoimmunity and inflammation</span></div><div class="casAuthors">Mohammadi Asadollah; Sharifi Atefeh; Pourpaknia Reza; Mohammadian Saeed; Sahebkar Amirhossein</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-18</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Macrophages are important player in defense against invading pathogens and their dysfunction is linked to most of inflammatory and autoimmune diseases.  Inflammation is a normal and physiological response of the immune system against harmful stimuli such as infection and injury.  However, when allowed to continue unchecked, under certain conditions it turns into autoimmune or inflammatory diseases, neurodegeneration, and carcinogenesis.  Currently, several safe and effective anti-inflammatory drugs are available with many more drugs in the development pipeline, among which are histone deacetylase inhibitors.  In this review we discuss how post-translational modifications of histones influence the innate and adaptive immunity through macrophage survival, proliferation, polarization and functional responses.  We also discuss how emerging classes of pharmacological agents which developed for use as anti-cancer agents, have been applied as anti-inflammatory drugs to treat macrophage-mediated inflammatory and autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQA9U7N2BuEAGLFM_lbR1VmfW6udTcc2eY2PvTChGVk8bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252Fjtl2qtw%253D%253D&md5=9c7e9610928e1158a2d2b73d95dd3cdc</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2018.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2018.05.009%26sid%3Dliteratum%253Aachs%26aulast%3DMohammadi%26aufirst%3DA.%26aulast%3DSharifi%26aufirst%3DA.%26aulast%3DPourpaknia%26aufirst%3DR.%26aulast%3DMohammadian%26aufirst%3DS.%26aulast%3DSahebkar%26aufirst%3DA.%26atitle%3DManipulating%2520Macrophage%2520Polarization%2520and%2520Function%2520Using%2520Classical%2520HDAC%2520Inhibitors%253A%2520Implications%2520for%2520Autoimmunity%2520and%2520Inflammation%26jtitle%3DCrit.%2520Rev.%2520Oncol.%2520Hematol.%26date%3D2018%26volume%3D128%26spage%3D1%26epage%3D18%26doi%3D10.1016%2Fj.critrevonc.2018.05.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de S. M. Pinheiro, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sagrillo, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraga, C. A. M.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylases as Targets for the Treatment of Neurodegenerative Disorders: Challenges and Future Opportunities</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2177</span>– <span class="NLM_lpage">2211</span>, <span class="refDoi"> DOI: 10.1002/med.21701</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1002%2Fmed.21701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=32588916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVKlurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2020&pages=2177-2211&author=D.+A.+Rodriguesauthor=P.+de+S.+M.+Pinheiroauthor=F.+S.+Sagrilloauthor=M.+L.+Bolognesiauthor=C.+A.+M.+Fraga&title=Histone+Deacetylases+as+Targets+for+the+Treatment+of+Neurodegenerative+Disorders%3A+Challenges+and+Future+Opportunities&doi=10.1002%2Fmed.21701"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities</span></div><div class="casAuthors">Rodrigues, Daniel A.; Pinheiro, Pedro de S. M.; Sagrillo, Fernanda S.; Bolognesi, Maria L.; Fraga, Carlos A. M.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2177-2211</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review of despite the applicability of histone deacetylase inhibitors (HDACis) for cancer treatment, several works in the literature have shown that these inhibitors can be used in several other diseases, such as neurodegenerative diseases (NDs).  This review begins by discussing the signaling pathways of HDACs, focused on the context of NDs, presenting a discussion about the pharmacophoric features of HDACis and crystal structure anal. and discussing interesting case studies from the literature about the development of HDACis.  Addnl., a discussion about the consequences of isoform-selective inhibition vs pan-HDACis on neurotoxic effects and clin. trial investigations of HDACis for NDs is also presented.  Finally, we describe our perspective related to the future use of these inhibitors in the pharmacotherapy of NDs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo1oAACMF_bVg90H21EOLACvtfcHk0ljLEugTwJAyaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVKlurnE&md5=62f3c0f86d2aeee5c150925eacecfb18</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1002%2Fmed.21701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21701%26sid%3Dliteratum%253Aachs%26aulast%3DRodrigues%26aufirst%3DD.%2BA.%26aulast%3Dde%2BS.%2BM.%2BPinheiro%26aufirst%3DP.%26aulast%3DSagrillo%26aufirst%3DF.%2BS.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DFraga%26aufirst%3DC.%2BA.%2BM.%26atitle%3DHistone%2520Deacetylases%2520as%2520Targets%2520for%2520the%2520Treatment%2520of%2520Neurodegenerative%2520Disorders%253A%2520Challenges%2520and%2520Future%2520Opportunities%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2020%26volume%3D40%26spage%3D2177%26epage%3D2211%26doi%3D10.1002%2Fmed.21701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahn, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardestani, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crisp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuniga, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shamloo, M.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Modulator of Sigma 2 Receptor Is Neuroprotective and Reduces Cognitive Deficits and Neuroinflammation in Experimental Models of Alzheimer’s Disease</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">575</span>, <span class="refDoi"> DOI: 10.1111/jnc.13917</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1111%2Fjnc.13917" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=27926996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFGitLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2017&pages=561-575&author=B.+Yiauthor=J.+J.+Sahnauthor=P.+M.+Ardestaniauthor=A.+K.+Evansauthor=L.+L.+Scottauthor=J.+Z.+Chanauthor=S.+Iyerauthor=A.+Crispauthor=G.+Zunigaauthor=J.+T.+Pierceauthor=S.+F.+Martinauthor=M.+Shamloo&title=Small+Molecule+Modulator+of+Sigma+2+Receptor+Is+Neuroprotective+and+Reduces+Cognitive+Deficits+and+Neuroinflammation+in+Experimental+Models+of+Alzheimer%E2%80%99s+Disease&doi=10.1111%2Fjnc.13917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule modulator of sigma 2 receptor is neuroprotective and reduces cognitive deficits and neuroinflammation in experimental models of Alzheimer's disease</span></div><div class="casAuthors">Yi, Bitna; Sahn, James J.; Ardestani, Pooneh Memar; Evans, Andrew K.; Scott, Luisa L.; Chan, Jessica Z.; Iyer, Sangeetha; Crisp, Ashley; Zuniga, Gabriella; Pierce, Jonathan T.; Martin, Stephen F.; Shamloo, Mehrdad</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">561-575</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Accumulating evidence suggests that modulating the sigma 2 receptor (Sig2R) can provide beneficial effects for neurodegenerative diseases.  Herein, we report the identification of a novel class of Sig2R ligands and their cellular and in vivo activity in exptl. models of Alzheimer's disease (AD).  We report that SAS-0132 and DKR-1051, selective ligands of Sig2R, modulate intracellular Ca2+ levels in human SK-N-SH neuroblastoma cells.  The Sig2R ligands SAS-0132 and JVW-1009 are neuroprotective in a C. elegans model of amyloid precursor protein-mediated neurodegeneration.  Since this neuroprotective effect is replicated by genetic knockdown and knockout of vem-1, the ortholog of progesterone receptor membrane component-1 (PGRMC1), these results suggest that Sig2R ligands modulate a PGRMC1-related pathway.  Last, we demonstrate that SAS-0132 improves cognitive performance both in the Thy-1 hAPPLond/Swe+ transgenic mouse model of AD and in healthy wild-type mice.  These results demonstrate that Sig2R is a promising therapeutic target for neurocognitive disorders including AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-cDNlji1FqbVg90H21EOLACvtfcHk0ljLEugTwJAyaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFGitLY%253D&md5=36b25fbbf8b4d729d09f98e292966b60</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1111%2Fjnc.13917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjnc.13917%26sid%3Dliteratum%253Aachs%26aulast%3DYi%26aufirst%3DB.%26aulast%3DSahn%26aufirst%3DJ.%2BJ.%26aulast%3DArdestani%26aufirst%3DP.%2BM.%26aulast%3DEvans%26aufirst%3DA.%2BK.%26aulast%3DScott%26aufirst%3DL.%2BL.%26aulast%3DChan%26aufirst%3DJ.%2BZ.%26aulast%3DIyer%26aufirst%3DS.%26aulast%3DCrisp%26aufirst%3DA.%26aulast%3DZuniga%26aufirst%3DG.%26aulast%3DPierce%26aufirst%3DJ.%2BT.%26aulast%3DMartin%26aufirst%3DS.%2BF.%26aulast%3DShamloo%26aufirst%3DM.%26atitle%3DSmall%2520Molecule%2520Modulator%2520of%2520Sigma%25202%2520Receptor%2520Is%2520Neuroprotective%2520and%2520Reduces%2520Cognitive%2520Deficits%2520and%2520Neuroinflammation%2520in%2520Experimental%2520Models%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Neurochem.%26date%3D2017%26volume%3D140%26spage%3D561%26epage%3D575%26doi%3D10.1111%2Fjnc.13917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span> <span> </span><span class="NLM_article-title">Molecular Mechanisms Underlying the Involvement of the Sigma-1 Receptor in Methamphetamine-Mediated Microglial Polarization</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">11540</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-11065-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fs41598-017-11065-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=28912535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BC1cboslOitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=11540&author=J.+Chaoauthor=Y.+Zhangauthor=L.+Duauthor=R.+Zhouauthor=X.+Wuauthor=K.+Shenauthor=H.+Yao&title=Molecular+Mechanisms+Underlying+the+Involvement+of+the+Sigma-1+Receptor+in+Methamphetamine-Mediated+Microglial+Polarization&doi=10.1038%2Fs41598-017-11065-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms underlying the involvement of the sigma-1 receptor in methamphetamine-mediated microglial polarization</span></div><div class="casAuthors">Chao Jie; Zhang Yuan; Du Longfei; Wu Xiaodong; Yao Honghong; Chao Jie; Zhou Rongbin; Shen Kai; Yao Honghong</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11540</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Our previous study demonstrated that the sigma-1 receptor is involved in methamphetamine-induced microglial apoptosis and death; however, whether the sigma-1 receptor is involved in microglial activation as well as the molecular mechanisms underlying this process remains poorly understood.  The aim of this study is to demonstrate the involvement of the sigma-1 receptor in methamphetamine-mediated microglial activation.  The expression of σ-1R, iNOS, arginase and SOCS was examined by Western blot; activation of cell signaling pathways was detected by Western blot analysis.  The role of σ-1R in microglial activation was further validated in C57BL/6 N WT and sigma-1 receptor knockout mice (male, 6-8 weeks) injected intraperitoneally with saline or methamphetamine (30 mg/kg) by Western blot combined with immunostaining specific for Iba-1.  Treatment of cells with methamphetamine (150 μM) induced the expression of M1 markers (iNOS) with concomitant decreased the expression of M2 markers (Arginase) via its cognate sigma-1 receptor followed by ROS generation.  Sequential activation of the downstream MAPK, Akt and STAT3 pathways resulted in microglial polarization.  Blockade of sigma-1 receptor significantly inhibited the generation of ROS and activation of the MAPK and Akt pathways.  These findings underscore the critical role of the sigma-1 receptor in methamphetamine-induced microglial activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ2XuDrQ2dPtrYtC3U5jeOifW6udTcc2eYzKAKx5xkJ7rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cboslOitg%253D%253D&md5=fa6c0dc4b3544f5a19dcb92e9784225e</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-11065-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-11065-8%26sid%3Dliteratum%253Aachs%26aulast%3DChao%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDu%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DShen%26aufirst%3DK.%26aulast%3DYao%26aufirst%3DH.%26atitle%3DMolecular%2520Mechanisms%2520Underlying%2520the%2520Involvement%2520of%2520the%2520Sigma-1%2520Receptor%2520in%2520Methamphetamine-Mediated%2520Microglial%2520Polarization%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D11540%26doi%3D10.1038%2Fs41598-017-11065-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moritz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peri, F.</span></span> <span> </span><span class="NLM_article-title">Live Imaging Reveals a New Role for the Sigma-1 (σ<sub>1</sub>) Receptor in Allowing Microglia to Leave Brain Injuries</span>. <i>Neurosci. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>591</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1016/j.neulet.2015.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.neulet.2015.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=25666889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVSgt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=591&publication_year=2015&pages=13-18&author=C.+Moritzauthor=F.+Berardiauthor=C.+Abateauthor=F.+Peri&title=Live+Imaging+Reveals+a+New+Role+for+the+Sigma-1+%28%CF%831%29+Receptor+in+Allowing+Microglia+to+Leave+Brain+Injuries&doi=10.1016%2Fj.neulet.2015.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Live imaging reveals a new role for the sigma-1 (σ1) receptor in allowing microglia to leave brain injuries</span></div><div class="casAuthors">Moritz, Christian; Berardi, Francesco; Abate, Carmen; Peri, Francesca</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">591</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13-18</span>CODEN:
                <span class="NLM_cas:coden">NELED5</span>;
        ISSN:<span class="NLM_cas:issn">0304-3940</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Microglial cells are responsible for clearing and maintaining the central nervous system (CNS) microenvironment.  Upon brain damage, they move toward injuries to clear the area by engulfing dying neurons.  However, in the context of many neurol. disorders chronic microglial responses are responsible for neurodegeneration.  Therefore, it is important to understand how these cells can be "switched-off" and regain their ramified state.  Current research suggests that microglial inflammatory responses can be inhibited by sigma (σ) receptor activation.  Here, we take advantage of the optical transparency of the zebrafish embryo to study the role of σ1 receptor in microglia in an intact living brain.  By combining chem. approaches with real time imaging we found that treatment with PB190, a σ1 agonist, blocks microglial migration toward injuries leaving cellular baseline motility and the engulfment of apoptotic neurons unaffected.  Most importantly, by taking a reverse genetic approach, we discovered that the role of σ1in vivo is to "switch-off" microglia after they responded to an injury allowing for these cells to leave the site of damage.  This indicates that pharmacol. manipulation of σ1 receptor modulates microglial responses providing new approaches to reduce the devastating impact that microglia have in neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0WcpnESIreLVg90H21EOLACvtfcHk0liwY0LFf09uKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVSgt7c%253D&md5=1000165e3b64b2f5f116a2fb1d68d783</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.neulet.2015.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neulet.2015.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DMoritz%26aufirst%3DC.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DPeri%26aufirst%3DF.%26atitle%3DLive%2520Imaging%2520Reveals%2520a%2520New%2520Role%2520for%2520the%2520Sigma-1%2520%2528%25CF%25831%2529%2520Receptor%2520in%2520Allowing%2520Microglia%2520to%2520Leave%2520Brain%2520Injuries%26jtitle%3DNeurosci.%2520Lett.%26date%3D2015%26volume%3D591%26spage%3D13%26epage%3D18%26doi%3D10.1016%2Fj.neulet.2015.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aso, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juves, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maldonado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, I.</span></span> <span> </span><span class="NLM_article-title">CB2 Cannabinoid Receptor Agonist Ameliorates Alzheimer-like Phenotype in AbetaPP/PS1 Mice</span>. <i>J. Alzheimer’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">847</span>– <span class="NLM_lpage">858</span>, <span class="refDoi"> DOI: 10.3233/JAD-130137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3233%2FJAD-130137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=23515018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BC3svotFCgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2013&pages=847-858&author=E.+Asoauthor=S.+Juvesauthor=R.+Maldonadoauthor=I.+Ferrer&title=CB2+Cannabinoid+Receptor+Agonist+Ameliorates+Alzheimer-like+Phenotype+in+AbetaPP%2FPS1+Mice&doi=10.3233%2FJAD-130137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AβPP/PS1 mice</span></div><div class="casAuthors">Aso Ester; Juves Salvador; Maldonado Rafael; Ferrer Isidro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's disease : JAD</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">847-58</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The specific CB2 cannabinoid receptor agonist JWH-133 induced cognitive improvement in double AβPP/PS1 transgenic mice, a genetic model of Alzheimer's disease.  This effect was more pronounced when administered at the pre-symptomatic rather than the early symptomatic stage.  The cognitive improvement was associated with decreased microglial reactivity and reduced expression of pro-inflammatory cytokines IL-1β, IL-6, TNFα, and IFNγ.  In addition, JWH-133 reduced the expression of active p38 and SAPK/JNK, increased the expression of inactive GSK3β, and lowered tau hyperphosphorylation at Thr181 in the vicinity of amyloid-β plaques.  Moreover, JWH-133 produced a decrease in the expression of hydroxynonenal adducts, and enhanced the expression of SOD1 and SOD2 around plaques.  In contrast, the chronic treatment with JWH-133 failed to modify the amyloid-β production or deposition in cortex and hippocampus.  In conclusion, the present study lends support to the idea that stimulation of CB2 receptors ameliorates several altered parameters in Alzheimer's disease such as impaired memory and learning, neuroinflammation, oxidative stress damage and oxidative stress responses, selected tau kinases, and tau hyperphosphorylation around plaques.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRClDhWU_rp-HRxY89Cm6SyfW6udTcc2eYCMM1kwfirBbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3svotFCgtg%253D%253D&md5=b25fa740d08962fe7897cebbeb04ee24</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.3233%2FJAD-130137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-130137%26sid%3Dliteratum%253Aachs%26aulast%3DAso%26aufirst%3DE.%26aulast%3DJuves%26aufirst%3DS.%26aulast%3DMaldonado%26aufirst%3DR.%26aulast%3DFerrer%26aufirst%3DI.%26atitle%3DCB2%2520Cannabinoid%2520Receptor%2520Agonist%2520Ameliorates%2520Alzheimer-like%2520Phenotype%2520in%2520AbetaPP%252FPS1%2520Mice%26jtitle%3DJ.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2013%26volume%3D35%26spage%3D847%26epage%3D858%26doi%3D10.3233%2FJAD-130137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niggemann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaenker, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entschladen, F.</span></span> <span> </span><span class="NLM_article-title">Anandamide Is an Endogenous Inhibitor for the Migration of Tumor Cells and T Lymphocytes</span>. <i>Cancer Immunol. Immunother.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">723</span>– <span class="NLM_lpage">728</span>, <span class="refDoi"> DOI: 10.1007/s00262-004-0509-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1007%2Fs00262-004-0509-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=15034673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltF2hsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2004&pages=723-728&author=J.+Josephauthor=B.+Niggemannauthor=K.+S.+Zaenkerauthor=F.+Entschladen&title=Anandamide+Is+an+Endogenous+Inhibitor+for+the+Migration+of+Tumor+Cells+and+T+Lymphocytes&doi=10.1007%2Fs00262-004-0509-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes</span></div><div class="casAuthors">Joseph, Jan; Niggemann, Bernd; Zaenker, Kurt S.; Entschladen, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Immunotherapy</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">723-728</span>CODEN:
                <span class="NLM_cas:coden">CIIMDN</span>;
        ISSN:<span class="NLM_cas:issn">0340-7004</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">Cell migration is of paramount importance in physiol. processes such as immune surveillance, but also in the pathol. processes of tumor cell migration and metastasis development.  The factors that regulate this tumor cell migration, most prominently neurotransmitters, have thus been the focus of intense investigation.  While the majority of neurotransmitters have a stimulatory effect on cell migration, the authors herein report the inhibitory effect of the endogenous substance anandamide on both tumor cell and lymphocyte migration.  Using a collagen-based three-dimensional migration assay and time-lapse videomicroscopy, the authors have obsd. that the anandamide-mediated signals for CD8+ T lymphocytes and SW 480 colon carcinoma cells are each mediated by distinct cannabinoid receptors (CB-Rs).  Using the specific agonist docosatetraenoylethanolamide (DEA), the authors have obsd. that the norepinephrine-induced migration of colon carcinoma cells is inhibited by the CB1-R.  The SDF-1-induced migration of CD8+ T lymphocytes was, however, inhibited via the CB2-R, as shown by using the specific agonist JWH 133.  Therefore, specific inhibition of tumor cell migration via CB1-R engagement might be a selective tool to prevent metastasis formation without depreciatory effects on the immune system of cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpd57IdcQv23rVg90H21EOLACvtfcHk0liiDvPE6ebP7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltF2hsrg%253D&md5=7790db3bad96e1d6b150aed33eb3bac9</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1007%2Fs00262-004-0509-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00262-004-0509-9%26sid%3Dliteratum%253Aachs%26aulast%3DJoseph%26aufirst%3DJ.%26aulast%3DNiggemann%26aufirst%3DB.%26aulast%3DZaenker%26aufirst%3DK.%2BS.%26aulast%3DEntschladen%26aufirst%3DF.%26atitle%3DAnandamide%2520Is%2520an%2520Endogenous%2520Inhibitor%2520for%2520the%2520Migration%2520of%2520Tumor%2520Cells%2520and%2520T%2520Lymphocytes%26jtitle%3DCancer%2520Immunol.%2520Immunother.%26date%3D2004%26volume%3D53%26spage%3D723%26epage%3D728%26doi%3D10.1007%2Fs00262-004-0509-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pasquini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semeraro, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mugnaini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligresti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palazzo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maione, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corelli, F.</span></span> <span> </span><span class="NLM_article-title">Investigations on the 4-Quinolone-3-Carboxylic Acid Motif. 2. Synthesis and Structure-Activity Relationship of Potent and Selective Cannabinoid-2 Receptor Agonists Endowed with Analgesic Activity in Vivo</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">5075</span>– <span class="NLM_lpage">5084</span>, <span class="refDoi"> DOI: 10.1021/jm800552f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800552f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptl2htro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5075-5084&author=S.+Pasquiniauthor=L.+Bottaauthor=T.+Semeraroauthor=C.+Mugnainiauthor=A.+Ligrestiauthor=E.+Palazzoauthor=S.+Maioneauthor=V.+Di+Marzoauthor=F.+Corelli&title=Investigations+on+the+4-Quinolone-3-Carboxylic+Acid+Motif.+2.+Synthesis+and+Structure-Activity+Relationship+of+Potent+and+Selective+Cannabinoid-2+Receptor+Agonists+Endowed+with+Analgesic+Activity+in+Vivo&doi=10.1021%2Fjm800552f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Investigations on the 4-quinolone-3-carboxylic acid motif. 2. synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo</span></div><div class="casAuthors">Pasquini, Serena; Botta, Lorenzo; Semeraro, Teresa; Mugnaini, Claudia; Ligresti, Alessia; Palazzo, Enza; Maione, Sabatino; Di Marzo, Vincenzo; Corelli, Federico</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5075-5084</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Quinolone-3-carboxamides bearing at position 5, 6, 7, or 8 diverse substituents such as halides, alkyl, aryl, alkoxy, and aryloxy groups differing in their steric/electronic properties, were prepd.  The new compds. were tested in vitro for CB1 and CB2 receptor affinity in comparison with the ref. compds. rimonabant and SR144528.  The tested compds. exhibited CB2 affinity in the range from 55.9 to 0.8 nM and CB1 affinity in the range from >10 000 to 5.3 nM, with selectivity indeces [Ki(CB1)/Ki(CB2)] varying from >2666.6 to 1.23.  On the basis of the structure-selectivity relationship developed, the presence of a substituent at C6/C8 or C7 well accounts for the high or low CB2 selectivity, resp.  Compd. I, characterized by high CB2 affinity and selectivity, showed analgesic activity in the formalin test of acute peripheral and inflammatory pain in mice as a result of selective CB2 agonistic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-nHfcuH__drVg90H21EOLACvtfcHk0liiDvPE6ebP7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptl2htro%253D&md5=5c461877098aec3a53c31676ced30c98</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm800552f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800552f%26sid%3Dliteratum%253Aachs%26aulast%3DPasquini%26aufirst%3DS.%26aulast%3DBotta%26aufirst%3DL.%26aulast%3DSemeraro%26aufirst%3DT.%26aulast%3DMugnaini%26aufirst%3DC.%26aulast%3DLigresti%26aufirst%3DA.%26aulast%3DPalazzo%26aufirst%3DE.%26aulast%3DMaione%26aufirst%3DS.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DCorelli%26aufirst%3DF.%26atitle%3DInvestigations%2520on%2520the%25204-Quinolone-3-Carboxylic%2520Acid%2520Motif.%25202.%2520Synthesis%2520and%2520Structure-Activity%2520Relationship%2520of%2520Potent%2520and%2520Selective%2520Cannabinoid-2%2520Receptor%2520Agonists%2520Endowed%2520with%2520Analgesic%2520Activity%2520in%2520Vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5075%26epage%3D5084%26doi%3D10.1021%2Fjm800552f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pasquini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligresti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mugnaini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semeraro, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cicione, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rosa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guida, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luongo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Chiaro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascio, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maione, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzo, V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corelli, F.</span></span> <span> </span><span class="NLM_article-title">Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 3. Synthesis, Structure-Affinity Relationships, and Pharmacological Characterization of 6-Substituted 4-Quinolone-3-carboxamides as Highly Selective Cannabinoid-2 Receptor Ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">5915</span>– <span class="NLM_lpage">5928</span>, <span class="refDoi"> DOI: 10.1021/jm100123x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100123x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCht78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5915-5928&author=S.+Pasquiniauthor=A.+Ligrestiauthor=C.+Mugnainiauthor=T.+Semeraroauthor=L.+Cicioneauthor=M.+De+Rosaauthor=F.+Guidaauthor=L.+Luongoauthor=M.+De+Chiaroauthor=M.+G.+Cascioauthor=D.+Bologniniauthor=P.+Mariniauthor=R.+Pertweeauthor=S.+Maioneauthor=V.+D.+Marzoauthor=F.+Corelli&title=Investigations+on+the+4-Quinolone-3-carboxylic+Acid+Motif.+3.+Synthesis%2C+Structure-Affinity+Relationships%2C+and+Pharmacological+Characterization+of+6-Substituted+4-Quinolone-3-carboxamides+as+Highly+Selective+Cannabinoid-2+Receptor+Ligands&doi=10.1021%2Fjm100123x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 3. Synthesis, Structure-Affinity Relationships, and Pharmacological Characterization of 6-Substituted 4-Quinolone-3-carboxamides as Highly Selective Cannabinoid-2 Receptor Ligands</span></div><div class="casAuthors">Pasquini, Serena; Ligresti, Alessia; Mugnaini, Claudia; Semeraro, Teresa; Cicione, Lavinia; De Rosa, Maria; Guida, Francesca; Luongo, Livio; De Chiaro, Maria; Cascio, Maria Grazia; Bolognini, Daniele; Marini, Pietro; Pertwee, Roger; Maione, Sabatino; Di Marzo, Vincenzo; Corelli, Federico</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5915-5928</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A set of quinolone-3-carboxamides I [R1 = (un)substituted Ph, 2-furyl, 1-cyclohexenyl, 1-isobutylpyrazol-4-yl, etc.; R2 = 1-adamantyl, 1-fenchyl, hexyl, 1-piperidinyl; R3 = pentyl, 1-buten-4-yl, allyl] bearing diverse substituents at position 1, 3, and 6 of the bicyclic nucleus was prepd.  Except for six compds. exhibiting Ki > 100 nM, all the quinolone-3-carboxamides I proved to be high affinity CB2 ligands, with Ki values ranging from 73.2 to 0.7 nM and selectivity [SI = Ki(CB1)/Ki(CB2)] varying from >14285 to 1.9, with only one compd. exhibiting a reverse selectivity (SI < 1).  In the formalin test of peripheral acute and inflammatory pain in mice, I [R1 = CH2CH2Ph, R2 = 1-adamantyl, R3 = pentyl] showed analgesic activity that was antagonized by a selective CB2 antagonist.  By contrast, I [R1 = 2-furyl, R2 = 1-adamantyl, R3 = pentyl] was inactive per se and antagonized the effect of a selective CB2 agonist.  Also, two of these compds. exhibited CB2 inverse agonist-like behavior in this in vivo test.  However, two different functional assays carried out in vitro indicated for both compds. an overall inverse agonist activity at CB2 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWqQVRHQABn7Vg90H21EOLACvtfcHk0lgm7WvlpWxzTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCht78%253D&md5=642a103b93312fd2f1e124173143b656</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Fjm100123x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100123x%26sid%3Dliteratum%253Aachs%26aulast%3DPasquini%26aufirst%3DS.%26aulast%3DLigresti%26aufirst%3DA.%26aulast%3DMugnaini%26aufirst%3DC.%26aulast%3DSemeraro%26aufirst%3DT.%26aulast%3DCicione%26aufirst%3DL.%26aulast%3DDe%2BRosa%26aufirst%3DM.%26aulast%3DGuida%26aufirst%3DF.%26aulast%3DLuongo%26aufirst%3DL.%26aulast%3DDe%2BChiaro%26aufirst%3DM.%26aulast%3DCascio%26aufirst%3DM.%2BG.%26aulast%3DBolognini%26aufirst%3DD.%26aulast%3DMarini%26aufirst%3DP.%26aulast%3DPertwee%26aufirst%3DR.%26aulast%3DMaione%26aufirst%3DS.%26aulast%3DMarzo%26aufirst%3DV.%2BD.%26aulast%3DCorelli%26aufirst%3DF.%26atitle%3DInvestigations%2520on%2520the%25204-Quinolone-3-carboxylic%2520Acid%2520Motif.%25203.%2520Synthesis%252C%2520Structure-Affinity%2520Relationships%252C%2520and%2520Pharmacological%2520Characterization%2520of%25206-Substituted%25204-Quinolone-3-carboxamides%2520as%2520Highly%2520Selective%2520Cannabinoid-2%2520Receptor%2520Ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5915%26epage%3D5928%26doi%3D10.1021%2Fjm100123x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pasquini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rosa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedani, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mugnaini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guida, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luongo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Chiaro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maione, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragoni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frosini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligresti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corelli, F.</span></span> <span> </span><span class="NLM_article-title">Investigations on the 4-Quinolone-3-Carboxylic Acid Motif. 4. Identification of New Potent and Selective Ligands for the Cannabinoid Type 2 Receptor with Diverse Substitution Patterns and Antihyperalgesic Effects in Mice</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">5444</span>– <span class="NLM_lpage">5453</span>, <span class="refDoi"> DOI: 10.1021/jm200476p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200476p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFCgtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=5444-5453&author=S.+Pasquiniauthor=M.+De+Rosaauthor=V.+Pedaniauthor=C.+Mugnainiauthor=F.+Guidaauthor=L.+Luongoauthor=M.+De+Chiaroauthor=S.+Maioneauthor=S.+Dragoniauthor=M.+Frosiniauthor=A.+Ligrestiauthor=V.+Di+Marzoauthor=F.+Corelli&title=Investigations+on+the+4-Quinolone-3-Carboxylic+Acid+Motif.+4.+Identification+of+New+Potent+and+Selective+Ligands+for+the+Cannabinoid+Type+2+Receptor+with+Diverse+Substitution+Patterns+and+Antihyperalgesic+Effects+in+Mice&doi=10.1021%2Fjm200476p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 4. Identification of New Potent and Selective Ligands for the Cannabinoid Type 2 Receptor with Diverse Substitution Patterns and Antihyperalgesic Effects in Mice</span></div><div class="casAuthors">Pasquini, Serena; De Rosa, Maria; Pedani, Valentina; Mugnaini, Claudia; Guida, Francesca; Luongo, Livio; De Chiaro, Maria; Maione, Sabatino; Dragoni, Stefania; Frosini, Maria; Ligresti, Alessia; Di Marzo, Vincenzo; Corelli, Federico</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5444-5453</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Exptl. evidence suggests that selective CB2 receptor modulators may provide access to antihyperalgesic agents devoid of psychotropic effects.  Taking advantage of previous findings on structure-activity/selectivity relationships for a class of 4-quinolone-3-carboxamides, further structural modifications of the heterocyclic scaffold were explored, leading to the discovery of the 8-methoxy deriv. 4a endowed with the highest affinity and selectivity ever reported for a CB2 ligand.  The compd., evaluated in vivo in the formalin test, behaved as an inverse agonist by reducing at a dose of 6 mg/kg the second phase of the formalin-induced nocifensive response in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogKusJC-_IlLVg90H21EOLACvtfcHk0lgm7WvlpWxzTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFCgtbo%253D&md5=4b9daccdccfddbbde2ef53fcca4a87bd</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fjm200476p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200476p%26sid%3Dliteratum%253Aachs%26aulast%3DPasquini%26aufirst%3DS.%26aulast%3DDe%2BRosa%26aufirst%3DM.%26aulast%3DPedani%26aufirst%3DV.%26aulast%3DMugnaini%26aufirst%3DC.%26aulast%3DGuida%26aufirst%3DF.%26aulast%3DLuongo%26aufirst%3DL.%26aulast%3DDe%2BChiaro%26aufirst%3DM.%26aulast%3DMaione%26aufirst%3DS.%26aulast%3DDragoni%26aufirst%3DS.%26aulast%3DFrosini%26aufirst%3DM.%26aulast%3DLigresti%26aufirst%3DA.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DCorelli%26aufirst%3DF.%26atitle%3DInvestigations%2520on%2520the%25204-Quinolone-3-Carboxylic%2520Acid%2520Motif.%25204.%2520Identification%2520of%2520New%2520Potent%2520and%2520Selective%2520Ligands%2520for%2520the%2520Cannabinoid%2520Type%25202%2520Receptor%2520with%2520Diverse%2520Substitution%2520Patterns%2520and%2520Antihyperalgesic%2520Effects%2520in%2520Mice%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D5444%26epage%3D5453%26doi%3D10.1021%2Fjm200476p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mugnaini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nocerino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedani, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tafi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Chiaro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellucci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valoti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guida, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luongo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragoni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligresti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascio, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moaddel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maione, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corelli, F.</span></span> <span> </span><span class="NLM_article-title">Investigations on the 4-Quinolone-3-Carboxylic Acid Motif Part 5: Modulation of the Physicochemical Profile of a Set of Potent and Selective Cannabinoid-2 Receptor Ligands through a Bioisosteric Approach</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">920</span>– <span class="NLM_lpage">934</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201100573</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1002%2Fcmdc.201100573" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=22383251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFOhtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=920-934&author=C.+Mugnainiauthor=S.+Nocerinoauthor=V.+Pedaniauthor=S.+Pasquiniauthor=A.+Tafiauthor=M.+De+Chiaroauthor=L.+Bellucciauthor=M.+Valotiauthor=F.+Guidaauthor=L.+Luongoauthor=S.+Dragoniauthor=A.+Ligrestiauthor=A.+Rosenbergauthor=D.+Bologniniauthor=M.+G.+Cascioauthor=R.+G.+Pertweeauthor=R.+Moaddelauthor=S.+Maioneauthor=V.+Di+Marzoauthor=F.+Corelli&title=Investigations+on+the+4-Quinolone-3-Carboxylic+Acid+Motif+Part+5%3A+Modulation+of+the+Physicochemical+Profile+of+a+Set+of+Potent+and+Selective+Cannabinoid-2+Receptor+Ligands+through+a+Bioisosteric+Approach&doi=10.1002%2Fcmdc.201100573"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Investigations on the 4-Quinolone-3-Carboxylic Acid Motif Part 5: Modulation of the Physicochemical Profile of a Set of Potent and Selective Cannabinoid-2 Receptor Ligands through a Bioisosteric Approach</span></div><div class="casAuthors">Mugnaini, Claudia; Nocerino, Stefania; Pedani, Valentina; Pasquini, Serena; Tafi, Andrea; De Chiaro, Maria; Bellucci, Luca; Valoti, Massimo; Guida, Francesca; Luongo, Livio; Dragoni, Stefania; Ligresti, Alessia; Rosenberg, Avraham; Bolognini, Daniele; Cascio, Maria Grazia; Pertwee, Roger G.; Moaddel, Ruin; Maione, Sabatino; Di Marzo, Vincenzo; Corelli, Federico</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">920-934</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Three heterocyclic systems were selected as potential bioisosteres of the amide linker for a series of 1,6-disubstituted-4-quinolone-3-carboxamides, which are potent and selective CB2 ligands that exhibit poor water soly., with the aim of improving their physicochem. profile and also of clarifying properties of importance for amide bond mimicry.  Among the newly synthesized compds., a 1,2,3-triazole deriv. (1-(adamantan-1-yl)-4-[6-(furan-2-yl)-1,4-dihydro-4-oxo-1-pentylquinolin-3-yl]-1H-1,2,3-triazole) emerged as the most promising in terms of both physicochem. and pharmacodynamic properties.  When assayed in vitro, this deriv. exhibited inverse agonist activity, whereas, in the formalin test in mice, it produced analgesic effects antagonized by a well-established inverse agonist.  Metabolic studies allowed the identification of a side chain hydroxylated deriv. as its only metabolite, which, in its racemic form, still showed appreciable CB2 selectivity, but was 150-fold less potent than the parent compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-q6Lelcgsf7Vg90H21EOLACvtfcHk0lhUNk_x-OioEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFOhtbo%253D&md5=4ac67390a8af749cd21afd9ef894099f</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201100573&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201100573%26sid%3Dliteratum%253Aachs%26aulast%3DMugnaini%26aufirst%3DC.%26aulast%3DNocerino%26aufirst%3DS.%26aulast%3DPedani%26aufirst%3DV.%26aulast%3DPasquini%26aufirst%3DS.%26aulast%3DTafi%26aufirst%3DA.%26aulast%3DDe%2BChiaro%26aufirst%3DM.%26aulast%3DBellucci%26aufirst%3DL.%26aulast%3DValoti%26aufirst%3DM.%26aulast%3DGuida%26aufirst%3DF.%26aulast%3DLuongo%26aufirst%3DL.%26aulast%3DDragoni%26aufirst%3DS.%26aulast%3DLigresti%26aufirst%3DA.%26aulast%3DRosenberg%26aufirst%3DA.%26aulast%3DBolognini%26aufirst%3DD.%26aulast%3DCascio%26aufirst%3DM.%2BG.%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26aulast%3DMoaddel%26aufirst%3DR.%26aulast%3DMaione%26aufirst%3DS.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DCorelli%26aufirst%3DF.%26atitle%3DInvestigations%2520on%2520the%25204-Quinolone-3-Carboxylic%2520Acid%2520Motif%2520Part%25205%253A%2520Modulation%2520of%2520the%2520Physicochemical%2520Profile%2520of%2520a%2520Set%2520of%2520Potent%2520and%2520Selective%2520Cannabinoid-2%2520Receptor%2520Ligands%2520through%2520a%2520Bioisosteric%2520Approach%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26spage%3D920%26epage%3D934%26doi%3D10.1002%2Fcmdc.201100573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccomanni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malfitano, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laezza, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligresti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucchesi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuccinardi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzolio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifulco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinelli, A.</span></span> <span> </span><span class="NLM_article-title">Rational Design, Synthesis and Anti-Proliferative Properties of New CB2 Selective Cannabinoid Receptor Ligands: An Investigation of the 1,8-Naphthyridin-2(1H)-One Scaffold</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">284</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2012.03.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2012.03.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=22483967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtlSksrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=284-294&author=C.+Maneraauthor=G.+Saccomanniauthor=A.+M.+Malfitanoauthor=S.+Bertiniauthor=F.+Castelliauthor=C.+Laezzaauthor=A.+Ligrestiauthor=V.+Lucchesiauthor=T.+Tuccinardiauthor=F.+Rizzolioauthor=M.+Bifulcoauthor=V.+Di+Marzoauthor=A.+Giordanoauthor=M.+Macchiaauthor=A.+Martinelli&title=Rational+Design%2C+Synthesis+and+Anti-Proliferative+Properties+of+New+CB2+Selective+Cannabinoid+Receptor+Ligands%3A+An+Investigation+of+the+1%2C8-Naphthyridin-2%281H%29-One+Scaffold&doi=10.1016%2Fj.ejmech.2012.03.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design, synthesis and anti-proliferative properties of new CB2 selective cannabinoid receptor ligands: An investigation of the 1,8-naphthyridin-2(1H)-one scaffold</span></div><div class="casAuthors">Manera, Clementina; Saccomanni, Giuseppe; Malfitano, Anna Maria; Bertini, Simone; Castelli, Francesca; Laezza, Chiara; Ligresti, Alessia; Lucchesi, Valentina; Tuccinardi, Tiziano; Rizzolio, Flavio; Bifulco, Maurizio; Di Marzo, Vincenzo; Giordano, Antonio; Macchia, Marco; Martinelli, Adriano</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">284-294</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">CB2 receptor ligands are becoming increasingly attractive drugs due to the potential role of this receptor in several physiopathol. processes.  Using the previously described series of 1,8-naphthyridin-2(1H)-on-3-carboxamides as a lead class, several nitrogen heterocyclic derivs., characterized by different central cores, were synthesized and tested for their affinity toward the human CB1 and CB2 cannabinoid receptors.  The obtained results suggest that the new series of quinolin-2(1H)-on-3-carboxamides, 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamides and 1,2-dihydro-2-oxopyridine-3-carboxamides represent novel scaffolds very suitable for the development of promising CB2 ligands.  Furthermore, the newly synthesized CB2 ligands inhibit proliferation of several cancer cell lines.  In particular, it was demonstrated that in DU-145 cell line these ligands exert a CB2-mediated anti-proliferative action and decrease the CB2 receptor expression levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSNc96QFpbgLVg90H21EOLACvtfcHk0lhUNk_x-OioEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtlSksrk%253D&md5=7bf4bb23e5ad31c00ea27ea8c324097d</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.03.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.03.031%26sid%3Dliteratum%253Aachs%26aulast%3DManera%26aufirst%3DC.%26aulast%3DSaccomanni%26aufirst%3DG.%26aulast%3DMalfitano%26aufirst%3DA.%2BM.%26aulast%3DBertini%26aufirst%3DS.%26aulast%3DCastelli%26aufirst%3DF.%26aulast%3DLaezza%26aufirst%3DC.%26aulast%3DLigresti%26aufirst%3DA.%26aulast%3DLucchesi%26aufirst%3DV.%26aulast%3DTuccinardi%26aufirst%3DT.%26aulast%3DRizzolio%26aufirst%3DF.%26aulast%3DBifulco%26aufirst%3DM.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DGiordano%26aufirst%3DA.%26aulast%3DMacchia%26aufirst%3DM.%26aulast%3DMartinelli%26aufirst%3DA.%26atitle%3DRational%2520Design%252C%2520Synthesis%2520and%2520Anti-Proliferative%2520Properties%2520of%2520New%2520CB2%2520Selective%2520Cannabinoid%2520Receptor%2520Ligands%253A%2520An%2520Investigation%2520of%2520the%25201%252C8-Naphthyridin-2%25281H%2529-One%2520Scaffold%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2012%26volume%3D52%26spage%3D284%26epage%3D294%26doi%3D10.1016%2Fj.ejmech.2012.03.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malfitano, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkkari, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucchesi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fogli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laezza, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligresti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccomanni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savinainen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciaglia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisanti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazzerro, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifulco, M.</span></span> <span> </span><span class="NLM_article-title">New Quinolone- and 1,8-Naphthyridine-3-Carboxamides as Selective CB2 Receptor Agonists with Anticancer and Immuno-Modulatory Activity</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">10</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.04.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2015.04.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=25935384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnt1Srurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2015&pages=10-18&author=C.+Maneraauthor=A.+M.+Malfitanoauthor=T.+Parkkariauthor=V.+Lucchesiauthor=S.+Carpiauthor=S.+Fogliauthor=S.+Bertiniauthor=C.+Laezzaauthor=A.+Ligrestiauthor=G.+Saccomanniauthor=J.+R.+Savinainenauthor=E.+Ciagliaauthor=S.+Pisantiauthor=P.+Gazzerroauthor=V.+Di+Marzoauthor=P.+Nieriauthor=M.+Macchiaauthor=M.+Bifulco&title=New+Quinolone-+and+1%2C8-Naphthyridine-3-Carboxamides+as+Selective+CB2+Receptor+Agonists+with+Anticancer+and+Immuno-Modulatory+Activity&doi=10.1016%2Fj.ejmech.2015.04.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">New quinolone- and 1,8-naphthyridine-3-carboxamides as selective CB2 receptor agonists with anticancer and immuno-modulatory activity</span></div><div class="casAuthors">Manera, Clementina; Malfitano, Anna Maria; Parkkari, Teija; Lucchesi, Valentina; Carpi, Sara; Fogli, Stefano; Bertini, Simone; Laezza, Chiara; Ligresti, Alessia; Saccomanni, Giuseppe; Savinainen, Juha R.; Ciaglia, Elena; Pisanti, Simona; Gazzerro, Patrizia; Di Marzo, Vincenzo; Nieri, Paola; Macchia, Marco; Bifulco, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10-18</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Several recent studies suggest that selective CB2 receptor agonists may represent a valid pharmacol. approach in the treatment of various diseases due to the absence of relevant psychoactive side effect.  The authors synthesized and tested a series of new quinoline-2(1H)-one- and 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine derivs. characterized by a 4-methylcyclohexylamido substituent in position 3 of the heterocyclic nucleus with high CB2 receptor affinity and selectivity.  Two compds. showing the best binding and selectivity profile behaved as a full agonist and a partial agonist at the CB2 receptor and induced a concn.-dependent decrease of cell viability on LNCaP, a prostatic cancer cell line expressing CB2 receptor.  Moreover considering that the CB2 receptor is mainly expressed in cells and organs of the immune system, the same compds. were studied for their potential immune-modulatory and antiinflammatory effects in activated lymphocytes isolated from healthy controls and multiple sclerosis (MS) patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOB_LeNeEMvrVg90H21EOLACvtfcHk0lhUNk_x-OioEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnt1Srurg%253D&md5=b6bbfe5695e72b75536c661ee3b5f2a9</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.04.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.04.034%26sid%3Dliteratum%253Aachs%26aulast%3DManera%26aufirst%3DC.%26aulast%3DMalfitano%26aufirst%3DA.%2BM.%26aulast%3DParkkari%26aufirst%3DT.%26aulast%3DLucchesi%26aufirst%3DV.%26aulast%3DCarpi%26aufirst%3DS.%26aulast%3DFogli%26aufirst%3DS.%26aulast%3DBertini%26aufirst%3DS.%26aulast%3DLaezza%26aufirst%3DC.%26aulast%3DLigresti%26aufirst%3DA.%26aulast%3DSaccomanni%26aufirst%3DG.%26aulast%3DSavinainen%26aufirst%3DJ.%2BR.%26aulast%3DCiaglia%26aufirst%3DE.%26aulast%3DPisanti%26aufirst%3DS.%26aulast%3DGazzerro%26aufirst%3DP.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DNieri%26aufirst%3DP.%26aulast%3DMacchia%26aufirst%3DM.%26aulast%3DBifulco%26aufirst%3DM.%26atitle%3DNew%2520Quinolone-%2520and%25201%252C8-Naphthyridine-3-Carboxamides%2520as%2520Selective%2520CB2%2520Receptor%2520Agonists%2520with%2520Anticancer%2520and%2520Immuno-Modulatory%2520Activity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D97%26spage%3D10%26epage%3D18%26doi%3D10.1016%2Fj.ejmech.2015.04.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucchesi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shore, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrmann, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allarà, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligresti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minutolo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccomanni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharir, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reggio, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manera, C.</span></span> <span> </span><span class="NLM_article-title">CB2-Selective Cannabinoid Receptor Ligands: Synthesis, Pharmacological Evaluation, and Molecular Modeling Investigation of 1,8-Naphthyridin-2(1H)-One-3-Carboxamides</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">8777</span>– <span class="NLM_lpage">8791</span>, <span class="refDoi"> DOI: 10.1021/jm500807e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500807e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1KhtbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8777-8791&author=V.+Lucchesiauthor=D.+P.+Hurstauthor=D.+M.+Shoreauthor=S.+Bertiniauthor=B.+M.+Ehrmannauthor=M.+Allar%C3%A0author=L.+Lawrenceauthor=A.+Ligrestiauthor=F.+Minutoloauthor=G.+Saccomanniauthor=H.+Sharirauthor=M.+Macchiaauthor=V.+Di+Marzoauthor=M.+Aboodauthor=P.+H.+Reggioauthor=C.+Manera&title=CB2-Selective+Cannabinoid+Receptor+Ligands%3A+Synthesis%2C+Pharmacological+Evaluation%2C+and+Molecular+Modeling+Investigation+of+1%2C8-Naphthyridin-2%281H%29-One-3-Carboxamides&doi=10.1021%2Fjm500807e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">CB2-Selective Cannabinoid Receptor Ligands: Synthesis, Pharmacological Evaluation, and Molecular Modeling Investigation of 1,8-Naphthyridin-2(1H)-one-3-carboxamides</span></div><div class="casAuthors">Lucchesi, Valentina; Hurst, Dow P.; Shore, Derek M.; Bertini, Simone; Ehrmann, Brandie M.; Allara, Marco; Lawrence, Lyle; Ligresti, Alessia; Minutolo, Filippo; Saccomanni, Giuseppe; Sharir, Haleli; Macchia, Marco; Di Marzo, Vincenzo; Abood, Mary E.; Reggio, Patricia H.; Manera, Clementina</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8777-8791</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have recently identified 1,8-naphthyridin-2(1H)-one-3-carboxamide as a new scaffold very suitable for the development of new CB2 receptor potent and selective ligands.  In this paper we describe a no. of addnl. derivs., e.g., I and II, in which the same central scaffold has been variously functionalized in position 1 or 6.  All new compds. showed high selectivity and affinity in the nanomolar range for the CB2 receptor.  Furthermore, we found that their functional activity is controlled by the presence of the substituents at position C-6 of the naphthyridine scaffold.  In fact, the introduction of substituents in this position detd. a functionality switch from agonist to antagonists/inverse agonists.  Finally, docking studies showed that the difference between the pharmacol. of these ligands may be in the ability/inability to block the Toggle Switch W6.48(258) (χ1 g+ → trans) transition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr52BQ7fcPn7Vg90H21EOLACvtfcHk0ljml9-zo5tUMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1KhtbvI&md5=9b7b38b9525133a488eae0bd6766206b</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fjm500807e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500807e%26sid%3Dliteratum%253Aachs%26aulast%3DLucchesi%26aufirst%3DV.%26aulast%3DHurst%26aufirst%3DD.%2BP.%26aulast%3DShore%26aufirst%3DD.%2BM.%26aulast%3DBertini%26aufirst%3DS.%26aulast%3DEhrmann%26aufirst%3DB.%2BM.%26aulast%3DAllar%25C3%25A0%26aufirst%3DM.%26aulast%3DLawrence%26aufirst%3DL.%26aulast%3DLigresti%26aufirst%3DA.%26aulast%3DMinutolo%26aufirst%3DF.%26aulast%3DSaccomanni%26aufirst%3DG.%26aulast%3DSharir%26aufirst%3DH.%26aulast%3DMacchia%26aufirst%3DM.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DAbood%26aufirst%3DM.%26aulast%3DReggio%26aufirst%3DP.%2BH.%26aulast%3DManera%26aufirst%3DC.%26atitle%3DCB2-Selective%2520Cannabinoid%2520Receptor%2520Ligands%253A%2520Synthesis%252C%2520Pharmacological%2520Evaluation%252C%2520and%2520Molecular%2520Modeling%2520Investigation%2520of%25201%252C8-Naphthyridin-2%25281H%2529-One-3-Carboxamides%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8777%26epage%3D8791%26doi%3D10.1021%2Fjm500807e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.-Z.</span></span> <span> </span><span class="NLM_article-title">Development of Quinoline-2,4(1H,3H)-Diones as Potent and Selective Ligands of the Cannabinoid Type 2 Receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5751</span>– <span class="NLM_lpage">5769</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00227</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00227" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFejtLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5751-5769&author=S.+Hanauthor=F.-F.+Zhangauthor=H.-Y.+Qianauthor=L.-L.+Chenauthor=J.-B.+Puauthor=X.+Xieauthor=J.-Z.+Chen&title=Development+of+Quinoline-2%2C4%281H%2C3H%29-Diones+as+Potent+and+Selective+Ligands+of+the+Cannabinoid+Type+2+Receptor&doi=10.1021%2Facs.jmedchem.5b00227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Quinoline-2,4(1H,3H)-diones as Potent and Selective Ligands of the Cannabinoid Type 2 Receptor</span></div><div class="casAuthors">Han, Shuang; Zhang, Fei-Fei; Qian, Hai-Yan; Chen, Li-Li; Pu, Jian-Bin; Xie, Xin; Chen, Jian-Zhong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5751-5769</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The cannabinoid type 2 receptors (CB2Rs) play crucial roles in inflammatory diseases.  There has been considerable interest in developing potent and selective ligands for CB2R.  In this study, quinoline-2,4(1H,3H)-dione analogs have been designed, synthesized, and evaluated for their potencies and binding properties toward the cannabinoid type 1 receptor (CB1R) and CB2R.  C5- or C8-substituted quinoline-2,4(1H,3H)-diones demonstrate CB2R agonist activity, while the C6- or C7-substituted analogs are antagonists of CB2R.  In addn., oral administration of I dose-dependently alleviates the clin. symptoms of exptl. autoimmune encephalomyelitis in a mouse model of multiple sclerosis and protects the central nervous system from immune damage.  Furthermore, the interaction modes predicted by docking simulations and the 3D-QSAR model generated with CoMFA may offer guidance for further design and modification of CB2R modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2s6_pJyGAhLVg90H21EOLACvtfcHk0ljml9-zo5tUMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFejtLfE&md5=95fccc14423947a2252835971acd92f6</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00227%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DF.-F.%26aulast%3DQian%26aufirst%3DH.-Y.%26aulast%3DChen%26aufirst%3DL.-L.%26aulast%3DPu%26aufirst%3DJ.-B.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DJ.-Z.%26atitle%3DDevelopment%2520of%2520Quinoline-2%252C4%25281H%252C3H%2529-Diones%2520as%2520Potent%2520and%2520Selective%2520Ligands%2520of%2520the%2520Cannabinoid%2520Type%25202%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5751%26epage%3D5769%26doi%3D10.1021%2Facs.jmedchem.5b00227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.-Z.</span></span> <span> </span><span class="NLM_article-title">Design, Syntheses, Structure-Activity Relationships and Docking Studies of Coumarin Derivatives as Novel Selective Ligands for the CB2 Receptor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">16</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.01.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2015.01.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=25644673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Slurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2015&pages=16-32&author=S.+Hanauthor=F.-F.+Zhangauthor=H.-Y.+Qianauthor=L.-L.+Chenauthor=J.-B.+Puauthor=X.+Xieauthor=J.-Z.+Chen&title=Design%2C+Syntheses%2C+Structure-Activity+Relationships+and+Docking+Studies+of+Coumarin+Derivatives+as+Novel+Selective+Ligands+for+the+CB2+Receptor&doi=10.1016%2Fj.ejmech.2015.01.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Design, syntheses, structure-activity relationships and docking studies of coumarin derivatives as novel selective ligands for the CB2 receptor</span></div><div class="casAuthors">Han, Shuang; Zhang, Fei-Fei; Qian, Hai-Yan; Chen, Li-Li; Pu, Jian-Bin; Xie, Xin; Chen, Jian-Zhong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">16-32</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The CB2 receptor has been considered as an inspiring drug target for the treatment of pain and immune-related diseases.  A series of coumarin derivs., e.g., I, is reported to be designed and synthesized by combining the structural features of some known ligands for the cannabinoid receptors based on the CoMFA model of the lead compds.  The compds. were evaluated to be highly selective ligands for the CB2 receptor over the CB1 receptor by calcium mobilization assays.  Furthermore, SAR results indicate that the functionality of a ligand is controlled by the substituent on the nucleus.  Therefore, mol. docking simulations were performed to calc. the receptor-ligand interactions of our synthesized compds. binding to the CB2 receptor.  The understanding of the binding modes could be advantageous for further development of selective ligands for the CB2 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaxXg-Vm6ho7Vg90H21EOLACvtfcHk0lijRJiVX6TrvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Slurc%253D&md5=38c0c3802ba442d61129df73751cc47c</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.01.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.01.054%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DF.-F.%26aulast%3DQian%26aufirst%3DH.-Y.%26aulast%3DChen%26aufirst%3DL.-L.%26aulast%3DPu%26aufirst%3DJ.-B.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DJ.-Z.%26atitle%3DDesign%252C%2520Syntheses%252C%2520Structure-Activity%2520Relationships%2520and%2520Docking%2520Studies%2520of%2520Coumarin%2520Derivatives%2520as%2520Novel%2520Selective%2520Ligands%2520for%2520the%2520CB2%2520Receptor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D93%26spage%3D16%26epage%3D32%26doi%3D10.1016%2Fj.ejmech.2015.01.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banister, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kevin, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edington, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longworth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beinat, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibbs, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glass, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGregor, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassiou, M.</span></span> <span> </span><span class="NLM_article-title">Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1445</span>– <span class="NLM_lpage">1458</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.5b00107</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.5b00107" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnt1ars7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1445-1458&author=S.+D.+Banisterauthor=J.+Stuartauthor=R.+C.+Kevinauthor=A.+Edingtonauthor=M.+Longworthauthor=S.+M.+Wilkinsonauthor=C.+Beinatauthor=A.+S.+Buchananauthor=D.+E.+Hibbsauthor=M.+Glassauthor=M.+Connorauthor=I.+S.+McGregorauthor=M.+Kassiou&title=Effects+of+Bioisosteric+Fluorine+in+Synthetic+Cannabinoid+Designer+Drugs+JWH-018%2C+AM-2201%2C+UR-144%2C+XLR-11%2C+PB-22%2C+5F-PB-22%2C+APICA%2C+and+STS-135&doi=10.1021%2Facschemneuro.5b00107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135</span></div><div class="casAuthors">Banister, Samuel D.; Stuart, Jordyn; Kevin, Richard C.; Edington, Amelia; Longworth, Mitchell; Wilkinson, Shane M.; Beinat, Corinne; Buchanan, Alexandra S.; Hibbs, David E.; Glass, Michelle; Connor, Mark; McGregor, Iain S.; Kassiou, Michael</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1445-1458</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Synthetic cannabinoid (SC) designer drugs featuring bioisosteric fluorine substitution are identified by forensic chemists and toxicologists with increasing frequency.  Although terminal fluorination of N-pentyl indole SCs is sometimes known to improve cannabinoid type 1 (CB1) receptor binding affinity, little is known of the effects of fluorination on functional activity of SCs.  This study explores the in vitro functional activities of SC designer drugs JWH-018, UR-144, PB-22, and APICA, and their resp. terminally fluorinated analogs AM-2201, XLR-11, 5F-PB-22, and STS-135 at human CB1 and CB2 receptors using a FLIPR membrane potential assay.  All compds. demonstrated agonist activity at CB1 (EC50 = 2.8-1959 nM) and CB2 (EC50 = 6.5-206 nM) receptors, with the fluorinated analogs generally showing increased CB1 receptor potency (∼2-5 times).  Addnl., the cannabimimetic activities and relative potencies of JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135 in vivo were evaluated in rats using biotelemetry.  All SCs dose-dependently induced hypothermia and reduced heart rate at doses of 0.3-10 mg/kg.  There was no consistent trend for increased potency of fluorinated SCs over the corresponding des-fluoro SCs in vivo.  Based on magnitude and duration of hypothermia, the SCs were ranked for potency (PB-22 > 5F-PB-22 = JWH-018 > AM-2201 > APICA = STS-135 = XLR-11 > UR-144).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH0UrddzwguLVg90H21EOLACvtfcHk0liaA3THbewxmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnt1ars7Y%253D&md5=0b6560a8bd5352f5226183f5410c8c86</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.5b00107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.5b00107%26sid%3Dliteratum%253Aachs%26aulast%3DBanister%26aufirst%3DS.%2BD.%26aulast%3DStuart%26aufirst%3DJ.%26aulast%3DKevin%26aufirst%3DR.%2BC.%26aulast%3DEdington%26aufirst%3DA.%26aulast%3DLongworth%26aufirst%3DM.%26aulast%3DWilkinson%26aufirst%3DS.%2BM.%26aulast%3DBeinat%26aufirst%3DC.%26aulast%3DBuchanan%26aufirst%3DA.%2BS.%26aulast%3DHibbs%26aufirst%3DD.%2BE.%26aulast%3DGlass%26aufirst%3DM.%26aulast%3DConnor%26aufirst%3DM.%26aulast%3DMcGregor%26aufirst%3DI.%2BS.%26aulast%3DKassiou%26aufirst%3DM.%26atitle%3DEffects%2520of%2520Bioisosteric%2520Fluorine%2520in%2520Synthetic%2520Cannabinoid%2520Designer%2520Drugs%2520JWH-018%252C%2520AM-2201%252C%2520UR-144%252C%2520XLR-11%252C%2520PB-22%252C%25205F-PB-22%252C%2520APICA%252C%2520and%2520STS-135%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2015%26volume%3D6%26spage%3D1445%26epage%3D1458%26doi%3D10.1021%2Facschemneuro.5b00107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banister, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conroy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longworth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manohar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beinat, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kevin, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibbs, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glass, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGregor, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassiou, M.</span></span> <span> </span><span class="NLM_article-title">Structure-Activity Relationships of Synthetic Cannabinoid Designer Drug RCS-4 and Its Regioisomers and C4 Homologues</span>. <i>Forensic Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">366</span>, <span class="refDoi"> DOI: 10.1007/s11419-015-0282-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1007%2Fs11419-015-0282-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpslGmu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=355-366&author=S.+D.+Banisterauthor=J.+Stuartauthor=T.+Conroyauthor=M.+Longworthauthor=M.+Manoharauthor=C.+Beinatauthor=S.+M.+Wilkinsonauthor=R.+C.+Kevinauthor=D.+E.+Hibbsauthor=M.+Glassauthor=M.+Connorauthor=I.+S.+McGregorauthor=M.+Kassiou&title=Structure-Activity+Relationships+of+Synthetic+Cannabinoid+Designer+Drug+RCS-4+and+Its+Regioisomers+and+C4+Homologues&doi=10.1007%2Fs11419-015-0282-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationships of synthetic cannabinoid designer drug RCS-4 and its regioisomers and C4 homologues</span></div><div class="casAuthors">Banister, Samuel D.; Stuart, Jordyn; Conroy, Trent; Longworth, Mitchell; Manohar, Madhura; Beinat, Corinne; Wilkinson, Shane M.; Kevin, Richard C.; Hibbs, David E.; Glass, Michelle; Connor, Mark; McGregor, Iain S.; Kassiou, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Forensic Toxicology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">355-366</span>CODEN:
                <span class="NLM_cas:coden">FTOOAU</span>;
        ISSN:<span class="NLM_cas:issn">1860-8965</span>.
    
            (<span class="NLM_cas:orgname">Springer Japan</span>)
        </div><div class="casAbstract">RCS-4 [(4-methoxyphenyl)-1-yl-(1-pentyl-1H-indol-3-yl)methanone] represents the first of several N-alkyl-3-(methoxybenzoyl)indoles identified by forensic scientists as synthetic cannabinoid (SC) designer drugs.  Despite the detection of RCS-4 and several analogs (RCS-2, RCS-3, RCS-2-C4, RCS-3-C4, and RCS-4-C4) in products intended for human consumption, relatively little is known about this class of cannabinoids.  The synthesis of all regioisomers of RCS-4 and their C4 homologues is described.  This study also systematically explored the structure-activity relationships of this class of SCs at human CB1 and CB2 receptors using an in vitro fluorometric imaging plate reader membrane potential assay.  All compds. demonstrated agonist activity at CB1 (EC50 = 54-574 nM) and CB2 (EC50 = 4.5-46 nM) receptors, with the C4 homologues showing a preference for CB2 receptors over CB1 receptors (31-42 times).  Since most of the analogs (RCS-2, RCS-3, RCS-2-C4, RCS-3-C4 and RCS-4-C4) are not subject to regulation in much of the world, despite their activities towards CB1 and CB2 receptors, there is a possibility that these analogs will emerge on the black market.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVYNWFf9NG1LVg90H21EOLACvtfcHk0liaA3THbewxmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpslGmu7o%253D&md5=33a338dc18c747679e246749a475e4a3</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1007%2Fs11419-015-0282-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11419-015-0282-9%26sid%3Dliteratum%253Aachs%26aulast%3DBanister%26aufirst%3DS.%2BD.%26aulast%3DStuart%26aufirst%3DJ.%26aulast%3DConroy%26aufirst%3DT.%26aulast%3DLongworth%26aufirst%3DM.%26aulast%3DManohar%26aufirst%3DM.%26aulast%3DBeinat%26aufirst%3DC.%26aulast%3DWilkinson%26aufirst%3DS.%2BM.%26aulast%3DKevin%26aufirst%3DR.%2BC.%26aulast%3DHibbs%26aufirst%3DD.%2BE.%26aulast%3DGlass%26aufirst%3DM.%26aulast%3DConnor%26aufirst%3DM.%26aulast%3DMcGregor%26aufirst%3DI.%2BS.%26aulast%3DKassiou%26aufirst%3DM.%26atitle%3DStructure-Activity%2520Relationships%2520of%2520Synthetic%2520Cannabinoid%2520Designer%2520Drug%2520RCS-4%2520and%2520Its%2520Regioisomers%2520and%2520C4%2520Homologues%26jtitle%3DForensic%2520Toxicol.%26date%3D2015%26volume%3D33%26spage%3D355%26epage%3D366%26doi%3D10.1007%2Fs11419-015-0282-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi
Vosough, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baradaran Rahimi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masoud, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirkarimi, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demneh, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abed, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banafshe, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Askari, V. R.</span></span> <span> </span><span class="NLM_article-title">Evaluation of Protective Effects of Non-Selective Cannabinoid Receptor Agonist WIN 55,212-2 against the Nitroglycerine-Induced Acute and Chronic Animal Models of Migraine: A Mechanistic Study</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>232</i></span>,  <span class="NLM_fpage">116670</span>, <span class="refDoi"> DOI: 10.1016/j.lfs.2019.116670</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.lfs.2019.116670" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=31330139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVCjt7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=232&publication_year=2019&pages=116670&author=E.+Mohammadi%0AVosoughauthor=V.+Baradaran+Rahimiauthor=S.+A.+Masoudauthor=H.+R.+Mirkarimiauthor=M.+K.+Demnehauthor=A.+Abedauthor=H.+R.+Banafsheauthor=V.+R.+Askari&title=Evaluation+of+Protective+Effects+of+Non-Selective+Cannabinoid+Receptor+Agonist+WIN+55%2C212-2+against+the+Nitroglycerine-Induced+Acute+and+Chronic+Animal+Models+of+Migraine%3A+A+Mechanistic+Study&doi=10.1016%2Fj.lfs.2019.116670"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of protective effects of non-selective cannabinoid receptor agonist WIN 55,212-2 against the nitroglycerine-induced acute and chronic animal models of migraine: A mechanistic study</span></div><div class="casAuthors">Mohammadi Vosough, Elahe; Baradaran Rahimi, Vafa; Masoud, Seyyed Ali; Mirkarimi, Hamid Reza; Demneh, Maryam Kazemi; Abed, Alireza; Banafshe, Hamid Reza; Askari, Vahid Reza</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">232</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">116670</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Migraine is a neurol. debilitating disorder.  Previous studies have shown that cannabinoid receptor agonists have analgesic effects in various models of pain.  In this study, therefore, we investigated anti-nociceptive effects of WIN 55,212-2, and the role of either CB1 or CB2 receptors in nitroglycerin (NTG)-induced animal model of migraine.  The present study was conducted on both male and female rats receiving NTG (10 mg/kg, i.p.) to induce acute (single dose of NTG) and chronic (repetitive doses of NTG) models of migraine.  Addnl., three groups received WIN 55,212-2 (0.33, 1, 3 mg/kg, i.p.) 45 min before behavioral tests.  Addnl., AM251 and AM630 (CB1 and CB2 receptor antagonist, resp., 1 mg/kg, i.p.) were used to evaluate the possible involvement of CB1 and CB2 receptors during the protective effects of WIN 55,212-2.  We found that NTG (10 mg/kg, i.p.) in both acute and chronic models increased sensitivity to pain.  In acute model, we found that WIN 55,212-2 (almost high doses) decreases the level of pain mainly through CB1 receptor due to CB1 antagonist abrogates its protective effects, however, in formalin test CB2 receptors also had crucial roles in both phases at 3 mg/kg of WIN 55,212-2.  In chronic model, WIN 55,212-2 (0.33, 1 and 3 mg/kg) significantly attenuated NTG-induced hyperalgesia through both CB1 and CB2 receptors.  Our data supported the argument that activation of CB1 and CB2 receptors by WIN 55,212-2 may be considered a new medication for migraine, however in lack of each receptor leads to different responses from deletion to the redn. of analgesic effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUjtU1r71BL7Vg90H21EOLACvtfcHk0lgSe3YMYitkbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVCjt7vE&md5=83c0188956f4f3e2b0ce1b1cfd766606</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2019.116670&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2019.116670%26sid%3Dliteratum%253Aachs%26aulast%3DMohammadi%2BVosough%26aufirst%3DE.%26aulast%3DBaradaran%2BRahimi%26aufirst%3DV.%26aulast%3DMasoud%26aufirst%3DS.%2BA.%26aulast%3DMirkarimi%26aufirst%3DH.%2BR.%26aulast%3DDemneh%26aufirst%3DM.%2BK.%26aulast%3DAbed%26aufirst%3DA.%26aulast%3DBanafshe%26aufirst%3DH.%2BR.%26aulast%3DAskari%26aufirst%3DV.%2BR.%26atitle%3DEvaluation%2520of%2520Protective%2520Effects%2520of%2520Non-Selective%2520Cannabinoid%2520Receptor%2520Agonist%2520WIN%252055%252C212-2%2520against%2520the%2520Nitroglycerine-Induced%2520Acute%2520and%2520Chronic%2520Animal%2520Models%2520of%2520Migraine%253A%2520A%2520Mechanistic%2520Study%26jtitle%3DLife%2520Sci.%26date%3D2019%26volume%3D232%26spage%3D116670%26doi%3D10.1016%2Fj.lfs.2019.116670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roberto, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klotz, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkateswaran, V.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid WIN 55,212-2 Induces Cell Cycle Arrest and Apoptosis, and Inhibits Proliferation, Migration, Invasion, and Tumor Growth in Prostate Cancer in a Cannabinoid-Receptor 2 Dependent Manner</span>. <i>Prostate</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1002/pros.23720</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1002%2Fpros.23720" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=30242861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1SgurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=151-159&author=D.+Robertoauthor=L.+H.+Klotzauthor=V.+Venkateswaran&title=Cannabinoid+WIN+55%2C212-2+Induces+Cell+Cycle+Arrest+and+Apoptosis%2C+and+Inhibits+Proliferation%2C+Migration%2C+Invasion%2C+and+Tumor+Growth+in+Prostate+Cancer+in+a+Cannabinoid-Receptor+2+Dependent+Manner&doi=10.1002%2Fpros.23720"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid WIN 55,212-2 induces cell cycle arrest and apoptosis, and inhibits proliferation, migration, invasion, and tumor growth in prostate cancer in a cannabinoid-receptor 2 dependent manner</span></div><div class="casAuthors">Roberto, Domenica; Klotz, Laurence H.; Venkateswaran, Vasundara</div><div class="citationInfo"><span class="NLM_cas:title">Prostate (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">151-159</span>CODEN:
                <span class="NLM_cas:coden">PRSTDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-4137</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background : Cannabinoids have demonstrated anticarcinogenic properties in a variety of malignancies, including in prostate cancer.  In the present study, we explored the anti-cancer effects of the synthetic cannabinoid WIN 55,212-2 (WIN) in prostate cancer.  Methods : Established prostate cancer cells (PC3, DU145, LNCaP) were treated with varying concns. of WIN.  Cell proliferation was detd. by the MTS assay.  The anti-migration and anti-invasive potential of WIN was examd. by the wound healing assay and the matrigel invasion assay.  Cell cycle anal. was performed by flow cytometry, and mechanistic studies were performed by Western blot.  Athymic mice (n = 10) were inoculated with human PC3 cells.  Once tumors reached 100 mm3, animals were randomized into two groups: saline control and WIN (5 mg/kg), delivered by i.p. injection three times per wk for 3 wk.  Results : WIN significantly reduced prostate cancer cell proliferation, migration, invasion, induced apoptosis, and arrested cells in Go/G1 phase in a dose-dependent manner.  Mechanistic studies revealed these effects were mediated through a pathway involving cell cycle regulators p27, Cdk4, and pRb.  Pre-treatment with a CB2 antagonist, AM630, followed by treatment with WIN resulted in a reversal of the anti-proliferation and cell cycle arrest previously seen with WIN alone.  In vivo, administration of WIN resulted in a redn. in the tumor growth rate compared to control (P < 0.05).  Conclusions : The following study provides evidence supporting the use of WIN as a novel therapeutic for prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1sg2m6maLR7Vg90H21EOLACvtfcHk0lgSe3YMYitkbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1SgurfJ&md5=5b2377b6874813f46ebc3ac2de28ff10</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1002%2Fpros.23720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpros.23720%26sid%3Dliteratum%253Aachs%26aulast%3DRoberto%26aufirst%3DD.%26aulast%3DKlotz%26aufirst%3DL.%2BH.%26aulast%3DVenkateswaran%26aufirst%3DV.%26atitle%3DCannabinoid%2520WIN%252055%252C212-2%2520Induces%2520Cell%2520Cycle%2520Arrest%2520and%2520Apoptosis%252C%2520and%2520Inhibits%2520Proliferation%252C%2520Migration%252C%2520Invasion%252C%2520and%2520Tumor%2520Growth%2520in%2520Prostate%2520Cancer%2520in%2520a%2520Cannabinoid-Receptor%25202%2520Dependent%2520Manner%26jtitle%3DProstate%26date%3D2019%26volume%3D79%26spage%3D151%26epage%3D159%26doi%3D10.1002%2Fpros.23720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al
Fawaz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al Deeb, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huffman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al Kholaif, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garlich, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, R.</span></span> <span> </span><span class="NLM_article-title">A Case of Status Epilepticus and Transient Stress Cardiomyopathy Associated with Smoking the Synthetic Psychoactive Cannabinoid, UR-144</span>. <i>Am. J. Case Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1902</span>– <span class="NLM_lpage">1906</span>, <span class="refDoi"> DOI: 10.12659/AJCR.918918</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.12659%2FAJCR.918918" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=31857571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BB3MbitFCgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1902-1906&author=S.+Al%0AFawazauthor=M.+Al+Deebauthor=J.+L.+Huffmanauthor=N.+A.+Al+Kholaifauthor=F.+Garlichauthor=R.+Chuang&title=A+Case+of+Status+Epilepticus+and+Transient+Stress+Cardiomyopathy+Associated+with+Smoking+the+Synthetic+Psychoactive+Cannabinoid%2C+UR-144&doi=10.12659%2FAJCR.918918"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">A Case of Status Epilepticus and Transient Stress Cardiomyopathy Associated with Smoking the Synthetic Psychoactive Cannabinoid, UR-144</span></div><div class="casAuthors">Al Fawaz Sarah; Al Deeb Mohammad; Huffman James L; Al Kholaif Naji A; Garlich Fiona; Chuang Ryan</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of case reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1902-1906</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND Synthetic cannabinoids have a higher affinity for the cannabinoid receptors CB1 and CB2 than natural cannabinoids.  Their use can be associated with cardiovascular disease and neurological complications.  A case is reported of status epilepticus and stress cardiomyopathy following the recreational use of the synthetic cannabinoid, UR-144.  CASE REPORT A 19-year-old woman presented to the emergency department in status epilepticus after smoking the synthetic cannabinoid known as 'space'.  Recurring seizure activity was controlled after three hours.  On hospital day 3, the patient developed severe biventricular failure.  Cardiac magnetic resonance imaging (MRI) confirmed the diagnosis of stress cardiomyopathy.  A comprehensive urine drug screen was performed using gas chromatography-mass spectrometry (GC-MS), which was positive for UR-144, or (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)-methanone, and negative for all other illicit recreational drugs.  The patient improved at one week following admission, with a left ventricular ejection fraction (LVEF) of 40%.  She was discharged home on hospital day 10.  CONCLUSIONS The use of the synthetic cannabinoid, UR-144, may be associated with prolonged status epilepticus and stress cardiomyopathy.  Physicians should be aware of these potentially lethal complications associated with the recreational use of this and other illicit synthetic cannabinoids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKwjqWvsIJ0dNTrvPZP1IpfW6udTcc2eZDxA2qA-JCN7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MbitFCgsw%253D%253D&md5=1b42ed1edf398855a6d571d4b155cdcc</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.12659%2FAJCR.918918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.12659%252FAJCR.918918%26sid%3Dliteratum%253Aachs%26aulast%3DAl%2BFawaz%26aufirst%3DS.%26aulast%3DAl%2BDeeb%26aufirst%3DM.%26aulast%3DHuffman%26aufirst%3DJ.%2BL.%26aulast%3DAl%2BKholaif%26aufirst%3DN.%2BA.%26aulast%3DGarlich%26aufirst%3DF.%26aulast%3DChuang%26aufirst%3DR.%26atitle%3DA%2520Case%2520of%2520Status%2520Epilepticus%2520and%2520Transient%2520Stress%2520Cardiomyopathy%2520Associated%2520with%2520Smoking%2520the%2520Synthetic%2520Psychoactive%2520Cannabinoid%252C%2520UR-144%26jtitle%3DAm.%2520J.%2520Case%2520Rep.%26date%3D2019%26volume%3D20%26spage%3D1902%26epage%3D1906%26doi%3D10.12659%2FAJCR.918918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganju, R. K.</span></span> <span> </span><span class="NLM_article-title">Cannabinoids as Therapeutic Agents in Cancer: Current Status and Future Implications</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">5852</span>– <span class="NLM_lpage">5872</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.2233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.18632%2Foncotarget.2233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=25115386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252Fht1SgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=5852-5872&author=B.+Chakravartiauthor=J.+Raviauthor=R.+K.+Ganju&title=Cannabinoids+as+Therapeutic+Agents+in+Cancer%3A+Current+Status+and+Future+Implications&doi=10.18632%2Foncotarget.2233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoids as therapeutic agents in cancer: current status and future implications</span></div><div class="casAuthors">Chakravarti Bandana; Ravi Janani; Ganju Ramesh K</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5852-72</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The pharmacological importance of cannabinoids has been in study for several years.  Cannabinoids comprise of (a) the active compounds of the Cannabis sativa plant, (b) endogenous as well as (c) synthetic cannabinoids.  Though cannabinoids are clinically used for anti-palliative effects, recent studies open a promising possibility as anti-cancer agents.  They have been shown to possess anti-proliferative and anti-angiogenic effects in vitro as well as in vivo in different cancer models.  Cannabinoids regulate key cell signaling pathways that are involved in cell survival, invasion, angiogenesis, metastasis, etc.  There is more focus on CB1 and CB2, the two cannabinoid receptors which are activated by most of the cannabinoids.  In this review article, we will focus on a broad range of cannabinoids, their receptor dependent and receptor independent functional roles against various cancer types with respect to growth, metastasis, energy metabolism, immune environment, stemness and future perspectives in exploring new possible therapeutic opportunities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTI4t9ZrFEBIXy-c-E1v-fmfW6udTcc2eY-i8kb0Nye07ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252Fht1SgtA%253D%253D&md5=a7337b09f46c5df725ab7ce07fd5fee5</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2233%26sid%3Dliteratum%253Aachs%26aulast%3DChakravarti%26aufirst%3DB.%26aulast%3DRavi%26aufirst%3DJ.%26aulast%3DGanju%26aufirst%3DR.%2BK.%26atitle%3DCannabinoids%2520as%2520Therapeutic%2520Agents%2520in%2520Cancer%253A%2520Current%2520Status%2520and%2520Future%2520Implications%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26spage%3D5852%26epage%3D5872%26doi%3D10.18632%2Foncotarget.2233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trotter, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanda, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgey, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potteiger, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartnett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kett, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henze, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Della Penna, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leitl, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemaire, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilodeau, M. T.</span></span> <span> </span><span class="NLM_article-title">Imidazopyridine CB2 Agonists: Optimization of CB2/CB1 Selectivity and Implications for in Vivo Analgesic Efficacy</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2354</span>– <span class="NLM_lpage">2358</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.02.082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmcl.2011.02.082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=21420860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkt12kur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=2354-2358&author=B.+W.+Trotterauthor=K.+K.+Nandaauthor=C.+S.+Burgeyauthor=C.+M.+Potteigerauthor=J.+Z.+Dengauthor=A.+I.+Greenauthor=J.+C.+Hartnettauthor=N.+R.+Kettauthor=Z.+Wuauthor=D.+D.+Henzeauthor=K.+Della+Pennaauthor=R.+Desaiauthor=M.+D.+Leitlauthor=W.+Lemaireauthor=R.+B.+Whiteauthor=S.+Yehauthor=M.+O.+Urbanauthor=S.+A.+Kaneauthor=G.+D.+Hartmanauthor=M.+T.+Bilodeau&title=Imidazopyridine+CB2+Agonists%3A+Optimization+of+CB2%2FCB1+Selectivity+and+Implications+for+in+Vivo+Analgesic+Efficacy&doi=10.1016%2Fj.bmcl.2011.02.082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Imidazopyridine CB2 agonists: Optimization of CB2/CB1 selectivity and implications for in vivo analgesic efficacy</span></div><div class="casAuthors">Trotter, B. Wesley; Nanda, Kausik K.; Burgey, Christopher S.; Potteiger, Craig M.; Deng, James Z.; Green, Ahren I.; Hartnett, John C.; Kett, Nathan R.; Wu, Zhicai; Henze, Darrell A.; Della Penna, Kimberly; Desai, Reshma; Leitl, Michael D.; Lemaire, Wei; White, Rebecca B.; Yeh, Suzie; Urban, Mark O.; Kane, Stefanie A.; Hartman, George D.; Bilodeau, Mark T.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2354-2358</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A new series of imidazopyridine CB2 agonists of general formula I-III was prepd. and tested.  Structural optimization improved CB2/CB1 selectivity in this series and conferred phys. properties that facilitated high in vivo exposure, both centrally and peripherally.  Exploration of SAR in this series has produced both CB2-preferring agonists and agonists that appear to be completely selective for CB2 vs. CB1.  In vivo evaluation of these compds. indicates a significant impact of the degree of CB2/CB1 selectivity on analgesic effects in this series.  Administration of a highly selective CB2 agonist (IV) in a rat model of analgesia was ineffective despite substantial CNS exposure, while administration of a moderately selective CB2/CB1 agonist (V) exhibited significant analgesic effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWaOUV5dsbLLVg90H21EOLACvtfcHk0lhSejHgASJVCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkt12kur0%253D&md5=d1b114a9ac85c46ceb62d257f4de7b6f</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.02.082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.02.082%26sid%3Dliteratum%253Aachs%26aulast%3DTrotter%26aufirst%3DB.%2BW.%26aulast%3DNanda%26aufirst%3DK.%2BK.%26aulast%3DBurgey%26aufirst%3DC.%2BS.%26aulast%3DPotteiger%26aufirst%3DC.%2BM.%26aulast%3DDeng%26aufirst%3DJ.%2BZ.%26aulast%3DGreen%26aufirst%3DA.%2BI.%26aulast%3DHartnett%26aufirst%3DJ.%2BC.%26aulast%3DKett%26aufirst%3DN.%2BR.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DHenze%26aufirst%3DD.%2BD.%26aulast%3DDella%2BPenna%26aufirst%3DK.%26aulast%3DDesai%26aufirst%3DR.%26aulast%3DLeitl%26aufirst%3DM.%2BD.%26aulast%3DLemaire%26aufirst%3DW.%26aulast%3DWhite%26aufirst%3DR.%2BB.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DUrban%26aufirst%3DM.%2BO.%26aulast%3DKane%26aufirst%3DS.%2BA.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DBilodeau%26aufirst%3DM.%2BT.%26atitle%3DImidazopyridine%2520CB2%2520Agonists%253A%2520Optimization%2520of%2520CB2%252FCB1%2520Selectivity%2520and%2520Implications%2520for%2520in%2520Vivo%2520Analgesic%2520Efficacy%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D2354%26epage%3D2358%26doi%3D10.1016%2Fj.bmcl.2011.02.082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nanda, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henze, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Della Penna, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leitl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemaire, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouillette, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilodeau, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trotter, B. W.</span></span> <span> </span><span class="NLM_article-title">Benzimidazole CB2 Agonists: Design, Synthesis and SAR</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1218</span>– <span class="NLM_lpage">1221</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.12.068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmcl.2013.12.068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=24461289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1yhs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=1218-1221&author=K.+K.+Nandaauthor=D.+A.+Henzeauthor=K.+Della+Pennaauthor=R.+Desaiauthor=M.+Leitlauthor=W.+Lemaireauthor=R.+B.+Whiteauthor=S.+Yehauthor=J.+N.+Brouilletteauthor=G.+D.+Hartmanauthor=M.+T.+Bilodeauauthor=B.+W.+Trotter&title=Benzimidazole+CB2+Agonists%3A+Design%2C+Synthesis+and+SAR&doi=10.1016%2Fj.bmcl.2013.12.068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Benzimidazole CB2 agonists: Design, synthesis and SAR</span></div><div class="casAuthors">Nanda, Kausik K.; Henze, Darrell A.; Della Penna, Kimberly; Desai, Reshma; Leitl, Michael; Lemaire, Wei; White, Rebecca B.; Yeh, Suzie; Brouillette, Janine N.; Hartman, George D.; Bilodeau, Mark T.; Trotter, B. Wesley</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1218-1221</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A new series of CB2-selective agonists contg. a benzimidazole core is reported.  Design, synthesis, SAR and pharmacokinetic data for selected compds. are described.  E.g., benzimidazole deriv. (I) showed 92-fold selectivity for CB2 receptors over CB1 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGparfJmbXjki7Vg90H21EOLACvtfcHk0lhSejHgASJVCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1yhs78%253D&md5=c81372c37c1848398ba3c8e6a25a9ee4</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.12.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.12.068%26sid%3Dliteratum%253Aachs%26aulast%3DNanda%26aufirst%3DK.%2BK.%26aulast%3DHenze%26aufirst%3DD.%2BA.%26aulast%3DDella%2BPenna%26aufirst%3DK.%26aulast%3DDesai%26aufirst%3DR.%26aulast%3DLeitl%26aufirst%3DM.%26aulast%3DLemaire%26aufirst%3DW.%26aulast%3DWhite%26aufirst%3DR.%2BB.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DBrouillette%26aufirst%3DJ.%2BN.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DBilodeau%26aufirst%3DM.%2BT.%26aulast%3DTrotter%26aufirst%3DB.%2BW.%26atitle%3DBenzimidazole%2520CB2%2520Agonists%253A%2520Design%252C%2520Synthesis%2520and%2520SAR%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D1218%26epage%3D1221%26doi%3D10.1016%2Fj.bmcl.2013.12.068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koba, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudo, M.</span></span> <span> </span><span class="NLM_article-title">Identification of a Highly Potent and Selective CB2 Agonist, RQ-00202730, for the Treatment of Irritable Bowel Syndrome</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">236</span>– <span class="NLM_lpage">240</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.11.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmcl.2014.11.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=25499880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVems7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=236-240&author=Y.+Iwataauthor=K.+Andoauthor=K.+Taniguchiauthor=N.+Kobaauthor=A.+Sugiuraauthor=M.+Sudo&title=Identification+of+a+Highly+Potent+and+Selective+CB2+Agonist%2C+RQ-00202730%2C+for+the+Treatment+of+Irritable+Bowel+Syndrome&doi=10.1016%2Fj.bmcl.2014.11.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a highly potent and selective CB2 agonist, RQ-00202730, for the treatment of irritable bowel syndrome</span></div><div class="casAuthors">Iwata, Yasuhiro; Ando, Kazuo; Taniguchi, Kana; Koba, Naomi; Sugiura, Akemi; Sudo, Masaki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">236-240</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein the authors report the identification of a highly potent and selective CB2 agonist, RQ-00202730 I, obtained by lead optimization of the benzimidazole scaffold.  Compd. I showed strong agonistic activity with an EC50 of 19 nM and excellent selectivity (>1300-fold) over the CB1 receptor.  Compd. I displayed a dose dependent analgesic effect on TNBS-induced visceral hypersensitivity in rats by oral administration (ED50 0.66 mg/kg at 2.5 h after oral administration).  In addn., I did not show a significant effect on body temp. in rats after oral administration at 300 mg/kg.  These findings suggest that highly selective CB2 agonists will be effective agents for IBS therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY99dK3pO2CbVg90H21EOLACvtfcHk0ljsHrE07e6X-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVems7fO&md5=ab88e62e468d744e4abbe1b2b4c0ad1e</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.11.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.11.062%26sid%3Dliteratum%253Aachs%26aulast%3DIwata%26aufirst%3DY.%26aulast%3DAndo%26aufirst%3DK.%26aulast%3DTaniguchi%26aufirst%3DK.%26aulast%3DKoba%26aufirst%3DN.%26aulast%3DSugiura%26aufirst%3DA.%26aulast%3DSudo%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520a%2520Highly%2520Potent%2520and%2520Selective%2520CB2%2520Agonist%252C%2520RQ-00202730%252C%2520for%2520the%2520Treatment%2520of%2520Irritable%2520Bowel%2520Syndrome%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D236%26epage%3D240%26doi%3D10.1016%2Fj.bmcl.2014.11.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Omura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shima, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makita, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, K.</span></span> <span> </span><span class="NLM_article-title">The SAR Studies of Novel CB2 Selective Agonists, Benzimidazolone Derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">3310</span>– <span class="NLM_lpage">3314</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.04.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmcl.2008.04.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=18440813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD1cXms1yhs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=3310-3314&author=H.+Omuraauthor=M.+Kawaiauthor=A.+Shimaauthor=Y.+Iwataauthor=F.+Itoauthor=T.+Masudaauthor=A.+Ohtaauthor=N.+Makitaauthor=K.+Omotoauthor=H.+Sugimotoauthor=A.+Kikuchiauthor=H.+Iwataauthor=K.+Ando&title=The+SAR+Studies+of+Novel+CB2+Selective+Agonists%2C+Benzimidazolone+Derivatives&doi=10.1016%2Fj.bmcl.2008.04.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">The SAR studies of novel CB2 selective agonists, benzimidazolone derivatives</span></div><div class="casAuthors">Omura, Hirofumi; Kawai, Makoto; Shima, Akiko; Iwata, Yasuhiro; Ito, Fumitaka; Masuda, Tsutomu; Ohta, Atsuko; Makita, Naoya; Omoto, Kiyoyuki; Sugimoto, Hiromi; Kikuchi, Akira; Iwata, Hiroshi; Ando, Kazuo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3310-3314</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Benzimidazolone derivs. were discovered as novel CB2 selective agonists.  Structure Activity Relationship (SAR) studies around them were examd. to improve metabolic stability.  Compd. 39 (I) exhibited excellent metabolic stability in human liver microsomes (HLM) and significant attenuation of the chronic colonic allodynia in the TNBS-treated rats by po administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWUT-3sSa6WrVg90H21EOLACvtfcHk0ljsHrE07e6X-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXms1yhs7g%253D&md5=9ce38fd3572c2c6bafa7bce18e842f39</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.04.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.04.032%26sid%3Dliteratum%253Aachs%26aulast%3DOmura%26aufirst%3DH.%26aulast%3DKawai%26aufirst%3DM.%26aulast%3DShima%26aufirst%3DA.%26aulast%3DIwata%26aufirst%3DY.%26aulast%3DIto%26aufirst%3DF.%26aulast%3DMasuda%26aufirst%3DT.%26aulast%3DOhta%26aufirst%3DA.%26aulast%3DMakita%26aufirst%3DN.%26aulast%3DOmoto%26aufirst%3DK.%26aulast%3DSugimoto%26aufirst%3DH.%26aulast%3DKikuchi%26aufirst%3DA.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DAndo%26aufirst%3DK.%26atitle%3DThe%2520SAR%2520Studies%2520of%2520Novel%2520CB2%2520Selective%2520Agonists%252C%2520Benzimidazolone%2520Derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D3310%26epage%3D3314%26doi%3D10.1016%2Fj.bmcl.2008.04.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hollinshead, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tidwell, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guidetti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanderson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oskins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratford, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Astles, P. C.</span></span> <span> </span><span class="NLM_article-title">Selective Cannabinoid Receptor Type 2 (CB2) Agonists: Optimization of a Series of Purines Leading to the Identification of a Clinical Candidate for the Treatment of Osteoarthritic Pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5722</span>– <span class="NLM_lpage">5733</span>, <span class="refDoi"> DOI: 10.1021/jm400305d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400305d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvFaksrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5722-5733&author=S.+P.+Hollinsheadauthor=M.+W.+Tidwellauthor=J.+Palmerauthor=R.+Guidettiauthor=A.+Sandersonauthor=M.+P.+Johnsonauthor=M.+G.+Chambersauthor=J.+Oskinsauthor=R.+Stratfordauthor=P.+C.+Astles&title=Selective+Cannabinoid+Receptor+Type+2+%28CB2%29+Agonists%3A+Optimization+of+a+Series+of+Purines+Leading+to+the+Identification+of+a+Clinical+Candidate+for+the+Treatment+of+Osteoarthritic+Pain&doi=10.1021%2Fjm400305d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Cannabinoid Receptor Type 2 (CB2) Agonists: Optimization of a Series of Purines Leading to the Identification of a Clinical Candidate for the Treatment of Osteoarthritic Pain</span></div><div class="casAuthors">Hollinshead, Sean P.; Tidwell, Michael W.; Palmer, John; Guidetti, Rossella; Sanderson, Adam; Johnson, Michael P.; Chambers, Mark G.; Oskins, Jennifer; Stratford, Robert; Astles, Peter C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5722-5733</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A focused screening strategy identified thienopyrimidine I as a cannabinoid receptor type 2 agonist (hCB2) with moderate selectivity over the hCB1 receptor.  This initial hit suffered from poor in vitro metabolic stability and high in vivo clearance.  Structure-activity relationships describe the optimization and modification to a new more polar series of purine CB2 agonists.  Examples from this novel scaffold were found to be highly potent and fully efficacious agonists of the human CB2 receptor with excellent selectivity against CB1, often having no CB1 agonist activity at the highest concn. measured (>100 μM).  Purine compd. II (R1 = tetrahydropyan-4-yl) is a centrally penetrant mol. which possesses good biopharmaceutical properties, is highly water-sol., and demonstrates robust oral activity in rodent models of joint pain.  In addn., the peripherally restricted mol. II (R1 = CH2CH2SO2Me) also demonstrated significant efficacy in the same analgesic model of rodent inflammatory pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK67SLculmNLVg90H21EOLACvtfcHk0lg4jksflUI_Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvFaksrw%253D&md5=62c14d8c1133fb025d405379ad352860</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1021%2Fjm400305d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400305d%26sid%3Dliteratum%253Aachs%26aulast%3DHollinshead%26aufirst%3DS.%2BP.%26aulast%3DTidwell%26aufirst%3DM.%2BW.%26aulast%3DPalmer%26aufirst%3DJ.%26aulast%3DGuidetti%26aufirst%3DR.%26aulast%3DSanderson%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DM.%2BP.%26aulast%3DChambers%26aufirst%3DM.%2BG.%26aulast%3DOskins%26aufirst%3DJ.%26aulast%3DStratford%26aufirst%3DR.%26aulast%3DAstles%26aufirst%3DP.%2BC.%26atitle%3DSelective%2520Cannabinoid%2520Receptor%2520Type%25202%2520%2528CB2%2529%2520Agonists%253A%2520Optimization%2520of%2520a%2520Series%2520of%2520Purines%2520Leading%2520to%2520the%2520Identification%2520of%2520a%2520Clinical%2520Candidate%2520for%2520the%2520Treatment%2520of%2520Osteoarthritic%2520Pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5722%26epage%3D5733%26doi%3D10.1021%2Fjm400305d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hollinshead, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Astles, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tidwell, M. W.</span></span> <span> </span><span class="NLM_article-title">Discovery and Optimization of Novel Purines as Potent and Selective CB2 Agonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">4962</span>– <span class="NLM_lpage">4966</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.06.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmcl.2012.06.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=22765893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC38Xps1Kktr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4962-4966&author=S.+P.+Hollinsheadauthor=P.+C.+Astlesauthor=M.+G.+Chambersauthor=M.+P.+Johnsonauthor=J.+Palmerauthor=M.+W.+Tidwell&title=Discovery+and+Optimization+of+Novel+Purines+as+Potent+and+Selective+CB2+Agonists&doi=10.1016%2Fj.bmcl.2012.06.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and optimization of novel purines as potent and selective CB2 agonists</span></div><div class="casAuthors">Hollinshead, Sean P.; Astles, Peter C.; Chambers, Mark G.; Johnson, Michael P.; Palmer, John; Tidwell, Michael W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4962-4966</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A focused screening strategy identified thienopyrimidine I as a hCB2 cannabinoid receptor agonist with moderate selectivity over the hCB1 receptor.  This initial hit suffered from poor in vitro metabolic stability and high in vivo clearance.  Structure-activity relationships describe the optimization and modification to a less lipophilic purine core.  Examples from this novel series were found to be highly potent and fully efficacious agonists of the human CB2 receptor with excellent selectivity against CB1.  Compd. II possesses good biopharmaceutical properties, is highly water sol. and demonstrates robust oral activity in rodent models of joint pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-stJ--MpAdrVg90H21EOLACvtfcHk0lg4jksflUI_Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xps1Kktr8%253D&md5=8620ee7602f5537a0c029c00de238137</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.06.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.06.035%26sid%3Dliteratum%253Aachs%26aulast%3DHollinshead%26aufirst%3DS.%2BP.%26aulast%3DAstles%26aufirst%3DP.%2BC.%26aulast%3DChambers%26aufirst%3DM.%2BG.%26aulast%3DJohnson%26aufirst%3DM.%2BP.%26aulast%3DPalmer%26aufirst%3DJ.%26aulast%3DTidwell%26aufirst%3DM.%2BW.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520Novel%2520Purines%2520as%2520Potent%2520and%2520Selective%2520CB2%2520Agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4962%26epage%3D4966%26doi%3D10.1016%2Fj.bmcl.2012.06.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osman, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligresti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allarà, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabbito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abouzid, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abadi, A. H.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel Tetrahydrobenzo[b]Thiophene and Pyrrole Based Scaffolds as Potent and Selective CB2 Receptor Ligands: The Structural Elements Controlling Binding Affinity, Selectivity and Functionality</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">619</span>– <span class="NLM_lpage">634</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.07.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2016.07.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=27448919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1agsb7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2016&pages=619-634&author=N.+A.+Osmanauthor=A.+Ligrestiauthor=C.+D.+Kleinauthor=M.+Allar%C3%A0author=A.+Rabbitoauthor=V.+Di+Marzoauthor=K.+A.+Abouzidauthor=A.+H.+Abadi&title=Discovery+of+Novel+Tetrahydrobenzo%5Bb%5DThiophene+and+Pyrrole+Based+Scaffolds+as+Potent+and+Selective+CB2+Receptor+Ligands%3A+The+Structural+Elements+Controlling+Binding+Affinity%2C+Selectivity+and+Functionality&doi=10.1016%2Fj.ejmech.2016.07.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel Tetrahydrobenzo[b]thiophene and pyrrole based scaffolds as potent and selective CB2 receptor ligands: The structural elements controlling binding affinity, selectivity and functionality</span></div><div class="casAuthors">Osman, Noha A.; Ligresti, Alessia; Klein, Christian D.; Allara, Marco; Rabbito, Alessandro; Di Marzo, Vincenzo; Abouzid, Khaled A.; Abadi, Ashraf H.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">619-634</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">CB2-based therapeutics show strong potential in the treatment of diverse diseases such as inflammation, multiple sclerosis, pain, immune-related disorders, osteoporosis and cancer, without eliciting the typical neurobehavioral side effects of CB1 ligands.  For this reason, research activities are currently directed towards the development of CB2 selective ligands.  Herein, the synthesis of novel heterocyclic-based CB2 selective compds. is reported.  A set of 2,5-dialkyl-1-phenyl-1H-pyrrole-3-carboxamides, 5-substituted-2-(acylamino)/(2-sulfonylamino)-thiophene-3-carboxylates and 2-(acylamino)/(2-sulfonylamino)-tetrahydrobenzo[b]thiophene-3-carboxylates were synthesized.  Biol. results revealed compds. with remarkably high CB2 binding affinity and CB2/CB1 subtype selectivity.  Compd. I (R = adamantan-1-yl, R1 = Me, Et) from the pyrrole series exhibited the highest CB2 receptor affinity (Ki = 7.59 and 6.15 nM, resp.), as well as the highest CB2/CB1 subtype selectivity (∼70 and ∼200-fold, resp.).  In addn., compd. II (R = adamantan-1-yl) from the tetrahydrobenzo[b]thiophene series presented the most potent and selective CB2 ligand in this series (Ki = 2.15 nM and CB2 subtype selectivity of almost 500-fold over CB1).  Compd. II (R = adamantan-1-yl) showed a full agonism, while compds. I (R = adamantan-1-yl, R1 = Me, Et) acted as inverse agonists when tested in an adenylate cyclase assay.  The present findings thus pave the way to the design and optimization of heterocyclic-based scaffolds with lipophilic carboxamide and/or retroamide substituent that can be exploited as potential CB2 receptor activity modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnd1ftLyoMLrVg90H21EOLACvtfcHk0lg4jksflUI_Hg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1agsb7I&md5=49a6678c95e6e0584aa5293d104c4810</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.07.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.07.012%26sid%3Dliteratum%253Aachs%26aulast%3DOsman%26aufirst%3DN.%2BA.%26aulast%3DLigresti%26aufirst%3DA.%26aulast%3DKlein%26aufirst%3DC.%2BD.%26aulast%3DAllar%25C3%25A0%26aufirst%3DM.%26aulast%3DRabbito%26aufirst%3DA.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DAbouzid%26aufirst%3DK.%2BA.%26aulast%3DAbadi%26aufirst%3DA.%2BH.%26atitle%3DDiscovery%2520of%2520Novel%2520Tetrahydrobenzo%255Bb%255DThiophene%2520and%2520Pyrrole%2520Based%2520Scaffolds%2520as%2520Potent%2520and%2520Selective%2520CB2%2520Receptor%2520Ligands%253A%2520The%2520Structural%2520Elements%2520Controlling%2520Binding%2520Affinity%252C%2520Selectivity%2520and%2520Functionality%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D122%26spage%3D619%26epage%3D634%26doi%3D10.1016%2Fj.ejmech.2016.07.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romero-Parra, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mella-Raipán, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmieri, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allarà, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pessoa-Mahana, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iturriaga-Vásquez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escobar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faúndez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pessoa-Mahana, C. D.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Binding Assays, Cytotoxic Activity and Docking Studies of Benzimidazole and Benzothiophene Derivatives with Selective Affinity for the CB2 Cannabinoid Receptor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2016.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=27560280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVOqsrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2016&pages=17-35&author=J.+Romero-Parraauthor=J.+Mella-Raip%C3%A1nauthor=V.+Palmieriauthor=M.+Allar%C3%A0author=M.+J.+Torresauthor=H.+Pessoa-Mahanaauthor=P.+Iturriaga-V%C3%A1squezauthor=R.+Escobarauthor=M.+Fa%C3%BAndezauthor=V.+Di+Marzoauthor=C.+D.+Pessoa-Mahana&title=Synthesis%2C+Binding+Assays%2C+Cytotoxic+Activity+and+Docking+Studies+of+Benzimidazole+and+Benzothiophene+Derivatives+with+Selective+Affinity+for+the+CB2+Cannabinoid+Receptor&doi=10.1016%2Fj.ejmech.2016.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, binding assays, cytotoxic activity and docking studies of benzimidazole and benzothiophene derivatives with selective affinity for the CB2 cannabinoid receptor</span></div><div class="casAuthors">Romero-Parra, Javier; Mella-Raipan, Jaime; Palmieri, Vittoria; Allara, Marco; Torres, Maria Jose; Pessoa-Mahana, Hernan; Iturriaga-Vasquez, Patricio; Escobar, Rossy; Faundez, Mario; Di Marzo, Vincenzo; Pessoa-Mahana, C. David</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17-35</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The design, synthesis, bioinformatic and biol. studies of benzimidazole and benzothiophene derivs. as new cannabinoid receptor ligands was reported.  To test the hypothesis that the lack of a hydrogen bond interaction between benzimidazole and benzothiophene derivs. with Lys192 reduced their affinity for CB1 receptors (as we previously reported) and led to CB2 selectivity, most of the tested compds. did not exhibit hydrogen bond acceptors.  All compds. displayed mostly CB2 selectivity, although this was more pronounced in the benzimidazoles derivs.  Furthermore, docking assays revealed a π-cation interaction with Lys109 which could play a key role for the CB2 selectivity index.  The series displayed low toxicity on five different cell lines.  Deriv. (2-(tert-butyl)-1H-benzo[d]imidazol-1-yl)(naphthalen-1-yl)methanone presented the best binding profile (Ki = 0.08 μM), high selectivity index (KiCB1/KiCB2) and a low citoxicity.  Interestingly, in-cell viability expts., using HL-60 cells (expressing exclusively CB2 receptors), all synthesized compds. were shown to be cytotoxic, suggesting that a CB2 agonist response may be involved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3NW06Xfx-b7Vg90H21EOLACvtfcHk0liZm0fq7qVm8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVOqsrzL&md5=d27e5322faed12a25e775b606a2fe88c</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DRomero-Parra%26aufirst%3DJ.%26aulast%3DMella-Raip%25C3%25A1n%26aufirst%3DJ.%26aulast%3DPalmieri%26aufirst%3DV.%26aulast%3DAllar%25C3%25A0%26aufirst%3DM.%26aulast%3DTorres%26aufirst%3DM.%2BJ.%26aulast%3DPessoa-Mahana%26aufirst%3DH.%26aulast%3DIturriaga-V%25C3%25A1squez%26aufirst%3DP.%26aulast%3DEscobar%26aufirst%3DR.%26aulast%3DFa%25C3%25BAndez%26aufirst%3DM.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DPessoa-Mahana%26aufirst%3DC.%2BD.%26atitle%3DSynthesis%252C%2520Binding%2520Assays%252C%2520Cytotoxic%2520Activity%2520and%2520Docking%2520Studies%2520of%2520Benzimidazole%2520and%2520Benzothiophene%2520Derivatives%2520with%2520Selective%2520Affinity%2520for%2520the%2520CB2%2520Cannabinoid%2520Receptor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D124%26spage%3D17%26epage%3D35%26doi%3D10.1016%2Fj.ejmech.2016.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yrjölä, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalliokoski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laitinen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkkari, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevalainen, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel Cannabinoid Receptor Ligands by a Virtual Screening Approach: Further Development of 2,4,6-Trisubstituted 1,3,5-Triazines as CB2 Agonists</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2012.10.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejps.2012.10.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=23131798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosFKjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2013&pages=9-20&author=S.+Yrj%C3%B6l%C3%A4author=T.+Kalliokoskiauthor=T.+Laitinenauthor=A.+Posoauthor=T.+Parkkariauthor=T.+Nevalainen&title=Discovery+of+Novel+Cannabinoid+Receptor+Ligands+by+a+Virtual+Screening+Approach%3A+Further+Development+of+2%2C4%2C6-Trisubstituted+1%2C3%2C5-Triazines+as+CB2+Agonists&doi=10.1016%2Fj.ejps.2012.10.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel cannabinoid receptor ligands by a virtual screening approach: Further development of 2,4,6-trisubstituted 1,3,5-triazines as CB2 agonists</span></div><div class="casAuthors">Yrjola, Sari; Kalliokoski, Tuomo; Laitinen, Tuomo; Poso, Antti; Parkkari, Teija; Nevalainen, Tapio</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">9-20</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">3D ligand-based virtual screening was employed to identify novel scaffolds for cannabinoid receptor ligand development.  A total of 112 compds. with diverse structures were purchased from com. vendors. 12 CB1 receptor antagonists/inverse agonists and 10 CB2 receptor agonists were identified in vitro.  One of the CB2 agonists, N-cyclopentyl-4-ethoxy-6-(4-methylpiperidin-1-yl)-1,3,5-triazin-2-amine (19, -log EC50 = 7.5, Emax = 255%) was selected for further development.  As far as we are aware, the compd.'s 1,3,5-triazine scaffold represents a new core structure for CB2 agonists.  A library of fifty-seven 2,4,6-trisubstituted-1,3,5-triazines was created to clarify the structure-activity relationship study of the analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrv7JzPj_96GbVg90H21EOLACvtfcHk0liZm0fq7qVm8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosFKjuw%253D%253D&md5=b0bcb09a66682d9552254363121deacc</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2012.10.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2012.10.020%26sid%3Dliteratum%253Aachs%26aulast%3DYrj%25C3%25B6l%25C3%25A4%26aufirst%3DS.%26aulast%3DKalliokoski%26aufirst%3DT.%26aulast%3DLaitinen%26aufirst%3DT.%26aulast%3DPoso%26aufirst%3DA.%26aulast%3DParkkari%26aufirst%3DT.%26aulast%3DNevalainen%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520Novel%2520Cannabinoid%2520Receptor%2520Ligands%2520by%2520a%2520Virtual%2520Screening%2520Approach%253A%2520Further%2520Development%2520of%25202%252C4%252C6-Trisubstituted%25201%252C3%252C5-Triazines%2520as%2520CB2%2520Agonists%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2013%26volume%3D48%26spage%3D9%26epage%3D20%26doi%3D10.1016%2Fj.ejps.2012.10.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yrjölä, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarparanta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Airaksinen, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hytti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauppinen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasonen-Seppänen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adinolfi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keinänen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevalainen, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkkari, T.</span></span> <span> </span><span class="NLM_article-title">Synthesis, in Vitro and in Vivo Evaluation of 1,3,5-Triazines as Cannabinoid CB2 Receptor Agonists</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2014.11.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejps.2014.11.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=25447744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFCnt7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2015&pages=85-96&author=S.+Yrj%C3%B6l%C3%A4author=M.+Sarparantaauthor=A.+J.+Airaksinenauthor=M.+Hyttiauthor=A.+Kauppinenauthor=S.+Pasonen-Sepp%C3%A4nenauthor=B.+Adinolfiauthor=P.+Nieriauthor=C.+Maneraauthor=O.+Kein%C3%A4nenauthor=A.+Posoauthor=T.+J.+Nevalainenauthor=T.+Parkkari&title=Synthesis%2C+in+Vitro+and+in+Vivo+Evaluation+of+1%2C3%2C5-Triazines+as+Cannabinoid+CB2+Receptor+Agonists&doi=10.1016%2Fj.ejps.2014.11.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists</span></div><div class="casAuthors">Yrjola, Sari; Sarparanta, Mirkka; Airaksinen, Anu J.; Hytti, Maria; Kauppinen, Anu; Pasonen-Seppanen, Sanna; Adinolfi, Barbara; Nieri, Paola; Manera, Clementina; Keinanen, Outi; Poso, Antti; Nevalainen, Tapio J.; Parkkari, Teija</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">85-96</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The cannabinoid receptors type 2 (CBR2) are attractive therapeutic targets of the endocannabinoid signaling system (ECS) as they are not displaying the undesired psychotropic and cardiovascular side-effects seen with cannabinoid receptor type 1 (CB1R) agonists.  In continuation of our previous work on 2,4,6-trisubstituted 1,3,5-triazines as potent CB2 agonists, we synthesized an addnl. series of more polar analogs (1-10), which were found to possess high CB2R agonist activity with enhanced water soly.  The most potent compd. in the series was N-(adamantan-1-yl)-4-ethoxy-6-(4-(2-fluoroethyl)piperazin-1-yl)-1,3,5-triazin-2-amine (9) with EC50 value of 0.60 nM.  To further evaluate the biol. effects of the compds., the selected compds. were tested in vitro against four different cell lines.  A human retinal pigment epithelial cell line (ARPE-19) was used to evaluate the cytotoxicity of the compds. whereas an androgen-sensitive human prostate adenocarcinoma cell line (LNCaP), a Jurkat leukemia cell line and a C8161 melanoma cell line were used to assess the antiproliferative activity of the compds.  The most interesting results were obtained for N-(adamantan-1-yl)-4-ethoxy-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-amine (6), which induced cell viability decrease in prostate and leukemia cell lines, and diminished proliferation of C8161 melanoma cells.  The results could be reversed in leukemia cells with the selective CB2R antagonist AM630, whereas in prostate cells the AM630 induced a significant cell viability decrease with a mechanism probably unlinked to CB2 cannabinoid receptor.  The antiproliferative effect of 6 on the melanoma cells seemed not to be mediated via the CB1R or CB2R.  No cytotoxicity was detected against ARPE-19 cell line at concns. of 1 and 10 μM for compd. 6.  However, at 30 μM concn. the compd. 6 decreased the cell viability.  Finally, in order to est. in vivo behavior of these compds., 18F labeled PET ligand, N-cyclopentyl-4-ethoxy-6-(4-(2-fluoro-18-ethyl)piperazin-1-yl)-1,3,5-triazin-2-amine ([18F]5), was synthesized and its biodistribution was detd. in healthy male Sprague-Dawley rats.  As a result, the tracer showed a rapid (<15 min) elimination in urine accompanied by a slower excretion via the hepatobiliary route.  In conclusion, we further demonstrated that 1,3,5-triazine scaffold serves as a suitable template for the design of highly potent CB2R agonists with reasonable water soly. properties.  The compds. may be useful when studying the role of the endocannabinoid system in different diseases.  The triazine scaffold is also a promising candidate for the development of new CB2R PET ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_1aEvtEgaW7Vg90H21EOLACvtfcHk0liRNBFmpxyZNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFCnt7bL&md5=8153b8fd95235ae3541e6bf209eef499</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2014.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2014.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DYrj%25C3%25B6l%25C3%25A4%26aufirst%3DS.%26aulast%3DSarparanta%26aufirst%3DM.%26aulast%3DAiraksinen%26aufirst%3DA.%2BJ.%26aulast%3DHytti%26aufirst%3DM.%26aulast%3DKauppinen%26aufirst%3DA.%26aulast%3DPasonen-Sepp%25C3%25A4nen%26aufirst%3DS.%26aulast%3DAdinolfi%26aufirst%3DB.%26aulast%3DNieri%26aufirst%3DP.%26aulast%3DManera%26aufirst%3DC.%26aulast%3DKein%25C3%25A4nen%26aufirst%3DO.%26aulast%3DPoso%26aufirst%3DA.%26aulast%3DNevalainen%26aufirst%3DT.%2BJ.%26aulast%3DParkkari%26aufirst%3DT.%26atitle%3DSynthesis%252C%2520in%2520Vitro%2520and%2520in%2520Vivo%2520Evaluation%2520of%25201%252C3%252C5-Triazines%2520as%2520Cannabinoid%2520CB2%2520Receptor%2520Agonists%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2015%26volume%3D67%26spage%3D85%26epage%3D96%26doi%3D10.1016%2Fj.ejps.2014.11.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Odan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishizuka, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiramatsu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashizume, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsumori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morioka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasui, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arimura, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of S-777469: An Orally Available CB2 Agonist as an Antipruritic Agent</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2803</span>– <span class="NLM_lpage">2806</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.02.072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmcl.2012.02.072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=22444677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC38XksV2itrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2803-2806&author=M.+Odanauthor=N.+Ishizukaauthor=Y.+Hiramatsuauthor=M.+Inagakiauthor=H.+Hashizumeauthor=Y.+Fujiiauthor=S.+Mitsumoriauthor=Y.+Moriokaauthor=M.+Sogaauthor=M.+Deguchiauthor=K.+Yasuiauthor=A.+Arimura&title=Discovery+of+S-777469%3A+An+Orally+Available+CB2+Agonist+as+an+Antipruritic+Agent&doi=10.1016%2Fj.bmcl.2012.02.072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of S-777469: An orally available CB2 agonist as an antipruritic agent</span></div><div class="casAuthors">Odan, Masahide; Ishizuka, Natsuki; Hiramatsu, Yoshiharu; Inagaki, Masanao; Hashizume, Hiroshi; Fujii, Yasuhiko; Mitsumori, Susumu; Morioka, Yasuhide; Soga, Masahiko; Deguchi, Masashi; Yasui, Kiyoshi; Arimura, Akinori</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2803-2806</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The discovery of novel CB2 ligands based on the 3-carbamoyl-2-pyridone derivs. by adjusting the size of side chain at 1-, 5- and 6-position is reported.  The structure-activity relationship around this template lead to the identification of S-777469 as a selective CB2 receptor agonist, which exhibited the significant inhibition of scratching induced by Compd. 48/80 at 1.0 mg/kg po and 10 mg/kg po (55% and 61%, resp.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzaovlzOzh1LVg90H21EOLACvtfcHk0liRNBFmpxyZNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksV2itrk%253D&md5=802f17b593a2a791c24caf226f808218</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.02.072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.02.072%26sid%3Dliteratum%253Aachs%26aulast%3DOdan%26aufirst%3DM.%26aulast%3DIshizuka%26aufirst%3DN.%26aulast%3DHiramatsu%26aufirst%3DY.%26aulast%3DInagaki%26aufirst%3DM.%26aulast%3DHashizume%26aufirst%3DH.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DMitsumori%26aufirst%3DS.%26aulast%3DMorioka%26aufirst%3DY.%26aulast%3DSoga%26aufirst%3DM.%26aulast%3DDeguchi%26aufirst%3DM.%26aulast%3DYasui%26aufirst%3DK.%26aulast%3DArimura%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520S-777469%253A%2520An%2520Orally%2520Available%2520CB2%2520Agonist%2520as%2520an%2520Antipruritic%2520Agent%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2803%26epage%3D2806%26doi%3D10.1016%2Fj.bmcl.2012.02.072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucchesi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkkari, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savinainen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malfitano, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allarà, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Carlo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laezza, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligresti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccomanni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifulco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manera, C.</span></span> <span> </span><span class="NLM_article-title">1,2-Dihydro-2-Oxopyridine-3-Carboxamides: The C-5 Substituent Is Responsible for Functionality Switch at CB2 Cannabinoid Receptor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">524</span>– <span class="NLM_lpage">532</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.10.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2013.10.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=24518874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlygu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=524-532&author=V.+Lucchesiauthor=T.+Parkkariauthor=J.+R.+Savinainenauthor=A.+M.+Malfitanoauthor=M.+Allar%C3%A0author=S.+Bertiniauthor=F.+Castelliauthor=S.+Del+Carloauthor=C.+Laezzaauthor=A.+Ligrestiauthor=G.+Saccomanniauthor=M.+Bifulcoauthor=V.+Di+Marzoauthor=M.+Macchiaauthor=C.+Manera&title=1%2C2-Dihydro-2-Oxopyridine-3-Carboxamides%3A+The+C-5+Substituent+Is+Responsible+for+Functionality+Switch+at+CB2+Cannabinoid+Receptor&doi=10.1016%2Fj.ejmech.2013.10.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">1,2-Dihydro-2-oxopyridine-3-carboxamides: The C-5 substituent is responsible for functionality switch at CB2 cannabinoid receptor</span></div><div class="casAuthors">Lucchesi, Valentina; Parkkari, Teija; Savinainen, Juha R.; Malfitano, Anna Maria; Allara, Marco; Bertini, Simone; Castelli, Francesca; Del Carlo, Sara; Laezza, Chiara; Ligresti, Alessia; Saccomanni, Giuseppe; Bifulco, Maurizio; Di Marzo, Vincenzo; Macchia, Marco; Manera, Clementina</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">524-532</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The relevance of CB2R-mediated therapeutic effects is well-known for the treatment of inflammatory and neuropathic pain and neurodegenerative disorders.  In our search for new cannabinoid receptor modulators, we report the optimization of a series of 1,2-dihydro-2-oxopyridine-3-carboxamide derivs. as CB2R ligands.  In particular, N-cycloheptyl-5-(4-methoxyphenyl)-1-(4-fluorobenzyl)-pyridin-2(1H)-on-3-carboxamide (17) showed high CB2R affinity (Ki = 1.0 nM), accompanied by interesting Ki(CB1R)/Ki(CB2R) selectivity ratio (SI = 43.4).  Compd. 17 was also identified as a potent CB2R neutral antagonist/weak partial inverse agonist.  Finally we found that the functionality activity of the series of 1,2-dihydro-2-oxopyridine is controlled by the presence of a substituent in position 5 of the heterocyclic nucleus.  In fact when the hydrogen atom in position 5 of the unsubstituted compd. 1 was replaced with a Ph group (compd. 18) the CB2R activity was shifted from agonism to inverse agonism whereas the introduction in the same position of p-methoxyphenyl group lead to compd. 17 which showed a behavior as CB2R neutral antagonist/weak partial inverse agonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg1gGlmi90MbVg90H21EOLACvtfcHk0ljgMwiD7cpkbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlygu78%253D&md5=f7d1c2ec2674cd0b2c9b99012cb12859</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.10.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.10.070%26sid%3Dliteratum%253Aachs%26aulast%3DLucchesi%26aufirst%3DV.%26aulast%3DParkkari%26aufirst%3DT.%26aulast%3DSavinainen%26aufirst%3DJ.%2BR.%26aulast%3DMalfitano%26aufirst%3DA.%2BM.%26aulast%3DAllar%25C3%25A0%26aufirst%3DM.%26aulast%3DBertini%26aufirst%3DS.%26aulast%3DCastelli%26aufirst%3DF.%26aulast%3DDel%2BCarlo%26aufirst%3DS.%26aulast%3DLaezza%26aufirst%3DC.%26aulast%3DLigresti%26aufirst%3DA.%26aulast%3DSaccomanni%26aufirst%3DG.%26aulast%3DBifulco%26aufirst%3DM.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DMacchia%26aufirst%3DM.%26aulast%3DManera%26aufirst%3DC.%26atitle%3D1%252C2-Dihydro-2-Oxopyridine-3-Carboxamides%253A%2520The%2520C-5%2520Substituent%2520Is%2520Responsible%2520for%2520Functionality%2520Switch%2520at%2520CB2%2520Cannabinoid%2520Receptor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D74%26spage%3D524%26epage%3D532%26doi%3D10.1016%2Fj.ejmech.2013.10.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El
Bakali, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muccioli, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renault, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Body-Malapel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djouina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamtiaux, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrzejak, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desreumaux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavatte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millet, R.</span></span> <span> </span><span class="NLM_article-title">4-Oxo-1,4-Dihydropyridines as Selective CB2 Cannabinoid Receptor Ligands: Structural Insights into the Design of a Novel Inverse Agonist Series</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">7918</span>– <span class="NLM_lpage">7931</span>, <span class="refDoi"> DOI: 10.1021/jm100286k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100286k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlCltbjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7918-7931&author=J.+El%0ABakaliauthor=G.+G.+Muccioliauthor=N.+Renaultauthor=D.+Pradalauthor=M.+Body-Malapelauthor=M.+Djouinaauthor=L.+Hamtiauxauthor=V.+Andrzejakauthor=P.+Desreumauxauthor=P.+Chavatteauthor=D.+M.+Lambertauthor=R.+Millet&title=4-Oxo-1%2C4-Dihydropyridines+as+Selective+CB2+Cannabinoid+Receptor+Ligands%3A+Structural+Insights+into+the+Design+of+a+Novel+Inverse+Agonist+Series&doi=10.1021%2Fjm100286k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">4-Oxo-1,4-dihydropyridines as Selective CB2 Cannabinoid Receptor Ligands: Structural Insights into the Design of a Novel Inverse Agonist Series</span></div><div class="casAuthors">El Bakali, Jamal; Muccioli, Giulio G.; Renault, Nicolas; Pradal, Delphine; Body-Malapel, Mathilde; Djouina, Madjid; Hamtiaux, Laurie; Andrzejak, Virginie; Desreumaux, Pierre; Chavatte, Philippe; Lambert, Didier M.; Millet, Regis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7918-7931</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Growing evidence shows that CB2 receptor is an attractive therapeutic target.  Starting from a series of 4-oxo-1,4-dihydroquinoline-3-carboxamides as selective CB2 agonists, the medicinal chem. approach leading to the development of CB2 receptor inverse agonists with a 4-oxo-1,4-dihydropyridine scaffold is described.  These compds. show high affinity and potency at the CB2 receptor while showing only modest affinity for the centrally expressed CB1 cannabinoid receptor.  Further, the functionality of this series is controlled by its C-6 substituent because agonists bear a Me or a tert-Bu group and inverse agonists, a Ph or 4-chlorophenyl group, resp.  Finally, in silico studies suggest that the C-6 substituent could modulate the conformation of W6.48 known to be crit. in GPCR activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcBOWW6IivurVg90H21EOLACvtfcHk0ljgMwiD7cpkbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlCltbjF&md5=65ead1fefed0288ac4469aa1c2740b45</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Fjm100286k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100286k%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BBakali%26aufirst%3DJ.%26aulast%3DMuccioli%26aufirst%3DG.%2BG.%26aulast%3DRenault%26aufirst%3DN.%26aulast%3DPradal%26aufirst%3DD.%26aulast%3DBody-Malapel%26aufirst%3DM.%26aulast%3DDjouina%26aufirst%3DM.%26aulast%3DHamtiaux%26aufirst%3DL.%26aulast%3DAndrzejak%26aufirst%3DV.%26aulast%3DDesreumaux%26aufirst%3DP.%26aulast%3DChavatte%26aufirst%3DP.%26aulast%3DLambert%26aufirst%3DD.%2BM.%26aulast%3DMillet%26aufirst%3DR.%26atitle%3D4-Oxo-1%252C4-Dihydropyridines%2520as%2520Selective%2520CB2%2520Cannabinoid%2520Receptor%2520Ligands%253A%2520Structural%2520Insights%2520into%2520the%2520Design%2520of%2520a%2520Novel%2520Inverse%2520Agonist%2520Series%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7918%26epage%3D7931%26doi%3D10.1021%2Fjm100286k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkkari, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savinainen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arena, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccomanni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saguto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligresti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allarà, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novellino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchia, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Biological Activity and Molecular Modeling of New Biphenylic Carboxamides as Potent and Selective CB2 Receptor Ligands</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">526</span>– <span class="NLM_lpage">536</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.11.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2014.11.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=25486424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVems7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2015&pages=526-536&author=S.+Bertiniauthor=T.+Parkkariauthor=J.+R.+Savinainenauthor=C.+Arenaauthor=G.+Saccomanniauthor=S.+Sagutoauthor=A.+Ligrestiauthor=M.+Allar%C3%A0author=A.+Brunoauthor=L.+Marinelliauthor=V.+Di+Marzoauthor=E.+Novellinoauthor=C.+Maneraauthor=M.+Macchia&title=Synthesis%2C+Biological+Activity+and+Molecular+Modeling+of+New+Biphenylic+Carboxamides+as+Potent+and+Selective+CB2+Receptor+Ligands&doi=10.1016%2Fj.ejmech.2014.11.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, biological activity and molecular modeling of new biphenylic carboxamides as potent and selective CB2 receptor ligands</span></div><div class="casAuthors">Bertini, Simone; Parkkari, Teija; Savinainen, Juha R.; Arena, Chiara; Saccomanni, Giuseppe; Saguto, Simone; Ligresti, Alessia; Allara, Marco; Bruno, Agostino; Marinelli, Luciana; Di Marzo, Vincenzo; Novellino, Ettore; Manera, Clementina; Macchia, Marco</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">526-536</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The CB2 receptor is a therapeutic target of increasing importance for several diseases, including pain, inflammation, neurodegeneration, cancer and osteoporosis.  While several compds. showing CB2-selective agonist or inverse agonist properties were developed, only few CB2 receptor selective neutral antagonists are actually known.  Such type of compds. could be useful to study more in depth the role of the CB2 receptor, because they lack the ability to counteract its "constitutive" activity.  Here the authors describe the synthesis and biol. activity of a series of biphenylic carboxamides as a new class of CB2 receptor selective ligands.  In binding assays, one of these compds. showed good CB2 receptor affinity and selectivity (Ki = 11.48 nM; Selectivity Index = 130).  Furthermore, in functional assays, the same compd. showed a very interesting pharmacol. profile as CB2 receptor selective neutral antagonist.  These results pave the way to further developments, including structural optimization, with the aim to obtain more potent CB2 receptor ligands with this peculiar feature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodBi4tSxSa6rVg90H21EOLACvtfcHk0ljgMwiD7cpkbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVems7zN&md5=c6b3a035419dbf4c4c4d15badfc57249</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.11.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.11.066%26sid%3Dliteratum%253Aachs%26aulast%3DBertini%26aufirst%3DS.%26aulast%3DParkkari%26aufirst%3DT.%26aulast%3DSavinainen%26aufirst%3DJ.%2BR.%26aulast%3DArena%26aufirst%3DC.%26aulast%3DSaccomanni%26aufirst%3DG.%26aulast%3DSaguto%26aufirst%3DS.%26aulast%3DLigresti%26aufirst%3DA.%26aulast%3DAllar%25C3%25A0%26aufirst%3DM.%26aulast%3DBruno%26aufirst%3DA.%26aulast%3DMarinelli%26aufirst%3DL.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DNovellino%26aufirst%3DE.%26aulast%3DManera%26aufirst%3DC.%26aulast%3DMacchia%26aufirst%3DM.%26atitle%3DSynthesis%252C%2520Biological%2520Activity%2520and%2520Molecular%2520Modeling%2520of%2520New%2520Biphenylic%2520Carboxamides%2520as%2520Potent%2520and%2520Selective%2520CB2%2520Receptor%2520Ligands%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D90%26spage%3D526%26epage%3D536%26doi%3D10.1016%2Fj.ejmech.2014.11.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chicca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arena, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chicca, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccomanni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gertsch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchia, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Pharmacological Evaluation of New Biphenylic Derivatives as CB2 Receptor Ligands</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">252</span>– <span class="NLM_lpage">266</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.03.072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2016.03.072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=27078864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVKit7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2016&pages=252-266&author=S.+Bertiniauthor=A.+Chiccaauthor=C.+Arenaauthor=S.+Chiccaauthor=G.+Saccomanniauthor=J.+Gertschauthor=C.+Maneraauthor=M.+Macchia&title=Synthesis+and+Pharmacological+Evaluation+of+New+Biphenylic+Derivatives+as+CB2+Receptor+Ligands&doi=10.1016%2Fj.ejmech.2016.03.072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and pharmacological evaluation of new biphenylic derivatives as CB2 receptor ligands</span></div><div class="casAuthors">Bertini, Simone; Chicca, Andrea; Arena, Chiara; Chicca, Stefano; Saccomanni, Giuseppe; Gertsch, Jurg; Manera, Clementina; Macchia, Marco</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">252-266</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Targeting type-2 cannabinoid receptor (CB2) is considered a feasible strategy to develop new drugs for the treatment of diseases like neuropathic pain, chronic inflammation, neurodegenerative disorders and cancer.  Such drugs are devoid of the undesired central side effects that are typically mediated by the CB1 receptor.  In this work we synthesized 18 biphenylic carboxamides as new CB2-selective ligands and evaluated their pharmacol. profiles.  The functional activity of these compds. is strongly influenced by the nature of the substituent at position 4' and 5 of the biphenyl scaffold.  Position 5 seems to be responsible for the agonist or inverse agonist behavior independently of the substituent in position 4', with the exception of the methoxyl group which transforms both full agonists and inverse agonists into neutral antagonists.  This study provides a novel complete toolbox of CB2 functional modulators that derive from the same chem. scaffold.  Such probes may be useful to investigate the biol. role of CB2 receptors in cellular assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6-re77MxhJ7Vg90H21EOLACvtfcHk0ljmFfmvD7fn2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVKit7o%253D&md5=c692074dad0f8dc5ed7ec2d739834925</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.03.072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.03.072%26sid%3Dliteratum%253Aachs%26aulast%3DBertini%26aufirst%3DS.%26aulast%3DChicca%26aufirst%3DA.%26aulast%3DArena%26aufirst%3DC.%26aulast%3DChicca%26aufirst%3DS.%26aulast%3DSaccomanni%26aufirst%3DG.%26aulast%3DGertsch%26aufirst%3DJ.%26aulast%3DManera%26aufirst%3DC.%26aulast%3DMacchia%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520Pharmacological%2520Evaluation%2520of%2520New%2520Biphenylic%2520Derivatives%2520as%2520CB2%2520Receptor%2520Ligands%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D116%26spage%3D252%26epage%3D266%26doi%3D10.1016%2Fj.ejmech.2016.03.072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zindell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirillo, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ermann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemkow, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riether, D.</span></span> <span> </span><span class="NLM_article-title">Selective CB2 Receptor Agonists. Part 1: The Identification of Novel Ligands through Computer-Aided Drug Design (CADD) Approaches</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">575</span>– <span class="NLM_lpage">580</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.12.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmcl.2014.12.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=25556098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFOqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=575-580&author=E.+R.+Hickeyauthor=R.+Zindellauthor=P.+F.+Cirilloauthor=L.+Wuauthor=M.+Ermannauthor=A.+K.+Berryauthor=D.+S.+Thomsonauthor=C.+Albrechtauthor=M.+J.+Gemkowauthor=D.+Riether&title=Selective+CB2+Receptor+Agonists.+Part+1%3A+The+Identification+of+Novel+Ligands+through+Computer-Aided+Drug+Design+%28CADD%29+Approaches&doi=10.1016%2Fj.bmcl.2014.12.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Selective CB2 receptor agonists. Part 1: The identification of novel ligands through computer-aided drug design (CADD) approaches</span></div><div class="casAuthors">Hickey, Eugene R.; Zindell, Renee; Cirillo, Pier F.; Wu, Lifen; Ermann, Monika; Berry, Angela K.; Thomson, David S.; Albrecht, Claudia; Gemkow, Mark J.; Riether, Doris</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">575-580</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Computer-aided drug design scaffold hopping strategies were utilized to identify new classes of CB2 agonists when compds. of an established series with low nanomolar potency were challenging to optimize for good drug-like properties.  Use of ligand-based design strategies through BI Builder (a tool for de novo design) and PharmShape (a virtual screening software package) approaches led to the discovery of new chemotypes.  Specifically, compds. contg. azetidine-, proline-, and piperidine-based cores were found to have low nanomolar and picomolar CB2 agonist activities with drug-like properties considered appropriate for early profiling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3aC9L4cUXHLVg90H21EOLACvtfcHk0ljmFfmvD7fn2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFOqtw%253D%253D&md5=c7d57590e3f6c08a3f19f2b67a6b46cb</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.12.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.12.033%26sid%3Dliteratum%253Aachs%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DZindell%26aufirst%3DR.%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DErmann%26aufirst%3DM.%26aulast%3DBerry%26aufirst%3DA.%2BK.%26aulast%3DThomson%26aufirst%3DD.%2BS.%26aulast%3DAlbrecht%26aufirst%3DC.%26aulast%3DGemkow%26aufirst%3DM.%2BJ.%26aulast%3DRiether%26aufirst%3DD.%26atitle%3DSelective%2520CB2%2520Receptor%2520Agonists.%2520Part%25201%253A%2520The%2520Identification%2520of%2520Novel%2520Ligands%2520through%2520Computer-Aided%2520Drug%2520Design%2520%2528CADD%2529%2520Approaches%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D575%26epage%3D580%26doi%3D10.1016%2Fj.bmcl.2014.12.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riether, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zindell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betageri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ermann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemkow, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraja, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romig, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, D. S.</span></span> <span> </span><span class="NLM_article-title">Selective CB2 Receptor Agonists. Part 2: Structure-Activity Relationship Studies and Optimization of Proline-Based Compounds</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">581</span>– <span class="NLM_lpage">586</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.12.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmcl.2014.12.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=25556092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2ksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=581-586&author=D.+Rietherauthor=R.+Zindellauthor=L.+Wuauthor=R.+Betageriauthor=J.+E.+Jenkinsauthor=S.+Khorauthor=A.+K.+Berryauthor=E.+R.+Hickeyauthor=M.+Ermannauthor=C.+Albrechtauthor=A.+Ceciauthor=M.+J.+Gemkowauthor=N.+V.+Nagarajaauthor=H.+Romigauthor=A.+Sauerauthor=D.+S.+Thomson&title=Selective+CB2+Receptor+Agonists.+Part+2%3A+Structure-Activity+Relationship+Studies+and+Optimization+of+Proline-Based+Compounds&doi=10.1016%2Fj.bmcl.2014.12.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Selective CB2 receptor agonists. Part 2: Structure-activity relationship studies and optimization of proline-based compounds</span></div><div class="casAuthors">Riether, Doris; Zindell, Renee; Wu, Lifen; Betageri, Raj; Jenkins, James E.; Khor, Someina; Berry, Angela K.; Hickey, Eugene R.; Ermann, Monika; Albrecht, Claudia; Ceci, Angelo; Gemkow, Mark J.; Nagaraja, Nelamangala V.; Romig, Helmut; Sauer, Achim; Thomson, David S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">581-586</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Through a ligand-based pharmacophore model (S)-proline based compds. were identified as potent cannabinoid receptor 2 (CB2) agonists with high selectivity over the cannabinoid receptor 1 (CB1).  Structure-activity relationship investigations for this compd. class lead to oxo-proline compds. I and II which combine an impressive CB1 selectivity profile with good pharmacokinetic properties.  In a streptozotocin induced diabetic neuropathy model, II demonstrated a dose-dependent reversal of mech. hyperalgesia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZQRf3dcb1fbVg90H21EOLACvtfcHk0ljmFfmvD7fn2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2ksw%253D%253D&md5=228e2d6883d4dc41741dae80ffa2db42</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.12.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.12.019%26sid%3Dliteratum%253Aachs%26aulast%3DRiether%26aufirst%3DD.%26aulast%3DZindell%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DBetageri%26aufirst%3DR.%26aulast%3DJenkins%26aufirst%3DJ.%2BE.%26aulast%3DKhor%26aufirst%3DS.%26aulast%3DBerry%26aufirst%3DA.%2BK.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DErmann%26aufirst%3DM.%26aulast%3DAlbrecht%26aufirst%3DC.%26aulast%3DCeci%26aufirst%3DA.%26aulast%3DGemkow%26aufirst%3DM.%2BJ.%26aulast%3DNagaraja%26aufirst%3DN.%2BV.%26aulast%3DRomig%26aufirst%3DH.%26aulast%3DSauer%26aufirst%3DA.%26aulast%3DThomson%26aufirst%3DD.%2BS.%26atitle%3DSelective%2520CB2%2520Receptor%2520Agonists.%2520Part%25202%253A%2520Structure-Activity%2520Relationship%2520Studies%2520and%2520Optimization%2520of%2520Proline-Based%2520Compounds%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D581%26epage%3D586%26doi%3D10.1016%2Fj.bmcl.2014.12.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bartolozzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirillo, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zindell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemkow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraja, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romig, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riether, D.</span></span> <span> </span><span class="NLM_article-title">Selective CB2 Receptor Agonists. Part 3: The Optimization of a Piperidine-Based Series That Demonstrated Efficacy in an in Vivo Neuropathic Pain Model</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">592</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.12.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmcl.2014.12.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=25575658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFyntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=587-592&author=A.+Bartolozziauthor=P.+F.+Cirilloauthor=A.+K.+Berryauthor=E.+R.+Hickeyauthor=D.+S.+Thomsonauthor=L.+Wuauthor=R.+Zindellauthor=C.+Albrechtauthor=A.+Ceciauthor=M.+Gemkowauthor=N.+V.+Nagarajaauthor=H.+Romigauthor=A.+Sauerauthor=D.+Riether&title=Selective+CB2+Receptor+Agonists.+Part+3%3A+The+Optimization+of+a+Piperidine-Based+Series+That+Demonstrated+Efficacy+in+an+in+Vivo+Neuropathic+Pain+Model&doi=10.1016%2Fj.bmcl.2014.12.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Selective CB2 receptor agonists. Part 3: The optimization of a piperidine-based series that demonstrated efficacy in an in vivo neuropathic pain model</span></div><div class="casAuthors">Bartolozzi, Alessandra; Cirillo, Pier Francesco; Berry, Angela K.; Hickey, Eugene R.; Thomson, David S.; Wu, Lifen; Zindell, Renee; Albrecht, Claudia; Ceci, Angelo; Gemkow, Mark J.; Nagaraja, Nelamangala V.; Romig, Helmut; Sauer, Achim; Riether, Doris</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">587-592</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel class of potent cannabinoid receptor 2 (CB2) agonists based on a (S)-piperidine scaffold was identified using ligand-based pharmacophore models.  Optimization of soly. and metabolic stability led to the identification of several potent CB2 agonists, e.g. I, that displayed selectivity over cannabinoid receptor 1 (CB1) and acceptable drug like properties.  In rats, compd. 30 demonstrated a favorable pharmacokinetic profile and efficacy in a Streptozotocin-induced diabetic neuropathy model, with full reversal of mech. hyperalgesia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozt6QBJ0p0HrVg90H21EOLACvtfcHk0ljetYMJNMUncw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFyntw%253D%253D&md5=33f1001f09733729506f2cda3f369879</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.12.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.12.031%26sid%3Dliteratum%253Aachs%26aulast%3DBartolozzi%26aufirst%3DA.%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26aulast%3DBerry%26aufirst%3DA.%2BK.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DThomson%26aufirst%3DD.%2BS.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DZindell%26aufirst%3DR.%26aulast%3DAlbrecht%26aufirst%3DC.%26aulast%3DCeci%26aufirst%3DA.%26aulast%3DGemkow%26aufirst%3DM.%26aulast%3DNagaraja%26aufirst%3DN.%2BV.%26aulast%3DRomig%26aufirst%3DH.%26aulast%3DSauer%26aufirst%3DA.%26aulast%3DRiether%26aufirst%3DD.%26atitle%3DSelective%2520CB2%2520Receptor%2520Agonists.%2520Part%25203%253A%2520The%2520Optimization%2520of%2520a%2520Piperidine-Based%2520Series%2520That%2520Demonstrated%2520Efficacy%2520in%2520an%2520in%2520Vivo%2520Neuropathic%2520Pain%2520Model%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D587%26epage%3D592%26doi%3D10.1016%2Fj.bmcl.2014.12.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huffman, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liddle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aung, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abood, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiley, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, B. R.</span></span> <span> </span><span class="NLM_article-title">3-(1′,1′-Dimethylbutyl)-1-Deoxy-Delta8-THC and Related Compounds: Synthesis of Selective Ligands for the CB2 Receptor</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2905</span>– <span class="NLM_lpage">2914</span>, <span class="refDoi"> DOI: 10.1016/S0968-0896(99)00219-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2FS0968-0896%2899%2900219-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10658595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntFCnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1999&pages=2905-2914&author=J.+W.+Huffmanauthor=J.+Liddleauthor=S.+Yuauthor=M.+M.+Aungauthor=M.+E.+Aboodauthor=J.+L.+Wileyauthor=B.+R.+Martin&title=3-%281%E2%80%B2%2C1%E2%80%B2-Dimethylbutyl%29-1-Deoxy-Delta8-THC+and+Related+Compounds%3A+Synthesis+of+Selective+Ligands+for+the+CB2+Receptor&doi=10.1016%2FS0968-0896%2899%2900219-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">3-(1',1'-Dimethylbutyl)-1-deoxy-Δ8-THC and related compounds: synthesis of selective ligands for the CB2 receptor</span></div><div class="casAuthors">Huffman, John W.; Liddle, John; Yu, Shu; Aung, Mie Mie; Abood, Mary E.; Wiley, Jenny L.; Martin, Billy R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2905-2914</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The synthesis and pharmacol. of 15 1-deoxy-Δ8-THC analogs, several of which have high affinity for the CB2 receptor, are described.  The deoxy cannabinoids include 1-deoxy-11-hydroxy-Δ8-THC, 1-deoxy-Δ8-THC, 1-deoxy-3-butyl-Δ8-THC, 1-deoxy-3-hexyl-Δ8-THC and a series of 3-(1',1'-dimethylalkyl)-1-deoxy-Δ8-THC analogs I (n = 0-4, 6, 7).  Three derivs. of deoxynabilone were also prepd.  The affinities of each compd. for the CB1 and CB2 receptors were detd. employing previously described procedures.  Five of the 3-(1',1'-dimethylalkyl)-1-deoxy-Δ8-THC analogs I (n = 1-5) have high affinity (Ki=<20 nM) for the CB2 receptor.  Four I (n = 1-4) also have little affinity for the CB1 receptor (Ki=>295 nM).  3-(1',1'-Dimethylbutyl)-1-deoxy-Δ8-THC (I, n = 2) has very high affinity for the CB2 receptor (Ki=3.4±1.0 nM) and little affinity for the CB1 receptor (Ki=677±132 nM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnqkYe1NcGUbVg90H21EOLACvtfcHk0ljetYMJNMUncw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntFCnsA%253D%253D&md5=50b84955605cd4c6e76d2cbf92791685</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2899%2900219-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252899%252900219-9%26sid%3Dliteratum%253Aachs%26aulast%3DHuffman%26aufirst%3DJ.%2BW.%26aulast%3DLiddle%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DAung%26aufirst%3DM.%2BM.%26aulast%3DAbood%26aufirst%3DM.%2BE.%26aulast%3DWiley%26aufirst%3DJ.%2BL.%26aulast%3DMartin%26aufirst%3DB.%2BR.%26atitle%3D3-%25281%25E2%2580%25B2%252C1%25E2%2580%25B2-Dimethylbutyl%2529-1-Deoxy-Delta8-THC%2520and%2520Related%2520Compounds%253A%2520Synthesis%2520of%2520Selective%2520Ligands%2520for%2520the%2520CB2%2520Receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D1999%26volume%3D7%26spage%3D2905%26epage%3D2914%26doi%3D10.1016%2FS0968-0896%2899%2900219-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanus, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breuer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tchilibon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiloah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldenberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horowitz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mechoulam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fride, E.</span></span> <span> </span><span class="NLM_article-title">HU-308: A Specific Agonist for CB(2), a Peripheral Cannabinoid Receptor</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">14228</span>– <span class="NLM_lpage">14233</span>, <span class="refDoi"> DOI: 10.1073/pnas.96.25.14228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1073%2Fpnas.96.25.14228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10588688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADyaK1MXnvFKltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=14228-14233&author=L.+Hanusauthor=A.+Breuerauthor=S.+Tchilibonauthor=S.+Shiloahauthor=D.+Goldenbergauthor=M.+Horowitzauthor=R.+G.+Pertweeauthor=R.+A.+Rossauthor=R.+Mechoulamauthor=E.+Fride&title=HU-308%3A+A+Specific+Agonist+for+CB%282%29%2C+a+Peripheral+Cannabinoid+Receptor&doi=10.1073%2Fpnas.96.25.14228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor</span></div><div class="casAuthors">Hanus, L.; Breuer, A.; Tchilibon, S.; Shiloah, S.; Goldenberg, D.; Horowitz, M.; Pertwee, R. G.; Ross, R. A.; Mechoulam, R.; Fride, E.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">14228-14233</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Two cannabinoid receptors have been identified: CB1, present in the central nervous system (CNS) and to a lesser extent in other tissues, and CB2, present outside the CNS, in peripheral organs.  There is evidence for the presence of CB2-like receptors in peripheral nerve terminals.  We report now that we have synthesized a CB2-specific agonist, code-named HU-308.  This cannabinoid does not bind to CB1 (Ki > 10 μM), but does so efficiently to CB2 (Ki = 22.7 ± 3.9 nM); it inhibits forskolin-stimulated cAMP prodn. in CB2-transfected cells, but does so much less in CB1-transfected cells.  HU-308 shows no activity in mice in a tetrad of behavioral tests, which together have been shown to be specific for tetrahydrocannabinol (THC)-type activity in the CNS mediated by CB1.  However, HU-308 reduces blood pressure, blocks defecation, and elicits anti-inflammatory and peripheral analgesic activity.  The hypotension, the inhibition of defecation, the anti-inflammatory and peripheral analgesic effects produced by HU-308 are blocked (or partially blocked) by the CB2 antagonist SR-144528, but not by the CB1 antagonist SR-141716A.  These results demonstrate the feasibility of discovering novel nonpsychotropic cannabinoids that may lead to new therapies for hypertension, inflammation, and pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh_IkaAv6DL7Vg90H21EOLACvtfcHk0lgsUlz77S0E3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXnvFKltLs%253D&md5=2f0a5be263419796a689b70d38a670e8</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.25.14228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.25.14228%26sid%3Dliteratum%253Aachs%26aulast%3DHanus%26aufirst%3DL.%26aulast%3DBreuer%26aufirst%3DA.%26aulast%3DTchilibon%26aufirst%3DS.%26aulast%3DShiloah%26aufirst%3DS.%26aulast%3DGoldenberg%26aufirst%3DD.%26aulast%3DHorowitz%26aufirst%3DM.%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26aulast%3DRoss%26aufirst%3DR.%2BA.%26aulast%3DMechoulam%26aufirst%3DR.%26aulast%3DFride%26aufirst%3DE.%26atitle%3DHU-308%253A%2520A%2520Specific%2520Agonist%2520for%2520CB%25282%2529%252C%2520a%2520Peripheral%2520Cannabinoid%2520Receptor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1999%26volume%3D96%26spage%3D14228%26epage%3D14233%26doi%3D10.1073%2Fpnas.96.25.14228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benetti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castelli, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavallini, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzarotti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pibiri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccomanni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuccinardi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vannacci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrarini, P. L.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Biological Evaluation of New 1,8-Naphthyridin-4(1H)-on-3-Carboxamide and Quinolin-4(1H)-on-3-Carboxamide Derivatives as CB2 Selective Agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">5947</span>– <span class="NLM_lpage">5957</span>, <span class="refDoi"> DOI: 10.1021/jm0603466</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0603466" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVylsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5947-5957&author=C.+Maneraauthor=V.+Benettiauthor=M.+P.+Castelliauthor=T.+Cavalliniauthor=S.+Lazzarottiauthor=F.+Pibiriauthor=G.+Saccomanniauthor=T.+Tuccinardiauthor=A.+Vannacciauthor=A.+Martinelliauthor=P.+L.+Ferrarini&title=Design%2C+Synthesis%2C+and+Biological+Evaluation+of+New+1%2C8-Naphthyridin-4%281H%29-on-3-Carboxamide+and+Quinolin-4%281H%29-on-3-Carboxamide+Derivatives+as+CB2+Selective+Agonists&doi=10.1021%2Fjm0603466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of New 1,8-Naphthyridin-4(1H)-one-3-carboxamide and Quinolin-4(1H)-one-3-carboxamide Derivatives as CB2 Selective Agonists</span></div><div class="casAuthors">Manera, Clementina; Benetti, Veronica; Castelli, M. Paola; Cavallini, Tiziana; Lazzarotti, Sara; Pibiri, Fabio; Saccomanni, Giuseppe; Tuccinardi, Tiziano; Vannacci, Alfredo; Martinelli, Adriano; Ferrarini, Pier Luigi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5947-5957</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">On the basis of docking studies carried out using the recently published cannabinoid receptor models, new 1,8-naphthyridin-4(1H)-one-3-carboxamide and quinolin-4(1H)-one-3-carboxamide derivs. I [X = N, CH; R1 = PhCH2, 2-FC6H4CH2, 4-MeOC6H4CH2, 2-(4-morpholinyl)ethyl, 2-(4-phenyl-1-piperazinyl)ethyl, etc.; R2 = cyclohexyl, cycloheptyl, 4-methylcyclohexyl; R3 = H, Cl, Me, 2-FC6H4CH2O] and some of their partially reduced analogs were synthesized and tested for their affinities toward the cannabinoid CB1 and CB2 receptors.  I (X = N; R1 = 4-FC6H4CH2; R2 = cycloheptyl; R3 = Me) showed a high CB2 affinity with a Ki of 1.0 nM.  The substitution of the naphthyridine-4-one nucleus with the quinoline-4-one system detd. a general increase in CB2 affinity.  In particular, I [X = CH; R1 = 2-(4-morpholinyl)ethyl; R2 = cyclohexyl; R3 = Cl] possessed a remarkable affinity with Ki of 3.3 nM, which was also accompanied by a high selectivity for the CB2 receptor (Ki(CB1)/Ki(CB2) ratio greater than 303).  Moreover, the [35S]GTPγ binding assay and functional studies on human basophils indicated that the 1,8-naphthyridin-4(1H)-one-3-carboxamide derivs. behaved as CB1 and CB2 receptor agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYlDVrqG-izrVg90H21EOLACvtfcHk0lgsUlz77S0E3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVylsrY%253D&md5=8c33739ef32a608be5f1aae93ed14fa3</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1021%2Fjm0603466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0603466%26sid%3Dliteratum%253Aachs%26aulast%3DManera%26aufirst%3DC.%26aulast%3DBenetti%26aufirst%3DV.%26aulast%3DCastelli%26aufirst%3DM.%2BP.%26aulast%3DCavallini%26aufirst%3DT.%26aulast%3DLazzarotti%26aufirst%3DS.%26aulast%3DPibiri%26aufirst%3DF.%26aulast%3DSaccomanni%26aufirst%3DG.%26aulast%3DTuccinardi%26aufirst%3DT.%26aulast%3DVannacci%26aufirst%3DA.%26aulast%3DMartinelli%26aufirst%3DA.%26aulast%3DFerrarini%26aufirst%3DP.%2BL.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520New%25201%252C8-Naphthyridin-4%25281H%2529-on-3-Carboxamide%2520and%2520Quinolin-4%25281H%2529-on-3-Carboxamide%2520Derivatives%2520as%2520CB2%2520Selective%2520Agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5947%26epage%3D5957%26doi%3D10.1021%2Fjm0603466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrison, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daza, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grayson, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooker, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dart, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M. D.</span></span> <span> </span><span class="NLM_article-title">In Vitro Pharmacological Characterization of AM1241: A Protean Agonist at the Cannabinoid CB2 Receptor?</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>149</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">154</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0706838</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fsj.bjp.0706838" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=16894349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD28XptlSlsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2006&pages=145-154&author=B.+B.+Yaoauthor=S.+Mukherjeeauthor=Y.+Fanauthor=T.+R.+Garrisonauthor=A.+V.+Dazaauthor=G.+K.+Graysonauthor=B.+A.+Hookerauthor=M.+J.+Dartauthor=J.+P.+Sullivanauthor=M.+D.+Meyer&title=In+Vitro+Pharmacological+Characterization+of+AM1241%3A+A+Protean+Agonist+at+the+Cannabinoid+CB2+Receptor%3F&doi=10.1038%2Fsj.bjp.0706838"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor?</span></div><div class="casAuthors">Yao, B. B.; Mukherjee, S.; Fan, Y.; Garrison, T. R.; Daza, A. V.; Grayson, G. K.; Hooker, B. A.; Dart, M. J.; Sullivan, J. P.; Meyer, M. D.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">145-154</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The CB2 receptor has been proposed as a novel target for the treatment of pain, and CB2 receptor agonists defined in in vitro assays have demonstrated analgesic activity in animal models.  Based on its in vivo analgesic efficacy, AM1241 has been classified as a CB2-selective agonist.  However, in vitro characterization of AM1241 in functional assays has not been reported.  Exptl. approach: In this study, AM1241 was characterized across multiple in vitro assays employing heterologous recombinant receptor expression systems to assess its binding potencies at the human CB2 and CB1 receptors and its functional efficacies at the human CB2 receptor.  Key results: AM1241 exhibited distinct functional properties depending on the assay conditions employed, a unique profile in contrast to those of the agonist CP 55,940 and the inverse agonist SR144528.  AM1241 displayed neutral antagonist activities in FLIPR and cyclase assays.  However, when cyclase assays were performed using lower forskolin concns. for stimulation, AM1241 exhibited partial agonist efficacy.  In addn., it behaved as a partial agonist in ERK (or MAP) kinase assays.  Conclusions and implications: The unusual phenomenon of inconsistent functional efficacies suggests that AM1241 is a protean agonist at the CB2 receptor.  We postulate that functional efficacies displayed by protean agonists in various assay systems may depend on the levels of receptor constitutive activities exhibited in the assay systems, and therefore, efficacies obsd. in in vitro assays may not predict in vivo activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAZCdaxRfuO7Vg90H21EOLACvtfcHk0lgsUlz77S0E3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptlSlsb0%253D&md5=7c257ec8fcc8acb7cdcf9243f3b377b1</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0706838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0706838%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DB.%2BB.%26aulast%3DMukherjee%26aufirst%3DS.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DGarrison%26aufirst%3DT.%2BR.%26aulast%3DDaza%26aufirst%3DA.%2BV.%26aulast%3DGrayson%26aufirst%3DG.%2BK.%26aulast%3DHooker%26aufirst%3DB.%2BA.%26aulast%3DDart%26aufirst%3DM.%2BJ.%26aulast%3DSullivan%26aufirst%3DJ.%2BP.%26aulast%3DMeyer%26aufirst%3DM.%2BD.%26atitle%3DIn%2520Vitro%2520Pharmacological%2520Characterization%2520of%2520AM1241%253A%2520A%2520Protean%2520Agonist%2520at%2520the%2520Cannabinoid%2520CB2%2520Receptor%253F%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2006%26volume%3D149%26spage%3D145%26epage%3D154%26doi%3D10.1038%2Fsj.bjp.0706838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gallant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufresne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gareau, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guay, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leblanc, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasit, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochette, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slipetz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremblay, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metters, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labelle, M.</span></span> <span> </span><span class="NLM_article-title">New class of potent ligands for the human peripheral cannabinoid receptor. New Class of Potent Ligands for the Human Peripheral Cannabinoid Receptor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">2263</span>– <span class="NLM_lpage">2268</span>, <span class="refDoi"> DOI: 10.1016/0960-894X(96)00426-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2F0960-894X%2896%2900426-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADyaK28Xmt1yrs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1996&pages=2263-2268&author=M.+Gallantauthor=C.+Dufresneauthor=Y.+Gareauauthor=D.+Guayauthor=Y.+Leblancauthor=P.+P.+Prasitauthor=C.+Rochetteauthor=N.+Sawyerauthor=D.+Slipetzauthor=N.+Tremblayauthor=K.+M.+Mettersauthor=M.+Labelle&title=New+class+of+potent+ligands+for+the+human+peripheral+cannabinoid+receptor.+New+Class+of+Potent+Ligands+for+the+Human+Peripheral+Cannabinoid+Receptor&doi=10.1016%2F0960-894X%2896%2900426-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">New class of potent ligands for the human peripheral cannabinoid receptor</span></div><div class="casAuthors">Gallant, Michel; Dufresne, Claude; Gareau, Yves; Guay, Daniel; Leblanc, Yves; Prasit, Petipibbon; Rochette, Chantal; Sawyer, Nicole; Slipetz, Deborah M.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2263-2268</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Indoles, e.g. I (R1 = morpholino, morpholinocarbonyl, CO2Me, CO2H, morpholinomethyl; R2 = 2-, 4-ClC6H4, 1-, 2-naphthyl, etc.), were prepd. as potent ligands for the human peripheral cannabinoid (hCB2) receptor.  Two of these indole analogs exhibited nanomolar potencies (Ki) with good selectivity for the hCB2 receptor over the human central cannabinoid (hCB1) receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVyw0x9VEfZrVg90H21EOLACvtfcHk0lhR9Bu9lZlfpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xmt1yrs7o%253D&md5=6c55898edb52047ddf96cd2595d4a740</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2F0960-894X%2896%2900426-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0960-894X%252896%252900426-X%26sid%3Dliteratum%253Aachs%26aulast%3DGallant%26aufirst%3DM.%26aulast%3DDufresne%26aufirst%3DC.%26aulast%3DGareau%26aufirst%3DY.%26aulast%3DGuay%26aufirst%3DD.%26aulast%3DLeblanc%26aufirst%3DY.%26aulast%3DPrasit%26aufirst%3DP.%2BP.%26aulast%3DRochette%26aufirst%3DC.%26aulast%3DSawyer%26aufirst%3DN.%26aulast%3DSlipetz%26aufirst%3DD.%26aulast%3DTremblay%26aufirst%3DN.%26aulast%3DMetters%26aufirst%3DK.%2BM.%26aulast%3DLabelle%26aufirst%3DM.%26atitle%3DNew%2520class%2520of%2520potent%2520ligands%2520for%2520the%2520human%2520peripheral%2520cannabinoid%2520receptor.%2520New%2520Class%2520of%2520Potent%2520Ligands%2520for%2520the%2520Human%2520Peripheral%2520Cannabinoid%2520Receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1996%26volume%3D6%26spage%3D2263%26epage%3D2268%26doi%3D10.1016%2F0960-894X%2896%2900426-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Showalter, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compton, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abood, M. E.</span></span> <span> </span><span class="NLM_article-title">Evaluation of Binding in a Transfected Cell Line Expressing a Peripheral Cannabinoid Receptor (CB2): Identification of Cannabinoid Receptor Subtype Selective Ligands</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">989</span>– <span class="NLM_lpage">999</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=8819477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADyaK28XmtVSjs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=1996&pages=989-999&author=V.+M.+Showalterauthor=D.+R.+Comptonauthor=B.+R.+Martinauthor=M.+E.+Abood&title=Evaluation+of+Binding+in+a+Transfected+Cell+Line+Expressing+a+Peripheral+Cannabinoid+Receptor+%28CB2%29%3A+Identification+of+Cannabinoid+Receptor+Subtype+Selective+Ligands"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands</span></div><div class="casAuthors">Showalter, Vincent M.; Compton, David R.; Martin, Billy R.; Abood, Mary E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">989-999</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">Two cannabinoid receptors have been identified to date; one is located predominantly in the central nervous system (CB1), whereas the other is located exclusively in the periphery (CB2).  The purposes of this study were to explore further the binding requirements of the CB2 receptor and to search for compds. displaying distinct affinities for either cannabinoid receptor.  The binding affinities for either cannabinoids tested previously at the CB1 receptor were detd. at cloned human CB1 and CB2 receptors using a filtration assay.  In addn., possible allosteric regulation of the CB2 receptor was examd.  Sodium and a GTP analog elicited a concn.-dependent decrease in specific binding to the CB2 receptor.  The affinity of cannabinol for CB2 receptors (Ki = 96.3±14 nM) was confirmed to be in approx. the same range as that of Δ9-THC (Ki = 36.4±10 nM).  Affinities at cloned CB1 and CB2 receptors were compared with affinities detd. in the brain.  Although most of the chosen compds. did not discriminate between CB1 and CB2, several ligands were identified that showed selectivity.  Affinity ratios demonstrated that two 2'-fluoro analogs of anandamide were over 23-fold selective for the CB1 receptor and confirmed the CB1 selectivity of SR141716A {N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride}.  In addn., WIN-55,212-2 {(R)-(+)-[2,3-dihydro-5-methyl-3-[(4-morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl](1-naphthalenyl)methanone} and a closely related Pr indole analog were shown to be 6.75- and 27.5-fold selective, resp., for the CB2 receptor.  These ligands can now serve as a basis for the design of compds. with even greater selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqYXeFFpwPo7Vg90H21EOLACvtfcHk0lhR9Bu9lZlfpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmtVSjs74%253D&md5=d765777f3b8763afa042ea068ffd7a28</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShowalter%26aufirst%3DV.%2BM.%26aulast%3DCompton%26aufirst%3DD.%2BR.%26aulast%3DMartin%26aufirst%3DB.%2BR.%26aulast%3DAbood%26aufirst%3DM.%2BE.%26atitle%3DEvaluation%2520of%2520Binding%2520in%2520a%2520Transfected%2520Cell%2520Line%2520Expressing%2520a%2520Peripheral%2520Cannabinoid%2520Receptor%2520%2528CB2%2529%253A%2520Identification%2520of%2520Cannabinoid%2520Receptor%2520Subtype%2520Selective%2520Ligands%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1996%26volume%3D278%26spage%3D989%26epage%3D999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frost, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dart, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tietje, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrison, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grayson, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daza, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kouhen, O. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandran, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M. D.</span></span> <span> </span><span class="NLM_article-title">Indol-3-Ylcycloalkyl Ketones: Effects of N1 Substituted Indole Side Chain Variations on CB(2) Cannabinoid Receptor Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">295</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1021/jm901214q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901214q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsValtbfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=295-315&author=J.+M.+Frostauthor=M.+J.+Dartauthor=K.+R.+Tietjeauthor=T.+R.+Garrisonauthor=G.+K.+Graysonauthor=A.+V.+Dazaauthor=O.+F.+El-Kouhenauthor=B.+B.+Yaoauthor=G.+C.+Hsiehauthor=M.+Paiauthor=C.+Z.+Zhuauthor=P.+Chandranauthor=M.+D.+Meyer&title=Indol-3-Ylcycloalkyl+Ketones%3A+Effects+of+N1+Substituted+Indole+Side+Chain+Variations+on+CB%282%29+Cannabinoid+Receptor+Activity&doi=10.1021%2Fjm901214q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Indol-3-ylcycloalkyl Ketones: Effects of N1 Substituted Indole Side Chain Variations on CB2 Cannabinoid Receptor Activity</span></div><div class="casAuthors">Frost, Jennifer M.; Dart, Michael J.; Tietje, Karin R.; Garrison, Tiffany R.; Grayson, George K.; Daza, Anthony V.; El-Kouhen, Odile F.; Yao, Betty B.; Hsieh, Gin C.; Pai, Madhavi; Zhu, Chang Z.; Chandran, Prasant; Meyer, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">295-315</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several 3-acylindoles with high affinity for the CB2 cannabinoid receptor and selectivity over the CB1 receptor have been prepd.  A variety of 3-acyl substituents were investigated, and the tetramethylcyclopropyl group was found to lead to high affinity CB2 agonists.  Substitution at the N1-indole position was then examd.  A series of aminoalkylindoles was prepd. and several substituted aminoethyl derivs. were active at the CB2 receptor.  A study of N1 nonarom. side chain variants provided potent agonists at the CB2 receptor.  Several polar side chains (alcs., oxazolidinone) were well tolerated for CB2 receptor activity, while others (amide, acid) led to weaker or inactive compds..  N1 arom. side chains also afforded several high affinity CB2 receptor agonists, but were generally less potent in an in vitro CB2 functional assay than were nonarom. side chain analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBqUcQi4rUorVg90H21EOLACvtfcHk0lhajGVSB020mQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsValtbfP&md5=5bdd69db011d3abc7924a9093209e84b</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Fjm901214q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901214q%26sid%3Dliteratum%253Aachs%26aulast%3DFrost%26aufirst%3DJ.%2BM.%26aulast%3DDart%26aufirst%3DM.%2BJ.%26aulast%3DTietje%26aufirst%3DK.%2BR.%26aulast%3DGarrison%26aufirst%3DT.%2BR.%26aulast%3DGrayson%26aufirst%3DG.%2BK.%26aulast%3DDaza%26aufirst%3DA.%2BV.%26aulast%3DEl-Kouhen%26aufirst%3DO.%2BF.%26aulast%3DYao%26aufirst%3DB.%2BB.%26aulast%3DHsieh%26aufirst%3DG.%2BC.%26aulast%3DPai%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DC.%2BZ.%26aulast%3DChandran%26aufirst%3DP.%26aulast%3DMeyer%26aufirst%3DM.%2BD.%26atitle%3DIndol-3-Ylcycloalkyl%2520Ketones%253A%2520Effects%2520of%2520N1%2520Substituted%2520Indole%2520Side%2520Chain%2520Variations%2520on%2520CB%25282%2529%2520Cannabinoid%2520Receptor%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D295%26epage%3D315%26doi%3D10.1021%2Fjm901214q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Felder, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briley, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansouri, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blond, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, R. L.</span></span> <span> </span><span class="NLM_article-title">Comparison of the Pharmacology and Signal Transduction of the Human Cannabinoid CB1 and CB2 Receptors</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">450</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=7565624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADyaK2MXosVKhu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1995&pages=443-450&author=C.+C.+Felderauthor=K.+E.+Joyceauthor=E.+M.+Brileyauthor=J.+Mansouriauthor=K.+Mackieauthor=O.+Blondauthor=Y.+Laiauthor=A.+L.+Maauthor=R.+L.+Mitchell&title=Comparison+of+the+Pharmacology+and+Signal+Transduction+of+the+Human+Cannabinoid+CB1+and+CB2+Receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors</span></div><div class="casAuthors">Felder, Christian C.; Joyce, Kelly E.; Briley, Eileen M.; Mansouri, Jaleh; Mackie, Ken; Blond, Olivier; Lai, Yvonne; Ma, Alice L.; Mitchell, Richard L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">443-50</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The recently cloned CB2 cannabinoid receptor subtype was stably transfected into AtT-20 and Chinese hamster ovary cells to compare the binding and signal transduction properties of this receptor with those of the CB1 receptor subtype.  The binding of [3H]CP 55,940 to both CB1 and CB2 was of similar high affinity (2.6 and 3.7 nM, resp.) and saturable.  In competitive binding expts., (-)-Δ9-tetrahydrocannabinol and CP 55,940 were equipotent at the CB1 and CB2 receptors, but WIN 55212-2 and cannabinol bound with higher affinity to the CB2 than the CB1 receptor.  HU 210 had a higher affinity for the CB1 receptor.  Anandamide, a recently identified endogenous cannabinoid agonist, was essentially equipotent at both receptor subtypes.  The structurally related fatty acid ethanol-amides dihomo-γ-linolenylethanolamine and mead ethanoamide also bound with relatively equal affinity to both receptors, but adrenylethanolamide had a higher affinity for the CB1 receptor.  The rank order of potency and efficacy for binding of the selected agonists to the CB1 and CB2 receptors was mimicked in functional inhibition of cAMP accumulation expts. for all compds. tested.  Both CB1 and CB2 receptors couple to the inhibition of cAMP accumulation that was pertussis toxin sensitive.  SR141716A, a CB1 receptor antagonist, was a poor antagonist at the CB2 receptor in both binding and functional inhibition of cAMP accumulation expts.  When expressed in AtT-20 cells, the CB1 receptor mediated an inhibition of Q-type calcium channels and an activation of inward rectifying potassium channels.  In contrast, the CB2 receptor did not modulate the activity of either channel under identical assay conditions.  Similar to results obtained for CB1 receptor, the CB2 receptor did not couple to the activation of phospholipases A2, C, or D or to the mobilization of intracellular Ca2+.  Except for its inability to couple to the modulation of Q-type calcium channels or inwardly rectifying potassium channels, the CB1 and CB2 receptors display similar pharmacol. and biochem. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRLDqNx6UzpLVg90H21EOLACvtfcHk0lhajGVSB020mQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXosVKhu7k%253D&md5=a2879002f7c74ca9ad8079016e62978a</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFelder%26aufirst%3DC.%2BC.%26aulast%3DJoyce%26aufirst%3DK.%2BE.%26aulast%3DBriley%26aufirst%3DE.%2BM.%26aulast%3DMansouri%26aufirst%3DJ.%26aulast%3DMackie%26aufirst%3DK.%26aulast%3DBlond%26aufirst%3DO.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DA.%2BL.%26aulast%3DMitchell%26aufirst%3DR.%2BL.%26atitle%3DComparison%2520of%2520the%2520Pharmacology%2520and%2520Signal%2520Transduction%2520of%2520the%2520Human%2520Cannabinoid%2520CB1%2520and%2520CB2%2520Receptors%26jtitle%3DMol.%2520Pharmacol.%26date%3D1995%26volume%3D48%26spage%3D443%26epage%3D450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stern, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muccioli, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millet, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goossens, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farce, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavatte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poupaert, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depreux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hénichart, J.-P.</span></span> <span> </span><span class="NLM_article-title">Novel 4-Oxo-1,4-Dihydroquinoline-3-Carboxamide Derivatives as New CB2 Cannabinoid Receptors Agonists: Synthesis, Pharmacological Properties and Molecular Modeling</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">70</span>– <span class="NLM_lpage">79</span>, <span class="refDoi"> DOI: 10.1021/jm050467q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050467q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht12rtbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=70-79&author=E.+Sternauthor=G.+G.+Muccioliauthor=R.+Milletauthor=J.-F.+Goossensauthor=A.+Farceauthor=P.+Chavatteauthor=J.+H.+Poupaertauthor=D.+M.+Lambertauthor=P.+Depreuxauthor=J.-P.+H%C3%A9nichart&title=Novel+4-Oxo-1%2C4-Dihydroquinoline-3-Carboxamide+Derivatives+as+New+CB2+Cannabinoid+Receptors+Agonists%3A+Synthesis%2C+Pharmacological+Properties+and+Molecular+Modeling&doi=10.1021%2Fjm050467q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New CB2 Cannabinoid Receptors Agonists: Synthesis, Pharmacological Properties and Molecular Modeling</span></div><div class="casAuthors">Stern, Eric; Muccioli, Giulio G.; Millet, Regis; Goossens, Jean-Francois; Farce, Amaury; Chavatte, Philippe; Poupaert, Jacques H.; Lambert, Didier M.; Depreux, Patrick; Henichart, Jean-Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">70-79</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recent data indicated that the CB2 cannabinoid receptor constitutes an attractive drug target due to its potential functional role in several physiol. and pathol. processes.  A set of 4-oxo-1,4-dihydroquinoline-3-carboxamide derivs. I (R = Bu, pentyl, hexyl, PhCH2; R1 = 4-MeOC6H4, PhCH2, 1-adamantyl, 2-naphthyl, etc.), characterized by the presence of some important structural requirements exhibited by other classes of cannabinoid ligands, such as an aliph. or arom. carboxamide group in position 3, and an alkyl or benzyl group in position 1, was synthesized and assayed to measure their resp. affinity for both human CB1 and CB2 cannabinoid receptors.  The results indicate that these 3-carboxamidoquinolones derivs. exhibited a CB2 receptor selectivity.  Moreover, in the [35S]-GTPγS binding assay, all the compds. behaved as CB2 receptor agonists.  Mol. modeling studies showed that compd. I (R = pentyl, R1 = 3,5-dimethyl-1-adamantyl) interacts with the CB2 receptor through a combination of hydrogen bond and arom./hydrophobic interactions.  In conclusion, 4-oxo-1,4-dihydroquinoline-3-carboxamide derivs. constitute a new class of potent and selective CB2 cannabinoid receptors agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGEjQIxUqkBbVg90H21EOLACvtfcHk0lhajGVSB020mQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht12rtbvF&md5=1684923b7ca4a4d858053142de4fa9f7</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Fjm050467q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050467q%26sid%3Dliteratum%253Aachs%26aulast%3DStern%26aufirst%3DE.%26aulast%3DMuccioli%26aufirst%3DG.%2BG.%26aulast%3DMillet%26aufirst%3DR.%26aulast%3DGoossens%26aufirst%3DJ.-F.%26aulast%3DFarce%26aufirst%3DA.%26aulast%3DChavatte%26aufirst%3DP.%26aulast%3DPoupaert%26aufirst%3DJ.%2BH.%26aulast%3DLambert%26aufirst%3DD.%2BM.%26aulast%3DDepreux%26aufirst%3DP.%26aulast%3DH%25C3%25A9nichart%26aufirst%3DJ.-P.%26atitle%3DNovel%25204-Oxo-1%252C4-Dihydroquinoline-3-Carboxamide%2520Derivatives%2520as%2520New%2520CB2%2520Cannabinoid%2520Receptors%2520Agonists%253A%2520Synthesis%252C%2520Pharmacological%2520Properties%2520and%2520Molecular%2520Modeling%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D70%26epage%3D79%26doi%3D10.1021%2Fjm050467q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pasquini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rosa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligresti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mugnaini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brizzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caradonna, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascio, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corelli, F.</span></span> <span> </span><span class="NLM_article-title">Investigations on the 4-Quinolone-3-Carboxylic Acid Motif. 6. Synthesis and Pharmacological Evaluation of 7-Substituted Quinolone-3-Carboxamide Derivatives as High Affinity Ligands for Cannabinoid Receptors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2012.09.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2012.09.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=23085772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslOktb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2012&pages=30-43&author=S.+Pasquiniauthor=M.+De+Rosaauthor=A.+Ligrestiauthor=C.+Mugnainiauthor=A.+Brizziauthor=N.+P.+Caradonnaauthor=M.+G.+Cascioauthor=D.+Bologniniauthor=R.+G.+Pertweeauthor=V.+Di+Marzoauthor=F.+Corelli&title=Investigations+on+the+4-Quinolone-3-Carboxylic+Acid+Motif.+6.+Synthesis+and+Pharmacological+Evaluation+of+7-Substituted+Quinolone-3-Carboxamide+Derivatives+as+High+Affinity+Ligands+for+Cannabinoid+Receptors&doi=10.1016%2Fj.ejmech.2012.09.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Investigations on the 4-quinolone-3-carboxylic acid motif. 6. Synthesis and pharmacological evaluation of 7-substituted quinolone-3-carboxamide derivatives as high affinity ligands for cannabinoid receptors</span></div><div class="casAuthors">Pasquini, Serena; De Rosa, Maria; Ligresti, Alessia; Mugnaini, Claudia; Brizzi, Antonella; Caradonna, Nicola P.; Cascio, Maria Grazia; Bolognini, Daniele; Pertwee, Roger G.; Di Marzo, Vincenzo; Corelli, Federico</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">30-43</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Within the authors' studies on structure-activity relationships of 4-quinolone-3-carboxamides as cannabinoid ligands, a new series of compds. characterized by a fluoro or phenylthio group at the 7-position and different substituents at N1 and the carboxamide nitrogen were synthesized and evaluated for their binding ability to cannabinoid type 1 (CB1) and type 2 (CB2) receptors.  Most of the compds. showed affinity for one or both cannabinoid receptors at nanomolar concn., with Ki(CB1) and Ki(CB2) values ranging from 2.45 to >10,000 nM and from 0.09 to 957 nM, resp.  The N-(3,4-dichlorobenzyl)amide derivs. I (R = Ph, PhS) displayed relatively low affinity, but high selectivity towards the CB1 receptor.  Compds. II and I (R = PhS), a CB2 and a CB1 ligand, resp., behaved as partial agonists in the [35S]GTPγS assay.  They showed very low permeability through (MDCK-MDR1) cells and might, therefore, represent possible lead structures for further optimization in the search for cannabinoid ligands unable to cross the blood-brain barrier.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof4hRj9XhonrVg90H21EOLACvtfcHk0lhGt2FrUf0_oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslOktb%252FM&md5=95ba92dca8488f8639aa8814d9ca4ea5</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.09.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.09.035%26sid%3Dliteratum%253Aachs%26aulast%3DPasquini%26aufirst%3DS.%26aulast%3DDe%2BRosa%26aufirst%3DM.%26aulast%3DLigresti%26aufirst%3DA.%26aulast%3DMugnaini%26aufirst%3DC.%26aulast%3DBrizzi%26aufirst%3DA.%26aulast%3DCaradonna%26aufirst%3DN.%2BP.%26aulast%3DCascio%26aufirst%3DM.%2BG.%26aulast%3DBolognini%26aufirst%3DD.%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DCorelli%26aufirst%3DF.%26atitle%3DInvestigations%2520on%2520the%25204-Quinolone-3-Carboxylic%2520Acid%2520Motif.%25206.%2520Synthesis%2520and%2520Pharmacological%2520Evaluation%2520of%25207-Substituted%2520Quinolone-3-Carboxamide%2520Derivatives%2520as%2520High%2520Affinity%2520Ligands%2520for%2520Cannabinoid%2520Receptors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2012%26volume%3D58%26spage%3D30%26epage%3D43%26doi%3D10.1016%2Fj.ejmech.2012.09.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El Bakali, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muccioli, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Body-Malapel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djouina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klupsch, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghinet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barczyk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renault, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavatte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desreumaux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millet, R.</span></span> <span> </span><span class="NLM_article-title">Conformational Restriction Leading to a Selective CB2 Cannabinoid Receptor Agonist Orally Active Against Colitis</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">198</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1021/ml500439x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500439x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVegtbnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=198-203&author=J.+El+Bakaliauthor=G.+G.+Muccioliauthor=M.+Body-Malapelauthor=M.+Djouinaauthor=F.+Klupschauthor=A.+Ghinetauthor=A.+Barczykauthor=N.+Renaultauthor=P.+Chavatteauthor=P.+Desreumauxauthor=D.+M.+Lambertauthor=R.+Millet&title=Conformational+Restriction+Leading+to+a+Selective+CB2+Cannabinoid+Receptor+Agonist+Orally+Active+Against+Colitis&doi=10.1021%2Fml500439x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational restriction leading to a selective CB2 cannabinoid receptor agonist orally active against colitis</span></div><div class="casAuthors">El Bakali, Jamal; Muccioli, Giulio G.; Body-Malapel, Mathilde; Djouina, Madjid; Klupsch, Frederique; Ghinet, Alina; Barczyk, Amelie; Renault, Nicolas; Chavatte, Philippe; Desreumaux, Pierre; Lambert, Didier M.; Millet, Regis</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">198-203</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The CB2 cannabinoid receptor has been implicated in the regulation of intestinal inflammation.  Following on from the promising activity of a series of 4-oxo-1,4-dihydroquinoline-3-carboxamide, the authors developed constrained analogs based on a 2H-pyrazolo[4,3-c]quinolin-3(5H)-one scaffold, with improved affinity for the hCB2 receptor and had very high selectivity over the hCB1 receptor.  Importantly, the lead of this series I (hCB2: Ki = 0.39 nM, hCB1: Ki > 3000 nM) was found to protect mice against exptl. colitis after oral administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPBwnfX2qnA7Vg90H21EOLACvtfcHk0lhGt2FrUf0_oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVegtbnF&md5=18a62366567b79e2a8d782a5626823f5</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1021%2Fml500439x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500439x%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BBakali%26aufirst%3DJ.%26aulast%3DMuccioli%26aufirst%3DG.%2BG.%26aulast%3DBody-Malapel%26aufirst%3DM.%26aulast%3DDjouina%26aufirst%3DM.%26aulast%3DKlupsch%26aufirst%3DF.%26aulast%3DGhinet%26aufirst%3DA.%26aulast%3DBarczyk%26aufirst%3DA.%26aulast%3DRenault%26aufirst%3DN.%26aulast%3DChavatte%26aufirst%3DP.%26aulast%3DDesreumaux%26aufirst%3DP.%26aulast%3DLambert%26aufirst%3DD.%2BM.%26aulast%3DMillet%26aufirst%3DR.%26atitle%3DConformational%2520Restriction%2520Leading%2520to%2520a%2520Selective%2520CB2%2520Cannabinoid%2520Receptor%2520Agonist%2520Orally%2520Active%2520Against%2520Colitis%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D198%26epage%3D203%26doi%3D10.1021%2Fml500439x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stern, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muccioli, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamtiaux, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millet, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poupaert, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hénichart, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depreux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goossens, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, D. M.</span></span> <span> </span><span class="NLM_article-title">Pharmacomodulations around the 4-Oxo-1,4-Dihydroquinoline-3-Carboxamides, a Class of Potent CB2-Selective Cannabinoid Receptor Ligands: Consequences in Receptor Affinity and Functionality</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">5471</span>– <span class="NLM_lpage">5484</span>, <span class="refDoi"> DOI: 10.1021/jm070387h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070387h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFWgu7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5471-5484&author=E.+Sternauthor=G.+G.+Muccioliauthor=B.+Bosierauthor=L.+Hamtiauxauthor=R.+Milletauthor=J.+H.+Poupaertauthor=J.-P.+H%C3%A9nichartauthor=P.+Depreuxauthor=J.-F.+Goossensauthor=D.+M.+Lambert&title=Pharmacomodulations+around+the+4-Oxo-1%2C4-Dihydroquinoline-3-Carboxamides%2C+a+Class+of+Potent+CB2-Selective+Cannabinoid+Receptor+Ligands%3A+Consequences+in+Receptor+Affinity+and+Functionality&doi=10.1021%2Fjm070387h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacomodulations around the 4-Oxo-1,4-dihydroquinoline-3-carboxamides, a Class of Potent CB2-Selective Cannabinoid Receptor Ligands: Consequences in Receptor Affinity and Functionality</span></div><div class="casAuthors">Stern, Eric; Muccioli, Giulio G.; Bosier, Barbara; Hamtiaux, Laurie; Millet, Regis; Poupaert, Jacques H.; Henichart, Jean-Pierre; Depreux, Patrick; Goossens, Jean-Francois; Lambert, Didier M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5471-5484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">CB2 receptor selective ligands are becoming increasingly attractive drugs due to the potential role of this receptor in several physiopathol. processes.  Thus, the development of our previously described series of 4-oxo-1,4-dihydroquinoline-3-carboxamides, e.g. I, was pursued with the aim to further characterize the structure-affinity and structure-functionality relationships of these derivs.  The influence of the side chain was investigated by synthesizing compds. bearing various carboxamido and keto substituents.  On the other hand, the role of the quinoline central scaffold was studied by synthesizing several 6-, 7-, or 8-chloro-4-oxo-1,4-dihydroquinolines, as well as 4-oxo-1,4-dihydronaphthyridine and 4-oxo-1,4-dihydrocinnoline derivs.  The effect of these modifications on the affinity and functionality at the CB2 receptor was studied and allowed for the characterization of new selective CB2 receptor ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplBvPAuk1aZLVg90H21EOLACvtfcHk0lhGt2FrUf0_oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFWgu7zP&md5=0cd8f355a2c6ab69fa7c6568e3f4d18a</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Fjm070387h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070387h%26sid%3Dliteratum%253Aachs%26aulast%3DStern%26aufirst%3DE.%26aulast%3DMuccioli%26aufirst%3DG.%2BG.%26aulast%3DBosier%26aufirst%3DB.%26aulast%3DHamtiaux%26aufirst%3DL.%26aulast%3DMillet%26aufirst%3DR.%26aulast%3DPoupaert%26aufirst%3DJ.%2BH.%26aulast%3DH%25C3%25A9nichart%26aufirst%3DJ.-P.%26aulast%3DDepreux%26aufirst%3DP.%26aulast%3DGoossens%26aufirst%3DJ.-F.%26aulast%3DLambert%26aufirst%3DD.%2BM.%26atitle%3DPharmacomodulations%2520around%2520the%25204-Oxo-1%252C4-Dihydroquinoline-3-Carboxamides%252C%2520a%2520Class%2520of%2520Potent%2520CB2-Selective%2520Cannabinoid%2520Receptor%2520Ligands%253A%2520Consequences%2520in%2520Receptor%2520Affinity%2520and%2520Functionality%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D5471%26epage%3D5484%26doi%3D10.1021%2Fjm070387h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dolles, D.</span>; <span class="NLM_string-name">Decker, M.</span></span> <i>Design of Hybrid Molecules for Drug Development</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, M.</span></span>, Eds.; <span class="NLM_publisher-name">Elsevier</span>, <span class="NLM_year">2017</span>; pp  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">165</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2FB978-0-08-101011-2.00005-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=137-165&author=D.+Dolles&author=M.+Deckerauthor=M.+Decker&title=Design+of+Hybrid+Molecules+for+Drug+Development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2FB978-0-08-101011-2.00005-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-08-101011-2.00005-2%26sid%3Dliteratum%253Aachs%26aulast%3DDolles%26aufirst%3DD.%26btitle%3DDesign%2520of%2520Hybrid%2520Molecules%2520for%2520Drug%2520Development%26aulast%3DDecker%26aufirst%3DM.%26pub%3DElsevier%26date%3D2017%26spage%3D137%26epage%3D165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ivasiv, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albertini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonçalves, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1694</span>– <span class="NLM_lpage">1711</span>, <span class="refDoi"> DOI: 10.2174/1568026619666190619115735</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.2174%2F1568026619666190619115735" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=31237210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVymtbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=1694-1711&author=V.+Ivasivauthor=C.+Albertiniauthor=A.+E.+Gon%C3%A7alvesauthor=M.+Rossiauthor=M.+L.+Bolognesi&title=Molecular+Hybridization+as+a+Tool+for+Designing+Multitarget+Drug+Candidates+for+Complex+Diseases&doi=10.2174%2F1568026619666190619115735"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases</span></div><div class="casAuthors">Ivasiv, Viktoriya; Albertini, Claudia; Goncalves, Ana E.; Rossi, Michele; Bolognesi, Maria L.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1694-1711</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Mol. hybridization is a well-exploited medicinal chem. strategy that aims to combine two mols. (or parts of them) in a new, single chem. entity.  Recently, it has been recognized as an effective approach to design ligands able to modulate multiple targets of interest.  Hybrid compds. can be obtained by linking (presence of a linker) or framework integration (merging or fusing) strategies.  Although very promising to combat the multifactorial nature of complex diseases, the development of mol. hybrids faces the crit. issues of selecting the right target combination and the achievement of a balanced activity towards them, while maintaining drug-like-properties.  In this review, we present recent case histories from our own research group that demonstrate why and how mol. hybridization can be carried out to address the challenges of multitarget drug discovery in two therapeutic areas that are Alzheimer's and parasitic diseases.  Selected examples spanning from linker- to fragment- based hybrids will allow to discuss issues and consequences relevant to drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWvQfYk-XT87Vg90H21EOLACvtfcHk0li8s7hOiiWecQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVymtbbK&md5=c993274dc1849e3aa5a6c4c8a2ac1ec8</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.2174%2F1568026619666190619115735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026619666190619115735%26sid%3Dliteratum%253Aachs%26aulast%3DIvasiv%26aufirst%3DV.%26aulast%3DAlbertini%26aufirst%3DC.%26aulast%3DGon%25C3%25A7alves%26aufirst%3DA.%2BE.%26aulast%3DRossi%26aufirst%3DM.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DMolecular%2520Hybridization%2520as%2520a%2520Tool%2520for%2520Designing%2520Multitarget%2520Drug%2520Candidates%2520for%2520Complex%2520Diseases%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2019%26volume%3D19%26spage%3D1694%26epage%3D1711%26doi%3D10.2174%2F1568026619666190619115735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popovic-Nikolic, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uliassi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">A Perspective on Multi-Target Drug Discovery and Design for Complex Diseases</span>. <i>Clin. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">3</span>, <span class="refDoi"> DOI: 10.1186/s40169-017-0181-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1186%2Fs40169-017-0181-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=29340951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BC1MvhsVaiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=3&author=R.+R.+Ramsayauthor=M.+R.+Popovic-Nikolicauthor=K.+Nikolicauthor=E.+Uliassiauthor=M.+L.+Bolognesi&title=A+Perspective+on+Multi-Target+Drug+Discovery+and+Design+for+Complex+Diseases&doi=10.1186%2Fs40169-017-0181-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">A perspective on multi-target drug discovery and design for complex diseases</span></div><div class="casAuthors">Ramsay Rona R; Popovic-Nikolic Marija R; Nikolic Katarina; Uliassi Elisa; Bolognesi Maria Laura</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and translational medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3</span>
        ISSN:<span class="NLM_cas:issn">2001-1326</span>.
    </div><div class="casAbstract">Diseases of infection, of neurodegeneration (such as Alzheimer's and Parkinson's diseases), and of malignancy (cancers) have complex and varied causative factors.  Modern drug discovery has the power to identify potential modulators for multiple targets from millions of compounds.  Computational approaches allow the determination of the association of each compound with its target before chemical synthesis and biological testing is done.  These approaches depend on the prior identification of clinically and biologically validated targets.  This Perspective will focus on the molecular and computational approaches that underpin drug design by medicinal chemists to promote understanding and collaboration with clinical scientists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJhSGsWpifCZcXNb62YGmbfW6udTcc2eaersfwUWUAF7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvhsVaiug%253D%253D&md5=5b05a73a3bbc955c77b9b2df93deb946</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1186%2Fs40169-017-0181-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40169-017-0181-2%26sid%3Dliteratum%253Aachs%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26aulast%3DPopovic-Nikolic%26aufirst%3DM.%2BR.%26aulast%3DNikolic%26aufirst%3DK.%26aulast%3DUliassi%26aufirst%3DE.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DA%2520Perspective%2520on%2520Multi-Target%2520Drug%2520Discovery%2520and%2520Design%2520for%2520Complex%2520Diseases%26jtitle%3DClin.%2520Transl.%2520Med.%26date%3D2018%26volume%3D7%26spage%3D3%26doi%3D10.1186%2Fs40169-017-0181-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">Harnessing Polypharmacology with Medicinal Chemistry</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">275</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00039</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00039" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVWjt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=273-275&author=M.+L.+Bolognesi&title=Harnessing+Polypharmacology+with+Medicinal+Chemistry&doi=10.1021%2Facsmedchemlett.9b00039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Harnessing Polypharmacology with Medicinal Chemistry</span></div><div class="casAuthors">Bolognesi, Maria Laura</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">273-275</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Polypharmacol. has expanded enormously over the last ten years, with several multitarget drugs (MTDs) already in the market.  This Viewpoint provides a basis for a discussion about the crit. need to develop MTDs in a more rationale and conscious way.  A checklist to maximize success in polypharmacol. is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4yXxJ_uU72bVg90H21EOLACvtfcHk0lizdCd8O6SkNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVWjt7g%253D&md5=28a8cc47ae2966a2ecd8a411adfb1ef5</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00039%26sid%3Dliteratum%253Aachs%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DHarnessing%2520Polypharmacology%2520with%2520Medicinal%2520Chemistry%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D273%26epage%3D275%26doi%3D10.1021%2Facsmedchemlett.9b00039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stribley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ticu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schopfer, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brimijoin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinrichs, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockridge, O.</span></span> <span> </span><span class="NLM_article-title">Abundant Tissue Butyrylcholinesterase and Its Possible Function in the Acetylcholinesterase Knockout Mouse</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">1320</span>– <span class="NLM_lpage">1331</span>, <span class="refDoi"> DOI: 10.1046/j.1471-4159.2000.751320.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1046%2Fj.1471-4159.2000.751320.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10936216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmtFyrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2000&pages=1320-1331&author=B.+Liauthor=J.+A.+Stribleyauthor=A.+Ticuauthor=W.+Xieauthor=L.+M.+Schopferauthor=P.+Hammondauthor=S.+Brimijoinauthor=S.+H.+Hinrichsauthor=O.+Lockridge&title=Abundant+Tissue+Butyrylcholinesterase+and+Its+Possible+Function+in+the+Acetylcholinesterase+Knockout+Mouse&doi=10.1046%2Fj.1471-4159.2000.751320.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Abundant tissue butyrylcholinesterase and its possible function in the acetylcholinesterase knockout mouse</span></div><div class="casAuthors">Li, Bin; Stribley, Judith A.; Ticu, Andreea; Xie, Weihua; Schopfer, Lawrence M.; Hammond, Pamela; Brimijoin, Stephen; Hinrichs, Steven H.; Lockridge, Oksana</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1320-1331</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">We have described recently an acetylcholinesterase (AChE) knockout mouse.  While comparing the tissue distribution of AChE and butyrylcholinesterase (BChE), we found that extn. buffers contg. Triton X-100 strongly inhibited mouse BChE activity.  In contrast, buffers with Tween 20 caused no inhibition of BChE.  Conventional techniques grossly underestimated BChE activity by up to 15-fold.  In Tween 20 buffer, the intestine, serum, lung, liver, and heart had higher BChE than AChE activity.  Only brain had higher AChE than BChE activity in AChE +/+ mice.  These findings contradict the dogma, based mainly on observations in Triton X-100 exts., that BChE is a minor cholinesterase in animal tissues.  AChE +/- mice had 50% of normal AChE activity and AChE -/- mice had none, but all mice had similar levels of BChE activity.  BChE was inhibited by Triton X-100 in all species tested, except rat and chicken.  Inhibition was reversible and competitive with substrate binding.  The active site of rat BChE was unique, having an arginine in place of leucine at position 286 (human BChE numbering) in the acyl-binding pocket of the active site, thus explaining the lack of inhibition of rat BChE by Triton X-100.  The generally high levels of BChE activity in tissues, including the motor endplate, and the observation that mice live without AChE, suggest that BChE has an essential function in nullizygous mice and probably in wild-type mice as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6cUNgoG0RlrVg90H21EOLACvtfcHk0lizdCd8O6SkNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmtFyrsbg%253D&md5=7fe96164b0f2fe7258525834081651bc</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.2000.751320.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.2000.751320.x%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DB.%26aulast%3DStribley%26aufirst%3DJ.%2BA.%26aulast%3DTicu%26aufirst%3DA.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DSchopfer%26aufirst%3DL.%2BM.%26aulast%3DHammond%26aufirst%3DP.%26aulast%3DBrimijoin%26aufirst%3DS.%26aulast%3DHinrichs%26aufirst%3DS.%2BH.%26aulast%3DLockridge%26aufirst%3DO.%26atitle%3DAbundant%2520Tissue%2520Butyrylcholinesterase%2520and%2520Its%2520Possible%2520Function%2520in%2520the%2520Acetylcholinesterase%2520Knockout%2520Mouse%26jtitle%3DJ.%2520Neurochem.%26date%3D2000%26volume%3D75%26spage%3D1320%26epage%3D1331%26doi%3D10.1046%2Fj.1471-4159.2000.751320.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hampel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesulam, M.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuello, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farlow, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacobini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossberg, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khachaturian, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergallo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavedo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khachaturian, Z. S.</span></span> <span> </span><span class="NLM_article-title">The Cholinergic System in the Pathophysiology and Treatment of Alzheimer’s Disease</span>. <i>Brain</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">1917</span>– <span class="NLM_lpage">1933</span>, <span class="refDoi"> DOI: 10.1093/brain/awy132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1093%2Fbrain%2Fawy132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=29850777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BC1MbitFKksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2018&pages=1917-1933&author=H.+Hampelauthor=M.-M.+Mesulamauthor=A.+C.+Cuelloauthor=M.+R.+Farlowauthor=E.+Giacobiniauthor=G.+T.+Grossbergauthor=A.+S.+Khachaturianauthor=A.+Vergalloauthor=E.+Cavedoauthor=P.+Snyderauthor=Z.+S.+Khachaturian&title=The+Cholinergic+System+in+the+Pathophysiology+and+Treatment+of+Alzheimer%E2%80%99s+Disease&doi=10.1093%2Fbrain%2Fawy132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">The cholinergic system in the pathophysiology and treatment of Alzheimer's disease</span></div><div class="casAuthors">Hampel Harald; Vergallo Andrea; Cavedo Enrica; Hampel Harald; Vergallo Andrea; Cavedo Enrica; Hampel Harald; Vergallo Andrea; Cavedo Enrica; Hampel Harald; Vergallo Andrea; Cavedo Enrica; Mesulam M-Marsel; Cuello A Claudio; Cuello A Claudio; Cuello A Claudio; Farlow Martin R; Giacobini Ezio; Grossberg George T; Khachaturian Ara S; Khachaturian Zaven S; Snyder Peter J; Snyder Peter J</div><div class="citationInfo"><span class="NLM_cas:title">Brain : a journal of neurology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1917-1933</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cholinergic synapses are ubiquitous in the human central nervous system.  Their high density in the thalamus, striatum, limbic system, and neocortex suggest that cholinergic transmission is likely to be critically important for memory, learning, attention and other higher brain functions.  Several lines of research suggest additional roles for cholinergic systems in overall brain homeostasis and plasticity.  As such, the brain's cholinergic system occupies a central role in ongoing research related to normal cognition and age-related cognitive decline, including dementias such as Alzheimer's disease.  The cholinergic hypothesis of Alzheimer's disease centres on the progressive loss of limbic and neocortical cholinergic innervation.  Neurofibrillary degeneration in the basal forebrain is believed to be the primary cause for the dysfunction and death of forebrain cholinergic neurons, giving rise to a widespread presynaptic cholinergic denervation.  Cholinesterase inhibitors increase the availability of acetylcholine at synapses in the brain and are one of the few drug therapies that have been proven clinically useful in the treatment of Alzheimer's disease dementia, thus validating the cholinergic system as an important therapeutic target in the disease.  This review includes an overview of the role of the cholinergic system in cognition and an updated understanding of how cholinergic deficits in Alzheimer's disease interact with other aspects of disease pathophysiology, including plaques composed of amyloid-β proteins.  This review also documents the benefits of cholinergic therapies at various stages of Alzheimer's disease and during long-term follow-up as visualized in novel imaging studies.  The weight of the evidence supports the continued value of cholinergic drugs as a standard, cornerstone pharmacological approach in Alzheimer's disease, particularly as we look ahead to future combination therapies that address symptoms as well as disease progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT5lCY2voWsVJWtyewyzkyLfW6udTcc2eZvyXjd4ARg77ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MbitFKksg%253D%253D&md5=c50bb2354aedec424a05295e06ca5be6</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2Fawy132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252Fawy132%26sid%3Dliteratum%253Aachs%26aulast%3DHampel%26aufirst%3DH.%26aulast%3DMesulam%26aufirst%3DM.-M.%26aulast%3DCuello%26aufirst%3DA.%2BC.%26aulast%3DFarlow%26aufirst%3DM.%2BR.%26aulast%3DGiacobini%26aufirst%3DE.%26aulast%3DGrossberg%26aufirst%3DG.%2BT.%26aulast%3DKhachaturian%26aufirst%3DA.%2BS.%26aulast%3DVergallo%26aufirst%3DA.%26aulast%3DCavedo%26aufirst%3DE.%26aulast%3DSnyder%26aufirst%3DP.%26aulast%3DKhachaturian%26aufirst%3DZ.%2BS.%26atitle%3DThe%2520Cholinergic%2520System%2520in%2520the%2520Pathophysiology%2520and%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DBrain%26date%3D2018%26volume%3D141%26spage%3D1917%26epage%3D1933%26doi%3D10.1093%2Fbrain%2Fawy132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anand, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, B.</span></span> <span> </span><span class="NLM_article-title">A Review on Cholinesterase Inhibitors for Alzheimer’s Disease</span>. <i>Arch. Pharmacal Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">375</span>– <span class="NLM_lpage">399</span>, <span class="refDoi"> DOI: 10.1007/s12272-013-0036-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1007%2Fs12272-013-0036-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=23435942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFWju70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2013&pages=375-399&author=P.+Anandauthor=B.+Singh&title=A+Review+on+Cholinesterase+Inhibitors+for+Alzheimer%E2%80%99s+Disease&doi=10.1007%2Fs12272-013-0036-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">A review on cholinesterase inhibitors for Alzheimer's disease</span></div><div class="casAuthors">Anand, Preet; Singh, Baldev</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Pharmacal Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">375-399</span>CODEN:
                <span class="NLM_cas:coden">APHRDQ</span>;
        ISSN:<span class="NLM_cas:issn">0253-6269</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Korea</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD), a progressive neurodegenerative disorder, is characterized by the deficits in the cholinergic system and deposition of beta amyloid (Aβ) in the form of neurofibrillary tangles and amyloid plaques.  Since the cholinergic system plays an important role in the regulation of learning and memory processes, it has been targetted for the design of anti-Alzheimer's drugs.  Cholinesterase inhibitors enhance cholinergic transmission directly by inhibiting the enzyme acetylcholinesterase (AChE) which hydrolyzes acetylcholine.  Furthermore, it has been also demonstrated that both acetylcholinesterase and butrylcholinesterase (BuChE) play an important role in Aβ-aggregation during the early stages of senile plaque formation.  Therefore, AChE and BuChE inhibition have been documented as crit. targets for the effective management of AD by an increase in the availability of acetylcholine in the brain regions and decrease in the Aβ deposition.  This review discusses the different classes of cholinesterase inhibitors including tacrine, donepezil, rivastigmine, galantamine, xanthostigmine, para-aminobenzoic acid, coumarin, flavonoid, and pyrrolo-isoxazole analogs developed for the treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe8p6U3r94ubVg90H21EOLACvtfcHk0liugUmLLxyAQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFWju70%253D&md5=a8b48dbf6a7e7b988759182ad8cd9b6a</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1007%2Fs12272-013-0036-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12272-013-0036-3%26sid%3Dliteratum%253Aachs%26aulast%3DAnand%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DB.%26atitle%3DA%2520Review%2520on%2520Cholinesterase%2520Inhibitors%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DArch.%2520Pharmacal%2520Res.%26date%3D2013%26volume%3D36%26spage%3D375%26epage%3D399%26doi%3D10.1007%2Fs12272-013-0036-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kamal, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Q.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweedie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greig, N. H.</span></span> <span> </span><span class="NLM_article-title">Tetrahydrofurobenzofuran Cymserine, a Potent Butyrylcholinesterase Inhibitor and Experimental Alzheimer Drug Candidate, Enzyme Kinetic Analysis</span>. <i>J. Neural Transm.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">889</span>– <span class="NLM_lpage">898</span>, <span class="refDoi"> DOI: 10.1007/s00702-008-0022-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1007%2Fs00702-008-0022-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=18235987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmslWrs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2008&pages=889-898&author=M.+A.+Kamalauthor=X.+Quauthor=Q.-S.+Yuauthor=D.+Tweedieauthor=H.+W.+Hollowayauthor=Y.+Liauthor=Y.+Tanauthor=N.+H.+Greig&title=Tetrahydrofurobenzofuran+Cymserine%2C+a+Potent+Butyrylcholinesterase+Inhibitor+and+Experimental+Alzheimer+Drug+Candidate%2C+Enzyme+Kinetic+Analysis&doi=10.1007%2Fs00702-008-0022-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis</span></div><div class="casAuthors">Kamal, Mohammad A.; Qu, Xianqin; Yu, Qian-sheng; Tweedie, David; Holloway, Harold W.; Li, Yazhou; Tan, Yi; Greig, Nigel H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neural Transmission</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">889-898</span>CODEN:
                <span class="NLM_cas:coden">JNTRF3</span>;
        ISSN:<span class="NLM_cas:issn">0300-9564</span>.
    
            (<span class="NLM_cas:orgname">Springer Wien</span>)
        </div><div class="casAbstract">Synaptic loss, particularly related to the forebrain cholinergic system, is considered to be an early event that leads to Alzheimer's disease (AD) and has led to the development of acetylcholinesterase inhibitors (AChE-Is) as the mainstay of treatment for several degenerative disorders that culminate in dementia.  The primary dose-limiting toxicities of all clin. available AChE-Is are, similar to useful actions on cognition, cholinergically mediated and they ultimately limit the value of this drug class in achieving anything but symptomatic improvements.  In addn., AChE levels in brain areas assocd. with AD decline with disease progression, which likely ultimately limits the therapeutic utility of this drug class.  New research indicates that selective inhibition of butyrylcholinesterase (BuChE), a closely related enzyme that is markedly elevated in AD brain, increases acetylcholine (ACh) and augments cognition in rodents free of the characteristic undesirable actions of AChE-Is.  BuChE inhibition hence represents an innovative treatment approach for AD, and agents are currently being synthesized to optimally achieve this.  The novel compd., tetrahydrofurobenzofuran cymserine (THFBFC), is derived from our effort to produce a potent and BuChE-selective inhibitor as a candidate to test the hypothesis that BuChE-Is would be efficacious and better tolerated than AChE-Is in AD.  Herein, we applied innovative enzyme kinetic analyses to characterize the quant. interaction of THFBFC with human BuChE.  These provided values for the agent's IC50, together with specific new kinetic consts., such as K T50, K T1/2, R I, o K RT, o P max, K PT and PT1/2, to aid define target concns. for clin. translation.  Addnl. classical kinetic parameters, including K i, K m or K s, k cat or V max and V mi were also detd.  THFBFC proved to be a potent competitive inhibitor of human BuChE and, like its isomer dihydrobenzodioxepine cymserine, is a potentially interesting AD drug candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlVk1HT9MyVLVg90H21EOLACvtfcHk0liugUmLLxyAQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmslWrs7s%253D&md5=f6ac27e74507eb20a9115e4ca80176ac</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1007%2Fs00702-008-0022-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00702-008-0022-y%26sid%3Dliteratum%253Aachs%26aulast%3DKamal%26aufirst%3DM.%2BA.%26aulast%3DQu%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DQ.-S.%26aulast%3DTweedie%26aufirst%3DD.%26aulast%3DHolloway%26aufirst%3DH.%2BW.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DTan%26aufirst%3DY.%26aulast%3DGreig%26aufirst%3DN.%2BH.%26atitle%3DTetrahydrofurobenzofuran%2520Cymserine%252C%2520a%2520Potent%2520Butyrylcholinesterase%2520Inhibitor%2520and%2520Experimental%2520Alzheimer%2520Drug%2520Candidate%252C%2520Enzyme%2520Kinetic%2520Analysis%26jtitle%3DJ.%2520Neural%2520Transm.%26date%3D2008%26volume%3D115%26spage%3D889%26epage%3D898%26doi%3D10.1007%2Fs00702-008-0022-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Andrade, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantoani, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonçalves Nunes, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magadán, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xavier, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hojo, E. T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campillo, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, I.</span></span> <span> </span><span class="NLM_article-title">Highly Potent and Selective Aryl-1,2,3-Triazolyl Benzylpiperidine Inhibitors toward Butyrylcholinesterase in Alzheimer’s Disease</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">931</span>– <span class="NLM_lpage">943</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.12.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmc.2018.12.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=30765302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1MXivVahtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=931-943&author=P.+de+Andradeauthor=S.+P.+Mantoaniauthor=P.+S.+Gon%C3%A7alves+Nunesauthor=C.+R.+Magad%C3%A1nauthor=C.+P%C3%A9rezauthor=D.+J.+Xavierauthor=E.+T.+S.+Hojoauthor=N.+E.+Campilloauthor=A.+Mart%C3%ADnezauthor=I.+Carvalho&title=Highly+Potent+and+Selective+Aryl-1%2C2%2C3-Triazolyl+Benzylpiperidine+Inhibitors+toward+Butyrylcholinesterase+in+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.bmc.2018.12.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Highly potent and selective aryl-1,2,3-triazolyl benzylpiperidine inhibitors toward butyrylcholinesterase in Alzheimer's disease</span></div><div class="casAuthors">de Andrade, Peterson; Mantoani, Susimaire P.; Goncalves Nunes, Paulo Sergio; Magadan, Carlos Roca; Perez, Concepcion; Xavier, Danilo Jordao; Hojo, Elza Tiemi Sakamoto; Campillo, Nuria E.; Martinez, Ana; Carvalho, Ivone</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">931-943</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Acetylcholinesterase (AChE) is the key enzyme targeted in Alzheimer's disease (AD) therapy, nevertheless butyrylcholinesterase (BuChE) has been drawing attention due to its role in the disease progression.  Thus, we aimed to synthesize novel cholinesterases inhibitors considering structural differences in their peripheral site, exploiting a moiety replacement approach based on the potent and selective hAChE drug donepezil.  Hence, two small series of N-benzylpiperidine based compds. have successfully been synthesized as novel potent and selective hBuChE inhibitors.  The most promising compds. (9(I) and 11(II)) were not cytotoxic and their kinetic study accounted for dual binding site mode of interaction, which is in agreement with further docking and mol. dynamics studies.  Therefore, this study demonstrates how our strategy enabled the discovery of novel promising and privileged structures.  Remarkably, II proved to be one of the most potent (0.17 nM) and selective (>58,000-fold) hBuChE inhibitor ever reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo18FzHODs2ArVg90H21EOLACvtfcHk0lh8EjoT32p7aQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXivVahtbc%253D&md5=0451105345c02e32c56a64087251d167</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.12.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.12.030%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BAndrade%26aufirst%3DP.%26aulast%3DMantoani%26aufirst%3DS.%2BP.%26aulast%3DGon%25C3%25A7alves%2BNunes%26aufirst%3DP.%2BS.%26aulast%3DMagad%25C3%25A1n%26aufirst%3DC.%2BR.%26aulast%3DP%25C3%25A9rez%26aufirst%3DC.%26aulast%3DXavier%26aufirst%3DD.%2BJ.%26aulast%3DHojo%26aufirst%3DE.%2BT.%2BS.%26aulast%3DCampillo%26aufirst%3DN.%2BE.%26aulast%3DMart%25C3%25ADnez%26aufirst%3DA.%26aulast%3DCarvalho%26aufirst%3DI.%26atitle%3DHighly%2520Potent%2520and%2520Selective%2520Aryl-1%252C2%252C3-Triazolyl%2520Benzylpiperidine%2520Inhibitors%2520toward%2520Butyrylcholinesterase%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2019%26volume%3D27%26spage%3D931%26epage%3D943%26doi%3D10.1016%2Fj.bmc.2018.12.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coquelle, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pišlar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Žakelj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jukič, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mravljak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nachon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brazzolotto, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colletier, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobec, S.</span></span> <span> </span><span class="NLM_article-title">Multi-Target-Directed Ligands for Treating Alzheimer’s Disease: Butyrylcholinesterase Inhibitors Displaying Antioxidant and Neuroprotective Activities</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">598</span>– <span class="NLM_lpage">617</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.07.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2018.07.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=30031971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlOjs7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2018&pages=598-617&author=D.+Knezauthor=N.+Coquelleauthor=A.+Pi%C5%A1larauthor=S.+%C5%BDakeljauthor=M.+Juki%C4%8Dauthor=M.+Sovaauthor=J.+Mravljakauthor=F.+Nachonauthor=X.+Brazzolottoauthor=J.+Kosauthor=J.+P.+Colletierauthor=S.+Gobec&title=Multi-Target-Directed+Ligands+for+Treating+Alzheimer%E2%80%99s+Disease%3A+Butyrylcholinesterase+Inhibitors+Displaying+Antioxidant+and+Neuroprotective+Activities&doi=10.1016%2Fj.ejmech.2018.07.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target-directed ligands for treating Alzheimer's disease: Butyrylcholinesterase inhibitors displaying antioxidant and neuroprotective activities</span></div><div class="casAuthors">Knez, Damijan; Coquelle, Nicolas; Pislar, Anja; Zakelj, Simon; Jukic, Marko; Sova, Matej; Mravljak, Janez; Nachon, Florian; Brazzolotto, Xavier; Kos, Janko; Colletier, Jacques-Philippe; Gobec, Stanislav</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">598-617</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The limited clin. efficacy of current symptomatic treatment and minute effect on progression of Alzheimer's disease has shifted the research focus from single targets towards multi-target-directed ligands.  Here, a potent selective inhibitor of human butyrylcholinesterase was used as the starting point to develop a new series of multifunctional ligands.  A focused library of derivs. was designed and synthesized that showed both butyrylcholinesterase inhibition and good antioxidant activity as detd. by the DPPH assay.  The crystal structure of compd. 11 in complex with butyrylcholinesterase revealed the mol. basis for its low nanomolar inhibition of butyrylcholinesterase (Ki = 1.09±0.12 nM).  In addn., compds. 8 and 11 show metal-chelating properties, and reduce the redox activity of chelated Cu2+ ions in a Cu-ascorbate redox system.  Compds. 8 and 11 decrease intracellular levels of reactive oxygen species, and are not substrates of the active efflux transport system, as detd. in Caco2 cells.  Compd. 11 also protects neuroblastoma SH-SY5Y cells from toxic Aβ1-42 species.  These data indicate that compds. 8 and 11 are promising multifunctional lead ligands for treatment of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNMjF5aAaK37Vg90H21EOLACvtfcHk0lh8EjoT32p7aQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlOjs7zI&md5=b72fe7de780ba1a4deb7a0ed4fa3326f</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.07.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.07.033%26sid%3Dliteratum%253Aachs%26aulast%3DKnez%26aufirst%3DD.%26aulast%3DCoquelle%26aufirst%3DN.%26aulast%3DPi%25C5%25A1lar%26aufirst%3DA.%26aulast%3D%25C5%25BDakelj%26aufirst%3DS.%26aulast%3DJuki%25C4%258D%26aufirst%3DM.%26aulast%3DSova%26aufirst%3DM.%26aulast%3DMravljak%26aufirst%3DJ.%26aulast%3DNachon%26aufirst%3DF.%26aulast%3DBrazzolotto%26aufirst%3DX.%26aulast%3DKos%26aufirst%3DJ.%26aulast%3DColletier%26aufirst%3DJ.%2BP.%26aulast%3DGobec%26aufirst%3DS.%26atitle%3DMulti-Target-Directed%2520Ligands%2520for%2520Treating%2520Alzheimer%25E2%2580%2599s%2520Disease%253A%2520Butyrylcholinesterase%2520Inhibitors%2520Displaying%2520Antioxidant%2520and%2520Neuroprotective%2520Activities%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D156%26spage%3D598%26epage%3D617%26doi%3D10.1016%2Fj.ejmech.2018.07.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benito, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolon, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazos, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castillo, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, J.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid CB2 Receptors in Human Brain Inflammation</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>153</i></span>,  <span class="NLM_fpage">277</span>– <span class="NLM_lpage">285</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0707505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fsj.bjp.0707505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=17934510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovFCktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=153&publication_year=2008&pages=277-285&author=C.+Benitoauthor=R.+M.+Tolonauthor=M.+R.+Pazosauthor=E.+Nunezauthor=A.+I.+Castilloauthor=J.+Romero&title=Cannabinoid+CB2+Receptors+in+Human+Brain+Inflammation&doi=10.1038%2Fsj.bjp.0707505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid CB2 receptors in human brain inflammation</span></div><div class="casAuthors">Benito, C.; Tolon, R. M.; Pazos, M. R.; Nunez, E.; Castillo, A. I.; Romero, J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">153</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">277-285</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The presence of functional cannabinoid CB2 receptors in the CNS has provoked considerable controversy over the past few years.  Formerly considered as an exclusively peripheral receptor, it is now accepted that it is also present in limited amts. and distinct locations in the brain of several animal species, including humans.  Furthermore, the inducible nature of these receptors under neuroinflammatory conditions, in contrast to CB1, makes them attractive targets for the development of novel therapeutic approaches.  In fact, the undesired psychoactive effects caused by CB1 activation have largely limited the clin. use of cannabinoid-related compds. that act on these receptors.  In this review some recent findings on the antiinflammatory properties of CB2 receptors are presented, as well as new perspectives that have been obtained based on studies of human postmortem brain samples.  In addn., various working hypotheses are also proposed and discussed.  British Journal of Pharmacol. (2008) 153, 277-285; doi:10.1038/sj.bjp.0707505; published online 15 Oct. 2007.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy1sC3kUak-7Vg90H21EOLACvtfcHk0lh8EjoT32p7aQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovFCktg%253D%253D&md5=acc7f2244e1db16d66e5953eadecb381</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0707505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0707505%26sid%3Dliteratum%253Aachs%26aulast%3DBenito%26aufirst%3DC.%26aulast%3DTolon%26aufirst%3DR.%2BM.%26aulast%3DPazos%26aufirst%3DM.%2BR.%26aulast%3DNunez%26aufirst%3DE.%26aulast%3DCastillo%26aufirst%3DA.%2BI.%26aulast%3DRomero%26aufirst%3DJ.%26atitle%3DCannabinoid%2520CB2%2520Receptors%2520in%2520Human%2520Brain%2520Inflammation%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D153%26spage%3D277%26epage%3D285%26doi%3D10.1038%2Fsj.bjp.0707505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eubanks, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beuscher, A. E.,  4th</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koob, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerson, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janda, K. D.</span></span> <span> </span><span class="NLM_article-title">A Molecular Link between the Active Component of Marijuana and Alzheimer’s Disease Pathology</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">773</span>– <span class="NLM_lpage">777</span>, <span class="refDoi"> DOI: 10.1021/mp060066m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp060066m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD28XnvValtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=773-777&author=L.+M.+Eubanksauthor=C.+J.+Rogersauthor=A.+E.+Beuscherauthor=G.+F.+Koobauthor=A.+J.+Olsonauthor=T.+J.+Dickersonauthor=K.+D.+Janda&title=A+Molecular+Link+between+the+Active+Component+of+Marijuana+and+Alzheimer%E2%80%99s+Disease+Pathology&doi=10.1021%2Fmp060066m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">A Molecular Link between the Active Component of Marijuana and Alzheimer's Disease Pathology</span></div><div class="casAuthors">Eubanks, Lisa M.; Rogers, Claude J.; Beuscher, Albert E., IV; Koob, George F.; Olson, Arthur J.; Dickerson, Tobin J.; Janda, Kim D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">773-777</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Alzheimer's disease is the leading cause of dementia among the elderly, and with the ever-increasing size of this population, cases of Alzheimer's disease are expected to triple over the next 50 years.  Consequently, the development of treatments that slow or halt the disease progression have become imperative to both improve the quality of life for patients and reduce the health care costs attributable to Alzheimer's disease.  Here, the authors demonstrate that the active component of marijuana, Δ9-tetrahydrocannabinol (THC), competitively inhibits the enzyme acetylcholinesterase (AChE) as well as prevents AChE-induced amyloid β-peptide (Aβ) aggregation, the key pathol. marker of Alzheimer's disease.  Computational modeling of the THC-AChE interaction revealed that THC binds in the peripheral anionic site of AChE, the crit. region involved in amyloidgenesis.  Compared to currently approved drugs prescribed for the treatment of Alzheimer's disease, THC is a considerably superior inhibitor of Aβ aggregation, and this study provides a previously unrecognized mol. mechanism through which cannabinoid mols. may directly impact the progression of this debilitating disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRJV3cNwOeGbVg90H21EOLACvtfcHk0lj5u6hVsLWoQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnvValtLk%253D&md5=b258fe1fc72a55f890867d97e00277ea</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1021%2Fmp060066m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp060066m%26sid%3Dliteratum%253Aachs%26aulast%3DEubanks%26aufirst%3DL.%2BM.%26aulast%3DRogers%26aufirst%3DC.%2BJ.%26aulast%3DBeuscher%26aufirst%3DA.%2BE.%26aulast%3DKoob%26aufirst%3DG.%2BF.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26aulast%3DDickerson%26aufirst%3DT.%2BJ.%26aulast%3DJanda%26aufirst%3DK.%2BD.%26atitle%3DA%2520Molecular%2520Link%2520between%2520the%2520Active%2520Component%2520of%2520Marijuana%2520and%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Pathology%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2006%26volume%3D3%26spage%3D773%26epage%3D777%26doi%3D10.1021%2Fmp060066m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montanari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahmoud, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pruccoli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabbito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naldi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petralla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moraleda, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iriepa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belluti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobbi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarozzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligresti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampa, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel Benzofuran-Based Compounds with Neuroprotective and Immunomodulatory Properties for Alzheimer’s Disease Treatment</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>178</i></span>,  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">258</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.05.080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2019.05.080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=31185414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFKqs7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2019&pages=243-258&author=S.+Montanariauthor=A.+M.+Mahmoudauthor=L.+Pruccoliauthor=A.+Rabbitoauthor=M.+Naldiauthor=S.+Petrallaauthor=I.+Moraledaauthor=M.+Bartoliniauthor=B.+Montiauthor=I.+Iriepaauthor=F.+Bellutiauthor=S.+Gobbiauthor=V.+Di+Marzoauthor=A.+Bisiauthor=A.+Tarozziauthor=A.+Ligrestiauthor=A.+Rampa&title=Discovery+of+Novel+Benzofuran-Based+Compounds+with+Neuroprotective+and+Immunomodulatory+Properties+for+Alzheimer%E2%80%99s+Disease+Treatment&doi=10.1016%2Fj.ejmech.2019.05.080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel benzofuran-based compounds with neuroprotective and immunomodulatory properties for Alzheimer's disease treatment</span></div><div class="casAuthors">Montanari, Serena; Mahmoud, Ali Mokhtar; Pruccoli, Letizia; Rabbito, Alessandro; Naldi, Marina; Petralla, Sabrina; Moraleda, Ignacio; Bartolini, Manuela; Monti, Barbara; Iriepa, Isabel; Belluti, Federica; Gobbi, Silvia; Di Marzo, Vincenzo; Bisi, Alessandra; Tarozzi, Andrea; Ligresti, Alessia; Rampa, Angela</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">243-258</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">To address the multifactorial nature of Alzheimer's Disease (AD), a multi-target-directed ligand approach was herein developed.  As a follow-up of our previous studies, a small library of newly designed 2-arylbenzofuran derivs. was evaluated towards cholinesterases and cannabinoid receptors.  The two most promising compds., 8(I) and 10(II), were then assessed for their neuroprotective activity and for their ability to modulate the microglial phenotype.  Compd. I emerged as able to fight AD from several directions: it restored the cholinergic system by inhibiting butyrylcholinesterase, showed neuroprotective activity against Aβ1-42 oligomers, was a potent and selective CB2 ligand and had immunomodulatory effects, switching microglia from the pro-inflammatory M1 to the neuroprotective M2 phenotype.  Deriv. II was a potent CB2 inverse agonist with promising immunomodulatory properties and could be considered as a tool for investigating the role of CB2 receptors and for developing potential immunomodulating drugs addressing the endocannabinoid system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjfqkpJQmwA7Vg90H21EOLACvtfcHk0lj5u6hVsLWoQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFKqs7fO&md5=219e8d3d1f59c4cee45397a8ba53a300</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.05.080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.05.080%26sid%3Dliteratum%253Aachs%26aulast%3DMontanari%26aufirst%3DS.%26aulast%3DMahmoud%26aufirst%3DA.%2BM.%26aulast%3DPruccoli%26aufirst%3DL.%26aulast%3DRabbito%26aufirst%3DA.%26aulast%3DNaldi%26aufirst%3DM.%26aulast%3DPetralla%26aufirst%3DS.%26aulast%3DMoraleda%26aufirst%3DI.%26aulast%3DBartolini%26aufirst%3DM.%26aulast%3DMonti%26aufirst%3DB.%26aulast%3DIriepa%26aufirst%3DI.%26aulast%3DBelluti%26aufirst%3DF.%26aulast%3DGobbi%26aufirst%3DS.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DBisi%26aufirst%3DA.%26aulast%3DTarozzi%26aufirst%3DA.%26aulast%3DLigresti%26aufirst%3DA.%26aulast%3DRampa%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520Novel%2520Benzofuran-Based%2520Compounds%2520with%2520Neuroprotective%2520and%2520Immunomodulatory%2520Properties%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Treatment%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D178%26spage%3D243%26epage%3D258%26doi%3D10.1016%2Fj.ejmech.2019.05.080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pagé, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaux, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boisvert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milburn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremblay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomaszewski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walpole, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodzic, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St-Onge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godbout, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salois, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payza, K.</span></span> <span> </span><span class="NLM_article-title">Novel Benzimidazole Derivatives as Selective CB2 Agonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">3695</span>– <span class="NLM_lpage">3700</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.05.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmcl.2008.05.073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=18522867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnt1Ohurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=3695-3700&author=D.+Pag%C3%A9author=E.+Balauxauthor=L.+Boisvertauthor=Z.+Liuauthor=C.+Milburnauthor=M.+Tremblayauthor=Z.+Weiauthor=S.+Wooauthor=X.+Luoauthor=Y.+X.+Chengauthor=H.+Yangauthor=S.+Srivastavaauthor=F.+Zhouauthor=W.+Brownauthor=M.+Tomaszewskiauthor=C.+Walpoleauthor=L.+Hodzicauthor=S.+St-Ongeauthor=C.+Godboutauthor=D.+Saloisauthor=K.+Payza&title=Novel+Benzimidazole+Derivatives+as+Selective+CB2+Agonists&doi=10.1016%2Fj.bmcl.2008.05.073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Novel benzimidazole derivatives as selective CB2 agonists</span></div><div class="casAuthors">Page, Daniel; Balaux, Elise; Boisvert, Luc; Liu, Ziping; Milburn, Claire; Tremblay, Maxime; Wei, Zhongyong; Woo, Simon; Luo, Xuehong; Cheng, Yun-Xing; Yang, Hua; Srivastava, Sanjay; Zhou, Fei; Brown, William; Tomaszewski, Miroslaw; Walpole, Christopher; Hodzic, Leila; St-Onge, Stephane; Godbout, Claude; Salois, Dominic; Payza, Keymal</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3695-3700</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The prepn. and evaluation of a novel class of CB2 agonists based on a benzimidazole moiety, e.g., I, are reported.  They showed binding affinities up to 1 nM towards the CB2 receptor with partial to full agonist potencies.  They also demonstrated good to excellent selectivity (>1000-fold) over the CB1 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbeiXe1I0Yg7Vg90H21EOLACvtfcHk0lj5u6hVsLWoQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnt1Ohurs%253D&md5=fa9e0921054b0d9f26044a1feb82a604</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.05.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.05.073%26sid%3Dliteratum%253Aachs%26aulast%3DPag%25C3%25A9%26aufirst%3DD.%26aulast%3DBalaux%26aufirst%3DE.%26aulast%3DBoisvert%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DMilburn%26aufirst%3DC.%26aulast%3DTremblay%26aufirst%3DM.%26aulast%3DWei%26aufirst%3DZ.%26aulast%3DWoo%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DY.%2BX.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DSrivastava%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DBrown%26aufirst%3DW.%26aulast%3DTomaszewski%26aufirst%3DM.%26aulast%3DWalpole%26aufirst%3DC.%26aulast%3DHodzic%26aufirst%3DL.%26aulast%3DSt-Onge%26aufirst%3DS.%26aulast%3DGodbout%26aufirst%3DC.%26aulast%3DSalois%26aufirst%3DD.%26aulast%3DPayza%26aufirst%3DK.%26atitle%3DNovel%2520Benzimidazole%2520Derivatives%2520as%2520Selective%2520CB2%2520Agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D3695%26epage%3D3700%26doi%3D10.1016%2Fj.bmcl.2008.05.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shogren-Knaak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davie, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, C. L.</span></span> <span> </span><span class="NLM_article-title">Histone H4-K16 Acetylation Controls Chromatin Structure and Protein Interactions</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>311</i></span>,  <span class="NLM_fpage">844</span>– <span class="NLM_lpage">847</span>, <span class="refDoi"> DOI: 10.1126/science.1124000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1126%2Fscience.1124000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=16469925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFylsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=2006&pages=844-847&author=M.+Shogren-Knaakauthor=H.+Ishiiauthor=J.-M.+Sunauthor=M.+J.+Pazinauthor=J.+R.+Davieauthor=C.+L.+Peterson&title=Histone+H4-K16+Acetylation+Controls+Chromatin+Structure+and+Protein+Interactions&doi=10.1126%2Fscience.1124000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Histone H4-K16 Acetylation Controls Chromatin Structure and Protein Interactions</span></div><div class="casAuthors">Shogren-Knaak, Michael; Ishii, Haruhiko; Sun, Jian-Min; Pazin, Michael J.; Davie, James R.; Peterson, Craig L.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue">5762</span>),
    <span class="NLM_cas:pages">844-847</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Acetylation of histone H4 on lysine 16 (H4-K16Ac) is a prevalent and reversible posttranslational chromatin modification in eukaryotes.  To characterize the structural and functional role of this mark, we used a native chem. ligation strategy to generate histone H4 that was homogeneously acetylated at K16.  The incorporation of this modified histone into nucleosomal arrays inhibits the formation of compact 30-nm-like fibers and impedes the ability of chromatin to form cross-fiber interactions.  H4-K16Ac also inhibits the ability of the ATP-utilizing chromatin assembly and remodeling enzyme ACF to mobilize a mononucleosome, indicating that this single histone modification modulates both higher order chromatin structure and functional interactions between a nonhistone protein and the chromatin fiber.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqawsTg7m9LQLVg90H21EOLACvtfcHk0licmDRlkW1gAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFylsLY%253D&md5=c82b2fe14098f9e30a0aba389d11fb67</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1126%2Fscience.1124000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1124000%26sid%3Dliteratum%253Aachs%26aulast%3DShogren-Knaak%26aufirst%3DM.%26aulast%3DIshii%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DJ.-M.%26aulast%3DPazin%26aufirst%3DM.%2BJ.%26aulast%3DDavie%26aufirst%3DJ.%2BR.%26aulast%3DPeterson%26aufirst%3DC.%2BL.%26atitle%3DHistone%2520H4-K16%2520Acetylation%2520Controls%2520Chromatin%2520Structure%2520and%2520Protein%2520Interactions%26jtitle%3DScience%26date%3D2006%26volume%3D311%26spage%3D844%26epage%3D847%26doi%3D10.1126%2Fscience.1124000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denu, J. M.</span></span> <span> </span><span class="NLM_article-title">Chemical Mechanisms of Histone Lysine and Arginine Modifications</span>. <i>Biochim. Biophys. Acta, Gene Regul. Mech.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>1789</i></span>,  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">57</span>, <span class="refDoi"> DOI: 10.1016/j.bbagrm.2008.06.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bbagrm.2008.06.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=18603028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVOis7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1789&publication_year=2009&pages=45-57&author=B.+C.+Smithauthor=J.+M.+Denu&title=Chemical+Mechanisms+of+Histone+Lysine+and+Arginine+Modifications&doi=10.1016%2Fj.bbagrm.2008.06.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical mechanisms of histone lysine and arginine modifications</span></div><div class="casAuthors">Smith, Brian C.; Denu, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Gene Regulatory Mechanisms</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">1789</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">45-57</span>CODEN:
                <span class="NLM_cas:coden">BBAGC6</span>;
        ISSN:<span class="NLM_cas:issn">1874-9399</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Histone Lys and Arg residues are subject to a wide array of post-translational modifications including methylation, citrullination, acetylation, ubiquitination, and sumoylation.  The combinatorial action of these modifications regulates crit. DNA processes including replication, repair, and transcription.  In addn., enzymes that modify histone Lys and Arg residues have been correlated with a variety of human diseases including arthritis, cancer, heart disease, diabetes, and neurodegenerative disorders.  Thus, it is important to fully understand the detailed kinetic and chem. mechanisms of these enzymes.  Here, the authors review recent progress toward detg. the mechanisms of histone Lys and Arg residue-modifying enzymes.  In particular, the mechanisms of S-adenosyl-L-methionine (AdoMet)-dependent methyltransferases, FAD-dependent demethylases, Fe-dependent demethylases, acetyl-CoA-dependent acetyltransferases, Zn-dependent deacetylases, NAD-dependent deacetylases, and protein arginine deiminases are covered.  Particular attention is paid to the conserved active site residues necessary for catalysis and the individual chem. steps along the catalytic pathway.  When appropriate, areas requiring further work are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5GV8HFQEtB7Vg90H21EOLACvtfcHk0licmDRlkW1gAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVOis7bI&md5=23b6c42b92de48d9d45e67561e5fbb34</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagrm.2008.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagrm.2008.06.005%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%2BC.%26aulast%3DDenu%26aufirst%3DJ.%2BM.%26atitle%3DChemical%2520Mechanisms%2520of%2520Histone%2520Lysine%2520and%2520Arginine%2520Modifications%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gene%2520Regul.%2520Mech.%26date%3D2009%26volume%3D1789%26spage%3D45%26epage%3D57%26doi%3D10.1016%2Fj.bbagrm.2008.06.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glozak, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, E.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylases and Cancer</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5420</span>– <span class="NLM_lpage">5432</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1210610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fsj.onc.1210610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=17694083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovFeku7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=5420-5432&author=M.+A.+Glozakauthor=E.+Seto&title=Histone+Deacetylases+and+Cancer&doi=10.1038%2Fsj.onc.1210610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases and cancer</span></div><div class="casAuthors">Glozak, M. A.; Seto, E.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">5420-5432</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) regulate the expression and activity of numerous proteins involved in both cancer initiation and cancer progression.  By removal of acetyl groups from histones, HDACs create a non-permissive chromatin conformation that prevents the transcription of genes that encode proteins involved in tumorigenesis.  In addn. to histones, HDACs bind to and deacetylate a variety of other protein targets including transcription factors and other abundant cellular proteins implicated in control of cell growth, differentiation and apoptosis.  This review provides a comprehensive examn. of the transcriptional and post-translational mechanisms by which HDACs alter the expression and function of cancer-assocd. proteins and examines the general impact of HDAC activity in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9hjug8fWrtbVg90H21EOLACvtfcHk0licmDRlkW1gAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovFeku7Y%253D&md5=b0a389027624e9f3d75b89f1f5d7a072</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210610%26sid%3Dliteratum%253Aachs%26aulast%3DGlozak%26aufirst%3DM.%2BA.%26aulast%3DSeto%26aufirst%3DE.%26atitle%3DHistone%2520Deacetylases%2520and%2520Cancer%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D5420%26epage%3D5432%26doi%3D10.1038%2Fsj.onc.1210610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ropero, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteller, M.</span></span> <span> </span><span class="NLM_article-title">The Role of Histone Deacetylases (HDACs) in Human Cancer</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1016/j.molonc.2007.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.molonc.2007.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=19383284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOitbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2007&pages=19-25&author=S.+Roperoauthor=M.+Esteller&title=The+Role+of+Histone+Deacetylases+%28HDACs%29+in+Human+Cancer&doi=10.1016%2Fj.molonc.2007.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">The role of histone deacetylases (HDACs) in human cancer</span></div><div class="casAuthors">Ropero, Santiago; Esteller, Manel</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-25</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The balance of histone acetylation and deacetylation is an epigenetic layer with a crit. role in the regulation of gene expression.  Histone acetylation induced by histone acetyl transferases (HATs) is assocd. with gene transcription, while histone hypoacetylation induced by histone deacetylase (HDAC) activity is assocd. with gene silencing.  Altered expression and mutations of genes that encode HDACs have been linked to tumor development since they both induce the aberrant transcription of key genes regulating important cellular functions such as cell proliferation, cell-cycle regulation and apoptosis.  Thus, HDACs are among the most promising therapeutic targets for cancer treatment, and they have inspired researchers to study and develop HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvbJD8bqroSLVg90H21EOLACvtfcHk0ljm9vbfgHHwXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOitbnI&md5=d925bcde258dce7d53cbb98563e1f2ae</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2007.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2007.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DRopero%26aufirst%3DS.%26aulast%3DEsteller%26aufirst%3DM.%26atitle%3DThe%2520Role%2520of%2520Histone%2520Deacetylases%2520%2528HDACs%2529%2520in%2520Human%2520Cancer%26jtitle%3DMol.%2520Oncol.%26date%3D2007%26volume%3D1%26spage%3D19%26epage%3D25%26doi%3D10.1016%2Fj.molonc.2007.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, J.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-S.</span></span> <span> </span><span class="NLM_article-title">Targeting Histone Deacetylase in Cancer Therapy</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">413</span>, <span class="refDoi"> DOI: 10.1002/med.20056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1002%2Fmed.20056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=16450343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD28XntFaltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2006&pages=397-413&author=H.-Y.+Linauthor=C.-S.+Chenauthor=S.-P.+Linauthor=J.-R.+Wengauthor=C.-S.+Chen&title=Targeting+Histone+Deacetylase+in+Cancer+Therapy&doi=10.1002%2Fmed.20056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting histone deacetylase in cancer therapy</span></div><div class="casAuthors">Lin, Hsiang-Yu; Chen, Chang-Shi; Lin, Shuan-Pei; Weng, Jing-Ru; Chen, Ching-Shih</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">397-413</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC) is recognized as one of the promising targets for cancer treatment as many HDAC inhibitors have entered clin. trials for both solid and liq. tumors.  Nevertheless, the mechanisms underlying the antiproliferative effects of HDAC inhibitors remain elusive.  Although they have been shown to regulate the transcription of a defined set of genes through chromatin remodeling, increasing evidence suggests that modifications of the epigenetic histone code may not be the primary mechanism for HDAC inhibitor-mediated growth inhibition and apoptosis in cancer cells.  While histones still represent a primary target for the physiol. function of HDACs, the antitumor effect of HDAC inhibitors might also be attributed to transcription-independent mechanisms by modulating the acetylation status of a series of nonhistone targets.  Also noteworthy is the effect of HDAC inhibitors on Akt downregulation through the alteration of protein phosphatase 1 (PP1) complex formation.  To provide an overview of the use of HDAC inhibitors in cancer treatment, this review addresses the following subjects: (1) the physiol. relevance of HDAC-mediated acetylation of histone and nonhistone substrates, (2) the chem. biol. of HDACs and development of a novel class of HDAC inhibitors, and (3) the protein acetylation-independent effect of HDAC inhibitors on the activation status of signaling kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsa6h2NkYnN7Vg90H21EOLACvtfcHk0ljm9vbfgHHwXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntFaltrc%253D&md5=4d663196ac8258cd0e079b47761f3128</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1002%2Fmed.20056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20056%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DH.-Y.%26aulast%3DChen%26aufirst%3DC.-S.%26aulast%3DLin%26aufirst%3DS.-P.%26aulast%3DWeng%26aufirst%3DJ.-R.%26aulast%3DChen%26aufirst%3DC.-S.%26atitle%3DTargeting%2520Histone%2520Deacetylase%2520in%2520Cancer%2520Therapy%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2006%26volume%3D26%26spage%3D397%26epage%3D413%26doi%3D10.1002%2Fmed.20056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fraguas-Sánchez, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martín-Sabroso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Suárez, A. I.</span></span> <span> </span><span class="NLM_article-title">Insights into the Effects of the Endocannabinoid System in Cancer: A Review</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">2566</span>– <span class="NLM_lpage">2580</span>, <span class="refDoi"> DOI: 10.1111/bph.14331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1111%2Fbph.14331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=29663308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpvFWmtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2018&pages=2566-2580&author=A.+I.+Fraguas-S%C3%A1nchezauthor=C.+Mart%C3%ADn-Sabrosoauthor=A.+I.+Torres-Su%C3%A1rez&title=Insights+into+the+Effects+of+the+Endocannabinoid+System+in+Cancer%3A+A+Review&doi=10.1111%2Fbph.14331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into the effects of the endocannabinoid system in cancer: a review</span></div><div class="casAuthors">Fraguas-Sanchez, Ana Isabel; Martin-Sabroso, Cristina; Torres-Suarez, Ana Isabel</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2566-2580</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">In the last few decades, the endocannabinoid system has attracted a great deal of interest in terms of its applications to clin. medicine.  In particular, its applications in cancer probably represent one of the therapeutic areas with most promise.  On the one hand, expression of the endocannabinoid system is altered in numerous types of tumors, compared to healthy tissue, and this aberrant expression has been related to cancer prognosis and disease outcome, suggesting a role of this system in tumor growth and progression that depends on cancer type.  On the other hand, cannabinoids exert an anticancer activity by inhibiting the proliferation, migration and/or invasion of cancer cells and also tumor angiogenesis.  However, some cannabinoids, at lower concns., may increase tumor proliferation, inducing cancer growth.  Enough data has been provided to consider the endocannabinoid system as a new therapeutic target in cancer, although further studies to fully establish the effect of cannabinoids on tumor progression are still needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSvh3gVbdbdbVg90H21EOLACvtfcHk0ljm9vbfgHHwXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpvFWmtbc%253D&md5=63a3df5832ceac97e667b32c997b6457</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1111%2Fbph.14331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.14331%26sid%3Dliteratum%253Aachs%26aulast%3DFraguas-S%25C3%25A1nchez%26aufirst%3DA.%2BI.%26aulast%3DMart%25C3%25ADn-Sabroso%26aufirst%3DC.%26aulast%3DTorres-Su%25C3%25A1rez%26aufirst%3DA.%2BI.%26atitle%3DInsights%2520into%2520the%2520Effects%2520of%2520the%2520Endocannabinoid%2520System%2520in%2520Cancer%253A%2520A%2520Review%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2018%26volume%3D175%26spage%3D2566%26epage%3D2580%26doi%3D10.1111%2Fbph.14331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, E.</span></span> <span> </span><span class="NLM_article-title">HDACs and HDAC Inhibitors in Cancer Development and Therapy</span>. <i>Cold Spring Harbor Perspect. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">a026831</span> <span class="refDoi"> DOI: 10.1101/cshperspect.a026831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1101%2Fcshperspect.a026831" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=27599530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpslCitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&author=Y.+Liauthor=E.+Seto&title=HDACs+and+HDAC+Inhibitors+in+Cancer+Development+and+Therapy&doi=10.1101%2Fcshperspect.a026831"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">HDACs and HDAC inhibitors in cancer development and therapy</span></div><div class="casAuthors">Li, Yixuan; Seto, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Cold Spring Harbor Perspectives in Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">a026831/1-a026831/35</span>CODEN:
                <span class="NLM_cas:coden">CSHPFV</span>;
        ISSN:<span class="NLM_cas:issn">2157-1422</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Over the last several decades, it has become clear that epigenetic abnormalities may be one of the hallmarks of cancer.  Posttranslational modifications of histones, for example, may play a crucial role in cancer development and progression by modulating gene transcription, chromatin remodeling, and nuclear architecture.  Histone acetylation, a well-studied posttranslational histone modification, is controlled by the opposing activities of histone acetyltransferases (HATs) and histone deacetylases (HDACs).  By removing acetyl groups, HDACs reverse chromatin acetylation and alter transcription of oncogenes and tumor suppressor genes.  In addn.,HDACs deacetylate numerous nonhistone cellular substrates that govern a wide array of biol. processes including cancer initiation and progression.  This review will discuss the role of HDACs in cancer and the therapeutic potential of HDAC inhibitors (HDACi) as emerging drugs in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnRL0Y7L3_s7Vg90H21EOLACvtfcHk0lh6Mz1uVZomeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpslCitb4%253D&md5=1c647aa38027de1c4c92f74340d9041a</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a026831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a026831%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DSeto%26aufirst%3DE.%26atitle%3DHDACs%2520and%2520HDAC%2520Inhibitors%2520in%2520Cancer%2520Development%2520and%2520Therapy%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2016%26volume%3D6%26doi%3D10.1101%2Fcshperspect.a026831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chevallier, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corcoran, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lennon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyjek, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chadburn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardwell, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Licht, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnick, A.</span></span> <span> </span><span class="NLM_article-title">ETO Protein of t(8;21) AML Is a Corepressor for Bcl-6 B-Cell Lymphoma Oncoprotein</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">1454</span>– <span class="NLM_lpage">1463</span>, <span class="refDoi"> DOI: 10.1182/blood-2003-06-2081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1182%2Fblood-2003-06-2081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=14551142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsVSlurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2004&pages=1454-1463&author=N.+Chevallierauthor=C.+M.+Corcoranauthor=C.+Lennonauthor=E.+Hyjekauthor=A.+Chadburnauthor=V.+J.+Bardwellauthor=J.+D.+Lichtauthor=A.+Melnick&title=ETO+Protein+of+t%288%3B21%29+AML+Is+a+Corepressor+for+Bcl-6+B-Cell+Lymphoma+Oncoprotein&doi=10.1182%2Fblood-2003-06-2081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein</span></div><div class="casAuthors">Chevallier, Nathalie; Corcoran, Connie M.; Lennon, Christine; Hyjek, Elizabeth; Chadburn, Amy; Bardwell, Vivian J.; Licht, Jonathan D.; Melnick, Ari</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1454-1463</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The multiplicity of transcription factors involved in hematol. malignancies suggests a complicated scenarlo in which many different mol. mechanisms lead to malignant transformation.  We hypothesized that some of these proteins might phys. and functionally interact and thus mechanistically link different diseases.  The ETO protein of t(8;21) acute myeloid leukemia (AML) is an excellent candidate as a common factor because it is normally expressed in human hematopoietic cells.  ETO protein binds to histone deacetylases (HDACs), and it interacts with the PLZF protein of t(11;17) acute promyelocytic leukemia.  To det. whether ETO functionally links a broader range of disease entities, we asked whether ETO forms a complex with the Bcl-6 oncoprotein of B-cell lymphomas.  We found that ETO and Bcl-6 are coexpressed in normal and malignant lymphoid tissue, where they interact and colocalize in nuclear speckles.  ETO binds to the fourth zinc finger of Bcl-6, enhances Bcl-6 repression of artificial and endogenous genes in an HDAC-dependent manner, and forms a complex with Bcl-6 on the promoters of its endogenous target genes in B-cell lymphoma cells.  Therefore, ETO is a bona fide corepressor that links the transcriptional pathogenesis of acute leukemias and B-cell lymphomas and offers a compelling target for transcriptional therapy of hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSkIWlWU_0k7Vg90H21EOLACvtfcHk0lh6Mz1uVZomeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsVSlurs%253D&md5=cdc678f69ae029e21b46d5e1438bc2c9</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1182%2Fblood-2003-06-2081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2003-06-2081%26sid%3Dliteratum%253Aachs%26aulast%3DChevallier%26aufirst%3DN.%26aulast%3DCorcoran%26aufirst%3DC.%2BM.%26aulast%3DLennon%26aufirst%3DC.%26aulast%3DHyjek%26aufirst%3DE.%26aulast%3DChadburn%26aufirst%3DA.%26aulast%3DBardwell%26aufirst%3DV.%2BJ.%26aulast%3DLicht%26aufirst%3DJ.%2BD.%26aulast%3DMelnick%26aufirst%3DA.%26atitle%3DETO%2520Protein%2520of%2520t%25288%253B21%2529%2520AML%2520Is%2520a%2520Corepressor%2520for%2520Bcl-6%2520B-Cell%2520Lymphoma%2520Oncoprotein%26jtitle%3DBlood%26date%3D2004%26volume%3D103%26spage%3D1454%26epage%3D1463%26doi%3D10.1182%2Fblood-2003-06-2081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laban, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. H.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salto-Tellez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raju, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooi, S. C.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Histone Deacetylase 2 Increases Apoptosis and P21Cip1/WAF1 Expression, Independent of Histone Deacetylase 1</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">395</span>– <span class="NLM_lpage">404</span>, <span class="refDoi"> DOI: 10.1038/sj.cdd.4401567</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fsj.cdd.4401567" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=15665816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitlCmsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2005&pages=395-404&author=B.+H.+Huangauthor=M.+Labanauthor=C.+H.-W.+Leungauthor=L.+Leeauthor=C.+K.+Leeauthor=M.+Salto-Tellezauthor=G.+C.+Rajuauthor=S.+C.+Hooi&title=Inhibition+of+Histone+Deacetylase+2+Increases+Apoptosis+and+P21Cip1%2FWAF1+Expression%2C+Independent+of+Histone+Deacetylase+1&doi=10.1038%2Fsj.cdd.4401567"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1</span></div><div class="casAuthors">Huang, B. H.; Laban, M.; Leung, C. H-W.; Lee, L.; Lee, C. K.; Salto-Tellez, M.; Raju, G. C.; Hooi, S. C.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death and Differentiation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">395-404</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) 1 and 2 share a high degree of homol. and coexist within the same protein complexes.  Despite their close assocn., each possesses unique functions.  We show that the upregulation of HDAC2 in colorectal cancer occurred early at the polyp stage, was more robust and occurred more frequently than HDAC1.  Similarly, while the expression of HDACs1 and 2 were increased in cervical dysplasia and invasive carcinoma, HDAC2 expression showed a clear demarcation of high-intensity staining at the transition region of dysplasia compared to HDAC1.  Upon HDAC2 knockdown, cells displayed an increased no. of cellular extensions reminiscent of cell differentiation.  There was also an increase in apoptosis, assocd. with increased p21Cip1/WAF1 expression that was independent of p53.  These results suggest that HDACs, esp. HDAC2, are important enzymes involved in the early events of carcinogenesis, making them candidate markers for tumor progression and targets for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGQVm9MySU7LVg90H21EOLACvtfcHk0lh6Mz1uVZomeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitlCmsLs%253D&md5=4fd824f68deea245e6b7dbcbe087b8d0</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1038%2Fsj.cdd.4401567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.cdd.4401567%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DB.%2BH.%26aulast%3DLaban%26aufirst%3DM.%26aulast%3DLeung%26aufirst%3DC.%2BH.-W.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLee%26aufirst%3DC.%2BK.%26aulast%3DSalto-Tellez%26aufirst%3DM.%26aulast%3DRaju%26aufirst%3DG.%2BC.%26aulast%3DHooi%26aufirst%3DS.%2BC.%26atitle%3DInhibition%2520of%2520Histone%2520Deacetylase%25202%2520Increases%2520Apoptosis%2520and%2520P21Cip1%252FWAF1%2520Expression%252C%2520Independent%2520of%2520Histone%2520Deacetylase%25201%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2005%26volume%3D12%26spage%3D395%26epage%3D404%26doi%3D10.1038%2Fsj.cdd.4401567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suraweera, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Byrne, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richard, D. J.</span></span> <span> </span><span class="NLM_article-title">Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">92</span>, <span class="refDoi"> DOI: 10.3389/fonc.2018.00092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3389%2Ffonc.2018.00092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=29651407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BC1MjitlSksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=92&author=A.+Suraweeraauthor=K.+J.+O%E2%80%99Byrneauthor=D.+J.+Richard&title=Combination+Therapy+With+Histone+Deacetylase+Inhibitors+%28HDACi%29+for+the+Treatment+of+Cancer%3A+Achieving+the+Full+Therapeutic+Potential+of+HDACi&doi=10.3389%2Ffonc.2018.00092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi</span></div><div class="casAuthors">Suraweera Amila; O'Byrne Kenneth J; Richard Derek J; O'Byrne Kenneth J</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">92</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Genetic and epigenetic changes in DNA are involved in cancer development and tumor progression.  Histone deacetylases (HDACs) are key regulators of gene expression that act as transcriptional repressors by removing acetyl groups from histones.  HDACs are dysregulated in many cancers, making them a therapeutic target for the treatment of cancer.  Histone deacetylase inhibitors (HDACi), a novel class of small-molecular therapeutics, are now approved by the Food and Drug Administration as anticancer agents.  While they have shown great promise, resistance to HDACi is often observed and furthermore, HDACi have shown limited success in treating solid tumors.  The combination of HDACi with standard chemotherapeutic drugs has demonstrated promising anticancer effects in both preclinical and clinical studies.  In this review, we summarize the research thus far on HDACi in combination therapy, with other anticancer agents and their translation into preclinical and clinical studies.  We additionally highlight the side effects associated with HDACi in cancer therapy and discuss potential biomarkers to either select or predict a patient's response to these agents, in order to limit the off-target toxicity associated with HDACi.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTprF0Hdrz8rZZoeNcnHOQ9fW6udTcc2ebL1G_21K5KYbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjitlSksA%253D%253D&md5=2f0ace7215bc7519c23cad264f73693d</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2018.00092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2018.00092%26sid%3Dliteratum%253Aachs%26aulast%3DSuraweera%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%2BJ.%26aulast%3DRichard%26aufirst%3DD.%2BJ.%26atitle%3DCombination%2520Therapy%2520With%2520Histone%2520Deacetylase%2520Inhibitors%2520%2528HDACi%2529%2520for%2520the%2520Treatment%2520of%2520Cancer%253A%2520Achieving%2520the%2520Full%2520Therapeutic%2520Potential%2520of%2520HDACi%26jtitle%3DFront.%2520Oncol.%26date%3D2018%26volume%3D8%26spage%3D92%26doi%3D10.3389%2Ffonc.2018.00092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eckschlager, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiborova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrabeta, J.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitors as Anticancer Drugs</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1414</span>, <span class="refDoi"> DOI: 10.3390/ijms18071414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3390%2Fijms18071414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=28671573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVGgt73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1414&author=T.+Eckschlagerauthor=J.+Plchauthor=M.+Stiborovaauthor=J.+Hrabeta&title=Histone+Deacetylase+Inhibitors+as+Anticancer+Drugs&doi=10.3390%2Fijms18071414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors as anticancer drugs</span></div><div class="casAuthors">Eckschlager, Tomas; Plch, Johana; Stiborova, Marie; Hrabeta, Jan</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1414/1-1414/25</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Carcinogenesis cannot be explained only by genetic alterations, but also involves epigenetic processes.  Modification of histones by acetylation plays a key role in epigenetic regulation of gene expression and is controlled by the balance between histone deacetylases (HDAC) and histone acetyltransferases (HAT).  HDAC inhibitors induce cancer cell cycle arrest, differentiation and cell death, reduce angiogenesis and modulate immune response.  Mechanisms of anticancer effects of HDAC inhibitors are not uniform; they may be different and depend on the cancer type, HDAC inhibitors, doses, etc.  HDAC inhibitors seem to be promising anti-cancer drugs particularly in the combination with other anti-cancer drugs and/or radiotherapy.  HDAC inhibitors vorinostat, romidepsin and belinostat have been approved for some T-cell lymphoma and panobinostat for multiple myeloma.  Other HDAC inhibitors are in clin. trials for the treatment of hematol. and solid malignancies.  The results of such studies are promising but further larger studies are needed.  Because of the reversibility of epigenetic changes during cancer development, the potency of epigenetic therapies seems to be of great importance.  Here, we summarize the data on different classes of HDAC inhibitors, mechanisms of their actions and discuss novel results of preclin. and clin. studies, including the combination with other therapeutic modalities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPNVhoLBAHnrVg90H21EOLACvtfcHk0lgbmMKAL1TnMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVGgt73P&md5=6018c7709a09548214bfe34bd91107a9</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.3390%2Fijms18071414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18071414%26sid%3Dliteratum%253Aachs%26aulast%3DEckschlager%26aufirst%3DT.%26aulast%3DPlch%26aufirst%3DJ.%26aulast%3DStiborova%26aufirst%3DM.%26aulast%3DHrabeta%26aufirst%3DJ.%26atitle%3DHistone%2520Deacetylase%2520Inhibitors%2520as%2520Anticancer%2520Drugs%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D1414%26doi%3D10.3390%2Fijms18071414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chipoy, C.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitors: New Drugs for the Treatment of Inflammatory Diseases?</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">204</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(04)03309-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2FS1359-6446%2804%2903309-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=15708534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlajsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=197-204&author=F.+Blanchardauthor=C.+Chipoy&title=Histone+Deacetylase+Inhibitors%3A+New+Drugs+for+the+Treatment+of+Inflammatory+Diseases%3F&doi=10.1016%2FS1359-6446%2804%2903309-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?</span></div><div class="casAuthors">Blanchard, Frederic; Chipoy, Celine</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">197-204</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC) inhibitors induce cell cycle arrest and differentiation in cancer cells and have been in Phase I-II clin. trials for the treatment of various solid or haematol. malignancies.  In recent years, HDAC inhibitors have emerged as potent contenders for anti-inflammatory drugs, offering new lines of therapeutic intervention for rheumatoid arthritis or lupus erythematosus.  The mol. mode of action of HDAC inhibitors is still controversial but seems to rely on reduced inflammatory mediator prodn., such as nitric oxide or cytokines, which implies inhibition of the transcription factor NF-κB.  These anti-inflammatory effects will hopefully lead us to appreciate the complex anti-tumor effects of HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvgwCeeoZzgrVg90H21EOLACvtfcHk0lgbmMKAL1TnMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlajsbY%253D&md5=ce9832fdf76caab29c7017fccccefade</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903309-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903309-4%26sid%3Dliteratum%253Aachs%26aulast%3DBlanchard%26aufirst%3DF.%26aulast%3DChipoy%26aufirst%3DC.%26atitle%3DHistone%2520Deacetylase%2520Inhibitors%253A%2520New%2520Drugs%2520for%2520the%2520Treatment%2520of%2520Inflammatory%2520Diseases%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2005%26volume%3D10%26spage%3D197%26epage%3D204%26doi%3D10.1016%2FS1359-6446%2804%2903309-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dekker, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Bosch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N. I.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Inhibitors of Histone Acetyltransferases and Deacetylases Are Potential Drugs for Inflammatory Diseases</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">654</span>– <span class="NLM_lpage">660</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2013.11.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.drudis.2013.11.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=24269836" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitVWjsrrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=654-660&author=F.+J.+Dekkerauthor=T.+van+den+Boschauthor=N.+I.+Martin&title=Small+Molecule+Inhibitors+of+Histone+Acetyltransferases+and+Deacetylases+Are+Potential+Drugs+for+Inflammatory+Diseases&doi=10.1016%2Fj.drudis.2013.11.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule inhibitors of histone acetyltransferases and deacetylases are potential drugs for inflammatory diseases</span></div><div class="casAuthors">Dekker, Frank J.; van den Bosch, Thea; Martin, Nathaniel I.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">654-660</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Lysine acetylation is a reversible post-translational modification (PTM) of cellular proteins and represents an important regulatory switch in signal transduction.  Lysine acetylation, in combination with other PTMs, directs the outcomes as well as the activation levels of important signal transduction pathways such as the nuclear factor (NF)-κB pathway.  Small mol. modulators of the 'writers' (HATs) and 'erasers' (HDACs) can regulate the NF-κB pathway in a specific manner.  This review focuses on the effects of frequently used HAT and HDAC inhibitors on the NF-κB signal transduction pathway and inflammatory responses, and their potential as novel therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmVBCrhkoMsLVg90H21EOLACvtfcHk0lgbmMKAL1TnMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitVWjsrrE&md5=d7d5eb5f350daa449cefd865433d4263</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.11.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.11.012%26sid%3Dliteratum%253Aachs%26aulast%3DDekker%26aufirst%3DF.%2BJ.%26aulast%3Dvan%2Bden%2BBosch%26aufirst%3DT.%26aulast%3DMartin%26aufirst%3DN.%2BI.%26atitle%3DSmall%2520Molecule%2520Inhibitors%2520of%2520Histone%2520Acetyltransferases%2520and%2520Deacetylases%2520Are%2520Potential%2520Drugs%2520for%2520Inflammatory%2520Diseases%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D654%26epage%3D660%26doi%3D10.1016%2Fj.drudis.2013.11.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Falkenberg, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylases and Their Inhibitors in Cancer, Neurological Diseases and Immune Disorders</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">673</span>– <span class="NLM_lpage">691</span>, <span class="refDoi"> DOI: 10.1038/nrd4360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fnrd4360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=25131830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlKrtLjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=673-691&author=K.+J.+Falkenbergauthor=R.+W.+Johnstone&title=Histone+Deacetylases+and+Their+Inhibitors+in+Cancer%2C+Neurological+Diseases+and+Immune+Disorders&doi=10.1038%2Fnrd4360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders</span></div><div class="casAuthors">Falkenberg, Katrina J.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">673-691</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Epigenetic aberrations, which are recognized as key drivers of several human diseases, are often caused by genetic defects that result in functional deregulation of epigenetic proteins, their altered expression and/or their atypical recruitment to certain gene promoters.  Importantly, epigenetic changes are reversible, and epigenetic enzymes and regulatory proteins can be targeted using small mols.  This Review discusses the role of altered expression and/or function of one class of epigenetic regulators - histone deacetylases (HDACs) - and their role in cancer, neurol. diseases and immune disorders.  We highlight the development of small-mol. HDAC inhibitors and their use in the lab., in preclin. models and in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXiWEG49LhebVg90H21EOLACvtfcHk0lhk-BVK_ZUX4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlKrtLjI&md5=ccfb68fa3fd4685e2305cdf8a6a9c81a</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1038%2Fnrd4360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4360%26sid%3Dliteratum%253Aachs%26aulast%3DFalkenberg%26aufirst%3DK.%2BJ.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DHistone%2520Deacetylases%2520and%2520Their%2520Inhibitors%2520in%2520Cancer%252C%2520Neurological%2520Diseases%2520and%2520Immune%2520Disorders%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D673%26epage%3D691%26doi%3D10.1038%2Fnrd4360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halili, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweet, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlie, D. P.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitors in Inflammatory Disease</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">319</span>, <span class="refDoi"> DOI: 10.2174/156802609788085250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.2174%2F156802609788085250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=19355993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntVCitrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=309-319&author=M.+A.+Haliliauthor=M.+R.+Andrewsauthor=M.+J.+Sweetauthor=D.+P.+Fairlie&title=Histone+Deacetylase+Inhibitors+in+Inflammatory+Disease&doi=10.2174%2F156802609788085250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors in inflammatory disease</span></div><div class="casAuthors">Halili, Maria A.; Andrews, Melanie R.; Sweet, Matthew J.; Fairlie, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">309-319</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Lysine acetylation is becoming increasingly appreciated as a key post-translational modification in the endogenous regulation of protein function.  The so-called histone acetyl transferases (HATs) and histone deacetylases (HDACs), best known for their roles in controlling chromatin remodeling via histone acetylation/deacetylation, are now known to modify a large no. of non-histone proteins to control diverse cell processes.  In relation to inflammation, acetylation modulates the activity or function of cytokine receptors, nuclear hormone receptors, intracellular signaling mols. and transcription factors.  Small mol. inhibitors of HDACs have been found to trigger both pro- and anti-inflammatory effects in a range of inflammation-relevant cell types.  Although their inflammatory profiles have only just begun to be elucidated, some HDAC inhibitors are already showing therapeutic promise in animal models of inflammatory diseases such as arthritis, inflammatory bowel diseases, septic shock, ischemia-reperfusion injury, airways inflammation and asthma, diabetes, age-related macular degeneration, cardiovascular diseases, multiple sclerosis and other CNS and neurodegenerative diseases.  This article describes those HDAC inhibitors which have been most examd. to date for their potentially beneficial effects on inflammatory cells or in animal models of inflammatory disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq22X2Keerbb7Vg90H21EOLACvtfcHk0lhk-BVK_ZUX4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntVCitrk%253D&md5=bb262a2ff3ddd73a89a1f865619b5daa</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.2174%2F156802609788085250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802609788085250%26sid%3Dliteratum%253Aachs%26aulast%3DHalili%26aufirst%3DM.%2BA.%26aulast%3DAndrews%26aufirst%3DM.%2BR.%26aulast%3DSweet%26aufirst%3DM.%2BJ.%26aulast%3DFairlie%26aufirst%3DD.%2BP.%26atitle%3DHistone%2520Deacetylase%2520Inhibitors%2520in%2520Inflammatory%2520Disease%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D309%26epage%3D319%26doi%3D10.2174%2F156802609788085250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shakespear, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halili, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irvine, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlie, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweet, M. J.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylases as Regulators of Inflammation and Immunity</span>. <i>Trends Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">335</span>– <span class="NLM_lpage">343</span>, <span class="refDoi"> DOI: 10.1016/j.it.2011.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.it.2011.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=21570914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFagt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2011&pages=335-343&author=M.+R.+Shakespearauthor=M.+A.+Haliliauthor=K.+M.+Irvineauthor=D.+P.+Fairlieauthor=M.+J.+Sweet&title=Histone+Deacetylases+as+Regulators+of+Inflammation+and+Immunity&doi=10.1016%2Fj.it.2011.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases as regulators of inflammation and immunity</span></div><div class="casAuthors">Shakespear, Melanie R.; Halili, Maria A.; Irvine, Katharine M.; Fairlie, David P.; Sweet, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">335-343</span>CODEN:
                <span class="NLM_cas:coden">TIRMAE</span>;
        ISSN:<span class="NLM_cas:issn">1471-4906</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) remove an acetyl group from lysine residues of target proteins to regulate cellular processes.  Small-mol. inhibitors of HDACs cause cellular growth arrest, differentiation and/or apoptosis, and some are used clin. as anticancer drugs.  In animal models, HDAC inhibitors are therapeutic for several inflammatory diseases, but exacerbate atherosclerosis and compromise host defense.  Loss of HDAC function has also been linked to chronic lung diseases in humans.  These contrasting effects might reflect distinct roles for individual HDACs in immune responses.  Here, we review the current understanding of innate and adaptive immune pathways that are regulated by classical HDAC enzymes.  The objective is to provide a rationale for targeting (or not targeting) individual HDAC enzymes with inhibitors for future immune-related applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMfUdRVPPTGrVg90H21EOLACvtfcHk0ljdHPjocTu42w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFagt7s%253D&md5=b99eac5fe3487afc612c501162a51fca</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1016%2Fj.it.2011.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.it.2011.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DShakespear%26aufirst%3DM.%2BR.%26aulast%3DHalili%26aufirst%3DM.%2BA.%26aulast%3DIrvine%26aufirst%3DK.%2BM.%26aulast%3DFairlie%26aufirst%3DD.%2BP.%26aulast%3DSweet%26aufirst%3DM.%2BJ.%26atitle%3DHistone%2520Deacetylases%2520as%2520Regulators%2520of%2520Inflammation%2520and%2520Immunity%26jtitle%3DTrends%2520Immunol.%26date%3D2011%26volume%3D32%26spage%3D335%26epage%3D343%26doi%3D10.1016%2Fj.it.2011.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shuttleworth, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, P. A.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitors: New Promise in the Treatment of Immune and Inflammatory Diseases</span>. <i>Curr. Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1430</span>– <span class="NLM_lpage">1438</span>, <span class="refDoi"> DOI: 10.2174/1389450111009011430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.2174%2F1389450111009011430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=20583972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVKksbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=1430-1438&author=S.+J.+Shuttleworthauthor=S.+G.+Baileyauthor=P.+A.+Townsend&title=Histone+Deacetylase+Inhibitors%3A+New+Promise+in+the+Treatment+of+Immune+and+Inflammatory+Diseases&doi=10.2174%2F1389450111009011430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases</span></div><div class="casAuthors">Shuttleworth, Stephen J.; Bailey, Sarah G.; Townsend, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1430-1438</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The development of Histone Deacetylase (HDAC) inhibitors has, until recently, principally been driven by their potential as anti-cancer agents.  However, there is emerging evidence that HDAC inhibitors could have utility in the treatment of chronic immune and inflammatory disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, airway hyperresponsiveness and organ transplant rejection.  Here we discuss the merits of various, structurally-distinct HDAC inhibitors as potential anti-inflammatory therapeutics and provide examples of the novel medicinal chem. approaches being undertaken to realize HDAC as a druggable target in this clin. setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9OetaQ7b8irVg90H21EOLACvtfcHk0ljdHPjocTu42w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVKksbrI&md5=1ac2b5811d59702fea79ffeca1793825</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.2174%2F1389450111009011430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389450111009011430%26sid%3Dliteratum%253Aachs%26aulast%3DShuttleworth%26aufirst%3DS.%2BJ.%26aulast%3DBailey%26aufirst%3DS.%2BG.%26aulast%3DTownsend%26aufirst%3DP.%2BA.%26atitle%3DHistone%2520Deacetylase%2520Inhibitors%253A%2520New%2520Promise%2520in%2520the%2520Treatment%2520of%2520Immune%2520and%2520Inflammatory%2520Diseases%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2010%26volume%3D11%26spage%3D1430%26epage%3D1438%26doi%3D10.2174%2F1389450111009011430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sweet, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespear, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamal, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlie, D. P.</span></span> <span> </span><span class="NLM_article-title">HDAC Inhibitors: Modulating Leukocyte Differentiation, Survival, Proliferation and Inflammation</span>. <i>Immunol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">14</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1038/icb.2011.88</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Ficb.2011.88" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=22024621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC38Xkslyksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2012&pages=14-22&author=M.+J.+Sweetauthor=M.+R.+Shakespearauthor=N.+A.+Kamalauthor=D.+P.+Fairlie&title=HDAC+Inhibitors%3A+Modulating+Leukocyte+Differentiation%2C+Survival%2C+Proliferation+and+Inflammation&doi=10.1038%2Ficb.2011.88"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation</span></div><div class="casAuthors">Sweet, Matthew J.; Shakespear, Melanie R.; Kamal, Nabilah A.; Fairlie, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Immunology & Cell Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14-22</span>CODEN:
                <span class="NLM_cas:coden">ICBIEZ</span>;
        ISSN:<span class="NLM_cas:issn">0818-9641</span>.
    
            (<span class="NLM_cas:orgname">NPG Nature Asia-Pacific</span>)
        </div><div class="casAbstract">A review.  Therapeutic effects of histone deacetylase (HDAC) inhibitors in cancer models were first linked to their ability to cause growth arrest and apoptosis of tumor cells.  It is now clear that these agents also have pleiotropic effects on angiogenesis and the immune system, and some of these properties are likely to contribute to their anti-cancer activities.  It is also emerging that inhibitors of specific HDACs affect the differentiation, survival and/or proliferation of distinct immune cell populations.  This is true for innate immune cells such as macrophages, as well as cells of the acquired immune system, for example, T-regulatory cells.  These effects may contribute to therapeutic profiles in some autoimmune and chronic inflammatory disease models.  Here, we review our current understanding of how classical HDACs (HDACs 1-11) and their inhibitors impact on differentiation, survival and proliferation of distinct leukocyte populations, as well as the likely relevance of these effects to autoimmune and inflammatory disease processes.  The ability of HDAC inhibitors to modulate leukocyte survival may have implications for the rationale of developing selective inhibitors as anti-inflammatory drugs.  Immunol. and Cell Biol. (2012) 90, 14-22; doi:10.1038/icb.2011.88; published online 25 Oct. 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVvbidL66w8bVg90H21EOLACvtfcHk0ljdHPjocTu42w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xkslyksw%253D%253D&md5=32329cded6ac66de08c81342b2551ca3</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1038%2Ficb.2011.88&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Ficb.2011.88%26sid%3Dliteratum%253Aachs%26aulast%3DSweet%26aufirst%3DM.%2BJ.%26aulast%3DShakespear%26aufirst%3DM.%2BR.%26aulast%3DKamal%26aufirst%3DN.%2BA.%26aulast%3DFairlie%26aufirst%3DD.%2BP.%26atitle%3DHDAC%2520Inhibitors%253A%2520Modulating%2520Leukocyte%2520Differentiation%252C%2520Survival%252C%2520Proliferation%2520and%2520Inflammation%26jtitle%3DImmunol.%2520Cell%2520Biol.%26date%3D2012%26volume%3D90%26spage%3D14%26epage%3D22%26doi%3D10.1038%2Ficb.2011.88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurkoff, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyeth, B. G.</span></span> <span> </span><span class="NLM_article-title">HDAC Inhibitor Increases Histone H3 Acetylation and Reduces Microglia Inflammatory Response Following Traumatic Brain Injury in Rats</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1226</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1016/j.brainres.2008.05.085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.brainres.2008.05.085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=18582446" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpvFGmtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1226&publication_year=2008&pages=181-191&author=B.+Zhangauthor=E.+J.+Westauthor=K.+C.+Vanauthor=G.+G.+Gurkoffauthor=J.+Zhouauthor=X.-M.+Zhangauthor=A.+P.+Kozikowskiauthor=B.+G.+Lyeth&title=HDAC+Inhibitor+Increases+Histone+H3+Acetylation+and+Reduces+Microglia+Inflammatory+Response+Following+Traumatic+Brain+Injury+in+Rats&doi=10.1016%2Fj.brainres.2008.05.085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in rats</span></div><div class="casAuthors">Zhang, Bin; West, Eric J.; Van, Ken C.; Gurkoff, Gene G.; Zhou, Jia; Zhang, Xiu-Mei; Kozikowski, Alan P.; Lyeth, Bruce G.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">1226</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">181-191</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Traumatic brain injury (TBI) produces a rapid and robust inflammatory response in the brain characterized in part by activation of microglia.  A novel histone deacetylase (HDAC) inhibitor, 4-dimethylamino-N-[5-(2-mercaptoacetylamino)pentyl]benzamide (DMA-PB), was administered (0, 0.25, 2.5, 25 mg/kg) systemically immediately after lateral fluid percussion TBI in rats.  Hippocampal CA2/3 tissue was processed for acetyl-histone H3 immunolocalization, OX-42 immunolocalization (for microglia), and Fluoro-Jade B histofluorescence (for degenerating neurons) at 24 h after injury.  Vehicle-treated TBI rats exhibited a significant redn. in acetyl-histone H3 immunostaining in the ipsilateral CA2/3 hippocampus compared to the sham TBI group (p < 0.05).  The redn. in acetyl-histone H3 immunostaining was attenuated by each of the DMA-PB dosage treatment groups.  Vehicle-treated TBI rats exhibited a high d. of phagocytic microglia in the ipsilateral CA2/3 hippocampus compared to sham TBI in which none were obsd.  All doses of DMA-PB significantly reduced the d. of phagocytic microglia (p < 0.05).  There was a trend for DMA-PB to reduce the no. of degenerating neurons in the ipsilateral CA2/3 hippocampus (p = 0.076).  We conclude that the HDAC inhibitor DMA-PB is a potential novel therapeutic for inhibiting neuroinflammation assocd. with TBI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-KbF3LWteNbVg90H21EOLACvtfcHk0lh5ip8qnb4IpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpvFGmtr0%253D&md5=7467685a308c64c9d9e4b44cd4c88331</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2008.05.085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2008.05.085%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DWest%26aufirst%3DE.%2BJ.%26aulast%3DVan%26aufirst%3DK.%2BC.%26aulast%3DGurkoff%26aufirst%3DG.%2BG.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DX.-M.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DLyeth%26aufirst%3DB.%2BG.%26atitle%3DHDAC%2520Inhibitor%2520Increases%2520Histone%2520H3%2520Acetylation%2520and%2520Reduces%2520Microglia%2520Inflammatory%2520Response%2520Following%2520Traumatic%2520Brain%2520Injury%2520in%2520Rats%26jtitle%3DBrain%2520Res.%26date%3D2008%26volume%3D1226%26spage%3D181%26epage%3D191%26doi%3D10.1016%2Fj.brainres.2008.05.085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stazi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fioravanti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattevi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valente, S.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylases as an Epigenetic Pillar for the Development of Hybrid Inhibitors in Cancer</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">100</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2019.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.cbpa.2019.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=30986654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnsFSgsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2019&pages=89-100&author=G.+Staziauthor=R.+Fioravantiauthor=A.+Maiauthor=A.+Matteviauthor=S.+Valente&title=Histone+Deacetylases+as+an+Epigenetic+Pillar+for+the+Development+of+Hybrid+Inhibitors+in+Cancer&doi=10.1016%2Fj.cbpa.2019.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases as an epigenetic pillar for the development of hybrid inhibitors in cancer</span></div><div class="casAuthors">Stazi, Giulia; Fioravanti, Rossella; Mai, Antonello; Mattevi, Andrea; Valente, Sergio</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89-100</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The polypharmacol. strategy of multi-targeting drugs acting on different biol. pathways is capturing the researchers' attention, particularly in cancer.  The simultaneous inhibition of two or more targets by drug combination or by a single 'hybrid mol.' can provide improved therapeutic efficacy when compared to the one-target inhibitors.  In this regard, because of their multiple anticancer effects, histone deacetylase inhibitors have become a privileged tool for the development of hybrid drugs.  The clin. trials of two multi-acting chimeras, HDAC/EGFR/HER2 and HDAC/PI3K inhibitors, encouraged the design of novel hybrids, such as compds. 22a (LSD1/HDAC) and 16a (CDK4/JAK1/HDAC), which showed superior anticancer effects than single-targeting agents or their combination both in cellular and mouse models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDkcMKMsqtjLVg90H21EOLACvtfcHk0lh5ip8qnb4IpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnsFSgsb4%253D&md5=8233a35ccdd5db5fd4c1d5dfdc3958b7</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2019.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2019.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DStazi%26aufirst%3DG.%26aulast%3DFioravanti%26aufirst%3DR.%26aulast%3DMai%26aufirst%3DA.%26aulast%3DMattevi%26aufirst%3DA.%26aulast%3DValente%26aufirst%3DS.%26atitle%3DHistone%2520Deacetylases%2520as%2520an%2520Epigenetic%2520Pillar%2520for%2520the%2520Development%2520of%2520Hybrid%2520Inhibitors%2520in%2520Cancer%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2019%26volume%3D50%26spage%3D89%26epage%3D100%26doi%3D10.1016%2Fj.cbpa.2019.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hesham, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasheen, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abouzid, K. A. M.</span></span> <span> </span><span class="NLM_article-title">Chimeric HDAC Inhibitors: Comprehensive Review on the HDAC-Based Strategies Developed to Combat Cancer</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">2058</span>– <span class="NLM_lpage">2109</span>, <span class="refDoi"> DOI: 10.1002/med.21505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1002%2Fmed.21505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=29733427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BC1MfgsV2htQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=2058-2109&author=H.+M.+Heshamauthor=D.+S.+Lasheenauthor=K.+A.+M.+Abouzid&title=Chimeric+HDAC+Inhibitors%3A+Comprehensive+Review+on+the+HDAC-Based+Strategies+Developed+to+Combat+Cancer&doi=10.1002%2Fmed.21505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer</span></div><div class="casAuthors">Hesham Heba M; Lasheen Deena S; Abouzid Khaled A M</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal research reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2058-2109</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Recently, molecular hybridization paradigm became an interesting and smart way to defeat the multifaceted cancer disease by a single molecular entity that acts via several mechanisms just like a magic bullet.  Also, HDAC is an important epigenetic target in drug discovery, and the HDAC inhibitors showed successful pattern as cytotoxic agents.  Because of their flexible structure activity relationship, it was easy to link them to other anticancer scaffolds.  So, many dual action HDAC inhibitors have been developed and most of these hybrids have higher potency than the constituting parents in fighting of the cancer cells.  This review describes potential applications of chimeric HDAC inhibitors, which simultaneously modulate not only HDAC but also multiple targets, in treatment of relapsing and drug-resistant cancers.  We have nearly collected most of the reported dual action HDAC inhibitors yet to provide a comprehensive guide for the drug discovery process for developing more efficient anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7h5aD28C1RtbHMBt0mMIXfW6udTcc2ea8Bt8yPh5Ihrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MfgsV2htQ%253D%253D&md5=c935014e94bf04c21eafbcb2f8ef8218</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1002%2Fmed.21505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21505%26sid%3Dliteratum%253Aachs%26aulast%3DHesham%26aufirst%3DH.%2BM.%26aulast%3DLasheen%26aufirst%3DD.%2BS.%26aulast%3DAbouzid%26aufirst%3DK.%2BA.%2BM.%26atitle%3DChimeric%2520HDAC%2520Inhibitors%253A%2520Comprehensive%2520Review%2520on%2520the%2520HDAC-Based%2520Strategies%2520Developed%2520to%2520Combat%2520Cancer%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2018%26volume%3D38%26spage%3D2058%26epage%3D2109%26doi%3D10.1002%2Fmed.21505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taliani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Da Settimo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laneri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novellino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, G.</span></span> <span> </span><span class="NLM_article-title">Exploiting the Indole Scaffold to Design Compounds Binding to Different Pharmacological Targets</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2331</span>, <span class="refDoi"> DOI: 10.3390/molecules25102331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3390%2Fmolecules25102331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFOksbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&pages=2331&author=S.+Talianiauthor=F.+Da+Settimoauthor=C.+Martiniauthor=S.+Laneriauthor=E.+Novellinoauthor=G.+Greco&title=Exploiting+the+Indole+Scaffold+to+Design+Compounds+Binding+to+Different+Pharmacological+Targets&doi=10.3390%2Fmolecules25102331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Exploiting the indole scaffold to design compounds binding to different pharmacological targets</span></div><div class="casAuthors">Taliani, Sabrina; Da Settimo, Federico; Martini, Claudia; Laneri, Sonia; Novellino, Ettore; Greco, Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2331</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Several indole derivs. have been disclosed by our research groups that have been collaborating for nearly 25 years.  The results of our investigations led to a variety of mols. binding selectively to different pharmacol. targets, specifically the type A γ-aminobutyric acid (GABAA) chloride channel, the translocator protein (TSPO), the murine double minute 2 (MDM2) protein, the A2B adenosine receptor (A2B AR) and the Kelch-like ECH-assocd. protein 1 (Keap1).  Herein, we describe how these works were conceived and carried out thanks to the versatility of indole nucleus to be exploited in the design and synthesis of drug-like mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvnxFInRwDvLVg90H21EOLACvtfcHk0lhHAUBNWyHCxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFOksbvF&md5=ddf9af0ccb4cb8ab324863b70eed8be6</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.3390%2Fmolecules25102331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules25102331%26sid%3Dliteratum%253Aachs%26aulast%3DTaliani%26aufirst%3DS.%26aulast%3DDa%2BSettimo%26aufirst%3DF.%26aulast%3DMartini%26aufirst%3DC.%26aulast%3DLaneri%26aufirst%3DS.%26aulast%3DNovellino%26aufirst%3DE.%26aulast%3DGreco%26aufirst%3DG.%26atitle%3DExploiting%2520the%2520Indole%2520Scaffold%2520to%2520Design%2520Compounds%2520Binding%2520to%2520Different%2520Pharmacological%2520Targets%26jtitle%3DMolecules%26date%3D2020%26volume%3D25%26spage%3D2331%26doi%3D10.3390%2Fmolecules25102331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cincinelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musso, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuco, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Cesare, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zunino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallavalle, S.</span></span> <span> </span><span class="NLM_article-title">Influence of the Adamantyl Moiety on the Activity of Biphenylacrylohydroxamic Acid-Based HDAC Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.04.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2014.04.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=24742384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnsFWns78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2014&pages=251-259&author=R.+Cincinelliauthor=L.+Mussoauthor=G.+Gianniniauthor=V.+Zucoauthor=M.+De+Cesareauthor=F.+Zuninoauthor=S.+Dallavalle&title=Influence+of+the+Adamantyl+Moiety+on+the+Activity+of+Biphenylacrylohydroxamic+Acid-Based+HDAC+Inhibitors&doi=10.1016%2Fj.ejmech.2014.04.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors</span></div><div class="casAuthors">Cincinelli, Raffaella; Musso, Loana; Giannini, Giuseppe; Zuco, Valentina; De Cesare, Michelandrea; Zunino, Franco; Dallavalle, Sabrina</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">251-259</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">To investigate the influence of the adamantyl group on the biol. properties of known HDAC inhibitors with a 4-phenylcinnamic skeleton, a series of compds. having the adamantyl moiety in the cap structure were synthesized and compared to the corresponding hydroxamic acids lacking this group.  An unexpected finding was the substantial redn. of inhibitory activity toward the tested enzymes, in particular HDAC6, following the introduction of the adamantyl group.  In spite of the reduced ability to function as HDAC inhibitors, the compds. contg. the adamantyl moiety still retained a good efficacy as antiproliferative and proapoptotic agents.  A selected compd. (2c; ST3056) of this series exhibited an appreciable antitumor activity against the colon carcinoma xenograft HCT116.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzJLw2Q-7h1LVg90H21EOLACvtfcHk0lhHAUBNWyHCxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnsFWns78%253D&md5=537039564ff230efc704ba246544cbc0</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.04.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.04.021%26sid%3Dliteratum%253Aachs%26aulast%3DCincinelli%26aufirst%3DR.%26aulast%3DMusso%26aufirst%3DL.%26aulast%3DGiannini%26aufirst%3DG.%26aulast%3DZuco%26aufirst%3DV.%26aulast%3DDe%2BCesare%26aufirst%3DM.%26aulast%3DZunino%26aufirst%3DF.%26aulast%3DDallavalle%26aufirst%3DS.%26atitle%3DInfluence%2520of%2520the%2520Adamantyl%2520Moiety%2520on%2520the%2520Activity%2520of%2520Biphenylacrylohydroxamic%2520Acid-Based%2520HDAC%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D79%26spage%3D251%26epage%3D259%26doi%3D10.1016%2Fj.ejmech.2014.04.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gopalan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponpandian, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kachhadia, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharathimohan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vignesh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivasudar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Praveen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saranya, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajagopal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajagopal, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of Adamantane Based Highly Potent HDAC Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2532</span>– <span class="NLM_lpage">2537</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmcl.2013.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=23538115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3sXks1Sisr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=2532-2537&author=B.+Gopalanauthor=T.+Ponpandianauthor=V.+Kachhadiaauthor=K.+Bharathimohanauthor=R.+Vigneshauthor=V.+Sivasudarauthor=S.+Narayananauthor=B.+Mandarauthor=R.+Praveenauthor=N.+Saranyaauthor=S.+Rajagopalauthor=S.+Rajagopal&title=Discovery+of+Adamantane+Based+Highly+Potent+HDAC+Inhibitors&doi=10.1016%2Fj.bmcl.2013.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of adamantane based highly potent HDAC inhibitors</span></div><div class="casAuthors">Gopalan, Balasubramanian; Ponpandian, Thanasekaran; Kachhadia, Virendra; Bharathimohan, Kuppusamy; Vignesh, Radhakrishnan; Sivasudar, Velaiah; Narayanan, Shridhar; Mandar, Bhonde; Praveen, Rajendran; Saranya, Nithyanandan; Rajagopal, Sriram; Rajagopal, Sridharan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2532-2537</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein, we report the development of highly potent HDAC (histone deacetylases) inhibitors for the treatment of cancer.  A series of adamantane and noradamantane based HDAC inhibitors were designed, synthesized and screened for the inhibitory activity of HDAC.  A no. of compds. exhibited GI50 of 10-100 nM in human HCT116, NCI-H460 and U251 cancer cells, in vitro.  Compd. I displays efficacy in human tumor animal xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNOU_JBIr18bVg90H21EOLACvtfcHk0lhu89eCYtshiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXks1Sisr4%253D&md5=24b3eb5233a6b27e5154713824e74d62</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DGopalan%26aufirst%3DB.%26aulast%3DPonpandian%26aufirst%3DT.%26aulast%3DKachhadia%26aufirst%3DV.%26aulast%3DBharathimohan%26aufirst%3DK.%26aulast%3DVignesh%26aufirst%3DR.%26aulast%3DSivasudar%26aufirst%3DV.%26aulast%3DNarayanan%26aufirst%3DS.%26aulast%3DMandar%26aufirst%3DB.%26aulast%3DPraveen%26aufirst%3DR.%26aulast%3DSaranya%26aufirst%3DN.%26aulast%3DRajagopal%26aufirst%3DS.%26aulast%3DRajagopal%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520Adamantane%2520Based%2520Highly%2520Potent%2520HDAC%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D2532%26epage%3D2537%26doi%3D10.1016%2Fj.bmcl.2013.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Fardon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romieu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, R. R.</span></span> <span> </span><span class="NLM_article-title">Sigma1 (σ<sub>1</sub>) Receptor Antagonists Represent a New Strategy against Cocaine Addiction and Toxicity</span>. <i>Neurosci. Biobehav. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">527</span>, <span class="refDoi"> DOI: 10.1016/S0149-7634(02)00017-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2FS0149-7634%2802%2900017-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=12204195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD38XmsVerurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2002&pages=499-527&author=T.+Mauriceauthor=R.+Martin-Fardonauthor=P.+Romieuauthor=R.+R.+Matsumoto&title=Sigma1+%28%CF%831%29+Receptor+Antagonists+Represent+a+New+Strategy+against+Cocaine+Addiction+and+Toxicity&doi=10.1016%2FS0149-7634%2802%2900017-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma1 (σ1) receptor antagonists represent a new strategy against cocaine addiction and toxicity</span></div><div class="casAuthors">Maurice, Tangui; Martin-Fardon, Remi; Romieu, Pascal; Matsumoto, Rae R.</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience and Biobehavioral Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">499-527</span>CODEN:
                <span class="NLM_cas:coden">NBREDE</span>;
        ISSN:<span class="NLM_cas:issn">0149-7634</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Cocaine is a highly addictive substance abused worldwide.  Its mechanism of action involves initially inhibition of neuronal monoamine transporters in precise brain structures and primarily the dopamine reuptake system located on mesolimbic neurons.  Cocaine rapidly increases the dopaminergic neurotransmission and triggers adaptive changes in numerous neuronal circuits underlying reinforcement, reward, sensitization and the high addictive potential of cocaine.  Current therapeutic strategies focus on counteracting the cocaine effects directly on the dopamine transporter, through post-synaptic D1, D2 or D3 receptors or through the glutamatergic, serotoninergic, opioid or corticotropin-releasing hormone systems.  However, cocaine administration also results in the activation of numerous particular targets.  Among them, the sigma1 (σ1) receptor is involved in several acute or chronic effects of cocaine.  The present review will first bring concise overviews of the present strategies followed to alleviate cocaine addiction and animal models developed to analyze the pharmacol. of cocaine addiction.  Evidence involving activation of the σ1 receptor in the different aspects of cocaine abuse, will then be detailed, following acute, repeated, or overdose administration.  The therapeutic potentials and neuropharmacol. perspectives opened by the use of selective σ1 receptor antagonists in cocaine addiction will finally be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqmpOYpzQ3t7Vg90H21EOLACvtfcHk0lhu89eCYtshiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmsVerurc%253D&md5=18192324720fbfe288fb39842f370a83</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2FS0149-7634%2802%2900017-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0149-7634%252802%252900017-9%26sid%3Dliteratum%253Aachs%26aulast%3DMaurice%26aufirst%3DT.%26aulast%3DMartin-Fardon%26aufirst%3DR.%26aulast%3DRomieu%26aufirst%3DP.%26aulast%3DMatsumoto%26aufirst%3DR.%2BR.%26atitle%3DSigma1%2520%2528%25CF%25831%2529%2520Receptor%2520Antagonists%2520Represent%2520a%2520New%2520Strategy%2520against%2520Cocaine%2520Addiction%2520and%2520Toxicity%26jtitle%3DNeurosci.%2520Biobehav.%2520Rev.%26date%3D2002%26volume%3D26%26spage%3D499%26epage%3D527%26doi%3D10.1016%2FS0149-7634%2802%2900017-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weng, T.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, S.-Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T.-P.</span></span> <span> </span><span class="NLM_article-title">Roles of Sigma-1 Receptors on Mitochondrial Functions Relevant to Neurodegenerative Diseases</span>. <i>J. Biomed. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">74</span>, <span class="refDoi"> DOI: 10.1186/s12929-017-0380-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1186%2Fs12929-017-0380-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=28917260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVOjsrjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=74&author=T.-Y.+Wengauthor=S.-Y.+A.+Tsaiauthor=T.-P.+Su&title=Roles+of+Sigma-1+Receptors+on+Mitochondrial+Functions+Relevant+to+Neurodegenerative+Diseases&doi=10.1186%2Fs12929-017-0380-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Roles of sigma-1 receptors on mitochondrial functions relevant to neurodegenerative diseases</span></div><div class="casAuthors">Weng, Tzu-Yu; Tsai, Shang-Yi Anne; Su, Tsung-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomedical Science (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">74/1-74/14</span>CODEN:
                <span class="NLM_cas:coden">JBCIEA</span>;
        ISSN:<span class="NLM_cas:issn">1423-0127</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">The sigma-1 receptor (Sig-1R) is a chaperone that resides mainly at the mitochondrion-assocd. endoplasmic reticulum (ER) membrane (called the MAMs) and acts as a dynamic pluripotent modulator in living systems.  At the MAM, the Sig-1R is known to play a role in regulating the Ca2+ signaling between ER and mitochondria and in maintaining the structural integrity of the MAM.  The MAM serves as bridges between ER and mitochondria regulating multiple functions such as Ca2+ transfer, energy exchange, lipid synthesis and transports, and protein folding that are pivotal to cell survival and defense.  Recently, emerging evidences indicate that the MAM is crit. in maintaining neuronal homeostasis.  Thus, given the specific localization of the Sig-1R at the MAM, we highlight and propose that the direct or indirect regulations of the Sig-1R on mitochondrial functions may relate to neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS).  In addn., the promising use of Sig-1R ligands to rescue mitochondrial dysfunction-induced neurodegeneration is addressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqomRZwYzYR6bVg90H21EOLACvtfcHk0lhu89eCYtshiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVOjsrjN&md5=53d2f910e875935072543cfb0b277497</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1186%2Fs12929-017-0380-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12929-017-0380-6%26sid%3Dliteratum%253Aachs%26aulast%3DWeng%26aufirst%3DT.-Y.%26aulast%3DTsai%26aufirst%3DS.-Y.%2BA.%26aulast%3DSu%26aufirst%3DT.-P.%26atitle%3DRoles%2520of%2520Sigma-1%2520Receptors%2520on%2520Mitochondrial%2520Functions%2520Relevant%2520to%2520Neurodegenerative%2520Diseases%26jtitle%3DJ.%2520Biomed.%2520Sci.%26date%3D2017%26volume%3D24%26spage%3D74%26doi%3D10.1186%2Fs12929-017-0380-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glennon, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ablordeppey, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismaiel, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Ashmawy, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howie, K. B.</span></span> <span> </span><span class="NLM_article-title">Structural Features Important for σ<sub>1</sub> Receptor Binding</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1214</span>– <span class="NLM_lpage">1219</span>, <span class="refDoi"> DOI: 10.1021/jm00034a020</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00034a020" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADyaK2cXksV2lsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=1214-1219&author=R.+A.+Glennonauthor=S.+Y.+Ablordeppeyauthor=A.+M.+Ismaielauthor=M.+B.+El-Ashmawyauthor=J.+B.+Fischerauthor=K.+B.+Howie&title=Structural+Features+Important+for+%CF%831+Receptor+Binding&doi=10.1021%2Fjm00034a020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Features Important for σ1 Receptor Binding</span></div><div class="casAuthors">Glennon, Richard A.; Ablordeppey, Seth Y.; Ismaiel, Abd M.; El-Ashmawy, Mahmoud B.; Fischer, James B.; Howie, Kathleen Burke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1214-19</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Two problems that have hampered σ receptor research are a lack of high-affinity agents and the recent identification of multiple populations of σ receptors (i.e., σ1 and σ2 sites).  Recently, several high-affinity σ ligands have been identified, and the term superpotent σ ligands has been coined to describe agents with Ki values of <1 nM.  It was previously shown that appropriately N-substituted phenylalkylamines bind at σ receptors with high affinity.  The structure-affinity relationships of these phenylalkylamine derivs. for σ1 binding are examd. and some of the first superpotent σ1 ligands described.  A binding model was developed to account for the structural features of the phenylalkylamines that appear to be important for the interaction of these agents with σ1 sites.  Some of the amines were prepd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6nnZHspQ0MLVg90H21EOLACvtfcHk0ljIYAqV95x3FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXksV2lsrY%253D&md5=3c9b4ff203d7c304da3779a874837bf5</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1021%2Fjm00034a020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00034a020%26sid%3Dliteratum%253Aachs%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26aulast%3DAblordeppey%26aufirst%3DS.%2BY.%26aulast%3DIsmaiel%26aufirst%3DA.%2BM.%26aulast%3DEl-Ashmawy%26aufirst%3DM.%2BB.%26aulast%3DFischer%26aufirst%3DJ.%2BB.%26aulast%3DHowie%26aufirst%3DK.%2BB.%26atitle%3DStructural%2520Features%2520Important%2520for%2520%25CF%25831%2520Receptor%2520Binding%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26spage%3D1214%26epage%3D1219%26doi%3D10.1021%2Fjm00034a020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span> <span> </span><span class="NLM_article-title">Is the σ<sub>2</sub> Receptor a Histone Binding Protein?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">4153</span>– <span class="NLM_lpage">4158</span>, <span class="refDoi"> DOI: 10.1021/jm0600592</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0600592" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFentrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4153-4158&author=N.+A.+Colabufoauthor=F.+Berardiauthor=C.+Abateauthor=M.+Continoauthor=M.+Nisoauthor=R.+Perrone&title=Is+the+%CF%832+Receptor+a+Histone+Binding+Protein%3F&doi=10.1021%2Fjm0600592"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Is the σ2 Receptor a Histone Binding Protein?</span></div><div class="casAuthors">Colabufo, Nicola Antonio; Berardi, Francesco; Abate, Carmen; Contino, Marialessandra; Niso, Mauro; Perrone, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4153-4158</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Starting from the high affinity σ2 receptor ligand 2, (PB28), we synthesized amino deriv. 4 and coupled it to an NHS-ester activated sepharose stationary phase column to elute a crude protein prepd. by lysed human SK-N-SH neuroblastoma cells.  We characterized the SDS-PAGE gel electrophoresis stained bands by MALDI-MS and LC-MS-MS anal.  The MASCOT MS-MS ion search program led to the identification of the protein components.  The six eluted proteins had a mol. wt. ranging from 13 kDa to 26 kDa and were human histone proteins.  A human 40S ribosomal protein S3 (SwissProt accession no.: P23396) was also identified as a comigrated band.  The human histone proteins that were characterized were H3.3A histone (NCBI accession no.: 51859376), H2B histone (NCBI accession no.:1568557), H2A.5 histone (NCBI accession no.: 70686), H1 (NCBI accession no.: 22770677), and H2.1 histone (SwissProt accession no.:P16403).  These results disclosed a dual hypothesis about the σ2 receptor, i.e., that it is formed by histones or that the σ2 ligands also bind histone proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfoEbIIW3bKbVg90H21EOLACvtfcHk0ljIYAqV95x3FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFentrY%253D&md5=e9c456f40e43e9bc8203588e6e7662d2</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1021%2Fjm0600592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0600592%26sid%3Dliteratum%253Aachs%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DContino%26aufirst%3DM.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DPerrone%26aufirst%3DR.%26atitle%3DIs%2520the%2520%25CF%25832%2520Receptor%2520a%2520Histone%2520Binding%2520Protein%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4153%26epage%3D4158%26doi%3D10.1021%2Fjm0600592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elenewski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azzariti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glennon, R. A.</span></span> <span> </span><span class="NLM_article-title">Interaction of the σ2 Receptor Ligand PB28 with the Human Nucleosome: Computational and Experimental Probes of Interaction with the H2A/H2B Dimer</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">268</span>– <span class="NLM_lpage">273</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200900402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1002%2Fcmdc.200900402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=20077462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtl2ntr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=268-273&author=C.+Abateauthor=J.+Elenewskiauthor=M.+Nisoauthor=F.+Berardiauthor=N.+A.+Colabufoauthor=A.+Azzaritiauthor=R.+Perroneauthor=R.+A.+Glennon&title=Interaction+of+the+%CF%832+Receptor+Ligand+PB28+with+the+Human+Nucleosome%3A+Computational+and+Experimental+Probes+of+Interaction+with+the+H2A%2FH2B+Dimer&doi=10.1002%2Fcmdc.200900402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of the σ2 Receptor Ligand PB28 with the Human Nucleosome: Computational and Experimental Probes of Interaction with the H2A/H2B Dimer</span></div><div class="casAuthors">Abate, Carmen; Elenewski, Justin; Niso, Mauro; Berardi, Francesco; Colabufo, Nicola Antonio; Azzariti, Amalia; Perrone, Roberto; Glennon, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">268-273</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Sigma-2 (σ2) binding sites are an emerging target for anti-neoplastic agents due to the strong apoptotic effect exhibited by σ2 agonists in vitro and the overexpression of these sites in tumor cells.  Nonetheless, no σ2 receptor protein has been identified.  Affinity chromatog. using the high-affinity σ2 ligand PB28 and human SK-N-SH neuroblastoma cells was previously utilized to identify σ2 ligand binding proteins, specifically histones H1, H2A, H2B, and H3.3a.  To rationalize this finding, homol. modeling and automated docking studies were employed to probe intermol. interactions between PB28 and human nucleosomal proteins.  These studies predicted interaction of PB28 with the H2A/H2B dimer at a series of sites previously implicated in chromatin compaction and nucleosomal assembly.  To exptl. verify this prediction, a competitive binding assay was performed on the reconstituted H2A/H2B dimer using [3H]PB28 as radioligand, and an IC50 value of 0.50 nM was detd. for PB28 binding.  In addn., [3H]PB28 was found to accumulate with up to a fivefold excess in nuclear fractions over cytosolic fractions of SK-N-SH and MCF7 cells, indicating that PB28 is capable of entering the nucleus to interact with histone proteins.  In conjunction with computational results, these data suggest that PB28 may exert its cytotoxic effect through direct interaction with nuclear material.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkk6FOeqP6z7Vg90H21EOLACvtfcHk0ljIYAqV95x3FA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtl2ntr4%253D&md5=34320626eb0e20f03b814697c5ee59b0</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200900402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200900402%26sid%3Dliteratum%253Aachs%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DElenewski%26aufirst%3DJ.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DAzzariti%26aufirst%3DA.%26aulast%3DPerrone%26aufirst%3DR.%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26atitle%3DInteraction%2520of%2520the%2520%25CF%25832%2520Receptor%2520Ligand%2520PB28%2520with%2520the%2520Human%2520Nucleosome%253A%2520Computational%2520and%2520Experimental%2520Probes%2520of%2520Interaction%2520with%2520the%2520H2A%252FH2B%2520Dimer%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26spage%3D268%26epage%3D273%26doi%3D10.1002%2Fcmdc.200900402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothfuss, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangveravong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotchkiss, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Identification of the PGRMC1 Protein Complex as the Putative Sigma-2 Receptor Binding Site</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">380</span>– <span class="NLM_lpage">387</span>, <span class="refDoi"> DOI: 10.1038/ncomms1386</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fncomms1386" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=21730960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BC3MnlvVKgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=380-387&author=J.+Xuauthor=C.+Zengauthor=W.+Chuauthor=F.+Panauthor=J.+M.+Rothfussauthor=F.+Zhangauthor=Z.+Tuauthor=D.+Zhouauthor=D.+Zengauthor=S.+Vangveravongauthor=F.+Johnstonauthor=D.+Spitzerauthor=K.+C.+Changauthor=R.+S.+Hotchkissauthor=W.+G.+Hawkinsauthor=K.+T.+Wheelerauthor=R.+H.+Mach&title=Identification+of+the+PGRMC1+Protein+Complex+as+the+Putative+Sigma-2+Receptor+Binding+Site&doi=10.1038%2Fncomms1386"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site</span></div><div class="casAuthors">Xu Jinbin; Zeng Chenbo; Chu Wenhua; Pan Fenghui; Rothfuss Justin M; Zhang Fanjie; Tu Zhude; Zhou Dong; Zeng Dexing; Vangveravong Suwanna; Johnston Fabian; Spitzer Dirk; Chang Katherine C; Hotchkiss Richard S; Hawkins William G; Wheeler Kenneth T; Mach Robert H</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">380</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The sigma-2 receptor, whose gene remains to be cloned, has been validated as a biomarker for tumour cell proliferation.  Here we report the use of a novel photoaffinity probe, WC-21, to identify the sigma-2 receptor-binding site.  WC-21, a sigma-2 ligand containing both a photoactive azide moiety and a fluorescein isothiocyanate group, irreversibly labels sigma-2 receptors in rat liver; the membrane-bound protein was identified as PGRMC1 (progesterone receptor membrane component 1).  Immunocytochemistry reveals that both PGRMC1 and SW120, a fluorescent sigma-2 receptor ligand, colocalize with molecular markers of the endoplasmic reticulum and mitochondria in HeLa cells.  Overexpression and knockdown of the PGRMC1 protein results in an increase and a decrease in binding of a sigma-2 selective radioligand, respectively.  The identification of the putative sigma-2 receptor-binding site as PGRMC1 should stimulate the development of unique imaging agents and cancer therapeutics that target the sigma-2 receptor/PGRMC1 complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKpNfsa0DIvIJKJbLTgsvCfW6udTcc2ebXKWe-MatuRLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MnlvVKgtQ%253D%253D&md5=46675c07c87eccab091f8a8ec0f12db6</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1038%2Fncomms1386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms1386%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DChu%26aufirst%3DW.%26aulast%3DPan%26aufirst%3DF.%26aulast%3DRothfuss%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DZeng%26aufirst%3DD.%26aulast%3DVangveravong%26aufirst%3DS.%26aulast%3DJohnston%26aufirst%3DF.%26aulast%3DSpitzer%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DK.%2BC.%26aulast%3DHotchkiss%26aufirst%3DR.%2BS.%26aulast%3DHawkins%26aufirst%3DW.%2BG.%26aulast%3DWheeler%26aufirst%3DK.%2BT.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DIdentification%2520of%2520the%2520PGRMC1%2520Protein%2520Complex%2520as%2520the%2520Putative%2520Sigma-2%2520Receptor%2520Binding%2520Site%26jtitle%3DNat.%2520Commun.%26date%3D2011%26volume%3D2%26spage%3D380%26epage%3D387%26doi%3D10.1038%2Fncomms1386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahn, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span> <span> </span><span class="NLM_article-title">Identification of the Gene That Codes for the σ<sub>2</sub> Receptor</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">7160</span>– <span class="NLM_lpage">7165</span>, <span class="refDoi"> DOI: 10.1073/pnas.1705154114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1073%2Fpnas.1705154114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=28559337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovVSisrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=7160-7165&author=A.+Alonauthor=H.+R.+Schmidtauthor=M.+D.+Woodauthor=J.+J.+Sahnauthor=S.+F.+Martinauthor=A.+C.+Kruse&title=Identification+of+the+Gene+That+Codes+for+the+%CF%832+Receptor&doi=10.1073%2Fpnas.1705154114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the gene that codes for the σ2 receptor</span></div><div class="casAuthors">Alon, Assaf; Schmidt, Hayden R.; Wood, Michael D.; Sahn, James J.; Martin, Stephen F.; Kruse, Andrew C.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">7160-7165</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The σ2 receptor is an enigmatic protein that has attracted significant attention because of its involvement in diseases as diverse as cancer and neurol. disorders.  Unlike virtually all other receptors of medical interest, it has eluded mol. cloning since its discovery, and the gene that codes for the receptor remains unknown, precluding the use of modern biol. methods to study its function.  Using a chem. biol. approach, we purified the σ2 receptor from tissue, revealing its identity as TMEM97, an endoplasmic reticulum-resident transmembrane protein that regulates the sterol transporter NPC1.  We show that TMEM97 possesses the full suite of mol. properties that define the σ2 receptor, and we identify Asp29 and Asp56 as essential for ligand recognition.  Cloning the σ2 receptor resolves a longstanding mystery and will enable therapeutic targeting of this potential drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsoAS9Q6KtY7Vg90H21EOLACvtfcHk0ljU2Si3y7HNQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovVSisrw%253D&md5=71d3c246ebe6ac84c33980b97cb9889c</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1705154114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1705154114%26sid%3Dliteratum%253Aachs%26aulast%3DAlon%26aufirst%3DA.%26aulast%3DSchmidt%26aufirst%3DH.%2BR.%26aulast%3DWood%26aufirst%3DM.%2BD.%26aulast%3DSahn%26aufirst%3DJ.%2BJ.%26aulast%3DMartin%26aufirst%3DS.%2BF.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26atitle%3DIdentification%2520of%2520the%2520Gene%2520That%2520Codes%2520for%2520the%2520%25CF%25832%2520Receptor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26spage%3D7160%26epage%3D7165%26doi%3D10.1073%2Fpnas.1705154114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gundlach, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Largent, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, S. H.</span></span> <span> </span><span class="NLM_article-title">Autoradiographic Localization of Sigma Receptor Binding Sites in Guinea Pig and Rat Central Nervous System with (+)<sup>3</sup>H-3-(3-Hydroxyphenyl)-N-(1-Propyl)Piperidine</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1757</span>– <span class="NLM_lpage">1770</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.06-06-01757.1986</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1523%2FJNEUROSCI.06-06-01757.1986" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=3012017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADyaL28Xkslaqt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1986&pages=1757-1770&author=A.+L.+Gundlachauthor=B.+L.+Largentauthor=S.+H.+Snyder&title=Autoradiographic+Localization+of+Sigma+Receptor+Binding+Sites+in+Guinea+Pig+and+Rat+Central+Nervous+System+with+%28%2B%293H-3-%283-Hydroxyphenyl%29-N-%281-Propyl%29Piperidine&doi=10.1523%2FJNEUROSCI.06-06-01757.1986"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Autoradiographic localization of sigma receptor binding sites in guinea pig and rat central nervous system with (+)3H-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine</span></div><div class="casAuthors">Gundlach, Andrew L.; Largent, Brian L.; Snyder, Solomon H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1757-70</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    </div><div class="casAbstract">(+)3H-3-(3-Hydroxyphenyl)-N-(1-propyl)-piperidine ((+)3H-3-PPP)  [103596-12-9] binds with high affinity to brain membranes with a pharmacol. profile consistent with that of sigma receptors.  The distribution of (+)3H-3-PPP binding sites in brain and spinal cord of both guinea pig and rat was detd. by in vitro autoradiog. with binding densities quantitated by computer-assisted densitometry.  (+)3H-3-PPP binding to slide-mounted brain sections is saturable and displays high affinity and a pharmacol. specificity very similar to sites labeled in homogenates.  (+)3H-3-PPP binding sites are heterogeneously distributed.  Highest concns. of binding sites occur in: the spinal cord, particularly the ventral horn and dorsal root ganglia; the pons-medulla, assocd. with the cranial nerve and pontine nuclei and throughout the brain stem reticular formation; the cerebellum, over the Purkinje cell layer; the midbrain, particularly the central gray and red nucleus; and the hippocampus, over the pyramidal cell layer.  Lowest levels are seen in the basal ganglia and parts of the thalamus, whereas all other areas, including hypothalamus and cerebral cortex, exhibit moderate grain densities.  Quinolinic acid-induced lesions of the hippocampus indicate that (+)3H-3-PPP labels hippocampal pyramidal cells and granule cells in the dentate gyrus.  Intrastriatal injection of ibotenic acid markedly reduces (+)3H-3-PPP binding in this area, whereas injection of 6-hydroxydopamine produces a relatively slight decrease.  The distribution of (+)3H-3-PPP binding sites does not correlate with the receptor distribution of any recognized neurotransmitter or neuropeptide, including dopamine.  However, there is a notable similarity between the distribution of (+)3H-3-PPP sites and high-affinity binding sites for psychotomimetic opioids, such as the benzomorphan (+)SKF 10,047.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUK88P9_rGbbVg90H21EOLACvtfcHk0lgWOdtfDNlM_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28Xkslaqt7Y%253D&md5=5364e73d8462bb062298751d3b75c23e</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.06-06-01757.1986&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.06-06-01757.1986%26sid%3Dliteratum%253Aachs%26aulast%3DGundlach%26aufirst%3DA.%2BL.%26aulast%3DLargent%26aufirst%3DB.%2BL.%26aulast%3DSnyder%26aufirst%3DS.%2BH.%26atitle%3DAutoradiographic%2520Localization%2520of%2520Sigma%2520Receptor%2520Binding%2520Sites%2520in%2520Guinea%2520Pig%2520and%2520Rat%2520Central%2520Nervous%2520System%2520with%2520%2528%252B%25293H-3-%25283-Hydroxyphenyl%2529-N-%25281-Propyl%2529Piperidine%26jtitle%3DJ.%2520Neurosci.%26date%3D1986%26volume%3D6%26spage%3D1757%26epage%3D1770%26doi%3D10.1523%2FJNEUROSCI.06-06-01757.1986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mavlyutov, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziskind-Conhaim, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruoho, A. E.</span></span> <span> </span><span class="NLM_article-title">The Sigma-1 Receptor Is Enriched in Postsynaptic Sites of C-Terminals in Mouse Motoneurons. An Anatomical and Behavioral Study</span>. <i>Neuroscience</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">247</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1016/j.neuroscience.2010.02.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.neuroscience.2010.02.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=20167253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksVehsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2010&pages=247-255&author=T.+A.+Mavlyutovauthor=M.+L.+Epsteinauthor=K.+A.+Andersenauthor=L.+Ziskind-Conhaimauthor=A.+E.+Ruoho&title=The+Sigma-1+Receptor+Is+Enriched+in+Postsynaptic+Sites+of+C-Terminals+in+Mouse+Motoneurons.+An+Anatomical+and+Behavioral+Study&doi=10.1016%2Fj.neuroscience.2010.02.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">The sigma-1 receptor is enriched in postsynaptic sites of C-terminals in mouse motoneurons. An anatomical and behavioral study</span></div><div class="casAuthors">Mavlyutov, T. A.; Epstein, M. L.; Andersen, K. A.; Ziskind-Conhaim, L.; Ruoho, A. E.</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">247-255</span>CODEN:
                <span class="NLM_cas:coden">NRSCDN</span>;
        ISSN:<span class="NLM_cas:issn">0306-4522</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The sigma-1 receptor regulates various ion channel activity and possesses protein chaperone function.  Using an antibody against the full sequence of the sigma-1 receptor we detected immunostaining in wild type but not in knockout mice.  The receptor was found primarily in motoneurons localized to the brainstem and spinal cord.  At the subcellular level the receptor is restricted to large cholinergic postsynaptic densities on the soma of motoneurons and is colocalized with the Kv2.1 potassium channel and the muscarinic type 2 cholinergic receptor.  Ultrastructural anal. of the neurons indicates that the immunostained receptor is located close but sep. from the plasma membrane, possibly in subsurface cisternae formed from the endoplasmic reticulum (ER), which are a prominent feature of cholinergic postsynaptic densities.  Behavioral testing on a rotarod revealed that Sigma-1 receptor knockout mice remained on the rotarod for significantly less time (a shorter latency period) compared to the wild type mice.  Together these data indicate that the sigma-1 receptor may play a role in the regulation of motor behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqjsVI80xkvrVg90H21EOLACvtfcHk0lgWOdtfDNlM_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksVehsLk%253D&md5=6517fe58d59ce56b314dc82bb54d4b05</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroscience.2010.02.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroscience.2010.02.022%26sid%3Dliteratum%253Aachs%26aulast%3DMavlyutov%26aufirst%3DT.%2BA.%26aulast%3DEpstein%26aufirst%3DM.%2BL.%26aulast%3DAndersen%26aufirst%3DK.%2BA.%26aulast%3DZiskind-Conhaim%26aufirst%3DL.%26aulast%3DRuoho%26aufirst%3DA.%2BE.%26atitle%3DThe%2520Sigma-1%2520Receptor%2520Is%2520Enriched%2520in%2520Postsynaptic%2520Sites%2520of%2520C-Terminals%2520in%2520Mouse%2520Motoneurons.%2520An%2520Anatomical%2520and%2520Behavioral%2520Study%26jtitle%3DNeuroscience%26date%3D2010%26volume%3D167%26spage%3D247%26epage%3D255%26doi%3D10.1016%2Fj.neuroscience.2010.02.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Saif, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Mohanna, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohlega, S.</span></span> <span> </span><span class="NLM_article-title">A Mutation in Sigma-1 Receptor Causes Juvenile Amyotrophic Lateral Sclerosis</span>. <i>Ann. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">913</span>– <span class="NLM_lpage">919</span>, <span class="refDoi"> DOI: 10.1002/ana.22534</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1002%2Fana.22534" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=21842496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1CqurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2011&pages=913-919&author=A.+Al-Saifauthor=F.+Al-Mohannaauthor=S.+Bohlega&title=A+Mutation+in+Sigma-1+Receptor+Causes+Juvenile+Amyotrophic+Lateral+Sclerosis&doi=10.1002%2Fana.22534"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis</span></div><div class="casAuthors">Al-Saif, Amr; Al-Mohanna, Futwan; Bohlega, Saeed</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Neurology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">913-919</span>CODEN:
                <span class="NLM_cas:coden">ANNED3</span>;
        ISSN:<span class="NLM_cas:issn">0364-5134</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Objective: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by loss of motor neurons in the brain and spinal cord, leading to muscle weakness and eventually death from respiratory failure.  ALS is familial in about 10% of cases, with SOD1 mutations accounting for 20% of familial cases.  Here we describe a consanguineous family segregating juvenile ALS in an autosomal recessive pattern and describe the genetic variant responsible for the disorder.  Methods: We performed homozygosity mapping and direct sequencing to detect the genetic variant and tested the effect of this variant on a motor neuron-like cell line model (NSC34) expressing the wild-type or mutant gene.  Results: We identified a shared homozygosity region in affected individuals that spans ∼120kbp on chromosome 9p13.3 contg. 9 RefSeq genes.  Sequencing the SIGMAR1 gene revealed a mutation affecting a highly conserved amino acid located in the transmembrane domain of the encoded protein, sigma-1 receptor.  The mutated protein showed an aberrant subcellular distribution in NSC34 cells.  Furthermore, cells expressing the mutant protein were less resistant to apoptosis induced by endoplasmic reticulum stress.  Interpretation: Sigma-1 receptors are known to have neuroprotective properties, and recently Sigmar1 knockout mice have been described to have motor deficiency.  Our findings emphasize the role of sigma-1 receptors in motor neuron function and disease.  ANN NEUROL 2011;.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBYWm6mJA60LVg90H21EOLACvtfcHk0lgWOdtfDNlM_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1CqurfI&md5=ca3b6746092861e44b37088f3c4f86ea</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1002%2Fana.22534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.22534%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Saif%26aufirst%3DA.%26aulast%3DAl-Mohanna%26aufirst%3DF.%26aulast%3DBohlega%26aufirst%3DS.%26atitle%3DA%2520Mutation%2520in%2520Sigma-1%2520Receptor%2520Causes%2520Juvenile%2520Amyotrophic%2520Lateral%2520Sclerosis%26jtitle%3DAnn.%2520Neurol.%26date%3D2011%26volume%3D70%26spage%3D913%26epage%3D919%26doi%3D10.1002%2Fana.22534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luty, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwok, J. B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobson-Stone, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loy, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coupland, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlström, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobow, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tchorzewska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruszak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barcikowska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panegyres, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zekanowski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mather, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachdev, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halliday, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schofield, P. R.</span></span> <span> </span><span class="NLM_article-title">Sigma Nonopioid Intracellular Receptor 1 Mutations Cause Frontotemporal Lobar Degeneration-Motor Neuron Disease</span>. <i>Ann. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">639</span>– <span class="NLM_lpage">649</span>, <span class="refDoi"> DOI: 10.1002/ana.22274</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1002%2Fana.22274" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=21031579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFOnsrbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2010&pages=639-649&author=A.+A.+Lutyauthor=J.+B.+J.+Kwokauthor=C.+Dobson-Stoneauthor=C.+T.+Loyauthor=K.+G.+Couplandauthor=H.+Karlstr%C3%B6mauthor=T.+Sobowauthor=J.+Tchorzewskaauthor=A.+Maruszakauthor=M.+Barcikowskaauthor=P.+K.+Panegyresauthor=C.+Zekanowskiauthor=W.+S.+Brooksauthor=K.+L.+Williamsauthor=I.+P.+Blairauthor=K.+A.+Matherauthor=P.+S.+Sachdevauthor=G.+Hallidayauthor=P.+R.+Schofield&title=Sigma+Nonopioid+Intracellular+Receptor+1+Mutations+Cause+Frontotemporal+Lobar+Degeneration-Motor+Neuron+Disease&doi=10.1002%2Fana.22274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease</span></div><div class="casAuthors">Luty, Agnes A.; Kwok, John B. J.; Dobson-Stone, Carol; Loy, Clement T.; Coupland, Kirsten G.; Karlstrom, Helena; Sobow, Tomasz; Tchorzewska, Joanna; Maruszak, Aleksandra; Barcikowska, Maria; Panegyres, Peter K.; Zekanowski, Cezary; Brooks, William S.; Williams, Kelly L.; Blair, Ian P.; Mather, Karen A.; Sachdev, Perminder S.; Halliday, Glenda M.; Schofield, Peter R.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Neurology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">639-649</span>CODEN:
                <span class="NLM_cas:coden">ANNED3</span>;
        ISSN:<span class="NLM_cas:issn">0364-5134</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Objective: Frontotemporal lobar degeneration (FTLD) is the most common cause of early-onset dementia.  Pathol. ubiquitinated inclusion bodies obsd. in FTLD and motor neuron disease (MND) comprise transactivating response element (TAR) DNA binding protein (TDP-43) and/or fused in sarcoma (FUS) protein.  Our objective was to identify the causative gene in an FTLD-MND pedigree with no mutations in known dementia genes.  Methods: A mutation screen of candidate genes, luciferase assays, and quant. polymerase chain reaction (PCR) was performed to identify the biol. role of the putative mutation.  Neuropathol. characterization of affected individuals and western blot studies of cell lines were performed to identify the pathol. mechanism of the mutation.  Results: We identified a nonpolymorphic mutation (c.672*51G>T) in the 3'-untranslated region (UTR) of the Sigma nonopioid intracellular receptor 1 (SIGMAR1) gene in affected individuals from the FTLD-MND pedigree.  The c.672*51G>T mutation increased gene expression by 1.4-fold, corresponding with a significant 1.5-fold to 2-fold change in the SIGMAR1 transcript or Sigma-1 protein in lymphocyte or brain tissue.  Brains of SIGMAR1 mutation carriers displayed a unique pathol. with cytoplasmic inclusions immunopos. for either TDP-43 or FUS but not Sigma-1.  Overexpression of SIGMAR1 shunted TDP-43 and FUS from the nucleus to the cytoplasm by 2.3-fold and 5.2-fold, resp.  Treatment of cells with Sigma-1 ligands significantly altered translocation of TDP-43 by up to 2-fold.  Interpretation: SIGMAR1 is a causative gene for familial FTLD-MND with a unique neuropathol. that differs from other FTLD and MND cases.  Our findings also suggest Sigma-1 drugs as potential treatments for the TDP-43/FUS proteinopathies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLlsN4nYXas7Vg90H21EOLACvtfcHk0ljn3GfJeIb9tQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFOnsrbM&md5=910ad11aa17d829a5d241efd932e96a6</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1002%2Fana.22274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.22274%26sid%3Dliteratum%253Aachs%26aulast%3DLuty%26aufirst%3DA.%2BA.%26aulast%3DKwok%26aufirst%3DJ.%2BB.%2BJ.%26aulast%3DDobson-Stone%26aufirst%3DC.%26aulast%3DLoy%26aufirst%3DC.%2BT.%26aulast%3DCoupland%26aufirst%3DK.%2BG.%26aulast%3DKarlstr%25C3%25B6m%26aufirst%3DH.%26aulast%3DSobow%26aufirst%3DT.%26aulast%3DTchorzewska%26aufirst%3DJ.%26aulast%3DMaruszak%26aufirst%3DA.%26aulast%3DBarcikowska%26aufirst%3DM.%26aulast%3DPanegyres%26aufirst%3DP.%2BK.%26aulast%3DZekanowski%26aufirst%3DC.%26aulast%3DBrooks%26aufirst%3DW.%2BS.%26aulast%3DWilliams%26aufirst%3DK.%2BL.%26aulast%3DBlair%26aufirst%3DI.%2BP.%26aulast%3DMather%26aufirst%3DK.%2BA.%26aulast%3DSachdev%26aufirst%3DP.%2BS.%26aulast%3DHalliday%26aufirst%3DG.%26aulast%3DSchofield%26aufirst%3DP.%2BR.%26atitle%3DSigma%2520Nonopioid%2520Intracellular%2520Receptor%25201%2520Mutations%2520Cause%2520Frontotemporal%2520Lobar%2520Degeneration-Motor%2520Neuron%2520Disease%26jtitle%3DAnn.%2520Neurol.%26date%3D2010%26volume%3D68%26spage%3D639%26epage%3D649%26doi%3D10.1002%2Fana.22274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mancuso, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliván, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rando, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, X.</span></span> <span> </span><span class="NLM_article-title">Sigma-1R Agonist Improves Motor Function and Motoneuron Survival in ALS Mice</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">814</span>– <span class="NLM_lpage">826</span>, <span class="refDoi"> DOI: 10.1007/s13311-012-0140-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1007%2Fs13311-012-0140-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=22935988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOqtbnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=814-826&author=R.+Mancusoauthor=S.+Oliv%C3%A1nauthor=A.+Randoauthor=C.+Casasauthor=R.+Ostaauthor=X.+Navarro&title=Sigma-1R+Agonist+Improves+Motor+Function+and+Motoneuron+Survival+in+ALS+Mice&doi=10.1007%2Fs13311-012-0140-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1R Agonist Improves Motor Function and Motoneuron Survival in ALS Mice</span></div><div class="casAuthors">Mancuso, Renzo; Olivan, Sara; Rando, Amaya; Casas, Caty; Osta, Rosario; Navarro, Xavier</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">814-826</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1878-7479</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Amyotrophic lateral sclerosis is a neurodegenerative disorder characterized by progressive weakness, muscle atrophy, and paralysis due to the loss of upper and lower motoneurons (MNs).  Sigma-1 receptor (sigma-1R) activation promotes neuroprotection after ischemic and traumatic injuries to the central nervous system.  We recently reported that sigma-1R agonist (PRE-084) improves the survival of MNs after root avulsion injury in rats.  Moreover, a mutation of the sigma-1R leading to frontotemporal lobar degeneration/amyotrophic lateral sclerosis (ALS) was recently described in human patients.  In the present study, we analyzed the potential therapeutic effect of the sigma-1R agonist (PRE-084) in the SOD1G93A mouse model of ALS.  Mice were daily administered with PRE-084 (0.25 mg/kg) from 8 to 16 wk of age.  Functional outcome was assessed by electrophysiol. tests and computerized anal. of locomotion.  Histol., immunohistochem. analyses and Western blot of the spinal cord were performed.  PRE-084 administration from 8 wk of age improved the function of MNs, which was manifested by maintenance of the amplitude of muscle action potentials and locomotor behavior, and preserved neuromuscular connections and MNs in the spinal cord.  Moreover, it extended survival in both female and male mice by more than 15 %.  Delayed administration of PRE-084 from 12 wk of age also significantly improved functional outcome and preservation of the MNs.  There was an induction of protein kinase C-specific phosphorylation of the NR1 subunit of the N-methyl-D-aspartate (NMDA) receptor in SOD1G93A animals, and a redn. of the microglial reactivity compared with untreated mice.  PRE-084 exerts a dual therapeutic contribution, modulating NMDA Ca2+ influx to protect MNs, and the microglial reactivity to ameliorate the MN environment.  In conclusion, sigma-1R agonists, such as PRE-084, may be promising candidates for a therapeutical strategy of ALS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo752Zuu4G6tbVg90H21EOLACvtfcHk0ljn3GfJeIb9tQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOqtbnO&md5=d058d70a447dbc778d0bec822a01225b</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1007%2Fs13311-012-0140-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13311-012-0140-y%26sid%3Dliteratum%253Aachs%26aulast%3DMancuso%26aufirst%3DR.%26aulast%3DOliv%25C3%25A1n%26aufirst%3DS.%26aulast%3DRando%26aufirst%3DA.%26aulast%3DCasas%26aufirst%3DC.%26aulast%3DOsta%26aufirst%3DR.%26aulast%3DNavarro%26aufirst%3DX.%26atitle%3DSigma-1R%2520Agonist%2520Improves%2520Motor%2520Function%2520and%2520Motoneuron%2520Survival%2520in%2520ALS%2520Mice%26jtitle%3DNeurotherapeutics%26date%3D2012%26volume%3D9%26spage%3D814%26epage%3D826%26doi%3D10.1007%2Fs13311-012-0140-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno-Delgado, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuentes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosell-Vilar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasperini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Ruiz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medrano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallol, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortés, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casadó, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lluís, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferré, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canela, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, P. J.</span></span> <span> </span><span class="NLM_article-title">Cocaine Disrupts Histamine H3 Receptor Modulation of Dopamine D1 Receptor Signaling: σ1-D1-H3 Receptor Complexes as Key Targets for Reducing Cocaine’s Effects</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">3545</span>– <span class="NLM_lpage">3558</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.4147-13.2014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1523%2FJNEUROSCI.4147-13.2014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=24599455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkt1ajtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=3545-3558&author=E.+Morenoauthor=D.+Moreno-Delgadoauthor=G.+Navarroauthor=H.+M.+Hoffmannauthor=S.+Fuentesauthor=S.+Rosell-Vilarauthor=P.+Gasperiniauthor=M.+Rodr%C3%ADguez-Ruizauthor=M.+Medranoauthor=J.+Mallolauthor=A.+Cort%C3%A9sauthor=V.+Casad%C3%B3author=C.+Llu%C3%ADsauthor=S.+Ferr%C3%A9author=J.+Ortizauthor=E.+Canelaauthor=P.+J.+McCormick&title=Cocaine+Disrupts+Histamine+H3+Receptor+Modulation+of+Dopamine+D1+Receptor+Signaling%3A+%CF%831-D1-H3+Receptor+Complexes+as+Key+Targets+for+Reducing+Cocaine%E2%80%99s+Effects&doi=10.1523%2FJNEUROSCI.4147-13.2014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Cocaine disrupts histamine H3 receptor modulation of dopamine D1 receptor signaling: σ1-D1-H3 receptor complexes as key targets for reducing cocaine's effects</span></div><div class="casAuthors">Moreno, Estefania; Moreno-Delgado, David; Navarro, Gemma; Hoffmann, Hanne M.; Fuentes, Silvia; Rosell-Vilar, Santi; Gasperini, Paola; Rodriguez-Ruiz, Mar; Medrano, Mireia; Mallol, Josefa; Cortes, Antoni; Casado, Vicent; Lluis, Carme; Ferre, Sergi; Ortiz, Jordi; Canela, Enric; McCormick, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3545-3558</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">The general effects of cocaine are not well understood at the mol. level.  What is known is that the dopamine D1 receptor plays an important role.  Here we show that a key mechanism may be cocaine's blockade of the histamine H3 receptor-mediated inhibition of D1 receptor function.  This blockade requires the σ1 receptor and occurs upon cocaine binding to σ1-D1-H3 receptor complexes.  The cocaine-mediated disruption leaves an uninhibited D1 receptor that activates Gs, freely recruits β-arrestin, increases p-ERK 1/2 levels, and induces cell death when over activated.  Using in vitro assays with transfected cells and in ex vivo expts. using both rats acutely treated or self-administered with cocaine along with mice depleted of σ1 receptor, we show that blockade of σ1 receptor by an antagonist restores the protective H3 receptor-mediated brake on D1 receptor signaling and prevents the cell death from elevated D1 receptor signaling.  These findings suggest that a combination therapy of σ1R antagonists with H3 receptor agonists could serve to reduce some effects of cocaine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_ARavI4E7T7Vg90H21EOLACvtfcHk0ljn3GfJeIb9tQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkt1ajtrc%253D&md5=6aea1fdccecd4373e3a36ecea9e5d9dd</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.4147-13.2014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.4147-13.2014%26sid%3Dliteratum%253Aachs%26aulast%3DMoreno%26aufirst%3DE.%26aulast%3DMoreno-Delgado%26aufirst%3DD.%26aulast%3DNavarro%26aufirst%3DG.%26aulast%3DHoffmann%26aufirst%3DH.%2BM.%26aulast%3DFuentes%26aufirst%3DS.%26aulast%3DRosell-Vilar%26aufirst%3DS.%26aulast%3DGasperini%26aufirst%3DP.%26aulast%3DRodr%25C3%25ADguez-Ruiz%26aufirst%3DM.%26aulast%3DMedrano%26aufirst%3DM.%26aulast%3DMallol%26aufirst%3DJ.%26aulast%3DCort%25C3%25A9s%26aufirst%3DA.%26aulast%3DCasad%25C3%25B3%26aufirst%3DV.%26aulast%3DLlu%25C3%25ADs%26aufirst%3DC.%26aulast%3DFerr%25C3%25A9%26aufirst%3DS.%26aulast%3DOrtiz%26aufirst%3DJ.%26aulast%3DCanela%26aufirst%3DE.%26aulast%3DMcCormick%26aufirst%3DP.%2BJ.%26atitle%3DCocaine%2520Disrupts%2520Histamine%2520H3%2520Receptor%2520Modulation%2520of%2520Dopamine%2520D1%2520Receptor%2520Signaling%253A%2520%25CF%25831-D1-H3%2520Receptor%2520Complexes%2520as%2520Key%2520Targets%2520for%2520Reducing%2520Cocaine%25E2%2580%2599s%2520Effects%26jtitle%3DJ.%2520Neurosci.%26date%3D2014%26volume%3D34%26spage%3D3545%26epage%3D3558%26doi%3D10.1523%2FJNEUROSCI.4147-13.2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonaventura, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brugarolas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farré, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguinaga, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallol, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortés, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casadó, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lluís, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canela, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, P. J.</span></span> <span> </span><span class="NLM_article-title">Cocaine Inhibits Dopamine D2 Receptor Signaling via Sigma-1-D2 Receptor Heteromers</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e61245</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0061245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1371%2Fjournal.pone.0061245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=23637801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvFaqs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&author=G.+Navarroauthor=E.+Morenoauthor=J.+Bonaventuraauthor=M.+Brugarolasauthor=D.+Farr%C3%A9author=D.+Aguinagaauthor=J.+Mallolauthor=A.+Cort%C3%A9sauthor=V.+Casad%C3%B3author=C.+Llu%C3%ADsauthor=S.+Ferreauthor=R.+Francoauthor=E.+Canelaauthor=P.+J.+McCormick&title=Cocaine+Inhibits+Dopamine+D2+Receptor+Signaling+via+Sigma-1-D2+Receptor+Heteromers&doi=10.1371%2Fjournal.pone.0061245"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Cocaine inhibits dopamine D2 receptor signaling via sigma-1-D2 receptor heteromers</span></div><div class="casAuthors">Navarro, Gemma; Moreno, Estefania; Bonaventura, Jordi; Brugarolas, Marc; Farre, Daniel; Aguinaga, David; Mallol, Josefa; Cortes, Antoni; Casado, Vicent; Lluis, Carmen; Ferre, Sergi; Franco, Rafael; Canela, Enric; McCormick, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e61245</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Under normal conditions the brain maintains a delicate balance between inputs of reward seeking controlled by neurons contg. the D1-like family of dopamine receptors and inputs of aversion coming from neurons contg. the D2-like family of dopamine receptors.  Cocaine is able to subvert these balanced inputs by altering the cell signaling of these two pathways such that D1 reward seeking pathway dominates.  Here, we provide an explanation at the cellular and biochem. level how cocaine may achieve this.  Exploring the effect of cocaine on dopamine D2 receptors function, we present evidence of σ1 receptor mol. and functional interaction with dopamine D2 receptors.  Using biophys., biochem. and cell biol. approaches, we discovered that D2 receptors (the long isoform of the D2 receptor) can complex with σ1 receptors, a result that is specific to D2 receptors, as D3 and D4 receptors did not form heteromers.  We demonstrate that the σ1-D2 receptor heteromers consist of higher order oligomers, are found in mouse striatum and that cocaine, by binding to σ1-D2 receptor heteromers, inhibits downstream signaling in both cultured cells and in mouse striatum.  In contrast, in striatum from σ1 knockout animals these complexes are not found and this inhibition is not seen.  Taken together, these data illuminate the mechanism by which the initial exposure to cocaine can inhibit signaling via D2 receptor contg. neurons, destabilizing the delicate signaling balance influencing drug seeking that emanates from the D1 and D2 receptor contg. neurons in the brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR4PjTJlFvzLVg90H21EOLACvtfcHk0lglO9m66TcVgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvFaqs7g%253D&md5=61bcdce4f07ad8dc8582c3d1b692359d</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0061245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0061245%26sid%3Dliteratum%253Aachs%26aulast%3DNavarro%26aufirst%3DG.%26aulast%3DMoreno%26aufirst%3DE.%26aulast%3DBonaventura%26aufirst%3DJ.%26aulast%3DBrugarolas%26aufirst%3DM.%26aulast%3DFarr%25C3%25A9%26aufirst%3DD.%26aulast%3DAguinaga%26aufirst%3DD.%26aulast%3DMallol%26aufirst%3DJ.%26aulast%3DCort%25C3%25A9s%26aufirst%3DA.%26aulast%3DCasad%25C3%25B3%26aufirst%3DV.%26aulast%3DLlu%25C3%25ADs%26aufirst%3DC.%26aulast%3DFerre%26aufirst%3DS.%26aulast%3DFranco%26aufirst%3DR.%26aulast%3DCanela%26aufirst%3DE.%26aulast%3DMcCormick%26aufirst%3DP.%2BJ.%26atitle%3DCocaine%2520Inhibits%2520Dopamine%2520D2%2520Receptor%2520Signaling%2520via%2520Sigma-1-D2%2520Receptor%2520Heteromers%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26doi%3D10.1371%2Fjournal.pone.0061245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Alvear, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werling, L. L.</span></span> <span> </span><span class="NLM_article-title">Regulation of [<sup>3</sup>H]Dopamine Release from Rat Striatal Slices by Sigma Receptor Ligands</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>271</i></span>,  <span class="NLM_fpage">212</span>– <span class="NLM_lpage">219</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=7965717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADyaK2cXmvFalsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1994&pages=212-219&author=G.+M.+Gonzalez-Alvearauthor=L.+L.+Werling&title=Regulation+of+%5B3H%5DDopamine+Release+from+Rat+Striatal+Slices+by+Sigma+Receptor+Ligands"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of [3H]dopamine release from rat striatal slices by sigma receptor ligands</span></div><div class="casAuthors">Gonzalez-Alvear, Grace M.; Werling, Linda L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">271</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">212-19</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">Sigma receptors have been located in several areas of the brain that control motor function, including on the dopaminergic projections from substantia nigra to striatum.  In the current study, the regulation of N-methyl-D-aspartate-stimulated [3H]dopamine release from slices of rat striatum by several sigma ligands has been tested.  Both isomers of the benzomorphans SKF10,047 and pentazocine inhibited the stimulated release of dopamine in a concn.-related manner.  All these compds. probably activate sigma and non-sigma receptors, including phencyclidine receptors, over the broad concn. ranges tested.  However, concns. of (+)pentazocine below about 100 nM appear to act solely through sigma receptors.  This phase of inhibition was reversed by the sigma antagonist N-[-2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-[1-pyrimidinyl]-1-piperazine butanol and by the sigma1-selective antagonist (1-(cyclopropylmethyl)-4-2'4''-fluorophenyl)-(2'-oxoethyl)piperidine HBr.  Neither of these antagonists affected stimulated release in the absence of (+)pentazocine.  The synthetic sigma ligands 2-(4-morpholino)ethyl 1-phenylcyclohexane-1-carboxylate hydrochloride, 6-[6-(4-hydroxypiperidinyl)hexoxy]-3-methylflavone hydrochloride and α-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol enhanced NMDA-stimulated DA release significantly in the presence of (+)pentazocine.  These drugs have affinity at non-sigma receptors as well, and their stimulatory effects may be mediated through these receptors along with nonreceptor mechanisms.  Our findings on the regulation of dopamine support earlier assertions that sigma receptors may be important in the regulation of motor function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocYAAK7ai78rVg90H21EOLACvtfcHk0lglO9m66TcVgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmvFalsbY%253D&md5=841e4f47964742ea17263c8c238e6303</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez-Alvear%26aufirst%3DG.%2BM.%26aulast%3DWerling%26aufirst%3DL.%2BL.%26atitle%3DRegulation%2520of%2520%255B3H%255DDopamine%2520Release%2520from%2520Rat%2520Striatal%2520Slices%2520by%2520Sigma%2520Receptor%2520Ligands%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1994%26volume%3D271%26spage%3D212%26epage%3D219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hong, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiranita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amara, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span> <span> </span><span class="NLM_article-title">The Sigma-1 Receptor Modulates Dopamine Transporter Conformation and Cocaine Binding and May Thereby Potentiate Cocaine Self-Administration in Rats</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>292</i></span>,  <span class="NLM_fpage">11250</span>– <span class="NLM_lpage">11261</span>, <span class="refDoi"> DOI: 10.1074/jbc.M116.774075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1074%2Fjbc.M116.774075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=28495886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFCisL7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=2017&pages=11250-11261&author=W.+C.+Hongauthor=H.+Yanoauthor=T.+Hiranitaauthor=F.+T.+Chinauthor=C.+R.+McCurdyauthor=T.+P.+Suauthor=S.+G.+Amaraauthor=J.+L.+Katz&title=The+Sigma-1+Receptor+Modulates+Dopamine+Transporter+Conformation+and+Cocaine+Binding+and+May+Thereby+Potentiate+Cocaine+Self-Administration+in+Rats&doi=10.1074%2Fjbc.M116.774075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">The sigma-1 receptor modulates dopamine transporter conformation and cocaine binding and may thereby potentiate cocaine self-administration in rats</span></div><div class="casAuthors">Hong, Weimin Conrad; Yano, Hideaki; Hiranita, Takato; Chin, Frederick T.; McCurdy, Christopher R.; Su, Tsung-Ping; Amara, Susan G.; Katz, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">292</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">11250-11261</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The dopamine transporter (DAT) regulates dopamine (DA) neurotransmission by recapturing DA into the presynaptic terminals and is a principal target of the psychostimulant cocaine.  The sigma-1 receptor (σ1R) is a mol. chaperone, and its ligands have been shown to modulate DA neuronal signaling, although their effects on DAT activity are unclear.  Here, the authors report that the prototypical σ1R agonist (+)-pentazocine potentiated the dose response of cocaine self-administration in rats, consistent with the effects of the σR agonists PRE-084 and DTG (1,3-di-o-tolylguanidine) reported previously.  These behavioral effects appeared to be correlated with functional changes of DAT.  Preincubation with (+)-pentazocine or PRE-084 increased the Bmax values of [3H]WIN35428 binding to DAT in rat striatal synaptosomes and transfected cells.  A specific interaction between σ1R and DAT was detected by co-immunopptn. and bioluminescence resonance energy transfer assays.  Mutational analyses indicated that the transmembrane domain of σ1R likely mediated this interaction.  Furthermore, cysteine accessibility assays showed that σ1R agonist preincubation potentiated cocaine-induced changes in DAT conformation, which were blocked by the specific σ1R antagonist CM304.  Moreover, σ1R ligands had distinct effects on σ1R multimerization.  CM304 increased the proportion of multimeric σ1Rs, whereas (+)-pentazocine increased monomeric σ1Rs.  Together these results support the hypothesis that σ1R agonists promote dissocn. of σ1R multimers into monomers, which then interact with DAT to stabilize an outward-facing DAT conformation and enhance cocaine binding.  The authors propose that this novel mol. mechanism underlies the behavioral potentiation of cocaine self-administration by σ1R agonists in animal models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9IZLHbohe7rVg90H21EOLACvtfcHk0ljJLGobmsooxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFCisL7F&md5=5366dbf409e7cbefeb52c79a3198023f</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M116.774075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M116.774075%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DW.%2BC.%26aulast%3DYano%26aufirst%3DH.%26aulast%3DHiranita%26aufirst%3DT.%26aulast%3DChin%26aufirst%3DF.%2BT.%26aulast%3DMcCurdy%26aufirst%3DC.%2BR.%26aulast%3DSu%26aufirst%3DT.%2BP.%26aulast%3DAmara%26aufirst%3DS.%2BG.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26atitle%3DThe%2520Sigma-1%2520Receptor%2520Modulates%2520Dopamine%2520Transporter%2520Conformation%2520and%2520Cocaine%2520Binding%2520and%2520May%2520Thereby%2520Potentiate%2520Cocaine%2520Self-Administration%2520in%2520Rats%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2017%26volume%3D292%26spage%3D11250%26epage%3D11261%26doi%3D10.1074%2Fjbc.M116.774075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Francardo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denis, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayden, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cenci, M. A.</span></span> <span> </span><span class="NLM_article-title">Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson’s Disease</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">465</span>– <span class="NLM_lpage">479</span>, <span class="refDoi"> DOI: 10.1007/s13311-018-00699-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1007%2Fs13311-018-00699-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=30756361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVyrtL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2019&pages=465-479&author=V.+Francardoauthor=M.+Gevaauthor=F.+Bezauthor=Q.+Denisauthor=L.+Steinerauthor=M.+R.+Haydenauthor=M.+A.+Cenci&title=Pridopidine+Induces+Functional+Neurorestoration+Via+the+Sigma-1+Receptor+in+a+Mouse+Model+of+Parkinson%E2%80%99s+Disease&doi=10.1007%2Fs13311-018-00699-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson's Disease</span></div><div class="casAuthors">Francardo, Veronica; Geva, Michal; Bez, Francesco; Denis, Quentin; Steiner, Lilach; Hayden, Michael R.; Cenci, M. Angela</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">465-479</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1878-7479</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Pridopidine is a small mol. in clin. development for the treatment of Huntington's disease.  It was recently found to have high binding affinity to the sigma-1 receptor, a chaperone protein involved in cellular defense mechanisms and neuroplasticity.  Here, we have evaluated the neuroprotective and neurorestorative effects of pridopidine in a unilateral 6-hydroxydopamine (6-OHDA) lesion model of parkinsonism in mice.  By 5 wk of daily administration, a low dose of pridopidine (0.3 mg/kg) had significantly improved deficits in forelimb use (cylinder test, stepping test) and abolished the ipsilateral rotational bias typical of hemiparkinsonian animals.  A higher dose of pridopidine (1 mg/kg) significantly improved only the rotational bias, with a trend towards improvement in forelimb use.  The behavioral recovery induced by pridopidine 0.3 mg/kg was accompanied by a significant protection of nigral dopamine cell bodies, an increased dopaminergic fiber d. in the striatum, and striatal upregulation of GDNF, BDNF, and phosphorylated ERK1/2.  The beneficial effects of pridopidine 0.3 mg/kg were absent in 6-OHDA-lesioned mice lacking the sigma-1 receptor.  Pharmacokinetic data confirmed that the ED of pridopidine reached brain concns. sufficient to bind S1R.  These results are the first to show that pridopidine promotes functional neurorestoration in the damaged nigrostriatal system acting via the sigma-1 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIU8OUezMugrVg90H21EOLACvtfcHk0ljJLGobmsooxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVyrtL3P&md5=04b464473e75e4ce8aaec9d65bf08231</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1007%2Fs13311-018-00699-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13311-018-00699-9%26sid%3Dliteratum%253Aachs%26aulast%3DFrancardo%26aufirst%3DV.%26aulast%3DGeva%26aufirst%3DM.%26aulast%3DBez%26aufirst%3DF.%26aulast%3DDenis%26aufirst%3DQ.%26aulast%3DSteiner%26aufirst%3DL.%26aulast%3DHayden%26aufirst%3DM.%2BR.%26aulast%3DCenci%26aufirst%3DM.%2BA.%26atitle%3DPridopidine%2520Induces%2520Functional%2520Neurorestoration%2520Via%2520the%2520Sigma-1%2520Receptor%2520in%2520a%2520Mouse%2520Model%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DNeurotherapeutics%26date%3D2019%26volume%3D16%26spage%3D465%26epage%3D479%26doi%3D10.1007%2Fs13311-018-00699-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hyrskyluoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulli, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Törnqvist, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korhonen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindholm, D.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 Receptor Agonist PRE084 Is Protective against Mutant Huntingtin-Induced Cell Degeneration: Involvement of Calpastatin and the NF-KB Pathway</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e646</span> <span class="refDoi"> DOI: 10.1038/cddis.2013.170</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fcddis.2013.170" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=23703391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVykt77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&author=A.+Hyrskyluotoauthor=I.+Pulliauthor=K.+T%C3%B6rnqvistauthor=T.+H.+Hoauthor=L.+Korhonenauthor=D.+Lindholm&title=Sigma-1+Receptor+Agonist+PRE084+Is+Protective+against+Mutant+Huntingtin-Induced+Cell+Degeneration%3A+Involvement+of+Calpastatin+and+the+NF-KB+Pathway&doi=10.1038%2Fcddis.2013.170"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-induced cell degeneration: involvement of calpastatin and the NF-κB pathway</span></div><div class="casAuthors">Hyrskyluoto, A.; Pulli, I.; Tornqvist, K.; Ho, T. Huu; Korhonen, L.; Lindholm, D.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">May</span>),
    <span class="NLM_cas:pages">e646</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Alterations in mitochondria and increased oxidative stress are assocd. with the disease progression in Huntington's disease (HD).  Endoplasmic reticulum (ER) stress and oxidative damage are linked through the close communication between the ER and mitochondria.  Sigma-1 receptor (Sig-1R) is a chaperone protein in the ER that is involved in ER stress regulation, but little is known about its role in HD or the mechanisms for cell protection.  Here we show that the Sig-1R agonist, PRE084 increases cell survival and counteracts the deleterious effects caused by N-terminal mutant huntingtin proteins in neuronal PC6.3 cells.  Particularly, PRE084 increased the levels of cellular antioxidants by activating the NF-κB pathway that is compromised by the expression of mutant huntingtin proteins.  These results show that the Sig-1R agonist has beneficial effects in models of HD and that compds. affecting the Sig-1R may be promising targets for future drug development in HD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoABRB1xtV29LVg90H21EOLACvtfcHk0ljJLGobmsooxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVykt77F&md5=987bdc296073218c5acfe69050f288d2</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1038%2Fcddis.2013.170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddis.2013.170%26sid%3Dliteratum%253Aachs%26aulast%3DHyrskyluoto%26aufirst%3DA.%26aulast%3DPulli%26aufirst%3DI.%26aulast%3DT%25C3%25B6rnqvist%26aufirst%3DK.%26aulast%3DHo%26aufirst%3DT.%2BH.%26aulast%3DKorhonen%26aufirst%3DL.%26aulast%3DLindholm%26aufirst%3DD.%26atitle%3DSigma-1%2520Receptor%2520Agonist%2520PRE084%2520Is%2520Protective%2520against%2520Mutant%2520Huntingtin-Induced%2520Cell%2520Degeneration%253A%2520Involvement%2520of%2520Calpastatin%2520and%2520the%2520NF-KB%2520Pathway%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2013%26volume%3D4%26doi%3D10.1038%2Fcddis.2013.170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith-Dijak, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nassrallah, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayden, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymond, L. A.</span></span> <span> </span><span class="NLM_article-title">Impairment and Restoration of Homeostatic Plasticity in Cultured Cortical Neurons From a Mouse Model of Huntington Disease</span>. <i>Front. Cell. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">209</span>, <span class="refDoi"> DOI: 10.3389/fncel.2019.00209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3389%2Ffncel.2019.00209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=31156395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslKms7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=209&author=A.+I.+Smith-Dijakauthor=W.+B.+Nassrallahauthor=L.+Y.+J.+Zhangauthor=M.+Gevaauthor=M.+R.+Haydenauthor=L.+A.+Raymond&title=Impairment+and+Restoration+of+Homeostatic+Plasticity+in+Cultured+Cortical+Neurons+From+a+Mouse+Model+of+Huntington+Disease&doi=10.3389%2Ffncel.2019.00209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Impairment and restoration of homeostatic plasticity in cultured cortical neurons from a mouse model of Huntington disease</span></div><div class="casAuthors">Smith-Dijak, Amy I.; Nassrallah, Wissam B.; Zhang, Lily Y. J.; Geva, Michal; Hayden, Michael R.; Raymond, Lynn A.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Cellular Neuroscience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">209</span>CODEN:
                <span class="NLM_cas:coden">FCNRAH</span>;
        ISSN:<span class="NLM_cas:issn">1662-5102</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Huntington disease (HD) is an inherited neurodegenerative disorder caused by a mutation in the huntingtin gene.  The onset of symptoms is preceded by synaptic dysfunction.  Homeostatic synaptic plasticity (HSP) refers to processes that maintain the stability of networks of neurons, thought to be required to enable new learning and cognitive flexibility.  One type of HSP is synaptic scaling, in which the strength of all of the synapses onto a cell increases or decreases following changes in the cell's level of activity.  Several pathways implicated in synaptic scaling are dysregulated in HD, including brain-derived neurotrophic factor (BDNF) and calcium signaling.  Here, we investigated whether HSP is disrupted in cortical neurons from an HD mouse model.  We treated cultured cortical neurons from wild-type (WT) FVB/N or YAC128 HD mice with tetrodotoxin (TTX) for 48 h to silence action potentials and then recorded miniature excitatory postsynaptic currents.  In WT cultures, these increased in both amplitude and frequency after TTX treatment, and further expts. showed that this was a result of insertion of AMPA receptors and formation of new synapses, resp.  Manipulation of BDNF concn. in the culture medium revealed that BDNF signaling contributed to these changes.  In contrast to WT cortical neurons, YAC128 cultures showed no response to action potential silencing.  Strikingly, we were able to restore the TTX-induced changes in YAC128 cultures by treating them with pridopidine, a drug which enhances BDNF signaling through stimulation of the sigma-1 receptor (S1R), and with the S1R agonist 3-PPP.  These data provide evidence for disruption of HSP in cortical neurons from an HD mouse model that is restored by stimulation of S1R.  Our results suggest a potential new direction for developing therapy to mitigate cognitive deficits in HD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7wLNy01XJ2rVg90H21EOLACvtfcHk0livHx8ba88RLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslKms7g%253D&md5=eb7194d47c11a35696fc5fe416563a28</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.3389%2Ffncel.2019.00209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffncel.2019.00209%26sid%3Dliteratum%253Aachs%26aulast%3DSmith-Dijak%26aufirst%3DA.%2BI.%26aulast%3DNassrallah%26aufirst%3DW.%2BB.%26aulast%3DZhang%26aufirst%3DL.%2BY.%2BJ.%26aulast%3DGeva%26aufirst%3DM.%26aulast%3DHayden%26aufirst%3DM.%2BR.%26aulast%3DRaymond%26aufirst%3DL.%2BA.%26atitle%3DImpairment%2520and%2520Restoration%2520of%2520Homeostatic%2520Plasticity%2520in%2520Cultured%2520Cortical%2520Neurons%2520From%2520a%2520Mouse%2520Model%2520of%2520Huntington%2520Disease%26jtitle%3DFront.%2520Cell.%2520Neurosci.%26date%3D2019%26volume%3D13%26spage%3D209%26doi%3D10.3389%2Ffncel.2019.00209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schreiner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedskog, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiehager, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ankarcrona, M.</span></span> <span> </span><span class="NLM_article-title">Amyloid-β Peptides Are Generated in Mitochondria-Associated Endoplasmic Reticulum Membranes</span>. <i>J. Alzheimer’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">369</span>– <span class="NLM_lpage">374</span>, <span class="refDoi"> DOI: 10.3233/JAD-132543</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3233%2FJAD-132543" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2014&pages=369-374&author=B.+Schreinerauthor=L.+Hedskogauthor=B.+Wiehagerauthor=M.+Ankarcrona&title=Amyloid-%CE%B2+Peptides+Are+Generated+in+Mitochondria-Associated+Endoplasmic+Reticulum+Membranes&doi=10.3233%2FJAD-132543"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.3233%2FJAD-132543&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-132543%26sid%3Dliteratum%253Aachs%26aulast%3DSchreiner%26aufirst%3DB.%26aulast%3DHedskog%26aufirst%3DL.%26aulast%3DWiehager%26aufirst%3DB.%26aulast%3DAnkarcrona%26aufirst%3DM.%26atitle%3DAmyloid-%25CE%25B2%2520Peptides%2520Are%2520Generated%2520in%2520Mitochondria-Associated%2520Endoplasmic%2520Reticulum%2520Membranes%26jtitle%3DJ.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2014%26volume%3D43%26spage%3D369%26epage%3D374%26doi%3D10.3233%2FJAD-132543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryskamp, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rammes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezprozvanny, I.</span></span> <span> </span><span class="NLM_article-title">Pridopidine Stabilizes Mushroom Spines in Mouse Models of Alzheimer’s Disease by Acting on the Sigma-1 Receptor</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">489</span>– <span class="NLM_lpage">504</span>, <span class="refDoi"> DOI: 10.1016/j.nbd.2018.12.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.nbd.2018.12.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=30594810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntFCrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2019&pages=489-504&author=D.+Ryskampauthor=L.+Wuauthor=J.+Wuauthor=D.+Kimauthor=G.+Rammesauthor=M.+Gevaauthor=M.+Haydenauthor=I.+Bezprozvanny&title=Pridopidine+Stabilizes+Mushroom+Spines+in+Mouse+Models+of+Alzheimer%E2%80%99s+Disease+by+Acting+on+the+Sigma-1+Receptor&doi=10.1016%2Fj.nbd.2018.12.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Pridopidine stabilizes mushroom spines in mouse models of Alzheimer's disease by acting on the sigma-1 receptor</span></div><div class="casAuthors">Ryskamp, Daniel; Wu, Lili; Wu, Jun; Kim, Dabin; Rammes, Gerhard; Geva, Michal; Hayden, Michael; Bezprozvanny, Ilya</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">489-504</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">There is evidence that cognitive decline in Alzheimer's disease (AD) results from deficiencies in synaptic communication (e.g., loss of mushroom-shaped 'memory spines') and neurodegenerative processes.  This might be treated with sigma-1 receptor (S1R) agonists, which are broadly neuroprotective and modulate synaptic plasticity.  For example, we previously found that the mixed muscarinic/S1R agonist AF710B prevents mushroom spine loss in hippocampal cultures from APP knock-in (APP-KI) and presenilin-1-M146 V knock-in (PS1-KI) mice.  We also found that the "dopaminergic stabilizer" pridopidine (structurally similar to the S1R agonist R(+)-3-PPP), is a high-affinity S1R agonist and is synaptoprotective in a mouse model of Huntington disease.  Here we tested whether pridopidine and R(+)-3-PPP are synaptoprotective in models of AD and whether this requires S1R.  We also examd. the effects of pridopidine on long-term potentiation (LTP), endoplasmic reticulum calcium and neuronal store-operated calcium entry (nSOC) in spines, all of which are dysregulated in AD, contributing to synaptic pathol.  We report here that pridopidine and 3-PPP protect mushroom spines from Aβ42 oligomer toxicity in primary WT hippocampal cultures from mice.  Pridopidine also reversed LTP defects in hippocampal slices resulting from application of Aβ42 oligomers.  Pridopidine and 3-PPP rescued mushroom spines in hippocampal cultures from APP-KI and PS1-KI mice.  S1R knockdown from lenti-viral shRNA expression destabilized WT mushroom spines and prevented the synaptoprotective effects of pridopidine in PS1-KI cultures.  Knockout of PS1/2 destabilized mushroom spines and pridopidine was unable to prevent this.  Pridopidine lowered endoplasmic reticulum calcium levels in WT, PS1-KO, PS1-KI and PS2 KO neurons, but not in PS1/2 KO neurons.  S1R was required for pridopidine to enhance spine nSOC in PS1-KI neurons.  Pridopidine was unable to rescue PS1-KI mushroom spines during pharmacol. or genetic inhibition of nSOC.  Oral pridopidine treatment rescued mushroom spines in vivo in aged PS1-KI-GFP mice.  Pridopidine stabilizes mushroom spines in mouse models of AD and this requires S1R, endoplasmic reticulum calcium leakage through PS1/2 and nSOC.  Thus, pridopidine may be useful to explore for the treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZa0vjyeC-9rVg90H21EOLACvtfcHk0ljie9f7X6xiEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntFCrsg%253D%253D&md5=70e9a25da577b8469533fda8b9316348</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2018.12.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2018.12.022%26sid%3Dliteratum%253Aachs%26aulast%3DRyskamp%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DD.%26aulast%3DRammes%26aufirst%3DG.%26aulast%3DGeva%26aufirst%3DM.%26aulast%3DHayden%26aufirst%3DM.%26aulast%3DBezprozvanny%26aufirst%3DI.%26atitle%3DPridopidine%2520Stabilizes%2520Mushroom%2520Spines%2520in%2520Mouse%2520Models%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%2520by%2520Acting%2520on%2520the%2520Sigma-1%2520Receptor%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2019%26volume%3D124%26spage%3D489%26epage%3D504%26doi%3D10.1016%2Fj.nbd.2018.12.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryskamp, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusko, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezprozvanny, I.</span></span> <span> </span><span class="NLM_article-title">The Sigma-1 Receptor Mediates the Beneficial Effects of Pridopidine in a Mouse Model of Huntington Disease</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1016/j.nbd.2016.10.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.nbd.2016.10.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=27818324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVKqtb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2017&pages=46-59&author=D.+Ryskampauthor=J.+Wuauthor=M.+Gevaauthor=R.+Kuskoauthor=I.+Grossmanauthor=M.+Haydenauthor=I.+Bezprozvanny&title=The+Sigma-1+Receptor+Mediates+the+Beneficial+Effects+of+Pridopidine+in+a+Mouse+Model+of+Huntington+Disease&doi=10.1016%2Fj.nbd.2016.10.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease</span></div><div class="casAuthors">Ryskamp, Daniel; Wu, Jun; Geva, Michal; Kusko, Rebecca; Grossman, Iris; Hayden, Michael; Bezprozvanny, Ilya</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">Part_A</span>),
    <span class="NLM_cas:pages">46-59</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The tri-nucleotide repeat expansion underlying Huntington disease (HD) results in corticostriatal synaptic dysfunction and subsequent neurodegeneration of striatal medium spiny neurons (MSNs).  HD is a devastating autosomal dominant disease with no disease-modifying treatments.  Pridopidine, a postulated "dopamine stabilizer", has been shown to improve motor symptoms in clin. trials of HD.  However, the target(s) and mechanism of action of pridopidine remain to be fully elucidated.  As binding studies identified sigma-1 receptor (S1R) as a high-affinity receptor for pridopidine, we evaluated the relevance of S1R as a therapeutic target of pridopidine in HD.  S1R is an endoplasmic reticulum - (ER) resident transmembrane protein and is regulated by ER calcium homeostasis, which is perturbed in HD.  Consistent with ER calcium dysregulation, we obsd. striatal upregulation of S1R in aged YAC128 transgenic HD mice and HD patients.  We previously demonstrated that dendritic MSN spines are lost in aged corticostriatal co-cultures from YAC128 mice.  We report here that pridopidine and the chem. similar S1R agonist 3-PPP prevent MSN spine loss in aging YAC128 co-cultures.  Spine protection was blocked by neuronal deletion of S1R.  Pridopidine treatment suppressed supranormal ER Ca2 + release, restored ER calcium levels and reduced excessive store-operated calcium (SOC) entry in spines, which may account for its synaptoprotective effects.  Normalization of ER Ca2 + levels by pridopidine was prevented by S1R deletion.  To evaluate long-term effects of pridopidine, we analyzed expression profiles of calcium signaling genes.  Pridopidine elevated striatal expression of calbindin and homer1a, whereas their striatal expression was reduced in aged Q175KI and YAC128 HD mouse models compared to WT.  Pridopidine and 3-PPP are proposed to prevent calcium dysregulation and synaptic loss in a YAC128 corticostriatal co-culture model of HD.  The actions of pridopidine were mediated by S1R and led to normalization of ER Ca2 + release, ER Ca2 + levels and spine SOC entry in YAC128 MSNs.  This is a new potential mechanism of action for pridopidine, highlighting S1R as a potential target for HD therapy.  Upregulation of striatal proteins that regulate calcium, including calbindin and homer1a, upon chronic therapy with pridopidine, may further contribute to long-term beneficial effects of pridopidine in HD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLP9zDH00CBLVg90H21EOLACvtfcHk0ljie9f7X6xiEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVKqtb7K&md5=81866000c3f2215fdb8a03f7f69bcff8</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2016.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2016.10.006%26sid%3Dliteratum%253Aachs%26aulast%3DRyskamp%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DGeva%26aufirst%3DM.%26aulast%3DKusko%26aufirst%3DR.%26aulast%3DGrossman%26aufirst%3DI.%26aulast%3DHayden%26aufirst%3DM.%26aulast%3DBezprozvanny%26aufirst%3DI.%26atitle%3DThe%2520Sigma-1%2520Receptor%2520Mediates%2520the%2520Beneficial%2520Effects%2520of%2520Pridopidine%2520in%2520a%2520Mouse%2520Model%2520of%2520Huntington%2520Disease%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2017%26volume%3D97%26spage%3D46%26epage%3D59%26doi%3D10.1016%2Fj.nbd.2016.10.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryskamp, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korban, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhemkov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraskovskaya, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezprozvanny, I.</span></span> <span> </span><span class="NLM_article-title">Neuronal Sigma-1 Receptors: Signaling Functions and Protective Roles in Neurodegenerative Diseases</span>. <i>Front. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">862</span>, <span class="refDoi"> DOI: 10.3389/fnins.2019.00862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3389%2Ffnins.2019.00862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=31551669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BB3MnhvVWjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=862&author=D.+A.+Ryskampauthor=S.+Korbanauthor=V.+Zhemkovauthor=N.+Kraskovskayaauthor=I.+Bezprozvanny&title=Neuronal+Sigma-1+Receptors%3A+Signaling+Functions+and+Protective+Roles+in+Neurodegenerative+Diseases&doi=10.3389%2Ffnins.2019.00862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Neuronal Sigma-1 Receptors: Signaling Functions and Protective Roles in Neurodegenerative Diseases</span></div><div class="casAuthors">Ryskamp Daniel A; Zhemkov Vladimir; Bezprozvanny Ilya; Korban Svetlana; Kraskovskaya Nina; Bezprozvanny Ilya</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">862</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">Sigma-1 receptor (S1R) is a multi-functional, ligand-operated protein situated in endoplasmic reticulum (ER) membranes and changes in its function and/or expression have been associated with various neurological disorders including amyotrophic lateral sclerosis/frontotemporal dementia, Alzheimer's (AD) and Huntington's diseases (HD).  S1R agonists are broadly neuroprotective and this is achieved through a diversity of S1R-mediated signaling functions that are generally pro-survival and anti-apoptotic; yet, relatively little is known regarding the exact mechanisms of receptor functioning at the molecular level.  This review summarizes therapeutically relevant mechanisms by which S1R modulates neurophysiology and implements neuroprotective functions in neurodegenerative diseases.  These mechanisms are diverse due to the fact that S1R can bind to and modulate a large range of client proteins, including many ion channels in both ER and plasma membranes.  We summarize the effect of S1R on its interaction partners and consider some of the cell type- and disease-specific aspects of these actions.  Besides direct protein interactions in the endoplasmic reticulum, S1R is likely to function at the cellular/interorganellar level by altering the activity of several plasmalemmal ion channels through control of trafficking, which may help to reduce excitotoxicity.  Moreover, S1R is situated in lipid rafts where it binds cholesterol and regulates lipid and protein trafficking and calcium flux at the mitochondrial-associated membrane (MAM) domain.  This may have important implications for MAM stability and function in neurodegenerative diseases as well as cellular bioenergetics.  We also summarize the structural and biochemical features of S1R proposed to underlie its activity.  In conclusion, S1R is incredibly versatile in its ability to foster neuronal homeostasis in the context of several neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTnXmondofHvmyYR5VtavbzfW6udTcc2ebTEa2JcflW4rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnhvVWjsA%253D%253D&md5=b8a65774a44e82a94e5049247c993883</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2019.00862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2019.00862%26sid%3Dliteratum%253Aachs%26aulast%3DRyskamp%26aufirst%3DD.%2BA.%26aulast%3DKorban%26aufirst%3DS.%26aulast%3DZhemkov%26aufirst%3DV.%26aulast%3DKraskovskaya%26aufirst%3DN.%26aulast%3DBezprozvanny%26aufirst%3DI.%26atitle%3DNeuronal%2520Sigma-1%2520Receptors%253A%2520Signaling%2520Functions%2520and%2520Protective%2520Roles%2520in%2520Neurodegenerative%2520Diseases%26jtitle%3DFront.%2520Neurosci.%26date%3D2019%26volume%3D13%26spage%3D862%26doi%3D10.3389%2Ffnins.2019.00862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Izzo, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staniszewski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teich, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeed, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wostein, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walko, T.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaswani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardius, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syed, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravenscroft, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mozzoni, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silky, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehak, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yurko, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Look, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rishton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safferstein, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johanson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stopa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windisch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutter-Paier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shamloo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arancio, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeVine, H.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catalano, S. M.</span></span> <span> </span><span class="NLM_article-title">Alzheimer’s Therapeutics Targeting Amyloid Beta 1–42 Oligomers I: Abeta 42 Oligomer Binding to Specific Neuronal Receptors Is Displaced by Drug Candidates That Improve Cognitive Deficits</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e111898</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0111898</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1371%2Fjournal.pone.0111898" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=25390368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFOnt73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&author=N.+J.+Izzoauthor=A.+Staniszewskiauthor=L.+Toauthor=M.+Faauthor=A.+F.+Teichauthor=F.+Saeedauthor=H.+Wosteinauthor=T.+Walkoauthor=A.+Vaswaniauthor=M.+Wardiusauthor=Z.+Syedauthor=J.+Ravenscroftauthor=K.+Mozzoniauthor=C.+Silkyauthor=C.+Rehakauthor=R.+Yurkoauthor=P.+Finnauthor=G.+Lookauthor=G.+Rishtonauthor=H.+Saffersteinauthor=M.+Millerauthor=C.+Johansonauthor=E.+Stopaauthor=M.+Windischauthor=B.+Hutter-Paierauthor=M.+Shamlooauthor=O.+Arancioauthor=H.+LeVineauthor=S.+M.+Catalano&title=Alzheimer%E2%80%99s+Therapeutics+Targeting+Amyloid+Beta+1%E2%80%9342+Oligomers+I%3A+Abeta+42+Oligomer+Binding+to+Specific+Neuronal+Receptors+Is+Displaced+by+Drug+Candidates+That+Improve+Cognitive+Deficits&doi=10.1371%2Fjournal.pone.0111898"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits</span></div><div class="casAuthors">Izzo, Nicholas J.; Staniszewski, Agnes; To, Lillian; Fa, Mauro; Teich, Andrew F.; Saeed, Faisal; Wostein, Harrison; Walko, Thomas, III; Vaswani, Anisha; Wardius, Meghan; Syed, Zanobia; Ravenscroft, Jessica; Mozzoni, Kelsie; Silky, Colleen; Rehak, Courtney; Yurko, Raymond; Finn, Patricia; Look, Gary; Rishton, Gilbert; Safferstein, Hank; Miller, Miles; Johanson, Conrad; Stopa, Edward; Windisch, Manfred; Hutter-Paier, Birgit; Shamloo, Mehrdad; Arancio, Ottavio; Le Vine, Harry, III; Catalano, Susan M.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e111898/1-e111898/19, 19 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Synaptic dysfunction and loss caused by age-dependent accumulation of synaptotoxic beta amyloid (Abeta) 1-42 oligomers is proposed to underlie cognitive decline in Alzheimer's disease (AD).  Alterations in membrane trafficking induced by Abeta oligomers mediates redn. in neuronal surface receptor expression that is the basis for inhibition of electrophysiol. measures of synaptic plasticity and thus learning and memory.  We have utilized phenotypic screens in mature, in vitro cultures of rat brain cells to identify small mols. which block or prevent the binding and effects of Abeta oligomers.  Synthetic Abeta oligomers bind saturably to a single site on neuronal synapses and induce deficits in membrane trafficking in neuronal cultures with an EC50 that corresponds to its binding affinity.  The therapeutic lead compds. we have found are pharmacol. antagonists of Abeta oligomers, reducing the binding of Abeta oligomers to neurons in vitro, preventing spine loss in neurons and preventing and treating oligomer-induced deficits in membrane trafficking.  These mols. are highly brain penetrant and prevent and restore cognitive deficits in mouse models of Alzheimer's disease.  Counter-screening these compds. against a broad panel of potential CNS targets revealed they are highly potent and specific ligands of the sigma-2/PGRMC1 receptor.  Brain concns. of the compds. corresponding to greater than 80% receptor occupancy at the sigma-2/PGRMC1 receptor restore cognitive function in transgenic hAPP Swe/Ldn mice.  These studies demonstrate that synthetic and human-derived Abeta oligomers act as pharmacol.-behaved ligands at neuronal receptors - i.e. they exhibit saturable binding to a target, they exert a functional effect related to their binding and their displacement by small mol. antagonists blocks their functional effect.  The first-in-class small mol. receptor antagonists described here restore memory to normal in multiple AD models and sustain improvement long-term, representing a novel mechanism of action for disease-modifying Alzheimer's therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyzEMMs3vvP7Vg90H21EOLACvtfcHk0lg1OD9qZ_eo3w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFOnt73I&md5=3672c523a12874998e3696c95ece6a08</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0111898&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0111898%26sid%3Dliteratum%253Aachs%26aulast%3DIzzo%26aufirst%3DN.%2BJ.%26aulast%3DStaniszewski%26aufirst%3DA.%26aulast%3DTo%26aufirst%3DL.%26aulast%3DFa%26aufirst%3DM.%26aulast%3DTeich%26aufirst%3DA.%2BF.%26aulast%3DSaeed%26aufirst%3DF.%26aulast%3DWostein%26aufirst%3DH.%26aulast%3DWalko%26aufirst%3DT.%26aulast%3DVaswani%26aufirst%3DA.%26aulast%3DWardius%26aufirst%3DM.%26aulast%3DSyed%26aufirst%3DZ.%26aulast%3DRavenscroft%26aufirst%3DJ.%26aulast%3DMozzoni%26aufirst%3DK.%26aulast%3DSilky%26aufirst%3DC.%26aulast%3DRehak%26aufirst%3DC.%26aulast%3DYurko%26aufirst%3DR.%26aulast%3DFinn%26aufirst%3DP.%26aulast%3DLook%26aufirst%3DG.%26aulast%3DRishton%26aufirst%3DG.%26aulast%3DSafferstein%26aufirst%3DH.%26aulast%3DMiller%26aufirst%3DM.%26aulast%3DJohanson%26aufirst%3DC.%26aulast%3DStopa%26aufirst%3DE.%26aulast%3DWindisch%26aufirst%3DM.%26aulast%3DHutter-Paier%26aufirst%3DB.%26aulast%3DShamloo%26aufirst%3DM.%26aulast%3DArancio%26aufirst%3DO.%26aulast%3DLeVine%26aufirst%3DH.%26aulast%3DCatalano%26aufirst%3DS.%2BM.%26atitle%3DAlzheimer%25E2%2580%2599s%2520Therapeutics%2520Targeting%2520Amyloid%2520Beta%25201%25E2%2580%259342%2520Oligomers%2520I%253A%2520Abeta%252042%2520Oligomer%2520Binding%2520to%2520Specific%2520Neuronal%2520Receptors%2520Is%2520Displaced%2520by%2520Drug%2520Candidates%2520That%2520Improve%2520Cognitive%2520Deficits%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26doi%3D10.1371%2Fjournal.pone.0111898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Izzo, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mozzoni, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silky, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehak, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yurko, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Look, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rishton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safferstein, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruchaga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goate, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cahill, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arancio, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craven, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeVine, H.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spires-Jones, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catalano, S. M.</span></span> <span> </span><span class="NLM_article-title">Alzheimer’s Therapeutics Targeting Amyloid Beta 1-42 Oligomers II: Sigma-2/PGRMC1 Receptors Mediate Abeta 42 Oligomer Binding and Synaptotoxicity</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e111899</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0111899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1371%2Fjournal.pone.0111899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=25390692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFyht77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&author=N.+J.+Izzoauthor=J.+Xuauthor=C.+Zengauthor=M.+J.+Kirkauthor=K.+Mozzoniauthor=C.+Silkyauthor=C.+Rehakauthor=R.+Yurkoauthor=G.+Lookauthor=G.+Rishtonauthor=H.+Saffersteinauthor=C.+Cruchagaauthor=A.+Goateauthor=M.+A.+Cahillauthor=O.+Arancioauthor=R.+H.+Machauthor=R.+Cravenauthor=E.+Headauthor=H.+LeVineauthor=T.+Spires-Jonesauthor=S.+M.+Catalano&title=Alzheimer%E2%80%99s+Therapeutics+Targeting+Amyloid+Beta+1-42+Oligomers+II%3A+Sigma-2%2FPGRMC1+Receptors+Mediate+Abeta+42+Oligomer+Binding+and+Synaptotoxicity&doi=10.1371%2Fjournal.pone.0111899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity</span></div><div class="casAuthors">Izzo, Nicholas J.; Xu, Jinbin; Zeng, Chenbo; Kirk, Molly J.; Mozzoni, Kelsie; Silky, Colleen; Rehak, Courtney; Yurko, Raymond; Look, Gary; Rishton, Gilbert; Safferstein, Hank; Cruchaga, Carlos; Goate, Alison; Cahill, Michael A.; Arancio, Ottavio; Mach, Robert H.; Craven, Rolf; Head, Elizabeth; LeVine, Harry; Spires-Jones, Tara L.; Catalano, Susan M.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e111899/1-e111899/15, 15 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Amyloid beta (Abeta) 1-42 oligomers accumulate in brains of patients with Mild Cognitive Impairment (MCI) and disrupt synaptic plasticity processes that underlie memory formation.  Synaptic binding of Abeta oligomers to several putative receptor proteins is reported to inhibit long-term potentiation, affect membrane trafficking and induce reversible spine loss in neurons, leading to impaired cognitive performance and ultimately to anterograde amnesia in the early stages of Alzheimer's disease (AD).  We have identified a receptor not previously assocd. with AD that mediates the binding of Abeta oligomers to neurons, and describe novel therapeutic antagonists of this receptor capable of blocking Abeta toxic effects on synapses in vitro and cognitive deficits in vivo.  Knockdown of sigma-2/PGRMC1 (progesterone receptor membrane component 1) protein expression in vitro using siRNA results in a highly correlated redn. in binding of exogenous Abeta oligomers to neurons of more than 90%.  Expression of sigma-2/PGRMC1 is upregulated in vitro by treatment with Abeta oligomers, and is dysregulated in Alzheimer's disease patients' brain compared to age-matched, normal individuals.  Specific, high affinity small mol. receptor antagonists and antibodies raised against specific regions on this receptor can displace synthetic Abeta oligomer binding to synaptic puncta in vitro and displace endogenous human AD patient oligomers from brain tissue sections in a dose-dependent manner.  These receptor antagonists prevent and reverse the effects of Abeta oligomers on membrane trafficking and synapse loss in vitro and cognitive deficits in AD mouse models.  These findings suggest sigma-2/PGRMC1 receptors mediate saturable oligomer binding to synaptic puncta on neurons and that brain penetrant, small mols. can displace endogenous and synthetic oligomers and improve cognitive deficits in AD models.  We propose that sigma-2/PGRMC1 is a key mediator of the pathol. effects of Abeta oligomers in AD and is a tractable target for small mol. disease-modifying therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7DydGr-ZJvbVg90H21EOLACvtfcHk0lgyrEjo7OwQkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFyht77K&md5=c6b3cb23c02818632de37efd3b10a6f2</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0111899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0111899%26sid%3Dliteratum%253Aachs%26aulast%3DIzzo%26aufirst%3DN.%2BJ.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DKirk%26aufirst%3DM.%2BJ.%26aulast%3DMozzoni%26aufirst%3DK.%26aulast%3DSilky%26aufirst%3DC.%26aulast%3DRehak%26aufirst%3DC.%26aulast%3DYurko%26aufirst%3DR.%26aulast%3DLook%26aufirst%3DG.%26aulast%3DRishton%26aufirst%3DG.%26aulast%3DSafferstein%26aufirst%3DH.%26aulast%3DCruchaga%26aufirst%3DC.%26aulast%3DGoate%26aufirst%3DA.%26aulast%3DCahill%26aufirst%3DM.%2BA.%26aulast%3DArancio%26aufirst%3DO.%26aulast%3DMach%26aufirst%3DR.%2BH.%26aulast%3DCraven%26aufirst%3DR.%26aulast%3DHead%26aufirst%3DE.%26aulast%3DLeVine%26aufirst%3DH.%26aulast%3DSpires-Jones%26aufirst%3DT.%26aulast%3DCatalano%26aufirst%3DS.%2BM.%26atitle%3DAlzheimer%25E2%2580%2599s%2520Therapeutics%2520Targeting%2520Amyloid%2520Beta%25201-42%2520Oligomers%2520II%253A%2520Sigma-2%252FPGRMC1%2520Receptors%2520Mediate%2520Abeta%252042%2520Oligomer%2520Binding%2520and%2520Synaptotoxicity%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26doi%3D10.1371%2Fjournal.pone.0111899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peruzzo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biasutto, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szabò, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leanza, L.</span></span> <span> </span><span class="NLM_article-title">Impact of Intracellular Ion Channels on Cancer Development and Progression</span>. <i>Eur. Biophys. J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">685</span>– <span class="NLM_lpage">707</span>, <span class="refDoi"> DOI: 10.1007/s00249-016-1143-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1007%2Fs00249-016-1143-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=27289382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC28XpvV2ntLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=685-707&author=R.+Peruzzoauthor=L.+Biasuttoauthor=I.+Szab%C3%B2author=L.+Leanza&title=Impact+of+Intracellular+Ion+Channels+on+Cancer+Development+and+Progression&doi=10.1007%2Fs00249-016-1143-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of intracellular ion channels on cancer development and progression</span></div><div class="casAuthors">Peruzzo, Roberta; Biasutto, Lucia; Szabo, Ildiko; Leanza, Luigi</div><div class="citationInfo"><span class="NLM_cas:title">European Biophysics Journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">685-707</span>CODEN:
                <span class="NLM_cas:coden">EBJOE8</span>;
        ISSN:<span class="NLM_cas:issn">0175-7571</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Cancer research is nowadays focused on the identification of possible new targets in order to try to develop new drugs for curing untreatable tumors.  Ion channels have emerged as "oncogenic" proteins, since they have an aberrant expression in cancers compared to normal tissues and contribute to several hallmarks of cancer, such as metabolic re-programming, limitless proliferative potential, apoptosis-resistance, stimulation of neo-angiogenesis as well as cell migration and invasiveness.  In recent years, not only the plasma membrane but also intracellular channels and transporters have arisen as oncol. targets and were proposed to be assocd. with tumorigenesis.  Therefore, the research is currently focusing on understanding the possible role of intracellular ion channels in cancer development and progression on one hand and, on the other, on developing new possible drugs able to modulate the expression and/or activity of these channels.  In a few cases, the efficacy of channel-targeting drugs in reducing tumors has already been demonstrated in vivo in preclin. mouse models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEB4xMw-_W3bVg90H21EOLACvtfcHk0lgyrEjo7OwQkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpvV2ntLw%253D&md5=9b0d1d4a312205381b1a634e913d9901</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1007%2Fs00249-016-1143-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00249-016-1143-0%26sid%3Dliteratum%253Aachs%26aulast%3DPeruzzo%26aufirst%3DR.%26aulast%3DBiasutto%26aufirst%3DL.%26aulast%3DSzab%25C3%25B2%26aufirst%3DI.%26aulast%3DLeanza%26aufirst%3DL.%26atitle%3DImpact%2520of%2520Intracellular%2520Ion%2520Channels%2520on%2520Cancer%2520Development%2520and%2520Progression%26jtitle%3DEur.%2520Biophys.%2520J.%26date%3D2016%26volume%3D45%26spage%3D685%26epage%3D707%26doi%3D10.1007%2Fs00249-016-1143-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crottès, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guizouarn, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgese, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriani, O.</span></span> <span> </span><span class="NLM_article-title">The Sigma-1 Receptor: A Regulator of Cancer Cell Electrical Plasticity?</span>. <i>Front. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">175</span>, <span class="refDoi"> DOI: 10.3389/fphys.2013.00175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3389%2Ffphys.2013.00175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=23882221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVOrtr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=175&author=D.+Crott%C3%A8sauthor=H.+Guizouarnauthor=P.+Martinauthor=F.+Borgeseauthor=O.+Soriani&title=The+Sigma-1+Receptor%3A+A+Regulator+of+Cancer+Cell+Electrical+Plasticity%3F&doi=10.3389%2Ffphys.2013.00175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">The sigma-1 receptor: a regulator of cancer cell electrical plasticity?</span></div><div class="casAuthors">Crottes, David; Guizouarn, Helene; Martin, Patrick; Borgese, Franck; Soriani, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Membrane Physiology and Membrane Biophysics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">July</span>),
    <span class="NLM_cas:pages">00175, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">FMPMEI</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Originally mistaken as an opioid receptor, the sigma-1 receptor (Sig1R) is a ubiquitous membrane protein that has been involved in many cellular processes.  While the precise function of Sig1R has long remained mysterious, recent studies have shed light on its role and the mol. mechanisms triggered.  Sig1R is in fact a stress-activated chaperone mainly assocd. with the ER-mitochondria interface that can regulate cell survival through the control of calcium homeostasis.  Sig1R functionally regulates ion channels belonging to various mol. families and it has thus been involved in neuronal plasticity and central nervous system diseases.  Interestingly, Sig1R is frequently expressed in tumors but its function in cancer has not been yet clarified.  In this review, we discuss the current understanding of Sig1R.  We suggest herein that Sig1R shapes cancer cell elec. signature upon environmental conditions.  Thus, Sig1R may be used as a novel therapeutic target to specifically abrogate pro-invasive functions of ion channels in cancer tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdYFdskWDj1rVg90H21EOLACvtfcHk0lgyrEjo7OwQkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVOrtr%252FL&md5=9dc47ce726d7469990cdd30f149fc9e1</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.3389%2Ffphys.2013.00175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphys.2013.00175%26sid%3Dliteratum%253Aachs%26aulast%3DCrott%25C3%25A8s%26aufirst%3DD.%26aulast%3DGuizouarn%26aufirst%3DH.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DBorgese%26aufirst%3DF.%26aulast%3DSoriani%26aufirst%3DO.%26atitle%3DThe%2520Sigma-1%2520Receptor%253A%2520A%2520Regulator%2520of%2520Cancer%2520Cell%2520Electrical%2520Plasticity%253F%26jtitle%3DFront.%2520Physiol.%26date%3D2013%26volume%3D4%26spage%3D175%26doi%3D10.3389%2Ffphys.2013.00175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spruce, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTavish, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleyard, M. V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safrany, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prescott, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nutley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downes, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, S.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Antagonists of the Sigma-1 Receptor Cause Selective Release of the Death Program in Tumor and Self-Reliant Cells and Inhibit Tumor Growth in Vitro and in Vivo</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">4875</span>– <span class="NLM_lpage">4886</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-03-3180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1158%2F0008-5472.CAN-03-3180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=15256458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD2cXls1Omtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=4875-4886&author=B.+A.+Spruceauthor=L.+A.+Campbellauthor=N.+McTavishauthor=M.+A.+Cooperauthor=M.+V.+L.+Appleyardauthor=M.+O%E2%80%99Neillauthor=J.+Howieauthor=J.+Samsonauthor=S.+Wattauthor=K.+Murrayauthor=D.+McLeanauthor=N.+K.+Leslieauthor=S.+T.+Safranyauthor=M.+J.+Fergusonauthor=J.+A.+Petersauthor=A.+R.+Prescottauthor=G.+Boxauthor=A.+Hayesauthor=B.+Nutleyauthor=F.+Raynaudauthor=C.+P.+Downesauthor=J.+J.+Lambertauthor=A.+M.+Thompsonauthor=S.+Eccles&title=Small+Molecule+Antagonists+of+the+Sigma-1+Receptor+Cause+Selective+Release+of+the+Death+Program+in+Tumor+and+Self-Reliant+Cells+and+Inhibit+Tumor+Growth+in+Vitro+and+in+Vivo&doi=10.1158%2F0008-5472.CAN-03-3180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Antagonists of the σ-1 Receptor Cause Selective Release of the Death Program in Tumor and Self-Reliant Cells and Inhibit Tumor Growth in Vitro and in Vivo</span></div><div class="casAuthors">Spruce, Barbara A.; Campbell, Lorna A.; McTavish, Niall; Cooper, Michelle A.; Appleyard, M. Virginia L.; O'Neill, Mary; Howie, Jacqueline; Samson, Jayne; Watt, Stephen; Murray, Karen; McLean, Doris; Leslie, Nick R.; Safrany, Stephen T.; Ferguson, Michelle J.; Peters, John A.; Prescott, Alan R.; Box, Gary; Hayes, Angela; Nutley, Bernard; Raynaud, Florence; Downes, C. Peter; Lambert, Jeremy J.; Thompson, Alastair M.; Eccles, Suzanne</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4875-4886</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The acquisition of resistance to apoptosis, the cell's intrinsic suicide program, is essential for cancers to arise and progress and is a major reason behind treatment failures.  We show in this article that small mol. antagonists of the σ-1 receptor inhibit tumor cell survival to reveal caspase-dependent apoptosis.  σ-Antagonist-mediated caspase activation and cell death are substantially attenuated by the prototypic -1 agonists (+)-SKF10,047 and (+)-pentazocine.  Although several normal cell types such as fibroblasts, epithelial cells, and even σ receptor-rich neurons are resistant to the apoptotic effects of σ antagonists, cells that can promote autocrine survival such as lens epithelial and microvascular endothelial cells are as susceptible as tumor cells.  Cellular susceptibility appears to correlate with differences in σ receptor coupling rather than levels of expression.  In susceptible cells only, σ antagonists evoke a rapid rise in cytosolic calcium that is inhibited by σ-1 agonists.  In at least some tumor cells, σ antagonists cause calcium-dependent activation of phospholipase C and concomitant calcium-independent inhibition of phosphatidylinositol 3'-kinase pathway signaling.  BSystemic administration of σ antagonists significantly inhibits the growth of evolving and established hormone-sensitive and hormone-insensitive mammary carcinoma xenografts, orthotopic prostate tumors, and p53-null lung carcinoma xenografts in immunocompromised mice in the absence of side effects.  Release of a σ receptor-mediated brake on apoptosis may offer a new approach to cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpSCoAyVi6oLVg90H21EOLACvtfcHk0lg2m4N2mNL2sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXls1Omtr8%253D&md5=a91eaaa7754714c7113c8107ffedc965</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-03-3180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-03-3180%26sid%3Dliteratum%253Aachs%26aulast%3DSpruce%26aufirst%3DB.%2BA.%26aulast%3DCampbell%26aufirst%3DL.%2BA.%26aulast%3DMcTavish%26aufirst%3DN.%26aulast%3DCooper%26aufirst%3DM.%2BA.%26aulast%3DAppleyard%26aufirst%3DM.%2BV.%2BL.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DM.%26aulast%3DHowie%26aufirst%3DJ.%26aulast%3DSamson%26aufirst%3DJ.%26aulast%3DWatt%26aufirst%3DS.%26aulast%3DMurray%26aufirst%3DK.%26aulast%3DMcLean%26aufirst%3DD.%26aulast%3DLeslie%26aufirst%3DN.%2BK.%26aulast%3DSafrany%26aufirst%3DS.%2BT.%26aulast%3DFerguson%26aufirst%3DM.%2BJ.%26aulast%3DPeters%26aufirst%3DJ.%2BA.%26aulast%3DPrescott%26aufirst%3DA.%2BR.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DNutley%26aufirst%3DB.%26aulast%3DRaynaud%26aufirst%3DF.%26aulast%3DDownes%26aufirst%3DC.%2BP.%26aulast%3DLambert%26aufirst%3DJ.%2BJ.%26aulast%3DThompson%26aufirst%3DA.%2BM.%26aulast%3DEccles%26aufirst%3DS.%26atitle%3DSmall%2520Molecule%2520Antagonists%2520of%2520the%2520Sigma-1%2520Receptor%2520Cause%2520Selective%2520Release%2520of%2520the%2520Death%2520Program%2520in%2520Tumor%2520and%2520Self-Reliant%2520Cells%2520and%2520Inhibit%2520Tumor%2520Growth%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D4875%26epage%3D4886%26doi%3D10.1158%2F0008-5472.CAN-03-3180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gasparre, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassano, G.</span></span> <span> </span><span class="NLM_article-title">The Sigma-1 Receptor Antagonist PB212 Reduces the Ca 2+-Release through the Inositol (1, 4, 5)-Trisphosphate Receptor in SK-N-SH Cells</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>684</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2012.03.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejphar.2012.03.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=22465185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvFynsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=684&publication_year=2012&pages=59-63&author=G.+Gasparreauthor=C.+Abateauthor=F.+Berardiauthor=G.+Cassano&title=The+Sigma-1+Receptor+Antagonist+PB212+Reduces+the+Ca+2%2B-Release+through+the+Inositol+%281%2C+4%2C+5%29-Trisphosphate+Receptor+in+SK-N-SH+Cells&doi=10.1016%2Fj.ejphar.2012.03.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">The sigma-1 receptor antagonist PB212 reduces the Ca2+-release through the inositol (1, 4, 5)-trisphosphate receptor in SK-N-SH cells</span></div><div class="casAuthors">Gasparre, Giuseppe; Abate, Carmen; Berardi, Francesco; Cassano, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">684</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">59-63</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Sigma-1 receptors are specifically located at the endoplasmic reticulum-mitochondrion interface, but upon stimulation by ligands or under prolonged cellular stress, they translocate to other areas of the cell.  Sigma-1 receptors are involved in the regulation of intracellular [Ca2+] by affecting the Ca2+-influx or the release from intracellular stores.  In SK-N-SH cells, we measured the affinity of 4-methyl-1-[4-(6-methoxynaphthalen-1-yl)butyl]piperidine (PB212) at sigma-1 receptor by using a competition binding assay with specific radioligand; we obtained a Ki value = 316 ± 19 nM.  PB212 also showed an antiproliferative effect in SK-N-SH cells (EC50 = 32 ± 4 μM) but had no effect in MCF7 cells, which only express sigma-2 receptor; these findings suggest that PB212 behaves as a sigma-1 receptor antagonist.  We have studied the effect of PB212 on Ca2+ homeostasis of the SK-N-SH cell line with the fluorescent probe Fura-2. 100 μM PB212 induced a Ca2+-efflux from the endoplasmic reticulum through the inositol (1, 4, 5)-trisphosphate (IP3) receptor.  Moreover, [PB212] ranging from 1 to 100 μM reduced the Ca2+-response, triggered by carbachol or bradykinin that engage the phospholipase C/IP3 pathway; such a response is generally increased by sigma-1 receptor agonists.  On the other hand, PB212 did not reduce the Ca2+-response mediated by IP3 in LoVo cells, which do not express neither sigma-1 nor sigma-2 receptors, and in MCF7 cells.  The fact that the activity of the sigma-1 receptor can be exptl. modulated by agonists and antagonists supports the intriguing hypothesis that some endogenous mols., unknown at the moment, modulate the sigma-1 receptor and its cellular targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrO9tdpeuIkCbVg90H21EOLACvtfcHk0lg2m4N2mNL2sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvFynsLw%253D&md5=a6ae6b3b38763757bcf367dc3c99ba71</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2012.03.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2012.03.021%26sid%3Dliteratum%253Aachs%26aulast%3DGasparre%26aufirst%3DG.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DCassano%26aufirst%3DG.%26atitle%3DThe%2520Sigma-1%2520Receptor%2520Antagonist%2520PB212%2520Reduces%2520the%2520Ca%25202%252B-Release%2520through%2520the%2520Inositol%2520%25281%252C%25204%252C%25205%2529-Trisphosphate%2520Receptor%2520in%2520SK-N-SH%2520Cells%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D684%26spage%3D59%26epage%3D63%26doi%3D10.1016%2Fj.ejphar.2012.03.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colgan, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Hashimi, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, R. C.</span></span> <span> </span><span class="NLM_article-title">Endoplasmic Reticulum Stress and Lipid Dysregulation</span>. <i>Expert Rev. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1017/S1462399410001742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1017%2FS1462399410001742" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=1-14&author=S.+M.+Colganauthor=A.+A.+Al-Hashimiauthor=R.+C.+Austin&title=Endoplasmic+Reticulum+Stress+and+Lipid+Dysregulation&doi=10.1017%2FS1462399410001742"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1017%2FS1462399410001742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1462399410001742%26sid%3Dliteratum%253Aachs%26aulast%3DColgan%26aufirst%3DS.%2BM.%26aulast%3DAl-Hashimi%26aufirst%3DA.%2BA.%26aulast%3DAustin%26aufirst%3DR.%2BC.%26atitle%3DEndoplasmic%2520Reticulum%2520Stress%2520and%2520Lipid%2520Dysregulation%26jtitle%3DExpert%2520Rev.%2520Mol.%2520Med.%26date%3D2011%26volume%3D13%26spage%3D1%26epage%3D14%26doi%3D10.1017%2FS1462399410001742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, W. G.</span></span> <span> </span><span class="NLM_article-title">The σ<sub>2</sub> Receptor: A Novel Protein for the Imaging and Treatment of Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7137</span>– <span class="NLM_lpage">7160</span>, <span class="refDoi"> DOI: 10.1021/jm301545c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301545c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovFWmtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7137-7160&author=R.+H.+Machauthor=C.+Zengauthor=W.+G.+Hawkins&title=The+%CF%832+Receptor%3A+A+Novel+Protein+for+the+Imaging+and+Treatment+of+Cancer&doi=10.1021%2Fjm301545c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">The σ2 Receptor: A Novel Protein for the Imaging and Treatment of Cancer</span></div><div class="casAuthors">Mach, Robert H.; Zeng, Chenbo; Hawkins, William G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7137-7160</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The σ2 receptor is an important target for the development of mol. probes in oncol. because of its 10-fold higher d. in proliferating tumor cells compared with that in quiescent tumor cells and because of the observation that σ2 receptor agonists are able to kill tumor cells via apoptotic and nonapoptotic mechanisms.  Although recent evidence indicates that the σ2 receptor binding site is localized within the progesterone receptor membrane component 1 (PGRMC1), most information regarding this protein has been obtained using either radiolabeled or fluorescent receptor-based probes and from biochem. anal. of the effect of σ2 selective ligands on cells grown in culture.  This article reviews the development of σ2 receptor ligands and presents an overview of how they have been used in vitro and in vivo to increase the authors' understanding of the role of the σ2 receptor in cancer and proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWf1ZnaveYT7Vg90H21EOLACvtfcHk0lhqU8fl7wXfNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovFWmtr0%253D&md5=55831988f692d39d423e8cfe7f18240f</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1021%2Fjm301545c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301545c%26sid%3Dliteratum%253Aachs%26aulast%3DMach%26aufirst%3DR.%2BH.%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DHawkins%26aufirst%3DW.%2BG.%26atitle%3DThe%2520%25CF%25832%2520Receptor%253A%2520A%2520Novel%2520Protein%2520for%2520the%2520Imaging%2520and%2520Treatment%2520of%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7137%26epage%3D7160%26doi%3D10.1021%2Fjm301545c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cantonero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camello, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salido, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosado, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redondo, P. C.</span></span> <span> </span><span class="NLM_article-title">NO1, a New Sigma 2 Receptor/TMEM97 Fluorescent Ligand, Downregulates SOCE and Promotes Apoptosis in the Triple Negative Breast Cancer Cell Lines</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">257</span>, <span class="refDoi"> DOI: 10.3390/cancers12020257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3390%2Fcancers12020257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1Klsb%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=257&author=C.+Cantoneroauthor=P.+J.+Camelloauthor=C.+Abateauthor=F.+Berardiauthor=G.+M.+Salidoauthor=J.+A.+Rosadoauthor=P.+C.+Redondo&title=NO1%2C+a+New+Sigma+2+Receptor%2FTMEM97+Fluorescent+Ligand%2C+Downregulates+SOCE+and+Promotes+Apoptosis+in+the+Triple+Negative+Breast+Cancer+Cell+Lines&doi=10.3390%2Fcancers12020257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">NO1, a new sigma 2 receptor/TMEM97 fluorescent ligand, downregulates SOCE and promotes apoptosis in the triple negative breast cancer cell lines</span></div><div class="casAuthors">Cantonero, Carlos; Camello, Pedro Javier; Abate, Carmen; Berardi, Francesco; Salido, Gines Maria; Rosado, Juan Antonio; Redondo, Pedro C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">257</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">(1) Background: The structure of the Sigma 2 receptor/TMEM97 (σ2RTMEM97) has recently been reported. (2, 3) Methods and results: We used genetic and biochem. approaches to identify the mol. mechanism downstream of σ2R/TMEM97.  The novel σ2R/TMEM97 fluorescent ligand, NO1, reduced the proliferation and survival of the triple neg. breast cancer cell lines (TNBC: MDA-MB-231 and MDA-MB-468 cell lines), due to NO1-induced apoptosis.  Greater bioaccumulation and faster uptake of NO1 in MDA-MB-231 cells compared to MCF10A or MCF7 cell lines were also shown.  Accordingly, elevated σ2R/TMEM97 expression was confirmed by Western blotting.  In contrast to NO1, other σ2R/TMEM97 ligands, such as SM21 and PB28, enhanced MDA-MB-231 cell proliferation and migration.  Store-operated calcium entry (SOCE) is crucial for different cancer hallmarks.  Here, we show that NO1, but not other σ2R/TMEM97 ligands, reduced SOCE in MDA-MB-231 cells.  Similarly, TMEM97 silencing in MDA-MB-231 cells also impaired SOCE.  NO1 administration downregulated STIM1-Orai1 interaction, probably by impairing the pos. regulatory effect of σ2R/TMEM97 on STIM1, as we were unable to detect interaction with Orai1. (4) Conclusion: σ2R/TMEM97 is a key protein for the survival of triple neg. breast cancer cells by promoting SOCE; therefore, NO1 may become a good pharmacol. tool to avoid their proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4LjswYuEa77Vg90H21EOLACvtfcHk0lhqU8fl7wXfNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1Klsb%252FP&md5=8410a8bed611defd39251c0d542da069</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.3390%2Fcancers12020257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers12020257%26sid%3Dliteratum%253Aachs%26aulast%3DCantonero%26aufirst%3DC.%26aulast%3DCamello%26aufirst%3DP.%2BJ.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DSalido%26aufirst%3DG.%2BM.%26aulast%3DRosado%26aufirst%3DJ.%2BA.%26aulast%3DRedondo%26aufirst%3DP.%2BC.%26atitle%3DNO1%252C%2520a%2520New%2520Sigma%25202%2520Receptor%252FTMEM97%2520Fluorescent%2520Ligand%252C%2520Downregulates%2520SOCE%2520and%2520Promotes%2520Apoptosis%2520in%2520the%2520Triple%2520Negative%2520Breast%2520Cancer%2520Cell%2520Lines%26jtitle%3DCancers%26date%3D2020%26volume%3D12%26spage%3D257%26doi%3D10.3390%2Fcancers12020257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hafner Ĉesen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repnik, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, B.</span></span> <span> </span><span class="NLM_article-title">Siramesine Triggers Cell Death through Destabilisation of Mitochondria, but Not Lysosomes</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">e818</span>, <span class="refDoi"> DOI: 10.1038/cddis.2013.361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fcddis.2013.361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=24091661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsF2nsb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=e818&author=M.+Hafner+%C4%88esenauthor=U.+Repnikauthor=V.+Turkauthor=B.+Turk&title=Siramesine+Triggers+Cell+Death+through+Destabilisation+of+Mitochondria%2C+but+Not+Lysosomes&doi=10.1038%2Fcddis.2013.361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Siramesine triggers cell death through destabilisation of mitochondria, but not lysosomes</span></div><div class="casAuthors">Hafner Cesen, M.; Repnik, U.; Turk, V.; Turk, B.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">Oct.</span>),
    <span class="NLM_cas:pages">e818</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A sigma-2 receptor agonist siramesine has been shown to trigger cell death of cancer cells and to exhibit a potent anticancer activity in vivo.  However, its mechanism of action is still poorly understood.  We show that siramesine can induce rapid cell death in a no. of cell lines at concns. above 20 μM.  In HaCaT cells, cell death was accompanied by caspase activation, rapid loss of mitochondrial membrane potential (MMP), cytochrome c release, cardiolipin peroxidn. and typical apoptotic morphol., whereas in U-87MG cells most apoptotic hallmarks were not notable, although MMP was rapidly lost.  In contrast to the rapid loss of MMP above 20 μM siramesine, a rapid increase in lysosomal pH was obsd. at all concns. tested (5-40 μM); however, it was not accompanied by lysosomal membrane permeabilisation (LMP) and the release of lysosomal enzymes into the cytosol.  Increased lysosomal pH reduced the lysosomal degrdn. potential as indicated by the accumulation of immature forms of cysteine cathepsins.  The lipophilic antioxidant α-tocopherol, but not the hydrophilic antioxidant N-acetyl-cysteine, considerably reduced cell death and destabilization of mitochondrial membranes, but did not prevent the increase in lysosomal pH.  At concns. below 15 μM, siramesine triggered cell death after 2 days or later, which seems to be assocd. with a general metabolic and energy imbalance due to defects in the endocytic pathway, intracellular trafficking and energy prodn., and not by a specific mol. event.  Overall, we show that cell death in siramesine-treated cells is induced by destabilization of mitochondria and is independent of LMP and the release of cathepsins into the cytosol.  Moreover, it is unlikely that siramesine acts exclusively through sigma-2 receptors, but rather through multiple mol. targets inside the cell.  Our findings are therefore of significant importance in designing the next generation of siramesine analogs with high anticancer potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5ykUgq2aIvLVg90H21EOLACvtfcHk0lhqU8fl7wXfNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsF2nsb3E&md5=bbc74af055d10a5fd50ba276bb20e10d</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1038%2Fcddis.2013.361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddis.2013.361%26sid%3Dliteratum%253Aachs%26aulast%3DHafner%2B%25C4%2588esen%26aufirst%3DM.%26aulast%3DRepnik%26aufirst%3DU.%26aulast%3DTurk%26aufirst%3DV.%26aulast%3DTurk%26aufirst%3DB.%26atitle%3DSiramesine%2520Triggers%2520Cell%2520Death%2520through%2520Destabilisation%2520of%2520Mitochondria%252C%2520but%2520Not%2520Lysosomes%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2013%26volume%3D4%26spage%3De818%26doi%3D10.1038%2Fcddis.2013.361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pati, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornick, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, W.</span></span> <span> </span><span class="NLM_article-title">Sigma-2 Receptor Agonist Derivatives of 1-Cyclohexyl-4-[3-(5-Methoxy-1,2,3,4-Tetrahydronaphthalen-1-Yl)Propyl]Piperazine (PB28) Induce Cell Death via Mitochondrial Superoxide Production and Caspase Activation in Pancreatic Cancer</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">51</span>, <span class="refDoi"> DOI: 10.1186/s12885-016-3040-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1186%2Fs12885-016-3040-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=28086830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjs12mtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=51&author=M.+L.+Patiauthor=J.+R.+Hornickauthor=M.+Nisoauthor=F.+Berardiauthor=D.+Spitzerauthor=C.+Abateauthor=W.+Hawkins&title=Sigma-2+Receptor+Agonist+Derivatives+of+1-Cyclohexyl-4-%5B3-%285-Methoxy-1%2C2%2C3%2C4-Tetrahydronaphthalen-1-Yl%29Propyl%5DPiperazine+%28PB28%29+Induce+Cell+Death+via+Mitochondrial+Superoxide+Production+and+Caspase+Activation+in+Pancreatic+Cancer&doi=10.1186%2Fs12885-016-3040-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-2 receptor agonist derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4- tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) induce cell death via mitochondrial superoxide production and caspase activation in pancreatic cancer</span></div><div class="casAuthors">Pati, Maria Laura; Hornick, John R.; Niso, Mauro; Berardi, Francesco; Spitzer, Dirk; Abate, Carmen; Hawkins, William</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">51/1-51/12</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Despite considerable efforts by scientific research, pancreatic cancer is the fourth leading cause of cancer related mortalities.  Sigma-2 receptors, which are overexpressed in several tumors, represent promising targets for triggering selective pancreatic cancer cells death.  We selected five differently structured high-affinity sigma-2 ligands (PB28, PB183, PB221, F281 and PB282) to study how they affect the viability of diverse pancreatic cancer cells (human cell lines BxPC3, AsPC1, Mia PaCa-2, and Panc1 and mouse Panc-02, KCKO and KP-02) and how this is reflected in vivo in a tumor model.  Important cytotoxicity was shown by the compds. in the aggressive Panc02 cells, where cytotoxic activity was caspase-3 independent for four of the five compds.  However, both cytotoxicity and caspase-3 activation involved generation of Reactive Oxygen Species (ROS), which could be partially reverted by the lipid antioxidant a-tocopherol, but not by the hydrophilic N-acetylcysteine (NAC) indicating crucial differences in the intracellular sites exposed to oxidative stress induced by sigma-2 receptor ligands.  Importantly, all the compds. strongly increased the prodn. of mitochondrial superoxide radicals except for PB282.  Despite a poor match between in vitro and the in vivo efficacy, daily treatment of C57BL/6 mice bearing Panc02 tumors resulted in promising effects with PB28 and PB282 which were similar compared to the current std.-of-care chemotherapeutic gemcitabine without showing signs of systemic toxicities.  Overall, this study identified differential sensitivities of pancreatic cancer cells to structurally diverse sigma-2 receptor ligands.  Of note, we identified the mitochondrial superoxide pathway as a previously unrecognized sigma-2 receptor-activated process, which encourages further studies on sigma-2 ligand-mediated cancer cell death for the targeted treatment of pancreatic tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokTrvVNhfXn7Vg90H21EOLACvtfcHk0lipUMeKBJbLMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjs12mtbo%253D&md5=f8dce42ee93876e672a4d0705d8dc890</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1186%2Fs12885-016-3040-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-016-3040-4%26sid%3Dliteratum%253Aachs%26aulast%3DPati%26aufirst%3DM.%2BL.%26aulast%3DHornick%26aufirst%3DJ.%2BR.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DSpitzer%26aufirst%3DD.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DHawkins%26aufirst%3DW.%26atitle%3DSigma-2%2520Receptor%2520Agonist%2520Derivatives%2520of%25201-Cyclohexyl-4-%255B3-%25285-Methoxy-1%252C2%252C3%252C4-Tetrahydronaphthalen-1-Yl%2529Propyl%255DPiperazine%2520%2528PB28%2529%2520Induce%2520Cell%2520Death%2520via%2520Mitochondrial%2520Superoxide%2520Production%2520and%2520Caspase%2520Activation%2520in%2520Pancreatic%2520Cancer%26jtitle%3DBMC%2520Cancer%26date%3D2017%26volume%3D17%26spage%3D51%26doi%3D10.1186%2Fs12885-016-3040-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Estrada-Valencia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrera-Arozamena, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viña, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales-García, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Castillo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Franco, M. I.</span></span> <span> </span><span class="NLM_article-title">New Flavonoid-N, N-Dibenzyl(N-Methyl)Amine Hybrids: Multi-Target-Directed Agents for Alzheimeŕs Disease Endowed with Neurogenic Properties</span>. <i>J. Enzyme Inhib. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">712</span>– <span class="NLM_lpage">727</span>, <span class="refDoi"> DOI: 10.1080/14756366.2019.1581184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1080%2F14756366.2019.1581184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=31852270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1MXksFKisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2019&pages=712-727&author=M.+Estrada-Valenciaauthor=C.+Herrera-Arozamenaauthor=C.+P%C3%A9rezauthor=D.+Vi%C3%B1aauthor=J.+A.+Morales-Garc%C3%ADaauthor=A.+P%C3%A9rez-Castilloauthor=E.+Ramosauthor=A.+Romeroauthor=E.+Lauriniauthor=S.+Priclauthor=M.+I.+Rodr%C3%ADguez-Franco&title=New+Flavonoid-N%2C+N-Dibenzyl%28N-Methyl%29Amine+Hybrids%3A+Multi-Target-Directed+Agents+for+Alzheime%C5%95s+Disease+Endowed+with+Neurogenic+Properties&doi=10.1080%2F14756366.2019.1581184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">New flavonoid - N,N-dibenzyl(N-methyl)amine hybrids: Multi-target-directed agents for Alzheimer's disease endowed with neurogenic properties</span></div><div class="casAuthors">Estrada-Valencia, Martin; Herrera-Arozamena, Clara; Perez, Concepcion; Vina, Dolores; Morales-Garcia, Jose A.; Perez-Castillo, Ana; Ramos, Eva; Romero, Alejandro; Laurini, Erik; Pricl, Sabrina; Rodriguez-Franco, Maria Isabel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Enzyme Inhibition and Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">712-727</span>CODEN:
                <span class="NLM_cas:coden">JEIMAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-6366</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The design of multi-target directed ligands (MTDLs) is a valid approach for obtaining effective drugs for complex pathologies.  MTDLs that combine neuro-repair properties and block the first steps of neurotoxic cascades could be the so long wanted remedies to treat neurodegenerative diseases (NDs).  By linking two privileged scaffolds with well-known activities in ND-targets, the flavonoid and the N,N-dibenzyl(N-methyl)amine (DBMA) fragments, new CNS-permeable flavonoid - DBMA hybrids (-) were obtained.  They were subjected to biol. evaluation in a battery of targets involved in Alzheimer's disease (AD) and other NDs, namely human cholinesterases (hAChE/hBuChE), β-secretase (hBACE-1), monoamine oxidases (hMAO-A/B), lipoxygenase-5 (hLOX-5) and sigma receptors (σ1R/σ2R).  After a funnel-type screening, 6,7-dimethoxychromone - DBMA () was highlighted due to its neurogenic properties and an interesting MTD-profile in hAChE, hLOX-5, hBACE-1 and σ1R.  Mol. dynamic simulations showed the most relevant drug-protein interactions of hybrid , which could synergistically contribute to neuronal regeneration and block neurodegeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxvt6TPaP_67Vg90H21EOLACvtfcHk0lipUMeKBJbLMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXksFKisLk%253D&md5=24e4282e83ea909ffd6fd72a74a8e509</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1080%2F14756366.2019.1581184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14756366.2019.1581184%26sid%3Dliteratum%253Aachs%26aulast%3DEstrada-Valencia%26aufirst%3DM.%26aulast%3DHerrera-Arozamena%26aufirst%3DC.%26aulast%3DP%25C3%25A9rez%26aufirst%3DC.%26aulast%3DVi%25C3%25B1a%26aufirst%3DD.%26aulast%3DMorales-Garc%25C3%25ADa%26aufirst%3DJ.%2BA.%26aulast%3DP%25C3%25A9rez-Castillo%26aufirst%3DA.%26aulast%3DRamos%26aufirst%3DE.%26aulast%3DRomero%26aufirst%3DA.%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DRodr%25C3%25ADguez-Franco%26aufirst%3DM.%2BI.%26atitle%3DNew%2520Flavonoid-N%252C%2520N-Dibenzyl%2528N-Methyl%2529Amine%2520Hybrids%253A%2520Multi-Target-Directed%2520Agents%2520for%2520Alzheime%25C5%2595s%2520Disease%2520Endowed%2520with%2520Neurogenic%2520Properties%26jtitle%3DJ.%2520Enzyme%2520Inhib.%2520Med.%2520Chem.%26date%3D2019%26volume%3D34%26spage%3D712%26epage%3D727%26doi%3D10.1080%2F14756366.2019.1581184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mugnaini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brizzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligresti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamponi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacondio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corelli, F.</span></span> <span> </span><span class="NLM_article-title">Investigations on the 4-Quinolone-3-Carboxylic Acid Motif. 7. Synthesis and Pharmacological Evaluation of 4-Quinolone-3-Carboxamides and 4-Hydroxy-2-Quinolone-3-Carboxamides as High Affinity Cannabinoid Receptor 2 (CB2R) Ligands with Improved Aqueous Solubility</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1052</span>– <span class="NLM_lpage">1067</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01559</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01559" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslemsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1052-1067&author=C.+Mugnainiauthor=A.+Brizziauthor=A.+Ligrestiauthor=M.+Allaraauthor=S.+Lamponiauthor=F.+Vacondioauthor=C.+Silvaauthor=M.+Morauthor=V.+Di+Marzoauthor=F.+Corelli&title=Investigations+on+the+4-Quinolone-3-Carboxylic+Acid+Motif.+7.+Synthesis+and+Pharmacological+Evaluation+of+4-Quinolone-3-Carboxamides+and+4-Hydroxy-2-Quinolone-3-Carboxamides+as+High+Affinity+Cannabinoid+Receptor+2+%28CB2R%29+Ligands+with+Improved+Aqueous+Solubility&doi=10.1021%2Facs.jmedchem.5b01559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 7. Synthesis and Pharmacological Evaluation of 4-Quinolone-3-carboxamides and 4-Hydroxy-2-quinolone-3-carboxamides as High Affinity Cannabinoid Receptor 2 (CB2R) Ligands with Improved Aqueous Solubility</span></div><div class="casAuthors">Mugnaini, Claudia; Brizzi, Antonella; Ligresti, Alessia; Allara, Marco; Lamponi, Stefania; Vacondio, Federica; Silva, Claudia; Mor, Marco; Di Marzo, Vincenzo; Corelli, Federico</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1052-1067</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">4-Quinolone-3-carboxamide derivs. have long been recognized as potent and selective cannabinoid type-2 receptor (CB2R) ligands.  With the aim to improve their physicochem. properties, basically aq. soly., two different approaches were followed, entailing the substitution of the alkyl chain with a basic replacement or scaffold modification to 4-hydroxy-2-quinolone structure.  According to the first approach, compd. I (R = NMe2) was obtained, showing slightly reduced receptor affinity (Ki = 60 nM) compared to the lead compd. I (R = n-Pr, Ki = 0.8 nM) but greatly enhanced soly. (400-3400 times depending on the pH of the medium).  On the other hand, shifting from 4-quinolone to 4-hydroxy-2-quinolone structure enabled the discovery of a novel class of CB2R ligands, such as II (R1 = 6-i-Pr, and 7-F), characterized by Ki < 1 nM and selectivity index [SI = Ki(CB1R)/Ki(CB2R)] > 1300.  At pH 7.4, compd. II (R1 = 7-F) resulted by 100-fold more sol. than I (R = n-Pr).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovdgV_KOadz7Vg90H21EOLACvtfcHk0lipUMeKBJbLMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslemsA%253D%253D&md5=303474ea5e8d265bf033c75c89e4ee9c</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01559%26sid%3Dliteratum%253Aachs%26aulast%3DMugnaini%26aufirst%3DC.%26aulast%3DBrizzi%26aufirst%3DA.%26aulast%3DLigresti%26aufirst%3DA.%26aulast%3DAllara%26aufirst%3DM.%26aulast%3DLamponi%26aufirst%3DS.%26aulast%3DVacondio%26aufirst%3DF.%26aulast%3DSilva%26aufirst%3DC.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DCorelli%26aufirst%3DF.%26atitle%3DInvestigations%2520on%2520the%25204-Quinolone-3-Carboxylic%2520Acid%2520Motif.%25207.%2520Synthesis%2520and%2520Pharmacological%2520Evaluation%2520of%25204-Quinolone-3-Carboxamides%2520and%25204-Hydroxy-2-Quinolone-3-Carboxamides%2520as%2520High%2520Affinity%2520Cannabinoid%2520Receptor%25202%2520%2528CB2R%2529%2520Ligands%2520with%2520Improved%2520Aqueous%2520Solubility%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1052%26epage%3D1067%26doi%3D10.1021%2Facs.jmedchem.5b01559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weber, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Medicinal Chemistry of σ(1) Receptor Ligands: Pharmacophore Models, Synthesis, Structure Affinity Relationships, and Pharmacological Applications</span>. <i>Handb. Exp. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>244</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">79</span>, <span class="refDoi"> DOI: 10.1007/164_2017_33</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1007%2F164_2017_33" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=28620761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFeitbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=244&publication_year=2017&pages=51-79&author=F.+Weberauthor=B.+W%C3%BCnsch&title=Medicinal+Chemistry+of+%CF%83%281%29+Receptor+Ligands%3A+Pharmacophore+Models%2C+Synthesis%2C+Structure+Affinity+Relationships%2C+and+Pharmacological+Applications&doi=10.1007%2F164_2017_33"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of σ1 receptor ligands: pharmacophore models, synthesis, structure affinity relationships, and pharmacological applications</span></div><div class="casAuthors">Weber, Frauke; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of Experimental Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">244</span>
        (<span class="NLM_cas:issue">Sigma Proteins: Evolution of the Concept of Sigma Receptors</span>),
    <span class="NLM_cas:pages">51-79</span>CODEN:
                <span class="NLM_cas:coden">HEPHD2</span>;
        ISSN:<span class="NLM_cas:issn">1865-0325</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  In the first part of this chapter, it summarize the various pharmacophore models for σ1 receptor ligands.  Common to all of them is a basic amine flanked by two hydrophobic regions, representing the pharmacophoric elements.  The development of computer-based models like the 3D homol. model is described as well as the first crystal structure of the σ1 receptor.  The second part focuses on the synthesis and biol. properties of different σ1 receptor ligands, identified as 1-9.  Monocyclic piperazines 1 and bicyclic piperazines 2 and 3 were developed as cytotoxic compds., thus the IC50 values of cell growth and survival inhibition studies are given for all derivs.  The mechanism of cell survival inhibition, induction of time-dependent apoptosis, of compd. ent-2a is discussed.  Exptl. detd. σ1 affinity shows good correlation with the results from mol. dynamics simulations based on a 3D homol. model.  Spirocyclic compds. 4 and 5 represent well-established σ1 receptor ligands.  The homologous fluoroalkyl derivs. 4 have favorable pharmacol. properties for use as fluorinated PET tracers.  The (S)-configured fluoroethyl substituted compd. (S)-4b is under investigation as PET tracer for imaging of σ1 receptors in the brain of patients affected by major depression.  1,3-Dioxanes 6c and 6d display a very potent σ1 antagonist profile and the racemic 1,3-dioxane 6c has high anti-allodynic activity at low doses.  The arylpropenylamines 7 are very potent σ1 receptor ligands with high σ1/s2 selectivity.  The top compd. 7g acts as an agonist as defined by its ability to potentiate neurite outgrowth at low concns.  Among the morpholinoethoxypyrazoles 8, 8c (known as S1RA) reveals the most promising pharmacokinetic and physicochem. properties.  Due to its good safety profile, 8c is currently being investigated in a phase II clin. trial for the treatment of neuropathic pain.  The most potent ligand 9e of 3,4-dihydro-2(1H)-quinolones 9 shows promising anti-nociceptive activity in the formalin test.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7YQ6_-x_GybVg90H21EOLACvtfcHk0ljKrS2GmBnvlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFeitbvM&md5=a86da9cd3be04ca53d9787ad9e73a54b</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1007%2F164_2017_33&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F164_2017_33%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DF.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DMedicinal%2520Chemistry%2520of%2520%25CF%2583%25281%2529%2520Receptor%2520Ligands%253A%2520Pharmacophore%2520Models%252C%2520Synthesis%252C%2520Structure%2520Affinity%2520Relationships%252C%2520and%2520Pharmacological%2520Applications%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2017%26volume%3D244%26spage%3D51%26epage%3D79%26doi%3D10.1007%2F164_2017_33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, L.</span></span> <span> </span><span class="NLM_article-title">Computational Multitarget Drug Design</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">403</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.6b00491</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.6b00491" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFCntr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2017&pages=403-412&author=W.+Zhangauthor=J.+Peiauthor=L.+Lai&title=Computational+Multitarget+Drug+Design&doi=10.1021%2Facs.jcim.6b00491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Computational Multitarget Drug Design</span></div><div class="casAuthors">Zhang, Weilin; Pei, Jianfeng; Lai, Luhua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">403-412</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Designing drugs that can simultaneously interact with multiple targets is a promising approach for treating complicated diseases.  Compared to using combinations of single target drugs, multitarget drugs have advantages of higher efficacy, improved safety profile, and simpler administration.  Many in silico methods have been developed to approach different aspects of this polypharmacol.-guided drug design, particularly for drug repurposing and multitarget drug design.  In this review, the authors summarize recent progress in computational multitarget drug design and discuss their advantages and limitations.  Perspectives for future drug development will also be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-J4p0tdEUR7Vg90H21EOLACvtfcHk0ljKrS2GmBnvlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFCntr8%253D&md5=e00ed6650471d786a04b828a8064f5e9</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.6b00491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.6b00491%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DPei%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DL.%26atitle%3DComputational%2520Multitarget%2520Drug%2520Design%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2017%26volume%3D57%26spage%3D403%26epage%3D412%26doi%3D10.1021%2Facs.jcim.6b00491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henrick, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, H.</span></span> <span> </span><span class="NLM_article-title">Announcing the Worldwide Protein Data Bank</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">980</span>, <span class="refDoi"> DOI: 10.1038/nsb1203-980</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fnsb1203-980" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptFOmsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2003&pages=980&author=H.+Bermanauthor=K.+Henrickauthor=H.+Nakamura&title=Announcing+the+Worldwide+Protein+Data+Bank&doi=10.1038%2Fnsb1203-980"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Announcing the worldwide Protein Data Bank</span></div><div class="casAuthors">Berman, Helen; Henrick, Kim; Nakamura, Haruki</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">980</span>CODEN:
                <span class="NLM_cas:coden">NSBIEW</span>;
        ISSN:<span class="NLM_cas:issn">1072-8368</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplInmv2AD6cbVg90H21EOLACvtfcHk0ljKrS2GmBnvlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptFOmsbY%253D&md5=8146ff5fc67f64e31b2f8c475473879c</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1038%2Fnsb1203-980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb1203-980%26sid%3Dliteratum%253Aachs%26aulast%3DBerman%26aufirst%3DH.%26aulast%3DHenrick%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DH.%26atitle%3DAnnouncing%2520the%2520Worldwide%2520Protein%2520Data%2520Bank%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2003%26volume%3D10%26spage%3D980%26doi%3D10.1038%2Fnsb1203-980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaulton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellis, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bento, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hersey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Light, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGlinchey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michalovich, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Lazikani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overington, J. P.</span></span> <span> </span><span class="NLM_article-title">ChEMBL: A Large-Scale Bioactivity Database for Drug Discovery</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">D1100</span>– <span class="NLM_lpage">D1107</span>, <span class="refDoi"> DOI: 10.1093/nar/gkr777</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1093%2Fnar%2Fgkr777" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=21948594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs12htbjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=D1100-D1107&author=A.+Gaultonauthor=L.+J.+Bellisauthor=A.+P.+Bentoauthor=J.+Chambersauthor=M.+Daviesauthor=A.+Herseyauthor=Y.+Lightauthor=S.+McGlincheyauthor=D.+Michalovichauthor=B.+Al-Lazikaniauthor=J.+P.+Overington&title=ChEMBL%3A+A+Large-Scale+Bioactivity+Database+for+Drug+Discovery&doi=10.1093%2Fnar%2Fgkr777"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">ChEMBL: a large-scale bioactivity database for drug discovery</span></div><div class="casAuthors">Gaulton, Anna; Bellis, Louisa J.; Bento, A. Patricia; Chambers, Jon; Davies, Mark; Hersey, Anne; Light, Yvonne; McGlinchey, Shaun; Michalovich, David; Al-Lazikani, Bissan; Overington, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">D1</span>),
    <span class="NLM_cas:pages">D1100-D1107</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">ChEMBL is an Open Data database contg. binding, functional and ADMET information for a large no. of drug-like bioactive compds.  These data are manually abstracted from the primary published literature on a regular basis, then further curated and standardized to maximize their quality and utility across a wide range of chem. biol. and drug-discovery research problems.  Currently, the database contains 5.4 million bioactivity measurements for more than 1 million compds. and 5200 protein targets.  Access is available through a web-based interface, data downloads and web services at: https://www.ebi.ac.uk/chembldb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9e9jRENTtubVg90H21EOLACvtfcHk0ljH5s3VFZS5BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs12htbjN&md5=aedf7793e1ca54b6a4fa272ea3ef7d0e</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkr777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkr777%26sid%3Dliteratum%253Aachs%26aulast%3DGaulton%26aufirst%3DA.%26aulast%3DBellis%26aufirst%3DL.%2BJ.%26aulast%3DBento%26aufirst%3DA.%2BP.%26aulast%3DChambers%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DM.%26aulast%3DHersey%26aufirst%3DA.%26aulast%3DLight%26aufirst%3DY.%26aulast%3DMcGlinchey%26aufirst%3DS.%26aulast%3DMichalovich%26aufirst%3DD.%26aulast%3DAl-Lazikani%26aufirst%3DB.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26atitle%3DChEMBL%253A%2520A%2520Large-Scale%2520Bioactivity%2520Database%2520for%2520Drug%2520Discovery%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2012%26volume%3D40%26spage%3DD1100%26epage%3DD1107%26doi%3D10.1093%2Fnar%2Fgkr777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref185"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref185'); return false;" data-citation="" class="refNumLink">185</a></strong><div class="NLM_citation" id="cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campillo, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goya, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Páez, J. A.</span></span> <span> </span><span class="NLM_article-title">Homology Models of the Cannabinoid CB1 and CB2 Receptors. A Docking Analysis Study</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">83</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2004.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2004.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=15642412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtF2jsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2005&pages=75-83&author=C.+Monteroauthor=N.+E.+Campilloauthor=P.+Goyaauthor=J.+A.+P%C3%A1ez&title=Homology+Models+of+the+Cannabinoid+CB1+and+CB2+Receptors.+A+Docking+Analysis+Study&doi=10.1016%2Fj.ejmech.2004.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Homology models of the cannabinoid CB1 and CB2 receptors. A docking analysis study</span></div><div class="casAuthors">Montero, Cristina; Campillo, Nuria Eugenia; Goya, Pilar; Paez, Juan Antonio</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-83</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The 3D models of both CB1 and CB2 human receptors have been established by homol. modeling using as template the x-ray structure of bovine Rhodopsin (code pdb: 1F88) a G-protein-coupled receptor (GPCR).  A recursive approach comprising sequence alignment and model building was used to build both models, followed by the refinement of non-conserved regions.  The cannabinoid system has been studied by means of docking techniques, using the 3D models of both CB1 and CB2 and well known ref. inverse agonist/antagonist compds.  An approach based on the flexibility of the structures has been used to model the receptor-ligand complexes.  The structural effects of ligand binding were studied and analyzed on the basis of hydrogen bond interactions, and binding energy calcns.  Potential interaction sites of the receptor were detd. from anal. of the difference accessible surface area (DASA) study of the protein with and without ligand.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoatifSMJvC57Vg90H21EOLACvtfcHk0ljH5s3VFZS5BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtF2jsQ%253D%253D&md5=0ef56ee1b6ed33769361b95510e70331</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2004.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2004.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DMontero%26aufirst%3DC.%26aulast%3DCampillo%26aufirst%3DN.%2BE.%26aulast%3DGoya%26aufirst%3DP.%26aulast%3DP%25C3%25A1ez%26aufirst%3DJ.%2BA.%26atitle%3DHomology%2520Models%2520of%2520the%2520Cannabinoid%2520CB1%2520and%2520CB2%2520Receptors.%2520A%2520Docking%2520Analysis%2520Study%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2005%26volume%3D40%26spage%3D75%26epage%3D83%26doi%3D10.1016%2Fj.ejmech.2004.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref186"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref186'); return false;" data-citation="" class="refNumLink">186</a></strong><div class="NLM_citation" id="cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cichero, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligresti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allarà, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzati, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Ursi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marabotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanesi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spallarossa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranise, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fossa, P.</span></span> <span> </span><span class="NLM_article-title">Homology Modeling in Tandem with 3D-QSAR Analyses: A Computational Approach to Depict the Agonist Binding Site of the Human CB2 Receptor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">4489</span>– <span class="NLM_lpage">4505</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2011.07.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2011.07.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=21835510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtV2rtb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=4489-4505&author=E.+Cicheroauthor=A.+Ligrestiauthor=M.+Allar%C3%A0author=V.+di+Marzoauthor=Z.+Lazzatiauthor=P.+D%E2%80%99Ursiauthor=A.+Marabottiauthor=L.+Milanesiauthor=A.+Spallarossaauthor=P.+Raniseauthor=P.+Fossa&title=Homology+Modeling+in+Tandem+with+3D-QSAR+Analyses%3A+A+Computational+Approach+to+Depict+the+Agonist+Binding+Site+of+the+Human+CB2+Receptor&doi=10.1016%2Fj.ejmech.2011.07.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Homology modeling in tandem with 3D-QSAR analyses: A computational approach to depict the agonist binding site of the human CB2 receptor</span></div><div class="casAuthors">Cichero, Elena; Ligresti, Alessia; Allara, Marco; di Marzo, Vincenzo; Lazzati, Zelda; D'Ursi, Pasqualina; Marabotti, Anna; Milanesi, Luciano; Spallarossa, Andrea; Ranise, Angelo; Fossa, Paola</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4489-4505</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">CB2 receptor belongs to the large family of G-protein coupled receptors (GPCRs) controlling a wide variety of signal transduction.  The recent crystallog. detn. of human β2 adrenoreceptor and its high sequence similarity with human CB2 receptor (hCB2) prompted us to compute a theor. model of hCB2 based also on β2 adrenoreceptor coordinates.  This model has been employed to perform docking and mol. dynamic simulations on WIN-55,212-2 (CB2 agonist commonly used in binding expts.), in order to identify the putative CB2 receptor agonist binding site, followed by mol. docking studies on a series of indol-3-yl-tetramethylcyclopropyl ketone derivs., a novel class of potent CB2 agonists.  Successively, docking-based Comparative Mol. Fields Anal. (CoMFA) and Comparative Mol. Similarity Indexes Anal. (CoMSIA) studies were also performed.  The CoMSIA model resulted to be the more predictive, showing r ncv 2 = 0.96, r cv 2 = 0.713, SEE = 0.193, F = 125.223, and r 2 pred = 0.78.  The obtained 3D-QSAR models allowed us to derive more complete guidelines for the design of new analogs with improved potency so as to synthesize new indoles showing high CB2 affinity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqUOoYxe3QXLVg90H21EOLACvtfcHk0ljH5s3VFZS5BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtV2rtb7P&md5=2c1840ef5f091c1472eeccf3dceb471d</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2011.07.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2011.07.023%26sid%3Dliteratum%253Aachs%26aulast%3DCichero%26aufirst%3DE.%26aulast%3DLigresti%26aufirst%3DA.%26aulast%3DAllar%25C3%25A0%26aufirst%3DM.%26aulast%3Ddi%2BMarzo%26aufirst%3DV.%26aulast%3DLazzati%26aufirst%3DZ.%26aulast%3DD%25E2%2580%2599Ursi%26aufirst%3DP.%26aulast%3DMarabotti%26aufirst%3DA.%26aulast%3DMilanesi%26aufirst%3DL.%26aulast%3DSpallarossa%26aufirst%3DA.%26aulast%3DRanise%26aufirst%3DP.%26aulast%3DFossa%26aufirst%3DP.%26atitle%3DHomology%2520Modeling%2520in%2520Tandem%2520with%25203D-QSAR%2520Analyses%253A%2520A%2520Computational%2520Approach%2520to%2520Depict%2520the%2520Agonist%2520Binding%2520Site%2520of%2520the%2520Human%2520CB2%2520Receptor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2011%26volume%3D46%26spage%3D4489%26epage%3D4505%26doi%3D10.1016%2Fj.ejmech.2011.07.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref187"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref187'); return false;" data-citation="" class="refNumLink">187</a></strong><div class="NLM_citation" id="cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tuccinardi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrarini, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortore, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccomanni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinelli, A.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid CB2/CB1 Selectivity. Receptor Modeling and Automated Docking Analysis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">984</span>– <span class="NLM_lpage">994</span>, <span class="refDoi"> DOI: 10.1021/jm050875u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050875u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD28XksFSmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=984-994&author=T.+Tuccinardiauthor=P.+L.+Ferrariniauthor=C.+Maneraauthor=G.+Ortoreauthor=G.+Saccomanniauthor=A.+Martinelli&title=Cannabinoid+CB2%2FCB1+Selectivity.+Receptor+Modeling+and+Automated+Docking+Analysis&doi=10.1021%2Fjm050875u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid CB2/CB1 Selectivity. Receptor Modeling and Automated Docking Analysis</span></div><div class="casAuthors">Tuccinardi, Tiziano; Ferrarini, Pier Luigi; Manera, Clementina; Ortore, Gabriella; Saccomanni, Giuseppe; Martinelli, Adriano</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">984-994</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Three-dimensional models of the CB1 and CB2 cannabinoid receptors were constructed by a mol. modeling procedure, using the x-ray structure of bovine rhodopsin as the initial template, and taking into account the available site-directed mutagenesis data.  The cannabinoid system was studied by docking techniques.  An anal. of the interaction of WIN55212-2 with both receptors showed that CB2/CB1 selectivity is mainly detd. by the interaction in the CB2 with the nonconserved residues S3.31 and F5.46, whose importance was suggested by site-directed mutagenesis data.  The authors also carried out an automated docking of several ligands into the CB2 model, using the AUTODOCK 3.0 program; the good correlation obtained between the estd. free energy binding and the exptl. binding data confirmed the authors binding hypothesis and the reliability of the model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY9HJjKUsl_LVg90H21EOLACvtfcHk0lhyWXktqt5ksQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksFSmsg%253D%253D&md5=4e61737ef2abacc73624e15a7748e272</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1021%2Fjm050875u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050875u%26sid%3Dliteratum%253Aachs%26aulast%3DTuccinardi%26aufirst%3DT.%26aulast%3DFerrarini%26aufirst%3DP.%2BL.%26aulast%3DManera%26aufirst%3DC.%26aulast%3DOrtore%26aufirst%3DG.%26aulast%3DSaccomanni%26aufirst%3DG.%26aulast%3DMartinelli%26aufirst%3DA.%26atitle%3DCannabinoid%2520CB2%252FCB1%2520Selectivity.%2520Receptor%2520Modeling%2520and%2520Automated%2520Docking%2520Analysis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D984%26epage%3D994%26doi%3D10.1021%2Fjm050875u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref188"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref188'); return false;" data-citation="" class="refNumLink">188</a></strong><div class="NLM_citation" id="cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vemuri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popov, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benchama, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvonok, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locke, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cinar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffey, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makriyannis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.-J.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of the Human Cannabinoid Receptor CB2</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">467</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2018.12.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.cell.2018.12.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=30639103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovFKktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2019&pages=459-467&author=X.+Liauthor=T.+Huaauthor=K.+Vemuriauthor=J.-H.+Hoauthor=Y.+Wuauthor=L.+Wuauthor=P.+Popovauthor=O.+Benchamaauthor=N.+Zvonokauthor=K.+Lockeauthor=L.+Quauthor=G.+W.+Hanauthor=M.+R.+Iyerauthor=R.+Cinarauthor=N.+J.+Coffeyauthor=J.+Wangauthor=M.+Wuauthor=V.+Katritchauthor=S.+Zhaoauthor=G.+Kunosauthor=L.+M.+Bohnauthor=A.+Makriyannisauthor=R.+C.+Stevensauthor=Z.-J.+Liu&title=Crystal+Structure+of+the+Human+Cannabinoid+Receptor+CB2&doi=10.1016%2Fj.cell.2018.12.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Human Cannabinoid Receptor CB2</span></div><div class="casAuthors">Li, Xiaoting; Hua, Tian; Vemuri, Kiran; Ho, Jo-Hao; Wu, Yiran; Wu, Lijie; Popov, Petr; Benchama, Othman; Zvonok, Nikolai; Locke, K'ara; Qu, Lu; Han, Gye Won; Iyer, Malliga R.; Cinar, Resat; Coffey, Nathan J.; Wang, Jingjing; Wu, Meng; Katritch, Vsevolod; Zhao, Suwen; Kunos, George; Bohn, Laura M.; Makriyannis, Alexandros; Stevens, Raymond C.; Liu, Zhi-Jie</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">459-467.e13</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The cannabinoid receptor CB2 is predominately expressed in the immune system, and selective modulation of CB2 without the psychoactivity of CB1 has therapeutic potential in inflammatory, fibrotic, and neurodegenerative diseases.  Here, we report the crystal structure of human CB2 in complex with a rationally designed antagonist, AM10257, at 2.8 Å resoln.  The CB2-AM10257 structure reveals a distinctly different binding pose compared with CB1.  However, the extracellular portion of the antagonist-bound CB2 shares a high degree of conformational similarity with the agonist-bound CB1, which led to the discovery of AM10257's unexpected opposing functional profile of CB2 antagonism vs. CB1 agonism.  Further structural anal. using mutagenesis studies and mol. docking revealed the mol. basis of their function and selectivity for CB2 and CB1.  Addnl. analyses of our designed antagonist and agonist pairs provide important insight into the activation mechanism of CB2.  The present findings should facilitate rational drug design toward precise modulation of the endocannabinoid system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFwNUEO0q03LVg90H21EOLACvtfcHk0lhyWXktqt5ksQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovFKktw%253D%253D&md5=90ee72a6dc13b74b84fb6799c3aa0471</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2018.12.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2018.12.011%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DHua%26aufirst%3DT.%26aulast%3DVemuri%26aufirst%3DK.%26aulast%3DHo%26aufirst%3DJ.-H.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DPopov%26aufirst%3DP.%26aulast%3DBenchama%26aufirst%3DO.%26aulast%3DZvonok%26aufirst%3DN.%26aulast%3DLocke%26aufirst%3DK.%26aulast%3DQu%26aufirst%3DL.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DIyer%26aufirst%3DM.%2BR.%26aulast%3DCinar%26aufirst%3DR.%26aulast%3DCoffey%26aufirst%3DN.%2BJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DKunos%26aufirst%3DG.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26aulast%3DMakriyannis%26aufirst%3DA.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DLiu%26aufirst%3DZ.-J.%26atitle%3DCrystal%2520Structure%2520of%2520the%2520Human%2520Cannabinoid%2520Receptor%2520CB2%26jtitle%3DCell%26date%3D2019%26volume%3D176%26spage%3D459%26epage%3D467%26doi%3D10.1016%2Fj.cell.2018.12.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref189"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref189'); return false;" data-citation="" class="refNumLink">189</a></strong><div class="NLM_citation" id="cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hua, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iliopoulos-Tsoutsouvas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikas, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grim, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benchama, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvonok, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makriyannis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.-J.</span></span> <span> </span><span class="NLM_article-title">Activation and Signaling Mechanism Revealed by Cannabinoid Receptor-G(i)Complex Structures</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>180</i></span>,  <span class="NLM_fpage">655</span>– <span class="NLM_lpage">665</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2020.01.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.cell.2020.01.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=32004463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFeqtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2020&pages=655-665&author=T.+Huaauthor=X.+Liauthor=L.+Wuauthor=C.+Iliopoulos-Tsoutsouvasauthor=Y.+Wangauthor=M.+Wuauthor=L.+Shenauthor=C.+A.+Johnstonauthor=S.+P.+Nikasauthor=F.+Songauthor=X.+Songauthor=S.+Yuanauthor=Q.+Sunauthor=Y.+Wuauthor=S.+Jiangauthor=T.+W.+Grimauthor=O.+Benchamaauthor=E.+L.+Stahlauthor=N.+Zvonokauthor=S.+Zhaoauthor=L.+M.+Bohnauthor=A.+Makriyannisauthor=Z.-J.+Liu&title=Activation+and+Signaling+Mechanism+Revealed+by+Cannabinoid+Receptor-G%28i%29Complex+Structures&doi=10.1016%2Fj.cell.2020.01.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Activation and Signaling Mechanism Revealed by Cannabinoid Receptor-Gi Complex Structures</span></div><div class="casAuthors">Hua, Tian; Li, Xiaoting; Wu, Lijie; Iliopoulos-Tsoutsouvas, Christos; Wang, Yuxia; Wu, Meng; Shen, Ling; Johnston, Christina A.; Nikas, Spyros P.; Song, Feng; Song, Xiyong; Yuan, Shuguang; Sun, Qianqian; Wu, Yiran; Jiang, Shan; Grim, Travis W.; Benchama, Othman; Stahl, Edward L.; Zvonok, Nikolai; Zhao, Suwen; Bohn, Laura M.; Makriyannis, Alexandros; Liu, Zhi-Jie</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">655-665.e18</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Human endocannabinoid systems modulate multiple physiol. processes mainly through the activation of cannabinoid receptors CB1 and CB2.  Their high sequence similarity, low agonist selectivity, and lack of activation and G protein-coupling knowledge have hindered the development of therapeutic applications.  Importantly, missing structural information has significantly held back the development of promising CB2-selective agonist drugs for treating inflammatory and neuropathic pain without the psychoactivity of CB1.  Here, we report the cryoelectron microscopy structures of synthetic cannabinoid-bound CB2 and CB1 in complex with Gi, as well as agonist-bound CB2 crystal structure.  Of important scientific and therapeutic benefit, our results reveal a diverse activation and signaling mechanism, the structural basis of CB2-selective agonists design, and the unexpected interaction of cholesterol with CB1, suggestive of its endogenous allosteric modulating role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgy9tDrt9HArVg90H21EOLACvtfcHk0lgv0bwX1Zsdsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFeqtbc%253D&md5=b9d4dd05094f3bae76b315a41a11c21b</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2020.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2020.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DHua%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DIliopoulos-Tsoutsouvas%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DJohnston%26aufirst%3DC.%2BA.%26aulast%3DNikas%26aufirst%3DS.%2BP.%26aulast%3DSong%26aufirst%3DF.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DGrim%26aufirst%3DT.%2BW.%26aulast%3DBenchama%26aufirst%3DO.%26aulast%3DStahl%26aufirst%3DE.%2BL.%26aulast%3DZvonok%26aufirst%3DN.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26aulast%3DMakriyannis%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DZ.-J.%26atitle%3DActivation%2520and%2520Signaling%2520Mechanism%2520Revealed%2520by%2520Cannabinoid%2520Receptor-G%2528i%2529Complex%2520Structures%26jtitle%3DCell%26date%3D2020%26volume%3D180%26spage%3D655%26epage%3D665%26doi%3D10.1016%2Fj.cell.2020.01.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref190"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref190'); return false;" data-citation="" class="refNumLink">190</a></strong><div class="NLM_citation" id="cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bressi, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skene, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melkus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimshaw, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navre, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangloff, A. R.</span></span> <span> </span><span class="NLM_article-title">Exploration of the HDAC2 Foot Pocket: Synthesis and SAR of Substituted N-(2-Aminophenyl)Benzamides</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">3142</span>– <span class="NLM_lpage">3145</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.03.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmcl.2010.03.091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=20392638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsFGnsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=3142-3145&author=J.+C.+Bressiauthor=A.+J.+Jenningsauthor=R.+Skeneauthor=Y.+Wuauthor=R.+Melkusauthor=R.+De+Jongauthor=S.+O%E2%80%99Connellauthor=C.+E.+Grimshawauthor=M.+Navreauthor=A.+R.+Gangloff&title=Exploration+of+the+HDAC2+Foot+Pocket%3A+Synthesis+and+SAR+of+Substituted+N-%282-Aminophenyl%29Benzamides&doi=10.1016%2Fj.bmcl.2010.03.091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides</span></div><div class="casAuthors">Bressi, Jerome C.; Jennings, Andy J.; Skene, Robert; Wu, Yiqin; Melkus, Robert; de Jong, Ron; O'Connell, Shawn; Grimshaw, Charles E.; Navre, Marc; Gangloff, Anthony R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3142-3145</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of N-(2-amino-5-substituted phenyl)benzamides were designed, synthesized and evaluated for their inhibition of HDAC2 and their cytotoxicity in HCT116 cancer cells.  Multiple compds. from this series demonstrated time-dependent binding kinetics that is rationalized using a co-complex crystal structure of HDAC2 and N-(4-aminobiphenyl-3-yl)benzamide I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN0N7gN89VAbVg90H21EOLACvtfcHk0lgv0bwX1Zsdsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsFGnsLs%253D&md5=a7cce9bd1fcb1c2d248d2aee0db3ffc7</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.03.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.03.091%26sid%3Dliteratum%253Aachs%26aulast%3DBressi%26aufirst%3DJ.%2BC.%26aulast%3DJennings%26aufirst%3DA.%2BJ.%26aulast%3DSkene%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DMelkus%26aufirst%3DR.%26aulast%3DDe%2BJong%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DS.%26aulast%3DGrimshaw%26aufirst%3DC.%2BE.%26aulast%3DNavre%26aufirst%3DM.%26aulast%3DGangloff%26aufirst%3DA.%2BR.%26atitle%3DExploration%2520of%2520the%2520HDAC2%2520Foot%2520Pocket%253A%2520Synthesis%2520and%2520SAR%2520of%2520Substituted%2520N-%25282-Aminophenyl%2529Benzamides%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D3142%26epage%3D3145%26doi%3D10.1016%2Fj.bmcl.2010.03.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref191"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref191'); return false;" data-citation="" class="refNumLink">191</a></strong><div class="NLM_citation" id="cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weïwer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbacher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schomburg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinemer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gale, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennig, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jefson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fass, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggarty, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holson, E. B.</span></span> <span> </span><span class="NLM_article-title">Kinetic and Structural Insights into the Binding of Histone Deacetylase 1 and 2 (HDAC1, 2) Inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4008</span>– <span class="NLM_lpage">4015</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.06.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmc.2016.06.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=27377864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFSgur7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=4008-4015&author=F.+F.+Wagnerauthor=M.+We%C3%AFwerauthor=S.+Steinbacherauthor=A.+Schomburgauthor=P.+Reinemerauthor=J.+P.+Galeauthor=A.+J.+Campbellauthor=S.+L.+Fisherauthor=W.-N.+Zhaoauthor=S.+A.+Reisauthor=K.+M.+Hennigauthor=M.+Thomasauthor=P.+M%C3%BCllerauthor=M.+R.+Jefsonauthor=D.+M.+Fassauthor=S.+J.+Haggartyauthor=Y.+L.+Zhangauthor=E.+B.+Holson&title=Kinetic+and+Structural+Insights+into+the+Binding+of+Histone+Deacetylase+1+and+2+%28HDAC1%2C+2%29+Inhibitors&doi=10.1016%2Fj.bmc.2016.06.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetic and structural insights into the binding of histone deacetylase 1 and 2 (HDAC1, 2) inhibitors</span></div><div class="casAuthors">Wagner, Florence F.; Weiwer, Michel; Steinbacher, Stefan; Schomburg, Adrian; Reinemer, Peter; Gale, Jennifer P.; Campbell, Arthur J.; Fisher, Stewart L.; Zhao, Wen-Ning; Reis, Surya A.; Hennig, Krista M.; Thomas, Meryl; Muller, Peter; Jefson, Martin R.; Fass, Daniel M.; Haggarty, Stephen J.; Zhang, Yan-Ling; Holson, Edward B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4008-4015</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The structure-activity and structure-kinetic relationships of a series of novel and selective ortho-aminoanilide inhibitors of histone deacetylases (HDACs) 1 and 2 are described.  Different kinetic and thermodn. selectivity profiles were obtained by varying the moiety occupying an 11 Å channel leading to the Zn2+ catalytic pocket of HDACs 1 and 2, two paralogs with a high degree of structural similarity.  The design of these novel inhibitors was informed by two ligand-bound crystal structures of truncated hHDAC2.  BRD4884 and BRD7232 possess kinetic selectivity for HDAC1 vs. HDAC2.  We demonstrate that the binding kinetics of HDAC inhibitors can be tuned for individual isoforms in order to modulate target residence time while retaining functional activity and increased histone H4K12 and H3K9 acetylation in primary mouse neuronal cell culture assays.  These chromatin modifiers, with tuned binding kinetic profiles, can be used to define the relation between target engagement requirements and the pharmacodynamic response of HDACs in different disease applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQpWplRRVod7Vg90H21EOLACvtfcHk0lgv0bwX1Zsdsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFSgur7E&md5=bcbe1addb5d30073f345fd77d529dcd4</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.06.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.06.040%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DF.%2BF.%26aulast%3DWe%25C3%25AFwer%26aufirst%3DM.%26aulast%3DSteinbacher%26aufirst%3DS.%26aulast%3DSchomburg%26aufirst%3DA.%26aulast%3DReinemer%26aufirst%3DP.%26aulast%3DGale%26aufirst%3DJ.%2BP.%26aulast%3DCampbell%26aufirst%3DA.%2BJ.%26aulast%3DFisher%26aufirst%3DS.%2BL.%26aulast%3DZhao%26aufirst%3DW.-N.%26aulast%3DReis%26aufirst%3DS.%2BA.%26aulast%3DHennig%26aufirst%3DK.%2BM.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DM%25C3%25BCller%26aufirst%3DP.%26aulast%3DJefson%26aufirst%3DM.%2BR.%26aulast%3DFass%26aufirst%3DD.%2BM.%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%2BL.%26aulast%3DHolson%26aufirst%3DE.%2BB.%26atitle%3DKinetic%2520and%2520Structural%2520Insights%2520into%2520the%2520Binding%2520of%2520Histone%2520Deacetylase%25201%2520and%25202%2520%2528HDAC1%252C%25202%2529%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D4008%26epage%3D4015%26doi%3D10.1016%2Fj.bmc.2016.06.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref192"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref192'); return false;" data-citation="" class="refNumLink">192</a></strong><div class="NLM_citation" id="cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolkenberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beshore, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fells, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnard, R. J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozlowski, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of Ethyl Ketone-Based HDACs 1, 2, and 3 Selective Inhibitors for HIV Latency Reactivation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">127197</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmcl.2020.127197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=32331932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnvFeisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127197&author=W.+Yuauthor=J.+Liuauthor=Y.+Yuauthor=V.+Zhangauthor=D.+Clausenauthor=J.+Kellyauthor=S.+Wolkenbergauthor=D.+Beshoreauthor=J.+L.+Duffyauthor=C.+C.+Chungauthor=R.+J.+Myersauthor=D.+L.+Kleinauthor=J.+Fellsauthor=K.+Hollowayauthor=J.+Wuauthor=G.+Wuauthor=B.+J.+Howellauthor=R.+J.+O.+Barnardauthor=J.+Kozlowski&title=Discovery+of+Ethyl+Ketone-Based+HDACs+1%2C+2%2C+and+3+Selective+Inhibitors+for+HIV+Latency+Reactivation&doi=10.1016%2Fj.bmcl.2020.127197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of ethyl ketone-based HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation</span></div><div class="casAuthors">Yu, Wensheng; Liu, Jian; Yu, Younong; Zhang, Vivian; Clausen, Dane; Kelly, Joseph; Wolkenberg, Scott; Beshore, Douglas; Duffy, Joseph L.; Chang, Christine C.; Myers, Robert W.; Klein, Daniel J.; Fells, James; Holloway, Kate; Wu, Jin; Wu, Guoxin; Howell, Bonnie J.; Barnard, Richard J. O.; Kozlowski, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">127197</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel series of Et ketone based HDACs 1, 2, and 3 selective inhibitors have been identified with good enzymic and cellular activity and high selectivity over HDACs 6 and 8.  These inhibitors contain a spirobicyclic group in the amide region.  Compd. 13 stands out as a lead due to its good potency, high selectivity, and reasonable rat and dog PK.  Compds. 33 and 34 show good potency and rat PK profiles as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCRDknBquRfbVg90H21EOLACvtfcHk0lh6AQZU_DVf6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnvFeisb8%253D&md5=d0fb2e00f70938578cebc54129de8ce9</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127197%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DV.%26aulast%3DClausen%26aufirst%3DD.%26aulast%3DKelly%26aufirst%3DJ.%26aulast%3DWolkenberg%26aufirst%3DS.%26aulast%3DBeshore%26aufirst%3DD.%26aulast%3DDuffy%26aufirst%3DJ.%2BL.%26aulast%3DChung%26aufirst%3DC.%2BC.%26aulast%3DMyers%26aufirst%3DR.%2BJ.%26aulast%3DKlein%26aufirst%3DD.%2BL.%26aulast%3DFells%26aufirst%3DJ.%26aulast%3DHolloway%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DHowell%26aufirst%3DB.%2BJ.%26aulast%3DBarnard%26aufirst%3DR.%2BJ.%2BO.%26aulast%3DKozlowski%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520Ethyl%2520Ketone-Based%2520HDACs%25201%252C%25202%252C%2520and%25203%2520Selective%2520Inhibitors%2520for%2520HIV%2520Latency%2520Reactivation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26spage%3D127197%26doi%3D10.1016%2Fj.bmcl.2020.127197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref193"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref193'); return false;" data-citation="" class="refNumLink">193</a></strong><div class="NLM_citation" id="cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fournier, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhurruth-Alcor, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musicki, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aurelly, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouix-Peter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouquet, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chantalat, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delorme, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drean, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duvert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleury-Bregeot, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grisendi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennequin, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isabet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joly, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafitte, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millois, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgentin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piwnica, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rival, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soulet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thoreau, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomas, L.</span></span> <span> </span><span class="NLM_article-title">Squaramides as Novel Class I and IIB Histone Deacetylase Inhibitors for Topical Treatment of Cutaneous T-Cell Lymphoma</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2985</span>– <span class="NLM_lpage">2992</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.06.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmcl.2018.06.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=30122227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1yrsrbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=2985-2992&author=J.-F.+Fournierauthor=Y.+Bhurruth-Alcorauthor=B.+Musickiauthor=J.+Aubertauthor=M.+Aurellyauthor=C.+Bouix-Peterauthor=K.+Bouquetauthor=L.+Chantalatauthor=M.+Delormeauthor=B.+Dreanauthor=G.+Duvertauthor=N.+Fleury-Bregeotauthor=B.+Gauthierauthor=K.+Grisendiauthor=C.+S.+Harrisauthor=L.+F.+Hennequinauthor=T.+Isabetauthor=F.+Jolyauthor=G.+Lafitteauthor=C.+Milloisauthor=R.+Morgentinauthor=J.+Pascauauthor=D.+Piwnicaauthor=Y.+Rivalauthor=C.+Souletauthor=E.+Thoreauauthor=L.+Tomas&title=Squaramides+as+Novel+Class+I+and+IIB+Histone+Deacetylase+Inhibitors+for+Topical+Treatment+of+Cutaneous+T-Cell+Lymphoma&doi=10.1016%2Fj.bmcl.2018.06.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Squaramides as novel class I and IIB histone deacetylase inhibitors for topical treatment of cutaneous t-cell lymphoma</span></div><div class="casAuthors">Fournier, Jean-Francois; Bhurruth-Alcor, Yushma; Musicki, Branislav; Aubert, Jerome; Aurelly, Michele; Bouix-Peter, Claire; Bouquet, Karinne; Chantalat, Laurent; Delorme, Marion; Drean, Benedicte; Duvert, Gwenaelle; Fleury-Bregeot, Nicolas; Gauthier, Blanche; Grisendi, Karine; Harris, Craig S.; Hennequin, Laurent F.; Isabet, Tatiana; Joly, Florence; Lafitte, Guillaume; Millois, Corinne; Morgentin, Remy; Pascau, Jonathan; Piwnica, David; Rival, Yves; Soulet, Catherine; Thoreau, Etienne; Tomas, Loic</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2985-2992</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of squaramide-based hydroxamic acids were designed, synthesized and evaluated against human HDAC enzyme.  Squaramides were found t o be potent in the Hut78 cell line, but initially suffered from low soly.  Leads with improved soly. and metabolic profiles were shown to be class I, IIB and IV selective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8Zi7nKMExXrVg90H21EOLACvtfcHk0lh6AQZU_DVf6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1yrsrbE&md5=f882594f1146d7d96f3e3860c3199cdb</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.06.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.06.029%26sid%3Dliteratum%253Aachs%26aulast%3DFournier%26aufirst%3DJ.-F.%26aulast%3DBhurruth-Alcor%26aufirst%3DY.%26aulast%3DMusicki%26aufirst%3DB.%26aulast%3DAubert%26aufirst%3DJ.%26aulast%3DAurelly%26aufirst%3DM.%26aulast%3DBouix-Peter%26aufirst%3DC.%26aulast%3DBouquet%26aufirst%3DK.%26aulast%3DChantalat%26aufirst%3DL.%26aulast%3DDelorme%26aufirst%3DM.%26aulast%3DDrean%26aufirst%3DB.%26aulast%3DDuvert%26aufirst%3DG.%26aulast%3DFleury-Bregeot%26aufirst%3DN.%26aulast%3DGauthier%26aufirst%3DB.%26aulast%3DGrisendi%26aufirst%3DK.%26aulast%3DHarris%26aufirst%3DC.%2BS.%26aulast%3DHennequin%26aufirst%3DL.%2BF.%26aulast%3DIsabet%26aufirst%3DT.%26aulast%3DJoly%26aufirst%3DF.%26aulast%3DLafitte%26aufirst%3DG.%26aulast%3DMillois%26aufirst%3DC.%26aulast%3DMorgentin%26aufirst%3DR.%26aulast%3DPascau%26aufirst%3DJ.%26aulast%3DPiwnica%26aufirst%3DD.%26aulast%3DRival%26aufirst%3DY.%26aulast%3DSoulet%26aufirst%3DC.%26aulast%3DThoreau%26aufirst%3DE.%26aulast%3DTomas%26aufirst%3DL.%26atitle%3DSquaramides%2520as%2520Novel%2520Class%2520I%2520and%2520IIB%2520Histone%2520Deacetylase%2520Inhibitors%2520for%2520Topical%2520Treatment%2520of%2520Cutaneous%2520T-Cell%2520Lymphoma%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D2985%26epage%3D2992%26doi%3D10.1016%2Fj.bmcl.2018.06.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref194"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref194'); return false;" data-citation="" class="refNumLink">194</a></strong><div class="NLM_citation" id="cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lauffer, B. E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mintzer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukund, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zilberleyb, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flicke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritscher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorowicz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunzner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modrusan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koth, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupardus, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminker, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heise, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, P.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">26926</span>– <span class="NLM_lpage">26943</span>, <span class="refDoi"> DOI: 10.1074/jbc.M113.490706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1074%2Fjbc.M113.490706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=23897821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVClt7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=26926-26943&author=B.+E.+L.+Laufferauthor=R.+Mintzerauthor=R.+Fongauthor=S.+Mukundauthor=C.+Tamauthor=I.+Zilberleybauthor=B.+Flickeauthor=A.+Ritscherauthor=G.+Fedorowiczauthor=R.+Valleroauthor=D.+F.+Ortwineauthor=J.+Gunznerauthor=Z.+Modrusanauthor=L.+Neumannauthor=C.+M.+Kothauthor=P.+J.+Lupardusauthor=J.+S.+Kaminkerauthor=C.+E.+Heiseauthor=P.+Steiner&title=Histone+Deacetylase+%28HDAC%29+Inhibitor+Kinetic+Rate+Constants+Correlate+with+Cellular+Histone+Acetylation+but+Not+Transcription+and+Cell+Viability&doi=10.1074%2Fjbc.M113.490706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability</span></div><div class="casAuthors">Lauffer, Benjamin E. L.; Mintzer, Robert; Fong, Rina; Mukund, Susmith; Tam, Christine; Zilberleyb, Inna; Flicke, Birgit; Ritscher, Allegra; Fedorowicz, Grazyna; Vallero, Roxanne; Ortwine, Daniel F.; Gunzner, Janet; Modrusan, Zora; Neumann, Lars; Koth, Christopher M.; Lupardus, Patrick J.; Kaminker, Joshua S.; Heise, Christopher E.; Steiner, Pascal</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">26926-26943</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are crit. in the control of gene expression, and dysregulation of their activity has been implicated in a broad range of diseases, including cancer, cardiovascular, and neurol. diseases.  HDAC inhibitors (HDACi) employing different zinc chelating functionalities such as hydroxamic acids and benzamides have shown promising results in cancer therapy.  Although it has also been suggested that HDACi with increased isoenzyme selectivity and potency may broaden their clin. utility and minimize side effects, the translation of this idea to the clinic remains to be investigated.  Moreover, a detailed understanding of how HDACi with different pharmacol. properties affect biol. functions in vitro and in vivo is still missing.  Here, we show that a panel of benzamide-contg. HDACi are slow tight-binding inhibitors with long residence times unlike the hydroxamate-contg. HDACi vorinostat and trichostatin-A.  Characterization of changes in H2BK5 and H4K14 acetylation following HDACi treatment in the neuroblastoma cell line SH-SY5Y revealed that the timing and magnitude of histone acetylation mirrored both the assocn. and dissocn. kinetic rates of the inhibitors.  In contrast, cell viability and microarray gene expression anal. indicated that cell death induction and changes in transcriptional regulation do not correlate with the dissocn. kinetic rates of the HDACi.  Therefore, our study suggests that detg. how the selective and kinetic inhibition properties of HDACi affect cell function will help to evaluate their therapeutic utility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2goaOx8CDGbVg90H21EOLACvtfcHk0liAjlyIaD4o4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVClt7jM&md5=af1074c79e8abd932313f4ae13333a98</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.490706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.490706%26sid%3Dliteratum%253Aachs%26aulast%3DLauffer%26aufirst%3DB.%2BE.%2BL.%26aulast%3DMintzer%26aufirst%3DR.%26aulast%3DFong%26aufirst%3DR.%26aulast%3DMukund%26aufirst%3DS.%26aulast%3DTam%26aufirst%3DC.%26aulast%3DZilberleyb%26aufirst%3DI.%26aulast%3DFlicke%26aufirst%3DB.%26aulast%3DRitscher%26aufirst%3DA.%26aulast%3DFedorowicz%26aufirst%3DG.%26aulast%3DVallero%26aufirst%3DR.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DGunzner%26aufirst%3DJ.%26aulast%3DModrusan%26aufirst%3DZ.%26aulast%3DNeumann%26aufirst%3DL.%26aulast%3DKoth%26aufirst%3DC.%2BM.%26aulast%3DLupardus%26aufirst%3DP.%2BJ.%26aulast%3DKaminker%26aufirst%3DJ.%2BS.%26aulast%3DHeise%26aufirst%3DC.%2BE.%26aulast%3DSteiner%26aufirst%3DP.%26atitle%3DHistone%2520Deacetylase%2520%2528HDAC%2529%2520Inhibitor%2520Kinetic%2520Rate%2520Constants%2520Correlate%2520with%2520Cellular%2520Histone%2520Acetylation%2520but%2520Not%2520Transcription%2520and%2520Cell%2520Viability%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D26926%26epage%3D26943%26doi%3D10.1074%2Fjbc.M113.490706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref195"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref195'); return false;" data-citation="" class="refNumLink">195</a></strong><div class="NLM_citation" id="cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bottomley, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo Surdo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Giovine, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirillo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrigno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neddermann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Francesco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinkühler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallinari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carfí, A.</span></span> <span> </span><span class="NLM_article-title">Structural and Functional Analysis of the Human HDAC4 Catalytic Domain Reveals a Regulatory Structural Zinc-Binding Domain</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">26694</span>– <span class="NLM_lpage">26704</span>, <span class="refDoi"> DOI: 10.1074/jbc.M803514200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1074%2Fjbc.M803514200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=18614528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFejtr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=26694-26704&author=M.+J.+Bottomleyauthor=P.+Lo+Surdoauthor=P.+Di+Giovineauthor=A.+Cirilloauthor=R.+Scarpelliauthor=F.+Ferrignoauthor=P.+Jonesauthor=P.+Neddermannauthor=R.+De+Francescoauthor=C.+Steink%C3%BChlerauthor=P.+Gallinariauthor=A.+Carf%C3%AD&title=Structural+and+Functional+Analysis+of+the+Human+HDAC4+Catalytic+Domain+Reveals+a+Regulatory+Structural+Zinc-Binding+Domain&doi=10.1074%2Fjbc.M803514200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Functional Analysis of the Human HDAC4 Catalytic Domain Reveals a Regulatory Structural Zinc-binding Domain</span></div><div class="casAuthors">Bottomley, Matthew J.; Lo Surdo, Paola; Di Giovine, Paolo; Cirillo, Agostino; Scarpelli, Rita; Ferrigno, Federica; Jones, Philip; Neddermann, Petra; De Francesco, Raffaele; Steinkuehler, Christian; Gallinari, Paola; Carfi, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">26694-26704</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) regulate chromatin status and gene expression, and their inhibition is of significant therapeutic interest.  To date, no biol. substrate for class IIa HDACs has been identified, and only low activity on acetylated lysines has been demonstrated.  Here, we describe inhibitor-bound and inhibitor-free structures of the histone deacetylase-4 catalytic domain (HDAC4cd) and of an HDAC4cd active site mutant with enhanced enzymic activity toward acetylated lysines.  The structures presented, coupled with activity data, provide the mol. basis for the intrinsically low enzymic activity of class IIa HDACs toward acetylated lysines and reveal active site features that may guide the design of class-specific inhibitors.  In addn., these structures reveal a conformationally flexible structural zinc-binding domain conserved in all class IIa enzymes.  Importantly, either the mutation of residues coordinating the structural zinc ion or the binding of a class IIa selective inhibitor prevented the assocn. of HDAC4 with the N-CoR·HDAC3 repressor complex.  Together, these data suggest a key role of the structural zinc-binding domain in the regulation of class IIa HDAC functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBLYPf6RysNrVg90H21EOLACvtfcHk0liAjlyIaD4o4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFejtr3O&md5=90431dcb431fe2a6002f82320f0af453</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M803514200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M803514200%26sid%3Dliteratum%253Aachs%26aulast%3DBottomley%26aufirst%3DM.%2BJ.%26aulast%3DLo%2BSurdo%26aufirst%3DP.%26aulast%3DDi%2BGiovine%26aufirst%3DP.%26aulast%3DCirillo%26aufirst%3DA.%26aulast%3DScarpelli%26aufirst%3DR.%26aulast%3DFerrigno%26aufirst%3DF.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DNeddermann%26aufirst%3DP.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26aulast%3DSteink%25C3%25BChler%26aufirst%3DC.%26aulast%3DGallinari%26aufirst%3DP.%26aulast%3DCarf%25C3%25AD%26aufirst%3DA.%26atitle%3DStructural%2520and%2520Functional%2520Analysis%2520of%2520the%2520Human%2520HDAC4%2520Catalytic%2520Domain%2520Reveals%2520a%2520Regulatory%2520Structural%2520Zinc-Binding%2520Domain%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D26694%26epage%3D26704%26doi%3D10.1074%2Fjbc.M803514200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref196"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref196'); return false;" data-citation="" class="refNumLink">196</a></strong><div class="NLM_citation" id="cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luckhurst, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breccia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stott, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aziz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birch, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bürli, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarvis, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAllister, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollack, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saville-Stones, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, C.</span></span> <span> </span><span class="NLM_article-title">Potent, Selective, and CNS-Penetrant Tetrasubstituted Cyclopropane Class IIa Histone Deacetylase (HDAC) Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00302</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00302" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2lt7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=34-39&author=C.+A.+Luckhurstauthor=P.+Brecciaauthor=A.+J.+Stottauthor=O.+Azizauthor=H.+L.+Birchauthor=R.+W.+B%C3%BCrliauthor=S.+J.+Hughesauthor=R.+E.+Jarvisauthor=M.+Lamersauthor=P.+M.+Leonardauthor=K.+L.+Matthewsauthor=G.+McAllisterauthor=S.+Pollackauthor=E.+Saville-Stonesauthor=G.+Wishartauthor=D.+Yatesauthor=C.+Dominguez&title=Potent%2C+Selective%2C+and+CNS-Penetrant+Tetrasubstituted+Cyclopropane+Class+IIa+Histone+Deacetylase+%28HDAC%29+Inhibitors&doi=10.1021%2Facsmedchemlett.5b00302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Potent, Selective, and CNS-Penetrant Tetrasubstituted Cyclopropane Class IIa Histone Deacetylase (HDAC) Inhibitors</span></div><div class="casAuthors">Luckhurst, Christopher A.; Breccia, Perla; Stott, Andrew J.; Aziz, Omar; Birch, Helen L.; Burli, Roland W.; Hughes, Samantha J.; Jarvis, Rebecca E.; Lamers, Marieke; Leonard, Philip M.; Matthews, Kim L.; McAllister, George; Pollack, Scott; Saville-Stones, Elizabeth; Wishart, Grant; Yates, Dawn; Dominguez, Celia</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-39</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Potent and selective class IIa HDAC tetrasubstituted cyclopropane hydroxamic acid inhibitors were identified with high oral bioavailability that exhibited good brain and muscle exposure.  Compd. (I) displayed suitable properties for assessment of the impact of class IIa HDAC catalytic site inhibition in preclin. disease models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq01yllqODDNLVg90H21EOLACvtfcHk0ljBciqwsJiixg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2lt7vE&md5=dfc4f299bc59bdb7bcf92f7e0bccda0d</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00302%26sid%3Dliteratum%253Aachs%26aulast%3DLuckhurst%26aufirst%3DC.%2BA.%26aulast%3DBreccia%26aufirst%3DP.%26aulast%3DStott%26aufirst%3DA.%2BJ.%26aulast%3DAziz%26aufirst%3DO.%26aulast%3DBirch%26aufirst%3DH.%2BL.%26aulast%3DB%25C3%25BCrli%26aufirst%3DR.%2BW.%26aulast%3DHughes%26aufirst%3DS.%2BJ.%26aulast%3DJarvis%26aufirst%3DR.%2BE.%26aulast%3DLamers%26aufirst%3DM.%26aulast%3DLeonard%26aufirst%3DP.%2BM.%26aulast%3DMatthews%26aufirst%3DK.%2BL.%26aulast%3DMcAllister%26aufirst%3DG.%26aulast%3DPollack%26aufirst%3DS.%26aulast%3DSaville-Stones%26aufirst%3DE.%26aulast%3DWishart%26aufirst%3DG.%26aulast%3DYates%26aufirst%3DD.%26aulast%3DDominguez%26aufirst%3DC.%26atitle%3DPotent%252C%2520Selective%252C%2520and%2520CNS-Penetrant%2520Tetrasubstituted%2520Cyclopropane%2520Class%2520IIa%2520Histone%2520Deacetylase%2520%2528HDAC%2529%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D34%26epage%3D39%26doi%3D10.1021%2Facsmedchemlett.5b00302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref197"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref197'); return false;" data-citation="" class="refNumLink">197</a></strong><div class="NLM_citation" id="cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luckhurst, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aziz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bürli, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breccia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maillard, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haughan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raphy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stott, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz-Sanjuan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, C.</span></span> <span> </span><span class="NLM_article-title">Development and Characterization of a CNS-Penetrant Benzhydryl Hydroxamic Acid Class IIa Histone Deacetylase Inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.11.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmcl.2018.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=30463802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1ChtbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=83-88&author=C.+A.+Luckhurstauthor=O.+Azizauthor=V.+Beaumontauthor=R.+W.+B%C3%BCrliauthor=P.+Brecciaauthor=M.+C.+Maillardauthor=A.+F.+Haughanauthor=M.+Lamersauthor=P.+Leonardauthor=K.+L.+Matthewsauthor=G.+Raphyauthor=A.+J.+Stottauthor=I.+Munoz-Sanjuanauthor=B.+Thomasauthor=M.+Wallauthor=G.+Wishartauthor=D.+Yatesauthor=C.+Dominguez&title=Development+and+Characterization+of+a+CNS-Penetrant+Benzhydryl+Hydroxamic+Acid+Class+IIa+Histone+Deacetylase+Inhibitor&doi=10.1016%2Fj.bmcl.2018.11.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitor</span></div><div class="casAuthors">Luckhurst, Christopher A.; Aziz, Omar; Beaumont, Vahri; Burli, Roland W.; Breccia, Perla; Maillard, Michel C.; Haughan, Alan F.; Lamers, Marieke; Leonard, Phil; Matthews, Kim L.; Raphy, Gilles; Stott, Andrew J.; Munoz-Sanjuan, Ignacio; Thomas, Beth; Wall, Michael; Wishart, Grant; Yates, Dawn; Dominguez, Celia</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">83-88</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We have identified a potent, cell permeable and CNS penetrant class IIa histone deacetylase (HDAC) inhibitor 22(I), with >500-fold selectivity over class I HDACs (1,2,3) and ∼150-fold selectivity over HDAC8 and the class IIb HDAC6 isoform.  Dose escalation pharmacokinetic anal. demonstrated that upon oral administration, compd. 22 can reach exposure levels in mouse plasma, muscle and brain in excess of cellular class IIa HDAC IC50 levels for ∼8 h.  Given the interest in aberrant class IIa HDAC function for a no. of neurodegenerative, neuromuscular, cardiac and oncol. indications, compd. 22 (also known as CHDI-390576) provides a selective and potent compd. to query the role of class IIa HDAC biol., and the impact of class IIa catalytic site occupancy in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYgNfS2AXrN7Vg90H21EOLACvtfcHk0ljBciqwsJiixg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1ChtbbM&md5=8348010d11e3fe0114ca1a2e596206d4</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DLuckhurst%26aufirst%3DC.%2BA.%26aulast%3DAziz%26aufirst%3DO.%26aulast%3DBeaumont%26aufirst%3DV.%26aulast%3DB%25C3%25BCrli%26aufirst%3DR.%2BW.%26aulast%3DBreccia%26aufirst%3DP.%26aulast%3DMaillard%26aufirst%3DM.%2BC.%26aulast%3DHaughan%26aufirst%3DA.%2BF.%26aulast%3DLamers%26aufirst%3DM.%26aulast%3DLeonard%26aufirst%3DP.%26aulast%3DMatthews%26aufirst%3DK.%2BL.%26aulast%3DRaphy%26aufirst%3DG.%26aulast%3DStott%26aufirst%3DA.%2BJ.%26aulast%3DMunoz-Sanjuan%26aufirst%3DI.%26aulast%3DThomas%26aufirst%3DB.%26aulast%3DWall%26aufirst%3DM.%26aulast%3DWishart%26aufirst%3DG.%26aulast%3DYates%26aufirst%3DD.%26aulast%3DDominguez%26aufirst%3DC.%26atitle%3DDevelopment%2520and%2520Characterization%2520of%2520a%2520CNS-Penetrant%2520Benzhydryl%2520Hydroxamic%2520Acid%2520Class%2520IIa%2520Histone%2520Deacetylase%2520Inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D83%26epage%3D88%26doi%3D10.1016%2Fj.bmcl.2018.11.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref198"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref198'); return false;" data-citation="" class="refNumLink">198</a></strong><div class="NLM_citation" id="cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lobera, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madauss, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pohlhaus, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, Q. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trocha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baloglu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trump, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray-Thompson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravorty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mander, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruidenier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhart, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turunen, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, M. A.</span></span> <span> </span><span class="NLM_article-title">Selective Class IIa Histone Deacetylase Inhibition via a Nonchelating Zinc-Binding Group</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">319</span>– <span class="NLM_lpage">325</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fnchembio.1223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=23524983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksVOiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=319-325&author=M.+Loberaauthor=K.+P.+Madaussauthor=D.+T.+Pohlhausauthor=Q.+G.+Wrightauthor=M.+Trochaauthor=D.+R.+Schmidtauthor=E.+Balogluauthor=R.+P.+Trumpauthor=M.+S.+Headauthor=G.+A.+Hofmannauthor=M.+Murray-Thompsonauthor=B.+Schwartzauthor=S.+Chakravortyauthor=Z.+Wuauthor=P.+K.+Manderauthor=L.+Kruidenierauthor=R.+A.+Reidauthor=W.+Burkhartauthor=B.+J.+Turunenauthor=J.+X.+Rongauthor=C.+Wagnerauthor=M.+B.+Moyerauthor=C.+Wellsauthor=X.+Hongauthor=J.+T.+Mooreauthor=J.+D.+Williamsauthor=D.+Solerauthor=S.+Ghoshauthor=M.+A.+Nolan&title=Selective+Class+IIa+Histone+Deacetylase+Inhibition+via+a+Nonchelating+Zinc-Binding+Group&doi=10.1038%2Fnchembio.1223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group</span></div><div class="casAuthors">Lobera, Mercedes; Madauss, Kevin P.; Pohlhaus, Denise T.; Wright, Quentin G.; Trocha, Mark; Schmidt, Darby R.; Baloglu, Erkan; Trump, Ryan P.; Head, Martha S.; Hofmann, Glenn A.; Murray-Thompson, Monique; Schwartz, Benjamin; Chakravorty, Subhas; Wu, Zining; Mander, Palwinder K.; Kruidenier, Laurens; Reid, Robert A.; Burkhart, William; Turunen, Brandon J.; Rong, James X.; Wagner, Craig; Moyer, Mary B.; Wells, Carrow; Hong, Xuan; Moore, John T.; Williams, Jon D.; Soler, Dulce; Ghosh, Shomir; Nolan, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">319-325</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In contrast to studies on class I histone deacetylase (HDAC) inhibitors, the elucidation of the mol. mechanisms and therapeutic potential of class IIa HDACs (HDAC4, HDAC5, HDAC7 and HDAC9) is impaired by the lack of potent and selective chem. probes.  Here we report the discovery of inhibitors that fill this void with an unprecedented metal-binding group, trifluoromethyloxadiazole (TFMO), which circumvents the selectivity and pharmacol. liabilities of hydroxamates.  We confirm direct metal binding of the TFMO through crystallog. approaches and use chemoproteomics to demonstrate the superior selectivity of the TFMO series relative to a hydroxamate-substituted analog.  We further apply these tool compds. to reveal gene regulation dependent on the catalytic active site of class IIa HDACs.  The discovery of these inhibitors challenges the design process for targeting metalloenzymes through a chelating metal-binding group and suggests therapeutic potential for class IIa HDAC enzyme blockers distinct in mechanism and application compared to current HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpglr3JvlNjhbVg90H21EOLACvtfcHk0li-7HLfKsiaEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksVOiur4%253D&md5=f15a4565213d7a0ec5dc0a0b6032b9ab</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1223%26sid%3Dliteratum%253Aachs%26aulast%3DLobera%26aufirst%3DM.%26aulast%3DMadauss%26aufirst%3DK.%2BP.%26aulast%3DPohlhaus%26aufirst%3DD.%2BT.%26aulast%3DWright%26aufirst%3DQ.%2BG.%26aulast%3DTrocha%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DD.%2BR.%26aulast%3DBaloglu%26aufirst%3DE.%26aulast%3DTrump%26aufirst%3DR.%2BP.%26aulast%3DHead%26aufirst%3DM.%2BS.%26aulast%3DHofmann%26aufirst%3DG.%2BA.%26aulast%3DMurray-Thompson%26aufirst%3DM.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DChakravorty%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DMander%26aufirst%3DP.%2BK.%26aulast%3DKruidenier%26aufirst%3DL.%26aulast%3DReid%26aufirst%3DR.%2BA.%26aulast%3DBurkhart%26aufirst%3DW.%26aulast%3DTurunen%26aufirst%3DB.%2BJ.%26aulast%3DRong%26aufirst%3DJ.%2BX.%26aulast%3DWagner%26aufirst%3DC.%26aulast%3DMoyer%26aufirst%3DM.%2BB.%26aulast%3DWells%26aufirst%3DC.%26aulast%3DHong%26aufirst%3DX.%26aulast%3DMoore%26aufirst%3DJ.%2BT.%26aulast%3DWilliams%26aufirst%3DJ.%2BD.%26aulast%3DSoler%26aufirst%3DD.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DNolan%26aufirst%3DM.%2BA.%26atitle%3DSelective%2520Class%2520IIa%2520Histone%2520Deacetylase%2520Inhibition%2520via%2520a%2520Nonchelating%2520Zinc-Binding%2520Group%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2013%26volume%3D9%26spage%3D319%26epage%3D325%26doi%3D10.1038%2Fnchembio.1223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref199"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref199'); return false;" data-citation="" class="refNumLink">199</a></strong><div class="NLM_citation" id="cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schuetz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allali-Hassani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schapira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loppnau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maglathin, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bochkarev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plotnikov, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vedadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, C. H.</span></span> <span> </span><span class="NLM_article-title">Human HDAC7 Harbors a Class IIa Histone Deacetylase-Specific Zinc Binding Motif and Cryptic Deacetylase Activity</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">11355</span>– <span class="NLM_lpage">11363</span>, <span class="refDoi"> DOI: 10.1074/jbc.M707362200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1074%2Fjbc.M707362200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=18285338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkvVSgtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=11355-11363&author=A.+Schuetzauthor=J.+Minauthor=A.+Allali-Hassaniauthor=M.+Schapiraauthor=M.+Shuenauthor=P.+Loppnauauthor=R.+Mazitschekauthor=N.+P.+Kwiatkowskiauthor=T.+A.+Lewisauthor=R.+L.+Maglathinauthor=T.+H.+McLeanauthor=A.+Bochkarevauthor=A.+N.+Plotnikovauthor=M.+Vedadiauthor=C.+H.+Arrowsmith&title=Human+HDAC7+Harbors+a+Class+IIa+Histone+Deacetylase-Specific+Zinc+Binding+Motif+and+Cryptic+Deacetylase+Activity&doi=10.1074%2Fjbc.M707362200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Human HDAC7 Harbors a Class IIa Histone Deacetylase-specific Zinc Binding Motif and Cryptic Deacetylase Activity</span></div><div class="casAuthors">Schuetz, Anja; Min, Jinrong; Allali-Hassani, Abdellah; Schapira, Matthieu; Shuen, Michael; Loppnau, Peter; Mazitschek, Ralph; Kwiatkowski, Nick P.; Lewis, Timothy A.; Maglathin, Rebecca L.; McLean, Thomas H.; Bochkarev, Alexey; Plotnikov, Alexander N.; Vedadi, Masoud; Arrowsmith, Cheryl H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">11355-11363</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are protein deacetylases that play a role in repression of gene transcription and are emerging targets in cancer therapy.  Here, we characterize the structure and enzymic activity of the catalytic domain of human HDAC7 (cdHDAC7).  Although HDAC7 normally exists as part of a multiprotein complex, we show that cdHDAC7 has a low level of deacetylase activity which can be inhibited by known HDAC inhibitors.  The crystal structures of human cdHDAC7 and its complexes with two hydroxamate inhibitors are the first structures of the catalytic domain of class IIa HDACs and demonstrate significant differences with previously reported class I and class IIb-like HDAC structures.  We show that cdHDAC7 has an addnl. class IIa HDAC-specific zinc binding motif adjacent to the active site which is likely to participate in substrate recognition and protein-protein interaction and may provide a site for modulation of activity.  Furthermore, a different active site topol. results in modified catalytic properties and in an enlarged active site pocket.  Our studies provide mechanistic insights into class IIa HDACs and facilitate the design of specific modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppuqRJohIAJrVg90H21EOLACvtfcHk0li-7HLfKsiaEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkvVSgtrw%253D&md5=717d5b72b5a08ca7ad1c655fc9af0bec</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M707362200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M707362200%26sid%3Dliteratum%253Aachs%26aulast%3DSchuetz%26aufirst%3DA.%26aulast%3DMin%26aufirst%3DJ.%26aulast%3DAllali-Hassani%26aufirst%3DA.%26aulast%3DSchapira%26aufirst%3DM.%26aulast%3DShuen%26aufirst%3DM.%26aulast%3DLoppnau%26aufirst%3DP.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DKwiatkowski%26aufirst%3DN.%2BP.%26aulast%3DLewis%26aufirst%3DT.%2BA.%26aulast%3DMaglathin%26aufirst%3DR.%2BL.%26aulast%3DMcLean%26aufirst%3DT.%2BH.%26aulast%3DBochkarev%26aufirst%3DA.%26aulast%3DPlotnikov%26aufirst%3DA.%2BN.%26aulast%3DVedadi%26aufirst%3DM.%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26atitle%3DHuman%2520HDAC7%2520Harbors%2520a%2520Class%2520IIa%2520Histone%2520Deacetylase-Specific%2520Zinc%2520Binding%2520Motif%2520and%2520Cryptic%2520Deacetylase%2520Activity%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D11355%26epage%3D11363%26doi%3D10.1074%2Fjbc.M707362200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref200"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref200'); return false;" data-citation="" class="refNumLink">200</a></strong><div class="NLM_citation" id="cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Somoza, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skene, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mol, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sang, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wynands, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leahy, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougan, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snell, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navre, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knuth, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McRee, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tari, L. W.</span></span> <span> </span><span class="NLM_article-title">Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1325</span>– <span class="NLM_lpage">1334</span>, <span class="refDoi"> DOI: 10.1016/j.str.2004.04.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.str.2004.04.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=15242608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlsFyrsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=1325-1334&author=J.+R.+Somozaauthor=R.+J.+Skeneauthor=B.+A.+Katzauthor=C.+Molauthor=J.+D.+Hoauthor=A.+J.+Jenningsauthor=C.+Luongauthor=A.+Arvaiauthor=J.+J.+Buggyauthor=E.+Chiauthor=J.+Tangauthor=B.+C.+Sangauthor=E.+Vernerauthor=R.+Wynandsauthor=E.+M.+Leahyauthor=D.+R.+Douganauthor=G.+Snellauthor=M.+Navreauthor=M.+W.+Knuthauthor=R.+V.+Swansonauthor=D.+E.+McReeauthor=L.+W.+Tari&title=Structural+Snapshots+of+Human+HDAC8+Provide+Insights+into+the+Class+I+Histone+Deacetylases&doi=10.1016%2Fj.str.2004.04.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases</span></div><div class="casAuthors">Somoza, John R.; Skene, Robert J.; Katz, Bradley A.; Mol, Clifford; Ho, Joseph D.; Jennings, Andy J.; Luong, Christine; Arvai, Andrew; Buggy, Joseph J.; Chi, Ellen; Tang, Jie; Sang, Bi-Ching; Verner, Erik; Wynands, Robert; Leahy, Ellen M.; Dougan, Douglas R.; Snell, Gyorgy; Navre, Marc; Knuth, Mark W.; Swanson, Ronald V.; McRee, Duncan E.; Tari, Leslie W.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1325-1334</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Modulation of the acetylation state of histones plays a pivotal role in the regulation of gene expression.  Histone deacetylases (HDACs) catalyze the removal of acetyl groups from lysines near the N termini of histones.  This reaction promotes the condensation of chromatin, leading to repression of transcription.  HDAC deregulation has been linked to several types of cancer, suggesting a potential use for HDAC inhibitors in oncol.  Here we describe the first crystal structures of a human HDAC: the structures of human HDAC8 complexed with four structurally diverse hydroxamate inhibitors.  This work sheds light on the catalytic mechanism of the HDACs, and on differences in substrate specificity across the HDAC family.  The structure also suggests how phosphorylation of Ser39 affects HDAC8 activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPLrZup76hGLVg90H21EOLACvtfcHk0lhAsU9jOuaC6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlsFyrsLc%253D&md5=3f1842802bac2543509a25f5ddbea5f6</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2004.04.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2004.04.012%26sid%3Dliteratum%253Aachs%26aulast%3DSomoza%26aufirst%3DJ.%2BR.%26aulast%3DSkene%26aufirst%3DR.%2BJ.%26aulast%3DKatz%26aufirst%3DB.%2BA.%26aulast%3DMol%26aufirst%3DC.%26aulast%3DHo%26aufirst%3DJ.%2BD.%26aulast%3DJennings%26aufirst%3DA.%2BJ.%26aulast%3DLuong%26aufirst%3DC.%26aulast%3DArvai%26aufirst%3DA.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DChi%26aufirst%3DE.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DSang%26aufirst%3DB.%2BC.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DWynands%26aufirst%3DR.%26aulast%3DLeahy%26aufirst%3DE.%2BM.%26aulast%3DDougan%26aufirst%3DD.%2BR.%26aulast%3DSnell%26aufirst%3DG.%26aulast%3DNavre%26aufirst%3DM.%26aulast%3DKnuth%26aufirst%3DM.%2BW.%26aulast%3DSwanson%26aufirst%3DR.%2BV.%26aulast%3DMcRee%26aufirst%3DD.%2BE.%26aulast%3DTari%26aufirst%3DL.%2BW.%26atitle%3DStructural%2520Snapshots%2520of%2520Human%2520HDAC8%2520Provide%2520Insights%2520into%2520the%2520Class%2520I%2520Histone%2520Deacetylases%26jtitle%3DStructure%26date%3D2004%26volume%3D12%26spage%3D1325%26epage%3D1334%26doi%3D10.1016%2Fj.str.2004.04.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref201"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref201'); return false;" data-citation="" class="refNumLink">201</a></strong><div class="NLM_citation" id="cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Decroos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gullett, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deardorff, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Biochemical and Structural Characterization of HDAC8 Mutants Associated with Cornelia de Lange Syndrome Spectrum Disorders</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6501</span>– <span class="NLM_lpage">6513</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.5b00881</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.5b00881" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1yisbzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=6501-6513&author=C.+Decroosauthor=N.+H.+Christiansonauthor=L.+E.+Gullettauthor=C.+M.+Bowmanauthor=K.+E.+Christiansonauthor=M.+A.+Deardorffauthor=D.+W.+Christianson&title=Biochemical+and+Structural+Characterization+of+HDAC8+Mutants+Associated+with+Cornelia+de+Lange+Syndrome+Spectrum+Disorders&doi=10.1021%2Facs.biochem.5b00881"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical and Structural Characterization of HDAC8 Mutants Associated with Cornelia de Lange Syndrome Spectrum Disorders</span></div><div class="casAuthors">Decroos, Christophe; Christianson, Nicolas H.; Gullett, Laura E.; Bowman, Christine M.; Christianson, Karen E.; Deardorff, Matthew A.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">6501-6513</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cornelia de Lange Syndrome (CdLS) spectrum disorders are characterized by multiple organ system congenital anomalies that result from mutations in genes encoding core cohesin proteins SMC1A, SMC3, and RAD21, or proteins that regulate cohesin function such as NIPBL and HDAC8.  HDAC8 is the Zn2+-dependent SMC3 deacetylase required for cohesin recycling during the cell cycle, and 17 different HDAC8 mutants have been identified to date in children diagnosed with CdLS.  As part of our continuing studies focusing on aberrant HDAC8 function in CdLS, we now report the prepn. and biophys. evaluation of five human HDAC8 mutants: P91L, G117E, H180R, D233G, and G304R.  Addnl., the double mutants D233G-Y306F and P91L-Y306F were prepd. to enable cocrystn. of intact enzyme-substrate complexes.  X-ray crystal structures of G117E, P91L-Y306F, and D233G-Y306F HDAC8 mutants reveal that each CdLS mutation causes structural changes that compromise catalysis and/or thermostability.  For example, the D233G mutation disrupts the D233-K202-S276 hydrogen bond network, which stabilizes key tertiary structure interactions, thereby significantly compromising thermostability.  Mol. dynamics simulations of H180R and G304R HDAC8 mutants suggest that the bulky arginine side chain of each mutant protrudes into the substrate binding site and also causes active site residue Y306 to fluctuate away from the position required for substrate activation and catalysis.  Significantly, the catalytic activities of most mutants can be partially or fully rescued by the activator N-(phenylcarbamothioyl)-benzamide, suggesting that HDAC8 activators may serve as possible leads in the therapeutic management of CdLS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWhipfyECul7Vg90H21EOLACvtfcHk0lhAsU9jOuaC6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1yisbzL&md5=ca96a25665a6266e9d54926b75b5b7a5</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.5b00881&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.5b00881%26sid%3Dliteratum%253Aachs%26aulast%3DDecroos%26aufirst%3DC.%26aulast%3DChristianson%26aufirst%3DN.%2BH.%26aulast%3DGullett%26aufirst%3DL.%2BE.%26aulast%3DBowman%26aufirst%3DC.%2BM.%26aulast%3DChristianson%26aufirst%3DK.%2BE.%26aulast%3DDeardorff%26aufirst%3DM.%2BA.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DBiochemical%2520and%2520Structural%2520Characterization%2520of%2520HDAC8%2520Mutants%2520Associated%2520with%2520Cornelia%2520de%2520Lange%2520Syndrome%2520Spectrum%2520Disorders%26jtitle%3DBiochemistry%26date%3D2015%26volume%3D54%26spage%3D6501%26epage%3D6513%26doi%3D10.1021%2Facs.biochem.5b00881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref202"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref202'); return false;" data-citation="" class="refNumLink">202</a></strong><div class="NLM_citation" id="cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vannini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volpari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallinari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carfí, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Francesco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinkühler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marco, S.</span></span> <span> </span><span class="NLM_article-title">Substrate Binding to Histone Deacetylases as Shown by the Crystal Structure of the HDAC8-Substrate Complex</span>. <i>EMBO Rep.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">879</span>– <span class="NLM_lpage">884</span>, <span class="refDoi"> DOI: 10.1038/sj.embor.7401047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fsj.embor.7401047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=17721440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpvFWks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=879-884&author=A.+Vanniniauthor=C.+Volpariauthor=P.+Gallinariauthor=P.+Jonesauthor=M.+Mattuauthor=A.+Carf%C3%ADauthor=R.+De+Francescoauthor=C.+Steink%C3%BChlerauthor=S.+Di+Marco&title=Substrate+Binding+to+Histone+Deacetylases+as+Shown+by+the+Crystal+Structure+of+the+HDAC8-Substrate+Complex&doi=10.1038%2Fsj.embor.7401047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex</span></div><div class="casAuthors">Vannini, Alessandro; Volpari, Cinzia; Gallinari, Paola; Jones, Philip; Mattu, Marco; Carfi, Andrea; De Francesco, Raffaele; Steinkuehler, Christian; Di Marco, Stefania</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Reports</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">879-884</span>CODEN:
                <span class="NLM_cas:coden">ERMEAX</span>;
        ISSN:<span class="NLM_cas:issn">1469-221X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) - an enzyme family that deacetylates histones and non-histone proteins - are implicated in human diseases such as cancer, and the first-generation of HDAC inhibitors are now in clin. trials.  Here, we report the 2.0 Å resoln. crystal structure of a catalytically inactive HDAC8 active-site mutant, Tyr306Phe, bound to an acetylated peptidic substrate.  The structure clarifies the role of active-site residues in the deacetylation reaction and substrate recognition.  Notably, the structure shows the unexpected role of a conserved residue at the active-site rim, Asp101, in positioning the substrate by directly interacting with the peptidic backbone and imposing a constrained cis-conformation.  A similar interaction is obsd. in a new hydroxamate inhibitor-HDAC8 structure that we also solved.  The crucial role of Asp101 in substrate and inhibitor recognition was confirmed by activity and binding assays of wild-type HDAC8 and Asp101Ala, Tyr306Phe and Asp101Ala/Tyr306Phe mutants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohnS-LTrNkPbVg90H21EOLACvtfcHk0ljPbchW48clCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpvFWks7Y%253D&md5=1362cac7c0820d5b250b05597fafa7dc</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1038%2Fsj.embor.7401047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.embor.7401047%26sid%3Dliteratum%253Aachs%26aulast%3DVannini%26aufirst%3DA.%26aulast%3DVolpari%26aufirst%3DC.%26aulast%3DGallinari%26aufirst%3DP.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DMattu%26aufirst%3DM.%26aulast%3DCarf%25C3%25AD%26aufirst%3DA.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26aulast%3DSteink%25C3%25BChler%26aufirst%3DC.%26aulast%3DDi%2BMarco%26aufirst%3DS.%26atitle%3DSubstrate%2520Binding%2520to%2520Histone%2520Deacetylases%2520as%2520Shown%2520by%2520the%2520Crystal%2520Structure%2520of%2520the%2520HDAC8-Substrate%2520Complex%26jtitle%3DEMBO%2520Rep.%26date%3D2007%26volume%3D8%26spage%3D879%26epage%3D884%26doi%3D10.1038%2Fsj.embor.7401047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref203"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref203'); return false;" data-citation="" class="refNumLink">203</a></strong><div class="NLM_citation" id="cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, T.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.-J.</span></span> <span> </span><span class="NLM_article-title">Novel Class IIa-Selective Histone Deacetylase Inhibitors Discovered Using an in Silico Virtual Screening Approach</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">3228</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-03417-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fs41598-017-03417-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=28607401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BC1cnnsF2qsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=3228&author=K.-C.+Hsuauthor=C.-Y.+Liuauthor=T.+E.+Linauthor=J.-H.+Hsiehauthor=T.-Y.+Sungauthor=H.-J.+Tsengauthor=J.-M.+Yangauthor=W.-J.+Huang&title=Novel+Class+IIa-Selective+Histone+Deacetylase+Inhibitors+Discovered+Using+an+in+Silico+Virtual+Screening+Approach&doi=10.1038%2Fs41598-017-03417-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Class IIa-Selective Histone Deacetylase Inhibitors Discovered Using an in Silico Virtual Screening Approach</span></div><div class="casAuthors">Hsu Kai-Cheng; Lin Tony Eight; Liu Chang-Yi; Huang Wei-Jan; Hsieh Jui-Hua; Sung Tzu-Ying; Yang Jinn-Moon; Tseng Hui-Ju; Huang Wei-Jan; Yang Jinn-Moon</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3228</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Histone deacetylases (HDAC) contain eighteen isoforms that can be divided into four classes.  Of these isoform enzymes, class IIa (containing HDAC4, 5, 7 and 9) target unique substrates, some of which are client proteins associated with epigenetic control.  Class IIa HDACs are reportedly associated with some neuronal disorders, making HDACs therapeutic targets for treating neurodegenerative diseases.  Additionally, some reported HDAC inhibitors contain hydroxamate moiety that chelates with zinc ion to become the cofactor of HDAC enzymes.  However, the hydroxamate functional group is shown to cause undesirable effects and has poor pharmacokinetic profile.  This study used in silico virtual screening methodology to identify several nonhydroxamate compounds, obtained from National Cancer Institute database, which potentially inhibited HDAC4.  Comparisons of the enzyme inhibitory activity against a panel of HDAC isoforms revealed these compounds had strong inhibitory activity against class IIa HDACs, but weak inhibitory activity against class I HDACs.  Further analysis revealed that a single residue affects the cavity size between class I and class IIa HDACs, thus contributing to the selectivity of HDAC inhibitors discovered in this study.  The discovery of these inhibitors presents the possibility of developing new therapeutic treatments that can circumvent the problems seen in traditional hydroxamate-based drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRxx_9DBwLcIlQKX3ooHxWjfW6udTcc2eZNhGCfsFBQB7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnnsF2qsQ%253D%253D&md5=a7d011c70786e075a3154f31df910435</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-03417-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-03417-1%26sid%3Dliteratum%253Aachs%26aulast%3DHsu%26aufirst%3DK.-C.%26aulast%3DLiu%26aufirst%3DC.-Y.%26aulast%3DLin%26aufirst%3DT.%2BE.%26aulast%3DHsieh%26aufirst%3DJ.-H.%26aulast%3DSung%26aufirst%3DT.-Y.%26aulast%3DTseng%26aufirst%3DH.-J.%26aulast%3DYang%26aufirst%3DJ.-M.%26aulast%3DHuang%26aufirst%3DW.-J.%26atitle%3DNovel%2520Class%2520IIa-Selective%2520Histone%2520Deacetylase%2520Inhibitors%2520Discovered%2520Using%2520an%2520in%2520Silico%2520Virtual%2520Screening%2520Approach%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D3228%26doi%3D10.1038%2Fs41598-017-03417-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref204"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref204'); return false;" data-citation="" class="refNumLink">204</a></strong><div class="NLM_citation" id="cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Q.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.-X.</span></span> <span> </span><span class="NLM_article-title">Virtual Screening and Experimental Validation of Novel Histone Deacetylase Inhibitors</span>. <i>BMC Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">32</span>, <span class="refDoi"> DOI: 10.1186/s40360-016-0075-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1186%2Fs40360-016-0075-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=27443303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvFWhu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=32&author=Y.-X.+Huangauthor=J.+Zhaoauthor=Q.-H.+Songauthor=L.-H.+Zhengauthor=C.+Fanauthor=T.-T.+Liuauthor=Y.-L.+Baoauthor=L.-G.+Sunauthor=L.-B.+Zhangauthor=Y.-X.+Li&title=Virtual+Screening+and+Experimental+Validation+of+Novel+Histone+Deacetylase+Inhibitors&doi=10.1186%2Fs40360-016-0075-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Virtual screening and experimental validation of novel histone deacetylase inhibitors</span></div><div class="casAuthors">Huang, Yan-xin; Zhao, Jian; Song, Qiu-hang; Zheng, Li-hua; Fan, Cong; Liu, Ting-ting; Bao, Yong-li; Sun, Lu-guo; Zhang, Li-biao; Li, Yu-xin</div><div class="citationInfo"><span class="NLM_cas:title">BMC Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">32/1-32/14</span>CODEN:
                <span class="NLM_cas:coden">BPTMAB</span>;
        ISSN:<span class="NLM_cas:issn">2050-6511</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Histone deacetylases (HDACs) are promising therapeutic targets for the treatment of cancer, diabetes and other human diseases.  HDAC inhibitors, as a new class of potential therapeutic agents, have attracted a great deal of interest for both research and clin. applications.  Increasing efforts have been focused on the discovery of HDAC inhibitors and some HDAC inhibitors have been approved for use in cancer therapy.  However, most HDAC inhibitors, including the clin. approved agents, do not selectively inhibit the deacetylase activity of class I and II HDAC is forms, and many suffer from metabolic instability.  This study aims to identify new HDAC inhibitors by using a high-throughput virtual screening approach.  Methods: An integration of in silico virtual screening and in vitro exptl. validation was used to identify novel HDAC inhibitors from a chem. database.  Results: A virtual screening work flow for HDAC inhibitors were created by integrating ligand- and receptor- based virtual screening methods.  Using the virtual screening work flow, 22 hit compds. were selected and further tested via in vitro assays.  Enzyme inhibition assays showed that three of the 22 compds. had HDAC inhibitory properties.  Among these three compds., ZINC12555961 significantly inhibited HDAC activity.  Further in vitro expts. indicated that ZINC12555961 can selectively inhibit proliferation and promote apoptosis of cancer cells.  Conclusions: In summary, our study presents three new and potent HDAC inhibitors and one of these HDAC inhibitors shows anti-proliferative and apoptosis-inducing activity against various cancer cell lines.  These results suggest that the developed virtual screening work flow can provide a useful source of information for the screening and validation of new HDAC inhibitors.  The new-found HDAC inhibitors are worthy to further and more comprehensive investigations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj4jqNd1ZcS7Vg90H21EOLACvtfcHk0ljPbchW48clCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvFWhu7w%253D&md5=d0f5e07f0a3180b0149fa5da9c9a0c28</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1186%2Fs40360-016-0075-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40360-016-0075-8%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.-X.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DQ.-H.%26aulast%3DZheng%26aufirst%3DL.-H.%26aulast%3DFan%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DT.-T.%26aulast%3DBao%26aufirst%3DY.-L.%26aulast%3DSun%26aufirst%3DL.-G.%26aulast%3DZhang%26aufirst%3DL.-B.%26aulast%3DLi%26aufirst%3DY.-X.%26atitle%3DVirtual%2520Screening%2520and%2520Experimental%2520Validation%2520of%2520Novel%2520Histone%2520Deacetylase%2520Inhibitors%26jtitle%3DBMC%2520Pharmacol.%2520Toxicol.%26date%3D2016%26volume%3D17%26spage%3D32%26doi%3D10.1186%2Fs40360-016-0075-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref205"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref205'); return false;" data-citation="" class="refNumLink">205</a></strong><div class="NLM_citation" id="cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halder, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shikha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, T.</span></span> <span> </span><span class="NLM_article-title">Design of Dual MMP-2/HDAC-8 Inhibitors by Pharmacophore Mapping, Molecular Docking, Synthesis and Biological Activity</span>. <i>RSC Adv.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">72373</span>– <span class="NLM_lpage">72386</span>, <span class="refDoi"> DOI: 10.1039/C5RA12606A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1039%2FC5RA12606A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlCktrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=72373-72386&author=A.+Halderauthor=S.+Mallickauthor=D.+Shikhaauthor=A.+Sahaauthor=K.+D.+Sahaauthor=T.+Jha&title=Design+of+Dual+MMP-2%2FHDAC-8+Inhibitors+by+Pharmacophore+Mapping%2C+Molecular+Docking%2C+Synthesis+and+Biological+Activity&doi=10.1039%2FC5RA12606A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Design of dual MMP-2/HDAC-8 inhibitors by pharmacophore mapping, molecular docking, synthesis and biological activity</span></div><div class="casAuthors">Halder, Amit K.; Mallick, Sumana; Shikha, Deep; Saha, Achintya; Saha, Krishna D.; Jha, Tarun</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">88</span>),
    <span class="NLM_cas:pages">72373-72386</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Recent analyses have highlighted the promotion of cancer migration and invasion, mediated through HDAC via MMP-2 and MMP-9.  Since both class 1 HDACs and MMP-2/9 are involved in the migration and invasion of cancer, an attempt has been taken to design dual MMP-2/HDAC-8 inhibitors by pharmacophore mapping and mol. docking approaches.  The designed mols. were synthesized and showed a range of inhibitory activity against different MMP subtypes.  Most of these designed compds. were selective towards MMP-2 but less potent against anti-targets like MMP-8, -12, etc.  The highly active MMP-2 inhibitors were also found to be active towards HDAC-8 but less potent against other class 1 HDACs (HDAC-1 and -2).  Mol. dynamics simulations revealed that the designed compds. may be acting through a distinct mechanism of action in the 'acetate ion channel' of HDAC-8.  Some potent dual MMP-2/HDAC-8 inhibitors were further explored for in vitro cellular assays against human lung carcinoma cell line A549.  These analyses revealed that some of these dual inhibitors have considerable anti-migratory and anti-invasive properties.  The work may help to obtain some useful dual inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHr-ImIiRTVLVg90H21EOLACvtfcHk0lhfXlNWUKoOrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlCktrvO&md5=6ea78d3a65d176a1af37c8408dfda5d2</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1039%2FC5RA12606A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5RA12606A%26sid%3Dliteratum%253Aachs%26aulast%3DHalder%26aufirst%3DA.%26aulast%3DMallick%26aufirst%3DS.%26aulast%3DShikha%26aufirst%3DD.%26aulast%3DSaha%26aufirst%3DA.%26aulast%3DSaha%26aufirst%3DK.%2BD.%26aulast%3DJha%26aufirst%3DT.%26atitle%3DDesign%2520of%2520Dual%2520MMP-2%252FHDAC-8%2520Inhibitors%2520by%2520Pharmacophore%2520Mapping%252C%2520Molecular%2520Docking%252C%2520Synthesis%2520and%2520Biological%2520Activity%26jtitle%3DRSC%2520Adv.%26date%3D2015%26volume%3D5%26spage%3D72373%26epage%3D72386%26doi%3D10.1039%2FC5RA12606A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref206"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref206'); return false;" data-citation="" class="refNumLink">206</a></strong><div class="NLM_citation" id="cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">Hierarchical Virtual Screening of the Dual MMP-2/HDAC-6 Inhibitors from Natural Products Based on Pharmacophore Models and Molecular Docking</span>. <i>J. Biomol. Struct. Dyn.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">649</span>– <span class="NLM_lpage">670</span>, <span class="refDoi"> DOI: 10.1080/07391102.2018.1434833</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1080%2F07391102.2018.1434833" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=29380672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXislSjt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=649-670&author=Y.+Wangauthor=L.+Yangauthor=J.+Houauthor=Q.+Zouauthor=Q.+Gaoauthor=W.+Yaoauthor=Q.+Yaoauthor=J.+Zhang&title=Hierarchical+Virtual+Screening+of+the+Dual+MMP-2%2FHDAC-6+Inhibitors+from+Natural+Products+Based+on+Pharmacophore+Models+and+Molecular+Docking&doi=10.1080%2F07391102.2018.1434833"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Hierarchical virtual screening of the dual MMP-2/HDAC-6 inhibitors from natural products based on pharmacophore models and molecular docking</span></div><div class="casAuthors">Wang, Yijun; Yang, Limei; Hou, Jiaying; Zou, Qing; Gao, Qi; Yao, Wenhui; Yao, Qizheng; Zhang, Ji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Structure and Dynamics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">649-670</span>CODEN:
                <span class="NLM_cas:coden">JBSDD6</span>;
        ISSN:<span class="NLM_cas:issn">0739-1102</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The dual-target inhibitors tend to improve the response rate in treating tumors, comparing with the single-target inhibitors.  Matrix metalloproteinase-2 (MMP-2) and histone deacetylase-6 (HDAC-6) are attractive targets for cancer therapy.  In this study, the hierarchical virtual screening of dual MMP-2/HDAC-6 inhibitors from natural products is investigated.  The pharmacophore model of MMP-2 inhibitors is built based on ligands, but the pharmacophore model of HDAC-6 inhibitors is built based on the exptl. crystal structures of multiple receptor-ligand complexes.  The reliability of these two pharmacophore models is validated subsequently.  The hierarchical virtual screening, combining these two different pharmacophore models of MMP-2 and HDAC-6 inhibitors with mol. docking, is carried out to identify the dual MMP-2/HDAC-6 inhibitors from a database of natural products.  The four potential dual MMP-2/HDAC-6 inhibitors of natural products, STOCK1 N-46177, STOCK1 N-52245, STOCK1 N-55477, and STOCK1 N-69706, are found.  The studies of binding modes show that the screened four natural products can simultaneously well bind with the MMP-2 and HDAC-6 active sites by different kinds of interactions, to inhibit the MMP-2 and HDAC-6 activities.  In addn., the ADMET properties of screened four natural products are assessed.  These found dual MMP-2/HDAC-6 inhibitors of natural products could serve as the lead compds. for designing the new dual MMP-2/HDAC-6 inhibitors having higher biol. activities by carrying out structural modifications and optimizations in the future studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrj-OBmoj28F7Vg90H21EOLACvtfcHk0lhfXlNWUKoOrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXislSjt7c%253D&md5=7fe92585a5c37b548ff3e569c851214f</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1080%2F07391102.2018.1434833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07391102.2018.1434833%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DQ.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DYao%26aufirst%3DW.%26aulast%3DYao%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DHierarchical%2520Virtual%2520Screening%2520of%2520the%2520Dual%2520MMP-2%252FHDAC-6%2520Inhibitors%2520from%2520Natural%2520Products%2520Based%2520on%2520Pharmacophore%2520Models%2520and%2520Molecular%2520Docking%26jtitle%3DJ.%2520Biomol.%2520Struct.%2520Dyn.%26date%3D2019%26volume%3D37%26spage%3D649%26epage%3D670%26doi%3D10.1080%2F07391102.2018.1434833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref207"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref207'); return false;" data-citation="" class="refNumLink">207</a></strong><div class="NLM_citation" id="cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurpinar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manglik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of the Human σ<sub>1</sub> Receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>532</i></span>,  <span class="NLM_fpage">527</span>– <span class="NLM_lpage">530</span>, <span class="refDoi"> DOI: 10.1038/nature17391</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fnature17391" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=27042935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlsl2gt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=532&publication_year=2016&pages=527-530&author=H.+R.+Schmidtauthor=S.+Zhengauthor=E.+Gurpinarauthor=A.+Koehlauthor=A.+Manglikauthor=A.+C.+Kruse&title=Crystal+Structure+of+the+Human+%CF%831+Receptor&doi=10.1038%2Fnature17391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the human σ1 receptor</span></div><div class="casAuthors">Schmidt, Hayden R.; Zheng, Sanduo; Gurpinar, Esin; Koehl, Antoine; Manglik, Aashish; Kruse, Andrew C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">532</span>
        (<span class="NLM_cas:issue">7600</span>),
    <span class="NLM_cas:pages">527-530</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The human σ1 receptor is an enigmatic endoplasmic reticulum (ER)-resident transmembrane protein implicated in a variety of disorders including depression, drug addiction, and neuropathic pain.  Recently, an addnl. connection to amyotrophic lateral sclerosis has emerged from studies of human genetics and mouse models.  Unlike many transmembrane receptors that belong to large, extensively studied families such as G-protein-coupled receptors or ligand-gated ion channels, the σ1 receptor is an evolutionary isolate with no discernible similarity to any other human protein.  Despite its increasingly clear importance in human physiol. and disease, the mol. architecture of the σ1 receptor and its regulation by drug-like compds. remain poorly defined.  Here, the authors report crystal structures of the human σ1 receptor in complex with 2 chem. divergent ligands, PD 144418 and 4-(N-benzylpiperidin-4-yl)-4-iodobenzamide (4-IBP).  The structures revealed a trimeric architecture with a single transmembrane domain in each protomer.  The C-terminal domain of the receptor showed an extensive flat, hydrophobic membrane-proximal surface, suggesting an intimate assocn. with the cytosolic surface of the ER membrane in cells.  This domain included a cupin-like β-barrel with the ligand-binding site buried at its center.  This large, hydrophobic ligand-binding cavity showed remarkable plasticity in ligand recognition, binding the 2 ligands in similar positions despite dissimilar chem. structures.  Taken together, these results revealed the overall architecture, oligomerization state, and mol. basis for ligand recognition by this important but poorly understood protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokQBAf03Pml7Vg90H21EOLACvtfcHk0ligt9YqYkVmrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlsl2gt7o%253D&md5=fb6df7814060fbd05ba41261ad1061f5</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1038%2Fnature17391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17391%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DH.%2BR.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DGurpinar%26aufirst%3DE.%26aulast%3DKoehl%26aufirst%3DA.%26aulast%3DManglik%26aufirst%3DA.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26atitle%3DCrystal%2520Structure%2520of%2520the%2520Human%2520%25CF%25831%2520Receptor%26jtitle%3DNature%26date%3D2016%26volume%3D532%26spage%3D527%26epage%3D530%26doi%3D10.1038%2Fnature17391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref208"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref208'); return false;" data-citation="" class="refNumLink">208</a></strong><div class="NLM_citation" id="cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for σ(1) Receptor Ligand Recognition</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">981</span>– <span class="NLM_lpage">987</span>, <span class="refDoi"> DOI: 10.1038/s41594-018-0137-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fs41594-018-0137-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=30291362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVOjsbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=981-987&author=H.+R.+Schmidtauthor=R.+M.+Betzauthor=R.+O.+Drorauthor=A.+C.+Kruse&title=Structural+Basis+for+%CF%83%281%29+Receptor+Ligand+Recognition&doi=10.1038%2Fs41594-018-0137-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for σ1 receptor ligand recognition</span></div><div class="casAuthors">Schmidt, Hayden R.; Betz, Robin M.; Dror, Ron O.; Kruse, Andrew C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">981-987</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The s1 receptor is a poorly understood membrane protein expressed throughout the human body.  Ligands targeting the s1 receptor are in clin. trials for treatment of Alzheimer's disease, ischemic stroke, and neuropathic pain.  However, relatively little is known regarding the s1 receptor's mol. function.  Here, we present crystal structures of human s1 receptor bound to the antagonists haloperidol and NE-100, and the agonist (+)-pentazocine, at crystallog. resolns. of 3.1 Å, 2.9 Å, and 3.1 Å, resp.  These structures reveal a unique binding pose for the agonist.  The structures and accompanying mol. dynamics (MD) simulations identify agonist-induced structural rearrangements in the receptor.  Addnl., we show that ligand binding to s1 is a multistep process that is rate limited by receptor conformational change.  We used MD simulations to reconstruct a ligand binding pathway involving two major conformational changes.  These data provide a framework for understanding the mol. basis for s1 agonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ2dgVTV70vbVg90H21EOLACvtfcHk0ligt9YqYkVmrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVOjsbvM&md5=d12d12aecbd89684824975977ec03e4b</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1038%2Fs41594-018-0137-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41594-018-0137-2%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DH.%2BR.%26aulast%3DBetz%26aufirst%3DR.%2BM.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26atitle%3DStructural%2520Basis%2520for%2520%25CF%2583%25281%2529%2520Receptor%2520Ligand%2520Recognition%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2018%26volume%3D25%26spage%3D981%26epage%3D987%26doi%3D10.1038%2Fs41594-018-0137-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref209"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref209'); return false;" data-citation="" class="refNumLink">209</a></strong><div class="NLM_citation" id="cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greenfield, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span> <span> </span><span class="NLM_article-title">Virtual Screening Identifies Novel High-Affinity σ<sub>1</sub> Receptor Ligands</span>. <i>bioRxiv</i> <span class="NLM_year" style="font-weight: bold;">2019</span>, <span class="refDoi"> DOI: 10.1101/699793</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1101%2F699793" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=D.+A.+Greenfieldauthor=H.+R.+Schmidtauthor=P.+Slizauthor=A.+C.+Kruse&title=Virtual+Screening+Identifies+Novel+High-Affinity+%CF%831+Receptor+Ligands&doi=10.1101%2F699793"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1101%2F699793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F699793%26sid%3Dliteratum%253Aachs%26aulast%3DGreenfield%26aufirst%3DD.%2BA.%26aulast%3DSchmidt%26aufirst%3DH.%2BR.%26aulast%3DSliz%26aufirst%3DP.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26atitle%3DVirtual%2520Screening%2520Identifies%2520Novel%2520High-Affinity%2520%25CF%25831%2520Receptor%2520Ligands%26jtitle%3DbioRxiv%26date%3D2019%26doi%3D10.1101%2F699793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref210"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref210'); return false;" data-citation="" class="refNumLink">210</a></strong><div class="NLM_citation" id="cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ehrt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinkjost, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, O.</span></span> <span> </span><span class="NLM_article-title">A Benchmark Driven Guide to Binding Site Comparison: An Exhaustive Evaluation Using Tailor-Made Data Sets (ProSPECCTs)</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>, <span class="NLM_elocation-id">e1006483</span> <span class="refDoi"> DOI: 10.1371/journal.pcbi.1006483</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1371%2Fjournal.pcbi.1006483" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=30408032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjsFCkt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&author=C.+Ehrtauthor=T.+Brinkjostauthor=O.+Koch&title=A+Benchmark+Driven+Guide+to+Binding+Site+Comparison%3A+An+Exhaustive+Evaluation+Using+Tailor-Made+Data+Sets+%28ProSPECCTs%29&doi=10.1371%2Fjournal.pcbi.1006483"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">A benchmark driven guide to binding site comparison: an exhaustive evaluation using tailor-made data sets (ProSPECCTs)</span></div><div class="casAuthors">Ehrt, Christiane; Brinkjost, Tobias; Koch, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Computational Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e1006483/1-e1006483/50</span>CODEN:
                <span class="NLM_cas:coden">PCBLBG</span>;
        ISSN:<span class="NLM_cas:issn">1553-7358</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The automated comparison of protein-ligand binding sites provides useful insights into yet unexplored site similarities.  Various stages of computational and chem. biol. research can benefit from this knowledge.  The search for putative off-targets and the establishment of polypharmacol. effects by comparing binding sites led to promising results for numerous projects.  Although many cavity comparison methods are available, a comprehensive anal. to guide the choice of a tool for a specific application is wanting.  Moreover, the broad variety of binding site modeling approaches, comparison algorithms, and scoring metrics impedes this choice.  Herein, we aim to elucidate strengths and weaknesses of binding site comparison methodologies.  A detailed benchmark study is the only possibility to rationalize the selection of appropriate tools for different scenarios.  Specific evaluation data sets were developed to shed light on multiple aspects of binding site comparison.  An assembly of all applied benchmark sets (ProSPECCTs-Protein Site Pairs for the Evaluation of Cavity Comparison Tools) is made available for the evaluation and optimization of further and still emerging methods.  The results indicate the importance of such analyses to facilitate the choice of a methodol. that complies with the requirements of a specific scientific challenge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1D8OLhutOVrVg90H21EOLACvtfcHk0ligt9YqYkVmrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjsFCkt7o%253D&md5=1660c344aaaeefb6fde2bd31be55c478</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1006483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1006483%26sid%3Dliteratum%253Aachs%26aulast%3DEhrt%26aufirst%3DC.%26aulast%3DBrinkjost%26aufirst%3DT.%26aulast%3DKoch%26aufirst%3DO.%26atitle%3DA%2520Benchmark%2520Driven%2520Guide%2520to%2520Binding%2520Site%2520Comparison%253A%2520An%2520Exhaustive%2520Evaluation%2520Using%2520Tailor-Made%2520Data%2520Sets%2520%2528ProSPECCTs%2529%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2018%26volume%3D14%26doi%3D10.1371%2Fjournal.pcbi.1006483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref211"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref211'); return false;" data-citation="" class="refNumLink">211</a></strong><div class="NLM_citation" id="cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duran-Frigola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siragusa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruppin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barril, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruciani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aloy, P.</span></span> <span> </span><span class="NLM_article-title">Detecting Similar Binding Pockets to Enable Systems Polypharmacology</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">e1005522</span> <span class="refDoi"> DOI: 10.1371/journal.pcbi.1005522</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1371%2Fjournal.pcbi.1005522" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=28662117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1agurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&author=M.+Duran-Frigolaauthor=L.+Siragusaauthor=E.+Ruppinauthor=X.+Barrilauthor=G.+Crucianiauthor=P.+Aloy&title=Detecting+Similar+Binding+Pockets+to+Enable+Systems+Polypharmacology&doi=10.1371%2Fjournal.pcbi.1005522"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Detecting similar binding pockets to enable systems polypharmacology</span></div><div class="casAuthors">Duran-Frigola, Miquel; Siragusa, Lydia; Ruppin, Eytan; Barril, Xavier; Cruciani, Gabriele; Aloy, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Computational Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e1005522/1-e1005522/18</span>CODEN:
                <span class="NLM_cas:coden">PCBLBG</span>;
        ISSN:<span class="NLM_cas:issn">1553-7358</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">In the era of systems biol., multi-target pharmacol. strategies hold promise for tackling disease-related networks.  In this regard, drug promiscuity may be leveraged to interfere with multiple receptors: the so-called polypharmacol. of drugs can be anticipated by analyzing the similarity of binding sites across the proteome.  Here, we perform a pairwise comparison of 90,000 putative binding pockets detected in 3,700 proteins, and find that 23,000 pairs of proteins have at least one similar cavity that could, in principle, accommodate similar ligands.  By inspecting these pairs, we demonstrate how the detection of similar binding sites expands the space of opportunities for the rational design of drug polypharmacol.  Finally, we illustrate how to leverage these opportunities in protein-protein interaction networks related to several therapeutic classes and tumor types, and in a genome-scale metabolic model of leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrncR4y_CryxbVg90H21EOLACvtfcHk0lghoCheBoWcow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1agurnE&md5=568e97aa21976360c76610cdfd4dbfd7</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1005522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1005522%26sid%3Dliteratum%253Aachs%26aulast%3DDuran-Frigola%26aufirst%3DM.%26aulast%3DSiragusa%26aufirst%3DL.%26aulast%3DRuppin%26aufirst%3DE.%26aulast%3DBarril%26aufirst%3DX.%26aulast%3DCruciani%26aufirst%3DG.%26aulast%3DAloy%26aufirst%3DP.%26atitle%3DDetecting%2520Similar%2520Binding%2520Pockets%2520to%2520Enable%2520Systems%2520Polypharmacology%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2017%26volume%3D13%26doi%3D10.1371%2Fjournal.pcbi.1005522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref212"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref212'); return false;" data-citation="" class="refNumLink">212</a></strong><div class="NLM_citation" id="cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linusson, A.</span></span> <span> </span><span class="NLM_article-title">Mapping of Ligand-Binding Cavities in Proteins</span>. <i>Proteins: Struct., Funct., Genet.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1408</span>– <span class="NLM_lpage">1422</span>, <span class="refDoi"> DOI: 10.1002/prot.22655</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1002%2Fprot.22655" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=20034113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjt1KksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2010&pages=1408-1422&author=C.+D.+Anderssonauthor=B.+Y.+Chenauthor=A.+Linusson&title=Mapping+of+Ligand-Binding+Cavities+in+Proteins&doi=10.1002%2Fprot.22655"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">Mapping of ligand-binding cavities in proteins</span></div><div class="casAuthors">Andersson, C. David; Chen, Brian Y.; Linusson, Anna</div><div class="citationInfo"><span class="NLM_cas:title">Proteins: Structure, Function, and Bioinformatics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1408-1422</span>CODEN:
                <span class="NLM_cas:coden">PSFBAF</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The complex interactions between proteins and small org. mols. (ligands) are intensively studied because they play key roles in biol. processes and drug activities.  Here, the authors present a novel approach to characterize and map the ligand-binding cavities of proteins without direct geometric comparison of structures, based on Principal Component Anal. of cavity properties (related mainly to size, polarity, and charge).  This approach can provide valuable information on the similarities and dissimilarities, of binding cavities due to mutations, between-species differences and flexibility upon ligand-binding.  The presented results show that information on ligand-binding cavity variations can complement information on protein similarity obtained from sequence comparisons.  The predictive aspect of the method is exemplified by successful predictions of serine proteases that were not included in the model construction.  The presented strategy to compare ligand-binding cavities of related and unrelated proteins has many potential applications within protein and medicinal chem., for example in the characterization and mapping of "orphan structures", selection of protein structures for docking studies in structure-based design, and identification of proteins for selectivity screens in drug design programs.  Proteins 2010. © 2009 Wiley-Liss, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmzqkXA3YhV7Vg90H21EOLACvtfcHk0lghoCheBoWcow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjt1KksrY%253D&md5=dab715eea79dd2fbedf04ee9b887f35d</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1002%2Fprot.22655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.22655%26sid%3Dliteratum%253Aachs%26aulast%3DAndersson%26aufirst%3DC.%2BD.%26aulast%3DChen%26aufirst%3DB.%2BY.%26aulast%3DLinusson%26aufirst%3DA.%26atitle%3DMapping%2520of%2520Ligand-Binding%2520Cavities%2520in%2520Proteins%26jtitle%3DProteins%253A%2520Struct.%252C%2520Funct.%252C%2520Genet.%26date%3D2010%26volume%3D78%26spage%3D1408%26epage%3D1422%26doi%3D10.1002%2Fprot.22655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref213"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref213'); return false;" data-citation="" class="refNumLink">213</a></strong><div class="NLM_citation" id="cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mangiatordi, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trisciuzzi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alberga, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denora, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacobazzi, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadaleta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolotti, O.</span></span> <span> </span><span class="NLM_article-title">Novel Chemotypes Targeting Tubulin at the Colchicine Binding Site and Unbiasing P-Glycoprotein</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">792</span>– <span class="NLM_lpage">803</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.07.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2017.07.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=28863359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVaht7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2017&pages=792-803&author=G.+F.+Mangiatordiauthor=D.+Trisciuzziauthor=D.+Albergaauthor=N.+Denoraauthor=R.+M.+Iacobazziauthor=D.+Gadaletaauthor=M.+Cattoauthor=O.+Nicolotti&title=Novel+Chemotypes+Targeting+Tubulin+at+the+Colchicine+Binding+Site+and+Unbiasing+P-Glycoprotein&doi=10.1016%2Fj.ejmech.2017.07.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">Novel chemotypes targeting tubulin at the colchicine binding site and unbiasing P-glycoprotein</span></div><div class="casAuthors">Mangiatordi, Giuseppe Felice; Trisciuzzi, Daniela; Alberga, Domenico; Denora, Nunzio; Iacobazzi, Rosa Maria; Gadaleta, Domenico; Catto, Marco; Nicolotti, Orazio</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">792-803</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Retrospective validation studies carried out on three benchmark databases contg. a small fraction (that is 2.80%) of known tubulin binders permitted us to develop a computational platform very effective in selecting easier manageable subsets showing by far higher percentages of actives (about 25%).  These studies relied on the hierarchical application of multilayer in silico screenings employing filters implying mol. shape similarity; a structure-based pharmacophore model and mol. docking campaigns.  Building on this validated approach, the authors performed intensive prospective studies to screen a large chem. collection, including up to 3.7 millions of com. compds., to across an unexplored and patent space in the search of novel colchicine binding site inhibitors.  The investigation was successful in identifying a pool of 31 initial hits showing new mol. scaffolds (such as 4,5-dihydro-1H-pyrrolo[3,4-c]pyrazol-6-one and pyrazolo[1,5-a]pyrimidine).  This panel of new hits resulted antiproliferative activity in the low μM range towards MCF-7 human breast cancer, HepG2 human liver cancer, HeLa human ovarian cancer and SHSY5Y human glioblastoma cell lines as well as interesting concn.-dependent inhibition of tubulin polymn. assessed through fluorescence polymn. assays.  Unlike typical tubulin inhibitors, a satisfactorily low sensitivity towards P-gp was also measured in bi-directional transport studies across MDCKII-MDR1 cells for a selected subset of seven compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKxndNEShwSbVg90H21EOLACvtfcHk0lghoCheBoWcow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVaht7rM&md5=eed524fb1b0c29300940c57a9eb51d79</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.07.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.07.037%26sid%3Dliteratum%253Aachs%26aulast%3DMangiatordi%26aufirst%3DG.%2BF.%26aulast%3DTrisciuzzi%26aufirst%3DD.%26aulast%3DAlberga%26aufirst%3DD.%26aulast%3DDenora%26aufirst%3DN.%26aulast%3DIacobazzi%26aufirst%3DR.%2BM.%26aulast%3DGadaleta%26aufirst%3DD.%26aulast%3DCatto%26aufirst%3DM.%26aulast%3DNicolotti%26aufirst%3DO.%26atitle%3DNovel%2520Chemotypes%2520Targeting%2520Tubulin%2520at%2520the%2520Colchicine%2520Binding%2520Site%2520and%2520Unbiasing%2520P-Glycoprotein%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D139%26spage%3D792%26epage%3D803%26doi%3D10.1016%2Fj.ejmech.2017.07.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref214"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref214'); return false;" data-citation="" class="refNumLink">214</a></strong><div class="NLM_citation" id="cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alberga, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trisciuzzi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montaruli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangiatordi, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolotti, O.</span></span> <span> </span><span class="NLM_article-title">A New Approach for Drug Target and Bioactivity Prediction: The Multifingerprint Similarity Search Algorithm (MuSSeL)</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">586</span>– <span class="NLM_lpage">596</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.8b00698</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.8b00698" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlegsLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2019&pages=586-596&author=D.+Albergaauthor=D.+Trisciuzziauthor=M.+Montaruliauthor=F.+Leonettiauthor=G.+F.+Mangiatordiauthor=O.+Nicolotti&title=A+New+Approach+for+Drug+Target+and+Bioactivity+Prediction%3A+The+Multifingerprint+Similarity+Search+Algorithm+%28MuSSeL%29&doi=10.1021%2Facs.jcim.8b00698"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">A New Approach for Drug Target and Bioactivity Prediction: The Multifingerprint Similarity Search Algorithm (MuSSeL)</span></div><div class="casAuthors">Alberga, Domenico; Trisciuzzi, Daniela; Montaruli, Michele; Leonetti, Francesco; Mangiatordi, Giuseppe Felice; Nicolotti, Orazio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">586-596</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We present MuSSeL, a multifingerprint similarity search algorithm, able to predict putative drug targets for a given query small mol. as well as to return a quant. assessment of its bioactivity in terms of Ki or IC50 values.  Predictions are automatically made exploiting a large collection of high quality exptl. bioactivity data available from ChEMBL (version 22.1) combining, in a consensus-like approach, predictions resulting from a similarity search performed using 13 different fingerprint definitions.  Importantly, the herein proposed algorithm is also effective in detecting and handling activity cliffs.  A calibration set including small mols. present in the last updated version of ChEMBL (version 23) was employed to properly tune the algorithm parameters.  Three randomly built external sets were instead challenged for model performances.  The potential use of MuSSeL was also challenged by a prospective exercise for the prediction of five bioactive compds. taken from articles published in the Journal of Medicinal Chem. just few months ago.  The paper emphasizes the importance of implementing multifingerprint consensus strategies to increase the confidence in prediction of similarity search algorithms and provides a fast and easy-to-run tool for drug target and bioactivity prediction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGbAS8w4eqNbVg90H21EOLACvtfcHk0lienpy7XpLdxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlegsLbF&md5=96acee376cd68dc164a0f29ee1e3fc4a</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.8b00698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.8b00698%26sid%3Dliteratum%253Aachs%26aulast%3DAlberga%26aufirst%3DD.%26aulast%3DTrisciuzzi%26aufirst%3DD.%26aulast%3DMontaruli%26aufirst%3DM.%26aulast%3DLeonetti%26aufirst%3DF.%26aulast%3DMangiatordi%26aufirst%3DG.%2BF.%26aulast%3DNicolotti%26aufirst%3DO.%26atitle%3DA%2520New%2520Approach%2520for%2520Drug%2520Target%2520and%2520Bioactivity%2520Prediction%253A%2520The%2520Multifingerprint%2520Similarity%2520Search%2520Algorithm%2520%2528MuSSeL%2529%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2019%26volume%3D59%26spage%3D586%26epage%3D596%26doi%3D10.1021%2Facs.jcim.8b00698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref215"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref215'); return false;" data-citation="" class="refNumLink">215</a></strong><div class="NLM_citation" id="cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prado-Prado, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez de la Vega, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uriarte, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ubeira, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-Díaz, H.</span></span> <span> </span><span class="NLM_article-title">Unified QSAR Approach to Antimicrobials. 4. Multi-Target QSAR Modeling and Comparative Multi-Distance Study of the Giant Components of Antiviral Drug-Drug Complex Networks</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">569</span>– <span class="NLM_lpage">575</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2008.11.075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmc.2008.11.075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=19112024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFerur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=569-575&author=F.+J.+Prado-Pradoauthor=O.+Martinez+de+la+Vegaauthor=E.+Uriarteauthor=F.+M.+Ubeiraauthor=K.-C.+Chouauthor=H.+Gonz%C3%A1lez-D%C3%ADaz&title=Unified+QSAR+Approach+to+Antimicrobials.+4.+Multi-Target+QSAR+Modeling+and+Comparative+Multi-Distance+Study+of+the+Giant+Components+of+Antiviral+Drug-Drug+Complex+Networks&doi=10.1016%2Fj.bmc.2008.11.075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks</span></div><div class="casAuthors">Prado-Prado, Francisco J.; de la Vega, Octavio Martinez; Uriarte, Eugenio; Ubeira, Florencio M.; Chou, Kuo-Chen; Gonzalez-Diaz, Humberto</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">569-575</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">One limitation of almost all antiviral Quant. Structure-Activity Relationships (QSAR) models is that they predict the biol. activity of drugs against only one species of virus.  Consequently, the development of multi-tasking QSAR models (mt-QSAR) to predict drugs activity against different species of virus is of the major vitally important.  These mt-QSARs offer also a good opportunity to construct drug-drug Complex Networks (CNs) that can be used to explore large and complex drug-viral species databases.  It is known that in very large CNs we can use the Giant Component (GC) as a representative sub-set of nodes (drugs) and but the drug-drug similarity function selected may strongly dets. the final network obtained.  In the three previous works of the present series we reported mt-QSAR models to predict the antimicrobial activity against different fungi, bacteria or parasite species.  However, including these works, we do not found any report of mt-QSAR models for antivirals drug, or a comparative study of the different GC extd. from drug-drug CNs based on different similarity functions.  In this work, we used Linear Discriminant Anal. (LDA) to fit a mt-QSAR model that classify 600 drugs as active or non-active against the 41 different tested species of virus.  The model correctly classifies 143 of 169 active compds. (specificity = 84.62%) and 119 of 139 non-active compds. (sensitivity = 85.61%) and presents overall training accuracy of 85.1% (262 of 308 cases).  Validation of the model was carried out by means of external predicting series, classifying the model 466 of 514, 90.7% of compds.  In order to illustrate the performance of the model in practice, we develop a virtual screening recognizing the model as active 92.7%, 102 of 110 antivirus compds.  These compds. were never use in training or predicting series.  Next, we obtained and compared the topol. of the CNs and their resp. GCs based on Euclidean, Manhattan, Chebychey, Pearson and other similarity measures.  The GC of the Manhattan network showed the more interesting features for drug-drug similarity search.  We also give the procedure for the construction of Back-Projection Maps for the contribution of each drug sub-structure to the antiviral activity against different species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYSYliyWPcQrVg90H21EOLACvtfcHk0lienpy7XpLdxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFerur0%253D&md5=4c617e881fd3709dc3e0a34f453d484b</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2008.11.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2008.11.075%26sid%3Dliteratum%253Aachs%26aulast%3DPrado-Prado%26aufirst%3DF.%2BJ.%26aulast%3DMartinez%2Bde%2Bla%2BVega%26aufirst%3DO.%26aulast%3DUriarte%26aufirst%3DE.%26aulast%3DUbeira%26aufirst%3DF.%2BM.%26aulast%3DChou%26aufirst%3DK.-C.%26aulast%3DGonz%25C3%25A1lez-D%25C3%25ADaz%26aufirst%3DH.%26atitle%3DUnified%2520QSAR%2520Approach%2520to%2520Antimicrobials.%25204.%2520Multi-Target%2520QSAR%2520Modeling%2520and%2520Comparative%2520Multi-Distance%2520Study%2520of%2520the%2520Giant%2520Components%2520of%2520Antiviral%2520Drug-Drug%2520Complex%2520Networks%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D17%26spage%3D569%26epage%3D575%26doi%3D10.1016%2Fj.bmc.2008.11.075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref216"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref216'); return false;" data-citation="" class="refNumLink">216</a></strong><div class="NLM_citation" id="cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iyaguchi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyota, E.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for the Design of Novel Schiff Base Metal Chelate Inhibitors of Trypsin</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2076</span>– <span class="NLM_lpage">2080</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.02.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmc.2010.02.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=20202854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtVCrsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=2076-2080&author=D.+Iyaguchiauthor=S.+Kawanoauthor=K.+Takadaauthor=E.+Toyota&title=Structural+Basis+for+the+Design+of+Novel+Schiff+Base+Metal+Chelate+Inhibitors+of+Trypsin&doi=10.1016%2Fj.bmc.2010.02.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the design of novel Schiff base metal chelate inhibitors of trypsin</span></div><div class="casAuthors">Iyaguchi, Daisuke; Kawano, Susumu; Takada, Kazuki; Toyota, Eiko</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2076-2080</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The crystal structures of the complexes of bovine trypsin with m-guanidinosalicylidene--alaninato(aqua)copper(II) hydrochloride (inhibitor 1), [N,N'-bis(m-guanidinosalicylidene)ethylenediaminato]copper(II) (inhibitor 2), and [N,N'-bis(m-amidinosalicylidene)ethylenediaminato]copper(II) (inhibitor 4) have been detd.  The guanidine-contg. trypsin-inhibitors (1 and 2) bind to the trypsin active site in a manner similar to that previously reported for amidine-contg. inhibitors, for example, m-amidinosalicylidene--alaninato(aqua)copper(II) hydrochloride (inhibitor 3).  However, the binding mode of the guanidino groups of inhibitors 1 and 2 to Asp189 in the S1 pocket of trypsin was found to be markedly different from that of the amidino group of inhibitor 3.  The present X-ray analyses revealed that the interactions of the metal ion of the inhibitors with the active site residues of trypsin play a crucial role in the binding affinity to the trypsin mol.  These structural information and inhibitory activity data for amidine- and guanidine-contg. Schiff base metal chelate inhibitors provide new avenues for designing novel inhibitors against physiol. important trypsin-like serine proteases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplf37tjGdS_bVg90H21EOLACvtfcHk0lienpy7XpLdxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtVCrsL8%253D&md5=8f692ca71ad1497e66b632e195776da0</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.02.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.02.016%26sid%3Dliteratum%253Aachs%26aulast%3DIyaguchi%26aufirst%3DD.%26aulast%3DKawano%26aufirst%3DS.%26aulast%3DTakada%26aufirst%3DK.%26aulast%3DToyota%26aufirst%3DE.%26atitle%3DStructural%2520Basis%2520for%2520the%2520Design%2520of%2520Novel%2520Schiff%2520Base%2520Metal%2520Chelate%2520Inhibitors%2520of%2520Trypsin%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D2076%26epage%3D2080%26doi%3D10.1016%2Fj.bmc.2010.02.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref217"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref217'); return false;" data-citation="" class="refNumLink">217</a></strong><div class="NLM_citation" id="cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyoda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, H.</span></span> <span> </span><span class="NLM_article-title">The Cell Adhesion and Proliferation Activities of a Peptide Derived from Human Tenascin-C Are Dependent on Two Ile Residues</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">4608</span>– <span class="NLM_lpage">4613</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2012.06.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmc.2012.06.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=22776297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvFCqtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=4608-4613&author=R.+Hayashiauthor=S.+Miuraauthor=Y.+Saitoauthor=S.+Osadaauthor=T.+Iyodaauthor=F.+Fukaiauthor=H.+Kodama&title=The+Cell+Adhesion+and+Proliferation+Activities+of+a+Peptide+Derived+from+Human+Tenascin-C+Are+Dependent+on+Two+Ile+Residues&doi=10.1016%2Fj.bmc.2012.06.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">The cell adhesion and proliferation activities of a peptide derived from human tenascin-C are dependent on two Ile residues</span></div><div class="casAuthors">Hayashi, Ryo; Miura, Shogo; Saito, Yohei; Osada, Satoshi; Iyoda, Takuya; Fukai, Fumio; Kodama, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4608-4613</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A tenascin-C derived peptide (TNIIIA2 peptide, 1) stimulated β1 integrin-mediated cell adhesion via binding to syndecan-4.  Ala-substituted peptides were synthesized to understand the structure-activity relationship.  Peptides in which basic amino acids were substituted showed reduced cell adhesion activity, but their proliferation activities were similar to or higher than those mediated by peptide 1.  In contrast, peptides in which the Ile residues of peptide 1 were replaced were inactive, indicating that the Ile residues are crit. for the peptide's activity.  CD anal. suggested that the Ile residues are necessary for the formation of a specific conformation required for binding to syndecan-4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJY3c2ifSVXrVg90H21EOLACvtfcHk0lgHKDFK-zA1IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvFCqtLk%253D&md5=5fd3a4ef9184d8baaaf6ea55d4c413a1</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2012.06.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2012.06.036%26sid%3Dliteratum%253Aachs%26aulast%3DHayashi%26aufirst%3DR.%26aulast%3DMiura%26aufirst%3DS.%26aulast%3DSaito%26aufirst%3DY.%26aulast%3DOsada%26aufirst%3DS.%26aulast%3DIyoda%26aufirst%3DT.%26aulast%3DFukai%26aufirst%3DF.%26aulast%3DKodama%26aufirst%3DH.%26atitle%3DThe%2520Cell%2520Adhesion%2520and%2520Proliferation%2520Activities%2520of%2520a%2520Peptide%2520Derived%2520from%2520Human%2520Tenascin-C%2520Are%2520Dependent%2520on%2520Two%2520Ile%2520Residues%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D4608%26epage%3D4613%26doi%3D10.1016%2Fj.bmc.2012.06.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref218"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref218'); return false;" data-citation="" class="refNumLink">218</a></strong><div class="NLM_citation" id="cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdolmaleki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghasemi, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghasemi, F.</span></span> <span> </span><span class="NLM_article-title">Computer Aided Drug Design for Multi-Target Drug Design: SAR /QSAR, Molecular Docking and Pharmacophore Methods</span>. <i>Curr. Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">556</span>– <span class="NLM_lpage">575</span>, <span class="refDoi"> DOI: 10.2174/1389450117666160101120822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.2174%2F1389450117666160101120822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=26721410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs12qt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=556-575&author=A.+Abdolmalekiauthor=J.+B.+Ghasemiauthor=F.+Ghasemi&title=Computer+Aided+Drug+Design+for+Multi-Target+Drug+Design%3A+SAR+%2FQSAR%2C+Molecular+Docking+and+Pharmacophore+Methods&doi=10.2174%2F1389450117666160101120822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">Computer Aided Drug Design for Multi-Target Drug Design: SAR /QSAR, Molecular Docking and Pharmacophore Methods</span></div><div class="casAuthors">Abdolmaleki, Azizeh; Ghasemi, Jahan B.; Ghasemi, Fatemeh</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">556-575</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Multi-target drugs against particular multiple targets get better protection, resistance profiles and curative influence by cooperative rules of a key beneficial target with resistance behavior and compensatory elements.  Computational techniques can assist us in the efforts to design novel drugs (ligands) with a preferred bioactivity outline and alternative bioactive mols. at an early stage.  A no. of in silico methods have been explored extensively in order to facilitate the investigation of individual target agents and to propose a selective drug.  A different, progressively more significant field which is used to predict the bioactivity of chem. compds. is the data mining method.  Some of the previously mentioned methods have been investigated for multi-target drug design (MTDD) to find drug leads interact simultaneously with multiple targets.  Several cheminformatics methods and structure-based approaches try to ext. information from units working cooperatively in a biomol. system to fulfill their task.  To dominate the difficulties of the exptl. specification of ligand-target structures, rational methods, namely mol. docking, SAR and QSAR are vital substitutes to obtain knowledge for each structure in at. insight.  These procedures are logically successful for the prediction of binding affinity and have shown promising potential in facilitating MTDD.  Here, we review some of the important features of the multi-target therapeutics discoveries using the computational approach, highlighting the SAR, QSAR, docking and pharmacophore methods to discover interactions between drug-target that could be leveraged for curative benefits.  A summary of each, followed by examples of its applications in drug design has been provided.  Computational efficiency of each method has been represented according to its main strengths and limitations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYCnlSlFtO_rVg90H21EOLACvtfcHk0lgHKDFK-zA1IQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs12qt7k%253D&md5=e62d8003ab7cccb962ef00a8e9355adc</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.2174%2F1389450117666160101120822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389450117666160101120822%26sid%3Dliteratum%253Aachs%26aulast%3DAbdolmaleki%26aufirst%3DA.%26aulast%3DGhasemi%26aufirst%3DJ.%2BB.%26aulast%3DGhasemi%26aufirst%3DF.%26atitle%3DComputer%2520Aided%2520Drug%2520Design%2520for%2520Multi-Target%2520Drug%2520Design%253A%2520SAR%2520%252FQSAR%252C%2520Molecular%2520Docking%2520and%2520Pharmacophore%2520Methods%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2017%26volume%3D18%26spage%3D556%26epage%3D575%26doi%3D10.2174%2F1389450117666160101120822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref219"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref219'); return false;" data-citation="" class="refNumLink">219</a></strong><div class="NLM_citation" id="cit219"><span>Schrödinger Release
2020-2:  <i>Canvas</i>; <span class="NLM_publisher-name">Schrödinger
LLC</span>: <span class="NLM_publisher-loc">New York,
NY</span>. <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Schr%C3%B6dinger+Release%0A2020-2%3A+Canvas%3B+Schr%C3%B6dinger%0ALLC%3A+New+York%2C%0ANY.+2020."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DCanvas%26pub%3DSchr%25C3%25B6dinger%250ALLC%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref220"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref220'); return false;" data-citation="" class="refNumLink">220</a></strong><div class="NLM_citation" id="cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lill, M. A.</span></span> <span> </span><span class="NLM_article-title">Integrating Structure-Based and Ligand-Based Approaches for Computational Drug Design</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">735</span>– <span class="NLM_lpage">750</span>, <span class="refDoi"> DOI: 10.4155/fmc.11.18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.4155%2Ffmc.11.18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=21554079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvFGisL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=735-750&author=G.+L.+Wilsonauthor=M.+A.+Lill&title=Integrating+Structure-Based+and+Ligand-Based+Approaches+for+Computational+Drug+Design&doi=10.4155%2Ffmc.11.18"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">Integrating structure-based and ligand-based approaches for computational drug design</span></div><div class="casAuthors">Wilson, Gregory L.; Lill, Markus A.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">735-750</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Methods utilized in computer-aided drug design can be classified into two major categories: structure based and ligand based, using information on the structure of the protein or on the biol. and physicochem. properties of bound ligands, resp.  In recent years there has been a trend towards integrating these two methods in order to enhance the reliability and efficiency of computer-aided drug-design approaches by combining information from both the ligand and the protein.  This trend resulted in a variety of methods that include: pseudoreceptor methods, pharmacophore methods, fingerprint methods and approaches integrating docking with similarity-based methods.  In this article, we will describe the concepts behind each method and selected applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9b-e495CSArVg90H21EOLACvtfcHk0li_DYomdoKPbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvFGisL4%253D&md5=ee5d34d69b26accc91c22e1faecc3814</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.4155%2Ffmc.11.18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.11.18%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DG.%2BL.%26aulast%3DLill%26aufirst%3DM.%2BA.%26atitle%3DIntegrating%2520Structure-Based%2520and%2520Ligand-Based%2520Approaches%2520for%2520Computational%2520Drug%2520Design%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2011%26volume%3D3%26spage%3D735%26epage%3D750%26doi%3D10.4155%2Ffmc.11.18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref221"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref221'); return false;" data-citation="" class="refNumLink">221</a></strong><div class="NLM_citation" id="cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knox, A. J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawlak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golfis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flood, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fayne, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meegan, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lloyd, D. G.</span></span> <span> </span><span class="NLM_article-title">Integration of Ligand and Structure-Based Virtual Screening for the Identification of the First Dual Targeting Agent for Heat Shock Protein 90 (Hsp90) and Tubulin</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">2177</span>– <span class="NLM_lpage">2180</span>, <span class="refDoi"> DOI: 10.1021/jm801569z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801569z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktFGrt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2177-2180&author=A.+J.+S.+Knoxauthor=T.+Priceauthor=M.+Pawlakauthor=G.+Golfisauthor=C.+T.+Floodauthor=D.+Fayneauthor=D.+C.+Williamsauthor=M.+J.+Meeganauthor=D.+G.+Lloyd&title=Integration+of+Ligand+and+Structure-Based+Virtual+Screening+for+the+Identification+of+the+First+Dual+Targeting+Agent+for+Heat+Shock+Protein+90+%28Hsp90%29+and+Tubulin&doi=10.1021%2Fjm801569z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Integration of Ligand and Structure-Based Virtual Screening for the Identification of the First Dual Targeting Agent for Heat Shock Protein 90 (Hsp90) and Tubulin</span></div><div class="casAuthors">Knox, Andrew J. S.; Price, Trevor; Pawlak, Michal; Golfis, Georgia; Flood, Christopher T.; Fayne, Darren; Williams, D. Clive; Meegan, Mary J.; Lloyd, David G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2177-2180</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We describe the discovery of a novel indazole-based scaffold that represents the "first-in-class" dual Hsp90/tubulin binding compd.  Individual known ligands for both targets shared similar 3',4',5'-trimethoxyphenyl cores, and from this it was hypothesized that application of an integrated ligand and structure-based virtual screening (VS) workflow could yield a single scaffold with dual binding affinity.  Following validation of the VS protocol, we successfully identified a novel dual inhibitor, sourced from a com. screening collection of 160 000 compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRptEHjoTCsLVg90H21EOLACvtfcHk0li_DYomdoKPbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktFGrt70%253D&md5=c8268f36a0da627404be37696c5afe4b</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1021%2Fjm801569z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801569z%26sid%3Dliteratum%253Aachs%26aulast%3DKnox%26aufirst%3DA.%2BJ.%2BS.%26aulast%3DPrice%26aufirst%3DT.%26aulast%3DPawlak%26aufirst%3DM.%26aulast%3DGolfis%26aufirst%3DG.%26aulast%3DFlood%26aufirst%3DC.%2BT.%26aulast%3DFayne%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DD.%2BC.%26aulast%3DMeegan%26aufirst%3DM.%2BJ.%26aulast%3DLloyd%26aufirst%3DD.%2BG.%26atitle%3DIntegration%2520of%2520Ligand%2520and%2520Structure-Based%2520Virtual%2520Screening%2520for%2520the%2520Identification%2520of%2520the%2520First%2520Dual%2520Targeting%2520Agent%2520for%2520Heat%2520Shock%2520Protein%252090%2520%2528Hsp90%2529%2520and%2520Tubulin%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2177%26epage%3D2180%26doi%3D10.1021%2Fjm801569z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref222"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref222'); return false;" data-citation="" class="refNumLink">222</a></strong><div class="NLM_citation" id="cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olivecrona, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaschke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engkvist, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span> <span> </span><span class="NLM_article-title">Molecular De-Novo Design through Deep Reinforcement Learning</span>. <i>J. Cheminf.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">48</span>, <span class="refDoi"> DOI: 10.1186/s13321-017-0235-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1186%2Fs13321-017-0235-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BC1M7mtVKisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=48&author=M.+Olivecronaauthor=T.+Blaschkeauthor=O.+Engkvistauthor=H.+Chen&title=Molecular+De-Novo+Design+through+Deep+Reinforcement+Learning&doi=10.1186%2Fs13321-017-0235-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular de-novo design through deep reinforcement learning</span></div><div class="casAuthors">Olivecrona Marcus; Blaschke Thomas; Engkvist Ola; Chen Hongming</div><div class="citationInfo"><span class="NLM_cas:title">Journal of cheminformatics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48</span>
        ISSN:<span class="NLM_cas:issn">1758-2946</span>.
    </div><div class="casAbstract">This work introduces a method to tune a sequence-based generative model for molecular de novo design that through augmented episodic likelihood can learn to generate structures with certain specified desirable properties.  We demonstrate how this model can execute a range of tasks such as generating analogues to a query structure and generating compounds predicted to be active against a biological target.  As a proof of principle, the model is first trained to generate molecules that do not contain sulphur.  As a second example, the model is trained to generate analogues to the drug Celecoxib, a technique that could be used for scaffold hopping or library expansion starting from a single molecule.  Finally, when tuning the model towards generating compounds predicted to be active against the dopamine receptor type 2, the model generates structures of which more than 95% are predicted to be active, including experimentally confirmed actives that have not been included in either the generative model nor the activity prediction model.  Graphical abstract .</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRyTcZ9MBhh28zK395ZObgVfW6udTcc2eYW2LdWQqdv0rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7mtVKisg%253D%253D&md5=68f5a1219ef81fbd52a5c8911cacbbfc</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1186%2Fs13321-017-0235-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13321-017-0235-x%26sid%3Dliteratum%253Aachs%26aulast%3DOlivecrona%26aufirst%3DM.%26aulast%3DBlaschke%26aufirst%3DT.%26aulast%3DEngkvist%26aufirst%3DO.%26aulast%3DChen%26aufirst%3DH.%26atitle%3DMolecular%2520De-Novo%2520Design%2520through%2520Deep%2520Reinforcement%2520Learning%26jtitle%3DJ.%2520Cheminf.%26date%3D2017%26volume%3D9%26spage%3D48%26doi%3D10.1186%2Fs13321-017-0235-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref223"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref223'); return false;" data-citation="" class="refNumLink">223</a></strong><div class="NLM_citation" id="cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vapnik, V. N.</span></span> <i>Statistical Learning Theory</i>; <span class="NLM_publisher-name">John Wiley & Sons Inc.</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">1998</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1998&author=V.+N.+Vapnik&title=Statistical+Learning+Theory"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DVapnik%26aufirst%3DV.%2BN.%26btitle%3DStatistical%2520Learning%2520Theory%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%2520Inc%26date%3D1998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref224"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref224'); return false;" data-citation="" class="refNumLink">224</a></strong><div class="NLM_citation" id="cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kingma, D. P.</span>; <span class="NLM_string-name">Welling, M.</span></span> <span> </span><span class="NLM_article-title">Auto-Encoding Variational Bayes</span> <i>arXiv:1312.6114 [stat.ML]</i>, <span class="NLM_year" style="font-weight: bold;">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=D.+P.+Kingma&author=M.+Welling&title=Auto-Encoding+Variational+Bayes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKingma%26aufirst%3DD.%2BP.%26atitle%3DAuto-Encoding%2520Variational%2520Bayes%26jtitle%3DarXiv%253A1312.6114%2520%255Bstat.ML%255D%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref225"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref225'); return false;" data-citation="" class="refNumLink">225</a></strong><div class="NLM_citation" id="cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huisman, B. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G.</span></span> <span> </span><span class="NLM_article-title">Generative Recurrent Networks for De Novo Drug Design</span>. <i>Mol. Inf.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1700111</span>, <span class="refDoi"> DOI: 10.1002/minf.201700111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1002%2Fminf.201700111" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=1700111&author=A.+Guptaauthor=A.+T.+M%C3%BCllerauthor=B.+J.+H.+Huismanauthor=J.+A.+Fuchsauthor=P.+Schneiderauthor=G.+Schneider&title=Generative+Recurrent+Networks+for+De+Novo+Drug+Design&doi=10.1002%2Fminf.201700111"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1002%2Fminf.201700111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fminf.201700111%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DA.%2BT.%26aulast%3DHuisman%26aufirst%3DB.%2BJ.%2BH.%26aulast%3DFuchs%26aufirst%3DJ.%2BA.%26aulast%3DSchneider%26aufirst%3DP.%26aulast%3DSchneider%26aufirst%3DG.%26atitle%3DGenerative%2520Recurrent%2520Networks%2520for%2520De%2520Novo%2520Drug%2520Design%26jtitle%3DMol.%2520Inf.%26date%3D2018%26volume%3D37%26spage%3D1700111%26doi%3D10.1002%2Fminf.201700111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref226"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref226'); return false;" data-citation="" class="refNumLink">226</a></strong><div class="NLM_citation" id="cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hochreiter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidhuber, J.</span></span> <span> </span><span class="NLM_article-title">Long Short-Term Memory</span>. <i>Neural Comput.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1735</span>– <span class="NLM_lpage">1780</span>, <span class="refDoi"> DOI: 10.1162/neco.1997.9.8.1735</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1162%2Fneco.1997.9.8.1735" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=9377276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADyaK1c%252FhvVahsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1997&pages=1735-1780&author=S.+Hochreiterauthor=J.+Schmidhuber&title=Long+Short-Term+Memory&doi=10.1162%2Fneco.1997.9.8.1735"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">Long short-term memory</span></div><div class="casAuthors">Hochreiter S; Schmidhuber J</div><div class="citationInfo"><span class="NLM_cas:title">Neural computation</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1735-80</span>
        ISSN:<span class="NLM_cas:issn">0899-7667</span>.
    </div><div class="casAbstract">Learning to store information over extended time intervals by recurrent backpropagation takes a very long time, mostly because of insufficient, decaying error backflow.  We briefly review Hochreiter's (1991) analysis of this problem, then address it by introducing a novel, efficient, gradient-based method called long short-term memory (LSTM).  Truncating the gradient where this does not do harm, LSTM can learn to bridge minimal time lags in excess of 1000 discrete-time steps by enforcing constant error flow through constant error carousels within special units.  Multiplicative gate units learn to open and close access to the constant error flow.  LSTM is local in space and time; its computational complexity per time step and weight is O(1).  Our experiments with artificial data involve local, distributed, real-valued, and noisy pattern representations.  In comparisons with real-time recurrent learning, back propagation through time, recurrent cascade correlation, Elman nets, and neural sequence chunking, LSTM leads to many more successful runs, and learns much faster.  LSTM also solves complex, artificial long-time-lag tasks that have never been solved by previous recurrent network algorithms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSijGIiEN1za0PI-fCgwosgfW6udTcc2eaJlTMhmiPpbbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c%252FhvVahsQ%253D%253D&md5=5da426ddc18e5bc1972e520bbcc33bec</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.1162%2Fneco.1997.9.8.1735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1162%252Fneco.1997.9.8.1735%26sid%3Dliteratum%253Aachs%26aulast%3DHochreiter%26aufirst%3DS.%26aulast%3DSchmidhuber%26aufirst%3DJ.%26atitle%3DLong%2520Short-Term%2520Memory%26jtitle%3DNeural%2520Comput.%26date%3D1997%26volume%3D9%26spage%3D1735%26epage%3D1780%26doi%3D10.1162%2Fneco.1997.9.8.1735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref227"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref227'); return false;" data-citation="" class="refNumLink">227</a></strong><div class="NLM_citation" id="cit227"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gómez-Bombarelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duvenaud, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernández-Lobato, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Lengeling, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheberla, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguilera-Iparraguirre, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirzel, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aspuru-Guzik, A.</span></span> <span> </span><span class="NLM_article-title">Automatic Chemical Design Using a Data-Driven Continuous Representation of Molecules</span>. <i>ACS Cent. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">268</span>– <span class="NLM_lpage">276</span>, <span class="refDoi"> DOI: 10.1021/acscentsci.7b00572</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acscentsci.7b00572" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntlWquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=268-276&author=R.+G%C3%B3mez-Bombarelliauthor=J.+N.+Weiauthor=D.+Duvenaudauthor=J.+M.+Hern%C3%A1ndez-Lobatoauthor=B.+S%C3%A1nchez-Lengelingauthor=D.+Sheberlaauthor=J.+Aguilera-Iparraguirreauthor=T.+D.+Hirzelauthor=R.+P.+Adamsauthor=A.+Aspuru-Guzik&title=Automatic+Chemical+Design+Using+a+Data-Driven+Continuous+Representation+of+Molecules&doi=10.1021%2Facscentsci.7b00572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit227R"><div class="casContent"><span class="casTitleNuber">227</span><div class="casTitle"><span class="NLM_cas:atitle">Automatic Chemical Design Using a Data-Driven Continuous Representation of Molecules</span></div><div class="casAuthors">Gomez-Bombarelli, Rafael; Wei, Jennifer N.; Duvenaud, David; Hernandez-Lobato, Jose Miguel; Sanchez-Lengeling, Benjamin; Sheberla, Dennis; Aguilera-Iparraguirre, Jorge; Hirzel, Timothy D.; Adams, Ryan P.; Aspuru-Guzik, Alan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Central Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">268-276</span>CODEN:
                <span class="NLM_cas:coden">ACSCII</span>;
        ISSN:<span class="NLM_cas:issn">2374-7951</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report a method to convert discrete representations of mols. to and from a multidimensional continuous representation.  This model allows us to generate new mols. for efficient exploration and optimization through open-ended spaces of chem. compds.  A deep neural network was trained on hundreds of thousands of existing chem. structures to construct three coupled functions: an encoder, a decoder, and a predictor.  The encoder converts the discrete representation of a mol. into a real-valued continuous vector, and the decoder converts these continuous vectors back to discrete mol. representations.  The predictor ests. chem. properties from the latent continuous vector representation of the mol.  Continuous representations of mols. allow us to automatically generate novel chem. structures by performing simple operations in the latent space, such as decoding random vectors, perturbing known chem. structures, or interpolating between mols.  Continuous representations also allow the use of powerful gradient-based optimization to efficiently guide the search for optimized functional compds.  We demonstrate our method in the domain of drug-like mols. and also in a set of mols. with fewer that nine heavy atoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXN9RuDQ2cp7Vg90H21EOLACvtfcHk0li2idSbUb0yPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntlWquw%253D%253D&md5=322d9ff569fc9c8831e91d915104d985</span></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1021%2Facscentsci.7b00572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facscentsci.7b00572%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25B3mez-Bombarelli%26aufirst%3DR.%26aulast%3DWei%26aufirst%3DJ.%2BN.%26aulast%3DDuvenaud%26aufirst%3DD.%26aulast%3DHern%25C3%25A1ndez-Lobato%26aufirst%3DJ.%2BM.%26aulast%3DS%25C3%25A1nchez-Lengeling%26aufirst%3DB.%26aulast%3DSheberla%26aufirst%3DD.%26aulast%3DAguilera-Iparraguirre%26aufirst%3DJ.%26aulast%3DHirzel%26aufirst%3DT.%2BD.%26aulast%3DAdams%26aufirst%3DR.%2BP.%26aulast%3DAspuru-Guzik%26aufirst%3DA.%26atitle%3DAutomatic%2520Chemical%2520Design%2520Using%2520a%2520Data-Driven%2520Continuous%2520Representation%2520of%2520Molecules%26jtitle%3DACS%2520Cent.%2520Sci.%26date%3D2018%26volume%3D4%26spage%3D268%26epage%3D276%26doi%3D10.1021%2Facscentsci.7b00572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref228"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref228'); return false;" data-citation="" class="refNumLink">228</a></strong><div class="NLM_citation" id="cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kadurin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolenko, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khrabrov, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliper, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhavoronkov, A.</span></span> <span> </span><span class="NLM_article-title">DruGAN: An Advanced Generative Adversarial Autoencoder Model for de Novo Generation of New Molecules with Desired Molecular Properties in Silico</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">3098</span>– <span class="NLM_lpage">3104</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.7b00346</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.7b00346" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFGitbbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=3098-3104&author=A.+Kadurinauthor=S.+Nikolenkoauthor=K.+Khrabrovauthor=A.+Aliperauthor=A.+Zhavoronkov&title=DruGAN%3A+An+Advanced+Generative+Adversarial+Autoencoder+Model+for+de+Novo+Generation+of+New+Molecules+with+Desired+Molecular+Properties+in+Silico&doi=10.1021%2Facs.molpharmaceut.7b00346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">druGAN: An Advanced Generative Adversarial Autoencoder Model for de Novo Generation of New Molecules with Desired Molecular Properties in Silico</span></div><div class="casAuthors">Kadurin, Artur; Nikolenko, Sergey; Khrabrov, Kuzma; Aliper, Alex; Zhavoronkov, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3098-3104</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Deep generative adversarial networks (GANs) are the emerging technol. in drug discovery and biomarker development.  In our recent work, we demonstrated a proof-of-concept of implementing deep generative adversarial autoencoder (AAE) to identify new mol. fingerprints with predefined anticancer properties.  Another popular generative model is the variational autoencoder (VAE), which is based on deep neural architectures.  In this work, we developed an advanced AAE model for mol. feature extn. problems, and demonstrated its advantages compared to VAE in terms of (a) adjustability in generating mol. fingerprints; (b) capacity of processing very large mol. data sets; and (c) efficiency in unsupervised pretraining for regression model.  Our results suggest that the proposed AAE model significantly enhances the capacity and efficiency of development of the new mols. with specific anticancer properties using the deep generative models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNg9wvc_4wlrVg90H21EOLACvtfcHk0ljlyvCJUFm9Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFGitbbF&md5=6fc20afd4c6a8188e830aa90a7875dd6</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.7b00346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.7b00346%26sid%3Dliteratum%253Aachs%26aulast%3DKadurin%26aufirst%3DA.%26aulast%3DNikolenko%26aufirst%3DS.%26aulast%3DKhrabrov%26aufirst%3DK.%26aulast%3DAliper%26aufirst%3DA.%26aulast%3DZhavoronkov%26aufirst%3DA.%26atitle%3DDruGAN%253A%2520An%2520Advanced%2520Generative%2520Adversarial%2520Autoencoder%2520Model%2520for%2520de%2520Novo%2520Generation%2520of%2520New%2520Molecules%2520with%2520Desired%2520Molecular%2520Properties%2520in%2520Silico%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2017%26volume%3D14%26spage%3D3098%26epage%3D3104%26doi%3D10.1021%2Facs.molpharmaceut.7b00346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref229"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref229'); return false;" data-citation="" class="refNumLink">229</a></strong><div class="NLM_citation" id="cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montanari, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briem, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noé, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clevert, D.-A.</span></span> <span> </span><span class="NLM_article-title">Efficient Multi-Objective Molecular Optimization in a Continuous Latent Space</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">8016</span>– <span class="NLM_lpage">8024</span>, <span class="refDoi"> DOI: 10.1039/C9SC01928F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1039%2FC9SC01928F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=31853357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlaltrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=8016-8024&author=R.+Winterauthor=F.+Montanariauthor=A.+Steffenauthor=H.+Briemauthor=F.+No%C3%A9author=D.-A.+Clevert&title=Efficient+Multi-Objective+Molecular+Optimization+in+a+Continuous+Latent+Space&doi=10.1039%2FC9SC01928F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit229R"><div class="casContent"><span class="casTitleNuber">229</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient multi-objective molecular optimization in a continuous latent space</span></div><div class="casAuthors">Winter, Robin; Montanari, Floriane; Steffen, Andreas; Briem, Hans; Noe, Frank; Clevert, Djork-Arne</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">8016-8024</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">One of the main challenges in small mol. drug discovery is finding novel chem. compds. with desirable properties.  In this work, we propose a novel method that combines in silico prediction of mol. properties such as biol. activity or pharmacokinetics with an in silico optimization algorithm, namely Particle Swarm Optimization.  Our method takes a starting compd. as input and proposes new mols. with more desirable (predicted) properties.  It navigates a machine-learned continuous representation of a drug-like chem. space guided by a defined objective function.  The objective function combines multiple in silico prediction models, defined desirability ranges and substructure constraints.  We demonstrate that our proposed method is able to consistently find more desirable mols. for the studied tasks in relatively short time.  We hope that our method can support medicinal chemists in accelerating and improving the lead optimization process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1KzYBvH6wCLVg90H21EOLACvtfcHk0ljlyvCJUFm9Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlaltrjO&md5=c63599dc8a30df8f805ce5457ecc053a</span></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.1039%2FC9SC01928F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9SC01928F%26sid%3Dliteratum%253Aachs%26aulast%3DWinter%26aufirst%3DR.%26aulast%3DMontanari%26aufirst%3DF.%26aulast%3DSteffen%26aufirst%3DA.%26aulast%3DBriem%26aufirst%3DH.%26aulast%3DNo%25C3%25A9%26aufirst%3DF.%26aulast%3DClevert%26aufirst%3DD.-A.%26atitle%3DEfficient%2520Multi-Objective%2520Molecular%2520Optimization%2520in%2520a%2520Continuous%2520Latent%2520Space%26jtitle%3DChem.%2520Sci.%26date%3D2019%26volume%3D10%26spage%3D8016%26epage%3D8024%26doi%3D10.1039%2FC9SC01928F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref230"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref230'); return false;" data-citation="" class="refNumLink">230</a></strong><div class="NLM_citation" id="cit230"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span> <span> </span><span class="NLM_article-title">Automated Design and Optimization of Multitarget Schizophrenia Drug Candidates by Deep Learning</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>204</i></span>,  <span class="NLM_fpage">112572</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112572</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2020.112572" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=32711293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVCksbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=2020&pages=112572&author=X.+Tanauthor=X.+Jiangauthor=Y.+Heauthor=F.+Zhongauthor=X.+Liauthor=Z.+Xiongauthor=Z.+Liauthor=X.+Liuauthor=C.+Cuiauthor=Q.+Zhaoauthor=Y.+Xieauthor=F.+Yangauthor=C.+Wuauthor=J.+Shenauthor=M.+Zhengauthor=Z.+Wangauthor=H.+Jiang&title=Automated+Design+and+Optimization+of+Multitarget+Schizophrenia+Drug+Candidates+by+Deep+Learning&doi=10.1016%2Fj.ejmech.2020.112572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">Automated design and optimization of multitarget schizophrenia drug candidates by deep learning</span></div><div class="casAuthors">Tan, Xiaoqin; Jiang, Xiangrui; He, Yang; Zhong, Feisheng; Li, Xutong; Xiong, Zhaoping; Li, Zhaojun; Liu, Xiaohong; Cui, Chen; Zhao, Qingjie; Xie, Yuanchao; Yang, Feipu; Wu, Chunhui; Shen, Jingshan; Zheng, Mingyue; Wang, Zhen; Jiang, Hualiang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">204</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112572</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Complex neuropsychiatric diseases such as schizophrenia require drugs that can target multiple G protein-coupled receptors (GPCRs) to modulate complex neuropsychiatric functions.  Here, we report an automated system comprising a deep recurrent neural network (RNN) and a multitask deep neural network (MTDNN) to design and optimize multitarget antipsychotic drugs.  The system has successfully generated novel mol. structures with desired multiple target activities, among which high-ranking compd. 3 was synthesized, and demonstrated potent activities against dopamine D2, serotonin 5-HT1A and 5-HT2A receptors.  Hit expansion based on the MTDNN was performed, 6 analogs of compd. 3 were evaluated exptl., among which compd. 8 not only exhibited specific polypharmacol. profiles but also showed antipsychotic effect in animal models with low potential for sedation and catalepsy, highlighting their suitability for further preclin. studies.  The approach can be an efficient tool for designing lead compds. with multitarget profiles to achieve the desired efficacy in the treatment of complex neuropsychiatric diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdRwvxROaCZbVg90H21EOLACvtfcHk0ljlyvCJUFm9Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVCksbnI&md5=dd01837fd3bdbb488e8781cea7d5103b</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112572%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DZhong%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DXiong%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DCui%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DH.%26atitle%3DAutomated%2520Design%2520and%2520Optimization%2520of%2520Multitarget%2520Schizophrenia%2520Drug%2520Candidates%2520by%2520Deep%2520Learning%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D204%26spage%3D112572%26doi%3D10.1016%2Fj.ejmech.2020.112572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184'],'ref185':['cit185'],'ref186':['cit186'],'ref187':['cit187'],'ref188':['cit188'],'ref189':['cit189'],'ref190':['cit190'],'ref191':['cit191'],'ref192':['cit192'],'ref193':['cit193'],'ref194':['cit194'],'ref195':['cit195'],'ref196':['cit196'],'ref197':['cit197'],'ref198':['cit198'],'ref199':['cit199'],'ref200':['cit200'],'ref201':['cit201'],'ref202':['cit202'],'ref203':['cit203'],'ref204':['cit204'],'ref205':['cit205'],'ref206':['cit206'],'ref207':['cit207'],'ref208':['cit208'],'ref209':['cit209'],'ref210':['cit210'],'ref211':['cit211'],'ref212':['cit212'],'ref213':['cit213'],'ref214':['cit214'],'ref215':['cit215'],'ref216':['cit216'],'ref217':['cit217'],'ref218':['cit218'],'ref219':['cit219'],'ref220':['cit220'],'ref221':['cit221'],'ref222':['cit222'],'ref223':['cit223'],'ref224':['cit224'],'ref225':['cit225'],'ref226':['cit226'],'ref227':['cit227'],'ref228':['cit228'],'ref229':['cit229'],'ref230':['cit230']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 3 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Antonino N. Fallica, Valeria Pittalà, Maria N. Modica, Loredana Salerno, Giuseppe Romeo, Agostino Marrazzo, Mohamed A. Helal, <span class="NLM_string-name hlFld-ContribAuthor">Sebastiano Intagliata</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in the Development of Sigma Receptor Ligands as Cytotoxic Agents: A Medicinal Chemistry Perspective. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (12)
                                     , 7926-7962. <a href="https://doi.org/10.1021/acs.jmedchem.0c02265" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02265</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02265%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252BAdvances%252Bin%252Bthe%252BDevelopment%252Bof%252BSigma%252BReceptor%252BLigands%252Bas%252BCytotoxic%252BAgents%25253A%252BA%252BMedicinal%252BChemistry%252BPerspective%26aulast%3DFallica%26aufirst%3DAntonino%2BN.%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D31122020%26date%3D02062021%26volume%3D64%26issue%3D12%26spage%3D7926%26epage%3D7962" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pusheng  Quan</span>, <span class="hlFld-ContribAuthor ">Kai  Wang</span>, <span class="hlFld-ContribAuthor ">Shi  Yan</span>, <span class="hlFld-ContribAuthor ">Shirong  Wen</span>, <span class="hlFld-ContribAuthor ">Chengqun  Wei</span>, <span class="hlFld-ContribAuthor ">Xinyu  Zhang</span>, <span class="hlFld-ContribAuthor ">Jingwei  Cao</span>, <span class="hlFld-ContribAuthor ">Lifen  Yao</span>. </span><span class="cited-content_cbyCitation_article-title">Integrated network analysis identifying potential novel drug candidates and targets for Parkinson's disease. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2021,</strong> <em>11 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-021-92701-2" title="DOI URL">https://doi.org/10.1038/s41598-021-92701-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-021-92701-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-021-92701-2%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DIntegrated%252Bnetwork%252Banalysis%252Bidentifying%252Bpotential%252Bnovel%252Bdrug%252Bcandidates%252Band%252Btargets%252Bfor%252BParkinson%252527s%252Bdisease%26aulast%3DQuan%26aufirst%3DPusheng%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Francesca Serena  Abatematteo</span>, <span class="hlFld-ContribAuthor ">Mauro  Niso</span>, <span class="hlFld-ContribAuthor ">Marialessandra  Contino</span>, <span class="hlFld-ContribAuthor ">Marcello  Leopoldo</span>, <span class="hlFld-ContribAuthor ">Carmen  Abate</span>. </span><span class="cited-content_cbyCitation_article-title">Multi-Target Directed Ligands (MTDLs) Binding the σ1 Receptor as Promising Therapeutics: State of the Art and Perspectives. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (12)
                                     , 6359. <a href="https://doi.org/10.3390/ijms22126359" title="DOI URL">https://doi.org/10.3390/ijms22126359</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22126359&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22126359%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DMulti-Target%252BDirected%252BLigands%252B%252528MTDLs%252529%252BBinding%252Bthe%252B%2525CF%2525831%252BReceptor%252Bas%252BPromising%252BTherapeutics%25253A%252BState%252Bof%252Bthe%252BArt%252Band%252BPerspectives%26aulast%3DAbatematteo%26aufirst%3DFrancesca%2BSerena%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D12%26spage%3D6359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/medium/jm0c01357_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/medium/jm0c01357_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative CB2R ligands bearing different scaffolds.<a onclick="showRef(event, 'ref62 ref95 ref96 ref97 ref98 ref99 ref100 ref101 ref102'); return false;" href="javascript:void(0);" class="ref ref62 ref95 ref96 ref97 ref98 ref99 ref100 ref101 ref102">(62,95−102)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/medium/jm0c01357_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Proposed CB2R pharmacophore.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/medium/jm0c01357_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. AChE inhibitors approved by FDA for AD treatment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/medium/jm0c01357_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. 2D sketch of the JWH-015 structural modifications proposed by Paez and colleagues<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> for designing dual CB2R/ChE indazole compounds ligands <b>14</b> and <b>15</b> and the CB2R/ChE/BACE-1 indazolyl ketone <b>16</b>.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/medium/jm0c01357_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Dual CB2R/BChE benzofuran derivatives proposed by Montanari and collegues.<a onclick="showRef(event, 'ref119'); return false;" href="javascript:void(0);" class="ref ref119">(119)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/medium/jm0c01357_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Pharmacophore model of BChE inhibitors and CB2R compound <b>14</b> (top). Benzimidazole derivative <b>19</b> proposed by Astra Zeneca<a onclick="showRef(event, 'ref120'); return false;" href="javascript:void(0);" class="ref ref120">(120)</a> as <i>h</i>CB2R agonist and studied by Dolles and co-workers as BchE/AchE inhibitor (bottom).<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/medium/jm0c01357_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Dual CB2R/BChE benzimidazole derivatives proposed by Dolles and colleagues: second generation.<a onclick="showRef(event, 'ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref29 ref30">(29,30)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/medium/jm0c01357_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Dual CB2R/BChE benzimidazole derivatives proposed by Dolles and collegues, third generation.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/medium/jm0c01357_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. General structures of hybrid compounds derived from the combination of tacrine and compound <b>20</b><a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> reported by Scheiner and collegues.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/medium/jm0c01357_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Representative HDAC inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/medium/jm0c01357_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Proposed dual CB2R/HDACi obtained by merging compound <b>8</b> and panobinostat.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/medium/jm0c01357_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Proposed strategy to design dual CB2R/HDACi: merging approach involving the structure of entinostat and the CB2R pharmacophore.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/medium/jm0c01357_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. General structure of Estrada-Valencia et al.’s ligands.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/medium/jm0c01357_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Mugnaini’s ligand <b>39</b> on the left, Weber’s ligand <b>40</b> on the right, and proposed strategy to design dual CB2R/σ, where an outline of possible modifications is reported at the bottom.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/medium/jm0c01357_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. Projection of (A) CB2R (black points) and HDAC (red points) and (B) CB2R (black points) and σ<sub>1</sub> (red points) high affinity (IC<sub>50</sub> or <i>K</i><sub>i</sub> of ≤1 μM) compounds into the top two PCs obtained from 11 topological and 323 physicochemical descriptors. Note that PC1 and PC2 are plotted accounting for (A) 90% and (B) 87% of the total variance.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-23/acs.jmedchem.0c01357/20201203/images/large/jm0c01357_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c01357&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i23">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_73480" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_73480" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 230 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capparelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bush, A. I.</span></span> <span> </span><span class="NLM_article-title">Editorial: The CB2 Cannabinoid System: A New Strategy in Neurodegenerative Disorder and Neuroinflammation</span>. <i>Front. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">196</span>, <span class="refDoi"> DOI: 10.3389/fnins.2017.00196</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3389%2Ffnins.2017.00196" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=28428743" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BC1cvpslCgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=196&author=M.+Continoauthor=E.+Capparelliauthor=N.+A.+Colabufoauthor=A.+I.+Bush&title=Editorial%3A+The+CB2+Cannabinoid+System%3A+A+New+Strategy+in+Neurodegenerative+Disorder+and+Neuroinflammation&doi=10.3389%2Ffnins.2017.00196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Editorial: The CB2 Cannabinoid System: A New Strategy in Neurodegenerative Disorder and Neuroinflammation</span></div><div class="casAuthors">Contino Marialessandra; Capparelli Elena; Colabufo Nicola A; Bush Ashley I</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">196</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSeo9MkHaT4STMsgLhIoICsfW6udTcc2eYelxe-ABVYhbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cvpslCgsg%253D%253D&md5=e7885fa8e8ab93b3d78c87bfbead1f63</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2017.00196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2017.00196%26sid%3Dliteratum%253Aachs%26aulast%3DContino%26aufirst%3DM.%26aulast%3DCapparelli%26aufirst%3DE.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DBush%26aufirst%3DA.%2BI.%26atitle%3DEditorial%253A%2520The%2520CB2%2520Cannabinoid%2520System%253A%2520A%2520New%2520Strategy%2520in%2520Neurodegenerative%2520Disorder%2520and%2520Neuroinflammation%26jtitle%3DFront.%2520Neurosci.%26date%3D2017%26volume%3D11%26spage%3D196%26doi%3D10.3389%2Ffnins.2017.00196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spinelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capparelli, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span> <span> </span><span class="NLM_article-title">Perspectives of Cannabinoid Type 2 Receptor (CB2R) Ligands in Neurodegenerative Disorders: Structure-Affinity Relationship (SAfiR) and Structure-Activity Relationship (SAR) Studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">9913</span>– <span class="NLM_lpage">9931</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00155</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00155" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpvFeisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=9913-9931&author=F.+Spinelliauthor=E.+Capparelliauthor=C.+Abateauthor=N.+A.+Colabufoauthor=M.+Contino&title=Perspectives+of+Cannabinoid+Type+2+Receptor+%28CB2R%29+Ligands+in+Neurodegenerative+Disorders%3A+Structure-Affinity+Relationship+%28SAfiR%29+and+Structure-Activity+Relationship+%28SAR%29+Studies&doi=10.1021%2Facs.jmedchem.7b00155"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Perspectives of Cannabinoid Type 2 Receptor (CB2R) Ligands in Neurodegenerative Disorders: Structure-Affinity Relationship (SAfiR) and Structure-Activity Relationship (SAR) Studies</span></div><div class="casAuthors">Spinelli, Francesco; Capparelli, Elena; Abate, Carmen; Colabufo, Nicola A.; Contino, Marialessandra</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">9913-9931</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Up-regulation of CB2R on activated microglial cells, the first step in neurodegeneration, has been widely demonstrated, and this finding makes the receptor a promising target in the early diagnosis and treatment of several neurodegenerative disorders such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and multiple sclerosis (MS).  The development of CB2R PET ligands could help demonstrate the neurodegenerative pathogenesis, thus providing useful tools for characterizing the role of neuroinflammation in the progression of these disorders.  CB2R agonists and inverse agonists have emerged as neuroprotective agents and CB2R agonists have entered several clin. trials.  CB2R ligands have therefore received great attention and different mol. scaffolds have been selected to target CB2R subtypes.  This perspective is focused on structure-activity relationship (SAR) and structure-affinity relationship (SAfiR) studies performed on different scaffolds with the aim to identify the mol. features useful for the design of both therapeutic and diagnostic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy3g8MJz6QjbVg90H21EOLACvtfcHk0ljaVXRedx6KDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpvFeisbY%253D&md5=e4dfd58a0cb94a9d00203a8f32de43f8</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00155&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00155%26sid%3Dliteratum%253Aachs%26aulast%3DSpinelli%26aufirst%3DF.%26aulast%3DCapparelli%26aufirst%3DE.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DContino%26aufirst%3DM.%26atitle%3DPerspectives%2520of%2520Cannabinoid%2520Type%25202%2520Receptor%2520%2528CB2R%2529%2520Ligands%2520in%2520Neurodegenerative%2520Disorders%253A%2520Structure-Affinity%2520Relationship%2520%2528SAfiR%2529%2520and%2520Structure-Activity%2520Relationship%2520%2528SAR%2529%2520Studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D9913%26epage%3D9931%26doi%3D10.1021%2Facs.jmedchem.7b00155" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, P. J.</span></span> <span> </span><span class="NLM_article-title">Editorial: The Canonical and Non-Canonical Endocannabinoid System as a Target in Cancer and Acute and Chronic Pain</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">312</span>, <span class="refDoi"> DOI: 10.3389/fphar.2020.00312</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3389%2Ffphar.2020.00312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=32218737" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BB383otVygtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=312&author=M.+Continoauthor=P.+J.+McCormick&title=Editorial%3A+The+Canonical+and+Non-Canonical+Endocannabinoid+System+as+a+Target+in+Cancer+and+Acute+and+Chronic+Pain&doi=10.3389%2Ffphar.2020.00312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Editorial: The Canonical and Non-Canonical Endocannabinoid System as a Target in Cancer and Acute and Chronic Pain</span></div><div class="casAuthors">Contino Marialessandra; McCormick Peter J</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">312</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR5mM0MqNbBQdts4TFFB11gfW6udTcc2eYelxe-ABVYhbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB383otVygtg%253D%253D&md5=c8e019c9707eb6449c76c17d87ff4e21</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2020.00312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2020.00312%26sid%3Dliteratum%253Aachs%26aulast%3DContino%26aufirst%3DM.%26aulast%3DMcCormick%26aufirst%3DP.%2BJ.%26atitle%3DEditorial%253A%2520The%2520Canonical%2520and%2520Non-Canonical%2520Endocannabinoid%2520System%2520as%2520a%2520Target%2520in%2520Cancer%2520and%2520Acute%2520and%2520Chronic%2520Pain%26jtitle%3DFront.%2520Pharmacol.%26date%3D2020%26volume%3D11%26spage%3D312%26doi%3D10.3389%2Ffphar.2020.00312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Howlett, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breivogel, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Childers, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deadwyler, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hampson, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porrino, L. J.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid Physiology and Pharmacology: 30 Years of Progress</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">358</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2004.07.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.neuropharm.2004.07.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=15464149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotF2htLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=345-358&author=A.+C.+Howlettauthor=C.+S.+Breivogelauthor=S.+R.+Childersauthor=S.+A.+Deadwylerauthor=R.+E.+Hampsonauthor=L.+J.+Porrino&title=Cannabinoid+Physiology+and+Pharmacology%3A+30+Years+of+Progress&doi=10.1016%2Fj.neuropharm.2004.07.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid physiology and pharmacology: 30 years of progress</span></div><div class="casAuthors">Howlett, Allyn C.; Breivogel, Christopher S.; Childers, Steven R.; Deadwyler, Samuel A.; Hampson, Robert E.; Porrino, Linda J.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">Suppl. 1</span>),
    <span class="NLM_cas:pages">345-358</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Δ9-Tetrahydrocannabinol from Cannabis sativa is mimicked by cannabimimetic analogs such as CP55940 and WIN55212-2, and antagonized by rimonabant and SR144528, through G-protein-coupled receptors, CB1 in the brain, and CB2 in the immune system.  Eicosanoids anandamide and 2-arachidonoylglycerol are the "endocannabinoid" agonists for these receptors.  CB1 receptors are abundant in basal ganglia, hippocampus and cerebellum, and their functional activity can be mapped during behaviors using cerebral metab. as the neuroimaging tool.  CB1 receptors couple to Gi/o to inhibit cAMP prodn., decrease Ca2+ conductance, increase K+ conductance, and increase mitogen-activated protein kinase activity.  Functional activation of G-proteins can be imaged by [35S]GTPγS autoradiog.  Post-synaptically generated endocannabinoids form the basis of a retrograde signaling mechanism referred to as depolarization-induced suppression of inhibition (DSI) or excitation (DSE).  Under circumstances of sufficient intracellular Ca2+ (e.g., burst activity in seizures), synthesis of endocannabinoids releases a diffusible retrograde messenger to stimulate presynaptic CB1 receptors.  This results in suppression of γ-aminobutyric acid (GABA) release, thereby relieving the post-synaptic inhibition.  Tolerance develops as neurons adjust both receptor no. and cellular signal transduction to the chronic administration of cannabinoid drugs.  Future therapeutic drug design can progress based upon our current understanding of the physiol. and pharmacol. of CB1, CB2 and related receptors.  One very important role for CB1 antagonists will be in the treatment of craving in the disease of substance abuse.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrK3XofJxHGFrVg90H21EOLACvtfcHk0lhxXZRN-gtDnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotF2htLw%253D&md5=33ee30df65c515d46caf49203ab885e9</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2004.07.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2004.07.030%26sid%3Dliteratum%253Aachs%26aulast%3DHowlett%26aufirst%3DA.%2BC.%26aulast%3DBreivogel%26aufirst%3DC.%2BS.%26aulast%3DChilders%26aufirst%3DS.%2BR.%26aulast%3DDeadwyler%26aufirst%3DS.%2BA.%26aulast%3DHampson%26aufirst%3DR.%2BE.%26aulast%3DPorrino%26aufirst%3DL.%2BJ.%26atitle%3DCannabinoid%2520Physiology%2520and%2520Pharmacology%253A%252030%2520Years%2520of%2520Progress%26jtitle%3DNeuropharmacology%26date%3D2004%26volume%3D47%26spage%3D345%26epage%3D358%26doi%3D10.1016%2Fj.neuropharm.2004.07.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Turcotte, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanchet, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laviolette, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flamand, N.</span></span> <span> </span><span class="NLM_article-title">The CB2 receptor and Its Role as a Regulator of Inflammation</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">4449</span>– <span class="NLM_lpage">4470</span>, <span class="refDoi"> DOI: 10.1007/s00018-016-2300-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1007%2Fs00018-016-2300-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=27402121" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFCrtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2016&pages=4449-4470&author=C.+Turcotteauthor=M.+R.+Blanchetauthor=M.+Lavioletteauthor=N.+Flamand&title=The+CB2+receptor+and+Its+Role+as+a+Regulator+of+Inflammation&doi=10.1007%2Fs00018-016-2300-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The CB2 receptor and its role as a regulator of inflammation</span></div><div class="casAuthors">Turcotte, Caroline; Blanchet, Marie-Renee; Laviolette, Michel; Flamand, Nicolas</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4449-4470</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">The CB2 receptor is the peripheral receptor for cannabinoids.  It is mainly expressed in immune tissues, highlighting the possibility that the endocannabinoid system has an immunomodulatory role.  In this respect, the CB2 receptor was shown to modulate immune cell functions, both in cellulo and in animal models of inflammatory diseases.  In this regard, numerous studies have reported that mice lacking the CB2 receptor have an exacerbated inflammatory phenotype.  This suggests that therapeutic strategies aiming at modulating CB2 signaling could be promising for the treatment of various inflammatory conditions.  Herein, we review the pharmacol. of the CB2 receptor, its expression pattern, and the signaling pathways induced by its activation.  We next examine the regulation of immune cell functions by the CB2 receptor and the evidence obtained from primary human cells, immortalized cell lines, and animal models of inflammation.  Finally, we discuss the possible therapies targeting the CB2 receptor and the questions that remain to be addressed to det. whether this receptor could be a potential target to treat inflammatory disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqa70FJsUK5IbVg90H21EOLACvtfcHk0lhxXZRN-gtDnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFCrtLrN&md5=572eaca44428863b1c69dde0bca87662</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1007%2Fs00018-016-2300-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-016-2300-4%26sid%3Dliteratum%253Aachs%26aulast%3DTurcotte%26aufirst%3DC.%26aulast%3DBlanchet%26aufirst%3DM.%2BR.%26aulast%3DLaviolette%26aufirst%3DM.%26aulast%3DFlamand%26aufirst%3DN.%26atitle%3DThe%2520CB2%2520receptor%2520and%2520Its%2520Role%2520as%2520a%2520Regulator%2520of%2520Inflammation%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2016%26volume%3D73%26spage%3D4449%26epage%3D4470%26doi%3D10.1007%2Fs00018-016-2300-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cabral, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raborn, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marciano-Cabral, F.</span></span> <span> </span><span class="NLM_article-title">CB2 Receptors in the Brain: Role in Central Immune Function</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>153</i></span>,  <span class="NLM_fpage">240</span>– <span class="NLM_lpage">251</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0707584</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fsj.bjp.0707584" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=18037916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovFCltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=153&publication_year=2008&pages=240-251&author=G.+A.+Cabralauthor=E.+S.+Rabornauthor=L.+Griffinauthor=J.+Dennisauthor=F.+Marciano-Cabral&title=CB2+Receptors+in+the+Brain%3A+Role+in+Central+Immune+Function&doi=10.1038%2Fsj.bjp.0707584"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">CB2 receptors in the brain: role in central immune function</span></div><div class="casAuthors">Cabral, G. A.; Raborn, E. S.; Griffin, L.; Dennis, J.; Marciano-Cabral, F.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">153</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">240-251</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Recently, it has been recognized that the cannabinoid receptor CB2 may play a functionally relevant role in the central nervous system (CNS).  This role is mediated primarily through microglia, a resident population of cells in the CNS that is morphol., phenotypically, and functionally related to macrophages.  These cells also express the cannabinoid receptor CB1.  The CB1 receptor (CB1R) is constitutively expressed at low levels while the CB2 receptor (CB2R) is expressed at higher levels and is modulated in relation to cell activation state.  The relatively high levels of the CB2R correspond with microglia being in responsive' and primed' states, suggesting the existence of a window' of functional relevance during which activation of the CB2R modulates microglial activities.  Signature activities of responsive' and primed' microglia are chemotaxis and antigen processing, resp.  The endocannabinoid 2-arachidonylglycerol has been reported to stimulate a chemotactic response from these cells through the CB2R.  In contrast, we have shown in vivo and in vitro that the exogenous cannabinoids delta-9-tetrahydrocannabinol and CP55940 inhibit the chemotactic response of microglia to Acanthamoeba culbertsoni, an opportunistic pathogen that is the causative agent of Granulomatous Amoebic Encephalitis, through activation of the CB2R.  It is postulated that these exogenous cannabinoids superimpose an inhibitory effect on pro-chemotactic endocannabinoids that are elicited in response to Acanthamoeba.  Furthermore, the collective results suggest that the CB2R plays a crit. immune functional role in the CNS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtGbYSu3oih7Vg90H21EOLACvtfcHk0lhy1EzTe2FZhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovFCltw%253D%253D&md5=c6b41ff809a36b2b29b327cd9e9f0e68</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0707584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0707584%26sid%3Dliteratum%253Aachs%26aulast%3DCabral%26aufirst%3DG.%2BA.%26aulast%3DRaborn%26aufirst%3DE.%2BS.%26aulast%3DGriffin%26aufirst%3DL.%26aulast%3DDennis%26aufirst%3DJ.%26aulast%3DMarciano-Cabral%26aufirst%3DF.%26atitle%3DCB2%2520Receptors%2520in%2520the%2520Brain%253A%2520Role%2520in%2520Central%2520Immune%2520Function%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D153%26spage%3D240%26epage%3D251%26doi%3D10.1038%2Fsj.bjp.0707584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heneka, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kummer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Latz, E.</span></span> <span> </span><span class="NLM_article-title">Innate Immune Activation in Neurodegenerative Disease</span>. <i>Nat. Rev. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">463</span>– <span class="NLM_lpage">477</span>, <span class="refDoi"> DOI: 10.1038/nri3705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fnri3705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=24962261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVemu7zJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=463-477&author=M.+T.+Henekaauthor=M.+P.+Kummerauthor=E.+Latz&title=Innate+Immune+Activation+in+Neurodegenerative+Disease&doi=10.1038%2Fnri3705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Innate immune activation in neurodegenerative disease</span></div><div class="casAuthors">Heneka, Michael T.; Kummer, Markus P.; Latz, Eicke</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">463-477</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The triggering of innate immune mechanisms is emerging as a crucial component of major neurodegenerative diseases.  Microglia and other cell types in the brain can be activated in response to misfolded proteins or aberrantly localized nucleic acids.  This diverts microglia from their physiol. and beneficial functions, and leads to their sustained release of pro-inflammatory mediators.  In this Review, we discuss how the activation of innate immune signalling pathways - in particular, the NOD-, LRR- and pyrin domain-contg. 3 (NLRP3) inflammasome - by aberrant host proteins may be a common step in the development of diverse neurodegenerative disorders.  During chronic activation of microglia, the sustained exposure of neurons to pro-inflammatory mediators can cause neuronal dysfunction and contribute to cell death.  As chronic neuroinflammation is obsd. at relatively early stages of neurodegenerative disease, targeting the mechanisms that drive this process may be useful for diagnostic and therapeutic purposes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3f5cVxCKo5bVg90H21EOLACvtfcHk0lhy1EzTe2FZhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVemu7zJ&md5=9050d14e40248997e8c9dd567a1c59b8</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fnri3705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri3705%26sid%3Dliteratum%253Aachs%26aulast%3DHeneka%26aufirst%3DM.%2BT.%26aulast%3DKummer%26aufirst%3DM.%2BP.%26aulast%3DLatz%26aufirst%3DE.%26atitle%3DInnate%2520Immune%2520Activation%2520in%2520Neurodegenerative%2520Disease%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2014%26volume%3D14%26spage%3D463%26epage%3D477%26doi%3D10.1038%2Fnri3705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McGeer, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGeer, E.</span></span> <span> </span><span class="NLM_article-title">Conquering Alzheimer’s Disease by Self Treatment</span>. <i>J. Alzheimer's Dis.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">S361</span>– <span class="NLM_lpage">S363</span>, <span class="refDoi"> DOI: 10.3233/JAD-179913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3233%2FJAD-179913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=29562519" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2018&pages=S361-S363&author=P.+L.+McGeerauthor=E.+McGeer&title=Conquering+Alzheimer%E2%80%99s+Disease+by+Self+Treatment&doi=10.3233%2FJAD-179913"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.3233%2FJAD-179913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-179913%26sid%3Dliteratum%253Aachs%26aulast%3DMcGeer%26aufirst%3DP.%2BL.%26aulast%3DMcGeer%26aufirst%3DE.%26atitle%3DConquering%2520Alzheimer%25E2%2580%2599s%2520Disease%2520by%2520Self%2520Treatment%26jtitle%3DJ.%2520Alzheimer%2527s%2520Dis.%26date%3D2018%26volume%3D64%26spage%3DS361%26epage%3DS363%26doi%3D10.3233%2FJAD-179913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cassano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calcagnini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pace, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Marco, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaetani, S.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target</span>. <i>Front. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">30</span>, <span class="refDoi"> DOI: 10.3389/fnins.2017.00030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3389%2Ffnins.2017.00030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=28210207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BC1c3nvV2msA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2017&pages=30&author=T.+Cassanoauthor=S.+Calcagniniauthor=L.+Paceauthor=F.+De+Marcoauthor=A.+Romanoauthor=S.+Gaetani&title=Cannabinoid+Receptor+2+Signaling+in+Neurodegenerative+Disorders%3A+From+Pathogenesis+to+a+Promising+Therapeutic+Target&doi=10.3389%2Ffnins.2017.00030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target</span></div><div class="casAuthors">Cassano Tommaso; Pace Lorenzo; Calcagnini Silvio; Romano Adele; Gaetani Silvana; De Marco Federico</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">30</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">As a consequence of an increasingly aging population, the number of people affected by neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease and Huntington's disease, is rapidly increasing.  Although the etiology of these diseases has not been completely defined, common molecular mechanisms including neuroinflammation, excitotoxicity and mitochondrial dysfunction have been confirmed and can be targeted therapeutically.  Moreover, recent studies have shown that endogenous cannabinoid signaling plays a number of modulatory roles throughout the central nervous system (CNS), including the neuroinflammation and neurogenesis.  In particular, the up-regulation of type-2 cannabinoid (CB2) receptors has been found in a number of neurodegenerative disorders.  Thus, the modulation of CB2 receptor signaling may represent a promising therapeutic target with minimal psychotropic effects that can be used to modulate endocannabinoid-based therapeutic approaches and to reduce neuronal degeneration.  For these reasons this review will focus on the CB2 receptor as a promising pharmacological target in a number of neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT1_cRDLQozygqdek-gHSrIfW6udTcc2ebnHtXHadgWrbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1c3nvV2msA%253D%253D&md5=138c88d7d465474f6f6a067fd6d0ffe9</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2017.00030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2017.00030%26sid%3Dliteratum%253Aachs%26aulast%3DCassano%26aufirst%3DT.%26aulast%3DCalcagnini%26aufirst%3DS.%26aulast%3DPace%26aufirst%3DL.%26aulast%3DDe%2BMarco%26aufirst%3DF.%26aulast%3DRomano%26aufirst%3DA.%26aulast%3DGaetani%26aufirst%3DS.%26atitle%3DCannabinoid%2520Receptor%25202%2520Signaling%2520in%2520Neurodegenerative%2520Disorders%253A%2520From%2520Pathogenesis%2520to%2520a%2520Promising%2520Therapeutic%2520Target%26jtitle%3DFront.%2520Neurosci.%26date%3D2017%26volume%3D11%26spage%3D30%26doi%3D10.3389%2Ffnins.2017.00030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cabral, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin-Thomas, L.</span></span> <span> </span><span class="NLM_article-title">Emerging Role of the Cannabinoid Receptor CB2 in Immune Regulation: Therapeutic Prospects for Neuroinflammation</span>. <i>Expert Rev. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">e3</span> <span class="refDoi"> DOI: 10.1017/S1462399409000957</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1017%2FS1462399409000957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=19152719" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&author=G.+A.+Cabralauthor=L.+Griffin-Thomas&title=Emerging+Role+of+the+Cannabinoid+Receptor+CB2+in+Immune+Regulation%3A+Therapeutic+Prospects+for+Neuroinflammation&doi=10.1017%2FS1462399409000957"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1017%2FS1462399409000957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1462399409000957%26sid%3Dliteratum%253Aachs%26aulast%3DCabral%26aufirst%3DG.%2BA.%26aulast%3DGriffin-Thomas%26aufirst%3DL.%26atitle%3DEmerging%2520Role%2520of%2520the%2520Cannabinoid%2520Receptor%2520CB2%2520in%2520Immune%2520Regulation%253A%2520Therapeutic%2520Prospects%2520for%2520Neuroinflammation%26jtitle%3DExpert%2520Rev.%2520Mol.%2520Med.%26date%3D2009%26volume%3D11%26doi%3D10.1017%2FS1462399409000957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krivokuca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casado, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canela, E.</span></span> <span> </span><span class="NLM_article-title">The Endocannabinoid System as a Target in Cancer Diseases: Are We There Yet?</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">339</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.00339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3389%2Ffphar.2019.00339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=31024307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVGlsLfO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=339&author=E.+Morenoauthor=M.+Cavicauthor=A.+Krivokucaauthor=V.+Casadoauthor=E.+Canela&title=The+Endocannabinoid+System+as+a+Target+in+Cancer+Diseases%3A+Are+We+There+Yet%3F&doi=10.3389%2Ffphar.2019.00339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">The endocannabinoid system as a target in cancer diseases: are we there yet?</span></div><div class="casAuthors">Moreno, Estefania; Cavic, Milena; Krivokuca, Ana; Casado, Vicent; Canela, Enric</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">339</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  The endocannabinoid system (ECS) has been placed in the anti-cancer spotlight in the last decade.  The immense data load published on its dual role in both tumorigenesis and inhibition of tumor growth and metastatic spread has transformed the cannabinoid receptors CB1 (CB1R) and CB2 (CB2R), and other members of the endocannabinoid-like system, into attractive new targets for the treatment of various cancer subtypes.  Although the clin. use of cannabinoids has been extensively documented in the palliative setting, clin. trials on their application as anti-cancer drugs are still ongoing.  As drug repurposing is significantly faster and more economical than de novo introduction of a new drug into the clinic, there is hope that the existing pharmacokinetic and safety data on the ECS ligands will contribute to their successful translation into oncol. healthcare.  CB1R and CB2R are members of a large family of membrane proteins called G protein-coupled receptors (GPCR).  GPCRs can form homodimers, heterodimers and higher order oligomers with other GPCRs or non-GPCRs.  Currently, several CB1R and CB2R-contg. heteromers have been reported and, in cancer cells, CB2R form heteromers with the G protein-coupled chemokine receptor CXCR4, the G protein-coupled receptor 55 (GPR55) and the tyrosine kinase receptor (TKR) human V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2).  These protein complexes possess unique pharmacol. and signaling properties, and their modulation might affect the antitumoral activity of the ECS.  This review will explore the potential of the endocannabinoid network in the anti-cancer setting as well as the clin. and ethical pitfalls behind it, and will develop on the value of cannabinoid receptor heteromers as potential new targets for anti-cancer therapies and as prognostic biomarkers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLnxgEkYRlV7Vg90H21EOLACvtfcHk0ljmFo1d6-vSzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVGlsLfO&md5=799d02287d5c179eba3e7cd79857667a</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.00339%26sid%3Dliteratum%253Aachs%26aulast%3DMoreno%26aufirst%3DE.%26aulast%3DCavic%26aufirst%3DM.%26aulast%3DKrivokuca%26aufirst%3DA.%26aulast%3DCasado%26aufirst%3DV.%26aulast%3DCanela%26aufirst%3DE.%26atitle%3DThe%2520Endocannabinoid%2520System%2520as%2520a%2520Target%2520in%2520Cancer%2520Diseases%253A%2520Are%2520We%2520There%2520Yet%253F%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D339%26doi%3D10.3389%2Ffphar.2019.00339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Capozzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattei, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martellucci, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manganelli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccomanni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garofalo, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorice, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misasi, R.</span></span> <span> </span><span class="NLM_article-title">Anti-Proliferative Properties and Proapoptotic Function of New CB2 Selective Cannabinoid Receptor Agonist in Jurkat Leukemia Cells</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1958</span>, <span class="refDoi"> DOI: 10.3390/ijms19071958</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3390%2Fijms19071958" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFKlt7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=1958&author=A.+Capozziauthor=V.+Matteiauthor=S.+Martellucciauthor=V.+Manganelliauthor=G.+Saccomanniauthor=T.+Garofaloauthor=M.+Soriceauthor=C.+Maneraauthor=R.+Misasi&title=Anti-Proliferative+Properties+and+Proapoptotic+Function+of+New+CB2+Selective+Cannabinoid+Receptor+Agonist+in+Jurkat+Leukemia+Cells&doi=10.3390%2Fijms19071958"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-proliferative properties and proapoptotic function of new CB2 selective cannabinoid receptor agonist in Jurkat leukemia cells</span></div><div class="casAuthors">Capozzi, Antonella; Mattei, Vincenzo; Martellucci, Stefano; Manganelli, Valeria; Saccomanni, Giuseppe; Garofalo, Tina; Sorice, Maurizio; Manera, Clementina; Misasi, Roberta</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1958/1-1958/20</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Several studies demonstrated that cannabinoids reduce tumor growth, inhibit angiogenesis, and decrease cancer cell migration.  As these mols. are well tolerated, it would be interesting to investigate the potential benefit of newly synthesized compds., binding cannabinoid receptors (CBRs).  In this study, we describe the synthesis and biol. effect of 2-oxo-1,8-naphthyridine-3-carboxamide deriv. LV50, a new compd. with high CB2 receptor (CB2R) affinity.  We demonstrated that it decreases viability of Jurkat leukemia cells, evaluated by Trypan Blue and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), but mainly induces a proapoptotic effect.  We obsd. an increase of a hypodiploid peak by propidium iodide staining and changes in nuclear morphol. by Hoechst 33258.  These data were confirmed by a significant increase of Annexin V staining, cleavage of the nuclear enzyme poly(ADP-ribose)-polymerase (PARP), and caspases activation.  In addn., in order to exclude that LV50 non-specifically triggers death of all normal leukocytes, we tested the new compd. on normal peripheral blood lymphocytes, excluding the idea of general cytotoxicity.  To characterize the involvement of CB2R in the anti-proliferative and proapoptotic effect of LV50, cells were pretreated with a specific CB2R antagonist and the obtained data showed reverse results.  Thus, we suggest a link between inhibition of cell survival and proapoptotic activity of the new compd. that elicits this effect as selective CB2R agonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1FtJUxLHRiLVg90H21EOLACvtfcHk0ljmFo1d6-vSzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFKlt7rM&md5=48bdbd3800b0a643fabb36f62178eaf0</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.3390%2Fijms19071958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms19071958%26sid%3Dliteratum%253Aachs%26aulast%3DCapozzi%26aufirst%3DA.%26aulast%3DMattei%26aufirst%3DV.%26aulast%3DMartellucci%26aufirst%3DS.%26aulast%3DManganelli%26aufirst%3DV.%26aulast%3DSaccomanni%26aufirst%3DG.%26aulast%3DGarofalo%26aufirst%3DT.%26aulast%3DSorice%26aufirst%3DM.%26aulast%3DManera%26aufirst%3DC.%26aulast%3DMisasi%26aufirst%3DR.%26atitle%3DAnti-Proliferative%2520Properties%2520and%2520Proapoptotic%2520Function%2520of%2520New%2520CB2%2520Selective%2520Cannabinoid%2520Receptor%2520Agonist%2520in%2520Jurkat%2520Leukemia%2520Cells%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2018%26volume%3D19%26spage%3D1958%26doi%3D10.3390%2Fijms19071958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guindon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hohmann, A. G.</span></span> <span> </span><span class="NLM_article-title">The Endocannabinoid System and Cancer: Therapeutic Implication</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>163</i></span>,  <span class="NLM_fpage">1447</span>– <span class="NLM_lpage">1463</span>, <span class="refDoi"> DOI: 10.1111/j.1476-5381.2011.01327.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1111%2Fj.1476-5381.2011.01327.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=21410463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3MXps1Sju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2011&pages=1447-1463&author=J.+Guindonauthor=A.+G.+Hohmann&title=The+Endocannabinoid+System+and+Cancer%3A+Therapeutic+Implication&doi=10.1111%2Fj.1476-5381.2011.01327.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">The endocannabinoid system and cancer: therapeutic implication</span></div><div class="casAuthors">Guindon, Josee; Hohmann, Andrea G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1447-1463</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  The endocannabinoid system is implicated in a variety of physiol. and pathol. conditions (inflammation, immunomodulation, analgesia, cancer and others).  The main active ingredient of cannabis, Δ9-tetrahydrocannabinol (Δ9-THC), produces its effects through activation of CB1 and CB2 receptors.  CB1 receptors are expressed at high levels in the central nervous system (CNS), whereas CB2 receptors are concd. predominantly, although not exclusively, in cells of the immune system.  Endocannabinoids are endogenous lipid-signaling mols. that are generated in the cell membrane from phospholipid precursors.  The 2 best characterized endocannabinoids identified to date are anandamide (AEA) and 2-arachidonoylglycerol (2-AG).  Here we review the relationship between the endocannabinoid system and anti-tumor actions (inhibition of cell proliferation and migration, induction of apoptosis, redn. of tumor growth) of the cannabinoids in different types of cancer.  This review will focus on examg. how activation of the endocannabinoid system impacts breast, prostate and bone cancers in both in vitro and in vivo systems.  The therapeutic potential of cannabinoids for cancer, as identified in clin. trials, is also discussed.  Identification of safe and effective treatments to manage and improve cancer therapy is crit. to improve quality of life and reduce unnecessary suffering in cancer patients.  In this regard, cannabis-like compds. offer therapeutic potential for the treatment of breast, prostate and bone cancer in patients.  Further basic research on anti-cancer properties of cannabinoids as well as clin. trials of cannabinoid therapeutic efficacy in breast, prostate and bone cancer is therefore warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_omB4D6NVN7Vg90H21EOLACvtfcHk0ljX6zuZrUnyag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXps1Sju7g%253D&md5=fb5ec332b401d12e51c229d291c1909d</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1111%2Fj.1476-5381.2011.01327.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1476-5381.2011.01327.x%26sid%3Dliteratum%253Aachs%26aulast%3DGuindon%26aufirst%3DJ.%26aulast%3DHohmann%26aufirst%3DA.%2BG.%26atitle%3DThe%2520Endocannabinoid%2520System%2520and%2520Cancer%253A%2520Therapeutic%2520Implication%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2011%26volume%3D163%26spage%3D1447%26epage%3D1463%26doi%3D10.1111%2Fj.1476-5381.2011.01327.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guzman, M.</span></span> <span> </span><span class="NLM_article-title">Anticancer Mechanisms of Cannabinoids</span>. <i>Curr. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">S23</span>– <span class="NLM_lpage">S32</span>, <span class="refDoi"> DOI: 10.3747/co.23.3080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3747%2Fco.23.3080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=27022311" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2016&pages=S23-S32&author=G.+Velascoauthor=C.+Sanchezauthor=M.+Guzman&title=Anticancer+Mechanisms+of+Cannabinoids&doi=10.3747%2Fco.23.3080"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.3747%2Fco.23.3080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3747%252Fco.23.3080%26sid%3Dliteratum%253Aachs%26aulast%3DVelasco%26aufirst%3DG.%26aulast%3DSanchez%26aufirst%3DC.%26aulast%3DGuzman%26aufirst%3DM.%26atitle%3DAnticancer%2520Mechanisms%2520of%2520Cannabinoids%26jtitle%3DCurr.%2520Oncol.%26date%3D2016%26volume%3D23%26spage%3DS23%26epage%3DS32%26doi%3D10.3747%2Fco.23.3080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aso, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, I.</span></span> <span> </span><span class="NLM_article-title">CB2 Cannabinoid Receptor As Potential Target against Alzheimer’s Disease</span>. <i>Front. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">243</span>, <span class="refDoi"> DOI: 10.3389/fnins.2016.00243</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3389%2Ffnins.2016.00243" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=27303261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BC2s7gtlGktA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=243&author=E.+Asoauthor=I.+Ferrer&title=CB2+Cannabinoid+Receptor+As+Potential+Target+against+Alzheimer%E2%80%99s+Disease&doi=10.3389%2Ffnins.2016.00243"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">CB2 Cannabinoid Receptor As Potential Target against Alzheimer's Disease</span></div><div class="casAuthors">Aso Ester; Ferrer Isidro</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">243</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">The CB2 receptor is one of the components of the endogenous cannabinoid system, a complex network of signaling molecules and receptors involved in the homeostatic control of several physiological functions.  Accumulated evidence suggests a role for CB2 receptors in Alzheimer's disease (AD) and indicates their potential as a therapeutic target against this neurodegenerative disease.  Levels of CB2 receptors are significantly increased in post-mortem AD brains, mainly in microglia surrounding senile plaques, and their expression levels correlate with the amounts of Aβ42 and β-amyloid plaque deposition.  Moreover, several studies on animal models of AD have demonstrated that specific CB2 receptor agonists, which are devoid of psychoactive effects, reduce AD-like pathology, resulting in attenuation of the inflammation associated with the disease but also modulating Aβ and tau aberrant processing, among other effects.  CB2 receptor activation also improves cognitive impairment in animal models of AD.  This review discusses available data regarding the role of CB2 receptors in AD and the potential usefulness of specific agonists of these receptors against AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQFAQnNocm8nuWhZTslLrfffW6udTcc2eb_8pthqZvUbLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2s7gtlGktA%253D%253D&md5=b3065b406c0d13c0f6493ddf33f3018a</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2016.00243&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2016.00243%26sid%3Dliteratum%253Aachs%26aulast%3DAso%26aufirst%3DE.%26aulast%3DFerrer%26aufirst%3DI.%26atitle%3DCB2%2520Cannabinoid%2520Receptor%2520As%2520Potential%2520Target%2520against%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DFront.%2520Neurosci.%26date%3D2016%26volume%3D10%26spage%3D243%26doi%3D10.3389%2Ffnins.2016.00243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aso, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, I.</span></span> <span> </span><span class="NLM_article-title">Cannabinoids for Treatment of Alzheimer’s Disease: Moving toward the Clinic</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">37</span>, <span class="refDoi"> DOI: 10.3389/fphar.2014.00037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3389%2Ffphar.2014.00037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=24634659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BC2cflslSltg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=37&author=E.+Asoauthor=I.+Ferrer&title=Cannabinoids+for+Treatment+of+Alzheimer%E2%80%99s+Disease%3A+Moving+toward+the+Clinic&doi=10.3389%2Ffphar.2014.00037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic</span></div><div class="casAuthors">Aso Ester; Ferrer Isidre</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">37</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">The limited effectiveness of current therapies against Alzheimer's disease (AD) highlights the need for intensifying research efforts devoted to developing new agents for preventing or retarding the disease process.  During the last few years, targeting the endogenous cannabinoid system has emerged as a potential therapeutic approach to treat Alzheimer.  The endocannabinoid system is composed by a number of cannabinoid receptors, including the well-characterized CB1 and CB2 receptors, with their endogenous ligands and the enzymes related to the synthesis and degradation of these endocannabinoid compounds.  Several findings indicate that the activation of both CB1 and CB2 receptors by natural or synthetic agonists, at non-psychoactive doses, have beneficial effects in Alzheimer experimental models by reducing the harmful β-amyloid peptide action and tau phosphorylation, as well as by promoting the brain's intrinsic repair mechanisms.  Moreover, endocannabinoid signaling has been demonstrated to modulate numerous concomitant pathological processes, including neuroinflammation, excitotoxicity, mitochondrial dysfunction, and oxidative stress.  The present paper summarizes the main experimental studies demonstrating the polyvalent properties of cannabinoid compounds for the treatment of AD, which together encourage progress toward a clinical trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQCYty_MiAZP50d-O_J5C0AfW6udTcc2eb_8pthqZvUbLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflslSltg%253D%253D&md5=18ab4f10157b9f6be7cf343ed9c3bde5</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2014.00037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2014.00037%26sid%3Dliteratum%253Aachs%26aulast%3DAso%26aufirst%3DE.%26aulast%3DFerrer%26aufirst%3DI.%26atitle%3DCannabinoids%2520for%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%253A%2520Moving%2520toward%2520the%2520Clinic%26jtitle%3DFront.%2520Pharmacol.%26date%3D2014%26volume%3D5%26spage%3D37%26doi%3D10.3389%2Ffphar.2014.00037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bie, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naguib, M.</span></span> <span> </span><span class="NLM_article-title">Activation of the CB2 Receptor System Reverses Amyloid-Induced Memory Deficiency</span>. <i>Neurobiol. Aging</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">791</span>– <span class="NLM_lpage">804</span>, <span class="refDoi"> DOI: 10.1016/j.neurobiolaging.2012.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.neurobiolaging.2012.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=22795792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVektLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=791-804&author=J.+Wuauthor=B.+Bieauthor=H.+Yangauthor=J.+J.+Xuauthor=D.+L.+Brownauthor=M.+Naguib&title=Activation+of+the+CB2+Receptor+System+Reverses+Amyloid-Induced+Memory+Deficiency&doi=10.1016%2Fj.neurobiolaging.2012.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the CB2 receptor system reverses amyloid-induced memory deficiency</span></div><div class="casAuthors">Wu, Jiang; Bie, Bihua; Yang, Hui; Xu, Jijun J.; Brown, David L.; Naguib, Mohamed</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Aging</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">791-804</span>CODEN:
                <span class="NLM_cas:coden">NEAGDO</span>;
        ISSN:<span class="NLM_cas:issn">0197-4580</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Cannabinoid type 2 (CB2) agonists are neuroprotective and appear to play modulatory roles in neurodegenerative processes in Alzheimer's disease.  We have studied the effect of 1-((3-benzyl-3-methyl-2,3-dihydro-1-benzofuran-6-yl) carbonyl) piperidine (MDA7)-a novel selective CB2 agonist that lacks psychoactivity-on ameliorating the neuroinflammatory process, synaptic dysfunction, and cognitive impairment induced by bilateral microinjection of amyloid-β (Aβ)1-40 fibrils into the hippocampal CA1 area of rats.  In rats injected with Aβ1-40 fibrils, compared with the administration of i.p. saline for 14 days, treatment with 15 mg/kg of i.p. MDA7 daily for 14 days (1) ameliorated the expression of CD11b (microglia marker) and glial fibrillary acidic protein (astrocyte marker), (2) decreased the secretion of interleukin-1β, (3) decreased the upsurge of CB2 receptors, (4) promoted Aβ clearance, and (5) restored synaptic plasticity, cognition, and memory.  Our findings suggest that MDA7 is an innovative therapeutic approach for the treatment of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqekBBhIM0ej7Vg90H21EOLACvtfcHk0ljbTOpp3H2Jww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVektLnO&md5=ee0c45a830bc6f4d2236ccfcee75b2ad</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.neurobiolaging.2012.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neurobiolaging.2012.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DBie%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DJ.%2BJ.%26aulast%3DBrown%26aufirst%3DD.%2BL.%26aulast%3DNaguib%26aufirst%3DM.%26atitle%3DActivation%2520of%2520the%2520CB2%2520Receptor%2520System%2520Reverses%2520Amyloid-Induced%2520Memory%2520Deficiency%26jtitle%3DNeurobiol.%2520Aging%26date%3D2013%26volume%3D34%26spage%3D791%26epage%3D804%26doi%3D10.1016%2Fj.neurobiolaging.2012.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Concannon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dowd, E.</span></span> <span> </span><span class="NLM_article-title">Cannabinoids in Parkinson’s Disease</span>. <i>Cannabinoids Neurol. Ment. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1016/B978-0-12-417041-4.00003-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2FB978-0-12-417041-4.00003-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2015&pages=35-59&author=R.+Concannonauthor=D.+P.+Finnauthor=E.+Dowd&title=Cannabinoids+in+Parkinson%E2%80%99s+Disease&doi=10.1016%2FB978-0-12-417041-4.00003-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-417041-4.00003-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-417041-4.00003-5%26sid%3Dliteratum%253Aachs%26aulast%3DConcannon%26aufirst%3DR.%26aulast%3DFinn%26aufirst%3DD.%2BP.%26aulast%3DDowd%26aufirst%3DE.%26atitle%3DCannabinoids%2520in%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DCannabinoids%2520Neurol.%2520Ment.%2520Dis.%26date%3D2015%26volume%3D2%26spage%3D35%26epage%3D59%26doi%3D10.1016%2FB978-0-12-417041-4.00003-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seely, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crow, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prather, P. L.</span></span> <span> </span><span class="NLM_article-title">The CB2 Cannabinoid Agonist AM-1241 Prolongs Survival in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis When Initiated at Symptom Onset</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">98</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2006.04346.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1111%2Fj.1471-4159.2006.04346.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=17241118" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksFSqsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2007&pages=87-98&author=J.+L.+Shoemakerauthor=K.+A.+Seelyauthor=R.+L.+Reedauthor=J.+P.+Crowauthor=P.+L.+Prather&title=The+CB2+Cannabinoid+Agonist+AM-1241+Prolongs+Survival+in+a+Transgenic+Mouse+Model+of+Amyotrophic+Lateral+Sclerosis+When+Initiated+at+Symptom+Onset&doi=10.1111%2Fj.1471-4159.2006.04346.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset</span></div><div class="casAuthors">Shoemaker, Jennifer L.; Seely, Kathryn A.; Reed, Ronald L.; Crow, John P.; Prather, Paul L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-98</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive motor neuron loss, paralysis and death within 2-5 years of diagnosis.  Currently, no effective pharmacol. agents exist for the treatment of this devastating disease.  Neuroinflammation may accelerate the progression of ALS.  Cannabinoids produce anti-inflammatory actions via cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2), and delay the progression of neuroinflammatory diseases.  Addnl., CB2 receptors, which normally exist primarily in the periphery, are dramatically up-regulated in inflamed neural tissues assocd. with CNS disorders.  In G93A-SOD1 mutant mice, the most well-characterized animal model of ALS, endogenous cannabinoids are elevated in spinal cords of symptomatic mice.  Furthermore, treatment with non-selective cannabinoid partial agonists prior to, or upon, symptom appearance minimally delays disease onset and prolongs survival through undefined mechanisms.  We demonstrate that mRNA, receptor binding and function of CB2, but not CB1, receptors are dramatically and selectively up-regulated in spinal cords of G93A-SOD1 mice in a temporal pattern paralleling disease progression.  More importantly, daily injections of the selective CB2 agonist AM-1241, initiated at symptom onset, increase the survival interval after disease onset by 56%.  Therefore, CB2 agonists may slow motor neuron degeneration and preserve motor function, and represent a novel therapeutic modality for treatment of ALS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp0tTHgAMzBILVg90H21EOLACvtfcHk0ljbTOpp3H2Jww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksFSqsb4%253D&md5=3d05001d4f2eb1ae8e10e1986b1d153c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2006.04346.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2006.04346.x%26sid%3Dliteratum%253Aachs%26aulast%3DShoemaker%26aufirst%3DJ.%2BL.%26aulast%3DSeely%26aufirst%3DK.%2BA.%26aulast%3DReed%26aufirst%3DR.%2BL.%26aulast%3DCrow%26aufirst%3DJ.%2BP.%26aulast%3DPrather%26aufirst%3DP.%2BL.%26atitle%3DThe%2520CB2%2520Cannabinoid%2520Agonist%2520AM-1241%2520Prolongs%2520Survival%2520in%2520a%2520Transgenic%2520Mouse%2520Model%2520of%2520Amyotrophic%2520Lateral%2520Sclerosis%2520When%2520Initiated%2520at%2520Symptom%2520Onset%26jtitle%3DJ.%2520Neurochem.%26date%3D2007%26volume%3D101%26spage%3D87%26epage%3D98%26doi%3D10.1111%2Fj.1471-4159.2006.04346.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spinelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giampietro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanachi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riganti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopecka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abatematteo, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangiatordi, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolotti, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brea, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loza, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Infantino, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span> <span> </span><span class="NLM_article-title">Design and Synthesis of Fluorescent Ligands for the Detection of Cannabinoid Type 2 Receptor (CB2R)</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>188</i></span>,  <span class="NLM_fpage">112037</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2020.112037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=31954990" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFCqtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=188&publication_year=2020&pages=112037&author=F.+Spinelliauthor=R.+Giampietroauthor=A.+Stefanachiauthor=C.+Rigantiauthor=J.+Kopeckaauthor=F.+S.+Abatematteoauthor=F.+Leonettiauthor=N.+A.+Colabufoauthor=G.+F.+Mangiatordiauthor=O.+Nicolottiauthor=M.+G.+Perroneauthor=J.+Breaauthor=M.+I.+Lozaauthor=V.+Infantinoauthor=C.+Abateauthor=M.+Contino&title=Design+and+Synthesis+of+Fluorescent+Ligands+for+the+Detection+of+Cannabinoid+Type+2+Receptor+%28CB2R%29&doi=10.1016%2Fj.ejmech.2020.112037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of fluorescent ligands for the detection of cannabinoid type 2 receptor (CB2R)</span></div><div class="casAuthors">Spinelli, Francesco; Giampietro, Roberta; Stefanachi, Angela; Riganti, Chiara; Kopecka, Joanna; Abatematteo, Francesca Serena; Leonetti, Francesco; Colabufo, Nicola Antonio; Mangiatordi, Giuseppe Felice; Nicolotti, Orazio; Perrone, Maria Grazia; Brea, Jose; Loza, Maria Isabel; Infantino, Vittoria; Abate, Carmen; Contino, Marialessandra</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">188</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112037</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The Cannabinoid 2 receptor, CB2R, belonging to the endocannabinoid system, ECS, is involved in the first steps of neurodegeneration and cancer evolution and progression and thus its modulation may be exploited in the therapeutic and diagnostic fields.  However, CB2Rs distribution and signaling pathways in physiol. and pathol. conditions are still controversial mainly because of the lack of reliable diagnostic tools.  With the aim to produce green and safe systems to detect CB2R, we designed a series of fluorescent ligands with three different green fluorescent moieties (4-dimethylaminophthalimide, 4-DMAP, 7-nitro-4-yl-aminobenzoxadiazole, NBD, and Fluorescein-thiourea, FTU) linked to the N1-position of the CB2R pharmacophore N-adamantyl-4-oxo-1,4-dihydroquinoline-3-carboxamide through polymethylene chains.  Compd. 28 emerged for its compromise between good pharmacodynamic properties (CB2R Ki = 130 nM and no affinity vs the other subtype CB1R) and optimal fluorescent spectroscopic properties.  Therefore, compd. 28 was studied through FACS (satn. and competitive binding studies) and fluorescence microscopy (visualization and competitive binding) in engineered cells (CB2R-HEK293 cells) and in diverse tumor cells.  The fluoligand binding assays were successfully set up, and affinity values for the two ref. compds. GW405833 and WIN55,212-2, comparable to the values obtained by radioligand binding assays, were obtained.  Fluoligand 28 also allowed the detection of the presence and quantification of the CB2R in the same cell lines.  The interactions of compd. 28 within the CB2R binding site were also investigated by mol. docking simulations, and indications for the improvement of the CB2R affinity of this class of compds. were provided.  Overall, the results obtained through these studies propose compd. 28 as a safe and green alternative to the commonly used radioligands for in vitro investigations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZMTpwQWQXdrVg90H21EOLACvtfcHk0lgg7V6an4ttkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFCqtbs%253D&md5=6288c692b0e56765fe08b24daadc8ee0</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112037%26sid%3Dliteratum%253Aachs%26aulast%3DSpinelli%26aufirst%3DF.%26aulast%3DGiampietro%26aufirst%3DR.%26aulast%3DStefanachi%26aufirst%3DA.%26aulast%3DRiganti%26aufirst%3DC.%26aulast%3DKopecka%26aufirst%3DJ.%26aulast%3DAbatematteo%26aufirst%3DF.%2BS.%26aulast%3DLeonetti%26aufirst%3DF.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DMangiatordi%26aufirst%3DG.%2BF.%26aulast%3DNicolotti%26aufirst%3DO.%26aulast%3DPerrone%26aufirst%3DM.%2BG.%26aulast%3DBrea%26aufirst%3DJ.%26aulast%3DLoza%26aufirst%3DM.%2BI.%26aulast%3DInfantino%26aufirst%3DV.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DContino%26aufirst%3DM.%26atitle%3DDesign%2520and%2520Synthesis%2520of%2520Fluorescent%2520Ligands%2520for%2520the%2520Detection%2520of%2520Cannabinoid%2520Type%25202%2520Receptor%2520%2528CB2R%2529%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D188%26spage%3D112037%26doi%3D10.1016%2Fj.ejmech.2020.112037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kisková, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mungenast, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suváková, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jäger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thalhammer, T.</span></span> <span> </span><span class="NLM_article-title">Future Aspects for Cannabinoids in Breast Cancer Therapy</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1673</span>, <span class="refDoi"> DOI: 10.3390/ijms20071673</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3390%2Fijms20071673" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BB3cXosVOqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1673&author=T.+Kiskov%C3%A1author=F.+Mungenastauthor=M.+Suv%C3%A1kov%C3%A1author=W.+J%C3%A4gerauthor=T.+Thalhammer&title=Future+Aspects+for+Cannabinoids+in+Breast+Cancer+Therapy&doi=10.3390%2Fijms20071673"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Future aspects for cannabinoids in breast cancer therapy</span></div><div class="casAuthors">Kiskova, Terezia; Mungenast, Felicitas; Suvakova, Maria; Jager, Walter; Thalhammer, Theresia</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1673</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Cannabinoids (CBs) from Cannabis sativa provide relief for tumor-assocd. symptoms (including nausea, anorexia, and neuropathic pain) in the palliative treatment of cancer patients.  Addnl., they may decelerate tumor progression in breast cancer patients.  Indeed, the psychoactive delta-9-tetrahydrocannabinol (THC), non-psychoactive cannabidiol (CBD) and other CBs inhibited disease progression in breast cancer models.  The effects of CBs on signaling pathways in cancer cells are conferred via G-protein coupled CB-receptors (CB-Rs), CB1-R and CB2-R, but also via other receptors, and in a receptor-independent way.  THC is a partial agonist for CB1-R and CB2-R; CBD is an inverse agonist for both.  In breast cancer, CB1-R expression is moderate, but CB2-R expression is high, which is related to tumor aggressiveness.  CBs block cell cycle progression and cell growth and induce cancer cell apoptosis by inhibiting constitutive active pro-oncogenic signaling pathways, such as the extracellular-signal-regulated kinase pathway.  They reduce angiogenesis and tumor metastasis in animal breast cancer models.  CBs are not only active against estrogen receptor-pos., but also against estrogen-resistant breast cancer cells.  In human epidermal growth factor receptor 2-pos. and triple-neg. breast cancer cells, blocking protein kinase B- and cyclooxygenase-2 signaling via CB2-R prevents tumor progression and metastasis.  Furthermore, selective estrogen receptor modulators (SERMs), including tamoxifen, bind to CB-Rs; this process may contribute to the growth inhibitory effect of SERMs in cancer cells lacking the estrogen receptor.  In summary, CBs are already administered to breast cancer patients at advanced stages of the disease, but they might also be effective at earlier stages to decelerate tumor progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplxc-IDLkQu7Vg90H21EOLACvtfcHk0lgg7V6an4ttkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXosVOqtA%253D%253D&md5=6e3743aa394e4024de70ff4252ec4f2d</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.3390%2Fijms20071673&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20071673%26sid%3Dliteratum%253Aachs%26aulast%3DKiskov%25C3%25A1%26aufirst%3DT.%26aulast%3DMungenast%26aufirst%3DF.%26aulast%3DSuv%25C3%25A1kov%25C3%25A1%26aufirst%3DM.%26aulast%3DJ%25C3%25A4ger%26aufirst%3DW.%26aulast%3DThalhammer%26aufirst%3DT.%26atitle%3DFuture%2520Aspects%2520for%2520Cannabinoids%2520in%2520Breast%2520Cancer%2520Therapy%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D1673%26doi%3D10.3390%2Fijms20071673" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, M.</span></span> <span> </span><span class="NLM_article-title">Combined CB2 Receptor Agonist and Photodynamic Therapy Synergistically Inhibit Tumor Growth in Triple Negative Breast Cancer</span>. <i>Photodiagn. Photodyn. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">185</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1016/j.pdpdt.2018.09.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.pdpdt.2018.09.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=30240926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVamsLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=185-191&author=J.+Zhangauthor=S.+Zhangauthor=Y.+Liuauthor=M.+Suauthor=X.+Lingauthor=F.+Liuauthor=Y.+Geauthor=M.+Bai&title=Combined+CB2+Receptor+Agonist+and+Photodynamic+Therapy+Synergistically+Inhibit+Tumor+Growth+in+Triple+Negative+Breast+Cancer&doi=10.1016%2Fj.pdpdt.2018.09.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Combined CB2 receptor agonist and photodynamic therapy synergistically inhibit tumor growth in triple negative breast cancer</span></div><div class="casAuthors">Zhang, Jiliang; Zhang, Shaojuan; Liu, Yang; Su, Meng; Ling, Xiaoxi; Liu, Funan; Ge, Yinghui; Bai, Mingfeng</div><div class="citationInfo"><span class="NLM_cas:title">Photodiagnosis and Photodynamic Therapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">185-191</span>CODEN:
                <span class="NLM_cas:coden">PPTHBF</span>;
        ISSN:<span class="NLM_cas:issn">1572-1000</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Triple neg. breast cancer (TNBC) is the deadliest form of breast cancer because it is more aggressive, diagnosed at later stage and more likely to develop local and systemic recurrence.  Many patients do not experience adequate tumor control after current clin. treatments involving surgical removal, chemotherapy and/or radiotherapy, leading to disease progression and significantly decreased quality of life.  Here we report a new combinatory therapy strategy involving cannabinoid-based medicine and photodynamic therapy (PDT) for the treatment of TNBC.  This combinatory therapy targets two proteins upregulated in TNBC: the cannabinoid CB2 receptor (CB2R, a G-protein coupled receptor) and translocator protein (TSPO, a mitochondria membrane receptor).  We found that the combined CB2R agonist and TSPO-PDT treatment resulted in synergistic inhibition in TNBC cell and tumor growth.  This combinatory therapy approach provides new opportunities to treat TNBC with high efficacy.  In addn., this study provides new evidence on the therapeutic potential of CB2R agonists for cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBC-J0AkR1Q7Vg90H21EOLACvtfcHk0lgg7V6an4ttkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVamsLnK&md5=28009f9579ba604637f0f7094da65c79</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.pdpdt.2018.09.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pdpdt.2018.09.006%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DSu%26aufirst%3DM.%26aulast%3DLing%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DGe%26aufirst%3DY.%26aulast%3DBai%26aufirst%3DM.%26atitle%3DCombined%2520CB2%2520Receptor%2520Agonist%2520and%2520Photodynamic%2520Therapy%2520Synergistically%2520Inhibit%2520Tumor%2520Growth%2520in%2520Triple%2520Negative%2520Breast%2520Cancer%26jtitle%3DPhotodiagn.%2520Photodyn.%2520Ther.%26date%3D2018%26volume%3D24%26spage%3D185%26epage%3D191%26doi%3D10.1016%2Fj.pdpdt.2018.09.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span> <span> </span><span class="NLM_article-title">Molecular Imaging of Pancreatic Duct Adenocarcinoma Using a Type 2 Cannabinoid Receptor-Targeted Near-Infrared Fluorescent Probe</span>. <i>Transl. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1065</span>– <span class="NLM_lpage">1073</span>, <span class="refDoi"> DOI: 10.1016/j.tranon.2018.06.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.tranon.2018.06.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=30005208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252FnvFSnsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2018&pages=1065-1073&author=X.+Guoauthor=X.+Lingauthor=F.+Duauthor=Q.+Wangauthor=W.+Huangauthor=Z.+Wangauthor=X.+Dingauthor=M.+Baiauthor=Z.+Wu&title=Molecular+Imaging+of+Pancreatic+Duct+Adenocarcinoma+Using+a+Type+2+Cannabinoid+Receptor-Targeted+Near-Infrared+Fluorescent+Probe&doi=10.1016%2Fj.tranon.2018.06.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Imaging of Pancreatic Duct Adenocarcinoma Using a Type 2 Cannabinoid Receptor-Targeted Near-Infrared Fluorescent Probe</span></div><div class="casAuthors">Guo Xiaoxia; Wang Qingbing; Huang Wei; Wang Zhongmin; Ding Xiaoyi; Ling Xiaoxi; Du Fang; Bai Mingfeng; Wu Zhiyuan</div><div class="citationInfo"><span class="NLM_cas:title">Translational oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1065-1073</span>
        ISSN:<span class="NLM_cas:issn">1936-5233</span>.
    </div><div class="casAbstract">Imaging probes targeting type 2 cannabinoid receptor (CB2R) overexpressed in pancreatic duct adenocarcinoma (PDAC) tissue have the potential to improve early detection and surgical outcome of PDAC.  The aim of our study was to evaluate the molecular imaging potential of a CB2R-targeted near-infrared (NIR) fluorescent probe (NIR760-XLP6) for PDAC.  CB2R overexpression was observed in both PDAC patient tissues and various pancreatic cancer cell lines.  In vitro fluorescence imaging indicated specific binding of NIR760-XLP6 to CB2R in human PDAC PANC-1 cells.  In a xenograft mouse tumor model, NIR760-XLP6 showed remarkable 50- (ex vivo) and 3.2-fold (in vivo) tumor to normal contrast enhancement with minimal liver and kidney uptake.  In a PDAC lymph node metastasis model, significant signal contrast was observed in bilateral axillary lymph nodes with PDAC metastasis after injection of the probe.  In conclusion, NIR760-XLP6 exhibits promising characteristics for imaging PDAC, and CB2R appears to be an attractive target for PDAC imaging.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRluw1KnvQw9ZdYoSR9eyvsfW6udTcc2eYioRbePW4kPbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252FnvFSnsw%253D%253D&md5=46c5f12dc88b818cf1bbe0e5eea68dd9</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.tranon.2018.06.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tranon.2018.06.009%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DX.%26aulast%3DLing%26aufirst%3DX.%26aulast%3DDu%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DBai%26aufirst%3DM.%26aulast%3DWu%26aufirst%3DZ.%26atitle%3DMolecular%2520Imaging%2520of%2520Pancreatic%2520Duct%2520Adenocarcinoma%2520Using%2520a%2520Type%25202%2520Cannabinoid%2520Receptor-Targeted%2520Near-Infrared%2520Fluorescent%2520Probe%26jtitle%3DTransl.%2520Oncol.%26date%3D2018%26volume%3D11%26spage%3D1065%26epage%3D1073%26doi%3D10.1016%2Fj.tranon.2018.06.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez-Tiedra, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davila, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorente, M.</span></span> <span> </span><span class="NLM_article-title">The Use of Cannabinoids as Anticancer Agents</span>. <i>Prog. Neuro-Psychopharmacol. Biol. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">259</span>– <span class="NLM_lpage">266</span>, <span class="refDoi"> DOI: 10.1016/j.pnpbp.2015.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.pnpbp.2015.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=26071989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFajsL7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2016&pages=259-266&author=G.+Velascoauthor=S.+Hernandez-Tiedraauthor=D.+Davilaauthor=M.+Lorente&title=The+Use+of+Cannabinoids+as+Anticancer+Agents&doi=10.1016%2Fj.pnpbp.2015.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The use of cannabinoids as anticancer agents</span></div><div class="casAuthors">Velasco, Guillermo; Hernandez-Tiedra, Sonia; Davila, David; Lorente, Mar</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neuro-Psychopharmacology & Biological Psychiatry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">259-266</span>CODEN:
                <span class="NLM_cas:coden">PNPPD7</span>;
        ISSN:<span class="NLM_cas:issn">0278-5846</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">It is well-established that cannabinoids exert palliative effects on some cancer-assocd. symptoms.  In addn. evidences obtained during the last fifteen years support that these compds. can reduce tumor growth in animal models of cancer.  Cannabinoids have been shown to activate an ER-stress related pathway that leads to the stimulation of autophagy-mediated cancer cell death.  In addn., cannabinoids inhibit tumor angiogenesis and decrease cancer cell migration.  The mechanisms of resistance to cannabinoid anticancer action as well as the possible strategies to develop cannabinoid-based combinational therapies to fight cancer have also started to be explored.  In this review we will summarize these observations (that have already helped to set the bases for the development of the first clin. studies to investigate the potential clin. benefit of using cannabinoids in anticancer therapies) and will discuss the possible future avenues of research in this area.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHl8_MWK7vUbVg90H21EOLACvtfcHk0li7WFae2uthYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFajsL7K&md5=4e20347b10118d585add29b8ad93b31a</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.pnpbp.2015.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pnpbp.2015.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DVelasco%26aufirst%3DG.%26aulast%3DHernandez-Tiedra%26aufirst%3DS.%26aulast%3DDavila%26aufirst%3DD.%26aulast%3DLorente%26aufirst%3DM.%26atitle%3DThe%2520Use%2520of%2520Cannabinoids%2520as%2520Anticancer%2520Agents%26jtitle%3DProg.%2520Neuro-Psychopharmacol.%2520Biol.%2520Psychiatry%26date%3D2016%26volume%3D64%26spage%3D259%26epage%3D266%26doi%3D10.1016%2Fj.pnpbp.2015.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basagni, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, M.</span></span> <span> </span><span class="NLM_article-title">Functionalized Cannabinoid Subtype 2 Receptor Ligands: Fluorescent, PET, Photochromic and Covalent Molecular Probes</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1374</span>– <span class="NLM_lpage">1389</span>, <span class="refDoi"> DOI: 10.1002/cmdc.202000298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1002%2Fcmdc.202000298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=32578963" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1akt7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2020&pages=1374-1389&author=F.+Basagniauthor=M.+Rosiniauthor=M.+Decker&title=Functionalized+Cannabinoid+Subtype+2+Receptor+Ligands%3A+Fluorescent%2C+PET%2C+Photochromic+and+Covalent+Molecular+Probes&doi=10.1002%2Fcmdc.202000298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Functionalized Cannabinoid Subtype 2 Receptor Ligands: Fluorescent, PET, Photochromic and Covalent Molecular Probes</span></div><div class="casAuthors">Basagni, Filippo; Rosini, Michela; Decker, Michael</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">1374-1389</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Cannabinoid subtype 2 receptors (CB2Rs) are G protein-coupled receptors (GPCRs) belonging to the endocannabinoid system, a complex network of signalling pathways leading to the regulation of key physiol. processes.  Interestingly, CB2Rs are strongly up-regulated in pathol. conditions correlated with the onset of inflammatory events like cancer and neurodegenerative diseases.  Therefore, CB2Rs represent an important biol. target for therapeutic as well as diagnostic purposes.  No CB2R-selective drugs are yet on the market, thus underlining a that deeper comprehension of CB2Rs' complex activation pathways and their role in the regulation of diseases is needed.  Herein, we report an overview of pharmacol. and imaging tools such as fluorescent, positron emission tomog. (PET), photochromic and covalent selective CB2R ligands.  These mol. probes can be used in vitro as well as in vivo to investigate and explore the unravelled role(s) of CB2Rs, and they can help to design suitable CB2R-targeted drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUlNKavII1OrVg90H21EOLACvtfcHk0li7WFae2uthYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1akt7%252FJ&md5=64ccc6dba1fd806dfa9394017b056599</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.202000298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.202000298%26sid%3Dliteratum%253Aachs%26aulast%3DBasagni%26aufirst%3DF.%26aulast%3DRosini%26aufirst%3DM.%26aulast%3DDecker%26aufirst%3DM.%26atitle%3DFunctionalized%2520Cannabinoid%2520Subtype%25202%2520Receptor%2520Ligands%253A%2520Fluorescent%252C%2520PET%252C%2520Photochromic%2520and%2520Covalent%2520Molecular%2520Probes%26jtitle%3DChemMedChem%26date%3D2020%26volume%3D15%26spage%3D1374%26epage%3D1389%26doi%3D10.1002%2Fcmdc.202000298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Naranjo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campillo, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paez, J. A.</span></span> <span> </span><span class="NLM_article-title">Multitarget Cannabinoids as Novel Strategy for Alzheimer Disease</span>. <i>Curr. Alzheimer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">239</span>, <span class="refDoi"> DOI: 10.2174/1567205011310030002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.2174%2F1567205011310030002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=23369066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosFSmu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2013&pages=229-239&author=P.+Gonzalez-Naranjoauthor=N.+E.+Campilloauthor=C.+Perezauthor=J.+A.+Paez&title=Multitarget+Cannabinoids+as+Novel+Strategy+for+Alzheimer+Disease&doi=10.2174%2F1567205011310030002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Multitarget cannabinoids as novel strategy for Alzheimer disease</span></div><div class="casAuthors">Gonzalez-Naranjo, Pedro; Campillo, Nuria E.; Perez, Concepcion; Paez, Juan A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Alzheimer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">229-239</span>CODEN:
                <span class="NLM_cas:coden">CARUBY</span>;
        ISSN:<span class="NLM_cas:issn">1567-2050</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">During the last years the development of approaches to multitarget drug design and discovery is gaining acceptance.  The cannabinoids are potentially excellent multi-target drug candidates because of their interesting pharmacol. profiles, among which stands out the dual capacity of cannabinoid ligands to act as cannabinoid agonist and cholinesterase inhibitors.  In this article, inhibition, kinetics studies and docking simulations with a representative set of cannabinoids are presented.  The results of these studies showed the inhibitory capacity of some agonist cannabinoids with selectivity at AChE or BuChE enzymes.  The kinetic and modeling studies allowed us to postulate the potential mode of action and the binding site of the cannabinoids.  In general, the studied cannabinoids showed a mixed type inhibition mode of action.  The exception to this behavior was found for the agonist CP-55,940 that showed a non-competitive inhibition, suggesting that this cannabinoid only binds to the peripheral site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJJBSiqIppQLVg90H21EOLACvtfcHk0lhX_h9dW3huWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosFSmu7s%253D&md5=68aaaf59f7f6c5ebb45462f67748e670</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.2174%2F1567205011310030002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1567205011310030002%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez-Naranjo%26aufirst%3DP.%26aulast%3DCampillo%26aufirst%3DN.%2BE.%26aulast%3DPerez%26aufirst%3DC.%26aulast%3DPaez%26aufirst%3DJ.%2BA.%26atitle%3DMultitarget%2520Cannabinoids%2520as%2520Novel%2520Strategy%2520for%2520Alzheimer%2520Disease%26jtitle%3DCurr.%2520Alzheimer%2520Res.%26date%3D2013%26volume%3D10%26spage%3D229%26epage%3D239%26doi%3D10.2174%2F1567205011310030002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Naranjo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Macias, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campillo, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aran, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giron, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Robles, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez-Canas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Arencibia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández-Ruiz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paez, J. A.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid Agonists Showing BuChE Inhibition as Potential Therapeutic Agents for Alzheimer’s Disease</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">56</span>– <span class="NLM_lpage">72</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.11.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2013.11.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=24378710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitlSgtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2014&pages=56-72&author=P.+Gonzalez-Naranjoauthor=N.+Perez-Maciasauthor=N.+E.+Campilloauthor=C.+Perezauthor=V.+J.+Aranauthor=R.+Gironauthor=E.+Sanchez-Roblesauthor=M.+I.+Martinauthor=M.+Gomez-Canasauthor=M.+Garc%C3%ADa-Arencibiaauthor=J.+Fern%C3%A1ndez-Ruizauthor=J.+A.+Paez&title=Cannabinoid+Agonists+Showing+BuChE+Inhibition+as+Potential+Therapeutic+Agents+for+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.ejmech.2013.11.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease</span></div><div class="casAuthors">Gonzalez-Naranjo, Pedro; Perez-Macias, Natalia; Campillo, Nuria E.; Perez, Concepcion; Aran, Vicente J.; Giron, Rocio; Sanchez-Robles, Eva; Martin, Maria Isabel; Gomez-Canas, Maria; Garcia-Arencibia, Moises; Fernandez-Ruiz, Javier; Paez, Juan A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">56-72</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Designing drugs with a specific multitarget profile is a promising approach against multifactorial illnesses as Alzheimer's disease.  In this work, new indazole ethers I [R1 = H, Br, NH2, O2N; R2 = Ph, 4-MeC6H4, 1-naphthyl, etc.] that possess dual activity as both cannabinoid agonists CB2 and inhibitors of BuChE have been designed by computational methods.  On the basis of this knowledge, the synthesis, pharmacol. evaluation and docking studies of a new class of indazoles has been performed.  Pharmacol. evaluation includes radioligand binding assays with [3H]-CP55940 for CB1R and CB2R and functional activity for cannabinoid receptors on isolated tissue.  Addnl., in vitro inhibitory assays of AChE/BuChE and the corresponding competition studies have been carried out.  The results of pharmacol. tests have revealed that three of these derivs. behave as CB2 cannabinoid agonists and simultaneously show BuChE inhibition.  Two compds. have emerged as promising candidates as novel cannabinoids that inhibit BuChE by a noncompetitive or mixed mechanism, resp.  Both mols. show antioxidant properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsEZ5i6Cu4urVg90H21EOLACvtfcHk0lhX_h9dW3huWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitlSgtLs%253D&md5=0f4334ed1444c18bf353a34351936e5a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.11.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.11.026%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez-Naranjo%26aufirst%3DP.%26aulast%3DPerez-Macias%26aufirst%3DN.%26aulast%3DCampillo%26aufirst%3DN.%2BE.%26aulast%3DPerez%26aufirst%3DC.%26aulast%3DAran%26aufirst%3DV.%2BJ.%26aulast%3DGiron%26aufirst%3DR.%26aulast%3DSanchez-Robles%26aufirst%3DE.%26aulast%3DMartin%26aufirst%3DM.%2BI.%26aulast%3DGomez-Canas%26aufirst%3DM.%26aulast%3DGarc%25C3%25ADa-Arencibia%26aufirst%3DM.%26aulast%3DFern%25C3%25A1ndez-Ruiz%26aufirst%3DJ.%26aulast%3DPaez%26aufirst%3DJ.%2BA.%26atitle%3DCannabinoid%2520Agonists%2520Showing%2520BuChE%2520Inhibition%2520as%2520Potential%2520Therapeutic%2520Agents%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D73%26spage%3D56%26epage%3D72%26doi%3D10.1016%2Fj.ejmech.2013.11.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Naranjo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Macias, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roca, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaca, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giron, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Robles, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Fontelles, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Ceballos, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Requero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campillo, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paez, J. A.</span></span> <span> </span><span class="NLM_article-title">Indazolylketones as New Multitarget Cannabinoid Drugs</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>166</i></span>,  <span class="NLM_fpage">90</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.01.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2019.01.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=30685536" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKks7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=166&publication_year=2019&pages=90-107&author=P.+Gonzalez-Naranjoauthor=N.+Perez-Maciasauthor=C.+Perezauthor=C.+Rocaauthor=G.+Vacaauthor=R.+Gironauthor=E.+Sanchez-Roblesauthor=M.+I.+Martin-Fontellesauthor=M.+L.+de+Ceballosauthor=A.+Martin-Requeroauthor=N.+E.+Campilloauthor=J.+A.+Paez&title=Indazolylketones+as+New+Multitarget+Cannabinoid+Drugs&doi=10.1016%2Fj.ejmech.2019.01.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Indazolylketones as new multitarget cannabinoid drugs</span></div><div class="casAuthors">Gonzalez-Naranjo, Pedro; Perez-Macias, Natalia; Perez, Concepcion; Roca, Carlos; Vaca, Gabriela; Giron, Rocio; Sanchez-Robles, Eva; Martin-Fontelles, Maria Isabel; de Ceballos, Maria L.; Martin-Requero, Angeles; Campillo, Nuria E.; Paez, Juan A.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">166</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">90-107</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">In this work, the synthesis and evaluation of a new class of indazolylketones I (R1 = 1-naphthyl, 2-chlorophenyl, 2-(benzyloxy)phenyl, etc.; R2 = pyrrolidinyl, piperidin-1-yl; n = 2, 3) have been performed.  Pharmacol. evaluation includes functional activity for cannabinoid receptors on isolated tissue.  In addn., in vitro inhibitory assays in AChE/BuChE enzymes and BACE-1 have been carried out.  Furthermore, studies of neuroprotective effects in human neuroblastoma SH-SY5Y cells and studies of the mechanisms of survival/death in lymphoblasts of patients with Alzheimer's disease have been achieved.  The results of pharmacol. tests have revealed that some of these derivs. I (R1 = 3-chloro-2-fluorophenyl, 2,3-dichlorophenyl; R2 = pyrrolidinyl, piperidin-1-yl; n = 2, 3) behave as CB2 cannabinoid agonists and simultaneously show BuChE and/or BACE-1 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_gzl9LX4C2bVg90H21EOLACvtfcHk0lhX_h9dW3huWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKks7k%253D&md5=bf3d193f39d132576511a4f8d96cb7e4</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.01.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.01.030%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez-Naranjo%26aufirst%3DP.%26aulast%3DPerez-Macias%26aufirst%3DN.%26aulast%3DPerez%26aufirst%3DC.%26aulast%3DRoca%26aufirst%3DC.%26aulast%3DVaca%26aufirst%3DG.%26aulast%3DGiron%26aufirst%3DR.%26aulast%3DSanchez-Robles%26aufirst%3DE.%26aulast%3DMartin-Fontelles%26aufirst%3DM.%2BI.%26aulast%3Dde%2BCeballos%26aufirst%3DM.%2BL.%26aulast%3DMartin-Requero%26aufirst%3DA.%26aulast%3DCampillo%26aufirst%3DN.%2BE.%26aulast%3DPaez%26aufirst%3DJ.%2BA.%26atitle%3DIndazolylketones%2520as%2520New%2520Multitarget%2520Cannabinoid%2520Drugs%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D166%26spage%3D90%26epage%3D107%26doi%3D10.1016%2Fj.ejmech.2019.01.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dolles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nimczick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheiner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadtmuller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawatzky, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drakopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotriffer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittmann, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, M.</span></span> <span> </span><span class="NLM_article-title">Aminobenzimidazoles and Structural Isomers as Templates for Dual-Acting Butyrylcholinesterase Inhibitors and HCB2 R Ligands To Combat Neurodegenerative Disorders</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1270</span>– <span class="NLM_lpage">1283</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1002%2Fcmdc.201500418" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=26548365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyms7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1270-1283&author=D.+Dollesauthor=M.+Nimczickauthor=M.+Scheinerauthor=J.+Ramlerauthor=P.+Stadtmullerauthor=E.+Sawatzkyauthor=A.+Drakopoulosauthor=C.+Sotrifferauthor=H.-J.+Wittmannauthor=A.+Strasserauthor=M.+Decker&title=Aminobenzimidazoles+and+Structural+Isomers+as+Templates+for+Dual-Acting+Butyrylcholinesterase+Inhibitors+and+HCB2+R+Ligands+To+Combat+Neurodegenerative+Disorders&doi=10.1002%2Fcmdc.201500418"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Aminobenzimidazoles and Structural Isomers as Templates for Dual-Acting Butyrylcholinesterase Inhibitors and hCB2R Ligands To Combat Neurodegenerative Disorders</span></div><div class="casAuthors">Dolles, Dominik; Nimczick, Martin; Scheiner, Matthias; Ramler, Jacqueline; Stadtmueller, Patricia; Sawatzky, Edgar; Drakopoulos, Antonios; Sotriffer, Christoph; Wittmann, Hans-Joachim; Strasser, Andrea; Decker, Michael</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1270-1283</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A pharmacophore model for butyrylcholinesterase (BChE) inhibitors was applied to a human cannabinoid subtype 2 receptor (hCB2R) agonist and verified it as a first-generation lead for resp. dual-acting compds.  The design, synthesis, and pharmacol. evaluation of various derivs. led to the identification of aminobenzimidazoles as second-generation leads with micro- or sub-micromolar activities at both targets and excellent selectivity over hCB1 and AChE, resp.  Computational studies of the first- and second-generation lead structures by applying mol. dynamics (MD) on the active hCB2R model, along with docking and MD on hBChE, has enabled an explanation of their binding profiles at the protein levels and opened the way for further optimization.  Dual-acting compds. with "balanced" affinities and excellent selectivities could be obtained that represent leads for treatment of both cognitive and pathophysiol. impairment occurring in neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP2lcUsRAXJ7Vg90H21EOLACvtfcHk0ljaaXpieX9-3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyms7%252FI&md5=dcd6f52f38134002413bd3d975ee9da3</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500418%26sid%3Dliteratum%253Aachs%26aulast%3DDolles%26aufirst%3DD.%26aulast%3DNimczick%26aufirst%3DM.%26aulast%3DScheiner%26aufirst%3DM.%26aulast%3DRamler%26aufirst%3DJ.%26aulast%3DStadtmuller%26aufirst%3DP.%26aulast%3DSawatzky%26aufirst%3DE.%26aulast%3DDrakopoulos%26aufirst%3DA.%26aulast%3DSotriffer%26aufirst%3DC.%26aulast%3DWittmann%26aufirst%3DH.-J.%26aulast%3DStrasser%26aufirst%3DA.%26aulast%3DDecker%26aufirst%3DM.%26atitle%3DAminobenzimidazoles%2520and%2520Structural%2520Isomers%2520as%2520Templates%2520for%2520Dual-Acting%2520Butyrylcholinesterase%2520Inhibitors%2520and%2520HCB2%2520R%2520Ligands%2520To%2520Combat%2520Neurodegenerative%2520Disorders%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D1270%26epage%3D1283%26doi%3D10.1002%2Fcmdc.201500418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dolles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunesch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinelli, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatonnet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohse, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittmann, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabissi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, M.</span></span> <span> </span><span class="NLM_article-title">Structure-Activity Relationships and Computational Investigations into the Development of Potent and Balanced Dual-Acting Butyrylcholinesterase Inhibitors and Human Cannabinoid Receptor 2 Ligands with Pro-Cognitive in Vivo Profiles</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1646</span>– <span class="NLM_lpage">1663</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01760</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Sqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1646-1663&author=D.+Dollesauthor=M.+Hoffmannauthor=S.+Guneschauthor=O.+Marinelliauthor=J.+Mollerauthor=G.+Santoniauthor=A.+Chatonnetauthor=M.+J.+Lohseauthor=H.-J.+Wittmannauthor=A.+Strasserauthor=M.+Nabissiauthor=T.+Mauriceauthor=M.+Decker&title=Structure-Activity+Relationships+and+Computational+Investigations+into+the+Development+of+Potent+and+Balanced+Dual-Acting+Butyrylcholinesterase+Inhibitors+and+Human+Cannabinoid+Receptor+2+Ligands+with+Pro-Cognitive+in+Vivo+Profiles&doi=10.1021%2Facs.jmedchem.7b01760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationships and Computational Investigations into the Development of Potent and Balanced Dual-Acting Butyrylcholinesterase Inhibitors and Human Cannabinoid Receptor 2 Ligands with Pro-Cognitive in Vivo Profiles</span></div><div class="casAuthors">Dolles, Dominik; Hoffmann, Matthias; Gunesch, Sandra; Marinelli, Oliviero; Moeller, Jan; Santoni, Giorgio; Chatonnet, Arnaud; Lohse, Martin J.; Wittmann, Hans-Joachim; Strasser, Andrea; Nabissi, Massimo; Maurice, Tangui; Decker, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1646-1663</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The enzyme butyrylcholinesterase (BChE) and the human cannabinoid receptor 2 (hCB2R) represent promising targets for pharmacotherapy in the later stages of Alzheimer's disease.  The authors merged pharmacophores for both targets into small benzimidazole-based mols., investigated SARs, and identified several dual-acting ligands with a balanced affinity/inhibitory activity and an excellent selectivity over both hCB1R and hAChE.  A homol. model for the hCB2R was developed based on the hCB1R crystal structure and used for mol. dynamics studies to investigate binding modes.  In vitro studies proved hCB2R agonism.  Unwanted μ-opioid receptor affinity could be designed out.  One well-balanced dual-acting and selective hBChE inhibitor/hCB2R agonist showed superior in vivo activity over the lead CB2 agonist with regards to cognition improvement.  The data shows the possibility to combine a small mol. with selective and balanced GPCR-activity/enzyme inhibition and in vivo activity for the therapy of AD and may help to rationalize the development of other dual-acting ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgCAoLm6nAVbVg90H21EOLACvtfcHk0ljaaXpieX9-3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Sqsbo%253D&md5=49e8e68c2c9a023b872e2522fad6e78c</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01760%26sid%3Dliteratum%253Aachs%26aulast%3DDolles%26aufirst%3DD.%26aulast%3DHoffmann%26aufirst%3DM.%26aulast%3DGunesch%26aufirst%3DS.%26aulast%3DMarinelli%26aufirst%3DO.%26aulast%3DMoller%26aufirst%3DJ.%26aulast%3DSantoni%26aufirst%3DG.%26aulast%3DChatonnet%26aufirst%3DA.%26aulast%3DLohse%26aufirst%3DM.%2BJ.%26aulast%3DWittmann%26aufirst%3DH.-J.%26aulast%3DStrasser%26aufirst%3DA.%26aulast%3DNabissi%26aufirst%3DM.%26aulast%3DMaurice%26aufirst%3DT.%26aulast%3DDecker%26aufirst%3DM.%26atitle%3DStructure-Activity%2520Relationships%2520and%2520Computational%2520Investigations%2520into%2520the%2520Development%2520of%2520Potent%2520and%2520Balanced%2520Dual-Acting%2520Butyrylcholinesterase%2520Inhibitors%2520and%2520Human%2520Cannabinoid%2520Receptor%25202%2520Ligands%2520with%2520Pro-Cognitive%2520in%2520Vivo%2520Profiles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1646%26epage%3D1663%26doi%3D10.1021%2Facs.jmedchem.7b01760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Scheiner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dolles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunesch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabissi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinelli, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naldi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petralla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poeta, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Falkeis, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vieth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hübner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gmeiner, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, M.</span></span> <span> </span><span class="NLM_article-title">Dual-Acting Cholinesterase-Human Cannabinoid Receptor 2 Ligands Show Pronounced Neuroprotection in Vitro and Overadditive and Disease-Modifying Neuroprotective Effects in Vivo</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">9078</span>– <span class="NLM_lpage">9102</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00623</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00623" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFCrs7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=9078-9102&author=M.+Scheinerauthor=D.+Dollesauthor=S.+Guneschauthor=M.+Hoffmannauthor=M.+Nabissiauthor=O.+Marinelliauthor=M.+Naldiauthor=M.+Bartoliniauthor=S.+Petrallaauthor=E.+Poetaauthor=B.+Montiauthor=C.+Falkeisauthor=M.+Viethauthor=H.+H%C3%BCbnerauthor=P.+Gmeinerauthor=R.+Maitraauthor=T.+Mauriceauthor=M.+Decker&title=Dual-Acting+Cholinesterase-Human+Cannabinoid+Receptor+2+Ligands+Show+Pronounced+Neuroprotection+in+Vitro+and+Overadditive+and+Disease-Modifying+Neuroprotective+Effects+in+Vivo&doi=10.1021%2Facs.jmedchem.9b00623"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Dual-Acting Cholinesterase-Human Cannabinoid Receptor 2 Ligands Show Pronounced Neuroprotection in Vitro and Overadditive and Disease-Modifying Neuroprotective Effects in Vivo</span></div><div class="casAuthors">Scheiner, Matthias; Dolles, Dominik; Gunesch, Sandra; Hoffmann, Matthias; Nabissi, Massimo; Marinelli, Oliviero; Naldi, Marina; Bartolini, Manuela; Petralla, Sabrina; Poeta, Eleonora; Monti, Barbara; Falkeis, Christina; Vieth, Michael; Huebner, Harald; Gmeiner, Peter; Maitra, Rangan; Maurice, Tangui; Decker, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9078-9102</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have designed and synthesized a series of 14 hybrid mols. out of the cholinesterase (ChE) inhibitor tacrine and a benzimidazole-based human cannabinoid receptor subtype 2 (hCB2R) agonist and investigated them in vitro and in vivo.  The compds. are potent ChE inhibitors, and for the most promising hybrids, the mechanism of human acetylcholinesterase (hAChE) inhibition as well as their ability to interfere with AChE-induced aggregation of β-amyloid (Aβ), and Aβ self-aggregation was assessed.  All hybrids were evaluated for affinity and selectivity for hCB1R and hCB2R.  To ensure that the hybrids retained their agonist character, the expression of cAMP-regulated genes was quantified, and potency and efficacy were detd.  Addnl., the effects of the hybrids on microglia activation and neuroprotection on HT-22 cells were investigated.  The most promising in vitro hybrids showed pronounced neuroprotection in an Alzheimer's mouse model at low dosage (0.1 mg/kg, i.p.), lacking hepatotoxicity even at high dose (3 mg/kg, i.p.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGRfz6xatTXLVg90H21EOLACvtfcHk0ljXh4T_eQ_vdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFCrs7%252FM&md5=f0148c8ba51a2d0cbe83a26bb388a446</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00623%26sid%3Dliteratum%253Aachs%26aulast%3DScheiner%26aufirst%3DM.%26aulast%3DDolles%26aufirst%3DD.%26aulast%3DGunesch%26aufirst%3DS.%26aulast%3DHoffmann%26aufirst%3DM.%26aulast%3DNabissi%26aufirst%3DM.%26aulast%3DMarinelli%26aufirst%3DO.%26aulast%3DNaldi%26aufirst%3DM.%26aulast%3DBartolini%26aufirst%3DM.%26aulast%3DPetralla%26aufirst%3DS.%26aulast%3DPoeta%26aufirst%3DE.%26aulast%3DMonti%26aufirst%3DB.%26aulast%3DFalkeis%26aufirst%3DC.%26aulast%3DVieth%26aufirst%3DM.%26aulast%3DH%25C3%25BCbner%26aufirst%3DH.%26aulast%3DGmeiner%26aufirst%3DP.%26aulast%3DMaitra%26aufirst%3DR.%26aulast%3DMaurice%26aufirst%3DT.%26aulast%3DDecker%26aufirst%3DM.%26atitle%3DDual-Acting%2520Cholinesterase-Human%2520Cannabinoid%2520Receptor%25202%2520Ligands%2520Show%2520Pronounced%2520Neuroprotection%2520in%2520Vitro%2520and%2520Overadditive%2520and%2520Disease-Modifying%2520Neuroprotective%2520Effects%2520in%2520Vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D9078%26epage%3D9102%26doi%3D10.1021%2Facs.jmedchem.9b00623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span> <span> </span><span class="NLM_article-title">Multitarget Drug Discovery and Polypharmacology</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1190</span>– <span class="NLM_lpage">1192</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201600161</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1002%2Fcmdc.201600161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=27061625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC28XlslajtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1190-1192&author=M.+L.+Bolognesiauthor=A.+Cavalli&title=Multitarget+Drug+Discovery+and+Polypharmacology&doi=10.1002%2Fcmdc.201600161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Multitarget Drug Discovery and Polypharmacology</span></div><div class="casAuthors">Bolognesi, Maria Laura; Cavalli, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1190-1192</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUatZ6EoEK6LVg90H21EOLACvtfcHk0ljXh4T_eQ_vdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XlslajtLc%253D&md5=f120fbd9eb2c96cbe283749c95b81cb0</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600161%26sid%3Dliteratum%253Aachs%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DCavalli%26aufirst%3DA.%26atitle%3DMultitarget%2520Drug%2520Discovery%2520and%2520Polypharmacology%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D1190%26epage%3D1192%26doi%3D10.1002%2Fcmdc.201600161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anighoro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bajorath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastelli, G.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology: Challenges and Opportunities in Drug Discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">7874</span>– <span class="NLM_lpage">7887</span>, <span class="refDoi"> DOI: 10.1021/jm5006463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7874-7887&author=A.+Anighoroauthor=J.+Bajorathauthor=G.+Rastelli&title=Polypharmacology%3A+Challenges+and+Opportunities+in+Drug+Discovery&doi=10.1021%2Fjm5006463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: Challenges and Opportunities in Drug Discovery</span></div><div class="casAuthors">Anighoro, Andrew; Bajorath, Jurgen; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7874-7887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biol. target, shares the spotlight with an emerging and alternative polypharmacol. approach.  Polypharmacol. suggests that more effective drugs can be developed by specifically modulating multiple targets.  It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches.  In this respect, a drug that "hits" multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs.  In this review, we will compare advantages and disadvantages of multitarget vs. combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOTyEu80AZrVg90H21EOLACvtfcHk0ljXh4T_eQ_vdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I&md5=5ab36c961a84462d90bc25130d90a281</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fjm5006463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006463%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DPolypharmacology%253A%2520Challenges%2520and%2520Opportunities%2520in%2520Drug%2520Discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7874%26epage%3D7887%26doi%3D10.1021%2Fjm5006463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Amelio, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lisitsa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melino, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonov, A. V.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology of Approved Anticancer Drugs</span>. <i>Curr. Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">534</span>– <span class="NLM_lpage">543</span>, <span class="refDoi"> DOI: 10.2174/1389450117666160301095233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.2174%2F1389450117666160301095233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=26926468" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjslSjtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=534-543&author=I.+Amelioauthor=A.+Lisitsaauthor=R.+A.+Knightauthor=G.+Melinoauthor=A.+V.+Antonov&title=Polypharmacology+of+Approved+Anticancer+Drugs&doi=10.2174%2F1389450117666160301095233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology of Approved Anticancer Drugs</span></div><div class="casAuthors">Amelio, Ivano; Lisitsa, Andrey; Knight, Richard A.; Melino, Gerry; Antonov, Alexey V.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">534-543</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">The major drug discovery efforts in oncol. have been concd. on the development of selective mols. that are supposed to act specifically on one anticancer mechanism by modulating a single or several closely related drug targets.  However, a bird's eye view on data from multiple available bioassays implies that most approved anticancer agents do, in fact, target many more proteins with different functions.  Here we will review and systematize currently available information on the targets of several anticancer drugs along with revision of their potential mechanisms of action.  Polypharmacol. of the current antineoplastic agents suggests that drug clin. efficacy in oncol. can be achieved only via modulation of multiple cellular mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZWxZCVA_iIrVg90H21EOLACvtfcHk0lgJPzMoQtpytw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjslSjtrc%253D&md5=316e3ae08072b1b984523b7642b8d271</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.2174%2F1389450117666160301095233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389450117666160301095233%26sid%3Dliteratum%253Aachs%26aulast%3DAmelio%26aufirst%3DI.%26aulast%3DLisitsa%26aufirst%3DA.%26aulast%3DKnight%26aufirst%3DR.%2BA.%26aulast%3DMelino%26aufirst%3DG.%26aulast%3DAntonov%26aufirst%3DA.%2BV.%26atitle%3DPolypharmacology%2520of%2520Approved%2520Anticancer%2520Drugs%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2017%26volume%3D18%26spage%3D534%26epage%3D543%26doi%3D10.2174%2F1389450117666160301095233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology in a Single Drug: Multitarget Drugs</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1639</span>– <span class="NLM_lpage">1645</span>, <span class="refDoi"> DOI: 10.2174/0929867311320130004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.2174%2F0929867311320130004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=23410164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotl2jtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1639-1645&author=M.+L.+Bolognesi&title=Polypharmacology+in+a+Single+Drug%3A+Multitarget+Drugs&doi=10.2174%2F0929867311320130004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology in a single drug: multitarget drugs</span></div><div class="casAuthors">Bolognesi, M. L.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1639-1645</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Polypharmacol. offers a model for the way drug discovery must evolve to develop therapies most suited to treating currently incurable diseases.  It is driven by a worldwide demand for safer, more effective, and affordable medicines against the most complex diseases, and by the failures of modern drug discovery to provide these.  Polypharmacol. can involve combinations and/or multitarget drugs (MTD).  Although not mutually exclusive, my premise is that MTDs have inherent advantages over combinations.  This review article focuses on MTDs from a medicinal chem. perspective.  I will explore their use in current clin. practice, their likely application in the future, and the challenges to be overcome to achieve this goal.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeSnmeFeRpMrVg90H21EOLACvtfcHk0lgJPzMoQtpytw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotl2jtLk%253D&md5=0e69395566711e018db8a61b1ae0f56e</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.2174%2F0929867311320130004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867311320130004%26sid%3Dliteratum%253Aachs%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DPolypharmacology%2520in%2520a%2520Single%2520Drug%253A%2520Multitarget%2520Drugs%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26spage%3D1639%26epage%3D1645%26doi%3D10.2174%2F0929867311320130004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designing Multiple Ligands - Medicinal Chemistry Strategies and Challenges</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">600</span>, <span class="refDoi"> DOI: 10.2174/138161209787315594</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.2174%2F138161209787315594" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=19199984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD1MXkvVSns70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2009&pages=587-600&author=R.+Morphyauthor=Z.+Rankovic&title=Designing+Multiple+Ligands+-+Medicinal+Chemistry+Strategies+and+Challenges&doi=10.2174%2F138161209787315594"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Designing multiple ligands - medicinal chemistry strategies and challenges</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">587-600</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  It has been widely recognized over the recent years that parallel modulation of multiple biol. targets can be beneficial for treatment of diseases with complex etiologies such as cancer asthma, and psychiatric disease.  In this article, current strategies for the generation of ligands with a specific multi-target profile (designed multiple ligands or DMLs) are described and a no. of illustrative example are given.  Designing multiple ligands is frequently a challenging endeavor for medicinal chemists, with the need to appropriately balance affinity for 2 or more targets while obtaining physicochem. and pharmacokinetic properties that are consistent with the administration of an oral drug.  Given that the properties of DMLs are influenced to a large extent by the proteomic superfamily to which the targets belong and the lead generation strategy that is pursued, an early assessment of the feasibility of any given DML project is essential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUo6NjoK5D-LVg90H21EOLACvtfcHk0lgJPzMoQtpytw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXkvVSns70%253D&md5=fa34039be6e9c3b489f530fc74fd0346</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.2174%2F138161209787315594&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161209787315594%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigning%2520Multiple%2520Ligands%2520-%2520Medicinal%2520Chemistry%2520Strategies%2520and%2520Challenges%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2009%26volume%3D15%26spage%3D587%26epage%3D600%26doi%3D10.2174%2F138161209787315594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">From Magic Bullets to Designed Multiple Ligands</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">641</span>– <span class="NLM_lpage">651</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(04)03163-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2FS1359-6446%2804%2903163-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=15279847" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2004&pages=641-651&author=R.+Morphyauthor=C.+Kayauthor=Z.+Rankovic&title=From+Magic+Bullets+to+Designed+Multiple+Ligands&doi=10.1016%2FS1359-6446%2804%2903163-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">From magic bullets to designed multiple ligands</span></div><div class="casAuthors">Morphy, Richard; Kay, Corinne; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">641-651</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  A major trend in medicinal chem. in the coming years will be the rational design of ligands that are capable of modulating multiple disease-relevant targets in a specific manner.  Increasingly, it is being recognized that a balanced modulation of several targets can provide a superior therapeutic effect and side effect profile compared to the action of a selective ligand.  Rational approaches in which structural features from selective ligands are combined have produced designed multiple ligands that span a wide variety of targets and target classes.  A key challenge in the design of multiple ligands is attaining a balanced activity at each target of interest while simultaneously achieving a wider selectivity and a suitable pharmacokinetic profile.  An anal. of literature examples reveals trends and insights that might help medicinal chemists discover the next generation of these types of compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcsGpfzZok5rVg90H21EOLACvtfcHk0lgJPzMoQtpytw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmtVSktb8%253D&md5=cd2491baad707043dbee4f59ccad9e1d</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903163-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903163-0%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DKay%26aufirst%3DC.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DFrom%2520Magic%2520Bullets%2520to%2520Designed%2520Multiple%2520Ligands%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2004%26volume%3D9%26spage%3D641%26epage%3D651%26doi%3D10.1016%2FS1359-6446%2804%2903163-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">The Physicochemical Challenges of Designing Multiple Ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">4961</span>– <span class="NLM_lpage">4970</span>, <span class="refDoi"> DOI: 10.1021/jm0603015</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0603015" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvFejtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4961-4970&author=R.+Morphyauthor=Z.+Rankovic&title=The+Physicochemical+Challenges+of+Designing+Multiple+Ligands&doi=10.1021%2Fjm0603015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">The Physicochemical Challenges of Designing Multiple Ligands</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">4961-4970</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Compds. designed to bind more than one target can provide a therapeutic benefit relative to highly target-selective ligands.  The physicochem. properties of designed multiple ligands were found to be less druglike than those for preclin. compds. in general.  These properties are controlled by the superfamily to which the targets belong and the lead discovery strategy that was followed.  The properties for peptide G-protein-coupled receptor (GPCR) ligands were the least favorable for oral delivery, whereas transporter, monoamine GPCR, and oxidase ligands were the most druglike.  The lead discovery strategy, framework combination or screening, exerts a profound influence on the property values.  Combining the frameworks from two selective ligands often results in large, complex dual ligands, but druglike ligands can be achieved if the degree of framework overlap is maximized and the size of the selective ligands minimized.  For some target combinations, a screening approach may provide a route to smaller, less complex leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonGHbXyxgv4LVg90H21EOLACvtfcHk0ljZ5LLAn10ZGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvFejtL4%253D&md5=c7a227848516d0aa58ed037a582943fe</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fjm0603015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0603015%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DThe%2520Physicochemical%2520Challenges%2520of%2520Designing%2520Multiple%2520Ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4961%26epage%3D4970%26doi%3D10.1021%2Fjm0603015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maher, C. M.</span></span> <span> </span><span class="NLM_article-title">Sigma1 Pharmacology in the Context of Cancer</span>. <i>Handb. Exp. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>244</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1007/164_2017_38</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1007%2F164_2017_38" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=28744586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFeitbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=244&publication_year=2017&pages=237-308&author=F.+J.+Kimauthor=C.+M.+Maher&title=Sigma1+Pharmacology+in+the+Context+of+Cancer&doi=10.1007%2F164_2017_38"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma1 pharmacology in the context of cancer</span></div><div class="casAuthors">Kim, Felix J.; Maher, Christina M.</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of Experimental Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">244</span>
        (<span class="NLM_cas:issue">Sigma Proteins: Evolution of the Concept of Sigma Receptors</span>),
    <span class="NLM_cas:pages">237-308</span>CODEN:
                <span class="NLM_cas:coden">HEPHD2</span>;
        ISSN:<span class="NLM_cas:issn">1865-0325</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  Sigma1 (also known as sigma-1 receptor, Sig1R, s1 receptor) is a unique pharmacol. regulated integral membrane chaperone or scaffolding protein.  The majority of publications on the subject have focused on the neuropharmacol. of Sigma1.  However, a no. of publications have also suggested a role for Sigma1 in cancer.  Although there is currently no clin. used anti-cancer drug that targets Sigma1, a growing body of evidence supports the potential of Sigma1 ligands as therapeutic agents to treat cancer.  In preclin. models, compds. with affinity for Sigma1 have been reported to inhibit cancer cell proliferation and survival, cell adhesion and migration, tumor growth, to alleviate cancer-assocd. pain, and to have immunomodulatory properties.  This review will highlight that although the literature supports a role for Sigma1 in cancer, several fundamental questions regarding drug mechanism of action and the physiol. relevance of aberrant SIGMAR1 transcript and Sigma1 protein expression in certain cancers remain unanswered or only partially answered.  However, emerging lines of evidence suggest that Sigma1 is a component of the cancer cell support machinery, that it facilitates protein interaction networks, that it allosterically modulates the activity of its assocd. proteins, and that Sigma1 is a selectively multifunctional drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolV7ANX6gwGLVg90H21EOLACvtfcHk0ljZ5LLAn10ZGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFeitbvI&md5=6c5d82c84dce7107d0d471a678bd6cd7</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1007%2F164_2017_38&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F164_2017_38%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DF.%2BJ.%26aulast%3DMaher%26aufirst%3DC.%2BM.%26atitle%3DSigma1%2520Pharmacology%2520in%2520the%2520Context%2520of%2520Cancer%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2017%26volume%3D244%26spage%3D237%26epage%3D308%26doi%3D10.1007%2F164_2017_38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span> <span> </span><span class="NLM_article-title">Sigma-2 Receptor Ligands and Their Perspectives in Cancer Diagnosis and Therapy</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">532</span>– <span class="NLM_lpage">566</span>, <span class="refDoi"> DOI: 10.1002/med.21297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1002%2Fmed.21297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=23922215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2cXlsl2qsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=532-566&author=Y.-S.+Huangauthor=H.-L.+Luauthor=L.-J.+Zhangauthor=Z.+Wu&title=Sigma-2+Receptor+Ligands+and+Their+Perspectives+in+Cancer+Diagnosis+and+Therapy&doi=10.1002%2Fmed.21297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-2 Receptor Ligands and Their Perspectives in Cancer Diagnosis and Therapy</span></div><div class="casAuthors">Huang, Yun-Sheng; Lu, He-Lin; Zhang, Lang-Jun; Wu, Zongwen</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">532-566</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  The sigma-2 receptor is highly expressed in various rapidly proliferating cancer cells and regarded as a cancer cell biomarker.  Selective sigma-2 ligands have been shown to specifically label the tumor sites, induce cancer cells to undergo apoptosis, and inhibit tumor growth.  Sigma-2 ligands are potentially useful as cancer diagnostics, anticancer therapeutics, or adjuvant anticancer treatment agents.  However, both the cloning of this receptor and the identification of its endogenous ligand have not been successful, and the lack of structural information has severely hindered the understanding of its physiol. roles, its signaling pathways, and the development of more selective sigma-2 ligands.  Recent data have implicated that sigma-2 binding sites are within the lipid rafts and that PGRMC1 (progesterone receptor membrane component 1) complex and sigma-2 receptor may be coupled with EGFR (epidermal growth factor receptor), mTOR (mammalian target of rapamycin), caspases, and ion channels.  Due to its promising applications in cancer management, there are rapidly increasing research efforts that are being directed into this field.  This review article updates the current understanding of sigma-2 receptor and its potential physiol. roles, applications, interaction with other effectors, with special focuses on the development of sigma-2 ligands, their chem. structures, pharmacol. profiles, applications in imaging and anticancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSJIQdLSWe4LVg90H21EOLACvtfcHk0ljZ5LLAn10ZGQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXlsl2qsrk%253D&md5=bce2e9be88f6cbb9e547f00b4734ce6a</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1002%2Fmed.21297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21297%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.-S.%26aulast%3DLu%26aufirst%3DH.-L.%26aulast%3DZhang%26aufirst%3DL.-J.%26aulast%3DWu%26aufirst%3DZ.%26atitle%3DSigma-2%2520Receptor%2520Ligands%2520and%2520Their%2520Perspectives%2520in%2520Cancer%2520Diagnosis%2520and%2520Therapy%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2014%26volume%3D34%26spage%3D532%26epage%3D566%26doi%3D10.1002%2Fmed.21297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ling, R.</span></span> <span> </span><span class="NLM_article-title">Small Molecule HDAC Inhibitors: Promising Agents for Breast Cancer Treatment</span>. <i>Bioorg. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>91</i></span>,  <span class="NLM_fpage">103184</span>, <span class="refDoi"> DOI: 10.1016/j.bioorg.2019.103184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bioorg.2019.103184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=31408831" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFyjsLvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2019&pages=103184&author=M.+Huangauthor=J.+Zhangauthor=C.+Yanauthor=X.+Liauthor=J.+Zhangauthor=R.+Ling&title=Small+Molecule+HDAC+Inhibitors%3A+Promising+Agents+for+Breast+Cancer+Treatment&doi=10.1016%2Fj.bioorg.2019.103184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule HDAC inhibitors: Promising agents for breast cancer treatment</span></div><div class="casAuthors">Huang, Meiling; Zhang, Jian; Yan, Changjiao; Li, Xiaohui; Zhang, Juliang; Ling, Rui</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">103184</span>CODEN:
                <span class="NLM_cas:coden">BOCMBM</span>;
        ISSN:<span class="NLM_cas:issn">0045-2068</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Breast cancer, a heterogeneous disease, is the most frequently diagnosed cancer and the second leading cause of cancer-related death among women worldwide.  Recently, epigenetic abnormalities have emerged as an important hallmark of cancer development and progression.  Given that histone deacetylases (HDACs) are crucial to chromatin remodeling and epigenetics, their inhibitors have become promising potential anticancer drugs for research.  Here we reviewed the mechanism and classification of histone deacetylases (HDACs), assocn. between HDACs and breast cancer, classification and structure-activity relationship (SAR) of HDACIs, pharmacokinetic and toxicol. properties of the HDACIs, and registered clin. studies for breast cancer treatment.  In conclusion, HDACIs have shown desirable effects on breast cancer, esp. when they are used in combination with other anticancer agents.  In the coming future, more multicenter and randomized Phase III studies are expected to be conducted pushing promising new therapies closer to the market.  In addn., the design and synthesis of novel HDACIs are also needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXhspBLLPfBrVg90H21EOLACvtfcHk0ljPStZ29yK3RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFyjsLvL&md5=f7d7d29939047fd8c74ceb489913df36</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1016%2Fj.bioorg.2019.103184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bioorg.2019.103184%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DYan%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLing%26aufirst%3DR.%26atitle%3DSmall%2520Molecule%2520HDAC%2520Inhibitors%253A%2520Promising%2520Agents%2520for%2520Breast%2520Cancer%2520Treatment%26jtitle%3DBioorg.%2520Chem.%26date%3D2019%26volume%3D91%26spage%3D103184%26doi%3D10.1016%2Fj.bioorg.2019.103184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guerriero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotayo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponichtera, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castrillon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pourzia, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schad, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrasco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lobera, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Letai, A.</span></span> <span> </span><span class="NLM_article-title">Class IIa HDAC Inhibition Reduces Breast Tumours and Metastases through Anti-Tumour Macrophages</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>543</i></span>,  <span class="NLM_fpage">428</span>– <span class="NLM_lpage">432</span>, <span class="refDoi"> DOI: 10.1038/nature21409</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fnature21409" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=28273064" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlslegtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=543&publication_year=2017&pages=428-432&author=J.+Guerrieroauthor=A.+Sotayoauthor=H.+Ponichteraauthor=J.+Castrillonauthor=A.+Pourziaauthor=S.+Schadauthor=S.+Johnsonauthor=R.+Carrascoauthor=S.+Lazoauthor=R.+T.+Bronsonauthor=S.+P.+Davisauthor=M.+Loberaauthor=M.+A.+Nolanauthor=A.+Letai&title=Class+IIa+HDAC+Inhibition+Reduces+Breast+Tumours+and+Metastases+through+Anti-Tumour+Macrophages&doi=10.1038%2Fnature21409"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Class IIa HDAC inhibition reduces breast tumors and metastases through anti-tumor macrophages</span></div><div class="casAuthors">Guerriero, Jennifer L.; Sotayo, Alaba; Ponichtera, Holly E.; Castrillon, Jessica A.; Pourzia, Alexandra L.; Schad, Sara; Johnson, Shawn F.; Carrasco, Ruben D.; Lazo, Suzan; Bronson, Roderick T.; Davis, Scott P.; Lobera, Mercedes; Nolan, Michael A.; Letai, Anthony</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">543</span>
        (<span class="NLM_cas:issue">7645</span>),
    <span class="NLM_cas:pages">428-432</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Although the main focus of immuno-oncol. has been manipulating the adaptive immune system, harnessing both the innate and adaptive arms of the immune system might produce superior tumor redn. and elimination.  Tumor-assocd. macrophages often have net pro-tumor effects, but their embedded location and their untapped potential provide impetus to discover strategies to turn them against tumors.  Strategies that deplete (anti-CSF-1 antibodies and CSF-1R inhibition) or stimulate (agonistic anti-CD40 or inhibitory anti-CD47 antibodies) tumor-assocd. macrophages have had some success.  We hypothesized that pharmacol. modulation of macrophage phenotype could produce an anti-tumor effect.  We previously reported that a first-in-class selective class IIa histone deacetylase (HDAC) inhibitor, TMP195, influenced human monocyte responses to the colony-stimulating factors CSF-1 and CSF-2 in vitro.  Here, we utilize a macrophage-dependent autochthonous mouse model of breast cancer to demonstrate that in vivo TMP195 treatment alters the tumor microenvironment and reduces tumor burden and pulmonary metastases by modulating macrophage phenotypes.  TMP195 induces the recruitment and differentiation of highly phagocytic and stimulatory macrophages within tumors.  Furthermore, combining TMP195 with chemotherapy regimens or T-cell checkpoint blockade in this model significantly enhances the durability of tumor redn.  These data introduce class IIa HDAC inhibition as a means to harness the anti-tumor potential of macrophages to enhance cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEzcFKak-anrVg90H21EOLACvtfcHk0ljPStZ29yK3RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlslegtbc%253D&md5=0356d851bbeb834038527f5190d0e4b8</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fnature21409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature21409%26sid%3Dliteratum%253Aachs%26aulast%3DGuerriero%26aufirst%3DJ.%26aulast%3DSotayo%26aufirst%3DA.%26aulast%3DPonichtera%26aufirst%3DH.%26aulast%3DCastrillon%26aufirst%3DJ.%26aulast%3DPourzia%26aufirst%3DA.%26aulast%3DSchad%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DS.%26aulast%3DCarrasco%26aufirst%3DR.%26aulast%3DLazo%26aufirst%3DS.%26aulast%3DBronson%26aufirst%3DR.%2BT.%26aulast%3DDavis%26aufirst%3DS.%2BP.%26aulast%3DLobera%26aufirst%3DM.%26aulast%3DNolan%26aufirst%3DM.%2BA.%26aulast%3DLetai%26aufirst%3DA.%26atitle%3DClass%2520IIa%2520HDAC%2520Inhibition%2520Reduces%2520Breast%2520Tumours%2520and%2520Metastases%2520through%2520Anti-Tumour%2520Macrophages%26jtitle%3DNature%26date%3D2017%26volume%3D543%26spage%3D428%26epage%3D432%26doi%3D10.1038%2Fnature21409" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span> <span> </span><span class="NLM_article-title">HDAC Inhibitors Induce Proline Dehydrogenase (POX) Transcription and Anti-Apoptotic Autophagy in Triple Negative Breast Cancer</span>. <i>Acta Biochim. Biophys. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">1064</span>– <span class="NLM_lpage">1070</span>, <span class="refDoi"> DOI: 10.1093/abbs/gmz097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1093%2Fabbs%2Fgmz097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=31559416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVehtrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2019&pages=1064-1070&author=H.+Fangauthor=G.+Duauthor=Q.+Wuauthor=R.+Liuauthor=C.+Chenauthor=J.+Feng&title=HDAC+Inhibitors+Induce+Proline+Dehydrogenase+%28POX%29+Transcription+and+Anti-Apoptotic+Autophagy+in+Triple+Negative+Breast+Cancer&doi=10.1093%2Fabbs%2Fgmz097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibitors induce proline dehydrogenase (POX) transcription and anti-apoptotic autophagy in triple negative breast cancer</span></div><div class="casAuthors">Fang, Huan; Du, Guangshi; Wu, Qiuju; Liu, Rong; Chen, Ceshi; Feng, Jing</div><div class="citationInfo"><span class="NLM_cas:title">Acta Biochimica et Biophysica Sinica</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1064-1070</span>CODEN:
                <span class="NLM_cas:coden">ABBSC2</span>;
        ISSN:<span class="NLM_cas:issn">1745-7270</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is the most aggressive subtype of breast cancer with poor clin. outcomes and without effective targeted therapies.  Numerous studies have suggested that HDAC inhibitors (TSA/SAHA) may be effective in TNBCs.  Proline oxidase, also known as proline dehydrogenase (POX/PRODH), is a key enzyme in the proline metab. pathway and plays a vital role in tumorigenesis.  In this study, we found that HDAC inhibitors (TSA/SAHA) significantly increased POX expression and autophagy through activating AMPK.  Depletion of POX decreased autophagy and increased apoptosis induced by HDAC inhibitors in TNBC cells.  These results suggest that POX contributes to cell survival under chemotherapeutic stresses and might serve as a potential target for treatment of TNBC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqva87oFArx5LVg90H21EOLACvtfcHk0ljPStZ29yK3RQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVehtrrJ&md5=338c0a2db77c2a704d48c63da2e834c6</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1093%2Fabbs%2Fgmz097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fabbs%252Fgmz097%26sid%3Dliteratum%253Aachs%26aulast%3DFang%26aufirst%3DH.%26aulast%3DDu%26aufirst%3DG.%26aulast%3DWu%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DJ.%26atitle%3DHDAC%2520Inhibitors%2520Induce%2520Proline%2520Dehydrogenase%2520%2528POX%2529%2520Transcription%2520and%2520Anti-Apoptotic%2520Autophagy%2520in%2520Triple%2520Negative%2520Breast%2520Cancer%26jtitle%3DActa%2520Biochim.%2520Biophys.%2520Sin.%26date%3D2019%26volume%3D51%26spage%3D1064%26epage%3D1070%26doi%3D10.1093%2Fabbs%2Fgmz097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fedele, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlando, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cinieri, S.</span></span> <span> </span><span class="NLM_article-title">Targeting Triple Negative Breast Cancer with Histone Deacetylase Inhibitors</span>. <i>Expert Opin. Invest. Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1199</span>– <span class="NLM_lpage">1206</span>, <span class="refDoi"> DOI: 10.1080/13543784.2017.1386172</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1080%2F13543784.2017.1386172" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=28952409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1alsbbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2017&pages=1199-1206&author=P.+Fedeleauthor=L.+Orlandoauthor=S.+Cinieri&title=Targeting+Triple+Negative+Breast+Cancer+with+Histone+Deacetylase+Inhibitors&doi=10.1080%2F13543784.2017.1386172"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting triple negative breast cancer with histone deacetylase inhibitors</span></div><div class="casAuthors">Fedele, Palma; Orlando, Laura; Cinieri, Saverio</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Investigational Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1199-1206</span>CODEN:
                <span class="NLM_cas:coden">EOIDER</span>;
        ISSN:<span class="NLM_cas:issn">1354-3784</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : Triple neg. breast cancer (TNBC) is a heterogeneous disease characterized by poor outcomes, higher rates of relapse, lack of biomarkers for rational use of targeted treatments and insensitivity to current available treatments.  Histone deacetylase inhibitors (HDACis) perform multiple cytotoxic actions and are emerging as promising multifunctional agents in TNBC.: This review focuses on the challenges so far addressed in the targeted treatment of TNBC and explores the various mechanisms by which HDACis control cancer cell growth, tumor progression and metastases.  Pivotal preclin. trials on HDACis like panobinostat, vorinostat, and entinostat show that these epigenetic agents exert an anti-proliferative effect on TNBC cells and control tumor growth by multiple mechanisms of action, including apoptosis and regulation of the epithelial to mesenchimal transition (EMT).  Combination studies have reported the synergism of HDACis with other anticancer agents.: In recent years, treatment of TNBC has recorded a high no. of failures in the development of targeted agents.  HDACis alone or in combination strategies show promising activity in TNBC and could have implications for the future targeted treatment of TNBC patients.  Future research should identify which agent synergizes better with HDACis and which patient will benefit more from these epigenetic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOqveSSSKwsbVg90H21EOLACvtfcHk0li2vewhk_iOHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1alsbbF&md5=c6df0d54d99bdbd171ce10f6431817df</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1080%2F13543784.2017.1386172&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543784.2017.1386172%26sid%3Dliteratum%253Aachs%26aulast%3DFedele%26aufirst%3DP.%26aulast%3DOrlando%26aufirst%3DL.%26aulast%3DCinieri%26aufirst%3DS.%26atitle%3DTargeting%2520Triple%2520Negative%2520Breast%2520Cancer%2520with%2520Histone%2520Deacetylase%2520Inhibitors%26jtitle%3DExpert%2520Opin.%2520Invest.%2520Drugs%26date%3D2017%26volume%3D26%26spage%3D1199%26epage%3D1206%26doi%3D10.1080%2F13543784.2017.1386172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cubitt, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiappori, A.</span></span> <span> </span><span class="NLM_article-title">Combination of HDAC and Topoisomerase Inhibitors in Small Cell Lung Cancer</span>. <i>Cancer Biol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">614</span>– <span class="NLM_lpage">622</span>, <span class="refDoi"> DOI: 10.4161/cbt.19848</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.4161%2Fcbt.19848" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=22441819" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1ensLfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=614-622&author=J.+Grayauthor=C.+L.+Cubittauthor=S.+Zhangauthor=A.+Chiappori&title=Combination+of+HDAC+and+Topoisomerase+Inhibitors+in+Small+Cell+Lung+Cancer&doi=10.4161%2Fcbt.19848"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of HDAC and topoisomerase inhibitors in small cell lung cancer</span></div><div class="casAuthors">Gray, Jhanelle; Cubitt, Christopher L.; Zhang, Shumin; Chiappori, Alberto</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Biology & Therapy</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">614-622</span>CODEN:
                <span class="NLM_cas:coden">CBTAAO</span>;
        ISSN:<span class="NLM_cas:issn">1538-4047</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">Histone deacetylase (HDAC) inhibitors, including MGCD0103 and vorinostat, have led to tumor growth inhibition and apoptosis in vivo.  However, with limited single-agent activity demonstrated in solid tumor trials, we examd. the potential for enhanced effects in combination with topoisomerase I and II inhibitors, a staple for treatment in refractory small cell lung cancer (SCLC).  SCLC cell lines were exposed to increasing concns. of single-agent HDAC inhibitors and topoisomerase inhibitors, in various combinations, to assess for cell viability, additivity or synergy and apoptosis.  We found that MGCD0103 and vorinostat decreased cell viability by at least 60 and 80%, resp.  In the majority of cell lines, the strongest synergism was seen when vorinostat was followed by either etoposide or topotecan; concurrent therapy led to antagonism in most cell lines.  Synergistic effects were seen when MGCD0103 was given concurrently or sequentially with both amrubicin and epirubicin.  Enhanced additive effects leading to caspase activation were noted for the combination of MGCD0103 or vorinostat with a topoisomerase inhibitor vs. either agent alone.  Thus, the combination of HDAC inhibitors and topoisomerase inhibitors showed enhanced cytotoxic effects in SCLC cell lines.  Further evaluation in a clin. setting may be warranted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB97O3PJ6oa7Vg90H21EOLACvtfcHk0li2vewhk_iOHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1ensLfJ&md5=55bf2ec649674011b2b0bb98ae8dd6a7</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.4161%2Fcbt.19848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcbt.19848%26sid%3Dliteratum%253Aachs%26aulast%3DGray%26aufirst%3DJ.%26aulast%3DCubitt%26aufirst%3DC.%2BL.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DChiappori%26aufirst%3DA.%26atitle%3DCombination%2520of%2520HDAC%2520and%2520Topoisomerase%2520Inhibitors%2520in%2520Small%2520Cell%2520Lung%2520Cancer%26jtitle%3DCancer%2520Biol.%2520Ther.%26date%3D2012%26volume%3D13%26spage%3D614%26epage%3D622%26doi%3D10.4161%2Fcbt.19848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Edderkaoui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chheda, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soufi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zayou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramanujan, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boros, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tajbakhsh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madhav, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhowmick, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habtezion, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murali, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pandol, S. J.</span></span> <span> </span><span class="NLM_article-title">An Inhibitor of GSK3B and HDACs Kills Pancreatic Cancer Cells and Slows Pancreatic Tumor Growth and Metastasis in Mice</span>. <i>Gastroenterology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>155</i></span>,  <span class="NLM_fpage">1985</span>– <span class="NLM_lpage">1998</span>, <span class="refDoi"> DOI: 10.1053/j.gastro.2018.08.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1053%2Fj.gastro.2018.08.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=30144430" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVSgtb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=155&publication_year=2018&pages=1985-1998&author=M.+Edderkaouiauthor=C.+Chhedaauthor=B.+Soufiauthor=F.+Zayouauthor=R.+W.+Huauthor=V.+K.+Ramanujanauthor=X.+Panauthor=L.+G.+Borosauthor=J.+Tajbakhshauthor=A.+Madhavauthor=N.+A.+Bhowmickauthor=Q.+Wangauthor=M.+Lewisauthor=R.+Tuliauthor=A.+Habtezionauthor=R.+Muraliauthor=S.+J.+Pandol&title=An+Inhibitor+of+GSK3B+and+HDACs+Kills+Pancreatic+Cancer+Cells+and+Slows+Pancreatic+Tumor+Growth+and+Metastasis+in+Mice&doi=10.1053%2Fj.gastro.2018.08.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">An Inhibitor of GSK3B and HDACs Kills Pancreatic Cancer Cells and Slows Pancreatic Tumor Growth and Metastasis in Mice</span></div><div class="casAuthors">Edderkaoui, Mouad; Chheda, Chintan; Soufi, Badr; Zayou, Fouzia; Hu, Robert W.; Ramanujan, V. Krishnan; Pan, Xinlei; Boros, Laszlo G.; Tajbakhsh, Jian; Madhav, Anisha; Bhowmick, Neil A.; Wang, Qiang; Lewis, Michael; Tuli, Richard; Habtezion, Aida; Murali, Ramachandran; Pandol, Stephen J.</div><div class="citationInfo"><span class="NLM_cas:title">Gastroenterology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">155</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1985-1998.e5</span>CODEN:
                <span class="NLM_cas:coden">GASTAB</span>;
        ISSN:<span class="NLM_cas:issn">0016-5085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Growth, progression, and drug resistance of pancreatic ductal adenocarcinomas (PDACs) have been assocd. with increased levels and activity of glycogen synthase kinase 3 beta (GSK3B) and histone deacetylases (HDACs).  We designed and synthesized mols. that simultaneously inhibit the activities of both enzymes.  We tested the effects of one of these mols., Metavert, in pancreatic cancer cells and mice with pancreatic tumors.  We tested the ability of Metavert to bind GSK3B and HDACs using surface plasmon resonance.  MIA PaCa-2, Bx-PC3, HPAF-II, and HPDE6 cell lines were incubated with different concns. of Metavert, with or without paclitaxel or gemcitabine, or with other inhibitors of GSK3B and HDACs; cells were analyzed for apoptosis and migration and by immunoblotting, immunofluorescence, and real-time polymerase chain reaction.  Kras[symbol omitted]/LSLG12D;Trp53[symbol omitted]/LSLR172H;Pdx-1-Cre (KPC) mice (2 mo old) were given injections of Metavert (5 mg/kg, 3 times/wk) or vehicle (control).  B6.129J mice with tumors grown from UN-KPC961-Luc cells were given injections of Metavert or vehicle.  Tumors and metastases were counted and pancreata were analyzed by immunohistochem.  Glucose metab. was measured using 13C-glucose tracer and mass spectroscopy and flow cytometry.  Cytokine levels in blood samples were measured using multiplexing ELISA.  Metavert significantly reduced survival of PDAC cells but not nontransformed cells; the agent reduced markers of the epithelial-to-mesenchymal transition and stem cells in PDAC cell lines.  Cells incubated with Metavert in combination with irradn. and paclitaxel or gemcitabine had reduced survival compared with cells incubated with either agent alone; Metavert increased killing of drug-resistant PDAC cells by paclitaxel and gemcitabine.  PDAC cells incubated with Metavert acquired normalized glucose metab.  Administration of Metavert (alone or in combination with gemcitibine) to KPC mice or mice with syngeneic tumors significantly increased their survival times, slowed tumor growth, prevented tumor metastasis, decreased tumor infiltration by tumor-assocd. macrophages, and decreased blood levels of cytokines.  In studies of PDAC cells and 2 mouse models of PDAC, we found a dual inhibitor of GSK3B and HDACs (Metavert) to induce cancer cell apoptosis, reduce migration and expression of stem cell markers, and slow growth of tumors and metastases.  Metavert had synergistic effects with gemcitabine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfpL9zAQLf7rVg90H21EOLACvtfcHk0li2vewhk_iOHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVSgtb3J&md5=aa8b71bf074275487b3f7b0d87729538</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1053%2Fj.gastro.2018.08.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.gastro.2018.08.028%26sid%3Dliteratum%253Aachs%26aulast%3DEdderkaoui%26aufirst%3DM.%26aulast%3DChheda%26aufirst%3DC.%26aulast%3DSoufi%26aufirst%3DB.%26aulast%3DZayou%26aufirst%3DF.%26aulast%3DHu%26aufirst%3DR.%2BW.%26aulast%3DRamanujan%26aufirst%3DV.%2BK.%26aulast%3DPan%26aufirst%3DX.%26aulast%3DBoros%26aufirst%3DL.%2BG.%26aulast%3DTajbakhsh%26aufirst%3DJ.%26aulast%3DMadhav%26aufirst%3DA.%26aulast%3DBhowmick%26aufirst%3DN.%2BA.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLewis%26aufirst%3DM.%26aulast%3DTuli%26aufirst%3DR.%26aulast%3DHabtezion%26aufirst%3DA.%26aulast%3DMurali%26aufirst%3DR.%26aulast%3DPandol%26aufirst%3DS.%2BJ.%26atitle%3DAn%2520Inhibitor%2520of%2520GSK3B%2520and%2520HDACs%2520Kills%2520Pancreatic%2520Cancer%2520Cells%2520and%2520Slows%2520Pancreatic%2520Tumor%2520Growth%2520and%2520Metastasis%2520in%2520Mice%26jtitle%3DGastroenterology%26date%3D2018%26volume%3D155%26spage%3D1985%26epage%3D1998%26doi%3D10.1053%2Fj.gastro.2018.08.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rana, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diermeier, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanif, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosengren, R. J.</span></span> <span> </span><span class="NLM_article-title">Understanding Failure and Improving Treatment Using HDAC Inhibitors for Prostate Cancer</span>. <i>Biomedicines</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">22</span>, <span class="refDoi"> DOI: 10.3390/biomedicines8020022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3390%2Fbiomedicines8020022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlant7nK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2020&pages=22&author=Z.+Ranaauthor=S.+Diermeierauthor=M.+Hanifauthor=R.+J.+Rosengren&title=Understanding+Failure+and+Improving+Treatment+Using+HDAC+Inhibitors+for+Prostate+Cancer&doi=10.3390%2Fbiomedicines8020022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Understanding failure and improving treatment using HDAC inhibitors for prostate cancer</span></div><div class="casAuthors">Rana, Zohaib; Diermeier, Sarah; Hanif, Muhammad; Rosengren, Rhonda J.</div><div class="citationInfo"><span class="NLM_cas:title">Biomedicines</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">22</span>CODEN:
                <span class="NLM_cas:coden">BIOMID</span>;
        ISSN:<span class="NLM_cas:issn">2227-9059</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Novel treatment regimens are required for castration-resistant prostate cancers (CRPCs) that become unresponsive to std. treatments, such as docetaxel and enzalutamide.  Histone deacetylase (HDAC) inhibitors showed promising results in hematol. malignancies, but they failed in solid tumors such as prostate cancer, despite the overexpression of HDACs in CRPC.  Four HDAC inhibitors, vorinostat, pracinostat, panobinostat and romidepsin, underwent phase II clin. trials for prostate cancers; however, phase III trials were not recommended due to a majority of patients exhibiting either toxicity or disease progression.  In this review, the pharmacodynamic reasons for the failure of HDAC inhibitors were assessed and placed in the context of the advancements in the understanding of CRPCs, HDACs and resistance mechanisms.  The review focuses on three themes: evolution of androgen receptor-neg. prostate cancers, development of resistance mechanisms and differential effects of HDACs.  In conclusion, advancements can be made in this field by characterizing HDACs in prostate tumors more extensively, as this will allow more specific drugs catering to the specific HDAC subtypes to be designed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPlgfpRIlu5rVg90H21EOLACvtfcHk0lhhP94RDUGDIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlant7nK&md5=ab6f27899dded24a2679b3497a9d1524</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.3390%2Fbiomedicines8020022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fbiomedicines8020022%26sid%3Dliteratum%253Aachs%26aulast%3DRana%26aufirst%3DZ.%26aulast%3DDiermeier%26aufirst%3DS.%26aulast%3DHanif%26aufirst%3DM.%26aulast%3DRosengren%26aufirst%3DR.%2BJ.%26atitle%3DUnderstanding%2520Failure%2520and%2520Improving%2520Treatment%2520Using%2520HDAC%2520Inhibitors%2520for%2520Prostate%2520Cancer%26jtitle%3DBiomedicines%26date%3D2020%26volume%3D8%26spage%3D22%26doi%3D10.3390%2Fbiomedicines8020022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tejada, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montilla-García, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cronin, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cikes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Fernández, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-Cano, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruiz-Cantero, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Penninger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baeyens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobos, E. J.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 Receptors Control Immune-Driven Peripheral Opioid Analgesia during Inflammation in Mice</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">8396</span>– <span class="NLM_lpage">8401</span>, <span class="refDoi"> DOI: 10.1073/pnas.1620068114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1073%2Fpnas.1620068114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=28716934" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFOru73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=8396-8401&author=M.+A.+Tejadaauthor=A.+Montilla-Garc%C3%ADaauthor=S.+J.+Croninauthor=D.+Cikesauthor=C.+S%C3%A1nchez-Fern%C3%A1ndezauthor=R.+Gonz%C3%A1lez-Canoauthor=M.+C.+Ruiz-Canteroauthor=J.+M.+Penningerauthor=J.+M.+Velaauthor=J.+Baeyensauthor=E.+J.+Cobos&title=Sigma-1+Receptors+Control+Immune-Driven+Peripheral+Opioid+Analgesia+during+Inflammation+in+Mice&doi=10.1073%2Fpnas.1620068114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptors control immune-driven peripheral opioid analgesia during inflammation in mice</span></div><div class="casAuthors">Tejada, Miguel A.; Montilla-Garcia, Angeles; Cronin, Shane J.; Cikes, Domagoj; Sanchez-Fernandez, Cristina; Gonzalez-Cano, Rafael; Ruiz-Cantero, M. Carmen; Penninger, Josef M.; Vela, Jose M.; Baeyens, Jose M.; Cobos, Enrique J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">31</span>),
    <span class="NLM_cas:pages">8396-8401</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Sigma-1 antagonism potentiates the antinociceptive effects of opioid drugs, so sigma-1 receptors constitute a biol. brake to opioid drug-induced analgesia.  The pathophysiol. role of this process is unknown.  We aimed to investigate whether sigma-1 antagonism reduces inflammatory pain through the disinhibition of the endogenous opioidergic system in mice.  The selective sigma-1 antagonists BD-1063 and S1RA abolished mech. and thermal hyperalgesia in mice with carrageenan-induced acute (3 h) inflammation.  Sigma-1-mediated antihyperalgesia was reversed by the opioid antagonists naloxone and naloxone methiodide (a peripherally restricted naloxone analog) and by local administration at the inflamed site of monoclonal antibody 3-E7, which recognizes the pan-opioid sequence Tyr-Gly-Gly-Phe at the N terminus of most endogenous opioid peptides (EOPs).  Neutrophils expressed pro-opiomelanocortin, the precursor of β-endorphin (a known EOP), and constituted the majority of the acute immune infiltrate. β-endorphin levels increased in the inflamed paw, and this increase and the antihyperalgesic effects of sigma-1 antagonism were abolished by reducing the neutrophil load with in vivo administration of an anti-Ly6G antibody.  The opioid-dependent sigma-1 antihyperalgesic effects were preserved 5 d after carrageenan administration, where macrophages/monocytes were found to express pro-opiomelanocortin and to now constitute the majority of the immune infiltrate.  These results suggest that immune cells harboring EOPs are needed for the antihyperalgesic effects of sigma-1 antagonism during inflammation.  In conclusion, sigma-1 receptors curtail immune-driven peripheral opioid analgesia, and sigma-1 antagonism produces local opioid analgesia by enhancing the action of EOPs of immune origin, maximizing the analgesic potential of immune cells that naturally accumulate in painful inflamed areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqktSX7oMTPDrVg90H21EOLACvtfcHk0lhhP94RDUGDIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFOru73P&md5=ede5abe4e1e51845e9bd46960a39d54a</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1620068114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1620068114%26sid%3Dliteratum%253Aachs%26aulast%3DTejada%26aufirst%3DM.%2BA.%26aulast%3DMontilla-Garc%25C3%25ADa%26aufirst%3DA.%26aulast%3DCronin%26aufirst%3DS.%2BJ.%26aulast%3DCikes%26aufirst%3DD.%26aulast%3DS%25C3%25A1nchez-Fern%25C3%25A1ndez%26aufirst%3DC.%26aulast%3DGonz%25C3%25A1lez-Cano%26aufirst%3DR.%26aulast%3DRuiz-Cantero%26aufirst%3DM.%2BC.%26aulast%3DPenninger%26aufirst%3DJ.%2BM.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26aulast%3DBaeyens%26aufirst%3DJ.%26aulast%3DCobos%26aufirst%3DE.%2BJ.%26atitle%3DSigma-1%2520Receptors%2520Control%2520Immune-Driven%2520Peripheral%2520Opioid%2520Analgesia%2520during%2520Inflammation%2520in%2520Mice%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26spage%3D8396%26epage%3D8401%26doi%3D10.1073%2Fpnas.1620068114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhen, X.</span></span> <span> </span><span class="NLM_article-title">Allosteric Modulation of Sigma-1 Receptors by SKF83959 Inhibits Microglia-Mediated Inflammation</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>134</i></span>,  <span class="NLM_fpage">904</span>– <span class="NLM_lpage">914</span>, <span class="refDoi"> DOI: 10.1111/jnc.13182</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1111%2Fjnc.13182" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=26031312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVWqtrfM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2015&pages=904-914&author=Z.+Wuauthor=L.+Liauthor=L.-T.+Zhengauthor=Z.+Xuauthor=L.+Guoauthor=X.+Zhen&title=Allosteric+Modulation+of+Sigma-1+Receptors+by+SKF83959+Inhibits+Microglia-Mediated+Inflammation&doi=10.1111%2Fjnc.13182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric modulation of sigma-1 receptors by SKF83959 inhibits microglia-mediated inflammation</span></div><div class="casAuthors">Wu, Zhuang; Li, Linlang; Zheng, Long-Tai; Xu, Zhihong; Guo, Lin; Zhen, Xuechu</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">904-914</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Recent studies have shown that sigma-1 receptor orthodox agonists can inhibit neuroinflammation.  SKF83959 (3-methyl-6-chloro-7,8-hydroxy-1-[3-methylphenyl]-2,3,4,5-tetrahydro-1H-3-benzazepine), an atypical dopamine receptor-1 agonist, has been recently identified as a potent allosteric modulator of sigma-1 receptor.  Here, the authors investigated the anti-inflammatory effects of SKF83959 in lipopolysaccharide (LPS)-stimulated BV2 microglia.  The authors' results indicated that SKF83959 significantly suppressed the expression/release of the pro-inflammatory mediators, such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), inducible nitric oxide synthase (iNOS), and inhibited the generation of reactive oxygen species.  All of these responses were blocked by selective sigma-1 receptor antagonists (BD1047 or BD1063) and by ketoconazole (an inhibitor of enzyme cytochrome c17 to inhibit the synthesis of endogenous dehydroepiandrosterone, DHEA).  Addnl., the authors found that SKF83959 promoted the binding activity of DHEA with sigma-1 receptors, and enhanced the inhibitory effects of DHEA on LPS-induced microglia activation in a synergic manner.  Furthermore, in a microglia-conditioned media system, SKF83959 inhibited the cytotoxicity of conditioned medium generated by LPS-activated microglia toward HT-22 neuroblastoma cells.  Taken together, the authors' study provides the first evidence that allosteric modulation of sigma-1 receptors by SKF83959 inhibits microglia-mediated inflammation.  SKF83959 is a potent allosteric modulator of sigma-1 receptor.  The authors' results indicated that SKF83959 enhanced the activity of endogenous dehydroepiandrosterone (DHEA) in a synergic manner, and inhibited the activation of BV2 microglia and the expression/release of the pro-inflammatory mediators, such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), inducible nitric oxide synthase (iNOS).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpn8L1hvvxV_LVg90H21EOLACvtfcHk0lhhP94RDUGDIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVWqtrfM&md5=e065dcdcf61b88a93eae9799d1af230a</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1111%2Fjnc.13182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjnc.13182%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DZheng%26aufirst%3DL.-T.%26aulast%3DXu%26aufirst%3DZ.%26aulast%3DGuo%26aufirst%3DL.%26aulast%3DZhen%26aufirst%3DX.%26atitle%3DAllosteric%2520Modulation%2520of%2520Sigma-1%2520Receptors%2520by%2520SKF83959%2520Inhibits%2520Microglia-Mediated%2520Inflammation%26jtitle%3DJ.%2520Neurochem.%26date%3D2015%26volume%3D134%26spage%3D904%26epage%3D914%26doi%3D10.1111%2Fjnc.13182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruscher, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inácio, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valind, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowshan Ravan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuric, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieloch, T.</span></span> <span> </span><span class="NLM_article-title">Effects of the Sigma-1 Receptor Agonist 1-(3,4-Dimethoxyphenethyl)-4-(3-Phenylpropyl)-Piperazine Dihydro-Chloride on Inflammation after Stroke</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">e45118</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0045118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1371%2Fjournal.pone.0045118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=23028794" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVWlsb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&author=K.+Ruscherauthor=A.+R.+In%C3%A1cioauthor=K.+Valindauthor=A.+Rowshan+Ravanauthor=E.+Kuricauthor=T.+Wieloch&title=Effects+of+the+Sigma-1+Receptor+Agonist+1-%283%2C4-Dimethoxyphenethyl%29-4-%283-Phenylpropyl%29-Piperazine+Dihydro-Chloride+on+Inflammation+after+Stroke&doi=10.1371%2Fjournal.pone.0045118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of the sigma-1 receptor agonist 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)-piperazine dihydro-chloride on inflammation after stroke</span></div><div class="casAuthors">Ruscher, Karsten; Inacio, Ana R.; Valind, Kristian; Ravan, Arman Rowshan; Kuric, Enida; Wieloch, Tadeusz</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">e45118</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Activation of the sigma-1 receptor (Sig-1R) improves functional recovery in models of exptl. stroke and is known to modulate microglia function.  The present study was conducted to investigate if Sig-1R activation after exptl. stroke affects mediators of the inflammatory response in the ischemic hemisphere.  Male Wistar rats were subjected to transient occlusion of the middle cerebral artery (MCAO) and injected with the specific Sig-1R agonist 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride (SA4503) or saline for 5 days starting on day 2 after MCAO.  Treatment did not affect the increased levels of the pro-inflammatory cytokines interleukin 1 beta (IL-1β), tumor necrosis factor alpha (TNF-α), interferon gamma (IFN-γ), interleukin 4 (IL-4), interleukin 5 (IL-5) and interleukin 13 (IL-13) in the infarct core and peri-infarct area after MCAO.  In addn., treatment with SA4503 did not affect elevated levels of nitrite, TNF-α and IL-1β obsd. in primary cultures of microglia exposed to combined Hypoxia/Aglycemia, while the unspecific sigma receptor ligand 1,3-di-o-tolylguanidine (DTG) significantly decreased the prodn. of nitrite and levels of TNF-α.  Anal. of the ischemic hemisphere also revealed increased levels of ionized calcium binding adaptor mol. 1 (Iba1) levels in the infarct core of SA4503 treated animals.  However, no difference in Iba1 immunoreactivity was detected in the infarct core.  Also, levels of the proliferation marker proliferating cell nuclear antigen (PCNA) and OX-42 were not increased in the infarct core in rats treated with SA4503.  Together, our results suggest that sigma-1 receptor activation affects Iba1 expression in microglia/macrophages of the ischemic hemisphere after exptl. stroke but does not affect post-stroke inflammatory mediators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAvyBGCVtvQ7Vg90H21EOLACvtfcHk0lgymG6dbUJGfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVWlsb7F&md5=838dcf5e3cf3d68402f0f51c8fdb5a37</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0045118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0045118%26sid%3Dliteratum%253Aachs%26aulast%3DRuscher%26aufirst%3DK.%26aulast%3DIn%25C3%25A1cio%26aufirst%3DA.%2BR.%26aulast%3DValind%26aufirst%3DK.%26aulast%3DRowshan%2BRavan%26aufirst%3DA.%26aulast%3DKuric%26aufirst%3DE.%26aulast%3DWieloch%26aufirst%3DT.%26atitle%3DEffects%2520of%2520the%2520Sigma-1%2520Receptor%2520Agonist%25201-%25283%252C4-Dimethoxyphenethyl%2529-4-%25283-Phenylpropyl%2529-Piperazine%2520Dihydro-Chloride%2520on%2520Inflammation%2520after%2520Stroke%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26doi%3D10.1371%2Fjournal.pone.0045118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seki, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernández-Castañeda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beiter, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodfolk, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaultier, A.</span></span> <span> </span><span class="NLM_article-title">Modulation of the Sigma-1 Receptor-IRE1 Pathway Is Beneficial in Preclinical Models of Inflammation and Sepsis</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>, <span class="NLM_elocation-id">eaau5266</span> <span class="refDoi"> DOI: 10.1126/scitranslmed.aau5266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1126%2Fscitranslmed.aau5266" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=30728287" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&author=D.+A.+Rosenauthor=S.+M.+Sekiauthor=A.+Fern%C3%A1ndez-Casta%C3%B1edaauthor=R.+M.+Beiterauthor=J.+D.+Ecclesauthor=J.+A.+Woodfolkauthor=A.+Gaultier&title=Modulation+of+the+Sigma-1+Receptor-IRE1+Pathway+Is+Beneficial+in+Preclinical+Models+of+Inflammation+and+Sepsis&doi=10.1126%2Fscitranslmed.aau5266"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.aau5266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.aau5266%26sid%3Dliteratum%253Aachs%26aulast%3DRosen%26aufirst%3DD.%2BA.%26aulast%3DSeki%26aufirst%3DS.%2BM.%26aulast%3DFern%25C3%25A1ndez-Casta%25C3%25B1eda%26aufirst%3DA.%26aulast%3DBeiter%26aufirst%3DR.%2BM.%26aulast%3DEccles%26aufirst%3DJ.%2BD.%26aulast%3DWoodfolk%26aufirst%3DJ.%2BA.%26aulast%3DGaultier%26aufirst%3DA.%26atitle%3DModulation%2520of%2520the%2520Sigma-1%2520Receptor-IRE1%2520Pathway%2520Is%2520Beneficial%2520in%2520Preclinical%2520Models%2520of%2520Inflammation%2520and%2520Sepsis%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2019%26volume%3D11%26doi%3D10.1126%2Fscitranslmed.aau5266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, T.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dou, X.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, Z.</span></span> <span> </span><span class="NLM_article-title">Paeoniflorin Exerts Neuroprotective Effects by Modulating the M1/M2 Subset Polarization of Microglia/Macrophages in the Hippocampal CA1 Region of Vascular Dementia Rats via Cannabinoid Receptor 2</span>. <i>Chin. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">14</span>, <span class="refDoi"> DOI: 10.1186/s13020-018-0173-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1186%2Fs13020-018-0173-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=29560022" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisV2ms7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=14&author=X.-Q.+Luoauthor=A.+Liauthor=X.+Yangauthor=X.+Xiaoauthor=R.+Huauthor=T.-W.+Wangauthor=X.-Y.+Douauthor=D.-J.+Yangauthor=Z.+Dong&title=Paeoniflorin+Exerts+Neuroprotective+Effects+by+Modulating+the+M1%2FM2+Subset+Polarization+of+Microglia%2FMacrophages+in+the+Hippocampal+CA1+Region+of+Vascular+Dementia+Rats+via+Cannabinoid+Receptor+2&doi=10.1186%2Fs13020-018-0173-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Paeoniflorin exerts neuroprotective effects by modulating the M1/M2 subset polarization of microglia/macrophages in the hippocampal CA1 region of vascular dementia rats via cannabinoid receptor 2</span></div><div class="casAuthors">Luo, Xian-Qin; Li, Ao; Yang, Xue; Xiao, Xiao; Hu, Rong; Wang, Tian-Wen; Dou, Xiao-Yun; Yang, Da-Jian; Dong, Zhi</div><div class="citationInfo"><span class="NLM_cas:title">Chinese Medicine (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14/1-14/17</span>CODEN:
                <span class="NLM_cas:coden">CMHEBK</span>;
        ISSN:<span class="NLM_cas:issn">1749-8546</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Cerebral hypoperfusion is a pivotal risk factor for vascular dementia (VD), for which effective therapy remains inadequate.  Persistent inflammatory responses and excessive chemotaxis of microglia/macrophages in the brain may accelerate the progression of VD.  Endocannabinoids are involved in neuronal protection against inflammation-induced neuronal injury.  Cannabinoids acting at cannabinoid receptor 2 (CB2R) can decrease inflammation.  Based on the identification of paeoniflorin (PF) as a CB2R agonist, we investigated the neuroprotective and microglia/macrophages M1 to M2 polarization promoting effects of PF in a permanent four-vessel occlusion rat model.  Methods: One week after surgery, PF was i.p. administered at a dose of 40 mg/kg once a day for 28 successive days.  The effects of PF on memory deficit were investigated by a Morris water maze test, and the effects of PF on hippocampal neuronal damage were evaluated by light microscope and electron microscope.  The mRNA and protein expression levels of key mols. related to the M1/M2 polarization of microglia/macrophages were assessed by RT-qPCR and Western blotting, resp.  Results: Administration of PF could significantly attenuate cerebral hypoperfusion-induced impairment of learning and memory and reduce the morphol. and ultrastructural changes in the hippocampal CA1 region of rats.  Moreover, PF promoted an M1 to M2 phenotype transition in microglia/macrophages in the hippocampus of rats.  In addn. to its inhibitory property against proinflammatory M1 mediator expression, such as IL-1β, IL-6, TNF-α and NO, PF dramatically up-regulated expression of anti-inflammatory cytokines IL-10 and TGF-β1.  Importantly, CB2R antagonist AM630 abolished these beneficial effects produced by PF on learning, memory and hippocampus structure in rats, as well as the polarization of microglia/macrophages to the M2 phenotype.  Addnl., PF treatment significantly inhibited cerebral hypoperfusion-induced mTOR/NF-κB proinflammatory pathway and enhanced PI3K/Akt anti-inflammatory pathway.  Effects of PF on these signaling pathways were effectively attenuated when rats were co-treated with PF and AM630, indicating that the mTOR/NF-κB and PI3K/Akt signaling pathways were involved in the PF effects through CB2R activation.  Conclusion: These findings demonstrated PF exerts its neuroprotective effect and shifts the inflammatory milieu toward resoln. by modulation of microglia/macrophage polarization via CB2R activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_ktU0wl5Y4rVg90H21EOLACvtfcHk0lgymG6dbUJGfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisV2ms7jJ&md5=130f2a1ec848eb6a3f18a133fa2fea8c</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1186%2Fs13020-018-0173-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13020-018-0173-1%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DX.-Q.%26aulast%3DLi%26aufirst%3DA.%26aulast%3DYang%26aufirst%3DX.%26aulast%3DXiao%26aufirst%3DX.%26aulast%3DHu%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DT.-W.%26aulast%3DDou%26aufirst%3DX.-Y.%26aulast%3DYang%26aufirst%3DD.-J.%26aulast%3DDong%26aufirst%3DZ.%26atitle%3DPaeoniflorin%2520Exerts%2520Neuroprotective%2520Effects%2520by%2520Modulating%2520the%2520M1%252FM2%2520Subset%2520Polarization%2520of%2520Microglia%252FMacrophages%2520in%2520the%2520Hippocampal%2520CA1%2520Region%2520of%2520Vascular%2520Dementia%2520Rats%2520via%2520Cannabinoid%2520Receptor%25202%26jtitle%3DChin.%2520Med.%26date%3D2018%26volume%3D13%26spage%3D14%26doi%3D10.1186%2Fs13020-018-0173-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, G.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid Receptor-2 Stimulation Suppresses Neuroinflammation by Regulating Microglial M1/M2 Polarization through the CAMP/PKA Pathway in an Experimental GMH Rat Model</span>. <i>Brain, Behav., Immun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">118</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1016/j.bbi.2016.05.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bbi.2016.05.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=27261088" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC28XpvFamsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2016&pages=118-129&author=Y.+Taoauthor=L.+Liauthor=B.+Jiangauthor=Z.+Fengauthor=L.+Yangauthor=J.+Tangauthor=Q.+Chenauthor=J.+Zhangauthor=Q.+Tanauthor=H.+Fengauthor=Z.+Chenauthor=G.+Zhu&title=Cannabinoid+Receptor-2+Stimulation+Suppresses+Neuroinflammation+by+Regulating+Microglial+M1%2FM2+Polarization+through+the+CAMP%2FPKA+Pathway+in+an+Experimental+GMH+Rat+Model&doi=10.1016%2Fj.bbi.2016.05.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid receptor-2 stimulation suppresses neuroinflammation by regulating microglial M1/M2 polarization through the cAMP/PKA pathway in an experimental GMH rat model</span></div><div class="casAuthors">Tao, Yihao; Li, Lin; Jiang, Bing; Feng, Zhou; Yang, Liming; Tang, Jun; Chen, Qianwei; Zhang, Jianbo; Tan, Qiang; Feng, Hua; Chen, Zhi; Zhu, Gang</div><div class="citationInfo"><span class="NLM_cas:title">Brain, Behavior, and Immunity</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">118-129</span>CODEN:
                <span class="NLM_cas:coden">BBIMEW</span>;
        ISSN:<span class="NLM_cas:issn">0889-1591</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Excessive inflammatory responses are involved in secondary brain injury during germinal matrix hemorrhage (GMH).  The process of microglial polarization to the pro-inflammatory M1 or anti-inflammatory M2 phenotypes is considered to occur in a major immunomodulatory manner during brain inflammation.  We previously found that cannabinoid receptor-2 (CB2R) stimulation attenuated microglial accumulation and brain injury following exptl. GMH.  However, whether CB2R has effects on microglial polarization after GMH remains unclear.  Herein, we investigated the effects of CB2R stimulation on neuroinflammation after exptl. GMH and the potential mechanisms that mediate M1/M2 microglial phenotype regulation.  The results indicated that during the GMH acute phase, microglia primarily polarized to the M1 phenotype and induced an overwhelming release of pro-inflammatory cytokines.  However, JWH133, a selective CB2R agonist, significantly prevented the pro-inflammatory cytokine release while promoting an M1 to M2 phenotype transformation in microglia, resulting in an increased anti-inflammatory cytokine release.  Moreover, in thrombin-induced rat primary microglial cells, JWH133 reduced the pro-inflammatory cytokine levels and M1 phenotype by enhancing the acquisition of the M2 phenotype.  Addnl., JWH133 facilitated synthesis of cAMP (cAMP) and its downstream effectors, phosphorylated cAMP-dependent protein kinase (p-PKA) and exchange protein activated by cyclic-AMP 1 (Epac1).  The promoting effects of JWH133 on M2 polarization were attenuated with a specific PKA inhibitor but not with an Epac inhibitor, indicating that the cAMP/PKA signaling pathway was involved in the JWH133 effects.  This is the first study to propose that promotion of microglial M2 polarization through the cAMP/PKA pathway participates in the CB2R-mediated anti-inflammatory effects after GMH induction.  The results will help to further understand the mechanisms that underlie neuroprotection by CB2R in GMH and promote clin. translational research for CB2R agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4Cj43phmm1bVg90H21EOLACvtfcHk0lj20f8kW_m8gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpvFamsr8%253D&md5=9fd6079a5ec6c68346109201d2a92124</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.bbi.2016.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbi.2016.05.020%26sid%3Dliteratum%253Aachs%26aulast%3DTao%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DB.%26aulast%3DFeng%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DQ.%26aulast%3DFeng%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DZhu%26aufirst%3DG.%26atitle%3DCannabinoid%2520Receptor-2%2520Stimulation%2520Suppresses%2520Neuroinflammation%2520by%2520Regulating%2520Microglial%2520M1%252FM2%2520Polarization%2520through%2520the%2520CAMP%252FPKA%2520Pathway%2520in%2520an%2520Experimental%2520GMH%2520Rat%2520Model%26jtitle%3DBrain%252C%2520Behav.%252C%2520Immun.%26date%3D2016%26volume%3D58%26spage%3D118%26epage%3D129%26doi%3D10.1016%2Fj.bbi.2016.05.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sackett, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span> <span> </span><span class="NLM_article-title">Endocannabinoid Modulation of Microglial Phenotypes in Neuropathology</span>. <i>Front. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">87</span>, <span class="refDoi"> DOI: 10.3389/fneur.2020.00087</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3389%2Ffneur.2020.00087" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=32117037" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BB387nvFOmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=87&author=M.+Tanakaauthor=S.+Sackettauthor=Y.+Zhang&title=Endocannabinoid+Modulation+of+Microglial+Phenotypes+in+Neuropathology&doi=10.3389%2Ffneur.2020.00087"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Endocannabinoid Modulation of Microglial Phenotypes in Neuropathology</span></div><div class="casAuthors">Tanaka Mikiei; Sackett Scott; Zhang Yumin</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neurology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">87</span>
        ISSN:<span class="NLM_cas:issn">1664-2295</span>.
    </div><div class="casAbstract">Microglia, the resident immune cells of the central nervous system, mediate brain homeostasis by controlling neuronal proliferation/differentiation and synaptic activity.  In response to external signals from neuropathological conditions, homeostatic (M0) microglia can adopt one of two activation states: the classical (M1) activation state, which secretes mediators of the proinflammatory response, and the alternative (M2) activation state, which presumably mediates the resolution of neuroinflammation and tissue repair/remodeling.  Since chronic inflammatory activation of microglia is correlated with several neurodegenerative diseases, functional modulation of microglial phenotypes has been considered as a potential therapeutic strategy.  The endocannabinoid (eCB) system, composed of cannabinoid receptors and ligands and their metabolic/biosynthetic enzymes, has been shown to activate anti-inflammatory signaling pathways that modulate immune cell functions.  Growing evidence has demonstrated that endogenous, synthetic, and plant-derived eCB agonists possess therapeutic effects on several neuropathologies; however, the molecular mechanisms that mediate the anti-inflammatory effects have not yet been identified.  Over the last decade, it has been revealed that the eCB system modulates microglial activation and population.  In this review, we thoroughly examine recent studies on microglial phenotype modulation by eCB in neuroinflammatory and neurodegenerative disease conditions.  We hypothesize that cannabinoid 2 receptor (CB2R) signaling shifts the balance of expression between neuroinflammatory (M1-type) genes, neuroprotective (M2-type) genes, and homeostatic (M0-type) genes toward the latter two gene expressions, by which microglia acquire therapeutic functionality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQr8TVfT8vUqWmbXvSEQle5fW6udTcc2eYTjsvRDlPIPrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB387nvFOmsQ%253D%253D&md5=ae51dd20a721dbc2fb5271359756ff49</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.3389%2Ffneur.2020.00087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffneur.2020.00087%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DM.%26aulast%3DSackett%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26atitle%3DEndocannabinoid%2520Modulation%2520of%2520Microglial%2520Phenotypes%2520in%2520Neuropathology%26jtitle%3DFront.%2520Neurol.%26date%3D2020%26volume%3D11%26spage%3D87%26doi%3D10.3389%2Ffneur.2020.00087" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharifi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pourpaknia, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahebkar, A.</span></span> <span> </span><span class="NLM_article-title">Manipulating Macrophage Polarization and Function Using Classical HDAC Inhibitors: Implications for Autoimmunity and Inflammation</span>. <i>Crit. Rev. Oncol. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1016/j.critrevonc.2018.05.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.critrevonc.2018.05.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=29958625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BB3c%252Fjtl2qtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2018&pages=1-18&author=A.+Mohammadiauthor=A.+Sharifiauthor=R.+Pourpakniaauthor=S.+Mohammadianauthor=A.+Sahebkar&title=Manipulating+Macrophage+Polarization+and+Function+Using+Classical+HDAC+Inhibitors%3A+Implications+for+Autoimmunity+and+Inflammation&doi=10.1016%2Fj.critrevonc.2018.05.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Manipulating macrophage polarization and function using classical HDAC inhibitors: Implications for autoimmunity and inflammation</span></div><div class="casAuthors">Mohammadi Asadollah; Sharifi Atefeh; Pourpaknia Reza; Mohammadian Saeed; Sahebkar Amirhossein</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-18</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Macrophages are important player in defense against invading pathogens and their dysfunction is linked to most of inflammatory and autoimmune diseases.  Inflammation is a normal and physiological response of the immune system against harmful stimuli such as infection and injury.  However, when allowed to continue unchecked, under certain conditions it turns into autoimmune or inflammatory diseases, neurodegeneration, and carcinogenesis.  Currently, several safe and effective anti-inflammatory drugs are available with many more drugs in the development pipeline, among which are histone deacetylase inhibitors.  In this review we discuss how post-translational modifications of histones influence the innate and adaptive immunity through macrophage survival, proliferation, polarization and functional responses.  We also discuss how emerging classes of pharmacological agents which developed for use as anti-cancer agents, have been applied as anti-inflammatory drugs to treat macrophage-mediated inflammatory and autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQA9U7N2BuEAGLFM_lbR1VmfW6udTcc2eYTjsvRDlPIPrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c%252Fjtl2qtw%253D%253D&md5=9c7e9610928e1158a2d2b73d95dd3cdc</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2018.05.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2018.05.009%26sid%3Dliteratum%253Aachs%26aulast%3DMohammadi%26aufirst%3DA.%26aulast%3DSharifi%26aufirst%3DA.%26aulast%3DPourpaknia%26aufirst%3DR.%26aulast%3DMohammadian%26aufirst%3DS.%26aulast%3DSahebkar%26aufirst%3DA.%26atitle%3DManipulating%2520Macrophage%2520Polarization%2520and%2520Function%2520Using%2520Classical%2520HDAC%2520Inhibitors%253A%2520Implications%2520for%2520Autoimmunity%2520and%2520Inflammation%26jtitle%3DCrit.%2520Rev.%2520Oncol.%2520Hematol.%26date%3D2018%26volume%3D128%26spage%3D1%26epage%3D18%26doi%3D10.1016%2Fj.critrevonc.2018.05.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigues, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de S. M. Pinheiro, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sagrillo, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraga, C. A. M.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylases as Targets for the Treatment of Neurodegenerative Disorders: Challenges and Future Opportunities</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">2177</span>– <span class="NLM_lpage">2211</span>, <span class="refDoi"> DOI: 10.1002/med.21701</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1002%2Fmed.21701" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=32588916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVKlurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2020&pages=2177-2211&author=D.+A.+Rodriguesauthor=P.+de+S.+M.+Pinheiroauthor=F.+S.+Sagrilloauthor=M.+L.+Bolognesiauthor=C.+A.+M.+Fraga&title=Histone+Deacetylases+as+Targets+for+the+Treatment+of+Neurodegenerative+Disorders%3A+Challenges+and+Future+Opportunities&doi=10.1002%2Fmed.21701"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities</span></div><div class="casAuthors">Rodrigues, Daniel A.; Pinheiro, Pedro de S. M.; Sagrillo, Fernanda S.; Bolognesi, Maria L.; Fraga, Carlos A. M.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2177-2211</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review of despite the applicability of histone deacetylase inhibitors (HDACis) for cancer treatment, several works in the literature have shown that these inhibitors can be used in several other diseases, such as neurodegenerative diseases (NDs).  This review begins by discussing the signaling pathways of HDACs, focused on the context of NDs, presenting a discussion about the pharmacophoric features of HDACis and crystal structure anal. and discussing interesting case studies from the literature about the development of HDACis.  Addnl., a discussion about the consequences of isoform-selective inhibition vs pan-HDACis on neurotoxic effects and clin. trial investigations of HDACis for NDs is also presented.  Finally, we describe our perspective related to the future use of these inhibitors in the pharmacotherapy of NDs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo1oAACMF_bVg90H21EOLACvtfcHk0lhUXNYPoDmcLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVKlurnE&md5=62f3c0f86d2aeee5c150925eacecfb18</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1002%2Fmed.21701&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21701%26sid%3Dliteratum%253Aachs%26aulast%3DRodrigues%26aufirst%3DD.%2BA.%26aulast%3Dde%2BS.%2BM.%2BPinheiro%26aufirst%3DP.%26aulast%3DSagrillo%26aufirst%3DF.%2BS.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DFraga%26aufirst%3DC.%2BA.%2BM.%26atitle%3DHistone%2520Deacetylases%2520as%2520Targets%2520for%2520the%2520Treatment%2520of%2520Neurodegenerative%2520Disorders%253A%2520Challenges%2520and%2520Future%2520Opportunities%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2020%26volume%3D40%26spage%3D2177%26epage%3D2211%26doi%3D10.1002%2Fmed.21701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahn, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ardestani, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crisp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuniga, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pierce, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shamloo, M.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Modulator of Sigma 2 Receptor Is Neuroprotective and Reduces Cognitive Deficits and Neuroinflammation in Experimental Models of Alzheimer’s Disease</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">561</span>– <span class="NLM_lpage">575</span>, <span class="refDoi"> DOI: 10.1111/jnc.13917</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1111%2Fjnc.13917" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=27926996" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFGitLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2017&pages=561-575&author=B.+Yiauthor=J.+J.+Sahnauthor=P.+M.+Ardestaniauthor=A.+K.+Evansauthor=L.+L.+Scottauthor=J.+Z.+Chanauthor=S.+Iyerauthor=A.+Crispauthor=G.+Zunigaauthor=J.+T.+Pierceauthor=S.+F.+Martinauthor=M.+Shamloo&title=Small+Molecule+Modulator+of+Sigma+2+Receptor+Is+Neuroprotective+and+Reduces+Cognitive+Deficits+and+Neuroinflammation+in+Experimental+Models+of+Alzheimer%E2%80%99s+Disease&doi=10.1111%2Fjnc.13917"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule modulator of sigma 2 receptor is neuroprotective and reduces cognitive deficits and neuroinflammation in experimental models of Alzheimer's disease</span></div><div class="casAuthors">Yi, Bitna; Sahn, James J.; Ardestani, Pooneh Memar; Evans, Andrew K.; Scott, Luisa L.; Chan, Jessica Z.; Iyer, Sangeetha; Crisp, Ashley; Zuniga, Gabriella; Pierce, Jonathan T.; Martin, Stephen F.; Shamloo, Mehrdad</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">561-575</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Accumulating evidence suggests that modulating the sigma 2 receptor (Sig2R) can provide beneficial effects for neurodegenerative diseases.  Herein, we report the identification of a novel class of Sig2R ligands and their cellular and in vivo activity in exptl. models of Alzheimer's disease (AD).  We report that SAS-0132 and DKR-1051, selective ligands of Sig2R, modulate intracellular Ca2+ levels in human SK-N-SH neuroblastoma cells.  The Sig2R ligands SAS-0132 and JVW-1009 are neuroprotective in a C. elegans model of amyloid precursor protein-mediated neurodegeneration.  Since this neuroprotective effect is replicated by genetic knockdown and knockout of vem-1, the ortholog of progesterone receptor membrane component-1 (PGRMC1), these results suggest that Sig2R ligands modulate a PGRMC1-related pathway.  Last, we demonstrate that SAS-0132 improves cognitive performance both in the Thy-1 hAPPLond/Swe+ transgenic mouse model of AD and in healthy wild-type mice.  These results demonstrate that Sig2R is a promising therapeutic target for neurocognitive disorders including AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-cDNlji1FqbVg90H21EOLACvtfcHk0lhUXNYPoDmcLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFGitLY%253D&md5=36b25fbbf8b4d729d09f98e292966b60</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1111%2Fjnc.13917&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjnc.13917%26sid%3Dliteratum%253Aachs%26aulast%3DYi%26aufirst%3DB.%26aulast%3DSahn%26aufirst%3DJ.%2BJ.%26aulast%3DArdestani%26aufirst%3DP.%2BM.%26aulast%3DEvans%26aufirst%3DA.%2BK.%26aulast%3DScott%26aufirst%3DL.%2BL.%26aulast%3DChan%26aufirst%3DJ.%2BZ.%26aulast%3DIyer%26aufirst%3DS.%26aulast%3DCrisp%26aufirst%3DA.%26aulast%3DZuniga%26aufirst%3DG.%26aulast%3DPierce%26aufirst%3DJ.%2BT.%26aulast%3DMartin%26aufirst%3DS.%2BF.%26aulast%3DShamloo%26aufirst%3DM.%26atitle%3DSmall%2520Molecule%2520Modulator%2520of%2520Sigma%25202%2520Receptor%2520Is%2520Neuroprotective%2520and%2520Reduces%2520Cognitive%2520Deficits%2520and%2520Neuroinflammation%2520in%2520Experimental%2520Models%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DJ.%2520Neurochem.%26date%3D2017%26volume%3D140%26spage%3D561%26epage%3D575%26doi%3D10.1111%2Fjnc.13917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, H.</span></span> <span> </span><span class="NLM_article-title">Molecular Mechanisms Underlying the Involvement of the Sigma-1 Receptor in Methamphetamine-Mediated Microglial Polarization</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">11540</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-11065-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fs41598-017-11065-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=28912535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BC1cboslOitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=11540&author=J.+Chaoauthor=Y.+Zhangauthor=L.+Duauthor=R.+Zhouauthor=X.+Wuauthor=K.+Shenauthor=H.+Yao&title=Molecular+Mechanisms+Underlying+the+Involvement+of+the+Sigma-1+Receptor+in+Methamphetamine-Mediated+Microglial+Polarization&doi=10.1038%2Fs41598-017-11065-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms underlying the involvement of the sigma-1 receptor in methamphetamine-mediated microglial polarization</span></div><div class="casAuthors">Chao Jie; Zhang Yuan; Du Longfei; Wu Xiaodong; Yao Honghong; Chao Jie; Zhou Rongbin; Shen Kai; Yao Honghong</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11540</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Our previous study demonstrated that the sigma-1 receptor is involved in methamphetamine-induced microglial apoptosis and death; however, whether the sigma-1 receptor is involved in microglial activation as well as the molecular mechanisms underlying this process remains poorly understood.  The aim of this study is to demonstrate the involvement of the sigma-1 receptor in methamphetamine-mediated microglial activation.  The expression of σ-1R, iNOS, arginase and SOCS was examined by Western blot; activation of cell signaling pathways was detected by Western blot analysis.  The role of σ-1R in microglial activation was further validated in C57BL/6 N WT and sigma-1 receptor knockout mice (male, 6-8 weeks) injected intraperitoneally with saline or methamphetamine (30 mg/kg) by Western blot combined with immunostaining specific for Iba-1.  Treatment of cells with methamphetamine (150 μM) induced the expression of M1 markers (iNOS) with concomitant decreased the expression of M2 markers (Arginase) via its cognate sigma-1 receptor followed by ROS generation.  Sequential activation of the downstream MAPK, Akt and STAT3 pathways resulted in microglial polarization.  Blockade of sigma-1 receptor significantly inhibited the generation of ROS and activation of the MAPK and Akt pathways.  These findings underscore the critical role of the sigma-1 receptor in methamphetamine-induced microglial activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ2XuDrQ2dPtrYtC3U5jeOifW6udTcc2eZBz0iDjdcOYrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cboslOitg%253D%253D&md5=fa6c0dc4b3544f5a19dcb92e9784225e</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-11065-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-11065-8%26sid%3Dliteratum%253Aachs%26aulast%3DChao%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DDu%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DShen%26aufirst%3DK.%26aulast%3DYao%26aufirst%3DH.%26atitle%3DMolecular%2520Mechanisms%2520Underlying%2520the%2520Involvement%2520of%2520the%2520Sigma-1%2520Receptor%2520in%2520Methamphetamine-Mediated%2520Microglial%2520Polarization%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D11540%26doi%3D10.1038%2Fs41598-017-11065-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moritz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peri, F.</span></span> <span> </span><span class="NLM_article-title">Live Imaging Reveals a New Role for the Sigma-1 (σ<sub>1</sub>) Receptor in Allowing Microglia to Leave Brain Injuries</span>. <i>Neurosci. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>591</i></span>,  <span class="NLM_fpage">13</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1016/j.neulet.2015.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.neulet.2015.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=25666889" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVSgt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=591&publication_year=2015&pages=13-18&author=C.+Moritzauthor=F.+Berardiauthor=C.+Abateauthor=F.+Peri&title=Live+Imaging+Reveals+a+New+Role+for+the+Sigma-1+%28%CF%831%29+Receptor+in+Allowing+Microglia+to+Leave+Brain+Injuries&doi=10.1016%2Fj.neulet.2015.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Live imaging reveals a new role for the sigma-1 (σ1) receptor in allowing microglia to leave brain injuries</span></div><div class="casAuthors">Moritz, Christian; Berardi, Francesco; Abate, Carmen; Peri, Francesca</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">591</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">13-18</span>CODEN:
                <span class="NLM_cas:coden">NELED5</span>;
        ISSN:<span class="NLM_cas:issn">0304-3940</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">Microglial cells are responsible for clearing and maintaining the central nervous system (CNS) microenvironment.  Upon brain damage, they move toward injuries to clear the area by engulfing dying neurons.  However, in the context of many neurol. disorders chronic microglial responses are responsible for neurodegeneration.  Therefore, it is important to understand how these cells can be "switched-off" and regain their ramified state.  Current research suggests that microglial inflammatory responses can be inhibited by sigma (σ) receptor activation.  Here, we take advantage of the optical transparency of the zebrafish embryo to study the role of σ1 receptor in microglia in an intact living brain.  By combining chem. approaches with real time imaging we found that treatment with PB190, a σ1 agonist, blocks microglial migration toward injuries leaving cellular baseline motility and the engulfment of apoptotic neurons unaffected.  Most importantly, by taking a reverse genetic approach, we discovered that the role of σ1in vivo is to "switch-off" microglia after they responded to an injury allowing for these cells to leave the site of damage.  This indicates that pharmacol. manipulation of σ1 receptor modulates microglial responses providing new approaches to reduce the devastating impact that microglia have in neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0WcpnESIreLVg90H21EOLACvtfcHk0lgOr8tNKUJ_QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVSgt7c%253D&md5=1000165e3b64b2f5f116a2fb1d68d783</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.neulet.2015.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neulet.2015.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DMoritz%26aufirst%3DC.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DPeri%26aufirst%3DF.%26atitle%3DLive%2520Imaging%2520Reveals%2520a%2520New%2520Role%2520for%2520the%2520Sigma-1%2520%2528%25CF%25831%2529%2520Receptor%2520in%2520Allowing%2520Microglia%2520to%2520Leave%2520Brain%2520Injuries%26jtitle%3DNeurosci.%2520Lett.%26date%3D2015%26volume%3D591%26spage%3D13%26epage%3D18%26doi%3D10.1016%2Fj.neulet.2015.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aso, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juves, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maldonado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, I.</span></span> <span> </span><span class="NLM_article-title">CB2 Cannabinoid Receptor Agonist Ameliorates Alzheimer-like Phenotype in AbetaPP/PS1 Mice</span>. <i>J. Alzheimer’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">847</span>– <span class="NLM_lpage">858</span>, <span class="refDoi"> DOI: 10.3233/JAD-130137</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3233%2FJAD-130137" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=23515018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BC3svotFCgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2013&pages=847-858&author=E.+Asoauthor=S.+Juvesauthor=R.+Maldonadoauthor=I.+Ferrer&title=CB2+Cannabinoid+Receptor+Agonist+Ameliorates+Alzheimer-like+Phenotype+in+AbetaPP%2FPS1+Mice&doi=10.3233%2FJAD-130137"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AβPP/PS1 mice</span></div><div class="casAuthors">Aso Ester; Juves Salvador; Maldonado Rafael; Ferrer Isidro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's disease : JAD</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">847-58</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The specific CB2 cannabinoid receptor agonist JWH-133 induced cognitive improvement in double AβPP/PS1 transgenic mice, a genetic model of Alzheimer's disease.  This effect was more pronounced when administered at the pre-symptomatic rather than the early symptomatic stage.  The cognitive improvement was associated with decreased microglial reactivity and reduced expression of pro-inflammatory cytokines IL-1β, IL-6, TNFα, and IFNγ.  In addition, JWH-133 reduced the expression of active p38 and SAPK/JNK, increased the expression of inactive GSK3β, and lowered tau hyperphosphorylation at Thr181 in the vicinity of amyloid-β plaques.  Moreover, JWH-133 produced a decrease in the expression of hydroxynonenal adducts, and enhanced the expression of SOD1 and SOD2 around plaques.  In contrast, the chronic treatment with JWH-133 failed to modify the amyloid-β production or deposition in cortex and hippocampus.  In conclusion, the present study lends support to the idea that stimulation of CB2 receptors ameliorates several altered parameters in Alzheimer's disease such as impaired memory and learning, neuroinflammation, oxidative stress damage and oxidative stress responses, selected tau kinases, and tau hyperphosphorylation around plaques.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRClDhWU_rp-HRxY89Cm6SyfW6udTcc2eZLskxO_V5uY7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3svotFCgtg%253D%253D&md5=b25fa740d08962fe7897cebbeb04ee24</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.3233%2FJAD-130137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-130137%26sid%3Dliteratum%253Aachs%26aulast%3DAso%26aufirst%3DE.%26aulast%3DJuves%26aufirst%3DS.%26aulast%3DMaldonado%26aufirst%3DR.%26aulast%3DFerrer%26aufirst%3DI.%26atitle%3DCB2%2520Cannabinoid%2520Receptor%2520Agonist%2520Ameliorates%2520Alzheimer-like%2520Phenotype%2520in%2520AbetaPP%252FPS1%2520Mice%26jtitle%3DJ.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2013%26volume%3D35%26spage%3D847%26epage%3D858%26doi%3D10.3233%2FJAD-130137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niggemann, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaenker, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Entschladen, F.</span></span> <span> </span><span class="NLM_article-title">Anandamide Is an Endogenous Inhibitor for the Migration of Tumor Cells and T Lymphocytes</span>. <i>Cancer Immunol. Immunother.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">723</span>– <span class="NLM_lpage">728</span>, <span class="refDoi"> DOI: 10.1007/s00262-004-0509-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1007%2Fs00262-004-0509-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=15034673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltF2hsrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2004&pages=723-728&author=J.+Josephauthor=B.+Niggemannauthor=K.+S.+Zaenkerauthor=F.+Entschladen&title=Anandamide+Is+an+Endogenous+Inhibitor+for+the+Migration+of+Tumor+Cells+and+T+Lymphocytes&doi=10.1007%2Fs00262-004-0509-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes</span></div><div class="casAuthors">Joseph, Jan; Niggemann, Bernd; Zaenker, Kurt S.; Entschladen, Frank</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Immunology Immunotherapy</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">723-728</span>CODEN:
                <span class="NLM_cas:coden">CIIMDN</span>;
        ISSN:<span class="NLM_cas:issn">0340-7004</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">Cell migration is of paramount importance in physiol. processes such as immune surveillance, but also in the pathol. processes of tumor cell migration and metastasis development.  The factors that regulate this tumor cell migration, most prominently neurotransmitters, have thus been the focus of intense investigation.  While the majority of neurotransmitters have a stimulatory effect on cell migration, the authors herein report the inhibitory effect of the endogenous substance anandamide on both tumor cell and lymphocyte migration.  Using a collagen-based three-dimensional migration assay and time-lapse videomicroscopy, the authors have obsd. that the anandamide-mediated signals for CD8+ T lymphocytes and SW 480 colon carcinoma cells are each mediated by distinct cannabinoid receptors (CB-Rs).  Using the specific agonist docosatetraenoylethanolamide (DEA), the authors have obsd. that the norepinephrine-induced migration of colon carcinoma cells is inhibited by the CB1-R.  The SDF-1-induced migration of CD8+ T lymphocytes was, however, inhibited via the CB2-R, as shown by using the specific agonist JWH 133.  Therefore, specific inhibition of tumor cell migration via CB1-R engagement might be a selective tool to prevent metastasis formation without depreciatory effects on the immune system of cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpd57IdcQv23rVg90H21EOLACvtfcHk0likWUIJEi3zxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltF2hsrg%253D&md5=7790db3bad96e1d6b150aed33eb3bac9</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1007%2Fs00262-004-0509-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00262-004-0509-9%26sid%3Dliteratum%253Aachs%26aulast%3DJoseph%26aufirst%3DJ.%26aulast%3DNiggemann%26aufirst%3DB.%26aulast%3DZaenker%26aufirst%3DK.%2BS.%26aulast%3DEntschladen%26aufirst%3DF.%26atitle%3DAnandamide%2520Is%2520an%2520Endogenous%2520Inhibitor%2520for%2520the%2520Migration%2520of%2520Tumor%2520Cells%2520and%2520T%2520Lymphocytes%26jtitle%3DCancer%2520Immunol.%2520Immunother.%26date%3D2004%26volume%3D53%26spage%3D723%26epage%3D728%26doi%3D10.1007%2Fs00262-004-0509-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pasquini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Botta, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semeraro, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mugnaini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligresti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palazzo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maione, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corelli, F.</span></span> <span> </span><span class="NLM_article-title">Investigations on the 4-Quinolone-3-Carboxylic Acid Motif. 2. Synthesis and Structure-Activity Relationship of Potent and Selective Cannabinoid-2 Receptor Agonists Endowed with Analgesic Activity in Vivo</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">5075</span>– <span class="NLM_lpage">5084</span>, <span class="refDoi"> DOI: 10.1021/jm800552f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800552f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptl2htro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5075-5084&author=S.+Pasquiniauthor=L.+Bottaauthor=T.+Semeraroauthor=C.+Mugnainiauthor=A.+Ligrestiauthor=E.+Palazzoauthor=S.+Maioneauthor=V.+Di+Marzoauthor=F.+Corelli&title=Investigations+on+the+4-Quinolone-3-Carboxylic+Acid+Motif.+2.+Synthesis+and+Structure-Activity+Relationship+of+Potent+and+Selective+Cannabinoid-2+Receptor+Agonists+Endowed+with+Analgesic+Activity+in+Vivo&doi=10.1021%2Fjm800552f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Investigations on the 4-quinolone-3-carboxylic acid motif. 2. synthesis and structure-activity relationship of potent and selective cannabinoid-2 receptor agonists endowed with analgesic activity in vivo</span></div><div class="casAuthors">Pasquini, Serena; Botta, Lorenzo; Semeraro, Teresa; Mugnaini, Claudia; Ligresti, Alessia; Palazzo, Enza; Maione, Sabatino; Di Marzo, Vincenzo; Corelli, Federico</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5075-5084</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Quinolone-3-carboxamides bearing at position 5, 6, 7, or 8 diverse substituents such as halides, alkyl, aryl, alkoxy, and aryloxy groups differing in their steric/electronic properties, were prepd.  The new compds. were tested in vitro for CB1 and CB2 receptor affinity in comparison with the ref. compds. rimonabant and SR144528.  The tested compds. exhibited CB2 affinity in the range from 55.9 to 0.8 nM and CB1 affinity in the range from >10 000 to 5.3 nM, with selectivity indeces [Ki(CB1)/Ki(CB2)] varying from >2666.6 to 1.23.  On the basis of the structure-selectivity relationship developed, the presence of a substituent at C6/C8 or C7 well accounts for the high or low CB2 selectivity, resp.  Compd. I, characterized by high CB2 affinity and selectivity, showed analgesic activity in the formalin test of acute peripheral and inflammatory pain in mice as a result of selective CB2 agonistic activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-nHfcuH__drVg90H21EOLACvtfcHk0likWUIJEi3zxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptl2htro%253D&md5=5c461877098aec3a53c31676ced30c98</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1021%2Fjm800552f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800552f%26sid%3Dliteratum%253Aachs%26aulast%3DPasquini%26aufirst%3DS.%26aulast%3DBotta%26aufirst%3DL.%26aulast%3DSemeraro%26aufirst%3DT.%26aulast%3DMugnaini%26aufirst%3DC.%26aulast%3DLigresti%26aufirst%3DA.%26aulast%3DPalazzo%26aufirst%3DE.%26aulast%3DMaione%26aufirst%3DS.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DCorelli%26aufirst%3DF.%26atitle%3DInvestigations%2520on%2520the%25204-Quinolone-3-Carboxylic%2520Acid%2520Motif.%25202.%2520Synthesis%2520and%2520Structure-Activity%2520Relationship%2520of%2520Potent%2520and%2520Selective%2520Cannabinoid-2%2520Receptor%2520Agonists%2520Endowed%2520with%2520Analgesic%2520Activity%2520in%2520Vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5075%26epage%3D5084%26doi%3D10.1021%2Fjm800552f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pasquini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligresti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mugnaini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semeraro, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cicione, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rosa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guida, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luongo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Chiaro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascio, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maione, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marzo, V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corelli, F.</span></span> <span> </span><span class="NLM_article-title">Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 3. Synthesis, Structure-Affinity Relationships, and Pharmacological Characterization of 6-Substituted 4-Quinolone-3-carboxamides as Highly Selective Cannabinoid-2 Receptor Ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">5915</span>– <span class="NLM_lpage">5928</span>, <span class="refDoi"> DOI: 10.1021/jm100123x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100123x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCht78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=5915-5928&author=S.+Pasquiniauthor=A.+Ligrestiauthor=C.+Mugnainiauthor=T.+Semeraroauthor=L.+Cicioneauthor=M.+De+Rosaauthor=F.+Guidaauthor=L.+Luongoauthor=M.+De+Chiaroauthor=M.+G.+Cascioauthor=D.+Bologniniauthor=P.+Mariniauthor=R.+Pertweeauthor=S.+Maioneauthor=V.+D.+Marzoauthor=F.+Corelli&title=Investigations+on+the+4-Quinolone-3-carboxylic+Acid+Motif.+3.+Synthesis%2C+Structure-Affinity+Relationships%2C+and+Pharmacological+Characterization+of+6-Substituted+4-Quinolone-3-carboxamides+as+Highly+Selective+Cannabinoid-2+Receptor+Ligands&doi=10.1021%2Fjm100123x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 3. Synthesis, Structure-Affinity Relationships, and Pharmacological Characterization of 6-Substituted 4-Quinolone-3-carboxamides as Highly Selective Cannabinoid-2 Receptor Ligands</span></div><div class="casAuthors">Pasquini, Serena; Ligresti, Alessia; Mugnaini, Claudia; Semeraro, Teresa; Cicione, Lavinia; De Rosa, Maria; Guida, Francesca; Luongo, Livio; De Chiaro, Maria; Cascio, Maria Grazia; Bolognini, Daniele; Marini, Pietro; Pertwee, Roger; Maione, Sabatino; Di Marzo, Vincenzo; Corelli, Federico</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">5915-5928</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A set of quinolone-3-carboxamides I [R1 = (un)substituted Ph, 2-furyl, 1-cyclohexenyl, 1-isobutylpyrazol-4-yl, etc.; R2 = 1-adamantyl, 1-fenchyl, hexyl, 1-piperidinyl; R3 = pentyl, 1-buten-4-yl, allyl] bearing diverse substituents at position 1, 3, and 6 of the bicyclic nucleus was prepd.  Except for six compds. exhibiting Ki > 100 nM, all the quinolone-3-carboxamides I proved to be high affinity CB2 ligands, with Ki values ranging from 73.2 to 0.7 nM and selectivity [SI = Ki(CB1)/Ki(CB2)] varying from >14285 to 1.9, with only one compd. exhibiting a reverse selectivity (SI < 1).  In the formalin test of peripheral acute and inflammatory pain in mice, I [R1 = CH2CH2Ph, R2 = 1-adamantyl, R3 = pentyl] showed analgesic activity that was antagonized by a selective CB2 antagonist.  By contrast, I [R1 = 2-furyl, R2 = 1-adamantyl, R3 = pentyl] was inactive per se and antagonized the effect of a selective CB2 agonist.  Also, two of these compds. exhibited CB2 inverse agonist-like behavior in this in vivo test.  However, two different functional assays carried out in vitro indicated for both compds. an overall inverse agonist activity at CB2 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWqQVRHQABn7Vg90H21EOLACvtfcHk0lhCH6aBPZ1pZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCht78%253D&md5=642a103b93312fd2f1e124173143b656</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Fjm100123x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100123x%26sid%3Dliteratum%253Aachs%26aulast%3DPasquini%26aufirst%3DS.%26aulast%3DLigresti%26aufirst%3DA.%26aulast%3DMugnaini%26aufirst%3DC.%26aulast%3DSemeraro%26aufirst%3DT.%26aulast%3DCicione%26aufirst%3DL.%26aulast%3DDe%2BRosa%26aufirst%3DM.%26aulast%3DGuida%26aufirst%3DF.%26aulast%3DLuongo%26aufirst%3DL.%26aulast%3DDe%2BChiaro%26aufirst%3DM.%26aulast%3DCascio%26aufirst%3DM.%2BG.%26aulast%3DBolognini%26aufirst%3DD.%26aulast%3DMarini%26aufirst%3DP.%26aulast%3DPertwee%26aufirst%3DR.%26aulast%3DMaione%26aufirst%3DS.%26aulast%3DMarzo%26aufirst%3DV.%2BD.%26aulast%3DCorelli%26aufirst%3DF.%26atitle%3DInvestigations%2520on%2520the%25204-Quinolone-3-carboxylic%2520Acid%2520Motif.%25203.%2520Synthesis%252C%2520Structure-Affinity%2520Relationships%252C%2520and%2520Pharmacological%2520Characterization%2520of%25206-Substituted%25204-Quinolone-3-carboxamides%2520as%2520Highly%2520Selective%2520Cannabinoid-2%2520Receptor%2520Ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D5915%26epage%3D5928%26doi%3D10.1021%2Fjm100123x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pasquini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rosa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedani, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mugnaini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guida, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luongo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Chiaro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maione, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragoni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frosini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligresti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corelli, F.</span></span> <span> </span><span class="NLM_article-title">Investigations on the 4-Quinolone-3-Carboxylic Acid Motif. 4. Identification of New Potent and Selective Ligands for the Cannabinoid Type 2 Receptor with Diverse Substitution Patterns and Antihyperalgesic Effects in Mice</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">5444</span>– <span class="NLM_lpage">5453</span>, <span class="refDoi"> DOI: 10.1021/jm200476p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200476p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFCgtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=5444-5453&author=S.+Pasquiniauthor=M.+De+Rosaauthor=V.+Pedaniauthor=C.+Mugnainiauthor=F.+Guidaauthor=L.+Luongoauthor=M.+De+Chiaroauthor=S.+Maioneauthor=S.+Dragoniauthor=M.+Frosiniauthor=A.+Ligrestiauthor=V.+Di+Marzoauthor=F.+Corelli&title=Investigations+on+the+4-Quinolone-3-Carboxylic+Acid+Motif.+4.+Identification+of+New+Potent+and+Selective+Ligands+for+the+Cannabinoid+Type+2+Receptor+with+Diverse+Substitution+Patterns+and+Antihyperalgesic+Effects+in+Mice&doi=10.1021%2Fjm200476p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 4. Identification of New Potent and Selective Ligands for the Cannabinoid Type 2 Receptor with Diverse Substitution Patterns and Antihyperalgesic Effects in Mice</span></div><div class="casAuthors">Pasquini, Serena; De Rosa, Maria; Pedani, Valentina; Mugnaini, Claudia; Guida, Francesca; Luongo, Livio; De Chiaro, Maria; Maione, Sabatino; Dragoni, Stefania; Frosini, Maria; Ligresti, Alessia; Di Marzo, Vincenzo; Corelli, Federico</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5444-5453</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Exptl. evidence suggests that selective CB2 receptor modulators may provide access to antihyperalgesic agents devoid of psychotropic effects.  Taking advantage of previous findings on structure-activity/selectivity relationships for a class of 4-quinolone-3-carboxamides, further structural modifications of the heterocyclic scaffold were explored, leading to the discovery of the 8-methoxy deriv. 4a endowed with the highest affinity and selectivity ever reported for a CB2 ligand.  The compd., evaluated in vivo in the formalin test, behaved as an inverse agonist by reducing at a dose of 6 mg/kg the second phase of the formalin-induced nocifensive response in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogKusJC-_IlLVg90H21EOLACvtfcHk0lhCH6aBPZ1pZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFCgtbo%253D&md5=4b9daccdccfddbbde2ef53fcca4a87bd</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1021%2Fjm200476p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200476p%26sid%3Dliteratum%253Aachs%26aulast%3DPasquini%26aufirst%3DS.%26aulast%3DDe%2BRosa%26aufirst%3DM.%26aulast%3DPedani%26aufirst%3DV.%26aulast%3DMugnaini%26aufirst%3DC.%26aulast%3DGuida%26aufirst%3DF.%26aulast%3DLuongo%26aufirst%3DL.%26aulast%3DDe%2BChiaro%26aufirst%3DM.%26aulast%3DMaione%26aufirst%3DS.%26aulast%3DDragoni%26aufirst%3DS.%26aulast%3DFrosini%26aufirst%3DM.%26aulast%3DLigresti%26aufirst%3DA.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DCorelli%26aufirst%3DF.%26atitle%3DInvestigations%2520on%2520the%25204-Quinolone-3-Carboxylic%2520Acid%2520Motif.%25204.%2520Identification%2520of%2520New%2520Potent%2520and%2520Selective%2520Ligands%2520for%2520the%2520Cannabinoid%2520Type%25202%2520Receptor%2520with%2520Diverse%2520Substitution%2520Patterns%2520and%2520Antihyperalgesic%2520Effects%2520in%2520Mice%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D5444%26epage%3D5453%26doi%3D10.1021%2Fjm200476p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mugnaini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nocerino, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedani, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasquini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tafi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Chiaro, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellucci, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valoti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guida, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luongo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dragoni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligresti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascio, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moaddel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maione, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corelli, F.</span></span> <span> </span><span class="NLM_article-title">Investigations on the 4-Quinolone-3-Carboxylic Acid Motif Part 5: Modulation of the Physicochemical Profile of a Set of Potent and Selective Cannabinoid-2 Receptor Ligands through a Bioisosteric Approach</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">920</span>– <span class="NLM_lpage">934</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201100573</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1002%2Fcmdc.201100573" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=22383251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtFOhtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=920-934&author=C.+Mugnainiauthor=S.+Nocerinoauthor=V.+Pedaniauthor=S.+Pasquiniauthor=A.+Tafiauthor=M.+De+Chiaroauthor=L.+Bellucciauthor=M.+Valotiauthor=F.+Guidaauthor=L.+Luongoauthor=S.+Dragoniauthor=A.+Ligrestiauthor=A.+Rosenbergauthor=D.+Bologniniauthor=M.+G.+Cascioauthor=R.+G.+Pertweeauthor=R.+Moaddelauthor=S.+Maioneauthor=V.+Di+Marzoauthor=F.+Corelli&title=Investigations+on+the+4-Quinolone-3-Carboxylic+Acid+Motif+Part+5%3A+Modulation+of+the+Physicochemical+Profile+of+a+Set+of+Potent+and+Selective+Cannabinoid-2+Receptor+Ligands+through+a+Bioisosteric+Approach&doi=10.1002%2Fcmdc.201100573"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Investigations on the 4-Quinolone-3-Carboxylic Acid Motif Part 5: Modulation of the Physicochemical Profile of a Set of Potent and Selective Cannabinoid-2 Receptor Ligands through a Bioisosteric Approach</span></div><div class="casAuthors">Mugnaini, Claudia; Nocerino, Stefania; Pedani, Valentina; Pasquini, Serena; Tafi, Andrea; De Chiaro, Maria; Bellucci, Luca; Valoti, Massimo; Guida, Francesca; Luongo, Livio; Dragoni, Stefania; Ligresti, Alessia; Rosenberg, Avraham; Bolognini, Daniele; Cascio, Maria Grazia; Pertwee, Roger G.; Moaddel, Ruin; Maione, Sabatino; Di Marzo, Vincenzo; Corelli, Federico</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">920-934</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Three heterocyclic systems were selected as potential bioisosteres of the amide linker for a series of 1,6-disubstituted-4-quinolone-3-carboxamides, which are potent and selective CB2 ligands that exhibit poor water soly., with the aim of improving their physicochem. profile and also of clarifying properties of importance for amide bond mimicry.  Among the newly synthesized compds., a 1,2,3-triazole deriv. (1-(adamantan-1-yl)-4-[6-(furan-2-yl)-1,4-dihydro-4-oxo-1-pentylquinolin-3-yl]-1H-1,2,3-triazole) emerged as the most promising in terms of both physicochem. and pharmacodynamic properties.  When assayed in vitro, this deriv. exhibited inverse agonist activity, whereas, in the formalin test in mice, it produced analgesic effects antagonized by a well-established inverse agonist.  Metabolic studies allowed the identification of a side chain hydroxylated deriv. as its only metabolite, which, in its racemic form, still showed appreciable CB2 selectivity, but was 150-fold less potent than the parent compd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-q6Lelcgsf7Vg90H21EOLACvtfcHk0lhxc5EaAUcZnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtFOhtbo%253D&md5=4ac67390a8af749cd21afd9ef894099f</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201100573&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201100573%26sid%3Dliteratum%253Aachs%26aulast%3DMugnaini%26aufirst%3DC.%26aulast%3DNocerino%26aufirst%3DS.%26aulast%3DPedani%26aufirst%3DV.%26aulast%3DPasquini%26aufirst%3DS.%26aulast%3DTafi%26aufirst%3DA.%26aulast%3DDe%2BChiaro%26aufirst%3DM.%26aulast%3DBellucci%26aufirst%3DL.%26aulast%3DValoti%26aufirst%3DM.%26aulast%3DGuida%26aufirst%3DF.%26aulast%3DLuongo%26aufirst%3DL.%26aulast%3DDragoni%26aufirst%3DS.%26aulast%3DLigresti%26aufirst%3DA.%26aulast%3DRosenberg%26aufirst%3DA.%26aulast%3DBolognini%26aufirst%3DD.%26aulast%3DCascio%26aufirst%3DM.%2BG.%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26aulast%3DMoaddel%26aufirst%3DR.%26aulast%3DMaione%26aufirst%3DS.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DCorelli%26aufirst%3DF.%26atitle%3DInvestigations%2520on%2520the%25204-Quinolone-3-Carboxylic%2520Acid%2520Motif%2520Part%25205%253A%2520Modulation%2520of%2520the%2520Physicochemical%2520Profile%2520of%2520a%2520Set%2520of%2520Potent%2520and%2520Selective%2520Cannabinoid-2%2520Receptor%2520Ligands%2520through%2520a%2520Bioisosteric%2520Approach%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26spage%3D920%26epage%3D934%26doi%3D10.1002%2Fcmdc.201100573" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccomanni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malfitano, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laezza, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligresti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucchesi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuccinardi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzolio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifulco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinelli, A.</span></span> <span> </span><span class="NLM_article-title">Rational Design, Synthesis and Anti-Proliferative Properties of New CB2 Selective Cannabinoid Receptor Ligands: An Investigation of the 1,8-Naphthyridin-2(1H)-One Scaffold</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">284</span>– <span class="NLM_lpage">294</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2012.03.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2012.03.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=22483967" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtlSksrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2012&pages=284-294&author=C.+Maneraauthor=G.+Saccomanniauthor=A.+M.+Malfitanoauthor=S.+Bertiniauthor=F.+Castelliauthor=C.+Laezzaauthor=A.+Ligrestiauthor=V.+Lucchesiauthor=T.+Tuccinardiauthor=F.+Rizzolioauthor=M.+Bifulcoauthor=V.+Di+Marzoauthor=A.+Giordanoauthor=M.+Macchiaauthor=A.+Martinelli&title=Rational+Design%2C+Synthesis+and+Anti-Proliferative+Properties+of+New+CB2+Selective+Cannabinoid+Receptor+Ligands%3A+An+Investigation+of+the+1%2C8-Naphthyridin-2%281H%29-One+Scaffold&doi=10.1016%2Fj.ejmech.2012.03.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design, synthesis and anti-proliferative properties of new CB2 selective cannabinoid receptor ligands: An investigation of the 1,8-naphthyridin-2(1H)-one scaffold</span></div><div class="casAuthors">Manera, Clementina; Saccomanni, Giuseppe; Malfitano, Anna Maria; Bertini, Simone; Castelli, Francesca; Laezza, Chiara; Ligresti, Alessia; Lucchesi, Valentina; Tuccinardi, Tiziano; Rizzolio, Flavio; Bifulco, Maurizio; Di Marzo, Vincenzo; Giordano, Antonio; Macchia, Marco; Martinelli, Adriano</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">284-294</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">CB2 receptor ligands are becoming increasingly attractive drugs due to the potential role of this receptor in several physiopathol. processes.  Using the previously described series of 1,8-naphthyridin-2(1H)-on-3-carboxamides as a lead class, several nitrogen heterocyclic derivs., characterized by different central cores, were synthesized and tested for their affinity toward the human CB1 and CB2 cannabinoid receptors.  The obtained results suggest that the new series of quinolin-2(1H)-on-3-carboxamides, 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamides and 1,2-dihydro-2-oxopyridine-3-carboxamides represent novel scaffolds very suitable for the development of promising CB2 ligands.  Furthermore, the newly synthesized CB2 ligands inhibit proliferation of several cancer cell lines.  In particular, it was demonstrated that in DU-145 cell line these ligands exert a CB2-mediated anti-proliferative action and decrease the CB2 receptor expression levels.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoSNc96QFpbgLVg90H21EOLACvtfcHk0lhxc5EaAUcZnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtlSksrk%253D&md5=7bf4bb23e5ad31c00ea27ea8c324097d</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.03.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.03.031%26sid%3Dliteratum%253Aachs%26aulast%3DManera%26aufirst%3DC.%26aulast%3DSaccomanni%26aufirst%3DG.%26aulast%3DMalfitano%26aufirst%3DA.%2BM.%26aulast%3DBertini%26aufirst%3DS.%26aulast%3DCastelli%26aufirst%3DF.%26aulast%3DLaezza%26aufirst%3DC.%26aulast%3DLigresti%26aufirst%3DA.%26aulast%3DLucchesi%26aufirst%3DV.%26aulast%3DTuccinardi%26aufirst%3DT.%26aulast%3DRizzolio%26aufirst%3DF.%26aulast%3DBifulco%26aufirst%3DM.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DGiordano%26aufirst%3DA.%26aulast%3DMacchia%26aufirst%3DM.%26aulast%3DMartinelli%26aufirst%3DA.%26atitle%3DRational%2520Design%252C%2520Synthesis%2520and%2520Anti-Proliferative%2520Properties%2520of%2520New%2520CB2%2520Selective%2520Cannabinoid%2520Receptor%2520Ligands%253A%2520An%2520Investigation%2520of%2520the%25201%252C8-Naphthyridin-2%25281H%2529-One%2520Scaffold%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2012%26volume%3D52%26spage%3D284%26epage%3D294%26doi%3D10.1016%2Fj.ejmech.2012.03.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malfitano, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkkari, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucchesi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carpi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fogli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laezza, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligresti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccomanni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savinainen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciaglia, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisanti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazzerro, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifulco, M.</span></span> <span> </span><span class="NLM_article-title">New Quinolone- and 1,8-Naphthyridine-3-Carboxamides as Selective CB2 Receptor Agonists with Anticancer and Immuno-Modulatory Activity</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">10</span>– <span class="NLM_lpage">18</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.04.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2015.04.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=25935384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnt1Srurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2015&pages=10-18&author=C.+Maneraauthor=A.+M.+Malfitanoauthor=T.+Parkkariauthor=V.+Lucchesiauthor=S.+Carpiauthor=S.+Fogliauthor=S.+Bertiniauthor=C.+Laezzaauthor=A.+Ligrestiauthor=G.+Saccomanniauthor=J.+R.+Savinainenauthor=E.+Ciagliaauthor=S.+Pisantiauthor=P.+Gazzerroauthor=V.+Di+Marzoauthor=P.+Nieriauthor=M.+Macchiaauthor=M.+Bifulco&title=New+Quinolone-+and+1%2C8-Naphthyridine-3-Carboxamides+as+Selective+CB2+Receptor+Agonists+with+Anticancer+and+Immuno-Modulatory+Activity&doi=10.1016%2Fj.ejmech.2015.04.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">New quinolone- and 1,8-naphthyridine-3-carboxamides as selective CB2 receptor agonists with anticancer and immuno-modulatory activity</span></div><div class="casAuthors">Manera, Clementina; Malfitano, Anna Maria; Parkkari, Teija; Lucchesi, Valentina; Carpi, Sara; Fogli, Stefano; Bertini, Simone; Laezza, Chiara; Ligresti, Alessia; Saccomanni, Giuseppe; Savinainen, Juha R.; Ciaglia, Elena; Pisanti, Simona; Gazzerro, Patrizia; Di Marzo, Vincenzo; Nieri, Paola; Macchia, Marco; Bifulco, Maurizio</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10-18</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Several recent studies suggest that selective CB2 receptor agonists may represent a valid pharmacol. approach in the treatment of various diseases due to the absence of relevant psychoactive side effect.  The authors synthesized and tested a series of new quinoline-2(1H)-one- and 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine derivs. characterized by a 4-methylcyclohexylamido substituent in position 3 of the heterocyclic nucleus with high CB2 receptor affinity and selectivity.  Two compds. showing the best binding and selectivity profile behaved as a full agonist and a partial agonist at the CB2 receptor and induced a concn.-dependent decrease of cell viability on LNCaP, a prostatic cancer cell line expressing CB2 receptor.  Moreover considering that the CB2 receptor is mainly expressed in cells and organs of the immune system, the same compds. were studied for their potential immune-modulatory and antiinflammatory effects in activated lymphocytes isolated from healthy controls and multiple sclerosis (MS) patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOB_LeNeEMvrVg90H21EOLACvtfcHk0lh5QyzL6Go_FQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnt1Srurg%253D&md5=b6bbfe5695e72b75536c661ee3b5f2a9</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.04.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.04.034%26sid%3Dliteratum%253Aachs%26aulast%3DManera%26aufirst%3DC.%26aulast%3DMalfitano%26aufirst%3DA.%2BM.%26aulast%3DParkkari%26aufirst%3DT.%26aulast%3DLucchesi%26aufirst%3DV.%26aulast%3DCarpi%26aufirst%3DS.%26aulast%3DFogli%26aufirst%3DS.%26aulast%3DBertini%26aufirst%3DS.%26aulast%3DLaezza%26aufirst%3DC.%26aulast%3DLigresti%26aufirst%3DA.%26aulast%3DSaccomanni%26aufirst%3DG.%26aulast%3DSavinainen%26aufirst%3DJ.%2BR.%26aulast%3DCiaglia%26aufirst%3DE.%26aulast%3DPisanti%26aufirst%3DS.%26aulast%3DGazzerro%26aufirst%3DP.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DNieri%26aufirst%3DP.%26aulast%3DMacchia%26aufirst%3DM.%26aulast%3DBifulco%26aufirst%3DM.%26atitle%3DNew%2520Quinolone-%2520and%25201%252C8-Naphthyridine-3-Carboxamides%2520as%2520Selective%2520CB2%2520Receptor%2520Agonists%2520with%2520Anticancer%2520and%2520Immuno-Modulatory%2520Activity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D97%26spage%3D10%26epage%3D18%26doi%3D10.1016%2Fj.ejmech.2015.04.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucchesi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurst, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shore, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ehrmann, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allarà, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligresti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minutolo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccomanni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharir, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reggio, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manera, C.</span></span> <span> </span><span class="NLM_article-title">CB2-Selective Cannabinoid Receptor Ligands: Synthesis, Pharmacological Evaluation, and Molecular Modeling Investigation of 1,8-Naphthyridin-2(1H)-One-3-Carboxamides</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">8777</span>– <span class="NLM_lpage">8791</span>, <span class="refDoi"> DOI: 10.1021/jm500807e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500807e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1KhtbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8777-8791&author=V.+Lucchesiauthor=D.+P.+Hurstauthor=D.+M.+Shoreauthor=S.+Bertiniauthor=B.+M.+Ehrmannauthor=M.+Allar%C3%A0author=L.+Lawrenceauthor=A.+Ligrestiauthor=F.+Minutoloauthor=G.+Saccomanniauthor=H.+Sharirauthor=M.+Macchiaauthor=V.+Di+Marzoauthor=M.+Aboodauthor=P.+H.+Reggioauthor=C.+Manera&title=CB2-Selective+Cannabinoid+Receptor+Ligands%3A+Synthesis%2C+Pharmacological+Evaluation%2C+and+Molecular+Modeling+Investigation+of+1%2C8-Naphthyridin-2%281H%29-One-3-Carboxamides&doi=10.1021%2Fjm500807e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">CB2-Selective Cannabinoid Receptor Ligands: Synthesis, Pharmacological Evaluation, and Molecular Modeling Investigation of 1,8-Naphthyridin-2(1H)-one-3-carboxamides</span></div><div class="casAuthors">Lucchesi, Valentina; Hurst, Dow P.; Shore, Derek M.; Bertini, Simone; Ehrmann, Brandie M.; Allara, Marco; Lawrence, Lyle; Ligresti, Alessia; Minutolo, Filippo; Saccomanni, Giuseppe; Sharir, Haleli; Macchia, Marco; Di Marzo, Vincenzo; Abood, Mary E.; Reggio, Patricia H.; Manera, Clementina</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">8777-8791</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have recently identified 1,8-naphthyridin-2(1H)-one-3-carboxamide as a new scaffold very suitable for the development of new CB2 receptor potent and selective ligands.  In this paper we describe a no. of addnl. derivs., e.g., I and II, in which the same central scaffold has been variously functionalized in position 1 or 6.  All new compds. showed high selectivity and affinity in the nanomolar range for the CB2 receptor.  Furthermore, we found that their functional activity is controlled by the presence of the substituents at position C-6 of the naphthyridine scaffold.  In fact, the introduction of substituents in this position detd. a functionality switch from agonist to antagonists/inverse agonists.  Finally, docking studies showed that the difference between the pharmacol. of these ligands may be in the ability/inability to block the Toggle Switch W6.48(258) (χ1 g+ → trans) transition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrr52BQ7fcPn7Vg90H21EOLACvtfcHk0lh5QyzL6Go_FQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1KhtbvI&md5=9b7b38b9525133a488eae0bd6766206b</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1021%2Fjm500807e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500807e%26sid%3Dliteratum%253Aachs%26aulast%3DLucchesi%26aufirst%3DV.%26aulast%3DHurst%26aufirst%3DD.%2BP.%26aulast%3DShore%26aufirst%3DD.%2BM.%26aulast%3DBertini%26aufirst%3DS.%26aulast%3DEhrmann%26aufirst%3DB.%2BM.%26aulast%3DAllar%25C3%25A0%26aufirst%3DM.%26aulast%3DLawrence%26aufirst%3DL.%26aulast%3DLigresti%26aufirst%3DA.%26aulast%3DMinutolo%26aufirst%3DF.%26aulast%3DSaccomanni%26aufirst%3DG.%26aulast%3DSharir%26aufirst%3DH.%26aulast%3DMacchia%26aufirst%3DM.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DAbood%26aufirst%3DM.%26aulast%3DReggio%26aufirst%3DP.%2BH.%26aulast%3DManera%26aufirst%3DC.%26atitle%3DCB2-Selective%2520Cannabinoid%2520Receptor%2520Ligands%253A%2520Synthesis%252C%2520Pharmacological%2520Evaluation%252C%2520and%2520Molecular%2520Modeling%2520Investigation%2520of%25201%252C8-Naphthyridin-2%25281H%2529-One-3-Carboxamides%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8777%26epage%3D8791%26doi%3D10.1021%2Fjm500807e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.-Z.</span></span> <span> </span><span class="NLM_article-title">Development of Quinoline-2,4(1H,3H)-Diones as Potent and Selective Ligands of the Cannabinoid Type 2 Receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">5751</span>– <span class="NLM_lpage">5769</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00227</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00227" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFejtLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=5751-5769&author=S.+Hanauthor=F.-F.+Zhangauthor=H.-Y.+Qianauthor=L.-L.+Chenauthor=J.-B.+Puauthor=X.+Xieauthor=J.-Z.+Chen&title=Development+of+Quinoline-2%2C4%281H%2C3H%29-Diones+as+Potent+and+Selective+Ligands+of+the+Cannabinoid+Type+2+Receptor&doi=10.1021%2Facs.jmedchem.5b00227"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Quinoline-2,4(1H,3H)-diones as Potent and Selective Ligands of the Cannabinoid Type 2 Receptor</span></div><div class="casAuthors">Han, Shuang; Zhang, Fei-Fei; Qian, Hai-Yan; Chen, Li-Li; Pu, Jian-Bin; Xie, Xin; Chen, Jian-Zhong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5751-5769</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The cannabinoid type 2 receptors (CB2Rs) play crucial roles in inflammatory diseases.  There has been considerable interest in developing potent and selective ligands for CB2R.  In this study, quinoline-2,4(1H,3H)-dione analogs have been designed, synthesized, and evaluated for their potencies and binding properties toward the cannabinoid type 1 receptor (CB1R) and CB2R.  C5- or C8-substituted quinoline-2,4(1H,3H)-diones demonstrate CB2R agonist activity, while the C6- or C7-substituted analogs are antagonists of CB2R.  In addn., oral administration of I dose-dependently alleviates the clin. symptoms of exptl. autoimmune encephalomyelitis in a mouse model of multiple sclerosis and protects the central nervous system from immune damage.  Furthermore, the interaction modes predicted by docking simulations and the 3D-QSAR model generated with CoMFA may offer guidance for further design and modification of CB2R modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2s6_pJyGAhLVg90H21EOLACvtfcHk0lh5QyzL6Go_FQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFejtLfE&md5=95fccc14423947a2252835971acd92f6</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00227&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00227%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DF.-F.%26aulast%3DQian%26aufirst%3DH.-Y.%26aulast%3DChen%26aufirst%3DL.-L.%26aulast%3DPu%26aufirst%3DJ.-B.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DJ.-Z.%26atitle%3DDevelopment%2520of%2520Quinoline-2%252C4%25281H%252C3H%2529-Diones%2520as%2520Potent%2520and%2520Selective%2520Ligands%2520of%2520the%2520Cannabinoid%2520Type%25202%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D5751%26epage%3D5769%26doi%3D10.1021%2Facs.jmedchem.5b00227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Han, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.-Z.</span></span> <span> </span><span class="NLM_article-title">Design, Syntheses, Structure-Activity Relationships and Docking Studies of Coumarin Derivatives as Novel Selective Ligands for the CB2 Receptor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">16</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2015.01.054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2015.01.054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=25644673" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Slurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2015&pages=16-32&author=S.+Hanauthor=F.-F.+Zhangauthor=H.-Y.+Qianauthor=L.-L.+Chenauthor=J.-B.+Puauthor=X.+Xieauthor=J.-Z.+Chen&title=Design%2C+Syntheses%2C+Structure-Activity+Relationships+and+Docking+Studies+of+Coumarin+Derivatives+as+Novel+Selective+Ligands+for+the+CB2+Receptor&doi=10.1016%2Fj.ejmech.2015.01.054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Design, syntheses, structure-activity relationships and docking studies of coumarin derivatives as novel selective ligands for the CB2 receptor</span></div><div class="casAuthors">Han, Shuang; Zhang, Fei-Fei; Qian, Hai-Yan; Chen, Li-Li; Pu, Jian-Bin; Xie, Xin; Chen, Jian-Zhong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">16-32</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The CB2 receptor has been considered as an inspiring drug target for the treatment of pain and immune-related diseases.  A series of coumarin derivs., e.g., I, is reported to be designed and synthesized by combining the structural features of some known ligands for the cannabinoid receptors based on the CoMFA model of the lead compds.  The compds. were evaluated to be highly selective ligands for the CB2 receptor over the CB1 receptor by calcium mobilization assays.  Furthermore, SAR results indicate that the functionality of a ligand is controlled by the substituent on the nucleus.  Therefore, mol. docking simulations were performed to calc. the receptor-ligand interactions of our synthesized compds. binding to the CB2 receptor.  The understanding of the binding modes could be advantageous for further development of selective ligands for the CB2 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaxXg-Vm6ho7Vg90H21EOLACvtfcHk0lj3ug8A6UvJLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Slurc%253D&md5=38c0c3802ba442d61129df73751cc47c</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2015.01.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2015.01.054%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DF.-F.%26aulast%3DQian%26aufirst%3DH.-Y.%26aulast%3DChen%26aufirst%3DL.-L.%26aulast%3DPu%26aufirst%3DJ.-B.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DJ.-Z.%26atitle%3DDesign%252C%2520Syntheses%252C%2520Structure-Activity%2520Relationships%2520and%2520Docking%2520Studies%2520of%2520Coumarin%2520Derivatives%2520as%2520Novel%2520Selective%2520Ligands%2520for%2520the%2520CB2%2520Receptor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D93%26spage%3D16%26epage%3D32%26doi%3D10.1016%2Fj.ejmech.2015.01.054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banister, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kevin, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edington, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longworth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beinat, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchanan, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibbs, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glass, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGregor, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassiou, M.</span></span> <span> </span><span class="NLM_article-title">Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1445</span>– <span class="NLM_lpage">1458</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.5b00107</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.5b00107" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnt1ars7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1445-1458&author=S.+D.+Banisterauthor=J.+Stuartauthor=R.+C.+Kevinauthor=A.+Edingtonauthor=M.+Longworthauthor=S.+M.+Wilkinsonauthor=C.+Beinatauthor=A.+S.+Buchananauthor=D.+E.+Hibbsauthor=M.+Glassauthor=M.+Connorauthor=I.+S.+McGregorauthor=M.+Kassiou&title=Effects+of+Bioisosteric+Fluorine+in+Synthetic+Cannabinoid+Designer+Drugs+JWH-018%2C+AM-2201%2C+UR-144%2C+XLR-11%2C+PB-22%2C+5F-PB-22%2C+APICA%2C+and+STS-135&doi=10.1021%2Facschemneuro.5b00107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135</span></div><div class="casAuthors">Banister, Samuel D.; Stuart, Jordyn; Kevin, Richard C.; Edington, Amelia; Longworth, Mitchell; Wilkinson, Shane M.; Beinat, Corinne; Buchanan, Alexandra S.; Hibbs, David E.; Glass, Michelle; Connor, Mark; McGregor, Iain S.; Kassiou, Michael</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1445-1458</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Synthetic cannabinoid (SC) designer drugs featuring bioisosteric fluorine substitution are identified by forensic chemists and toxicologists with increasing frequency.  Although terminal fluorination of N-pentyl indole SCs is sometimes known to improve cannabinoid type 1 (CB1) receptor binding affinity, little is known of the effects of fluorination on functional activity of SCs.  This study explores the in vitro functional activities of SC designer drugs JWH-018, UR-144, PB-22, and APICA, and their resp. terminally fluorinated analogs AM-2201, XLR-11, 5F-PB-22, and STS-135 at human CB1 and CB2 receptors using a FLIPR membrane potential assay.  All compds. demonstrated agonist activity at CB1 (EC50 = 2.8-1959 nM) and CB2 (EC50 = 6.5-206 nM) receptors, with the fluorinated analogs generally showing increased CB1 receptor potency (∼2-5 times).  Addnl., the cannabimimetic activities and relative potencies of JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135 in vivo were evaluated in rats using biotelemetry.  All SCs dose-dependently induced hypothermia and reduced heart rate at doses of 0.3-10 mg/kg.  There was no consistent trend for increased potency of fluorinated SCs over the corresponding des-fluoro SCs in vivo.  Based on magnitude and duration of hypothermia, the SCs were ranked for potency (PB-22 > 5F-PB-22 = JWH-018 > AM-2201 > APICA = STS-135 = XLR-11 > UR-144).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrH0UrddzwguLVg90H21EOLACvtfcHk0lj3ug8A6UvJLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnt1ars7Y%253D&md5=0b6560a8bd5352f5226183f5410c8c86</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.5b00107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.5b00107%26sid%3Dliteratum%253Aachs%26aulast%3DBanister%26aufirst%3DS.%2BD.%26aulast%3DStuart%26aufirst%3DJ.%26aulast%3DKevin%26aufirst%3DR.%2BC.%26aulast%3DEdington%26aufirst%3DA.%26aulast%3DLongworth%26aufirst%3DM.%26aulast%3DWilkinson%26aufirst%3DS.%2BM.%26aulast%3DBeinat%26aufirst%3DC.%26aulast%3DBuchanan%26aufirst%3DA.%2BS.%26aulast%3DHibbs%26aufirst%3DD.%2BE.%26aulast%3DGlass%26aufirst%3DM.%26aulast%3DConnor%26aufirst%3DM.%26aulast%3DMcGregor%26aufirst%3DI.%2BS.%26aulast%3DKassiou%26aufirst%3DM.%26atitle%3DEffects%2520of%2520Bioisosteric%2520Fluorine%2520in%2520Synthetic%2520Cannabinoid%2520Designer%2520Drugs%2520JWH-018%252C%2520AM-2201%252C%2520UR-144%252C%2520XLR-11%252C%2520PB-22%252C%25205F-PB-22%252C%2520APICA%252C%2520and%2520STS-135%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2015%26volume%3D6%26spage%3D1445%26epage%3D1458%26doi%3D10.1021%2Facschemneuro.5b00107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banister, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stuart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conroy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longworth, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manohar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beinat, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kevin, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibbs, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glass, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGregor, I. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassiou, M.</span></span> <span> </span><span class="NLM_article-title">Structure-Activity Relationships of Synthetic Cannabinoid Designer Drug RCS-4 and Its Regioisomers and C4 Homologues</span>. <i>Forensic Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">366</span>, <span class="refDoi"> DOI: 10.1007/s11419-015-0282-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1007%2Fs11419-015-0282-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpslGmu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=355-366&author=S.+D.+Banisterauthor=J.+Stuartauthor=T.+Conroyauthor=M.+Longworthauthor=M.+Manoharauthor=C.+Beinatauthor=S.+M.+Wilkinsonauthor=R.+C.+Kevinauthor=D.+E.+Hibbsauthor=M.+Glassauthor=M.+Connorauthor=I.+S.+McGregorauthor=M.+Kassiou&title=Structure-Activity+Relationships+of+Synthetic+Cannabinoid+Designer+Drug+RCS-4+and+Its+Regioisomers+and+C4+Homologues&doi=10.1007%2Fs11419-015-0282-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-activity relationships of synthetic cannabinoid designer drug RCS-4 and its regioisomers and C4 homologues</span></div><div class="casAuthors">Banister, Samuel D.; Stuart, Jordyn; Conroy, Trent; Longworth, Mitchell; Manohar, Madhura; Beinat, Corinne; Wilkinson, Shane M.; Kevin, Richard C.; Hibbs, David E.; Glass, Michelle; Connor, Mark; McGregor, Iain S.; Kassiou, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Forensic Toxicology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">355-366</span>CODEN:
                <span class="NLM_cas:coden">FTOOAU</span>;
        ISSN:<span class="NLM_cas:issn">1860-8965</span>.
    
            (<span class="NLM_cas:orgname">Springer Japan</span>)
        </div><div class="casAbstract">RCS-4 [(4-methoxyphenyl)-1-yl-(1-pentyl-1H-indol-3-yl)methanone] represents the first of several N-alkyl-3-(methoxybenzoyl)indoles identified by forensic scientists as synthetic cannabinoid (SC) designer drugs.  Despite the detection of RCS-4 and several analogs (RCS-2, RCS-3, RCS-2-C4, RCS-3-C4, and RCS-4-C4) in products intended for human consumption, relatively little is known about this class of cannabinoids.  The synthesis of all regioisomers of RCS-4 and their C4 homologues is described.  This study also systematically explored the structure-activity relationships of this class of SCs at human CB1 and CB2 receptors using an in vitro fluorometric imaging plate reader membrane potential assay.  All compds. demonstrated agonist activity at CB1 (EC50 = 54-574 nM) and CB2 (EC50 = 4.5-46 nM) receptors, with the C4 homologues showing a preference for CB2 receptors over CB1 receptors (31-42 times).  Since most of the analogs (RCS-2, RCS-3, RCS-2-C4, RCS-3-C4 and RCS-4-C4) are not subject to regulation in much of the world, despite their activities towards CB1 and CB2 receptors, there is a possibility that these analogs will emerge on the black market.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVYNWFf9NG1LVg90H21EOLACvtfcHk0lj3ug8A6UvJLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpslGmu7o%253D&md5=33a338dc18c747679e246749a475e4a3</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1007%2Fs11419-015-0282-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11419-015-0282-9%26sid%3Dliteratum%253Aachs%26aulast%3DBanister%26aufirst%3DS.%2BD.%26aulast%3DStuart%26aufirst%3DJ.%26aulast%3DConroy%26aufirst%3DT.%26aulast%3DLongworth%26aufirst%3DM.%26aulast%3DManohar%26aufirst%3DM.%26aulast%3DBeinat%26aufirst%3DC.%26aulast%3DWilkinson%26aufirst%3DS.%2BM.%26aulast%3DKevin%26aufirst%3DR.%2BC.%26aulast%3DHibbs%26aufirst%3DD.%2BE.%26aulast%3DGlass%26aufirst%3DM.%26aulast%3DConnor%26aufirst%3DM.%26aulast%3DMcGregor%26aufirst%3DI.%2BS.%26aulast%3DKassiou%26aufirst%3DM.%26atitle%3DStructure-Activity%2520Relationships%2520of%2520Synthetic%2520Cannabinoid%2520Designer%2520Drug%2520RCS-4%2520and%2520Its%2520Regioisomers%2520and%2520C4%2520Homologues%26jtitle%3DForensic%2520Toxicol.%26date%3D2015%26volume%3D33%26spage%3D355%26epage%3D366%26doi%3D10.1007%2Fs11419-015-0282-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mohammadi
Vosough, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baradaran Rahimi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masoud, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirkarimi, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demneh, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abed, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banafshe, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Askari, V. R.</span></span> <span> </span><span class="NLM_article-title">Evaluation of Protective Effects of Non-Selective Cannabinoid Receptor Agonist WIN 55,212-2 against the Nitroglycerine-Induced Acute and Chronic Animal Models of Migraine: A Mechanistic Study</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>232</i></span>,  <span class="NLM_fpage">116670</span>, <span class="refDoi"> DOI: 10.1016/j.lfs.2019.116670</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.lfs.2019.116670" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=31330139" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVCjt7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=232&publication_year=2019&pages=116670&author=E.+Mohammadi%0AVosoughauthor=V.+Baradaran+Rahimiauthor=S.+A.+Masoudauthor=H.+R.+Mirkarimiauthor=M.+K.+Demnehauthor=A.+Abedauthor=H.+R.+Banafsheauthor=V.+R.+Askari&title=Evaluation+of+Protective+Effects+of+Non-Selective+Cannabinoid+Receptor+Agonist+WIN+55%2C212-2+against+the+Nitroglycerine-Induced+Acute+and+Chronic+Animal+Models+of+Migraine%3A+A+Mechanistic+Study&doi=10.1016%2Fj.lfs.2019.116670"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of protective effects of non-selective cannabinoid receptor agonist WIN 55,212-2 against the nitroglycerine-induced acute and chronic animal models of migraine: A mechanistic study</span></div><div class="casAuthors">Mohammadi Vosough, Elahe; Baradaran Rahimi, Vafa; Masoud, Seyyed Ali; Mirkarimi, Hamid Reza; Demneh, Maryam Kazemi; Abed, Alireza; Banafshe, Hamid Reza; Askari, Vahid Reza</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">232</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">116670</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Migraine is a neurol. debilitating disorder.  Previous studies have shown that cannabinoid receptor agonists have analgesic effects in various models of pain.  In this study, therefore, we investigated anti-nociceptive effects of WIN 55,212-2, and the role of either CB1 or CB2 receptors in nitroglycerin (NTG)-induced animal model of migraine.  The present study was conducted on both male and female rats receiving NTG (10 mg/kg, i.p.) to induce acute (single dose of NTG) and chronic (repetitive doses of NTG) models of migraine.  Addnl., three groups received WIN 55,212-2 (0.33, 1, 3 mg/kg, i.p.) 45 min before behavioral tests.  Addnl., AM251 and AM630 (CB1 and CB2 receptor antagonist, resp., 1 mg/kg, i.p.) were used to evaluate the possible involvement of CB1 and CB2 receptors during the protective effects of WIN 55,212-2.  We found that NTG (10 mg/kg, i.p.) in both acute and chronic models increased sensitivity to pain.  In acute model, we found that WIN 55,212-2 (almost high doses) decreases the level of pain mainly through CB1 receptor due to CB1 antagonist abrogates its protective effects, however, in formalin test CB2 receptors also had crucial roles in both phases at 3 mg/kg of WIN 55,212-2.  In chronic model, WIN 55,212-2 (0.33, 1 and 3 mg/kg) significantly attenuated NTG-induced hyperalgesia through both CB1 and CB2 receptors.  Our data supported the argument that activation of CB1 and CB2 receptors by WIN 55,212-2 may be considered a new medication for migraine, however in lack of each receptor leads to different responses from deletion to the redn. of analgesic effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUjtU1r71BL7Vg90H21EOLACvtfcHk0lh-ReMtFeMlXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVCjt7vE&md5=83c0188956f4f3e2b0ce1b1cfd766606</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2019.116670&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2019.116670%26sid%3Dliteratum%253Aachs%26aulast%3DMohammadi%2BVosough%26aufirst%3DE.%26aulast%3DBaradaran%2BRahimi%26aufirst%3DV.%26aulast%3DMasoud%26aufirst%3DS.%2BA.%26aulast%3DMirkarimi%26aufirst%3DH.%2BR.%26aulast%3DDemneh%26aufirst%3DM.%2BK.%26aulast%3DAbed%26aufirst%3DA.%26aulast%3DBanafshe%26aufirst%3DH.%2BR.%26aulast%3DAskari%26aufirst%3DV.%2BR.%26atitle%3DEvaluation%2520of%2520Protective%2520Effects%2520of%2520Non-Selective%2520Cannabinoid%2520Receptor%2520Agonist%2520WIN%252055%252C212-2%2520against%2520the%2520Nitroglycerine-Induced%2520Acute%2520and%2520Chronic%2520Animal%2520Models%2520of%2520Migraine%253A%2520A%2520Mechanistic%2520Study%26jtitle%3DLife%2520Sci.%26date%3D2019%26volume%3D232%26spage%3D116670%26doi%3D10.1016%2Fj.lfs.2019.116670" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roberto, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klotz, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkateswaran, V.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid WIN 55,212-2 Induces Cell Cycle Arrest and Apoptosis, and Inhibits Proliferation, Migration, Invasion, and Tumor Growth in Prostate Cancer in a Cannabinoid-Receptor 2 Dependent Manner</span>. <i>Prostate</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">151</span>– <span class="NLM_lpage">159</span>, <span class="refDoi"> DOI: 10.1002/pros.23720</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1002%2Fpros.23720" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=30242861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1SgurfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=151-159&author=D.+Robertoauthor=L.+H.+Klotzauthor=V.+Venkateswaran&title=Cannabinoid+WIN+55%2C212-2+Induces+Cell+Cycle+Arrest+and+Apoptosis%2C+and+Inhibits+Proliferation%2C+Migration%2C+Invasion%2C+and+Tumor+Growth+in+Prostate+Cancer+in+a+Cannabinoid-Receptor+2+Dependent+Manner&doi=10.1002%2Fpros.23720"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid WIN 55,212-2 induces cell cycle arrest and apoptosis, and inhibits proliferation, migration, invasion, and tumor growth in prostate cancer in a cannabinoid-receptor 2 dependent manner</span></div><div class="casAuthors">Roberto, Domenica; Klotz, Laurence H.; Venkateswaran, Vasundara</div><div class="citationInfo"><span class="NLM_cas:title">Prostate (Hoboken, NJ, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">151-159</span>CODEN:
                <span class="NLM_cas:coden">PRSTDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-4137</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background : Cannabinoids have demonstrated anticarcinogenic properties in a variety of malignancies, including in prostate cancer.  In the present study, we explored the anti-cancer effects of the synthetic cannabinoid WIN 55,212-2 (WIN) in prostate cancer.  Methods : Established prostate cancer cells (PC3, DU145, LNCaP) were treated with varying concns. of WIN.  Cell proliferation was detd. by the MTS assay.  The anti-migration and anti-invasive potential of WIN was examd. by the wound healing assay and the matrigel invasion assay.  Cell cycle anal. was performed by flow cytometry, and mechanistic studies were performed by Western blot.  Athymic mice (n = 10) were inoculated with human PC3 cells.  Once tumors reached 100 mm3, animals were randomized into two groups: saline control and WIN (5 mg/kg), delivered by i.p. injection three times per wk for 3 wk.  Results : WIN significantly reduced prostate cancer cell proliferation, migration, invasion, induced apoptosis, and arrested cells in Go/G1 phase in a dose-dependent manner.  Mechanistic studies revealed these effects were mediated through a pathway involving cell cycle regulators p27, Cdk4, and pRb.  Pre-treatment with a CB2 antagonist, AM630, followed by treatment with WIN resulted in a reversal of the anti-proliferation and cell cycle arrest previously seen with WIN alone.  In vivo, administration of WIN resulted in a redn. in the tumor growth rate compared to control (P < 0.05).  Conclusions : The following study provides evidence supporting the use of WIN as a novel therapeutic for prostate cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1sg2m6maLR7Vg90H21EOLACvtfcHk0lh-ReMtFeMlXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1SgurfJ&md5=5b2377b6874813f46ebc3ac2de28ff10</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1002%2Fpros.23720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpros.23720%26sid%3Dliteratum%253Aachs%26aulast%3DRoberto%26aufirst%3DD.%26aulast%3DKlotz%26aufirst%3DL.%2BH.%26aulast%3DVenkateswaran%26aufirst%3DV.%26atitle%3DCannabinoid%2520WIN%252055%252C212-2%2520Induces%2520Cell%2520Cycle%2520Arrest%2520and%2520Apoptosis%252C%2520and%2520Inhibits%2520Proliferation%252C%2520Migration%252C%2520Invasion%252C%2520and%2520Tumor%2520Growth%2520in%2520Prostate%2520Cancer%2520in%2520a%2520Cannabinoid-Receptor%25202%2520Dependent%2520Manner%26jtitle%3DProstate%26date%3D2019%26volume%3D79%26spage%3D151%26epage%3D159%26doi%3D10.1002%2Fpros.23720" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al
Fawaz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al Deeb, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huffman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al Kholaif, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garlich, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuang, R.</span></span> <span> </span><span class="NLM_article-title">A Case of Status Epilepticus and Transient Stress Cardiomyopathy Associated with Smoking the Synthetic Psychoactive Cannabinoid, UR-144</span>. <i>Am. J. Case Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1902</span>– <span class="NLM_lpage">1906</span>, <span class="refDoi"> DOI: 10.12659/AJCR.918918</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.12659%2FAJCR.918918" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=31857571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BB3MbitFCgsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=1902-1906&author=S.+Al%0AFawazauthor=M.+Al+Deebauthor=J.+L.+Huffmanauthor=N.+A.+Al+Kholaifauthor=F.+Garlichauthor=R.+Chuang&title=A+Case+of+Status+Epilepticus+and+Transient+Stress+Cardiomyopathy+Associated+with+Smoking+the+Synthetic+Psychoactive+Cannabinoid%2C+UR-144&doi=10.12659%2FAJCR.918918"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">A Case of Status Epilepticus and Transient Stress Cardiomyopathy Associated with Smoking the Synthetic Psychoactive Cannabinoid, UR-144</span></div><div class="casAuthors">Al Fawaz Sarah; Al Deeb Mohammad; Huffman James L; Al Kholaif Naji A; Garlich Fiona; Chuang Ryan</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of case reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1902-1906</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND Synthetic cannabinoids have a higher affinity for the cannabinoid receptors CB1 and CB2 than natural cannabinoids.  Their use can be associated with cardiovascular disease and neurological complications.  A case is reported of status epilepticus and stress cardiomyopathy following the recreational use of the synthetic cannabinoid, UR-144.  CASE REPORT A 19-year-old woman presented to the emergency department in status epilepticus after smoking the synthetic cannabinoid known as 'space'.  Recurring seizure activity was controlled after three hours.  On hospital day 3, the patient developed severe biventricular failure.  Cardiac magnetic resonance imaging (MRI) confirmed the diagnosis of stress cardiomyopathy.  A comprehensive urine drug screen was performed using gas chromatography-mass spectrometry (GC-MS), which was positive for UR-144, or (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)-methanone, and negative for all other illicit recreational drugs.  The patient improved at one week following admission, with a left ventricular ejection fraction (LVEF) of 40%.  She was discharged home on hospital day 10.  CONCLUSIONS The use of the synthetic cannabinoid, UR-144, may be associated with prolonged status epilepticus and stress cardiomyopathy.  Physicians should be aware of these potentially lethal complications associated with the recreational use of this and other illicit synthetic cannabinoids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKwjqWvsIJ0dNTrvPZP1IpfW6udTcc2eaWvA5yyzbjtLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MbitFCgsw%253D%253D&md5=1b42ed1edf398855a6d571d4b155cdcc</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.12659%2FAJCR.918918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.12659%252FAJCR.918918%26sid%3Dliteratum%253Aachs%26aulast%3DAl%2BFawaz%26aufirst%3DS.%26aulast%3DAl%2BDeeb%26aufirst%3DM.%26aulast%3DHuffman%26aufirst%3DJ.%2BL.%26aulast%3DAl%2BKholaif%26aufirst%3DN.%2BA.%26aulast%3DGarlich%26aufirst%3DF.%26aulast%3DChuang%26aufirst%3DR.%26atitle%3DA%2520Case%2520of%2520Status%2520Epilepticus%2520and%2520Transient%2520Stress%2520Cardiomyopathy%2520Associated%2520with%2520Smoking%2520the%2520Synthetic%2520Psychoactive%2520Cannabinoid%252C%2520UR-144%26jtitle%3DAm.%2520J.%2520Case%2520Rep.%26date%3D2019%26volume%3D20%26spage%3D1902%26epage%3D1906%26doi%3D10.12659%2FAJCR.918918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chakravarti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganju, R. K.</span></span> <span> </span><span class="NLM_article-title">Cannabinoids as Therapeutic Agents in Cancer: Current Status and Future Implications</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">5852</span>– <span class="NLM_lpage">5872</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.2233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.18632%2Foncotarget.2233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=25115386" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BC2M%252Fht1SgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=5852-5872&author=B.+Chakravartiauthor=J.+Raviauthor=R.+K.+Ganju&title=Cannabinoids+as+Therapeutic+Agents+in+Cancer%3A+Current+Status+and+Future+Implications&doi=10.18632%2Foncotarget.2233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoids as therapeutic agents in cancer: current status and future implications</span></div><div class="casAuthors">Chakravarti Bandana; Ravi Janani; Ganju Ramesh K</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5852-72</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The pharmacological importance of cannabinoids has been in study for several years.  Cannabinoids comprise of (a) the active compounds of the Cannabis sativa plant, (b) endogenous as well as (c) synthetic cannabinoids.  Though cannabinoids are clinically used for anti-palliative effects, recent studies open a promising possibility as anti-cancer agents.  They have been shown to possess anti-proliferative and anti-angiogenic effects in vitro as well as in vivo in different cancer models.  Cannabinoids regulate key cell signaling pathways that are involved in cell survival, invasion, angiogenesis, metastasis, etc.  There is more focus on CB1 and CB2, the two cannabinoid receptors which are activated by most of the cannabinoids.  In this review article, we will focus on a broad range of cannabinoids, their receptor dependent and receptor independent functional roles against various cancer types with respect to growth, metastasis, energy metabolism, immune environment, stemness and future perspectives in exploring new possible therapeutic opportunities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTI4t9ZrFEBIXy-c-E1v-fmfW6udTcc2eaWvA5yyzbjtLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M%252Fht1SgtA%253D%253D&md5=a7337b09f46c5df725ab7ce07fd5fee5</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2233%26sid%3Dliteratum%253Aachs%26aulast%3DChakravarti%26aufirst%3DB.%26aulast%3DRavi%26aufirst%3DJ.%26aulast%3DGanju%26aufirst%3DR.%2BK.%26atitle%3DCannabinoids%2520as%2520Therapeutic%2520Agents%2520in%2520Cancer%253A%2520Current%2520Status%2520and%2520Future%2520Implications%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26spage%3D5852%26epage%3D5872%26doi%3D10.18632%2Foncotarget.2233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Trotter, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nanda, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgey, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potteiger, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Green, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartnett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kett, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henze, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Della Penna, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leitl, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemaire, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urban, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kane, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilodeau, M. T.</span></span> <span> </span><span class="NLM_article-title">Imidazopyridine CB2 Agonists: Optimization of CB2/CB1 Selectivity and Implications for in Vivo Analgesic Efficacy</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2354</span>– <span class="NLM_lpage">2358</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.02.082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmcl.2011.02.082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=21420860" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkt12kur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=2354-2358&author=B.+W.+Trotterauthor=K.+K.+Nandaauthor=C.+S.+Burgeyauthor=C.+M.+Potteigerauthor=J.+Z.+Dengauthor=A.+I.+Greenauthor=J.+C.+Hartnettauthor=N.+R.+Kettauthor=Z.+Wuauthor=D.+D.+Henzeauthor=K.+Della+Pennaauthor=R.+Desaiauthor=M.+D.+Leitlauthor=W.+Lemaireauthor=R.+B.+Whiteauthor=S.+Yehauthor=M.+O.+Urbanauthor=S.+A.+Kaneauthor=G.+D.+Hartmanauthor=M.+T.+Bilodeau&title=Imidazopyridine+CB2+Agonists%3A+Optimization+of+CB2%2FCB1+Selectivity+and+Implications+for+in+Vivo+Analgesic+Efficacy&doi=10.1016%2Fj.bmcl.2011.02.082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Imidazopyridine CB2 agonists: Optimization of CB2/CB1 selectivity and implications for in vivo analgesic efficacy</span></div><div class="casAuthors">Trotter, B. Wesley; Nanda, Kausik K.; Burgey, Christopher S.; Potteiger, Craig M.; Deng, James Z.; Green, Ahren I.; Hartnett, John C.; Kett, Nathan R.; Wu, Zhicai; Henze, Darrell A.; Della Penna, Kimberly; Desai, Reshma; Leitl, Michael D.; Lemaire, Wei; White, Rebecca B.; Yeh, Suzie; Urban, Mark O.; Kane, Stefanie A.; Hartman, George D.; Bilodeau, Mark T.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2354-2358</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A new series of imidazopyridine CB2 agonists of general formula I-III was prepd. and tested.  Structural optimization improved CB2/CB1 selectivity in this series and conferred phys. properties that facilitated high in vivo exposure, both centrally and peripherally.  Exploration of SAR in this series has produced both CB2-preferring agonists and agonists that appear to be completely selective for CB2 vs. CB1.  In vivo evaluation of these compds. indicates a significant impact of the degree of CB2/CB1 selectivity on analgesic effects in this series.  Administration of a highly selective CB2 agonist (IV) in a rat model of analgesia was ineffective despite substantial CNS exposure, while administration of a moderately selective CB2/CB1 agonist (V) exhibited significant analgesic effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWaOUV5dsbLLVg90H21EOLACvtfcHk0li2xcKvoqxvpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkt12kur0%253D&md5=d1b114a9ac85c46ceb62d257f4de7b6f</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.02.082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.02.082%26sid%3Dliteratum%253Aachs%26aulast%3DTrotter%26aufirst%3DB.%2BW.%26aulast%3DNanda%26aufirst%3DK.%2BK.%26aulast%3DBurgey%26aufirst%3DC.%2BS.%26aulast%3DPotteiger%26aufirst%3DC.%2BM.%26aulast%3DDeng%26aufirst%3DJ.%2BZ.%26aulast%3DGreen%26aufirst%3DA.%2BI.%26aulast%3DHartnett%26aufirst%3DJ.%2BC.%26aulast%3DKett%26aufirst%3DN.%2BR.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DHenze%26aufirst%3DD.%2BD.%26aulast%3DDella%2BPenna%26aufirst%3DK.%26aulast%3DDesai%26aufirst%3DR.%26aulast%3DLeitl%26aufirst%3DM.%2BD.%26aulast%3DLemaire%26aufirst%3DW.%26aulast%3DWhite%26aufirst%3DR.%2BB.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DUrban%26aufirst%3DM.%2BO.%26aulast%3DKane%26aufirst%3DS.%2BA.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DBilodeau%26aufirst%3DM.%2BT.%26atitle%3DImidazopyridine%2520CB2%2520Agonists%253A%2520Optimization%2520of%2520CB2%252FCB1%2520Selectivity%2520and%2520Implications%2520for%2520in%2520Vivo%2520Analgesic%2520Efficacy%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D2354%26epage%3D2358%26doi%3D10.1016%2Fj.bmcl.2011.02.082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nanda, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henze, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Della Penna, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desai, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leitl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemaire, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brouillette, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hartman, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bilodeau, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trotter, B. W.</span></span> <span> </span><span class="NLM_article-title">Benzimidazole CB2 Agonists: Design, Synthesis and SAR</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1218</span>– <span class="NLM_lpage">1221</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.12.068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmcl.2013.12.068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=24461289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1yhs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=1218-1221&author=K.+K.+Nandaauthor=D.+A.+Henzeauthor=K.+Della+Pennaauthor=R.+Desaiauthor=M.+Leitlauthor=W.+Lemaireauthor=R.+B.+Whiteauthor=S.+Yehauthor=J.+N.+Brouilletteauthor=G.+D.+Hartmanauthor=M.+T.+Bilodeauauthor=B.+W.+Trotter&title=Benzimidazole+CB2+Agonists%3A+Design%2C+Synthesis+and+SAR&doi=10.1016%2Fj.bmcl.2013.12.068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Benzimidazole CB2 agonists: Design, synthesis and SAR</span></div><div class="casAuthors">Nanda, Kausik K.; Henze, Darrell A.; Della Penna, Kimberly; Desai, Reshma; Leitl, Michael; Lemaire, Wei; White, Rebecca B.; Yeh, Suzie; Brouillette, Janine N.; Hartman, George D.; Bilodeau, Mark T.; Trotter, B. Wesley</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1218-1221</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A new series of CB2-selective agonists contg. a benzimidazole core is reported.  Design, synthesis, SAR and pharmacokinetic data for selected compds. are described.  E.g., benzimidazole deriv. (I) showed 92-fold selectivity for CB2 receptors over CB1 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGparfJmbXjki7Vg90H21EOLACvtfcHk0lgUBD42swkdhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1yhs78%253D&md5=c81372c37c1848398ba3c8e6a25a9ee4</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.12.068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.12.068%26sid%3Dliteratum%253Aachs%26aulast%3DNanda%26aufirst%3DK.%2BK.%26aulast%3DHenze%26aufirst%3DD.%2BA.%26aulast%3DDella%2BPenna%26aufirst%3DK.%26aulast%3DDesai%26aufirst%3DR.%26aulast%3DLeitl%26aufirst%3DM.%26aulast%3DLemaire%26aufirst%3DW.%26aulast%3DWhite%26aufirst%3DR.%2BB.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DBrouillette%26aufirst%3DJ.%2BN.%26aulast%3DHartman%26aufirst%3DG.%2BD.%26aulast%3DBilodeau%26aufirst%3DM.%2BT.%26aulast%3DTrotter%26aufirst%3DB.%2BW.%26atitle%3DBenzimidazole%2520CB2%2520Agonists%253A%2520Design%252C%2520Synthesis%2520and%2520SAR%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2014%26volume%3D24%26spage%3D1218%26epage%3D1221%26doi%3D10.1016%2Fj.bmcl.2013.12.068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koba, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugiura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sudo, M.</span></span> <span> </span><span class="NLM_article-title">Identification of a Highly Potent and Selective CB2 Agonist, RQ-00202730, for the Treatment of Irritable Bowel Syndrome</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">236</span>– <span class="NLM_lpage">240</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.11.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmcl.2014.11.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=25499880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVems7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=236-240&author=Y.+Iwataauthor=K.+Andoauthor=K.+Taniguchiauthor=N.+Kobaauthor=A.+Sugiuraauthor=M.+Sudo&title=Identification+of+a+Highly+Potent+and+Selective+CB2+Agonist%2C+RQ-00202730%2C+for+the+Treatment+of+Irritable+Bowel+Syndrome&doi=10.1016%2Fj.bmcl.2014.11.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of a highly potent and selective CB2 agonist, RQ-00202730, for the treatment of irritable bowel syndrome</span></div><div class="casAuthors">Iwata, Yasuhiro; Ando, Kazuo; Taniguchi, Kana; Koba, Naomi; Sugiura, Akemi; Sudo, Masaki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">236-240</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein the authors report the identification of a highly potent and selective CB2 agonist, RQ-00202730 I, obtained by lead optimization of the benzimidazole scaffold.  Compd. I showed strong agonistic activity with an EC50 of 19 nM and excellent selectivity (>1300-fold) over the CB1 receptor.  Compd. I displayed a dose dependent analgesic effect on TNBS-induced visceral hypersensitivity in rats by oral administration (ED50 0.66 mg/kg at 2.5 h after oral administration).  In addn., I did not show a significant effect on body temp. in rats after oral administration at 300 mg/kg.  These findings suggest that highly selective CB2 agonists will be effective agents for IBS therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY99dK3pO2CbVg90H21EOLACvtfcHk0lgUBD42swkdhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVems7fO&md5=ab88e62e468d744e4abbe1b2b4c0ad1e</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.11.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.11.062%26sid%3Dliteratum%253Aachs%26aulast%3DIwata%26aufirst%3DY.%26aulast%3DAndo%26aufirst%3DK.%26aulast%3DTaniguchi%26aufirst%3DK.%26aulast%3DKoba%26aufirst%3DN.%26aulast%3DSugiura%26aufirst%3DA.%26aulast%3DSudo%26aufirst%3DM.%26atitle%3DIdentification%2520of%2520a%2520Highly%2520Potent%2520and%2520Selective%2520CB2%2520Agonist%252C%2520RQ-00202730%252C%2520for%2520the%2520Treatment%2520of%2520Irritable%2520Bowel%2520Syndrome%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D236%26epage%3D240%26doi%3D10.1016%2Fj.bmcl.2014.11.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Omura, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shima, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makita, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sugimoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kikuchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ando, K.</span></span> <span> </span><span class="NLM_article-title">The SAR Studies of Novel CB2 Selective Agonists, Benzimidazolone Derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">3310</span>– <span class="NLM_lpage">3314</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.04.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmcl.2008.04.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=18440813" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD1cXms1yhs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=3310-3314&author=H.+Omuraauthor=M.+Kawaiauthor=A.+Shimaauthor=Y.+Iwataauthor=F.+Itoauthor=T.+Masudaauthor=A.+Ohtaauthor=N.+Makitaauthor=K.+Omotoauthor=H.+Sugimotoauthor=A.+Kikuchiauthor=H.+Iwataauthor=K.+Ando&title=The+SAR+Studies+of+Novel+CB2+Selective+Agonists%2C+Benzimidazolone+Derivatives&doi=10.1016%2Fj.bmcl.2008.04.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">The SAR studies of novel CB2 selective agonists, benzimidazolone derivatives</span></div><div class="casAuthors">Omura, Hirofumi; Kawai, Makoto; Shima, Akiko; Iwata, Yasuhiro; Ito, Fumitaka; Masuda, Tsutomu; Ohta, Atsuko; Makita, Naoya; Omoto, Kiyoyuki; Sugimoto, Hiromi; Kikuchi, Akira; Iwata, Hiroshi; Ando, Kazuo</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3310-3314</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Benzimidazolone derivs. were discovered as novel CB2 selective agonists.  Structure Activity Relationship (SAR) studies around them were examd. to improve metabolic stability.  Compd. 39 (I) exhibited excellent metabolic stability in human liver microsomes (HLM) and significant attenuation of the chronic colonic allodynia in the TNBS-treated rats by po administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWUT-3sSa6WrVg90H21EOLACvtfcHk0lj6GpgR7H-WaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXms1yhs7g%253D&md5=9ce38fd3572c2c6bafa7bce18e842f39</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.04.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.04.032%26sid%3Dliteratum%253Aachs%26aulast%3DOmura%26aufirst%3DH.%26aulast%3DKawai%26aufirst%3DM.%26aulast%3DShima%26aufirst%3DA.%26aulast%3DIwata%26aufirst%3DY.%26aulast%3DIto%26aufirst%3DF.%26aulast%3DMasuda%26aufirst%3DT.%26aulast%3DOhta%26aufirst%3DA.%26aulast%3DMakita%26aufirst%3DN.%26aulast%3DOmoto%26aufirst%3DK.%26aulast%3DSugimoto%26aufirst%3DH.%26aulast%3DKikuchi%26aufirst%3DA.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DAndo%26aufirst%3DK.%26atitle%3DThe%2520SAR%2520Studies%2520of%2520Novel%2520CB2%2520Selective%2520Agonists%252C%2520Benzimidazolone%2520Derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D3310%26epage%3D3314%26doi%3D10.1016%2Fj.bmcl.2008.04.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hollinshead, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tidwell, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guidetti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanderson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oskins, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratford, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Astles, P. C.</span></span> <span> </span><span class="NLM_article-title">Selective Cannabinoid Receptor Type 2 (CB2) Agonists: Optimization of a Series of Purines Leading to the Identification of a Clinical Candidate for the Treatment of Osteoarthritic Pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">5722</span>– <span class="NLM_lpage">5733</span>, <span class="refDoi"> DOI: 10.1021/jm400305d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400305d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3sXpvFaksrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=5722-5733&author=S.+P.+Hollinsheadauthor=M.+W.+Tidwellauthor=J.+Palmerauthor=R.+Guidettiauthor=A.+Sandersonauthor=M.+P.+Johnsonauthor=M.+G.+Chambersauthor=J.+Oskinsauthor=R.+Stratfordauthor=P.+C.+Astles&title=Selective+Cannabinoid+Receptor+Type+2+%28CB2%29+Agonists%3A+Optimization+of+a+Series+of+Purines+Leading+to+the+Identification+of+a+Clinical+Candidate+for+the+Treatment+of+Osteoarthritic+Pain&doi=10.1021%2Fjm400305d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Cannabinoid Receptor Type 2 (CB2) Agonists: Optimization of a Series of Purines Leading to the Identification of a Clinical Candidate for the Treatment of Osteoarthritic Pain</span></div><div class="casAuthors">Hollinshead, Sean P.; Tidwell, Michael W.; Palmer, John; Guidetti, Rossella; Sanderson, Adam; Johnson, Michael P.; Chambers, Mark G.; Oskins, Jennifer; Stratford, Robert; Astles, Peter C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5722-5733</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A focused screening strategy identified thienopyrimidine I as a cannabinoid receptor type 2 agonist (hCB2) with moderate selectivity over the hCB1 receptor.  This initial hit suffered from poor in vitro metabolic stability and high in vivo clearance.  Structure-activity relationships describe the optimization and modification to a new more polar series of purine CB2 agonists.  Examples from this novel scaffold were found to be highly potent and fully efficacious agonists of the human CB2 receptor with excellent selectivity against CB1, often having no CB1 agonist activity at the highest concn. measured (>100 μM).  Purine compd. II (R1 = tetrahydropyan-4-yl) is a centrally penetrant mol. which possesses good biopharmaceutical properties, is highly water-sol., and demonstrates robust oral activity in rodent models of joint pain.  In addn., the peripherally restricted mol. II (R1 = CH2CH2SO2Me) also demonstrated significant efficacy in the same analgesic model of rodent inflammatory pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqK67SLculmNLVg90H21EOLACvtfcHk0lj6GpgR7H-WaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXpvFaksrw%253D&md5=62c14d8c1133fb025d405379ad352860</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1021%2Fjm400305d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400305d%26sid%3Dliteratum%253Aachs%26aulast%3DHollinshead%26aufirst%3DS.%2BP.%26aulast%3DTidwell%26aufirst%3DM.%2BW.%26aulast%3DPalmer%26aufirst%3DJ.%26aulast%3DGuidetti%26aufirst%3DR.%26aulast%3DSanderson%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DM.%2BP.%26aulast%3DChambers%26aufirst%3DM.%2BG.%26aulast%3DOskins%26aufirst%3DJ.%26aulast%3DStratford%26aufirst%3DR.%26aulast%3DAstles%26aufirst%3DP.%2BC.%26atitle%3DSelective%2520Cannabinoid%2520Receptor%2520Type%25202%2520%2528CB2%2529%2520Agonists%253A%2520Optimization%2520of%2520a%2520Series%2520of%2520Purines%2520Leading%2520to%2520the%2520Identification%2520of%2520a%2520Clinical%2520Candidate%2520for%2520the%2520Treatment%2520of%2520Osteoarthritic%2520Pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D5722%26epage%3D5733%26doi%3D10.1021%2Fjm400305d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hollinshead, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Astles, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tidwell, M. W.</span></span> <span> </span><span class="NLM_article-title">Discovery and Optimization of Novel Purines as Potent and Selective CB2 Agonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">4962</span>– <span class="NLM_lpage">4966</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.06.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmcl.2012.06.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=22765893" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC38Xps1Kktr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=4962-4966&author=S.+P.+Hollinsheadauthor=P.+C.+Astlesauthor=M.+G.+Chambersauthor=M.+P.+Johnsonauthor=J.+Palmerauthor=M.+W.+Tidwell&title=Discovery+and+Optimization+of+Novel+Purines+as+Potent+and+Selective+CB2+Agonists&doi=10.1016%2Fj.bmcl.2012.06.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and optimization of novel purines as potent and selective CB2 agonists</span></div><div class="casAuthors">Hollinshead, Sean P.; Astles, Peter C.; Chambers, Mark G.; Johnson, Michael P.; Palmer, John; Tidwell, Michael W.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4962-4966</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A focused screening strategy identified thienopyrimidine I as a hCB2 cannabinoid receptor agonist with moderate selectivity over the hCB1 receptor.  This initial hit suffered from poor in vitro metabolic stability and high in vivo clearance.  Structure-activity relationships describe the optimization and modification to a less lipophilic purine core.  Examples from this novel series were found to be highly potent and fully efficacious agonists of the human CB2 receptor with excellent selectivity against CB1.  Compd. II possesses good biopharmaceutical properties, is highly water sol. and demonstrates robust oral activity in rodent models of joint pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-stJ--MpAdrVg90H21EOLACvtfcHk0lj6GpgR7H-WaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xps1Kktr8%253D&md5=8620ee7602f5537a0c029c00de238137</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.06.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.06.035%26sid%3Dliteratum%253Aachs%26aulast%3DHollinshead%26aufirst%3DS.%2BP.%26aulast%3DAstles%26aufirst%3DP.%2BC.%26aulast%3DChambers%26aufirst%3DM.%2BG.%26aulast%3DJohnson%26aufirst%3DM.%2BP.%26aulast%3DPalmer%26aufirst%3DJ.%26aulast%3DTidwell%26aufirst%3DM.%2BW.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520Novel%2520Purines%2520as%2520Potent%2520and%2520Selective%2520CB2%2520Agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D4962%26epage%3D4966%26doi%3D10.1016%2Fj.bmcl.2012.06.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Osman, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligresti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allarà, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabbito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abouzid, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abadi, A. H.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel Tetrahydrobenzo[b]Thiophene and Pyrrole Based Scaffolds as Potent and Selective CB2 Receptor Ligands: The Structural Elements Controlling Binding Affinity, Selectivity and Functionality</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">619</span>– <span class="NLM_lpage">634</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.07.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2016.07.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=27448919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1agsb7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2016&pages=619-634&author=N.+A.+Osmanauthor=A.+Ligrestiauthor=C.+D.+Kleinauthor=M.+Allar%C3%A0author=A.+Rabbitoauthor=V.+Di+Marzoauthor=K.+A.+Abouzidauthor=A.+H.+Abadi&title=Discovery+of+Novel+Tetrahydrobenzo%5Bb%5DThiophene+and+Pyrrole+Based+Scaffolds+as+Potent+and+Selective+CB2+Receptor+Ligands%3A+The+Structural+Elements+Controlling+Binding+Affinity%2C+Selectivity+and+Functionality&doi=10.1016%2Fj.ejmech.2016.07.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel Tetrahydrobenzo[b]thiophene and pyrrole based scaffolds as potent and selective CB2 receptor ligands: The structural elements controlling binding affinity, selectivity and functionality</span></div><div class="casAuthors">Osman, Noha A.; Ligresti, Alessia; Klein, Christian D.; Allara, Marco; Rabbito, Alessandro; Di Marzo, Vincenzo; Abouzid, Khaled A.; Abadi, Ashraf H.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">619-634</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">CB2-based therapeutics show strong potential in the treatment of diverse diseases such as inflammation, multiple sclerosis, pain, immune-related disorders, osteoporosis and cancer, without eliciting the typical neurobehavioral side effects of CB1 ligands.  For this reason, research activities are currently directed towards the development of CB2 selective ligands.  Herein, the synthesis of novel heterocyclic-based CB2 selective compds. is reported.  A set of 2,5-dialkyl-1-phenyl-1H-pyrrole-3-carboxamides, 5-substituted-2-(acylamino)/(2-sulfonylamino)-thiophene-3-carboxylates and 2-(acylamino)/(2-sulfonylamino)-tetrahydrobenzo[b]thiophene-3-carboxylates were synthesized.  Biol. results revealed compds. with remarkably high CB2 binding affinity and CB2/CB1 subtype selectivity.  Compd. I (R = adamantan-1-yl, R1 = Me, Et) from the pyrrole series exhibited the highest CB2 receptor affinity (Ki = 7.59 and 6.15 nM, resp.), as well as the highest CB2/CB1 subtype selectivity (∼70 and ∼200-fold, resp.).  In addn., compd. II (R = adamantan-1-yl) from the tetrahydrobenzo[b]thiophene series presented the most potent and selective CB2 ligand in this series (Ki = 2.15 nM and CB2 subtype selectivity of almost 500-fold over CB1).  Compd. II (R = adamantan-1-yl) showed a full agonism, while compds. I (R = adamantan-1-yl, R1 = Me, Et) acted as inverse agonists when tested in an adenylate cyclase assay.  The present findings thus pave the way to the design and optimization of heterocyclic-based scaffolds with lipophilic carboxamide and/or retroamide substituent that can be exploited as potential CB2 receptor activity modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnd1ftLyoMLrVg90H21EOLACvtfcHk0lhV4cyxtg3LJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1agsb7I&md5=49a6678c95e6e0584aa5293d104c4810</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.07.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.07.012%26sid%3Dliteratum%253Aachs%26aulast%3DOsman%26aufirst%3DN.%2BA.%26aulast%3DLigresti%26aufirst%3DA.%26aulast%3DKlein%26aufirst%3DC.%2BD.%26aulast%3DAllar%25C3%25A0%26aufirst%3DM.%26aulast%3DRabbito%26aufirst%3DA.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DAbouzid%26aufirst%3DK.%2BA.%26aulast%3DAbadi%26aufirst%3DA.%2BH.%26atitle%3DDiscovery%2520of%2520Novel%2520Tetrahydrobenzo%255Bb%255DThiophene%2520and%2520Pyrrole%2520Based%2520Scaffolds%2520as%2520Potent%2520and%2520Selective%2520CB2%2520Receptor%2520Ligands%253A%2520The%2520Structural%2520Elements%2520Controlling%2520Binding%2520Affinity%252C%2520Selectivity%2520and%2520Functionality%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D122%26spage%3D619%26epage%3D634%26doi%3D10.1016%2Fj.ejmech.2016.07.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romero-Parra, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mella-Raipán, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmieri, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allarà, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pessoa-Mahana, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iturriaga-Vásquez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Escobar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faúndez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pessoa-Mahana, C. D.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Binding Assays, Cytotoxic Activity and Docking Studies of Benzimidazole and Benzothiophene Derivatives with Selective Affinity for the CB2 Cannabinoid Receptor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">35</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.08.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2016.08.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=27560280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVOqsrzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2016&pages=17-35&author=J.+Romero-Parraauthor=J.+Mella-Raip%C3%A1nauthor=V.+Palmieriauthor=M.+Allar%C3%A0author=M.+J.+Torresauthor=H.+Pessoa-Mahanaauthor=P.+Iturriaga-V%C3%A1squezauthor=R.+Escobarauthor=M.+Fa%C3%BAndezauthor=V.+Di+Marzoauthor=C.+D.+Pessoa-Mahana&title=Synthesis%2C+Binding+Assays%2C+Cytotoxic+Activity+and+Docking+Studies+of+Benzimidazole+and+Benzothiophene+Derivatives+with+Selective+Affinity+for+the+CB2+Cannabinoid+Receptor&doi=10.1016%2Fj.ejmech.2016.08.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, binding assays, cytotoxic activity and docking studies of benzimidazole and benzothiophene derivatives with selective affinity for the CB2 cannabinoid receptor</span></div><div class="casAuthors">Romero-Parra, Javier; Mella-Raipan, Jaime; Palmieri, Vittoria; Allara, Marco; Torres, Maria Jose; Pessoa-Mahana, Hernan; Iturriaga-Vasquez, Patricio; Escobar, Rossy; Faundez, Mario; Di Marzo, Vincenzo; Pessoa-Mahana, C. David</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17-35</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The design, synthesis, bioinformatic and biol. studies of benzimidazole and benzothiophene derivs. as new cannabinoid receptor ligands was reported.  To test the hypothesis that the lack of a hydrogen bond interaction between benzimidazole and benzothiophene derivs. with Lys192 reduced their affinity for CB1 receptors (as we previously reported) and led to CB2 selectivity, most of the tested compds. did not exhibit hydrogen bond acceptors.  All compds. displayed mostly CB2 selectivity, although this was more pronounced in the benzimidazoles derivs.  Furthermore, docking assays revealed a π-cation interaction with Lys109 which could play a key role for the CB2 selectivity index.  The series displayed low toxicity on five different cell lines.  Deriv. (2-(tert-butyl)-1H-benzo[d]imidazol-1-yl)(naphthalen-1-yl)methanone presented the best binding profile (Ki = 0.08 μM), high selectivity index (KiCB1/KiCB2) and a low citoxicity.  Interestingly, in-cell viability expts., using HL-60 cells (expressing exclusively CB2 receptors), all synthesized compds. were shown to be cytotoxic, suggesting that a CB2 agonist response may be involved.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3NW06Xfx-b7Vg90H21EOLACvtfcHk0lhV4cyxtg3LJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVOqsrzL&md5=d27e5322faed12a25e775b606a2fe88c</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.08.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.08.005%26sid%3Dliteratum%253Aachs%26aulast%3DRomero-Parra%26aufirst%3DJ.%26aulast%3DMella-Raip%25C3%25A1n%26aufirst%3DJ.%26aulast%3DPalmieri%26aufirst%3DV.%26aulast%3DAllar%25C3%25A0%26aufirst%3DM.%26aulast%3DTorres%26aufirst%3DM.%2BJ.%26aulast%3DPessoa-Mahana%26aufirst%3DH.%26aulast%3DIturriaga-V%25C3%25A1squez%26aufirst%3DP.%26aulast%3DEscobar%26aufirst%3DR.%26aulast%3DFa%25C3%25BAndez%26aufirst%3DM.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DPessoa-Mahana%26aufirst%3DC.%2BD.%26atitle%3DSynthesis%252C%2520Binding%2520Assays%252C%2520Cytotoxic%2520Activity%2520and%2520Docking%2520Studies%2520of%2520Benzimidazole%2520and%2520Benzothiophene%2520Derivatives%2520with%2520Selective%2520Affinity%2520for%2520the%2520CB2%2520Cannabinoid%2520Receptor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D124%26spage%3D17%26epage%3D35%26doi%3D10.1016%2Fj.ejmech.2016.08.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yrjölä, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalliokoski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laitinen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkkari, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevalainen, T.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel Cannabinoid Receptor Ligands by a Virtual Screening Approach: Further Development of 2,4,6-Trisubstituted 1,3,5-Triazines as CB2 Agonists</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">9</span>– <span class="NLM_lpage">20</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2012.10.020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejps.2012.10.020" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=23131798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3sXosFKjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2013&pages=9-20&author=S.+Yrj%C3%B6l%C3%A4author=T.+Kalliokoskiauthor=T.+Laitinenauthor=A.+Posoauthor=T.+Parkkariauthor=T.+Nevalainen&title=Discovery+of+Novel+Cannabinoid+Receptor+Ligands+by+a+Virtual+Screening+Approach%3A+Further+Development+of+2%2C4%2C6-Trisubstituted+1%2C3%2C5-Triazines+as+CB2+Agonists&doi=10.1016%2Fj.ejps.2012.10.020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel cannabinoid receptor ligands by a virtual screening approach: Further development of 2,4,6-trisubstituted 1,3,5-triazines as CB2 agonists</span></div><div class="casAuthors">Yrjola, Sari; Kalliokoski, Tuomo; Laitinen, Tuomo; Poso, Antti; Parkkari, Teija; Nevalainen, Tapio</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">9-20</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">3D ligand-based virtual screening was employed to identify novel scaffolds for cannabinoid receptor ligand development.  A total of 112 compds. with diverse structures were purchased from com. vendors. 12 CB1 receptor antagonists/inverse agonists and 10 CB2 receptor agonists were identified in vitro.  One of the CB2 agonists, N-cyclopentyl-4-ethoxy-6-(4-methylpiperidin-1-yl)-1,3,5-triazin-2-amine (19, -log EC50 = 7.5, Emax = 255%) was selected for further development.  As far as we are aware, the compd.'s 1,3,5-triazine scaffold represents a new core structure for CB2 agonists.  A library of fifty-seven 2,4,6-trisubstituted-1,3,5-triazines was created to clarify the structure-activity relationship study of the analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrv7JzPj_96GbVg90H21EOLACvtfcHk0lhV4cyxtg3LJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXosFKjuw%253D%253D&md5=b0bcb09a66682d9552254363121deacc</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2012.10.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2012.10.020%26sid%3Dliteratum%253Aachs%26aulast%3DYrj%25C3%25B6l%25C3%25A4%26aufirst%3DS.%26aulast%3DKalliokoski%26aufirst%3DT.%26aulast%3DLaitinen%26aufirst%3DT.%26aulast%3DPoso%26aufirst%3DA.%26aulast%3DParkkari%26aufirst%3DT.%26aulast%3DNevalainen%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520Novel%2520Cannabinoid%2520Receptor%2520Ligands%2520by%2520a%2520Virtual%2520Screening%2520Approach%253A%2520Further%2520Development%2520of%25202%252C4%252C6-Trisubstituted%25201%252C3%252C5-Triazines%2520as%2520CB2%2520Agonists%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2013%26volume%3D48%26spage%3D9%26epage%3D20%26doi%3D10.1016%2Fj.ejps.2012.10.020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yrjölä, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarparanta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Airaksinen, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hytti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kauppinen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasonen-Seppänen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adinolfi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nieri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keinänen, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nevalainen, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkkari, T.</span></span> <span> </span><span class="NLM_article-title">Synthesis, in Vitro and in Vivo Evaluation of 1,3,5-Triazines as Cannabinoid CB2 Receptor Agonists</span>. <i>Eur. J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">96</span>, <span class="refDoi"> DOI: 10.1016/j.ejps.2014.11.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejps.2014.11.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=25447744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFCnt7bL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2015&pages=85-96&author=S.+Yrj%C3%B6l%C3%A4author=M.+Sarparantaauthor=A.+J.+Airaksinenauthor=M.+Hyttiauthor=A.+Kauppinenauthor=S.+Pasonen-Sepp%C3%A4nenauthor=B.+Adinolfiauthor=P.+Nieriauthor=C.+Maneraauthor=O.+Kein%C3%A4nenauthor=A.+Posoauthor=T.+J.+Nevalainenauthor=T.+Parkkari&title=Synthesis%2C+in+Vitro+and+in+Vivo+Evaluation+of+1%2C3%2C5-Triazines+as+Cannabinoid+CB2+Receptor+Agonists&doi=10.1016%2Fj.ejps.2014.11.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists</span></div><div class="casAuthors">Yrjola, Sari; Sarparanta, Mirkka; Airaksinen, Anu J.; Hytti, Maria; Kauppinen, Anu; Pasonen-Seppanen, Sanna; Adinolfi, Barbara; Nieri, Paola; Manera, Clementina; Keinanen, Outi; Poso, Antti; Nevalainen, Tapio J.; Parkkari, Teija</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">85-96</span>CODEN:
                <span class="NLM_cas:coden">EPSCED</span>;
        ISSN:<span class="NLM_cas:issn">0928-0987</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The cannabinoid receptors type 2 (CBR2) are attractive therapeutic targets of the endocannabinoid signaling system (ECS) as they are not displaying the undesired psychotropic and cardiovascular side-effects seen with cannabinoid receptor type 1 (CB1R) agonists.  In continuation of our previous work on 2,4,6-trisubstituted 1,3,5-triazines as potent CB2 agonists, we synthesized an addnl. series of more polar analogs (1-10), which were found to possess high CB2R agonist activity with enhanced water soly.  The most potent compd. in the series was N-(adamantan-1-yl)-4-ethoxy-6-(4-(2-fluoroethyl)piperazin-1-yl)-1,3,5-triazin-2-amine (9) with EC50 value of 0.60 nM.  To further evaluate the biol. effects of the compds., the selected compds. were tested in vitro against four different cell lines.  A human retinal pigment epithelial cell line (ARPE-19) was used to evaluate the cytotoxicity of the compds. whereas an androgen-sensitive human prostate adenocarcinoma cell line (LNCaP), a Jurkat leukemia cell line and a C8161 melanoma cell line were used to assess the antiproliferative activity of the compds.  The most interesting results were obtained for N-(adamantan-1-yl)-4-ethoxy-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-amine (6), which induced cell viability decrease in prostate and leukemia cell lines, and diminished proliferation of C8161 melanoma cells.  The results could be reversed in leukemia cells with the selective CB2R antagonist AM630, whereas in prostate cells the AM630 induced a significant cell viability decrease with a mechanism probably unlinked to CB2 cannabinoid receptor.  The antiproliferative effect of 6 on the melanoma cells seemed not to be mediated via the CB1R or CB2R.  No cytotoxicity was detected against ARPE-19 cell line at concns. of 1 and 10 μM for compd. 6.  However, at 30 μM concn. the compd. 6 decreased the cell viability.  Finally, in order to est. in vivo behavior of these compds., 18F labeled PET ligand, N-cyclopentyl-4-ethoxy-6-(4-(2-fluoro-18-ethyl)piperazin-1-yl)-1,3,5-triazin-2-amine ([18F]5), was synthesized and its biodistribution was detd. in healthy male Sprague-Dawley rats.  As a result, the tracer showed a rapid (<15 min) elimination in urine accompanied by a slower excretion via the hepatobiliary route.  In conclusion, we further demonstrated that 1,3,5-triazine scaffold serves as a suitable template for the design of highly potent CB2R agonists with reasonable water soly. properties.  The compds. may be useful when studying the role of the endocannabinoid system in different diseases.  The triazine scaffold is also a promising candidate for the development of new CB2R PET ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_1aEvtEgaW7Vg90H21EOLACvtfcHk0lg41fmck8o__g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFCnt7bL&md5=8153b8fd95235ae3541e6bf209eef499</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.ejps.2014.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejps.2014.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DYrj%25C3%25B6l%25C3%25A4%26aufirst%3DS.%26aulast%3DSarparanta%26aufirst%3DM.%26aulast%3DAiraksinen%26aufirst%3DA.%2BJ.%26aulast%3DHytti%26aufirst%3DM.%26aulast%3DKauppinen%26aufirst%3DA.%26aulast%3DPasonen-Sepp%25C3%25A4nen%26aufirst%3DS.%26aulast%3DAdinolfi%26aufirst%3DB.%26aulast%3DNieri%26aufirst%3DP.%26aulast%3DManera%26aufirst%3DC.%26aulast%3DKein%25C3%25A4nen%26aufirst%3DO.%26aulast%3DPoso%26aufirst%3DA.%26aulast%3DNevalainen%26aufirst%3DT.%2BJ.%26aulast%3DParkkari%26aufirst%3DT.%26atitle%3DSynthesis%252C%2520in%2520Vitro%2520and%2520in%2520Vivo%2520Evaluation%2520of%25201%252C3%252C5-Triazines%2520as%2520Cannabinoid%2520CB2%2520Receptor%2520Agonists%26jtitle%3DEur.%2520J.%2520Pharm.%2520Sci.%26date%3D2015%26volume%3D67%26spage%3D85%26epage%3D96%26doi%3D10.1016%2Fj.ejps.2014.11.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Odan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishizuka, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiramatsu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inagaki, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashizume, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsumori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morioka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soga, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deguchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasui, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arimura, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of S-777469: An Orally Available CB2 Agonist as an Antipruritic Agent</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">2803</span>– <span class="NLM_lpage">2806</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2012.02.072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmcl.2012.02.072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=22444677" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC38XksV2itrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=2803-2806&author=M.+Odanauthor=N.+Ishizukaauthor=Y.+Hiramatsuauthor=M.+Inagakiauthor=H.+Hashizumeauthor=Y.+Fujiiauthor=S.+Mitsumoriauthor=Y.+Moriokaauthor=M.+Sogaauthor=M.+Deguchiauthor=K.+Yasuiauthor=A.+Arimura&title=Discovery+of+S-777469%3A+An+Orally+Available+CB2+Agonist+as+an+Antipruritic+Agent&doi=10.1016%2Fj.bmcl.2012.02.072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of S-777469: An orally available CB2 agonist as an antipruritic agent</span></div><div class="casAuthors">Odan, Masahide; Ishizuka, Natsuki; Hiramatsu, Yoshiharu; Inagaki, Masanao; Hashizume, Hiroshi; Fujii, Yasuhiko; Mitsumori, Susumu; Morioka, Yasuhide; Soga, Masahiko; Deguchi, Masashi; Yasui, Kiyoshi; Arimura, Akinori</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2803-2806</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The discovery of novel CB2 ligands based on the 3-carbamoyl-2-pyridone derivs. by adjusting the size of side chain at 1-, 5- and 6-position is reported.  The structure-activity relationship around this template lead to the identification of S-777469 as a selective CB2 receptor agonist, which exhibited the significant inhibition of scratching induced by Compd. 48/80 at 1.0 mg/kg po and 10 mg/kg po (55% and 61%, resp.).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzaovlzOzh1LVg90H21EOLACvtfcHk0lg41fmck8o__g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksV2itrk%253D&md5=802f17b593a2a791c24caf226f808218</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2012.02.072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2012.02.072%26sid%3Dliteratum%253Aachs%26aulast%3DOdan%26aufirst%3DM.%26aulast%3DIshizuka%26aufirst%3DN.%26aulast%3DHiramatsu%26aufirst%3DY.%26aulast%3DInagaki%26aufirst%3DM.%26aulast%3DHashizume%26aufirst%3DH.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DMitsumori%26aufirst%3DS.%26aulast%3DMorioka%26aufirst%3DY.%26aulast%3DSoga%26aufirst%3DM.%26aulast%3DDeguchi%26aufirst%3DM.%26aulast%3DYasui%26aufirst%3DK.%26aulast%3DArimura%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520S-777469%253A%2520An%2520Orally%2520Available%2520CB2%2520Agonist%2520as%2520an%2520Antipruritic%2520Agent%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D2803%26epage%3D2806%26doi%3D10.1016%2Fj.bmcl.2012.02.072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lucchesi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkkari, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savinainen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malfitano, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allarà, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castelli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Carlo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laezza, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligresti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccomanni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bifulco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manera, C.</span></span> <span> </span><span class="NLM_article-title">1,2-Dihydro-2-Oxopyridine-3-Carboxamides: The C-5 Substituent Is Responsible for Functionality Switch at CB2 Cannabinoid Receptor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>74</i></span>,  <span class="NLM_fpage">524</span>– <span class="NLM_lpage">532</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.10.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2013.10.070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=24518874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2cXjtlygu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=524-532&author=V.+Lucchesiauthor=T.+Parkkariauthor=J.+R.+Savinainenauthor=A.+M.+Malfitanoauthor=M.+Allar%C3%A0author=S.+Bertiniauthor=F.+Castelliauthor=S.+Del+Carloauthor=C.+Laezzaauthor=A.+Ligrestiauthor=G.+Saccomanniauthor=M.+Bifulcoauthor=V.+Di+Marzoauthor=M.+Macchiaauthor=C.+Manera&title=1%2C2-Dihydro-2-Oxopyridine-3-Carboxamides%3A+The+C-5+Substituent+Is+Responsible+for+Functionality+Switch+at+CB2+Cannabinoid+Receptor&doi=10.1016%2Fj.ejmech.2013.10.070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">1,2-Dihydro-2-oxopyridine-3-carboxamides: The C-5 substituent is responsible for functionality switch at CB2 cannabinoid receptor</span></div><div class="casAuthors">Lucchesi, Valentina; Parkkari, Teija; Savinainen, Juha R.; Malfitano, Anna Maria; Allara, Marco; Bertini, Simone; Castelli, Francesca; Del Carlo, Sara; Laezza, Chiara; Ligresti, Alessia; Saccomanni, Giuseppe; Bifulco, Maurizio; Di Marzo, Vincenzo; Macchia, Marco; Manera, Clementina</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">524-532</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The relevance of CB2R-mediated therapeutic effects is well-known for the treatment of inflammatory and neuropathic pain and neurodegenerative disorders.  In our search for new cannabinoid receptor modulators, we report the optimization of a series of 1,2-dihydro-2-oxopyridine-3-carboxamide derivs. as CB2R ligands.  In particular, N-cycloheptyl-5-(4-methoxyphenyl)-1-(4-fluorobenzyl)-pyridin-2(1H)-on-3-carboxamide (17) showed high CB2R affinity (Ki = 1.0 nM), accompanied by interesting Ki(CB1R)/Ki(CB2R) selectivity ratio (SI = 43.4).  Compd. 17 was also identified as a potent CB2R neutral antagonist/weak partial inverse agonist.  Finally we found that the functionality activity of the series of 1,2-dihydro-2-oxopyridine is controlled by the presence of a substituent in position 5 of the heterocyclic nucleus.  In fact when the hydrogen atom in position 5 of the unsubstituted compd. 1 was replaced with a Ph group (compd. 18) the CB2R activity was shifted from agonism to inverse agonism whereas the introduction in the same position of p-methoxyphenyl group lead to compd. 17 which showed a behavior as CB2R neutral antagonist/weak partial inverse agonist.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpg1gGlmi90MbVg90H21EOLACvtfcHk0ljgYitEpYry_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXjtlygu78%253D&md5=f7d1c2ec2674cd0b2c9b99012cb12859</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.10.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.10.070%26sid%3Dliteratum%253Aachs%26aulast%3DLucchesi%26aufirst%3DV.%26aulast%3DParkkari%26aufirst%3DT.%26aulast%3DSavinainen%26aufirst%3DJ.%2BR.%26aulast%3DMalfitano%26aufirst%3DA.%2BM.%26aulast%3DAllar%25C3%25A0%26aufirst%3DM.%26aulast%3DBertini%26aufirst%3DS.%26aulast%3DCastelli%26aufirst%3DF.%26aulast%3DDel%2BCarlo%26aufirst%3DS.%26aulast%3DLaezza%26aufirst%3DC.%26aulast%3DLigresti%26aufirst%3DA.%26aulast%3DSaccomanni%26aufirst%3DG.%26aulast%3DBifulco%26aufirst%3DM.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DMacchia%26aufirst%3DM.%26aulast%3DManera%26aufirst%3DC.%26atitle%3D1%252C2-Dihydro-2-Oxopyridine-3-Carboxamides%253A%2520The%2520C-5%2520Substituent%2520Is%2520Responsible%2520for%2520Functionality%2520Switch%2520at%2520CB2%2520Cannabinoid%2520Receptor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D74%26spage%3D524%26epage%3D532%26doi%3D10.1016%2Fj.ejmech.2013.10.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El
Bakali, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muccioli, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renault, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pradal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Body-Malapel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djouina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamtiaux, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrzejak, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desreumaux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavatte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millet, R.</span></span> <span> </span><span class="NLM_article-title">4-Oxo-1,4-Dihydropyridines as Selective CB2 Cannabinoid Receptor Ligands: Structural Insights into the Design of a Novel Inverse Agonist Series</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">7918</span>– <span class="NLM_lpage">7931</span>, <span class="refDoi"> DOI: 10.1021/jm100286k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100286k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlCltbjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7918-7931&author=J.+El%0ABakaliauthor=G.+G.+Muccioliauthor=N.+Renaultauthor=D.+Pradalauthor=M.+Body-Malapelauthor=M.+Djouinaauthor=L.+Hamtiauxauthor=V.+Andrzejakauthor=P.+Desreumauxauthor=P.+Chavatteauthor=D.+M.+Lambertauthor=R.+Millet&title=4-Oxo-1%2C4-Dihydropyridines+as+Selective+CB2+Cannabinoid+Receptor+Ligands%3A+Structural+Insights+into+the+Design+of+a+Novel+Inverse+Agonist+Series&doi=10.1021%2Fjm100286k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">4-Oxo-1,4-dihydropyridines as Selective CB2 Cannabinoid Receptor Ligands: Structural Insights into the Design of a Novel Inverse Agonist Series</span></div><div class="casAuthors">El Bakali, Jamal; Muccioli, Giulio G.; Renault, Nicolas; Pradal, Delphine; Body-Malapel, Mathilde; Djouina, Madjid; Hamtiaux, Laurie; Andrzejak, Virginie; Desreumaux, Pierre; Chavatte, Philippe; Lambert, Didier M.; Millet, Regis</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7918-7931</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Growing evidence shows that CB2 receptor is an attractive therapeutic target.  Starting from a series of 4-oxo-1,4-dihydroquinoline-3-carboxamides as selective CB2 agonists, the medicinal chem. approach leading to the development of CB2 receptor inverse agonists with a 4-oxo-1,4-dihydropyridine scaffold is described.  These compds. show high affinity and potency at the CB2 receptor while showing only modest affinity for the centrally expressed CB1 cannabinoid receptor.  Further, the functionality of this series is controlled by its C-6 substituent because agonists bear a Me or a tert-Bu group and inverse agonists, a Ph or 4-chlorophenyl group, resp.  Finally, in silico studies suggest that the C-6 substituent could modulate the conformation of W6.48 known to be crit. in GPCR activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcBOWW6IivurVg90H21EOLACvtfcHk0ljgYitEpYry_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlCltbjF&md5=65ead1fefed0288ac4469aa1c2740b45</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1021%2Fjm100286k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100286k%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BBakali%26aufirst%3DJ.%26aulast%3DMuccioli%26aufirst%3DG.%2BG.%26aulast%3DRenault%26aufirst%3DN.%26aulast%3DPradal%26aufirst%3DD.%26aulast%3DBody-Malapel%26aufirst%3DM.%26aulast%3DDjouina%26aufirst%3DM.%26aulast%3DHamtiaux%26aufirst%3DL.%26aulast%3DAndrzejak%26aufirst%3DV.%26aulast%3DDesreumaux%26aufirst%3DP.%26aulast%3DChavatte%26aufirst%3DP.%26aulast%3DLambert%26aufirst%3DD.%2BM.%26aulast%3DMillet%26aufirst%3DR.%26atitle%3D4-Oxo-1%252C4-Dihydropyridines%2520as%2520Selective%2520CB2%2520Cannabinoid%2520Receptor%2520Ligands%253A%2520Structural%2520Insights%2520into%2520the%2520Design%2520of%2520a%2520Novel%2520Inverse%2520Agonist%2520Series%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7918%26epage%3D7931%26doi%3D10.1021%2Fjm100286k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parkkari, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savinainen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arena, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccomanni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saguto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligresti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allarà, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruno, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novellino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchia, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis, Biological Activity and Molecular Modeling of New Biphenylic Carboxamides as Potent and Selective CB2 Receptor Ligands</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">526</span>– <span class="NLM_lpage">536</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.11.066</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2014.11.066" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=25486424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVems7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2015&pages=526-536&author=S.+Bertiniauthor=T.+Parkkariauthor=J.+R.+Savinainenauthor=C.+Arenaauthor=G.+Saccomanniauthor=S.+Sagutoauthor=A.+Ligrestiauthor=M.+Allar%C3%A0author=A.+Brunoauthor=L.+Marinelliauthor=V.+Di+Marzoauthor=E.+Novellinoauthor=C.+Maneraauthor=M.+Macchia&title=Synthesis%2C+Biological+Activity+and+Molecular+Modeling+of+New+Biphenylic+Carboxamides+as+Potent+and+Selective+CB2+Receptor+Ligands&doi=10.1016%2Fj.ejmech.2014.11.066"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, biological activity and molecular modeling of new biphenylic carboxamides as potent and selective CB2 receptor ligands</span></div><div class="casAuthors">Bertini, Simone; Parkkari, Teija; Savinainen, Juha R.; Arena, Chiara; Saccomanni, Giuseppe; Saguto, Simone; Ligresti, Alessia; Allara, Marco; Bruno, Agostino; Marinelli, Luciana; Di Marzo, Vincenzo; Novellino, Ettore; Manera, Clementina; Macchia, Marco</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">526-536</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The CB2 receptor is a therapeutic target of increasing importance for several diseases, including pain, inflammation, neurodegeneration, cancer and osteoporosis.  While several compds. showing CB2-selective agonist or inverse agonist properties were developed, only few CB2 receptor selective neutral antagonists are actually known.  Such type of compds. could be useful to study more in depth the role of the CB2 receptor, because they lack the ability to counteract its "constitutive" activity.  Here the authors describe the synthesis and biol. activity of a series of biphenylic carboxamides as a new class of CB2 receptor selective ligands.  In binding assays, one of these compds. showed good CB2 receptor affinity and selectivity (Ki = 11.48 nM; Selectivity Index = 130).  Furthermore, in functional assays, the same compd. showed a very interesting pharmacol. profile as CB2 receptor selective neutral antagonist.  These results pave the way to further developments, including structural optimization, with the aim to obtain more potent CB2 receptor ligands with this peculiar feature.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodBi4tSxSa6rVg90H21EOLACvtfcHk0liApNC5fG4jAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVems7zN&md5=c6b3a035419dbf4c4c4d15badfc57249</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.11.066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.11.066%26sid%3Dliteratum%253Aachs%26aulast%3DBertini%26aufirst%3DS.%26aulast%3DParkkari%26aufirst%3DT.%26aulast%3DSavinainen%26aufirst%3DJ.%2BR.%26aulast%3DArena%26aufirst%3DC.%26aulast%3DSaccomanni%26aufirst%3DG.%26aulast%3DSaguto%26aufirst%3DS.%26aulast%3DLigresti%26aufirst%3DA.%26aulast%3DAllar%25C3%25A0%26aufirst%3DM.%26aulast%3DBruno%26aufirst%3DA.%26aulast%3DMarinelli%26aufirst%3DL.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DNovellino%26aufirst%3DE.%26aulast%3DManera%26aufirst%3DC.%26aulast%3DMacchia%26aufirst%3DM.%26atitle%3DSynthesis%252C%2520Biological%2520Activity%2520and%2520Molecular%2520Modeling%2520of%2520New%2520Biphenylic%2520Carboxamides%2520as%2520Potent%2520and%2520Selective%2520CB2%2520Receptor%2520Ligands%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2015%26volume%3D90%26spage%3D526%26epage%3D536%26doi%3D10.1016%2Fj.ejmech.2014.11.066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bertini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chicca, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arena, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chicca, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccomanni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gertsch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macchia, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and Pharmacological Evaluation of New Biphenylic Derivatives as CB2 Receptor Ligands</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">252</span>– <span class="NLM_lpage">266</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2016.03.072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2016.03.072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=27078864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC28XmtVKit7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2016&pages=252-266&author=S.+Bertiniauthor=A.+Chiccaauthor=C.+Arenaauthor=S.+Chiccaauthor=G.+Saccomanniauthor=J.+Gertschauthor=C.+Maneraauthor=M.+Macchia&title=Synthesis+and+Pharmacological+Evaluation+of+New+Biphenylic+Derivatives+as+CB2+Receptor+Ligands&doi=10.1016%2Fj.ejmech.2016.03.072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and pharmacological evaluation of new biphenylic derivatives as CB2 receptor ligands</span></div><div class="casAuthors">Bertini, Simone; Chicca, Andrea; Arena, Chiara; Chicca, Stefano; Saccomanni, Giuseppe; Gertsch, Jurg; Manera, Clementina; Macchia, Marco</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">252-266</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Targeting type-2 cannabinoid receptor (CB2) is considered a feasible strategy to develop new drugs for the treatment of diseases like neuropathic pain, chronic inflammation, neurodegenerative disorders and cancer.  Such drugs are devoid of the undesired central side effects that are typically mediated by the CB1 receptor.  In this work we synthesized 18 biphenylic carboxamides as new CB2-selective ligands and evaluated their pharmacol. profiles.  The functional activity of these compds. is strongly influenced by the nature of the substituent at position 4' and 5 of the biphenyl scaffold.  Position 5 seems to be responsible for the agonist or inverse agonist behavior independently of the substituent in position 4', with the exception of the methoxyl group which transforms both full agonists and inverse agonists into neutral antagonists.  This study provides a novel complete toolbox of CB2 functional modulators that derive from the same chem. scaffold.  Such probes may be useful to investigate the biol. role of CB2 receptors in cellular assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6-re77MxhJ7Vg90H21EOLACvtfcHk0liApNC5fG4jAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmtVKit7o%253D&md5=c692074dad0f8dc5ed7ec2d739834925</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2016.03.072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2016.03.072%26sid%3Dliteratum%253Aachs%26aulast%3DBertini%26aufirst%3DS.%26aulast%3DChicca%26aufirst%3DA.%26aulast%3DArena%26aufirst%3DC.%26aulast%3DChicca%26aufirst%3DS.%26aulast%3DSaccomanni%26aufirst%3DG.%26aulast%3DGertsch%26aufirst%3DJ.%26aulast%3DManera%26aufirst%3DC.%26aulast%3DMacchia%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520Pharmacological%2520Evaluation%2520of%2520New%2520Biphenylic%2520Derivatives%2520as%2520CB2%2520Receptor%2520Ligands%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2016%26volume%3D116%26spage%3D252%26epage%3D266%26doi%3D10.1016%2Fj.ejmech.2016.03.072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zindell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirillo, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ermann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemkow, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riether, D.</span></span> <span> </span><span class="NLM_article-title">Selective CB2 Receptor Agonists. Part 1: The Identification of Novel Ligands through Computer-Aided Drug Design (CADD) Approaches</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">575</span>– <span class="NLM_lpage">580</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.12.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmcl.2014.12.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=25556098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFOqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=575-580&author=E.+R.+Hickeyauthor=R.+Zindellauthor=P.+F.+Cirilloauthor=L.+Wuauthor=M.+Ermannauthor=A.+K.+Berryauthor=D.+S.+Thomsonauthor=C.+Albrechtauthor=M.+J.+Gemkowauthor=D.+Riether&title=Selective+CB2+Receptor+Agonists.+Part+1%3A+The+Identification+of+Novel+Ligands+through+Computer-Aided+Drug+Design+%28CADD%29+Approaches&doi=10.1016%2Fj.bmcl.2014.12.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Selective CB2 receptor agonists. Part 1: The identification of novel ligands through computer-aided drug design (CADD) approaches</span></div><div class="casAuthors">Hickey, Eugene R.; Zindell, Renee; Cirillo, Pier F.; Wu, Lifen; Ermann, Monika; Berry, Angela K.; Thomson, David S.; Albrecht, Claudia; Gemkow, Mark J.; Riether, Doris</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">575-580</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Computer-aided drug design scaffold hopping strategies were utilized to identify new classes of CB2 agonists when compds. of an established series with low nanomolar potency were challenging to optimize for good drug-like properties.  Use of ligand-based design strategies through BI Builder (a tool for de novo design) and PharmShape (a virtual screening software package) approaches led to the discovery of new chemotypes.  Specifically, compds. contg. azetidine-, proline-, and piperidine-based cores were found to have low nanomolar and picomolar CB2 agonist activities with drug-like properties considered appropriate for early profiling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3aC9L4cUXHLVg90H21EOLACvtfcHk0liApNC5fG4jAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFOqtw%253D%253D&md5=c7d57590e3f6c08a3f19f2b67a6b46cb</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.12.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.12.033%26sid%3Dliteratum%253Aachs%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DZindell%26aufirst%3DR.%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DErmann%26aufirst%3DM.%26aulast%3DBerry%26aufirst%3DA.%2BK.%26aulast%3DThomson%26aufirst%3DD.%2BS.%26aulast%3DAlbrecht%26aufirst%3DC.%26aulast%3DGemkow%26aufirst%3DM.%2BJ.%26aulast%3DRiether%26aufirst%3DD.%26atitle%3DSelective%2520CB2%2520Receptor%2520Agonists.%2520Part%25201%253A%2520The%2520Identification%2520of%2520Novel%2520Ligands%2520through%2520Computer-Aided%2520Drug%2520Design%2520%2528CADD%2529%2520Approaches%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D575%26epage%3D580%26doi%3D10.1016%2Fj.bmcl.2014.12.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riether, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zindell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betageri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ermann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemkow, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraja, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romig, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, D. S.</span></span> <span> </span><span class="NLM_article-title">Selective CB2 Receptor Agonists. Part 2: Structure-Activity Relationship Studies and Optimization of Proline-Based Compounds</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">581</span>– <span class="NLM_lpage">586</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.12.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmcl.2014.12.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=25556092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2ksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=581-586&author=D.+Rietherauthor=R.+Zindellauthor=L.+Wuauthor=R.+Betageriauthor=J.+E.+Jenkinsauthor=S.+Khorauthor=A.+K.+Berryauthor=E.+R.+Hickeyauthor=M.+Ermannauthor=C.+Albrechtauthor=A.+Ceciauthor=M.+J.+Gemkowauthor=N.+V.+Nagarajaauthor=H.+Romigauthor=A.+Sauerauthor=D.+S.+Thomson&title=Selective+CB2+Receptor+Agonists.+Part+2%3A+Structure-Activity+Relationship+Studies+and+Optimization+of+Proline-Based+Compounds&doi=10.1016%2Fj.bmcl.2014.12.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Selective CB2 receptor agonists. Part 2: Structure-activity relationship studies and optimization of proline-based compounds</span></div><div class="casAuthors">Riether, Doris; Zindell, Renee; Wu, Lifen; Betageri, Raj; Jenkins, James E.; Khor, Someina; Berry, Angela K.; Hickey, Eugene R.; Ermann, Monika; Albrecht, Claudia; Ceci, Angelo; Gemkow, Mark J.; Nagaraja, Nelamangala V.; Romig, Helmut; Sauer, Achim; Thomson, David S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">581-586</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Through a ligand-based pharmacophore model (S)-proline based compds. were identified as potent cannabinoid receptor 2 (CB2) agonists with high selectivity over the cannabinoid receptor 1 (CB1).  Structure-activity relationship investigations for this compd. class lead to oxo-proline compds. I and II which combine an impressive CB1 selectivity profile with good pharmacokinetic properties.  In a streptozotocin induced diabetic neuropathy model, II demonstrated a dose-dependent reversal of mech. hyperalgesia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZQRf3dcb1fbVg90H21EOLACvtfcHk0ljXZG-tnJC3Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2ksw%253D%253D&md5=228e2d6883d4dc41741dae80ffa2db42</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.12.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.12.019%26sid%3Dliteratum%253Aachs%26aulast%3DRiether%26aufirst%3DD.%26aulast%3DZindell%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DBetageri%26aufirst%3DR.%26aulast%3DJenkins%26aufirst%3DJ.%2BE.%26aulast%3DKhor%26aufirst%3DS.%26aulast%3DBerry%26aufirst%3DA.%2BK.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DErmann%26aufirst%3DM.%26aulast%3DAlbrecht%26aufirst%3DC.%26aulast%3DCeci%26aufirst%3DA.%26aulast%3DGemkow%26aufirst%3DM.%2BJ.%26aulast%3DNagaraja%26aufirst%3DN.%2BV.%26aulast%3DRomig%26aufirst%3DH.%26aulast%3DSauer%26aufirst%3DA.%26aulast%3DThomson%26aufirst%3DD.%2BS.%26atitle%3DSelective%2520CB2%2520Receptor%2520Agonists.%2520Part%25202%253A%2520Structure-Activity%2520Relationship%2520Studies%2520and%2520Optimization%2520of%2520Proline-Based%2520Compounds%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D581%26epage%3D586%26doi%3D10.1016%2Fj.bmcl.2014.12.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bartolozzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirillo, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berry, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickey, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomson, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zindell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ceci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemkow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagaraja, N. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romig, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riether, D.</span></span> <span> </span><span class="NLM_article-title">Selective CB2 Receptor Agonists. Part 3: The Optimization of a Piperidine-Based Series That Demonstrated Efficacy in an in Vivo Neuropathic Pain Model</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">587</span>– <span class="NLM_lpage">592</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2014.12.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmcl.2014.12.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=25575658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFyntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=587-592&author=A.+Bartolozziauthor=P.+F.+Cirilloauthor=A.+K.+Berryauthor=E.+R.+Hickeyauthor=D.+S.+Thomsonauthor=L.+Wuauthor=R.+Zindellauthor=C.+Albrechtauthor=A.+Ceciauthor=M.+Gemkowauthor=N.+V.+Nagarajaauthor=H.+Romigauthor=A.+Sauerauthor=D.+Riether&title=Selective+CB2+Receptor+Agonists.+Part+3%3A+The+Optimization+of+a+Piperidine-Based+Series+That+Demonstrated+Efficacy+in+an+in+Vivo+Neuropathic+Pain+Model&doi=10.1016%2Fj.bmcl.2014.12.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Selective CB2 receptor agonists. Part 3: The optimization of a piperidine-based series that demonstrated efficacy in an in vivo neuropathic pain model</span></div><div class="casAuthors">Bartolozzi, Alessandra; Cirillo, Pier Francesco; Berry, Angela K.; Hickey, Eugene R.; Thomson, David S.; Wu, Lifen; Zindell, Renee; Albrecht, Claudia; Ceci, Angelo; Gemkow, Mark J.; Nagaraja, Nelamangala V.; Romig, Helmut; Sauer, Achim; Riether, Doris</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">587-592</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel class of potent cannabinoid receptor 2 (CB2) agonists based on a (S)-piperidine scaffold was identified using ligand-based pharmacophore models.  Optimization of soly. and metabolic stability led to the identification of several potent CB2 agonists, e.g. I, that displayed selectivity over cannabinoid receptor 1 (CB1) and acceptable drug like properties.  In rats, compd. 30 demonstrated a favorable pharmacokinetic profile and efficacy in a Streptozotocin-induced diabetic neuropathy model, with full reversal of mech. hyperalgesia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozt6QBJ0p0HrVg90H21EOLACvtfcHk0ljXZG-tnJC3Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFyntw%253D%253D&md5=33f1001f09733729506f2cda3f369879</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2014.12.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2014.12.031%26sid%3Dliteratum%253Aachs%26aulast%3DBartolozzi%26aufirst%3DA.%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26aulast%3DBerry%26aufirst%3DA.%2BK.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DThomson%26aufirst%3DD.%2BS.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DZindell%26aufirst%3DR.%26aulast%3DAlbrecht%26aufirst%3DC.%26aulast%3DCeci%26aufirst%3DA.%26aulast%3DGemkow%26aufirst%3DM.%26aulast%3DNagaraja%26aufirst%3DN.%2BV.%26aulast%3DRomig%26aufirst%3DH.%26aulast%3DSauer%26aufirst%3DA.%26aulast%3DRiether%26aufirst%3DD.%26atitle%3DSelective%2520CB2%2520Receptor%2520Agonists.%2520Part%25203%253A%2520The%2520Optimization%2520of%2520a%2520Piperidine-Based%2520Series%2520That%2520Demonstrated%2520Efficacy%2520in%2520an%2520in%2520Vivo%2520Neuropathic%2520Pain%2520Model%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D587%26epage%3D592%26doi%3D10.1016%2Fj.bmcl.2014.12.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huffman, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liddle, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aung, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abood, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiley, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, B. R.</span></span> <span> </span><span class="NLM_article-title">3-(1′,1′-Dimethylbutyl)-1-Deoxy-Delta8-THC and Related Compounds: Synthesis of Selective Ligands for the CB2 Receptor</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2905</span>– <span class="NLM_lpage">2914</span>, <span class="refDoi"> DOI: 10.1016/S0968-0896(99)00219-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2FS0968-0896%2899%2900219-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10658595" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntFCnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1999&pages=2905-2914&author=J.+W.+Huffmanauthor=J.+Liddleauthor=S.+Yuauthor=M.+M.+Aungauthor=M.+E.+Aboodauthor=J.+L.+Wileyauthor=B.+R.+Martin&title=3-%281%E2%80%B2%2C1%E2%80%B2-Dimethylbutyl%29-1-Deoxy-Delta8-THC+and+Related+Compounds%3A+Synthesis+of+Selective+Ligands+for+the+CB2+Receptor&doi=10.1016%2FS0968-0896%2899%2900219-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">3-(1',1'-Dimethylbutyl)-1-deoxy-Δ8-THC and related compounds: synthesis of selective ligands for the CB2 receptor</span></div><div class="casAuthors">Huffman, John W.; Liddle, John; Yu, Shu; Aung, Mie Mie; Abood, Mary E.; Wiley, Jenny L.; Martin, Billy R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2905-2914</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">The synthesis and pharmacol. of 15 1-deoxy-Δ8-THC analogs, several of which have high affinity for the CB2 receptor, are described.  The deoxy cannabinoids include 1-deoxy-11-hydroxy-Δ8-THC, 1-deoxy-Δ8-THC, 1-deoxy-3-butyl-Δ8-THC, 1-deoxy-3-hexyl-Δ8-THC and a series of 3-(1',1'-dimethylalkyl)-1-deoxy-Δ8-THC analogs I (n = 0-4, 6, 7).  Three derivs. of deoxynabilone were also prepd.  The affinities of each compd. for the CB1 and CB2 receptors were detd. employing previously described procedures.  Five of the 3-(1',1'-dimethylalkyl)-1-deoxy-Δ8-THC analogs I (n = 1-5) have high affinity (Ki=<20 nM) for the CB2 receptor.  Four I (n = 1-4) also have little affinity for the CB1 receptor (Ki=>295 nM).  3-(1',1'-Dimethylbutyl)-1-deoxy-Δ8-THC (I, n = 2) has very high affinity for the CB2 receptor (Ki=3.4±1.0 nM) and little affinity for the CB1 receptor (Ki=677±132 nM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnqkYe1NcGUbVg90H21EOLACvtfcHk0lig5ddO3K5ftw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntFCnsA%253D%253D&md5=50b84955605cd4c6e76d2cbf92791685</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2899%2900219-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252899%252900219-9%26sid%3Dliteratum%253Aachs%26aulast%3DHuffman%26aufirst%3DJ.%2BW.%26aulast%3DLiddle%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DAung%26aufirst%3DM.%2BM.%26aulast%3DAbood%26aufirst%3DM.%2BE.%26aulast%3DWiley%26aufirst%3DJ.%2BL.%26aulast%3DMartin%26aufirst%3DB.%2BR.%26atitle%3D3-%25281%25E2%2580%25B2%252C1%25E2%2580%25B2-Dimethylbutyl%2529-1-Deoxy-Delta8-THC%2520and%2520Related%2520Compounds%253A%2520Synthesis%2520of%2520Selective%2520Ligands%2520for%2520the%2520CB2%2520Receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D1999%26volume%3D7%26spage%3D2905%26epage%3D2914%26doi%3D10.1016%2FS0968-0896%2899%2900219-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanus, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breuer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tchilibon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiloah, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldenberg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horowitz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mechoulam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fride, E.</span></span> <span> </span><span class="NLM_article-title">HU-308: A Specific Agonist for CB(2), a Peripheral Cannabinoid Receptor</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">14228</span>– <span class="NLM_lpage">14233</span>, <span class="refDoi"> DOI: 10.1073/pnas.96.25.14228</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1073%2Fpnas.96.25.14228" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10588688" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADyaK1MXnvFKltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=1999&pages=14228-14233&author=L.+Hanusauthor=A.+Breuerauthor=S.+Tchilibonauthor=S.+Shiloahauthor=D.+Goldenbergauthor=M.+Horowitzauthor=R.+G.+Pertweeauthor=R.+A.+Rossauthor=R.+Mechoulamauthor=E.+Fride&title=HU-308%3A+A+Specific+Agonist+for+CB%282%29%2C+a+Peripheral+Cannabinoid+Receptor&doi=10.1073%2Fpnas.96.25.14228"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">HU-308: a specific agonist for CB2, a peripheral cannabinoid receptor</span></div><div class="casAuthors">Hanus, L.; Breuer, A.; Tchilibon, S.; Shiloah, S.; Goldenberg, D.; Horowitz, M.; Pertwee, R. G.; Ross, R. A.; Mechoulam, R.; Fride, E.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">14228-14233</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Two cannabinoid receptors have been identified: CB1, present in the central nervous system (CNS) and to a lesser extent in other tissues, and CB2, present outside the CNS, in peripheral organs.  There is evidence for the presence of CB2-like receptors in peripheral nerve terminals.  We report now that we have synthesized a CB2-specific agonist, code-named HU-308.  This cannabinoid does not bind to CB1 (Ki > 10 μM), but does so efficiently to CB2 (Ki = 22.7 ± 3.9 nM); it inhibits forskolin-stimulated cAMP prodn. in CB2-transfected cells, but does so much less in CB1-transfected cells.  HU-308 shows no activity in mice in a tetrad of behavioral tests, which together have been shown to be specific for tetrahydrocannabinol (THC)-type activity in the CNS mediated by CB1.  However, HU-308 reduces blood pressure, blocks defecation, and elicits anti-inflammatory and peripheral analgesic activity.  The hypotension, the inhibition of defecation, the anti-inflammatory and peripheral analgesic effects produced by HU-308 are blocked (or partially blocked) by the CB2 antagonist SR-144528, but not by the CB1 antagonist SR-141716A.  These results demonstrate the feasibility of discovering novel nonpsychotropic cannabinoids that may lead to new therapies for hypertension, inflammation, and pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh_IkaAv6DL7Vg90H21EOLACvtfcHk0lig5ddO3K5ftw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXnvFKltLs%253D&md5=2f0a5be263419796a689b70d38a670e8</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1073%2Fpnas.96.25.14228&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.96.25.14228%26sid%3Dliteratum%253Aachs%26aulast%3DHanus%26aufirst%3DL.%26aulast%3DBreuer%26aufirst%3DA.%26aulast%3DTchilibon%26aufirst%3DS.%26aulast%3DShiloah%26aufirst%3DS.%26aulast%3DGoldenberg%26aufirst%3DD.%26aulast%3DHorowitz%26aufirst%3DM.%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26aulast%3DRoss%26aufirst%3DR.%2BA.%26aulast%3DMechoulam%26aufirst%3DR.%26aulast%3DFride%26aufirst%3DE.%26atitle%3DHU-308%253A%2520A%2520Specific%2520Agonist%2520for%2520CB%25282%2529%252C%2520a%2520Peripheral%2520Cannabinoid%2520Receptor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1999%26volume%3D96%26spage%3D14228%26epage%3D14233%26doi%3D10.1073%2Fpnas.96.25.14228" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Manera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benetti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castelli, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavallini, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzarotti, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pibiri, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccomanni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuccinardi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vannacci, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrarini, P. L.</span></span> <span> </span><span class="NLM_article-title">Design, Synthesis, and Biological Evaluation of New 1,8-Naphthyridin-4(1H)-on-3-Carboxamide and Quinolin-4(1H)-on-3-Carboxamide Derivatives as CB2 Selective Agonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">5947</span>– <span class="NLM_lpage">5957</span>, <span class="refDoi"> DOI: 10.1021/jm0603466</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0603466" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVylsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5947-5957&author=C.+Maneraauthor=V.+Benettiauthor=M.+P.+Castelliauthor=T.+Cavalliniauthor=S.+Lazzarottiauthor=F.+Pibiriauthor=G.+Saccomanniauthor=T.+Tuccinardiauthor=A.+Vannacciauthor=A.+Martinelliauthor=P.+L.+Ferrarini&title=Design%2C+Synthesis%2C+and+Biological+Evaluation+of+New+1%2C8-Naphthyridin-4%281H%29-on-3-Carboxamide+and+Quinolin-4%281H%29-on-3-Carboxamide+Derivatives+as+CB2+Selective+Agonists&doi=10.1021%2Fjm0603466"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of New 1,8-Naphthyridin-4(1H)-one-3-carboxamide and Quinolin-4(1H)-one-3-carboxamide Derivatives as CB2 Selective Agonists</span></div><div class="casAuthors">Manera, Clementina; Benetti, Veronica; Castelli, M. Paola; Cavallini, Tiziana; Lazzarotti, Sara; Pibiri, Fabio; Saccomanni, Giuseppe; Tuccinardi, Tiziano; Vannacci, Alfredo; Martinelli, Adriano; Ferrarini, Pier Luigi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5947-5957</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">On the basis of docking studies carried out using the recently published cannabinoid receptor models, new 1,8-naphthyridin-4(1H)-one-3-carboxamide and quinolin-4(1H)-one-3-carboxamide derivs. I [X = N, CH; R1 = PhCH2, 2-FC6H4CH2, 4-MeOC6H4CH2, 2-(4-morpholinyl)ethyl, 2-(4-phenyl-1-piperazinyl)ethyl, etc.; R2 = cyclohexyl, cycloheptyl, 4-methylcyclohexyl; R3 = H, Cl, Me, 2-FC6H4CH2O] and some of their partially reduced analogs were synthesized and tested for their affinities toward the cannabinoid CB1 and CB2 receptors.  I (X = N; R1 = 4-FC6H4CH2; R2 = cycloheptyl; R3 = Me) showed a high CB2 affinity with a Ki of 1.0 nM.  The substitution of the naphthyridine-4-one nucleus with the quinoline-4-one system detd. a general increase in CB2 affinity.  In particular, I [X = CH; R1 = 2-(4-morpholinyl)ethyl; R2 = cyclohexyl; R3 = Cl] possessed a remarkable affinity with Ki of 3.3 nM, which was also accompanied by a high selectivity for the CB2 receptor (Ki(CB1)/Ki(CB2) ratio greater than 303).  Moreover, the [35S]GTPγ binding assay and functional studies on human basophils indicated that the 1,8-naphthyridin-4(1H)-one-3-carboxamide derivs. behaved as CB1 and CB2 receptor agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYlDVrqG-izrVg90H21EOLACvtfcHk0li4Ym_p-nWC-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVylsrY%253D&md5=8c33739ef32a608be5f1aae93ed14fa3</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1021%2Fjm0603466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0603466%26sid%3Dliteratum%253Aachs%26aulast%3DManera%26aufirst%3DC.%26aulast%3DBenetti%26aufirst%3DV.%26aulast%3DCastelli%26aufirst%3DM.%2BP.%26aulast%3DCavallini%26aufirst%3DT.%26aulast%3DLazzarotti%26aufirst%3DS.%26aulast%3DPibiri%26aufirst%3DF.%26aulast%3DSaccomanni%26aufirst%3DG.%26aulast%3DTuccinardi%26aufirst%3DT.%26aulast%3DVannacci%26aufirst%3DA.%26aulast%3DMartinelli%26aufirst%3DA.%26aulast%3DFerrarini%26aufirst%3DP.%2BL.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520New%25201%252C8-Naphthyridin-4%25281H%2529-on-3-Carboxamide%2520and%2520Quinolin-4%25281H%2529-on-3-Carboxamide%2520Derivatives%2520as%2520CB2%2520Selective%2520Agonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5947%26epage%3D5957%26doi%3D10.1021%2Fjm0603466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrison, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daza, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grayson, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooker, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dart, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M. D.</span></span> <span> </span><span class="NLM_article-title">In Vitro Pharmacological Characterization of AM1241: A Protean Agonist at the Cannabinoid CB2 Receptor?</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>149</i></span>,  <span class="NLM_fpage">145</span>– <span class="NLM_lpage">154</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0706838</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fsj.bjp.0706838" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=16894349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD28XptlSlsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2006&pages=145-154&author=B.+B.+Yaoauthor=S.+Mukherjeeauthor=Y.+Fanauthor=T.+R.+Garrisonauthor=A.+V.+Dazaauthor=G.+K.+Graysonauthor=B.+A.+Hookerauthor=M.+J.+Dartauthor=J.+P.+Sullivanauthor=M.+D.+Meyer&title=In+Vitro+Pharmacological+Characterization+of+AM1241%3A+A+Protean+Agonist+at+the+Cannabinoid+CB2+Receptor%3F&doi=10.1038%2Fsj.bjp.0706838"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor?</span></div><div class="casAuthors">Yao, B. B.; Mukherjee, S.; Fan, Y.; Garrison, T. R.; Daza, A. V.; Grayson, G. K.; Hooker, B. A.; Dart, M. J.; Sullivan, J. P.; Meyer, M. D.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">145-154</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The CB2 receptor has been proposed as a novel target for the treatment of pain, and CB2 receptor agonists defined in in vitro assays have demonstrated analgesic activity in animal models.  Based on its in vivo analgesic efficacy, AM1241 has been classified as a CB2-selective agonist.  However, in vitro characterization of AM1241 in functional assays has not been reported.  Exptl. approach: In this study, AM1241 was characterized across multiple in vitro assays employing heterologous recombinant receptor expression systems to assess its binding potencies at the human CB2 and CB1 receptors and its functional efficacies at the human CB2 receptor.  Key results: AM1241 exhibited distinct functional properties depending on the assay conditions employed, a unique profile in contrast to those of the agonist CP 55,940 and the inverse agonist SR144528.  AM1241 displayed neutral antagonist activities in FLIPR and cyclase assays.  However, when cyclase assays were performed using lower forskolin concns. for stimulation, AM1241 exhibited partial agonist efficacy.  In addn., it behaved as a partial agonist in ERK (or MAP) kinase assays.  Conclusions and implications: The unusual phenomenon of inconsistent functional efficacies suggests that AM1241 is a protean agonist at the CB2 receptor.  We postulate that functional efficacies displayed by protean agonists in various assay systems may depend on the levels of receptor constitutive activities exhibited in the assay systems, and therefore, efficacies obsd. in in vitro assays may not predict in vivo activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAZCdaxRfuO7Vg90H21EOLACvtfcHk0li4Ym_p-nWC-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptlSlsb0%253D&md5=7c257ec8fcc8acb7cdcf9243f3b377b1</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0706838&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0706838%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DB.%2BB.%26aulast%3DMukherjee%26aufirst%3DS.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DGarrison%26aufirst%3DT.%2BR.%26aulast%3DDaza%26aufirst%3DA.%2BV.%26aulast%3DGrayson%26aufirst%3DG.%2BK.%26aulast%3DHooker%26aufirst%3DB.%2BA.%26aulast%3DDart%26aufirst%3DM.%2BJ.%26aulast%3DSullivan%26aufirst%3DJ.%2BP.%26aulast%3DMeyer%26aufirst%3DM.%2BD.%26atitle%3DIn%2520Vitro%2520Pharmacological%2520Characterization%2520of%2520AM1241%253A%2520A%2520Protean%2520Agonist%2520at%2520the%2520Cannabinoid%2520CB2%2520Receptor%253F%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2006%26volume%3D149%26spage%3D145%26epage%3D154%26doi%3D10.1038%2Fsj.bjp.0706838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gallant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dufresne, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gareau, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guay, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leblanc, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prasit, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rochette, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawyer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slipetz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremblay, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metters, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labelle, M.</span></span> <span> </span><span class="NLM_article-title">New class of potent ligands for the human peripheral cannabinoid receptor. New Class of Potent Ligands for the Human Peripheral Cannabinoid Receptor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">2263</span>– <span class="NLM_lpage">2268</span>, <span class="refDoi"> DOI: 10.1016/0960-894X(96)00426-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2F0960-894X%2896%2900426-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADyaK28Xmt1yrs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1996&pages=2263-2268&author=M.+Gallantauthor=C.+Dufresneauthor=Y.+Gareauauthor=D.+Guayauthor=Y.+Leblancauthor=P.+P.+Prasitauthor=C.+Rochetteauthor=N.+Sawyerauthor=D.+Slipetzauthor=N.+Tremblayauthor=K.+M.+Mettersauthor=M.+Labelle&title=New+class+of+potent+ligands+for+the+human+peripheral+cannabinoid+receptor.+New+Class+of+Potent+Ligands+for+the+Human+Peripheral+Cannabinoid+Receptor&doi=10.1016%2F0960-894X%2896%2900426-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">New class of potent ligands for the human peripheral cannabinoid receptor</span></div><div class="casAuthors">Gallant, Michel; Dufresne, Claude; Gareau, Yves; Guay, Daniel; Leblanc, Yves; Prasit, Petipibbon; Rochette, Chantal; Sawyer, Nicole; Slipetz, Deborah M.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2263-2268</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Indoles, e.g. I (R1 = morpholino, morpholinocarbonyl, CO2Me, CO2H, morpholinomethyl; R2 = 2-, 4-ClC6H4, 1-, 2-naphthyl, etc.), were prepd. as potent ligands for the human peripheral cannabinoid (hCB2) receptor.  Two of these indole analogs exhibited nanomolar potencies (Ki) with good selectivity for the hCB2 receptor over the human central cannabinoid (hCB1) receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVyw0x9VEfZrVg90H21EOLACvtfcHk0liNj6ShqQ5LUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xmt1yrs7o%253D&md5=6c55898edb52047ddf96cd2595d4a740</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1016%2F0960-894X%2896%2900426-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0960-894X%252896%252900426-X%26sid%3Dliteratum%253Aachs%26aulast%3DGallant%26aufirst%3DM.%26aulast%3DDufresne%26aufirst%3DC.%26aulast%3DGareau%26aufirst%3DY.%26aulast%3DGuay%26aufirst%3DD.%26aulast%3DLeblanc%26aufirst%3DY.%26aulast%3DPrasit%26aufirst%3DP.%2BP.%26aulast%3DRochette%26aufirst%3DC.%26aulast%3DSawyer%26aufirst%3DN.%26aulast%3DSlipetz%26aufirst%3DD.%26aulast%3DTremblay%26aufirst%3DN.%26aulast%3DMetters%26aufirst%3DK.%2BM.%26aulast%3DLabelle%26aufirst%3DM.%26atitle%3DNew%2520class%2520of%2520potent%2520ligands%2520for%2520the%2520human%2520peripheral%2520cannabinoid%2520receptor.%2520New%2520Class%2520of%2520Potent%2520Ligands%2520for%2520the%2520Human%2520Peripheral%2520Cannabinoid%2520Receptor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D1996%26volume%3D6%26spage%3D2263%26epage%3D2268%26doi%3D10.1016%2F0960-894X%2896%2900426-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Showalter, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Compton, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abood, M. E.</span></span> <span> </span><span class="NLM_article-title">Evaluation of Binding in a Transfected Cell Line Expressing a Peripheral Cannabinoid Receptor (CB2): Identification of Cannabinoid Receptor Subtype Selective Ligands</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">989</span>– <span class="NLM_lpage">999</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=8819477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADyaK28XmtVSjs74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=1996&pages=989-999&author=V.+M.+Showalterauthor=D.+R.+Comptonauthor=B.+R.+Martinauthor=M.+E.+Abood&title=Evaluation+of+Binding+in+a+Transfected+Cell+Line+Expressing+a+Peripheral+Cannabinoid+Receptor+%28CB2%29%3A+Identification+of+Cannabinoid+Receptor+Subtype+Selective+Ligands"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands</span></div><div class="casAuthors">Showalter, Vincent M.; Compton, David R.; Martin, Billy R.; Abood, Mary E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">989-999</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">Two cannabinoid receptors have been identified to date; one is located predominantly in the central nervous system (CB1), whereas the other is located exclusively in the periphery (CB2).  The purposes of this study were to explore further the binding requirements of the CB2 receptor and to search for compds. displaying distinct affinities for either cannabinoid receptor.  The binding affinities for either cannabinoids tested previously at the CB1 receptor were detd. at cloned human CB1 and CB2 receptors using a filtration assay.  In addn., possible allosteric regulation of the CB2 receptor was examd.  Sodium and a GTP analog elicited a concn.-dependent decrease in specific binding to the CB2 receptor.  The affinity of cannabinol for CB2 receptors (Ki = 96.3±14 nM) was confirmed to be in approx. the same range as that of Δ9-THC (Ki = 36.4±10 nM).  Affinities at cloned CB1 and CB2 receptors were compared with affinities detd. in the brain.  Although most of the chosen compds. did not discriminate between CB1 and CB2, several ligands were identified that showed selectivity.  Affinity ratios demonstrated that two 2'-fluoro analogs of anandamide were over 23-fold selective for the CB1 receptor and confirmed the CB1 selectivity of SR141716A {N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride}.  In addn., WIN-55,212-2 {(R)-(+)-[2,3-dihydro-5-methyl-3-[(4-morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl](1-naphthalenyl)methanone} and a closely related Pr indole analog were shown to be 6.75- and 27.5-fold selective, resp., for the CB2 receptor.  These ligands can now serve as a basis for the design of compds. with even greater selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoqYXeFFpwPo7Vg90H21EOLACvtfcHk0liNj6ShqQ5LUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XmtVSjs74%253D&md5=d765777f3b8763afa042ea068ffd7a28</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DShowalter%26aufirst%3DV.%2BM.%26aulast%3DCompton%26aufirst%3DD.%2BR.%26aulast%3DMartin%26aufirst%3DB.%2BR.%26aulast%3DAbood%26aufirst%3DM.%2BE.%26atitle%3DEvaluation%2520of%2520Binding%2520in%2520a%2520Transfected%2520Cell%2520Line%2520Expressing%2520a%2520Peripheral%2520Cannabinoid%2520Receptor%2520%2528CB2%2529%253A%2520Identification%2520of%2520Cannabinoid%2520Receptor%2520Subtype%2520Selective%2520Ligands%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1996%26volume%3D278%26spage%3D989%26epage%3D999" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Frost, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dart, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tietje, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrison, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grayson, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daza, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Kouhen, O. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandran, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M. D.</span></span> <span> </span><span class="NLM_article-title">Indol-3-Ylcycloalkyl Ketones: Effects of N1 Substituted Indole Side Chain Variations on CB(2) Cannabinoid Receptor Activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">295</span>– <span class="NLM_lpage">315</span>, <span class="refDoi"> DOI: 10.1021/jm901214q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901214q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsValtbfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=295-315&author=J.+M.+Frostauthor=M.+J.+Dartauthor=K.+R.+Tietjeauthor=T.+R.+Garrisonauthor=G.+K.+Graysonauthor=A.+V.+Dazaauthor=O.+F.+El-Kouhenauthor=B.+B.+Yaoauthor=G.+C.+Hsiehauthor=M.+Paiauthor=C.+Z.+Zhuauthor=P.+Chandranauthor=M.+D.+Meyer&title=Indol-3-Ylcycloalkyl+Ketones%3A+Effects+of+N1+Substituted+Indole+Side+Chain+Variations+on+CB%282%29+Cannabinoid+Receptor+Activity&doi=10.1021%2Fjm901214q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Indol-3-ylcycloalkyl Ketones: Effects of N1 Substituted Indole Side Chain Variations on CB2 Cannabinoid Receptor Activity</span></div><div class="casAuthors">Frost, Jennifer M.; Dart, Michael J.; Tietje, Karin R.; Garrison, Tiffany R.; Grayson, George K.; Daza, Anthony V.; El-Kouhen, Odile F.; Yao, Betty B.; Hsieh, Gin C.; Pai, Madhavi; Zhu, Chang Z.; Chandran, Prasant; Meyer, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">295-315</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several 3-acylindoles with high affinity for the CB2 cannabinoid receptor and selectivity over the CB1 receptor have been prepd.  A variety of 3-acyl substituents were investigated, and the tetramethylcyclopropyl group was found to lead to high affinity CB2 agonists.  Substitution at the N1-indole position was then examd.  A series of aminoalkylindoles was prepd. and several substituted aminoethyl derivs. were active at the CB2 receptor.  A study of N1 nonarom. side chain variants provided potent agonists at the CB2 receptor.  Several polar side chains (alcs., oxazolidinone) were well tolerated for CB2 receptor activity, while others (amide, acid) led to weaker or inactive compds..  N1 arom. side chains also afforded several high affinity CB2 receptor agonists, but were generally less potent in an in vitro CB2 functional assay than were nonarom. side chain analogs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBqUcQi4rUorVg90H21EOLACvtfcHk0ljqL73t71WtrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsValtbfP&md5=5bdd69db011d3abc7924a9093209e84b</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1021%2Fjm901214q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901214q%26sid%3Dliteratum%253Aachs%26aulast%3DFrost%26aufirst%3DJ.%2BM.%26aulast%3DDart%26aufirst%3DM.%2BJ.%26aulast%3DTietje%26aufirst%3DK.%2BR.%26aulast%3DGarrison%26aufirst%3DT.%2BR.%26aulast%3DGrayson%26aufirst%3DG.%2BK.%26aulast%3DDaza%26aufirst%3DA.%2BV.%26aulast%3DEl-Kouhen%26aufirst%3DO.%2BF.%26aulast%3DYao%26aufirst%3DB.%2BB.%26aulast%3DHsieh%26aufirst%3DG.%2BC.%26aulast%3DPai%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DC.%2BZ.%26aulast%3DChandran%26aufirst%3DP.%26aulast%3DMeyer%26aufirst%3DM.%2BD.%26atitle%3DIndol-3-Ylcycloalkyl%2520Ketones%253A%2520Effects%2520of%2520N1%2520Substituted%2520Indole%2520Side%2520Chain%2520Variations%2520on%2520CB%25282%2529%2520Cannabinoid%2520Receptor%2520Activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D295%26epage%3D315%26doi%3D10.1021%2Fjm901214q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Felder, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joyce, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briley, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansouri, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blond, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, R. L.</span></span> <span> </span><span class="NLM_article-title">Comparison of the Pharmacology and Signal Transduction of the Human Cannabinoid CB1 and CB2 Receptors</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">443</span>– <span class="NLM_lpage">450</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=7565624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADyaK2MXosVKhu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=1995&pages=443-450&author=C.+C.+Felderauthor=K.+E.+Joyceauthor=E.+M.+Brileyauthor=J.+Mansouriauthor=K.+Mackieauthor=O.+Blondauthor=Y.+Laiauthor=A.+L.+Maauthor=R.+L.+Mitchell&title=Comparison+of+the+Pharmacology+and+Signal+Transduction+of+the+Human+Cannabinoid+CB1+and+CB2+Receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors</span></div><div class="casAuthors">Felder, Christian C.; Joyce, Kelly E.; Briley, Eileen M.; Mansouri, Jaleh; Mackie, Ken; Blond, Olivier; Lai, Yvonne; Ma, Alice L.; Mitchell, Richard L.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">443-50</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The recently cloned CB2 cannabinoid receptor subtype was stably transfected into AtT-20 and Chinese hamster ovary cells to compare the binding and signal transduction properties of this receptor with those of the CB1 receptor subtype.  The binding of [3H]CP 55,940 to both CB1 and CB2 was of similar high affinity (2.6 and 3.7 nM, resp.) and saturable.  In competitive binding expts., (-)-Δ9-tetrahydrocannabinol and CP 55,940 were equipotent at the CB1 and CB2 receptors, but WIN 55212-2 and cannabinol bound with higher affinity to the CB2 than the CB1 receptor.  HU 210 had a higher affinity for the CB1 receptor.  Anandamide, a recently identified endogenous cannabinoid agonist, was essentially equipotent at both receptor subtypes.  The structurally related fatty acid ethanol-amides dihomo-γ-linolenylethanolamine and mead ethanoamide also bound with relatively equal affinity to both receptors, but adrenylethanolamide had a higher affinity for the CB1 receptor.  The rank order of potency and efficacy for binding of the selected agonists to the CB1 and CB2 receptors was mimicked in functional inhibition of cAMP accumulation expts. for all compds. tested.  Both CB1 and CB2 receptors couple to the inhibition of cAMP accumulation that was pertussis toxin sensitive.  SR141716A, a CB1 receptor antagonist, was a poor antagonist at the CB2 receptor in both binding and functional inhibition of cAMP accumulation expts.  When expressed in AtT-20 cells, the CB1 receptor mediated an inhibition of Q-type calcium channels and an activation of inward rectifying potassium channels.  In contrast, the CB2 receptor did not modulate the activity of either channel under identical assay conditions.  Similar to results obtained for CB1 receptor, the CB2 receptor did not couple to the activation of phospholipases A2, C, or D or to the mobilization of intracellular Ca2+.  Except for its inability to couple to the modulation of Q-type calcium channels or inwardly rectifying potassium channels, the CB1 and CB2 receptors display similar pharmacol. and biochem. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRLDqNx6UzpLVg90H21EOLACvtfcHk0ljqL73t71WtrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXosVKhu7k%253D&md5=a2879002f7c74ca9ad8079016e62978a</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFelder%26aufirst%3DC.%2BC.%26aulast%3DJoyce%26aufirst%3DK.%2BE.%26aulast%3DBriley%26aufirst%3DE.%2BM.%26aulast%3DMansouri%26aufirst%3DJ.%26aulast%3DMackie%26aufirst%3DK.%26aulast%3DBlond%26aufirst%3DO.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DA.%2BL.%26aulast%3DMitchell%26aufirst%3DR.%2BL.%26atitle%3DComparison%2520of%2520the%2520Pharmacology%2520and%2520Signal%2520Transduction%2520of%2520the%2520Human%2520Cannabinoid%2520CB1%2520and%2520CB2%2520Receptors%26jtitle%3DMol.%2520Pharmacol.%26date%3D1995%26volume%3D48%26spage%3D443%26epage%3D450" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stern, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muccioli, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millet, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goossens, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farce, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavatte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poupaert, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depreux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hénichart, J.-P.</span></span> <span> </span><span class="NLM_article-title">Novel 4-Oxo-1,4-Dihydroquinoline-3-Carboxamide Derivatives as New CB2 Cannabinoid Receptors Agonists: Synthesis, Pharmacological Properties and Molecular Modeling</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">70</span>– <span class="NLM_lpage">79</span>, <span class="refDoi"> DOI: 10.1021/jm050467q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050467q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht12rtbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=70-79&author=E.+Sternauthor=G.+G.+Muccioliauthor=R.+Milletauthor=J.-F.+Goossensauthor=A.+Farceauthor=P.+Chavatteauthor=J.+H.+Poupaertauthor=D.+M.+Lambertauthor=P.+Depreuxauthor=J.-P.+H%C3%A9nichart&title=Novel+4-Oxo-1%2C4-Dihydroquinoline-3-Carboxamide+Derivatives+as+New+CB2+Cannabinoid+Receptors+Agonists%3A+Synthesis%2C+Pharmacological+Properties+and+Molecular+Modeling&doi=10.1021%2Fjm050467q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New CB2 Cannabinoid Receptors Agonists: Synthesis, Pharmacological Properties and Molecular Modeling</span></div><div class="casAuthors">Stern, Eric; Muccioli, Giulio G.; Millet, Regis; Goossens, Jean-Francois; Farce, Amaury; Chavatte, Philippe; Poupaert, Jacques H.; Lambert, Didier M.; Depreux, Patrick; Henichart, Jean-Pierre</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">70-79</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recent data indicated that the CB2 cannabinoid receptor constitutes an attractive drug target due to its potential functional role in several physiol. and pathol. processes.  A set of 4-oxo-1,4-dihydroquinoline-3-carboxamide derivs. I (R = Bu, pentyl, hexyl, PhCH2; R1 = 4-MeOC6H4, PhCH2, 1-adamantyl, 2-naphthyl, etc.), characterized by the presence of some important structural requirements exhibited by other classes of cannabinoid ligands, such as an aliph. or arom. carboxamide group in position 3, and an alkyl or benzyl group in position 1, was synthesized and assayed to measure their resp. affinity for both human CB1 and CB2 cannabinoid receptors.  The results indicate that these 3-carboxamidoquinolones derivs. exhibited a CB2 receptor selectivity.  Moreover, in the [35S]-GTPγS binding assay, all the compds. behaved as CB2 receptor agonists.  Mol. modeling studies showed that compd. I (R = pentyl, R1 = 3,5-dimethyl-1-adamantyl) interacts with the CB2 receptor through a combination of hydrogen bond and arom./hydrophobic interactions.  In conclusion, 4-oxo-1,4-dihydroquinoline-3-carboxamide derivs. constitute a new class of potent and selective CB2 cannabinoid receptors agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGEjQIxUqkBbVg90H21EOLACvtfcHk0ljqL73t71WtrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht12rtbvF&md5=1684923b7ca4a4d858053142de4fa9f7</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Fjm050467q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050467q%26sid%3Dliteratum%253Aachs%26aulast%3DStern%26aufirst%3DE.%26aulast%3DMuccioli%26aufirst%3DG.%2BG.%26aulast%3DMillet%26aufirst%3DR.%26aulast%3DGoossens%26aufirst%3DJ.-F.%26aulast%3DFarce%26aufirst%3DA.%26aulast%3DChavatte%26aufirst%3DP.%26aulast%3DPoupaert%26aufirst%3DJ.%2BH.%26aulast%3DLambert%26aufirst%3DD.%2BM.%26aulast%3DDepreux%26aufirst%3DP.%26aulast%3DH%25C3%25A9nichart%26aufirst%3DJ.-P.%26atitle%3DNovel%25204-Oxo-1%252C4-Dihydroquinoline-3-Carboxamide%2520Derivatives%2520as%2520New%2520CB2%2520Cannabinoid%2520Receptors%2520Agonists%253A%2520Synthesis%252C%2520Pharmacological%2520Properties%2520and%2520Molecular%2520Modeling%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D70%26epage%3D79%26doi%3D10.1021%2Fjm050467q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pasquini, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Rosa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligresti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mugnaini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brizzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caradonna, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascio, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognini, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corelli, F.</span></span> <span> </span><span class="NLM_article-title">Investigations on the 4-Quinolone-3-Carboxylic Acid Motif. 6. Synthesis and Pharmacological Evaluation of 7-Substituted Quinolone-3-Carboxamide Derivatives as High Affinity Ligands for Cannabinoid Receptors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">30</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2012.09.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2012.09.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=23085772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslOktb%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2012&pages=30-43&author=S.+Pasquiniauthor=M.+De+Rosaauthor=A.+Ligrestiauthor=C.+Mugnainiauthor=A.+Brizziauthor=N.+P.+Caradonnaauthor=M.+G.+Cascioauthor=D.+Bologniniauthor=R.+G.+Pertweeauthor=V.+Di+Marzoauthor=F.+Corelli&title=Investigations+on+the+4-Quinolone-3-Carboxylic+Acid+Motif.+6.+Synthesis+and+Pharmacological+Evaluation+of+7-Substituted+Quinolone-3-Carboxamide+Derivatives+as+High+Affinity+Ligands+for+Cannabinoid+Receptors&doi=10.1016%2Fj.ejmech.2012.09.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Investigations on the 4-quinolone-3-carboxylic acid motif. 6. Synthesis and pharmacological evaluation of 7-substituted quinolone-3-carboxamide derivatives as high affinity ligands for cannabinoid receptors</span></div><div class="casAuthors">Pasquini, Serena; De Rosa, Maria; Ligresti, Alessia; Mugnaini, Claudia; Brizzi, Antonella; Caradonna, Nicola P.; Cascio, Maria Grazia; Bolognini, Daniele; Pertwee, Roger G.; Di Marzo, Vincenzo; Corelli, Federico</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">30-43</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Within the authors' studies on structure-activity relationships of 4-quinolone-3-carboxamides as cannabinoid ligands, a new series of compds. characterized by a fluoro or phenylthio group at the 7-position and different substituents at N1 and the carboxamide nitrogen were synthesized and evaluated for their binding ability to cannabinoid type 1 (CB1) and type 2 (CB2) receptors.  Most of the compds. showed affinity for one or both cannabinoid receptors at nanomolar concn., with Ki(CB1) and Ki(CB2) values ranging from 2.45 to >10,000 nM and from 0.09 to 957 nM, resp.  The N-(3,4-dichlorobenzyl)amide derivs. I (R = Ph, PhS) displayed relatively low affinity, but high selectivity towards the CB1 receptor.  Compds. II and I (R = PhS), a CB2 and a CB1 ligand, resp., behaved as partial agonists in the [35S]GTPγS assay.  They showed very low permeability through (MDCK-MDR1) cells and might, therefore, represent possible lead structures for further optimization in the search for cannabinoid ligands unable to cross the blood-brain barrier.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof4hRj9XhonrVg90H21EOLACvtfcHk0lhhb8MZMYEhbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslOktb%252FM&md5=95ba92dca8488f8639aa8814d9ca4ea5</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.09.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.09.035%26sid%3Dliteratum%253Aachs%26aulast%3DPasquini%26aufirst%3DS.%26aulast%3DDe%2BRosa%26aufirst%3DM.%26aulast%3DLigresti%26aufirst%3DA.%26aulast%3DMugnaini%26aufirst%3DC.%26aulast%3DBrizzi%26aufirst%3DA.%26aulast%3DCaradonna%26aufirst%3DN.%2BP.%26aulast%3DCascio%26aufirst%3DM.%2BG.%26aulast%3DBolognini%26aufirst%3DD.%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DCorelli%26aufirst%3DF.%26atitle%3DInvestigations%2520on%2520the%25204-Quinolone-3-Carboxylic%2520Acid%2520Motif.%25206.%2520Synthesis%2520and%2520Pharmacological%2520Evaluation%2520of%25207-Substituted%2520Quinolone-3-Carboxamide%2520Derivatives%2520as%2520High%2520Affinity%2520Ligands%2520for%2520Cannabinoid%2520Receptors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2012%26volume%3D58%26spage%3D30%26epage%3D43%26doi%3D10.1016%2Fj.ejmech.2012.09.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">El Bakali, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muccioli, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Body-Malapel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Djouina, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klupsch, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghinet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barczyk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Renault, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chavatte, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Desreumaux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millet, R.</span></span> <span> </span><span class="NLM_article-title">Conformational Restriction Leading to a Selective CB2 Cannabinoid Receptor Agonist Orally Active Against Colitis</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">198</span>– <span class="NLM_lpage">203</span>, <span class="refDoi"> DOI: 10.1021/ml500439x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml500439x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVegtbnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=198-203&author=J.+El+Bakaliauthor=G.+G.+Muccioliauthor=M.+Body-Malapelauthor=M.+Djouinaauthor=F.+Klupschauthor=A.+Ghinetauthor=A.+Barczykauthor=N.+Renaultauthor=P.+Chavatteauthor=P.+Desreumauxauthor=D.+M.+Lambertauthor=R.+Millet&title=Conformational+Restriction+Leading+to+a+Selective+CB2+Cannabinoid+Receptor+Agonist+Orally+Active+Against+Colitis&doi=10.1021%2Fml500439x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational restriction leading to a selective CB2 cannabinoid receptor agonist orally active against colitis</span></div><div class="casAuthors">El Bakali, Jamal; Muccioli, Giulio G.; Body-Malapel, Mathilde; Djouina, Madjid; Klupsch, Frederique; Ghinet, Alina; Barczyk, Amelie; Renault, Nicolas; Chavatte, Philippe; Desreumaux, Pierre; Lambert, Didier M.; Millet, Regis</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">198-203</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The CB2 cannabinoid receptor has been implicated in the regulation of intestinal inflammation.  Following on from the promising activity of a series of 4-oxo-1,4-dihydroquinoline-3-carboxamide, the authors developed constrained analogs based on a 2H-pyrazolo[4,3-c]quinolin-3(5H)-one scaffold, with improved affinity for the hCB2 receptor and had very high selectivity over the hCB1 receptor.  Importantly, the lead of this series I (hCB2: Ki = 0.39 nM, hCB1: Ki > 3000 nM) was found to protect mice against exptl. colitis after oral administration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPBwnfX2qnA7Vg90H21EOLACvtfcHk0lhhb8MZMYEhbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVegtbnF&md5=18a62366567b79e2a8d782a5626823f5</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1021%2Fml500439x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml500439x%26sid%3Dliteratum%253Aachs%26aulast%3DEl%2BBakali%26aufirst%3DJ.%26aulast%3DMuccioli%26aufirst%3DG.%2BG.%26aulast%3DBody-Malapel%26aufirst%3DM.%26aulast%3DDjouina%26aufirst%3DM.%26aulast%3DKlupsch%26aufirst%3DF.%26aulast%3DGhinet%26aufirst%3DA.%26aulast%3DBarczyk%26aufirst%3DA.%26aulast%3DRenault%26aufirst%3DN.%26aulast%3DChavatte%26aufirst%3DP.%26aulast%3DDesreumaux%26aufirst%3DP.%26aulast%3DLambert%26aufirst%3DD.%2BM.%26aulast%3DMillet%26aufirst%3DR.%26atitle%3DConformational%2520Restriction%2520Leading%2520to%2520a%2520Selective%2520CB2%2520Cannabinoid%2520Receptor%2520Agonist%2520Orally%2520Active%2520Against%2520Colitis%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D6%26spage%3D198%26epage%3D203%26doi%3D10.1021%2Fml500439x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stern, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muccioli, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamtiaux, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millet, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poupaert, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hénichart, J.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Depreux, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goossens, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, D. M.</span></span> <span> </span><span class="NLM_article-title">Pharmacomodulations around the 4-Oxo-1,4-Dihydroquinoline-3-Carboxamides, a Class of Potent CB2-Selective Cannabinoid Receptor Ligands: Consequences in Receptor Affinity and Functionality</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">5471</span>– <span class="NLM_lpage">5484</span>, <span class="refDoi"> DOI: 10.1021/jm070387h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070387h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFWgu7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=5471-5484&author=E.+Sternauthor=G.+G.+Muccioliauthor=B.+Bosierauthor=L.+Hamtiauxauthor=R.+Milletauthor=J.+H.+Poupaertauthor=J.-P.+H%C3%A9nichartauthor=P.+Depreuxauthor=J.-F.+Goossensauthor=D.+M.+Lambert&title=Pharmacomodulations+around+the+4-Oxo-1%2C4-Dihydroquinoline-3-Carboxamides%2C+a+Class+of+Potent+CB2-Selective+Cannabinoid+Receptor+Ligands%3A+Consequences+in+Receptor+Affinity+and+Functionality&doi=10.1021%2Fjm070387h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacomodulations around the 4-Oxo-1,4-dihydroquinoline-3-carboxamides, a Class of Potent CB2-Selective Cannabinoid Receptor Ligands: Consequences in Receptor Affinity and Functionality</span></div><div class="casAuthors">Stern, Eric; Muccioli, Giulio G.; Bosier, Barbara; Hamtiaux, Laurie; Millet, Regis; Poupaert, Jacques H.; Henichart, Jean-Pierre; Depreux, Patrick; Goossens, Jean-Francois; Lambert, Didier M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5471-5484</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">CB2 receptor selective ligands are becoming increasingly attractive drugs due to the potential role of this receptor in several physiopathol. processes.  Thus, the development of our previously described series of 4-oxo-1,4-dihydroquinoline-3-carboxamides, e.g. I, was pursued with the aim to further characterize the structure-affinity and structure-functionality relationships of these derivs.  The influence of the side chain was investigated by synthesizing compds. bearing various carboxamido and keto substituents.  On the other hand, the role of the quinoline central scaffold was studied by synthesizing several 6-, 7-, or 8-chloro-4-oxo-1,4-dihydroquinolines, as well as 4-oxo-1,4-dihydronaphthyridine and 4-oxo-1,4-dihydrocinnoline derivs.  The effect of these modifications on the affinity and functionality at the CB2 receptor was studied and allowed for the characterization of new selective CB2 receptor ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplBvPAuk1aZLVg90H21EOLACvtfcHk0lg-odYiiLcQww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFWgu7zP&md5=0cd8f355a2c6ab69fa7c6568e3f4d18a</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1021%2Fjm070387h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070387h%26sid%3Dliteratum%253Aachs%26aulast%3DStern%26aufirst%3DE.%26aulast%3DMuccioli%26aufirst%3DG.%2BG.%26aulast%3DBosier%26aufirst%3DB.%26aulast%3DHamtiaux%26aufirst%3DL.%26aulast%3DMillet%26aufirst%3DR.%26aulast%3DPoupaert%26aufirst%3DJ.%2BH.%26aulast%3DH%25C3%25A9nichart%26aufirst%3DJ.-P.%26aulast%3DDepreux%26aufirst%3DP.%26aulast%3DGoossens%26aufirst%3DJ.-F.%26aulast%3DLambert%26aufirst%3DD.%2BM.%26atitle%3DPharmacomodulations%2520around%2520the%25204-Oxo-1%252C4-Dihydroquinoline-3-Carboxamides%252C%2520a%2520Class%2520of%2520Potent%2520CB2-Selective%2520Cannabinoid%2520Receptor%2520Ligands%253A%2520Consequences%2520in%2520Receptor%2520Affinity%2520and%2520Functionality%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D5471%26epage%3D5484%26doi%3D10.1021%2Fjm070387h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dolles, D.</span>; <span class="NLM_string-name">Decker, M.</span></span> <i>Design of Hybrid Molecules for Drug Development</i>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, M.</span></span>, Eds.; <span class="NLM_publisher-name">Elsevier</span>, <span class="NLM_year">2017</span>; pp  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">165</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2FB978-0-08-101011-2.00005-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=137-165&author=D.+Dolles&author=M.+Deckerauthor=M.+Decker&title=Design+of+Hybrid+Molecules+for+Drug+Development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1016%2FB978-0-08-101011-2.00005-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-08-101011-2.00005-2%26sid%3Dliteratum%253Aachs%26aulast%3DDolles%26aufirst%3DD.%26btitle%3DDesign%2520of%2520Hybrid%2520Molecules%2520for%2520Drug%2520Development%26aulast%3DDecker%26aufirst%3DM.%26pub%3DElsevier%26date%3D2017%26spage%3D137%26epage%3D165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ivasiv, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albertini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonçalves, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1694</span>– <span class="NLM_lpage">1711</span>, <span class="refDoi"> DOI: 10.2174/1568026619666190619115735</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.2174%2F1568026619666190619115735" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=31237210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVymtbbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=1694-1711&author=V.+Ivasivauthor=C.+Albertiniauthor=A.+E.+Gon%C3%A7alvesauthor=M.+Rossiauthor=M.+L.+Bolognesi&title=Molecular+Hybridization+as+a+Tool+for+Designing+Multitarget+Drug+Candidates+for+Complex+Diseases&doi=10.2174%2F1568026619666190619115735"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases</span></div><div class="casAuthors">Ivasiv, Viktoriya; Albertini, Claudia; Goncalves, Ana E.; Rossi, Michele; Bolognesi, Maria L.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1694-1711</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Mol. hybridization is a well-exploited medicinal chem. strategy that aims to combine two mols. (or parts of them) in a new, single chem. entity.  Recently, it has been recognized as an effective approach to design ligands able to modulate multiple targets of interest.  Hybrid compds. can be obtained by linking (presence of a linker) or framework integration (merging or fusing) strategies.  Although very promising to combat the multifactorial nature of complex diseases, the development of mol. hybrids faces the crit. issues of selecting the right target combination and the achievement of a balanced activity towards them, while maintaining drug-like-properties.  In this review, we present recent case histories from our own research group that demonstrate why and how mol. hybridization can be carried out to address the challenges of multitarget drug discovery in two therapeutic areas that are Alzheimer's and parasitic diseases.  Selected examples spanning from linker- to fragment- based hybrids will allow to discuss issues and consequences relevant to drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWvQfYk-XT87Vg90H21EOLACvtfcHk0ljPjo7kAfMKJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVymtbbK&md5=c993274dc1849e3aa5a6c4c8a2ac1ec8</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.2174%2F1568026619666190619115735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026619666190619115735%26sid%3Dliteratum%253Aachs%26aulast%3DIvasiv%26aufirst%3DV.%26aulast%3DAlbertini%26aufirst%3DC.%26aulast%3DGon%25C3%25A7alves%26aufirst%3DA.%2BE.%26aulast%3DRossi%26aufirst%3DM.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DMolecular%2520Hybridization%2520as%2520a%2520Tool%2520for%2520Designing%2520Multitarget%2520Drug%2520Candidates%2520for%2520Complex%2520Diseases%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2019%26volume%3D19%26spage%3D1694%26epage%3D1711%26doi%3D10.2174%2F1568026619666190619115735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramsay, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popovic-Nikolic, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolic, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uliassi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">A Perspective on Multi-Target Drug Discovery and Design for Complex Diseases</span>. <i>Clin. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">3</span>, <span class="refDoi"> DOI: 10.1186/s40169-017-0181-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1186%2Fs40169-017-0181-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=29340951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BC1MvhsVaiug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&pages=3&author=R.+R.+Ramsayauthor=M.+R.+Popovic-Nikolicauthor=K.+Nikolicauthor=E.+Uliassiauthor=M.+L.+Bolognesi&title=A+Perspective+on+Multi-Target+Drug+Discovery+and+Design+for+Complex+Diseases&doi=10.1186%2Fs40169-017-0181-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">A perspective on multi-target drug discovery and design for complex diseases</span></div><div class="casAuthors">Ramsay Rona R; Popovic-Nikolic Marija R; Nikolic Katarina; Uliassi Elisa; Bolognesi Maria Laura</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and translational medicine</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3</span>
        ISSN:<span class="NLM_cas:issn">2001-1326</span>.
    </div><div class="casAbstract">Diseases of infection, of neurodegeneration (such as Alzheimer's and Parkinson's diseases), and of malignancy (cancers) have complex and varied causative factors.  Modern drug discovery has the power to identify potential modulators for multiple targets from millions of compounds.  Computational approaches allow the determination of the association of each compound with its target before chemical synthesis and biological testing is done.  These approaches depend on the prior identification of clinically and biologically validated targets.  This Perspective will focus on the molecular and computational approaches that underpin drug design by medicinal chemists to promote understanding and collaboration with clinical scientists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSJhSGsWpifCZcXNb62YGmbfW6udTcc2eb492wr-Y2hGbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MvhsVaiug%253D%253D&md5=5b05a73a3bbc955c77b9b2df93deb946</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1186%2Fs40169-017-0181-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40169-017-0181-2%26sid%3Dliteratum%253Aachs%26aulast%3DRamsay%26aufirst%3DR.%2BR.%26aulast%3DPopovic-Nikolic%26aufirst%3DM.%2BR.%26aulast%3DNikolic%26aufirst%3DK.%26aulast%3DUliassi%26aufirst%3DE.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DA%2520Perspective%2520on%2520Multi-Target%2520Drug%2520Discovery%2520and%2520Design%2520for%2520Complex%2520Diseases%26jtitle%3DClin.%2520Transl.%2520Med.%26date%3D2018%26volume%3D7%26spage%3D3%26doi%3D10.1186%2Fs40169-017-0181-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span> <span> </span><span class="NLM_article-title">Harnessing Polypharmacology with Medicinal Chemistry</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">273</span>– <span class="NLM_lpage">275</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00039</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00039" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtVWjt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=273-275&author=M.+L.+Bolognesi&title=Harnessing+Polypharmacology+with+Medicinal+Chemistry&doi=10.1021%2Facsmedchemlett.9b00039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Harnessing Polypharmacology with Medicinal Chemistry</span></div><div class="casAuthors">Bolognesi, Maria Laura</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">273-275</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Polypharmacol. has expanded enormously over the last ten years, with several multitarget drugs (MTDs) already in the market.  This Viewpoint provides a basis for a discussion about the crit. need to develop MTDs in a more rationale and conscious way.  A checklist to maximize success in polypharmacol. is proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4yXxJ_uU72bVg90H21EOLACvtfcHk0liznV7Pzk3umA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtVWjt7g%253D&md5=28a8cc47ae2966a2ecd8a411adfb1ef5</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00039%26sid%3Dliteratum%253Aachs%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26atitle%3DHarnessing%2520Polypharmacology%2520with%2520Medicinal%2520Chemistry%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D273%26epage%3D275%26doi%3D10.1021%2Facsmedchemlett.9b00039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stribley, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ticu, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schopfer, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammond, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brimijoin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinrichs, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockridge, O.</span></span> <span> </span><span class="NLM_article-title">Abundant Tissue Butyrylcholinesterase and Its Possible Function in the Acetylcholinesterase Knockout Mouse</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">1320</span>– <span class="NLM_lpage">1331</span>, <span class="refDoi"> DOI: 10.1046/j.1471-4159.2000.751320.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1046%2Fj.1471-4159.2000.751320.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10936216" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmtFyrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2000&pages=1320-1331&author=B.+Liauthor=J.+A.+Stribleyauthor=A.+Ticuauthor=W.+Xieauthor=L.+M.+Schopferauthor=P.+Hammondauthor=S.+Brimijoinauthor=S.+H.+Hinrichsauthor=O.+Lockridge&title=Abundant+Tissue+Butyrylcholinesterase+and+Its+Possible+Function+in+the+Acetylcholinesterase+Knockout+Mouse&doi=10.1046%2Fj.1471-4159.2000.751320.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Abundant tissue butyrylcholinesterase and its possible function in the acetylcholinesterase knockout mouse</span></div><div class="casAuthors">Li, Bin; Stribley, Judith A.; Ticu, Andreea; Xie, Weihua; Schopfer, Lawrence M.; Hammond, Pamela; Brimijoin, Stephen; Hinrichs, Steven H.; Lockridge, Oksana</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1320-1331</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">We have described recently an acetylcholinesterase (AChE) knockout mouse.  While comparing the tissue distribution of AChE and butyrylcholinesterase (BChE), we found that extn. buffers contg. Triton X-100 strongly inhibited mouse BChE activity.  In contrast, buffers with Tween 20 caused no inhibition of BChE.  Conventional techniques grossly underestimated BChE activity by up to 15-fold.  In Tween 20 buffer, the intestine, serum, lung, liver, and heart had higher BChE than AChE activity.  Only brain had higher AChE than BChE activity in AChE +/+ mice.  These findings contradict the dogma, based mainly on observations in Triton X-100 exts., that BChE is a minor cholinesterase in animal tissues.  AChE +/- mice had 50% of normal AChE activity and AChE -/- mice had none, but all mice had similar levels of BChE activity.  BChE was inhibited by Triton X-100 in all species tested, except rat and chicken.  Inhibition was reversible and competitive with substrate binding.  The active site of rat BChE was unique, having an arginine in place of leucine at position 286 (human BChE numbering) in the acyl-binding pocket of the active site, thus explaining the lack of inhibition of rat BChE by Triton X-100.  The generally high levels of BChE activity in tissues, including the motor endplate, and the observation that mice live without AChE, suggest that BChE has an essential function in nullizygous mice and probably in wild-type mice as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6cUNgoG0RlrVg90H21EOLACvtfcHk0liznV7Pzk3umA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmtFyrsbg%253D&md5=7fe96164b0f2fe7258525834081651bc</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.2000.751320.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.2000.751320.x%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DB.%26aulast%3DStribley%26aufirst%3DJ.%2BA.%26aulast%3DTicu%26aufirst%3DA.%26aulast%3DXie%26aufirst%3DW.%26aulast%3DSchopfer%26aufirst%3DL.%2BM.%26aulast%3DHammond%26aufirst%3DP.%26aulast%3DBrimijoin%26aufirst%3DS.%26aulast%3DHinrichs%26aufirst%3DS.%2BH.%26aulast%3DLockridge%26aufirst%3DO.%26atitle%3DAbundant%2520Tissue%2520Butyrylcholinesterase%2520and%2520Its%2520Possible%2520Function%2520in%2520the%2520Acetylcholinesterase%2520Knockout%2520Mouse%26jtitle%3DJ.%2520Neurochem.%26date%3D2000%26volume%3D75%26spage%3D1320%26epage%3D1331%26doi%3D10.1046%2Fj.1471-4159.2000.751320.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hampel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesulam, M.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuello, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farlow, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacobini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossberg, G. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khachaturian, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergallo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavedo, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khachaturian, Z. S.</span></span> <span> </span><span class="NLM_article-title">The Cholinergic System in the Pathophysiology and Treatment of Alzheimer’s Disease</span>. <i>Brain</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>141</i></span>,  <span class="NLM_fpage">1917</span>– <span class="NLM_lpage">1933</span>, <span class="refDoi"> DOI: 10.1093/brain/awy132</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1093%2Fbrain%2Fawy132" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=29850777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BC1MbitFKksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=141&publication_year=2018&pages=1917-1933&author=H.+Hampelauthor=M.-M.+Mesulamauthor=A.+C.+Cuelloauthor=M.+R.+Farlowauthor=E.+Giacobiniauthor=G.+T.+Grossbergauthor=A.+S.+Khachaturianauthor=A.+Vergalloauthor=E.+Cavedoauthor=P.+Snyderauthor=Z.+S.+Khachaturian&title=The+Cholinergic+System+in+the+Pathophysiology+and+Treatment+of+Alzheimer%E2%80%99s+Disease&doi=10.1093%2Fbrain%2Fawy132"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">The cholinergic system in the pathophysiology and treatment of Alzheimer's disease</span></div><div class="casAuthors">Hampel Harald; Vergallo Andrea; Cavedo Enrica; Hampel Harald; Vergallo Andrea; Cavedo Enrica; Hampel Harald; Vergallo Andrea; Cavedo Enrica; Hampel Harald; Vergallo Andrea; Cavedo Enrica; Mesulam M-Marsel; Cuello A Claudio; Cuello A Claudio; Cuello A Claudio; Farlow Martin R; Giacobini Ezio; Grossberg George T; Khachaturian Ara S; Khachaturian Zaven S; Snyder Peter J; Snyder Peter J</div><div class="citationInfo"><span class="NLM_cas:title">Brain : a journal of neurology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">141</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1917-1933</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cholinergic synapses are ubiquitous in the human central nervous system.  Their high density in the thalamus, striatum, limbic system, and neocortex suggest that cholinergic transmission is likely to be critically important for memory, learning, attention and other higher brain functions.  Several lines of research suggest additional roles for cholinergic systems in overall brain homeostasis and plasticity.  As such, the brain's cholinergic system occupies a central role in ongoing research related to normal cognition and age-related cognitive decline, including dementias such as Alzheimer's disease.  The cholinergic hypothesis of Alzheimer's disease centres on the progressive loss of limbic and neocortical cholinergic innervation.  Neurofibrillary degeneration in the basal forebrain is believed to be the primary cause for the dysfunction and death of forebrain cholinergic neurons, giving rise to a widespread presynaptic cholinergic denervation.  Cholinesterase inhibitors increase the availability of acetylcholine at synapses in the brain and are one of the few drug therapies that have been proven clinically useful in the treatment of Alzheimer's disease dementia, thus validating the cholinergic system as an important therapeutic target in the disease.  This review includes an overview of the role of the cholinergic system in cognition and an updated understanding of how cholinergic deficits in Alzheimer's disease interact with other aspects of disease pathophysiology, including plaques composed of amyloid-β proteins.  This review also documents the benefits of cholinergic therapies at various stages of Alzheimer's disease and during long-term follow-up as visualized in novel imaging studies.  The weight of the evidence supports the continued value of cholinergic drugs as a standard, cornerstone pharmacological approach in Alzheimer's disease, particularly as we look ahead to future combination therapies that address symptoms as well as disease progression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT5lCY2voWsVJWtyewyzkyLfW6udTcc2eafZDmPwyLbjbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MbitFKksg%253D%253D&md5=c50bb2354aedec424a05295e06ca5be6</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1093%2Fbrain%2Fawy132&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbrain%252Fawy132%26sid%3Dliteratum%253Aachs%26aulast%3DHampel%26aufirst%3DH.%26aulast%3DMesulam%26aufirst%3DM.-M.%26aulast%3DCuello%26aufirst%3DA.%2BC.%26aulast%3DFarlow%26aufirst%3DM.%2BR.%26aulast%3DGiacobini%26aufirst%3DE.%26aulast%3DGrossberg%26aufirst%3DG.%2BT.%26aulast%3DKhachaturian%26aufirst%3DA.%2BS.%26aulast%3DVergallo%26aufirst%3DA.%26aulast%3DCavedo%26aufirst%3DE.%26aulast%3DSnyder%26aufirst%3DP.%26aulast%3DKhachaturian%26aufirst%3DZ.%2BS.%26atitle%3DThe%2520Cholinergic%2520System%2520in%2520the%2520Pathophysiology%2520and%2520Treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DBrain%26date%3D2018%26volume%3D141%26spage%3D1917%26epage%3D1933%26doi%3D10.1093%2Fbrain%2Fawy132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anand, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, B.</span></span> <span> </span><span class="NLM_article-title">A Review on Cholinesterase Inhibitors for Alzheimer’s Disease</span>. <i>Arch. Pharmacal Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">375</span>– <span class="NLM_lpage">399</span>, <span class="refDoi"> DOI: 10.1007/s12272-013-0036-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1007%2Fs12272-013-0036-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=23435942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFWju70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2013&pages=375-399&author=P.+Anandauthor=B.+Singh&title=A+Review+on+Cholinesterase+Inhibitors+for+Alzheimer%E2%80%99s+Disease&doi=10.1007%2Fs12272-013-0036-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">A review on cholinesterase inhibitors for Alzheimer's disease</span></div><div class="casAuthors">Anand, Preet; Singh, Baldev</div><div class="citationInfo"><span class="NLM_cas:title">Archives of Pharmacal Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">375-399</span>CODEN:
                <span class="NLM_cas:coden">APHRDQ</span>;
        ISSN:<span class="NLM_cas:issn">0253-6269</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Society of Korea</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD), a progressive neurodegenerative disorder, is characterized by the deficits in the cholinergic system and deposition of beta amyloid (Aβ) in the form of neurofibrillary tangles and amyloid plaques.  Since the cholinergic system plays an important role in the regulation of learning and memory processes, it has been targetted for the design of anti-Alzheimer's drugs.  Cholinesterase inhibitors enhance cholinergic transmission directly by inhibiting the enzyme acetylcholinesterase (AChE) which hydrolyzes acetylcholine.  Furthermore, it has been also demonstrated that both acetylcholinesterase and butrylcholinesterase (BuChE) play an important role in Aβ-aggregation during the early stages of senile plaque formation.  Therefore, AChE and BuChE inhibition have been documented as crit. targets for the effective management of AD by an increase in the availability of acetylcholine in the brain regions and decrease in the Aβ deposition.  This review discusses the different classes of cholinesterase inhibitors including tacrine, donepezil, rivastigmine, galantamine, xanthostigmine, para-aminobenzoic acid, coumarin, flavonoid, and pyrrolo-isoxazole analogs developed for the treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe8p6U3r94ubVg90H21EOLACvtfcHk0lj2XYcJUExNhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFWju70%253D&md5=a8b48dbf6a7e7b988759182ad8cd9b6a</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1007%2Fs12272-013-0036-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12272-013-0036-3%26sid%3Dliteratum%253Aachs%26aulast%3DAnand%26aufirst%3DP.%26aulast%3DSingh%26aufirst%3DB.%26atitle%3DA%2520Review%2520on%2520Cholinesterase%2520Inhibitors%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DArch.%2520Pharmacal%2520Res.%26date%3D2013%26volume%3D36%26spage%3D375%26epage%3D399%26doi%3D10.1007%2Fs12272-013-0036-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kamal, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Q.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tweedie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greig, N. H.</span></span> <span> </span><span class="NLM_article-title">Tetrahydrofurobenzofuran Cymserine, a Potent Butyrylcholinesterase Inhibitor and Experimental Alzheimer Drug Candidate, Enzyme Kinetic Analysis</span>. <i>J. Neural Transm.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>115</i></span>,  <span class="NLM_fpage">889</span>– <span class="NLM_lpage">898</span>, <span class="refDoi"> DOI: 10.1007/s00702-008-0022-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1007%2Fs00702-008-0022-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=18235987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmslWrs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2008&pages=889-898&author=M.+A.+Kamalauthor=X.+Quauthor=Q.-S.+Yuauthor=D.+Tweedieauthor=H.+W.+Hollowayauthor=Y.+Liauthor=Y.+Tanauthor=N.+H.+Greig&title=Tetrahydrofurobenzofuran+Cymserine%2C+a+Potent+Butyrylcholinesterase+Inhibitor+and+Experimental+Alzheimer+Drug+Candidate%2C+Enzyme+Kinetic+Analysis&doi=10.1007%2Fs00702-008-0022-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Tetrahydrofurobenzofuran cymserine, a potent butyrylcholinesterase inhibitor and experimental Alzheimer drug candidate, enzyme kinetic analysis</span></div><div class="casAuthors">Kamal, Mohammad A.; Qu, Xianqin; Yu, Qian-sheng; Tweedie, David; Holloway, Harold W.; Li, Yazhou; Tan, Yi; Greig, Nigel H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neural Transmission</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">115</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">889-898</span>CODEN:
                <span class="NLM_cas:coden">JNTRF3</span>;
        ISSN:<span class="NLM_cas:issn">0300-9564</span>.
    
            (<span class="NLM_cas:orgname">Springer Wien</span>)
        </div><div class="casAbstract">Synaptic loss, particularly related to the forebrain cholinergic system, is considered to be an early event that leads to Alzheimer's disease (AD) and has led to the development of acetylcholinesterase inhibitors (AChE-Is) as the mainstay of treatment for several degenerative disorders that culminate in dementia.  The primary dose-limiting toxicities of all clin. available AChE-Is are, similar to useful actions on cognition, cholinergically mediated and they ultimately limit the value of this drug class in achieving anything but symptomatic improvements.  In addn., AChE levels in brain areas assocd. with AD decline with disease progression, which likely ultimately limits the therapeutic utility of this drug class.  New research indicates that selective inhibition of butyrylcholinesterase (BuChE), a closely related enzyme that is markedly elevated in AD brain, increases acetylcholine (ACh) and augments cognition in rodents free of the characteristic undesirable actions of AChE-Is.  BuChE inhibition hence represents an innovative treatment approach for AD, and agents are currently being synthesized to optimally achieve this.  The novel compd., tetrahydrofurobenzofuran cymserine (THFBFC), is derived from our effort to produce a potent and BuChE-selective inhibitor as a candidate to test the hypothesis that BuChE-Is would be efficacious and better tolerated than AChE-Is in AD.  Herein, we applied innovative enzyme kinetic analyses to characterize the quant. interaction of THFBFC with human BuChE.  These provided values for the agent's IC50, together with specific new kinetic consts., such as K T50, K T1/2, R I, o K RT, o P max, K PT and PT1/2, to aid define target concns. for clin. translation.  Addnl. classical kinetic parameters, including K i, K m or K s, k cat or V max and V mi were also detd.  THFBFC proved to be a potent competitive inhibitor of human BuChE and, like its isomer dihydrobenzodioxepine cymserine, is a potentially interesting AD drug candidate.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlVk1HT9MyVLVg90H21EOLACvtfcHk0lgmJVhIYAgsYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmslWrs7s%253D&md5=f6ac27e74507eb20a9115e4ca80176ac</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1007%2Fs00702-008-0022-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00702-008-0022-y%26sid%3Dliteratum%253Aachs%26aulast%3DKamal%26aufirst%3DM.%2BA.%26aulast%3DQu%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DQ.-S.%26aulast%3DTweedie%26aufirst%3DD.%26aulast%3DHolloway%26aufirst%3DH.%2BW.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DTan%26aufirst%3DY.%26aulast%3DGreig%26aufirst%3DN.%2BH.%26atitle%3DTetrahydrofurobenzofuran%2520Cymserine%252C%2520a%2520Potent%2520Butyrylcholinesterase%2520Inhibitor%2520and%2520Experimental%2520Alzheimer%2520Drug%2520Candidate%252C%2520Enzyme%2520Kinetic%2520Analysis%26jtitle%3DJ.%2520Neural%2520Transm.%26date%3D2008%26volume%3D115%26spage%3D889%26epage%3D898%26doi%3D10.1007%2Fs00702-008-0022-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Andrade, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantoani, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonçalves Nunes, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magadán, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xavier, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hojo, E. T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campillo, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martínez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carvalho, I.</span></span> <span> </span><span class="NLM_article-title">Highly Potent and Selective Aryl-1,2,3-Triazolyl Benzylpiperidine Inhibitors toward Butyrylcholinesterase in Alzheimer’s Disease</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">931</span>– <span class="NLM_lpage">943</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.12.030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmc.2018.12.030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=30765302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1MXivVahtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=931-943&author=P.+de+Andradeauthor=S.+P.+Mantoaniauthor=P.+S.+Gon%C3%A7alves+Nunesauthor=C.+R.+Magad%C3%A1nauthor=C.+P%C3%A9rezauthor=D.+J.+Xavierauthor=E.+T.+S.+Hojoauthor=N.+E.+Campilloauthor=A.+Mart%C3%ADnezauthor=I.+Carvalho&title=Highly+Potent+and+Selective+Aryl-1%2C2%2C3-Triazolyl+Benzylpiperidine+Inhibitors+toward+Butyrylcholinesterase+in+Alzheimer%E2%80%99s+Disease&doi=10.1016%2Fj.bmc.2018.12.030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Highly potent and selective aryl-1,2,3-triazolyl benzylpiperidine inhibitors toward butyrylcholinesterase in Alzheimer's disease</span></div><div class="casAuthors">de Andrade, Peterson; Mantoani, Susimaire P.; Goncalves Nunes, Paulo Sergio; Magadan, Carlos Roca; Perez, Concepcion; Xavier, Danilo Jordao; Hojo, Elza Tiemi Sakamoto; Campillo, Nuria E.; Martinez, Ana; Carvalho, Ivone</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">931-943</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Acetylcholinesterase (AChE) is the key enzyme targeted in Alzheimer's disease (AD) therapy, nevertheless butyrylcholinesterase (BuChE) has been drawing attention due to its role in the disease progression.  Thus, we aimed to synthesize novel cholinesterases inhibitors considering structural differences in their peripheral site, exploiting a moiety replacement approach based on the potent and selective hAChE drug donepezil.  Hence, two small series of N-benzylpiperidine based compds. have successfully been synthesized as novel potent and selective hBuChE inhibitors.  The most promising compds. (9(I) and 11(II)) were not cytotoxic and their kinetic study accounted for dual binding site mode of interaction, which is in agreement with further docking and mol. dynamics studies.  Therefore, this study demonstrates how our strategy enabled the discovery of novel promising and privileged structures.  Remarkably, II proved to be one of the most potent (0.17 nM) and selective (>58,000-fold) hBuChE inhibitor ever reported.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo18FzHODs2ArVg90H21EOLACvtfcHk0lgmJVhIYAgsYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXivVahtbc%253D&md5=0451105345c02e32c56a64087251d167</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.12.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.12.030%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BAndrade%26aufirst%3DP.%26aulast%3DMantoani%26aufirst%3DS.%2BP.%26aulast%3DGon%25C3%25A7alves%2BNunes%26aufirst%3DP.%2BS.%26aulast%3DMagad%25C3%25A1n%26aufirst%3DC.%2BR.%26aulast%3DP%25C3%25A9rez%26aufirst%3DC.%26aulast%3DXavier%26aufirst%3DD.%2BJ.%26aulast%3DHojo%26aufirst%3DE.%2BT.%2BS.%26aulast%3DCampillo%26aufirst%3DN.%2BE.%26aulast%3DMart%25C3%25ADnez%26aufirst%3DA.%26aulast%3DCarvalho%26aufirst%3DI.%26atitle%3DHighly%2520Potent%2520and%2520Selective%2520Aryl-1%252C2%252C3-Triazolyl%2520Benzylpiperidine%2520Inhibitors%2520toward%2520Butyrylcholinesterase%2520in%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2019%26volume%3D27%26spage%3D931%26epage%3D943%26doi%3D10.1016%2Fj.bmc.2018.12.030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knez, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coquelle, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pišlar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Žakelj, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jukič, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mravljak, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nachon, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brazzolotto, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kos, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colletier, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobec, S.</span></span> <span> </span><span class="NLM_article-title">Multi-Target-Directed Ligands for Treating Alzheimer’s Disease: Butyrylcholinesterase Inhibitors Displaying Antioxidant and Neuroprotective Activities</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">598</span>– <span class="NLM_lpage">617</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.07.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2018.07.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=30031971" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlOjs7zI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2018&pages=598-617&author=D.+Knezauthor=N.+Coquelleauthor=A.+Pi%C5%A1larauthor=S.+%C5%BDakeljauthor=M.+Juki%C4%8Dauthor=M.+Sovaauthor=J.+Mravljakauthor=F.+Nachonauthor=X.+Brazzolottoauthor=J.+Kosauthor=J.+P.+Colletierauthor=S.+Gobec&title=Multi-Target-Directed+Ligands+for+Treating+Alzheimer%E2%80%99s+Disease%3A+Butyrylcholinesterase+Inhibitors+Displaying+Antioxidant+and+Neuroprotective+Activities&doi=10.1016%2Fj.ejmech.2018.07.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target-directed ligands for treating Alzheimer's disease: Butyrylcholinesterase inhibitors displaying antioxidant and neuroprotective activities</span></div><div class="casAuthors">Knez, Damijan; Coquelle, Nicolas; Pislar, Anja; Zakelj, Simon; Jukic, Marko; Sova, Matej; Mravljak, Janez; Nachon, Florian; Brazzolotto, Xavier; Kos, Janko; Colletier, Jacques-Philippe; Gobec, Stanislav</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">598-617</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The limited clin. efficacy of current symptomatic treatment and minute effect on progression of Alzheimer's disease has shifted the research focus from single targets towards multi-target-directed ligands.  Here, a potent selective inhibitor of human butyrylcholinesterase was used as the starting point to develop a new series of multifunctional ligands.  A focused library of derivs. was designed and synthesized that showed both butyrylcholinesterase inhibition and good antioxidant activity as detd. by the DPPH assay.  The crystal structure of compd. 11 in complex with butyrylcholinesterase revealed the mol. basis for its low nanomolar inhibition of butyrylcholinesterase (Ki = 1.09±0.12 nM).  In addn., compds. 8 and 11 show metal-chelating properties, and reduce the redox activity of chelated Cu2+ ions in a Cu-ascorbate redox system.  Compds. 8 and 11 decrease intracellular levels of reactive oxygen species, and are not substrates of the active efflux transport system, as detd. in Caco2 cells.  Compd. 11 also protects neuroblastoma SH-SY5Y cells from toxic Aβ1-42 species.  These data indicate that compds. 8 and 11 are promising multifunctional lead ligands for treatment of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNMjF5aAaK37Vg90H21EOLACvtfcHk0li1OGS06gpxmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlOjs7zI&md5=b72fe7de780ba1a4deb7a0ed4fa3326f</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.07.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.07.033%26sid%3Dliteratum%253Aachs%26aulast%3DKnez%26aufirst%3DD.%26aulast%3DCoquelle%26aufirst%3DN.%26aulast%3DPi%25C5%25A1lar%26aufirst%3DA.%26aulast%3D%25C5%25BDakelj%26aufirst%3DS.%26aulast%3DJuki%25C4%258D%26aufirst%3DM.%26aulast%3DSova%26aufirst%3DM.%26aulast%3DMravljak%26aufirst%3DJ.%26aulast%3DNachon%26aufirst%3DF.%26aulast%3DBrazzolotto%26aufirst%3DX.%26aulast%3DKos%26aufirst%3DJ.%26aulast%3DColletier%26aufirst%3DJ.%2BP.%26aulast%3DGobec%26aufirst%3DS.%26atitle%3DMulti-Target-Directed%2520Ligands%2520for%2520Treating%2520Alzheimer%25E2%2580%2599s%2520Disease%253A%2520Butyrylcholinesterase%2520Inhibitors%2520Displaying%2520Antioxidant%2520and%2520Neuroprotective%2520Activities%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D156%26spage%3D598%26epage%3D617%26doi%3D10.1016%2Fj.ejmech.2018.07.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benito, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolon, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazos, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castillo, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, J.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid CB2 Receptors in Human Brain Inflammation</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>153</i></span>,  <span class="NLM_fpage">277</span>– <span class="NLM_lpage">285</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0707505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fsj.bjp.0707505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=17934510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovFCktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=153&publication_year=2008&pages=277-285&author=C.+Benitoauthor=R.+M.+Tolonauthor=M.+R.+Pazosauthor=E.+Nunezauthor=A.+I.+Castilloauthor=J.+Romero&title=Cannabinoid+CB2+Receptors+in+Human+Brain+Inflammation&doi=10.1038%2Fsj.bjp.0707505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid CB2 receptors in human brain inflammation</span></div><div class="casAuthors">Benito, C.; Tolon, R. M.; Pazos, M. R.; Nunez, E.; Castillo, A. I.; Romero, J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">153</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">277-285</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The presence of functional cannabinoid CB2 receptors in the CNS has provoked considerable controversy over the past few years.  Formerly considered as an exclusively peripheral receptor, it is now accepted that it is also present in limited amts. and distinct locations in the brain of several animal species, including humans.  Furthermore, the inducible nature of these receptors under neuroinflammatory conditions, in contrast to CB1, makes them attractive targets for the development of novel therapeutic approaches.  In fact, the undesired psychoactive effects caused by CB1 activation have largely limited the clin. use of cannabinoid-related compds. that act on these receptors.  In this review some recent findings on the antiinflammatory properties of CB2 receptors are presented, as well as new perspectives that have been obtained based on studies of human postmortem brain samples.  In addn., various working hypotheses are also proposed and discussed.  British Journal of Pharmacol. (2008) 153, 277-285; doi:10.1038/sj.bjp.0707505; published online 15 Oct. 2007.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqy1sC3kUak-7Vg90H21EOLACvtfcHk0lhKNibQYCzApA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovFCktg%253D%253D&md5=acc7f2244e1db16d66e5953eadecb381</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0707505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0707505%26sid%3Dliteratum%253Aachs%26aulast%3DBenito%26aufirst%3DC.%26aulast%3DTolon%26aufirst%3DR.%2BM.%26aulast%3DPazos%26aufirst%3DM.%2BR.%26aulast%3DNunez%26aufirst%3DE.%26aulast%3DCastillo%26aufirst%3DA.%2BI.%26aulast%3DRomero%26aufirst%3DJ.%26atitle%3DCannabinoid%2520CB2%2520Receptors%2520in%2520Human%2520Brain%2520Inflammation%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D153%26spage%3D277%26epage%3D285%26doi%3D10.1038%2Fsj.bjp.0707505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eubanks, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beuscher, A. E.,  4th</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koob, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerson, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janda, K. D.</span></span> <span> </span><span class="NLM_article-title">A Molecular Link between the Active Component of Marijuana and Alzheimer’s Disease Pathology</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">773</span>– <span class="NLM_lpage">777</span>, <span class="refDoi"> DOI: 10.1021/mp060066m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp060066m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD28XnvValtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2006&pages=773-777&author=L.+M.+Eubanksauthor=C.+J.+Rogersauthor=A.+E.+Beuscherauthor=G.+F.+Koobauthor=A.+J.+Olsonauthor=T.+J.+Dickersonauthor=K.+D.+Janda&title=A+Molecular+Link+between+the+Active+Component+of+Marijuana+and+Alzheimer%E2%80%99s+Disease+Pathology&doi=10.1021%2Fmp060066m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">A Molecular Link between the Active Component of Marijuana and Alzheimer's Disease Pathology</span></div><div class="casAuthors">Eubanks, Lisa M.; Rogers, Claude J.; Beuscher, Albert E., IV; Koob, George F.; Olson, Arthur J.; Dickerson, Tobin J.; Janda, Kim D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">773-777</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Alzheimer's disease is the leading cause of dementia among the elderly, and with the ever-increasing size of this population, cases of Alzheimer's disease are expected to triple over the next 50 years.  Consequently, the development of treatments that slow or halt the disease progression have become imperative to both improve the quality of life for patients and reduce the health care costs attributable to Alzheimer's disease.  Here, the authors demonstrate that the active component of marijuana, Δ9-tetrahydrocannabinol (THC), competitively inhibits the enzyme acetylcholinesterase (AChE) as well as prevents AChE-induced amyloid β-peptide (Aβ) aggregation, the key pathol. marker of Alzheimer's disease.  Computational modeling of the THC-AChE interaction revealed that THC binds in the peripheral anionic site of AChE, the crit. region involved in amyloidgenesis.  Compared to currently approved drugs prescribed for the treatment of Alzheimer's disease, THC is a considerably superior inhibitor of Aβ aggregation, and this study provides a previously unrecognized mol. mechanism through which cannabinoid mols. may directly impact the progression of this debilitating disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRJV3cNwOeGbVg90H21EOLACvtfcHk0lhKNibQYCzApA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnvValtLk%253D&md5=b258fe1fc72a55f890867d97e00277ea</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1021%2Fmp060066m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp060066m%26sid%3Dliteratum%253Aachs%26aulast%3DEubanks%26aufirst%3DL.%2BM.%26aulast%3DRogers%26aufirst%3DC.%2BJ.%26aulast%3DBeuscher%26aufirst%3DA.%2BE.%26aulast%3DKoob%26aufirst%3DG.%2BF.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26aulast%3DDickerson%26aufirst%3DT.%2BJ.%26aulast%3DJanda%26aufirst%3DK.%2BD.%26atitle%3DA%2520Molecular%2520Link%2520between%2520the%2520Active%2520Component%2520of%2520Marijuana%2520and%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Pathology%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2006%26volume%3D3%26spage%3D773%26epage%3D777%26doi%3D10.1021%2Fmp060066m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montanari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahmoud, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pruccoli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabbito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naldi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petralla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moraleda, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iriepa, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belluti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gobbi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bisi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarozzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligresti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampa, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of Novel Benzofuran-Based Compounds with Neuroprotective and Immunomodulatory Properties for Alzheimer’s Disease Treatment</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>178</i></span>,  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">258</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.05.080</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2019.05.080" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=31185414" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFKqs7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2019&pages=243-258&author=S.+Montanariauthor=A.+M.+Mahmoudauthor=L.+Pruccoliauthor=A.+Rabbitoauthor=M.+Naldiauthor=S.+Petrallaauthor=I.+Moraledaauthor=M.+Bartoliniauthor=B.+Montiauthor=I.+Iriepaauthor=F.+Bellutiauthor=S.+Gobbiauthor=V.+Di+Marzoauthor=A.+Bisiauthor=A.+Tarozziauthor=A.+Ligrestiauthor=A.+Rampa&title=Discovery+of+Novel+Benzofuran-Based+Compounds+with+Neuroprotective+and+Immunomodulatory+Properties+for+Alzheimer%E2%80%99s+Disease+Treatment&doi=10.1016%2Fj.ejmech.2019.05.080"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of novel benzofuran-based compounds with neuroprotective and immunomodulatory properties for Alzheimer's disease treatment</span></div><div class="casAuthors">Montanari, Serena; Mahmoud, Ali Mokhtar; Pruccoli, Letizia; Rabbito, Alessandro; Naldi, Marina; Petralla, Sabrina; Moraleda, Ignacio; Bartolini, Manuela; Monti, Barbara; Iriepa, Isabel; Belluti, Federica; Gobbi, Silvia; Di Marzo, Vincenzo; Bisi, Alessandra; Tarozzi, Andrea; Ligresti, Alessia; Rampa, Angela</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">243-258</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">To address the multifactorial nature of Alzheimer's Disease (AD), a multi-target-directed ligand approach was herein developed.  As a follow-up of our previous studies, a small library of newly designed 2-arylbenzofuran derivs. was evaluated towards cholinesterases and cannabinoid receptors.  The two most promising compds., 8(I) and 10(II), were then assessed for their neuroprotective activity and for their ability to modulate the microglial phenotype.  Compd. I emerged as able to fight AD from several directions: it restored the cholinergic system by inhibiting butyrylcholinesterase, showed neuroprotective activity against Aβ1-42 oligomers, was a potent and selective CB2 ligand and had immunomodulatory effects, switching microglia from the pro-inflammatory M1 to the neuroprotective M2 phenotype.  Deriv. II was a potent CB2 inverse agonist with promising immunomodulatory properties and could be considered as a tool for investigating the role of CB2 receptors and for developing potential immunomodulating drugs addressing the endocannabinoid system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjfqkpJQmwA7Vg90H21EOLACvtfcHk0ljoyJnFHk4pMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFKqs7fO&md5=219e8d3d1f59c4cee45397a8ba53a300</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.05.080&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.05.080%26sid%3Dliteratum%253Aachs%26aulast%3DMontanari%26aufirst%3DS.%26aulast%3DMahmoud%26aufirst%3DA.%2BM.%26aulast%3DPruccoli%26aufirst%3DL.%26aulast%3DRabbito%26aufirst%3DA.%26aulast%3DNaldi%26aufirst%3DM.%26aulast%3DPetralla%26aufirst%3DS.%26aulast%3DMoraleda%26aufirst%3DI.%26aulast%3DBartolini%26aufirst%3DM.%26aulast%3DMonti%26aufirst%3DB.%26aulast%3DIriepa%26aufirst%3DI.%26aulast%3DBelluti%26aufirst%3DF.%26aulast%3DGobbi%26aufirst%3DS.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DBisi%26aufirst%3DA.%26aulast%3DTarozzi%26aufirst%3DA.%26aulast%3DLigresti%26aufirst%3DA.%26aulast%3DRampa%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520Novel%2520Benzofuran-Based%2520Compounds%2520with%2520Neuroprotective%2520and%2520Immunomodulatory%2520Properties%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Treatment%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D178%26spage%3D243%26epage%3D258%26doi%3D10.1016%2Fj.ejmech.2019.05.080" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pagé, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaux, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boisvert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milburn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremblay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomaszewski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walpole, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodzic, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St-Onge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godbout, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salois, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payza, K.</span></span> <span> </span><span class="NLM_article-title">Novel Benzimidazole Derivatives as Selective CB2 Agonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">3695</span>– <span class="NLM_lpage">3700</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.05.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmcl.2008.05.073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=18522867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnt1Ohurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=3695-3700&author=D.+Pag%C3%A9author=E.+Balauxauthor=L.+Boisvertauthor=Z.+Liuauthor=C.+Milburnauthor=M.+Tremblayauthor=Z.+Weiauthor=S.+Wooauthor=X.+Luoauthor=Y.+X.+Chengauthor=H.+Yangauthor=S.+Srivastavaauthor=F.+Zhouauthor=W.+Brownauthor=M.+Tomaszewskiauthor=C.+Walpoleauthor=L.+Hodzicauthor=S.+St-Ongeauthor=C.+Godboutauthor=D.+Saloisauthor=K.+Payza&title=Novel+Benzimidazole+Derivatives+as+Selective+CB2+Agonists&doi=10.1016%2Fj.bmcl.2008.05.073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Novel benzimidazole derivatives as selective CB2 agonists</span></div><div class="casAuthors">Page, Daniel; Balaux, Elise; Boisvert, Luc; Liu, Ziping; Milburn, Claire; Tremblay, Maxime; Wei, Zhongyong; Woo, Simon; Luo, Xuehong; Cheng, Yun-Xing; Yang, Hua; Srivastava, Sanjay; Zhou, Fei; Brown, William; Tomaszewski, Miroslaw; Walpole, Christopher; Hodzic, Leila; St-Onge, Stephane; Godbout, Claude; Salois, Dominic; Payza, Keymal</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3695-3700</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The prepn. and evaluation of a novel class of CB2 agonists based on a benzimidazole moiety, e.g., I, are reported.  They showed binding affinities up to 1 nM towards the CB2 receptor with partial to full agonist potencies.  They also demonstrated good to excellent selectivity (>1000-fold) over the CB1 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbeiXe1I0Yg7Vg90H21EOLACvtfcHk0lhoLbNaVjp-RA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnt1Ohurs%253D&md5=fa9e0921054b0d9f26044a1feb82a604</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.05.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.05.073%26sid%3Dliteratum%253Aachs%26aulast%3DPag%25C3%25A9%26aufirst%3DD.%26aulast%3DBalaux%26aufirst%3DE.%26aulast%3DBoisvert%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DMilburn%26aufirst%3DC.%26aulast%3DTremblay%26aufirst%3DM.%26aulast%3DWei%26aufirst%3DZ.%26aulast%3DWoo%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DY.%2BX.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DSrivastava%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DBrown%26aufirst%3DW.%26aulast%3DTomaszewski%26aufirst%3DM.%26aulast%3DWalpole%26aufirst%3DC.%26aulast%3DHodzic%26aufirst%3DL.%26aulast%3DSt-Onge%26aufirst%3DS.%26aulast%3DGodbout%26aufirst%3DC.%26aulast%3DSalois%26aufirst%3DD.%26aulast%3DPayza%26aufirst%3DK.%26atitle%3DNovel%2520Benzimidazole%2520Derivatives%2520as%2520Selective%2520CB2%2520Agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D3695%26epage%3D3700%26doi%3D10.1016%2Fj.bmcl.2008.05.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shogren-Knaak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishii, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davie, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, C. L.</span></span> <span> </span><span class="NLM_article-title">Histone H4-K16 Acetylation Controls Chromatin Structure and Protein Interactions</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>311</i></span>,  <span class="NLM_fpage">844</span>– <span class="NLM_lpage">847</span>, <span class="refDoi"> DOI: 10.1126/science.1124000</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1126%2Fscience.1124000" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=16469925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFylsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=311&publication_year=2006&pages=844-847&author=M.+Shogren-Knaakauthor=H.+Ishiiauthor=J.-M.+Sunauthor=M.+J.+Pazinauthor=J.+R.+Davieauthor=C.+L.+Peterson&title=Histone+H4-K16+Acetylation+Controls+Chromatin+Structure+and+Protein+Interactions&doi=10.1126%2Fscience.1124000"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">Histone H4-K16 Acetylation Controls Chromatin Structure and Protein Interactions</span></div><div class="casAuthors">Shogren-Knaak, Michael; Ishii, Haruhiko; Sun, Jian-Min; Pazin, Michael J.; Davie, James R.; Peterson, Craig L.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">311</span>
        (<span class="NLM_cas:issue">5762</span>),
    <span class="NLM_cas:pages">844-847</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Acetylation of histone H4 on lysine 16 (H4-K16Ac) is a prevalent and reversible posttranslational chromatin modification in eukaryotes.  To characterize the structural and functional role of this mark, we used a native chem. ligation strategy to generate histone H4 that was homogeneously acetylated at K16.  The incorporation of this modified histone into nucleosomal arrays inhibits the formation of compact 30-nm-like fibers and impedes the ability of chromatin to form cross-fiber interactions.  H4-K16Ac also inhibits the ability of the ATP-utilizing chromatin assembly and remodeling enzyme ACF to mobilize a mononucleosome, indicating that this single histone modification modulates both higher order chromatin structure and functional interactions between a nonhistone protein and the chromatin fiber.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqawsTg7m9LQLVg90H21EOLACvtfcHk0lhoLbNaVjp-RA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFylsLY%253D&md5=c82b2fe14098f9e30a0aba389d11fb67</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1126%2Fscience.1124000&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1124000%26sid%3Dliteratum%253Aachs%26aulast%3DShogren-Knaak%26aufirst%3DM.%26aulast%3DIshii%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DJ.-M.%26aulast%3DPazin%26aufirst%3DM.%2BJ.%26aulast%3DDavie%26aufirst%3DJ.%2BR.%26aulast%3DPeterson%26aufirst%3DC.%2BL.%26atitle%3DHistone%2520H4-K16%2520Acetylation%2520Controls%2520Chromatin%2520Structure%2520and%2520Protein%2520Interactions%26jtitle%3DScience%26date%3D2006%26volume%3D311%26spage%3D844%26epage%3D847%26doi%3D10.1126%2Fscience.1124000" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denu, J. M.</span></span> <span> </span><span class="NLM_article-title">Chemical Mechanisms of Histone Lysine and Arginine Modifications</span>. <i>Biochim. Biophys. Acta, Gene Regul. Mech.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>1789</i></span>,  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">57</span>, <span class="refDoi"> DOI: 10.1016/j.bbagrm.2008.06.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bbagrm.2008.06.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=18603028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVOis7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1789&publication_year=2009&pages=45-57&author=B.+C.+Smithauthor=J.+M.+Denu&title=Chemical+Mechanisms+of+Histone+Lysine+and+Arginine+Modifications&doi=10.1016%2Fj.bbagrm.2008.06.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit122R"><div class="casContent"><span class="casTitleNuber">122</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical mechanisms of histone lysine and arginine modifications</span></div><div class="casAuthors">Smith, Brian C.; Denu, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Gene Regulatory Mechanisms</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">1789</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">45-57</span>CODEN:
                <span class="NLM_cas:coden">BBAGC6</span>;
        ISSN:<span class="NLM_cas:issn">1874-9399</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Histone Lys and Arg residues are subject to a wide array of post-translational modifications including methylation, citrullination, acetylation, ubiquitination, and sumoylation.  The combinatorial action of these modifications regulates crit. DNA processes including replication, repair, and transcription.  In addn., enzymes that modify histone Lys and Arg residues have been correlated with a variety of human diseases including arthritis, cancer, heart disease, diabetes, and neurodegenerative disorders.  Thus, it is important to fully understand the detailed kinetic and chem. mechanisms of these enzymes.  Here, the authors review recent progress toward detg. the mechanisms of histone Lys and Arg residue-modifying enzymes.  In particular, the mechanisms of S-adenosyl-L-methionine (AdoMet)-dependent methyltransferases, FAD-dependent demethylases, Fe-dependent demethylases, acetyl-CoA-dependent acetyltransferases, Zn-dependent deacetylases, NAD-dependent deacetylases, and protein arginine deiminases are covered.  Particular attention is paid to the conserved active site residues necessary for catalysis and the individual chem. steps along the catalytic pathway.  When appropriate, areas requiring further work are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5GV8HFQEtB7Vg90H21EOLACvtfcHk0lhoLbNaVjp-RA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVOis7bI&md5=23b6c42b92de48d9d45e67561e5fbb34</span></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagrm.2008.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagrm.2008.06.005%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%2BC.%26aulast%3DDenu%26aufirst%3DJ.%2BM.%26atitle%3DChemical%2520Mechanisms%2520of%2520Histone%2520Lysine%2520and%2520Arginine%2520Modifications%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gene%2520Regul.%2520Mech.%26date%3D2009%26volume%3D1789%26spage%3D45%26epage%3D57%26doi%3D10.1016%2Fj.bbagrm.2008.06.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glozak, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, E.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylases and Cancer</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5420</span>– <span class="NLM_lpage">5432</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1210610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fsj.onc.1210610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=17694083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovFeku7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=5420-5432&author=M.+A.+Glozakauthor=E.+Seto&title=Histone+Deacetylases+and+Cancer&doi=10.1038%2Fsj.onc.1210610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases and cancer</span></div><div class="casAuthors">Glozak, M. A.; Seto, E.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">5420-5432</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) regulate the expression and activity of numerous proteins involved in both cancer initiation and cancer progression.  By removal of acetyl groups from histones, HDACs create a non-permissive chromatin conformation that prevents the transcription of genes that encode proteins involved in tumorigenesis.  In addn. to histones, HDACs bind to and deacetylate a variety of other protein targets including transcription factors and other abundant cellular proteins implicated in control of cell growth, differentiation and apoptosis.  This review provides a comprehensive examn. of the transcriptional and post-translational mechanisms by which HDACs alter the expression and function of cancer-assocd. proteins and examines the general impact of HDAC activity in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9hjug8fWrtbVg90H21EOLACvtfcHk0lhqdQciXpjLkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovFeku7Y%253D&md5=b0a389027624e9f3d75b89f1f5d7a072</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210610%26sid%3Dliteratum%253Aachs%26aulast%3DGlozak%26aufirst%3DM.%2BA.%26aulast%3DSeto%26aufirst%3DE.%26atitle%3DHistone%2520Deacetylases%2520and%2520Cancer%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D5420%26epage%3D5432%26doi%3D10.1038%2Fsj.onc.1210610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ropero, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Esteller, M.</span></span> <span> </span><span class="NLM_article-title">The Role of Histone Deacetylases (HDACs) in Human Cancer</span>. <i>Mol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">19</span>– <span class="NLM_lpage">25</span>, <span class="refDoi"> DOI: 10.1016/j.molonc.2007.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.molonc.2007.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=19383284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlOitbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2007&pages=19-25&author=S.+Roperoauthor=M.+Esteller&title=The+Role+of+Histone+Deacetylases+%28HDACs%29+in+Human+Cancer&doi=10.1016%2Fj.molonc.2007.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">The role of histone deacetylases (HDACs) in human cancer</span></div><div class="casAuthors">Ropero, Santiago; Esteller, Manel</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Oncology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">19-25</span>CODEN:
                <span class="NLM_cas:coden">MOONC3</span>;
        ISSN:<span class="NLM_cas:issn">1574-7891</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The balance of histone acetylation and deacetylation is an epigenetic layer with a crit. role in the regulation of gene expression.  Histone acetylation induced by histone acetyl transferases (HATs) is assocd. with gene transcription, while histone hypoacetylation induced by histone deacetylase (HDAC) activity is assocd. with gene silencing.  Altered expression and mutations of genes that encode HDACs have been linked to tumor development since they both induce the aberrant transcription of key genes regulating important cellular functions such as cell proliferation, cell-cycle regulation and apoptosis.  Thus, HDACs are among the most promising therapeutic targets for cancer treatment, and they have inspired researchers to study and develop HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvbJD8bqroSLVg90H21EOLACvtfcHk0lhqdQciXpjLkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlOitbnI&md5=d925bcde258dce7d53cbb98563e1f2ae</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2Fj.molonc.2007.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molonc.2007.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DRopero%26aufirst%3DS.%26aulast%3DEsteller%26aufirst%3DM.%26atitle%3DThe%2520Role%2520of%2520Histone%2520Deacetylases%2520%2528HDACs%2529%2520in%2520Human%2520Cancer%26jtitle%3DMol.%2520Oncol.%26date%3D2007%26volume%3D1%26spage%3D19%26epage%3D25%26doi%3D10.1016%2Fj.molonc.2007.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, S.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, J.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-S.</span></span> <span> </span><span class="NLM_article-title">Targeting Histone Deacetylase in Cancer Therapy</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">397</span>– <span class="NLM_lpage">413</span>, <span class="refDoi"> DOI: 10.1002/med.20056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1002%2Fmed.20056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=16450343" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD28XntFaltrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2006&pages=397-413&author=H.-Y.+Linauthor=C.-S.+Chenauthor=S.-P.+Linauthor=J.-R.+Wengauthor=C.-S.+Chen&title=Targeting+Histone+Deacetylase+in+Cancer+Therapy&doi=10.1002%2Fmed.20056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting histone deacetylase in cancer therapy</span></div><div class="casAuthors">Lin, Hsiang-Yu; Chen, Chang-Shi; Lin, Shuan-Pei; Weng, Jing-Ru; Chen, Ching-Shih</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">397-413</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC) is recognized as one of the promising targets for cancer treatment as many HDAC inhibitors have entered clin. trials for both solid and liq. tumors.  Nevertheless, the mechanisms underlying the antiproliferative effects of HDAC inhibitors remain elusive.  Although they have been shown to regulate the transcription of a defined set of genes through chromatin remodeling, increasing evidence suggests that modifications of the epigenetic histone code may not be the primary mechanism for HDAC inhibitor-mediated growth inhibition and apoptosis in cancer cells.  While histones still represent a primary target for the physiol. function of HDACs, the antitumor effect of HDAC inhibitors might also be attributed to transcription-independent mechanisms by modulating the acetylation status of a series of nonhistone targets.  Also noteworthy is the effect of HDAC inhibitors on Akt downregulation through the alteration of protein phosphatase 1 (PP1) complex formation.  To provide an overview of the use of HDAC inhibitors in cancer treatment, this review addresses the following subjects: (1) the physiol. relevance of HDAC-mediated acetylation of histone and nonhistone substrates, (2) the chem. biol. of HDACs and development of a novel class of HDAC inhibitors, and (3) the protein acetylation-independent effect of HDAC inhibitors on the activation status of signaling kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsa6h2NkYnN7Vg90H21EOLACvtfcHk0lhqdQciXpjLkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XntFaltrc%253D&md5=4d663196ac8258cd0e079b47761f3128</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1002%2Fmed.20056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.20056%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DH.-Y.%26aulast%3DChen%26aufirst%3DC.-S.%26aulast%3DLin%26aufirst%3DS.-P.%26aulast%3DWeng%26aufirst%3DJ.-R.%26aulast%3DChen%26aufirst%3DC.-S.%26atitle%3DTargeting%2520Histone%2520Deacetylase%2520in%2520Cancer%2520Therapy%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2006%26volume%3D26%26spage%3D397%26epage%3D413%26doi%3D10.1002%2Fmed.20056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fraguas-Sánchez, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martín-Sabroso, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torres-Suárez, A. I.</span></span> <span> </span><span class="NLM_article-title">Insights into the Effects of the Endocannabinoid System in Cancer: A Review</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>175</i></span>,  <span class="NLM_fpage">2566</span>– <span class="NLM_lpage">2580</span>, <span class="refDoi"> DOI: 10.1111/bph.14331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1111%2Fbph.14331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=29663308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpvFWmtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=175&publication_year=2018&pages=2566-2580&author=A.+I.+Fraguas-S%C3%A1nchezauthor=C.+Mart%C3%ADn-Sabrosoauthor=A.+I.+Torres-Su%C3%A1rez&title=Insights+into+the+Effects+of+the+Endocannabinoid+System+in+Cancer%3A+A+Review&doi=10.1111%2Fbph.14331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into the effects of the endocannabinoid system in cancer: a review</span></div><div class="casAuthors">Fraguas-Sanchez, Ana Isabel; Martin-Sabroso, Cristina; Torres-Suarez, Ana Isabel</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">175</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2566-2580</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">1476-5381</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">In the last few decades, the endocannabinoid system has attracted a great deal of interest in terms of its applications to clin. medicine.  In particular, its applications in cancer probably represent one of the therapeutic areas with most promise.  On the one hand, expression of the endocannabinoid system is altered in numerous types of tumors, compared to healthy tissue, and this aberrant expression has been related to cancer prognosis and disease outcome, suggesting a role of this system in tumor growth and progression that depends on cancer type.  On the other hand, cannabinoids exert an anticancer activity by inhibiting the proliferation, migration and/or invasion of cancer cells and also tumor angiogenesis.  However, some cannabinoids, at lower concns., may increase tumor proliferation, inducing cancer growth.  Enough data has been provided to consider the endocannabinoid system as a new therapeutic target in cancer, although further studies to fully establish the effect of cannabinoids on tumor progression are still needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSvh3gVbdbdbVg90H21EOLACvtfcHk0liabELcSLP04w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpvFWmtbc%253D&md5=63a3df5832ceac97e667b32c997b6457</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1111%2Fbph.14331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbph.14331%26sid%3Dliteratum%253Aachs%26aulast%3DFraguas-S%25C3%25A1nchez%26aufirst%3DA.%2BI.%26aulast%3DMart%25C3%25ADn-Sabroso%26aufirst%3DC.%26aulast%3DTorres-Su%25C3%25A1rez%26aufirst%3DA.%2BI.%26atitle%3DInsights%2520into%2520the%2520Effects%2520of%2520the%2520Endocannabinoid%2520System%2520in%2520Cancer%253A%2520A%2520Review%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2018%26volume%3D175%26spage%3D2566%26epage%3D2580%26doi%3D10.1111%2Fbph.14331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, E.</span></span> <span> </span><span class="NLM_article-title">HDACs and HDAC Inhibitors in Cancer Development and Therapy</span>. <i>Cold Spring Harbor Perspect. Med.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">a026831</span> <span class="refDoi"> DOI: 10.1101/cshperspect.a026831</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1101%2Fcshperspect.a026831" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=27599530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXpslCitb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&author=Y.+Liauthor=E.+Seto&title=HDACs+and+HDAC+Inhibitors+in+Cancer+Development+and+Therapy&doi=10.1101%2Fcshperspect.a026831"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">HDACs and HDAC inhibitors in cancer development and therapy</span></div><div class="casAuthors">Li, Yixuan; Seto, Edward</div><div class="citationInfo"><span class="NLM_cas:title">Cold Spring Harbor Perspectives in Medicine</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">a026831/1-a026831/35</span>CODEN:
                <span class="NLM_cas:coden">CSHPFV</span>;
        ISSN:<span class="NLM_cas:issn">2157-1422</span>.
    
            (<span class="NLM_cas:orgname">Cold Spring Harbor Laboratory Press</span>)
        </div><div class="casAbstract">Over the last several decades, it has become clear that epigenetic abnormalities may be one of the hallmarks of cancer.  Posttranslational modifications of histones, for example, may play a crucial role in cancer development and progression by modulating gene transcription, chromatin remodeling, and nuclear architecture.  Histone acetylation, a well-studied posttranslational histone modification, is controlled by the opposing activities of histone acetyltransferases (HATs) and histone deacetylases (HDACs).  By removing acetyl groups, HDACs reverse chromatin acetylation and alter transcription of oncogenes and tumor suppressor genes.  In addn.,HDACs deacetylate numerous nonhistone cellular substrates that govern a wide array of biol. processes including cancer initiation and progression.  This review will discuss the role of HDACs in cancer and the therapeutic potential of HDAC inhibitors (HDACi) as emerging drugs in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnRL0Y7L3_s7Vg90H21EOLACvtfcHk0liabELcSLP04w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXpslCitb4%253D&md5=1c647aa38027de1c4c92f74340d9041a</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1101%2Fcshperspect.a026831&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252Fcshperspect.a026831%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DSeto%26aufirst%3DE.%26atitle%3DHDACs%2520and%2520HDAC%2520Inhibitors%2520in%2520Cancer%2520Development%2520and%2520Therapy%26jtitle%3DCold%2520Spring%2520Harbor%2520Perspect.%2520Med.%26date%3D2016%26volume%3D6%26doi%3D10.1101%2Fcshperspect.a026831" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chevallier, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corcoran, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lennon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyjek, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chadburn, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardwell, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Licht, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnick, A.</span></span> <span> </span><span class="NLM_article-title">ETO Protein of t(8;21) AML Is a Corepressor for Bcl-6 B-Cell Lymphoma Oncoprotein</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">1454</span>– <span class="NLM_lpage">1463</span>, <span class="refDoi"> DOI: 10.1182/blood-2003-06-2081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1182%2Fblood-2003-06-2081" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=14551142" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsVSlurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2004&pages=1454-1463&author=N.+Chevallierauthor=C.+M.+Corcoranauthor=C.+Lennonauthor=E.+Hyjekauthor=A.+Chadburnauthor=V.+J.+Bardwellauthor=J.+D.+Lichtauthor=A.+Melnick&title=ETO+Protein+of+t%288%3B21%29+AML+Is+a+Corepressor+for+Bcl-6+B-Cell+Lymphoma+Oncoprotein&doi=10.1182%2Fblood-2003-06-2081"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein</span></div><div class="casAuthors">Chevallier, Nathalie; Corcoran, Connie M.; Lennon, Christine; Hyjek, Elizabeth; Chadburn, Amy; Bardwell, Vivian J.; Licht, Jonathan D.; Melnick, Ari</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1454-1463</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">The multiplicity of transcription factors involved in hematol. malignancies suggests a complicated scenarlo in which many different mol. mechanisms lead to malignant transformation.  We hypothesized that some of these proteins might phys. and functionally interact and thus mechanistically link different diseases.  The ETO protein of t(8;21) acute myeloid leukemia (AML) is an excellent candidate as a common factor because it is normally expressed in human hematopoietic cells.  ETO protein binds to histone deacetylases (HDACs), and it interacts with the PLZF protein of t(11;17) acute promyelocytic leukemia.  To det. whether ETO functionally links a broader range of disease entities, we asked whether ETO forms a complex with the Bcl-6 oncoprotein of B-cell lymphomas.  We found that ETO and Bcl-6 are coexpressed in normal and malignant lymphoid tissue, where they interact and colocalize in nuclear speckles.  ETO binds to the fourth zinc finger of Bcl-6, enhances Bcl-6 repression of artificial and endogenous genes in an HDAC-dependent manner, and forms a complex with Bcl-6 on the promoters of its endogenous target genes in B-cell lymphoma cells.  Therefore, ETO is a bona fide corepressor that links the transcriptional pathogenesis of acute leukemias and B-cell lymphomas and offers a compelling target for transcriptional therapy of hematol. malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSkIWlWU_0k7Vg90H21EOLACvtfcHk0liabELcSLP04w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsVSlurs%253D&md5=cdc678f69ae029e21b46d5e1438bc2c9</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1182%2Fblood-2003-06-2081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2003-06-2081%26sid%3Dliteratum%253Aachs%26aulast%3DChevallier%26aufirst%3DN.%26aulast%3DCorcoran%26aufirst%3DC.%2BM.%26aulast%3DLennon%26aufirst%3DC.%26aulast%3DHyjek%26aufirst%3DE.%26aulast%3DChadburn%26aufirst%3DA.%26aulast%3DBardwell%26aufirst%3DV.%2BJ.%26aulast%3DLicht%26aufirst%3DJ.%2BD.%26aulast%3DMelnick%26aufirst%3DA.%26atitle%3DETO%2520Protein%2520of%2520t%25288%253B21%2529%2520AML%2520Is%2520a%2520Corepressor%2520for%2520Bcl-6%2520B-Cell%2520Lymphoma%2520Oncoprotein%26jtitle%3DBlood%26date%3D2004%26volume%3D103%26spage%3D1454%26epage%3D1463%26doi%3D10.1182%2Fblood-2003-06-2081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laban, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leung, C. H.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salto-Tellez, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raju, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hooi, S. C.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Histone Deacetylase 2 Increases Apoptosis and P21Cip1/WAF1 Expression, Independent of Histone Deacetylase 1</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">395</span>– <span class="NLM_lpage">404</span>, <span class="refDoi"> DOI: 10.1038/sj.cdd.4401567</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fsj.cdd.4401567" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=15665816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitlCmsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2005&pages=395-404&author=B.+H.+Huangauthor=M.+Labanauthor=C.+H.-W.+Leungauthor=L.+Leeauthor=C.+K.+Leeauthor=M.+Salto-Tellezauthor=G.+C.+Rajuauthor=S.+C.+Hooi&title=Inhibition+of+Histone+Deacetylase+2+Increases+Apoptosis+and+P21Cip1%2FWAF1+Expression%2C+Independent+of+Histone+Deacetylase+1&doi=10.1038%2Fsj.cdd.4401567"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1</span></div><div class="casAuthors">Huang, B. H.; Laban, M.; Leung, C. H-W.; Lee, L.; Lee, C. K.; Salto-Tellez, M.; Raju, G. C.; Hooi, S. C.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death and Differentiation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">395-404</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) 1 and 2 share a high degree of homol. and coexist within the same protein complexes.  Despite their close assocn., each possesses unique functions.  We show that the upregulation of HDAC2 in colorectal cancer occurred early at the polyp stage, was more robust and occurred more frequently than HDAC1.  Similarly, while the expression of HDACs1 and 2 were increased in cervical dysplasia and invasive carcinoma, HDAC2 expression showed a clear demarcation of high-intensity staining at the transition region of dysplasia compared to HDAC1.  Upon HDAC2 knockdown, cells displayed an increased no. of cellular extensions reminiscent of cell differentiation.  There was also an increase in apoptosis, assocd. with increased p21Cip1/WAF1 expression that was independent of p53.  These results suggest that HDACs, esp. HDAC2, are important enzymes involved in the early events of carcinogenesis, making them candidate markers for tumor progression and targets for cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGQVm9MySU7LVg90H21EOLACvtfcHk0lhvsaxbdZaKKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitlCmsLs%253D&md5=4fd824f68deea245e6b7dbcbe087b8d0</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1038%2Fsj.cdd.4401567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.cdd.4401567%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DB.%2BH.%26aulast%3DLaban%26aufirst%3DM.%26aulast%3DLeung%26aufirst%3DC.%2BH.-W.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLee%26aufirst%3DC.%2BK.%26aulast%3DSalto-Tellez%26aufirst%3DM.%26aulast%3DRaju%26aufirst%3DG.%2BC.%26aulast%3DHooi%26aufirst%3DS.%2BC.%26atitle%3DInhibition%2520of%2520Histone%2520Deacetylase%25202%2520Increases%2520Apoptosis%2520and%2520P21Cip1%252FWAF1%2520Expression%252C%2520Independent%2520of%2520Histone%2520Deacetylase%25201%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2005%26volume%3D12%26spage%3D395%26epage%3D404%26doi%3D10.1038%2Fsj.cdd.4401567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Suraweera, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Byrne, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richard, D. J.</span></span> <span> </span><span class="NLM_article-title">Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi</span>. <i>Front. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">92</span>, <span class="refDoi"> DOI: 10.3389/fonc.2018.00092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3389%2Ffonc.2018.00092" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=29651407" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BC1MjitlSksA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=92&author=A.+Suraweeraauthor=K.+J.+O%E2%80%99Byrneauthor=D.+J.+Richard&title=Combination+Therapy+With+Histone+Deacetylase+Inhibitors+%28HDACi%29+for+the+Treatment+of+Cancer%3A+Achieving+the+Full+Therapeutic+Potential+of+HDACi&doi=10.3389%2Ffonc.2018.00092"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi</span></div><div class="casAuthors">Suraweera Amila; O'Byrne Kenneth J; Richard Derek J; O'Byrne Kenneth J</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">92</span>
        ISSN:<span class="NLM_cas:issn">2234-943X</span>.
    </div><div class="casAbstract">Genetic and epigenetic changes in DNA are involved in cancer development and tumor progression.  Histone deacetylases (HDACs) are key regulators of gene expression that act as transcriptional repressors by removing acetyl groups from histones.  HDACs are dysregulated in many cancers, making them a therapeutic target for the treatment of cancer.  Histone deacetylase inhibitors (HDACi), a novel class of small-molecular therapeutics, are now approved by the Food and Drug Administration as anticancer agents.  While they have shown great promise, resistance to HDACi is often observed and furthermore, HDACi have shown limited success in treating solid tumors.  The combination of HDACi with standard chemotherapeutic drugs has demonstrated promising anticancer effects in both preclinical and clinical studies.  In this review, we summarize the research thus far on HDACi in combination therapy, with other anticancer agents and their translation into preclinical and clinical studies.  We additionally highlight the side effects associated with HDACi in cancer therapy and discuss potential biomarkers to either select or predict a patient's response to these agents, in order to limit the off-target toxicity associated with HDACi.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTprF0Hdrz8rZZoeNcnHOQ9fW6udTcc2eajQKapyWyxqLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MjitlSksA%253D%253D&md5=2f0ace7215bc7519c23cad264f73693d</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2018.00092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2018.00092%26sid%3Dliteratum%253Aachs%26aulast%3DSuraweera%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%2BJ.%26aulast%3DRichard%26aufirst%3DD.%2BJ.%26atitle%3DCombination%2520Therapy%2520With%2520Histone%2520Deacetylase%2520Inhibitors%2520%2528HDACi%2529%2520for%2520the%2520Treatment%2520of%2520Cancer%253A%2520Achieving%2520the%2520Full%2520Therapeutic%2520Potential%2520of%2520HDACi%26jtitle%3DFront.%2520Oncol.%26date%3D2018%26volume%3D8%26spage%3D92%26doi%3D10.3389%2Ffonc.2018.00092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eckschlager, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiborova, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrabeta, J.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitors as Anticancer Drugs</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1414</span>, <span class="refDoi"> DOI: 10.3390/ijms18071414</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3390%2Fijms18071414" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=28671573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVGgt73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=1414&author=T.+Eckschlagerauthor=J.+Plchauthor=M.+Stiborovaauthor=J.+Hrabeta&title=Histone+Deacetylase+Inhibitors+as+Anticancer+Drugs&doi=10.3390%2Fijms18071414"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors as anticancer drugs</span></div><div class="casAuthors">Eckschlager, Tomas; Plch, Johana; Stiborova, Marie; Hrabeta, Jan</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1414/1-1414/25</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Carcinogenesis cannot be explained only by genetic alterations, but also involves epigenetic processes.  Modification of histones by acetylation plays a key role in epigenetic regulation of gene expression and is controlled by the balance between histone deacetylases (HDAC) and histone acetyltransferases (HAT).  HDAC inhibitors induce cancer cell cycle arrest, differentiation and cell death, reduce angiogenesis and modulate immune response.  Mechanisms of anticancer effects of HDAC inhibitors are not uniform; they may be different and depend on the cancer type, HDAC inhibitors, doses, etc.  HDAC inhibitors seem to be promising anti-cancer drugs particularly in the combination with other anti-cancer drugs and/or radiotherapy.  HDAC inhibitors vorinostat, romidepsin and belinostat have been approved for some T-cell lymphoma and panobinostat for multiple myeloma.  Other HDAC inhibitors are in clin. trials for the treatment of hematol. and solid malignancies.  The results of such studies are promising but further larger studies are needed.  Because of the reversibility of epigenetic changes during cancer development, the potency of epigenetic therapies seems to be of great importance.  Here, we summarize the data on different classes of HDAC inhibitors, mechanisms of their actions and discuss novel results of preclin. and clin. studies, including the combination with other therapeutic modalities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPNVhoLBAHnrVg90H21EOLACvtfcHk0lhvsaxbdZaKKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVGgt73P&md5=6018c7709a09548214bfe34bd91107a9</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.3390%2Fijms18071414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms18071414%26sid%3Dliteratum%253Aachs%26aulast%3DEckschlager%26aufirst%3DT.%26aulast%3DPlch%26aufirst%3DJ.%26aulast%3DStiborova%26aufirst%3DM.%26aulast%3DHrabeta%26aufirst%3DJ.%26atitle%3DHistone%2520Deacetylase%2520Inhibitors%2520as%2520Anticancer%2520Drugs%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2017%26volume%3D18%26spage%3D1414%26doi%3D10.3390%2Fijms18071414" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blanchard, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chipoy, C.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitors: New Drugs for the Treatment of Inflammatory Diseases?</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">197</span>– <span class="NLM_lpage">204</span>, <span class="refDoi"> DOI: 10.1016/S1359-6446(04)03309-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2FS1359-6446%2804%2903309-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=15708534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlajsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=197-204&author=F.+Blanchardauthor=C.+Chipoy&title=Histone+Deacetylase+Inhibitors%3A+New+Drugs+for+the+Treatment+of+Inflammatory+Diseases%3F&doi=10.1016%2FS1359-6446%2804%2903309-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?</span></div><div class="casAuthors">Blanchard, Frederic; Chipoy, Celine</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">197-204</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Histone deacetylase (HDAC) inhibitors induce cell cycle arrest and differentiation in cancer cells and have been in Phase I-II clin. trials for the treatment of various solid or haematol. malignancies.  In recent years, HDAC inhibitors have emerged as potent contenders for anti-inflammatory drugs, offering new lines of therapeutic intervention for rheumatoid arthritis or lupus erythematosus.  The mol. mode of action of HDAC inhibitors is still controversial but seems to rely on reduced inflammatory mediator prodn., such as nitric oxide or cytokines, which implies inhibition of the transcription factor NF-κB.  These anti-inflammatory effects will hopefully lead us to appreciate the complex anti-tumor effects of HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvgwCeeoZzgrVg90H21EOLACvtfcHk0lhvsaxbdZaKKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlajsbY%253D&md5=ce9832fdf76caab29c7017fccccefade</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1016%2FS1359-6446%2804%2903309-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1359-6446%252804%252903309-4%26sid%3Dliteratum%253Aachs%26aulast%3DBlanchard%26aufirst%3DF.%26aulast%3DChipoy%26aufirst%3DC.%26atitle%3DHistone%2520Deacetylase%2520Inhibitors%253A%2520New%2520Drugs%2520for%2520the%2520Treatment%2520of%2520Inflammatory%2520Diseases%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2005%26volume%3D10%26spage%3D197%26epage%3D204%26doi%3D10.1016%2FS1359-6446%2804%2903309-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dekker, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van den Bosch, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N. I.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Inhibitors of Histone Acetyltransferases and Deacetylases Are Potential Drugs for Inflammatory Diseases</span>. <i>Drug Discovery Today</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">654</span>– <span class="NLM_lpage">660</span>, <span class="refDoi"> DOI: 10.1016/j.drudis.2013.11.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.drudis.2013.11.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=24269836" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitVWjsrrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=654-660&author=F.+J.+Dekkerauthor=T.+van+den+Boschauthor=N.+I.+Martin&title=Small+Molecule+Inhibitors+of+Histone+Acetyltransferases+and+Deacetylases+Are+Potential+Drugs+for+Inflammatory+Diseases&doi=10.1016%2Fj.drudis.2013.11.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">Small molecule inhibitors of histone acetyltransferases and deacetylases are potential drugs for inflammatory diseases</span></div><div class="casAuthors">Dekker, Frank J.; van den Bosch, Thea; Martin, Nathaniel I.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">654-660</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Lysine acetylation is a reversible post-translational modification (PTM) of cellular proteins and represents an important regulatory switch in signal transduction.  Lysine acetylation, in combination with other PTMs, directs the outcomes as well as the activation levels of important signal transduction pathways such as the nuclear factor (NF)-κB pathway.  Small mol. modulators of the 'writers' (HATs) and 'erasers' (HDACs) can regulate the NF-κB pathway in a specific manner.  This review focuses on the effects of frequently used HAT and HDAC inhibitors on the NF-κB signal transduction pathway and inflammatory responses, and their potential as novel therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrmVBCrhkoMsLVg90H21EOLACvtfcHk0likdX4whW6vcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitVWjsrrE&md5=d7d5eb5f350daa449cefd865433d4263</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.11.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.11.012%26sid%3Dliteratum%253Aachs%26aulast%3DDekker%26aufirst%3DF.%2BJ.%26aulast%3Dvan%2Bden%2BBosch%26aufirst%3DT.%26aulast%3DMartin%26aufirst%3DN.%2BI.%26atitle%3DSmall%2520Molecule%2520Inhibitors%2520of%2520Histone%2520Acetyltransferases%2520and%2520Deacetylases%2520Are%2520Potential%2520Drugs%2520for%2520Inflammatory%2520Diseases%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2014%26volume%3D19%26spage%3D654%26epage%3D660%26doi%3D10.1016%2Fj.drudis.2013.11.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Falkenberg, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, R. W.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylases and Their Inhibitors in Cancer, Neurological Diseases and Immune Disorders</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">673</span>– <span class="NLM_lpage">691</span>, <span class="refDoi"> DOI: 10.1038/nrd4360</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fnrd4360" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=25131830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtlKrtLjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=673-691&author=K.+J.+Falkenbergauthor=R.+W.+Johnstone&title=Histone+Deacetylases+and+Their+Inhibitors+in+Cancer%2C+Neurological+Diseases+and+Immune+Disorders&doi=10.1038%2Fnrd4360"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders</span></div><div class="casAuthors">Falkenberg, Katrina J.; Johnstone, Ricky W.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">673-691</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Epigenetic aberrations, which are recognized as key drivers of several human diseases, are often caused by genetic defects that result in functional deregulation of epigenetic proteins, their altered expression and/or their atypical recruitment to certain gene promoters.  Importantly, epigenetic changes are reversible, and epigenetic enzymes and regulatory proteins can be targeted using small mols.  This Review discusses the role of altered expression and/or function of one class of epigenetic regulators - histone deacetylases (HDACs) - and their role in cancer, neurol. diseases and immune disorders.  We highlight the development of small-mol. HDAC inhibitors and their use in the lab., in preclin. models and in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXiWEG49LhebVg90H21EOLACvtfcHk0likdX4whW6vcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtlKrtLjI&md5=ccfb68fa3fd4685e2305cdf8a6a9c81a</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1038%2Fnrd4360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4360%26sid%3Dliteratum%253Aachs%26aulast%3DFalkenberg%26aufirst%3DK.%2BJ.%26aulast%3DJohnstone%26aufirst%3DR.%2BW.%26atitle%3DHistone%2520Deacetylases%2520and%2520Their%2520Inhibitors%2520in%2520Cancer%252C%2520Neurological%2520Diseases%2520and%2520Immune%2520Disorders%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2014%26volume%3D13%26spage%3D673%26epage%3D691%26doi%3D10.1038%2Fnrd4360" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halili, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweet, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlie, D. P.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitors in Inflammatory Disease</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">309</span>– <span class="NLM_lpage">319</span>, <span class="refDoi"> DOI: 10.2174/156802609788085250</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.2174%2F156802609788085250" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=19355993" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntVCitrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=309-319&author=M.+A.+Haliliauthor=M.+R.+Andrewsauthor=M.+J.+Sweetauthor=D.+P.+Fairlie&title=Histone+Deacetylase+Inhibitors+in+Inflammatory+Disease&doi=10.2174%2F156802609788085250"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors in inflammatory disease</span></div><div class="casAuthors">Halili, Maria A.; Andrews, Melanie R.; Sweet, Matthew J.; Fairlie, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">309-319</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Lysine acetylation is becoming increasingly appreciated as a key post-translational modification in the endogenous regulation of protein function.  The so-called histone acetyl transferases (HATs) and histone deacetylases (HDACs), best known for their roles in controlling chromatin remodeling via histone acetylation/deacetylation, are now known to modify a large no. of non-histone proteins to control diverse cell processes.  In relation to inflammation, acetylation modulates the activity or function of cytokine receptors, nuclear hormone receptors, intracellular signaling mols. and transcription factors.  Small mol. inhibitors of HDACs have been found to trigger both pro- and anti-inflammatory effects in a range of inflammation-relevant cell types.  Although their inflammatory profiles have only just begun to be elucidated, some HDAC inhibitors are already showing therapeutic promise in animal models of inflammatory diseases such as arthritis, inflammatory bowel diseases, septic shock, ischemia-reperfusion injury, airways inflammation and asthma, diabetes, age-related macular degeneration, cardiovascular diseases, multiple sclerosis and other CNS and neurodegenerative diseases.  This article describes those HDAC inhibitors which have been most examd. to date for their potentially beneficial effects on inflammatory cells or in animal models of inflammatory disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq22X2Keerbb7Vg90H21EOLACvtfcHk0likdX4whW6vcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntVCitrk%253D&md5=bb262a2ff3ddd73a89a1f865619b5daa</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.2174%2F156802609788085250&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802609788085250%26sid%3Dliteratum%253Aachs%26aulast%3DHalili%26aufirst%3DM.%2BA.%26aulast%3DAndrews%26aufirst%3DM.%2BR.%26aulast%3DSweet%26aufirst%3DM.%2BJ.%26aulast%3DFairlie%26aufirst%3DD.%2BP.%26atitle%3DHistone%2520Deacetylase%2520Inhibitors%2520in%2520Inflammatory%2520Disease%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D309%26epage%3D319%26doi%3D10.2174%2F156802609788085250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shakespear, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halili, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irvine, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlie, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sweet, M. J.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylases as Regulators of Inflammation and Immunity</span>. <i>Trends Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">335</span>– <span class="NLM_lpage">343</span>, <span class="refDoi"> DOI: 10.1016/j.it.2011.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.it.2011.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=21570914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFagt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2011&pages=335-343&author=M.+R.+Shakespearauthor=M.+A.+Haliliauthor=K.+M.+Irvineauthor=D.+P.+Fairlieauthor=M.+J.+Sweet&title=Histone+Deacetylases+as+Regulators+of+Inflammation+and+Immunity&doi=10.1016%2Fj.it.2011.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases as regulators of inflammation and immunity</span></div><div class="casAuthors">Shakespear, Melanie R.; Halili, Maria A.; Irvine, Katharine M.; Fairlie, David P.; Sweet, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Immunology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">335-343</span>CODEN:
                <span class="NLM_cas:coden">TIRMAE</span>;
        ISSN:<span class="NLM_cas:issn">1471-4906</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Histone deacetylases (HDACs) remove an acetyl group from lysine residues of target proteins to regulate cellular processes.  Small-mol. inhibitors of HDACs cause cellular growth arrest, differentiation and/or apoptosis, and some are used clin. as anticancer drugs.  In animal models, HDAC inhibitors are therapeutic for several inflammatory diseases, but exacerbate atherosclerosis and compromise host defense.  Loss of HDAC function has also been linked to chronic lung diseases in humans.  These contrasting effects might reflect distinct roles for individual HDACs in immune responses.  Here, we review the current understanding of innate and adaptive immune pathways that are regulated by classical HDAC enzymes.  The objective is to provide a rationale for targeting (or not targeting) individual HDAC enzymes with inhibitors for future immune-related applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMfUdRVPPTGrVg90H21EOLACvtfcHk0lj8plUnE7kjuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFagt7s%253D&md5=b99eac5fe3487afc612c501162a51fca</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1016%2Fj.it.2011.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.it.2011.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DShakespear%26aufirst%3DM.%2BR.%26aulast%3DHalili%26aufirst%3DM.%2BA.%26aulast%3DIrvine%26aufirst%3DK.%2BM.%26aulast%3DFairlie%26aufirst%3DD.%2BP.%26aulast%3DSweet%26aufirst%3DM.%2BJ.%26atitle%3DHistone%2520Deacetylases%2520as%2520Regulators%2520of%2520Inflammation%2520and%2520Immunity%26jtitle%3DTrends%2520Immunol.%26date%3D2011%26volume%3D32%26spage%3D335%26epage%3D343%26doi%3D10.1016%2Fj.it.2011.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shuttleworth, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, P. A.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase Inhibitors: New Promise in the Treatment of Immune and Inflammatory Diseases</span>. <i>Curr. Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1430</span>– <span class="NLM_lpage">1438</span>, <span class="refDoi"> DOI: 10.2174/1389450111009011430</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.2174%2F1389450111009011430" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=20583972" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVKksbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=1430-1438&author=S.+J.+Shuttleworthauthor=S.+G.+Baileyauthor=P.+A.+Townsend&title=Histone+Deacetylase+Inhibitors%3A+New+Promise+in+the+Treatment+of+Immune+and+Inflammatory+Diseases&doi=10.2174%2F1389450111009011430"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases</span></div><div class="casAuthors">Shuttleworth, Stephen J.; Bailey, Sarah G.; Townsend, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1430-1438</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The development of Histone Deacetylase (HDAC) inhibitors has, until recently, principally been driven by their potential as anti-cancer agents.  However, there is emerging evidence that HDAC inhibitors could have utility in the treatment of chronic immune and inflammatory disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, airway hyperresponsiveness and organ transplant rejection.  Here we discuss the merits of various, structurally-distinct HDAC inhibitors as potential anti-inflammatory therapeutics and provide examples of the novel medicinal chem. approaches being undertaken to realize HDAC as a druggable target in this clin. setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9OetaQ7b8irVg90H21EOLACvtfcHk0lj8plUnE7kjuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVKksbrI&md5=1ac2b5811d59702fea79ffeca1793825</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.2174%2F1389450111009011430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389450111009011430%26sid%3Dliteratum%253Aachs%26aulast%3DShuttleworth%26aufirst%3DS.%2BJ.%26aulast%3DBailey%26aufirst%3DS.%2BG.%26aulast%3DTownsend%26aufirst%3DP.%2BA.%26atitle%3DHistone%2520Deacetylase%2520Inhibitors%253A%2520New%2520Promise%2520in%2520the%2520Treatment%2520of%2520Immune%2520and%2520Inflammatory%2520Diseases%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2010%26volume%3D11%26spage%3D1430%26epage%3D1438%26doi%3D10.2174%2F1389450111009011430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sweet, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shakespear, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamal, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fairlie, D. P.</span></span> <span> </span><span class="NLM_article-title">HDAC Inhibitors: Modulating Leukocyte Differentiation, Survival, Proliferation and Inflammation</span>. <i>Immunol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">14</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1038/icb.2011.88</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Ficb.2011.88" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=22024621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC38Xkslyksw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2012&pages=14-22&author=M.+J.+Sweetauthor=M.+R.+Shakespearauthor=N.+A.+Kamalauthor=D.+P.+Fairlie&title=HDAC+Inhibitors%3A+Modulating+Leukocyte+Differentiation%2C+Survival%2C+Proliferation+and+Inflammation&doi=10.1038%2Ficb.2011.88"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation</span></div><div class="casAuthors">Sweet, Matthew J.; Shakespear, Melanie R.; Kamal, Nabilah A.; Fairlie, David P.</div><div class="citationInfo"><span class="NLM_cas:title">Immunology & Cell Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">14-22</span>CODEN:
                <span class="NLM_cas:coden">ICBIEZ</span>;
        ISSN:<span class="NLM_cas:issn">0818-9641</span>.
    
            (<span class="NLM_cas:orgname">NPG Nature Asia-Pacific</span>)
        </div><div class="casAbstract">A review.  Therapeutic effects of histone deacetylase (HDAC) inhibitors in cancer models were first linked to their ability to cause growth arrest and apoptosis of tumor cells.  It is now clear that these agents also have pleiotropic effects on angiogenesis and the immune system, and some of these properties are likely to contribute to their anti-cancer activities.  It is also emerging that inhibitors of specific HDACs affect the differentiation, survival and/or proliferation of distinct immune cell populations.  This is true for innate immune cells such as macrophages, as well as cells of the acquired immune system, for example, T-regulatory cells.  These effects may contribute to therapeutic profiles in some autoimmune and chronic inflammatory disease models.  Here, we review our current understanding of how classical HDACs (HDACs 1-11) and their inhibitors impact on differentiation, survival and proliferation of distinct leukocyte populations, as well as the likely relevance of these effects to autoimmune and inflammatory disease processes.  The ability of HDAC inhibitors to modulate leukocyte survival may have implications for the rationale of developing selective inhibitors as anti-inflammatory drugs.  Immunol. and Cell Biol. (2012) 90, 14-22; doi:10.1038/icb.2011.88; published online 25 Oct. 2011.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVvbidL66w8bVg90H21EOLACvtfcHk0lj8plUnE7kjuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xkslyksw%253D%253D&md5=32329cded6ac66de08c81342b2551ca3</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1038%2Ficb.2011.88&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Ficb.2011.88%26sid%3Dliteratum%253Aachs%26aulast%3DSweet%26aufirst%3DM.%2BJ.%26aulast%3DShakespear%26aufirst%3DM.%2BR.%26aulast%3DKamal%26aufirst%3DN.%2BA.%26aulast%3DFairlie%26aufirst%3DD.%2BP.%26atitle%3DHDAC%2520Inhibitors%253A%2520Modulating%2520Leukocyte%2520Differentiation%252C%2520Survival%252C%2520Proliferation%2520and%2520Inflammation%26jtitle%3DImmunol.%2520Cell%2520Biol.%26date%3D2012%26volume%3D90%26spage%3D14%26epage%3D22%26doi%3D10.1038%2Ficb.2011.88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurkoff, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyeth, B. G.</span></span> <span> </span><span class="NLM_article-title">HDAC Inhibitor Increases Histone H3 Acetylation and Reduces Microglia Inflammatory Response Following Traumatic Brain Injury in Rats</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>1226</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">191</span>, <span class="refDoi"> DOI: 10.1016/j.brainres.2008.05.085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.brainres.2008.05.085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=18582446" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpvFGmtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1226&publication_year=2008&pages=181-191&author=B.+Zhangauthor=E.+J.+Westauthor=K.+C.+Vanauthor=G.+G.+Gurkoffauthor=J.+Zhouauthor=X.-M.+Zhangauthor=A.+P.+Kozikowskiauthor=B.+G.+Lyeth&title=HDAC+Inhibitor+Increases+Histone+H3+Acetylation+and+Reduces+Microglia+Inflammatory+Response+Following+Traumatic+Brain+Injury+in+Rats&doi=10.1016%2Fj.brainres.2008.05.085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in rats</span></div><div class="casAuthors">Zhang, Bin; West, Eric J.; Van, Ken C.; Gurkoff, Gene G.; Zhou, Jia; Zhang, Xiu-Mei; Kozikowski, Alan P.; Lyeth, Bruce G.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">1226</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">181-191</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Traumatic brain injury (TBI) produces a rapid and robust inflammatory response in the brain characterized in part by activation of microglia.  A novel histone deacetylase (HDAC) inhibitor, 4-dimethylamino-N-[5-(2-mercaptoacetylamino)pentyl]benzamide (DMA-PB), was administered (0, 0.25, 2.5, 25 mg/kg) systemically immediately after lateral fluid percussion TBI in rats.  Hippocampal CA2/3 tissue was processed for acetyl-histone H3 immunolocalization, OX-42 immunolocalization (for microglia), and Fluoro-Jade B histofluorescence (for degenerating neurons) at 24 h after injury.  Vehicle-treated TBI rats exhibited a significant redn. in acetyl-histone H3 immunostaining in the ipsilateral CA2/3 hippocampus compared to the sham TBI group (p < 0.05).  The redn. in acetyl-histone H3 immunostaining was attenuated by each of the DMA-PB dosage treatment groups.  Vehicle-treated TBI rats exhibited a high d. of phagocytic microglia in the ipsilateral CA2/3 hippocampus compared to sham TBI in which none were obsd.  All doses of DMA-PB significantly reduced the d. of phagocytic microglia (p < 0.05).  There was a trend for DMA-PB to reduce the no. of degenerating neurons in the ipsilateral CA2/3 hippocampus (p = 0.076).  We conclude that the HDAC inhibitor DMA-PB is a potential novel therapeutic for inhibiting neuroinflammation assocd. with TBI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-KbF3LWteNbVg90H21EOLACvtfcHk0lgHd8GyDEEFYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpvFGmtr0%253D&md5=7467685a308c64c9d9e4b44cd4c88331</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2008.05.085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2008.05.085%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DWest%26aufirst%3DE.%2BJ.%26aulast%3DVan%26aufirst%3DK.%2BC.%26aulast%3DGurkoff%26aufirst%3DG.%2BG.%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DX.-M.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26aulast%3DLyeth%26aufirst%3DB.%2BG.%26atitle%3DHDAC%2520Inhibitor%2520Increases%2520Histone%2520H3%2520Acetylation%2520and%2520Reduces%2520Microglia%2520Inflammatory%2520Response%2520Following%2520Traumatic%2520Brain%2520Injury%2520in%2520Rats%26jtitle%3DBrain%2520Res.%26date%3D2008%26volume%3D1226%26spage%3D181%26epage%3D191%26doi%3D10.1016%2Fj.brainres.2008.05.085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stazi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fioravanti, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattevi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valente, S.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylases as an Epigenetic Pillar for the Development of Hybrid Inhibitors in Cancer</span>. <i>Curr. Opin. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">89</span>– <span class="NLM_lpage">100</span>, <span class="refDoi"> DOI: 10.1016/j.cbpa.2019.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.cbpa.2019.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=30986654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnsFSgsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2019&pages=89-100&author=G.+Staziauthor=R.+Fioravantiauthor=A.+Maiauthor=A.+Matteviauthor=S.+Valente&title=Histone+Deacetylases+as+an+Epigenetic+Pillar+for+the+Development+of+Hybrid+Inhibitors+in+Cancer&doi=10.1016%2Fj.cbpa.2019.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Histone deacetylases as an epigenetic pillar for the development of hybrid inhibitors in cancer</span></div><div class="casAuthors">Stazi, Giulia; Fioravanti, Rossella; Mai, Antonello; Mattevi, Andrea; Valente, Sergio</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">89-100</span>CODEN:
                <span class="NLM_cas:coden">COCBF4</span>;
        ISSN:<span class="NLM_cas:issn">1367-5931</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The polypharmacol. strategy of multi-targeting drugs acting on different biol. pathways is capturing the researchers' attention, particularly in cancer.  The simultaneous inhibition of two or more targets by drug combination or by a single 'hybrid mol.' can provide improved therapeutic efficacy when compared to the one-target inhibitors.  In this regard, because of their multiple anticancer effects, histone deacetylase inhibitors have become a privileged tool for the development of hybrid drugs.  The clin. trials of two multi-acting chimeras, HDAC/EGFR/HER2 and HDAC/PI3K inhibitors, encouraged the design of novel hybrids, such as compds. 22a (LSD1/HDAC) and 16a (CDK4/JAK1/HDAC), which showed superior anticancer effects than single-targeting agents or their combination both in cellular and mouse models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDkcMKMsqtjLVg90H21EOLACvtfcHk0lgHd8GyDEEFYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnsFSgsb4%253D&md5=8233a35ccdd5db5fd4c1d5dfdc3958b7</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1016%2Fj.cbpa.2019.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cbpa.2019.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DStazi%26aufirst%3DG.%26aulast%3DFioravanti%26aufirst%3DR.%26aulast%3DMai%26aufirst%3DA.%26aulast%3DMattevi%26aufirst%3DA.%26aulast%3DValente%26aufirst%3DS.%26atitle%3DHistone%2520Deacetylases%2520as%2520an%2520Epigenetic%2520Pillar%2520for%2520the%2520Development%2520of%2520Hybrid%2520Inhibitors%2520in%2520Cancer%26jtitle%3DCurr.%2520Opin.%2520Chem.%2520Biol.%26date%3D2019%26volume%3D50%26spage%3D89%26epage%3D100%26doi%3D10.1016%2Fj.cbpa.2019.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hesham, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasheen, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abouzid, K. A. M.</span></span> <span> </span><span class="NLM_article-title">Chimeric HDAC Inhibitors: Comprehensive Review on the HDAC-Based Strategies Developed to Combat Cancer</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">2058</span>– <span class="NLM_lpage">2109</span>, <span class="refDoi"> DOI: 10.1002/med.21505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1002%2Fmed.21505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=29733427" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BC1MfgsV2htQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2018&pages=2058-2109&author=H.+M.+Heshamauthor=D.+S.+Lasheenauthor=K.+A.+M.+Abouzid&title=Chimeric+HDAC+Inhibitors%3A+Comprehensive+Review+on+the+HDAC-Based+Strategies+Developed+to+Combat+Cancer&doi=10.1002%2Fmed.21505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">Chimeric HDAC inhibitors: Comprehensive review on the HDAC-based strategies developed to combat cancer</span></div><div class="casAuthors">Hesham Heba M; Lasheen Deena S; Abouzid Khaled A M</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal research reviews</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2058-2109</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Recently, molecular hybridization paradigm became an interesting and smart way to defeat the multifaceted cancer disease by a single molecular entity that acts via several mechanisms just like a magic bullet.  Also, HDAC is an important epigenetic target in drug discovery, and the HDAC inhibitors showed successful pattern as cytotoxic agents.  Because of their flexible structure activity relationship, it was easy to link them to other anticancer scaffolds.  So, many dual action HDAC inhibitors have been developed and most of these hybrids have higher potency than the constituting parents in fighting of the cancer cells.  This review describes potential applications of chimeric HDAC inhibitors, which simultaneously modulate not only HDAC but also multiple targets, in treatment of relapsing and drug-resistant cancers.  We have nearly collected most of the reported dual action HDAC inhibitors yet to provide a comprehensive guide for the drug discovery process for developing more efficient anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT7h5aD28C1RtbHMBt0mMIXfW6udTcc2ebzMqEcFpnWorntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MfgsV2htQ%253D%253D&md5=c935014e94bf04c21eafbcb2f8ef8218</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1002%2Fmed.21505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21505%26sid%3Dliteratum%253Aachs%26aulast%3DHesham%26aufirst%3DH.%2BM.%26aulast%3DLasheen%26aufirst%3DD.%2BS.%26aulast%3DAbouzid%26aufirst%3DK.%2BA.%2BM.%26atitle%3DChimeric%2520HDAC%2520Inhibitors%253A%2520Comprehensive%2520Review%2520on%2520the%2520HDAC-Based%2520Strategies%2520Developed%2520to%2520Combat%2520Cancer%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2018%26volume%3D38%26spage%3D2058%26epage%3D2109%26doi%3D10.1002%2Fmed.21505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Taliani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Da Settimo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laneri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novellino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greco, G.</span></span> <span> </span><span class="NLM_article-title">Exploiting the Indole Scaffold to Design Compounds Binding to Different Pharmacological Targets</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">2331</span>, <span class="refDoi"> DOI: 10.3390/molecules25102331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3390%2Fmolecules25102331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtFOksbvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&pages=2331&author=S.+Talianiauthor=F.+Da+Settimoauthor=C.+Martiniauthor=S.+Laneriauthor=E.+Novellinoauthor=G.+Greco&title=Exploiting+the+Indole+Scaffold+to+Design+Compounds+Binding+to+Different+Pharmacological+Targets&doi=10.3390%2Fmolecules25102331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit142R"><div class="casContent"><span class="casTitleNuber">142</span><div class="casTitle"><span class="NLM_cas:atitle">Exploiting the indole scaffold to design compounds binding to different pharmacological targets</span></div><div class="casAuthors">Taliani, Sabrina; Da Settimo, Federico; Martini, Claudia; Laneri, Sonia; Novellino, Ettore; Greco, Giovanni</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2331</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  Several indole derivs. have been disclosed by our research groups that have been collaborating for nearly 25 years.  The results of our investigations led to a variety of mols. binding selectively to different pharmacol. targets, specifically the type A γ-aminobutyric acid (GABAA) chloride channel, the translocator protein (TSPO), the murine double minute 2 (MDM2) protein, the A2B adenosine receptor (A2B AR) and the Kelch-like ECH-assocd. protein 1 (Keap1).  Herein, we describe how these works were conceived and carried out thanks to the versatility of indole nucleus to be exploited in the design and synthesis of drug-like mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvnxFInRwDvLVg90H21EOLACvtfcHk0lh3_5q754JBBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtFOksbvF&md5=ddf9af0ccb4cb8ab324863b70eed8be6</span></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.3390%2Fmolecules25102331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules25102331%26sid%3Dliteratum%253Aachs%26aulast%3DTaliani%26aufirst%3DS.%26aulast%3DDa%2BSettimo%26aufirst%3DF.%26aulast%3DMartini%26aufirst%3DC.%26aulast%3DLaneri%26aufirst%3DS.%26aulast%3DNovellino%26aufirst%3DE.%26aulast%3DGreco%26aufirst%3DG.%26atitle%3DExploiting%2520the%2520Indole%2520Scaffold%2520to%2520Design%2520Compounds%2520Binding%2520to%2520Different%2520Pharmacological%2520Targets%26jtitle%3DMolecules%26date%3D2020%26volume%3D25%26spage%3D2331%26doi%3D10.3390%2Fmolecules25102331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cincinelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musso, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuco, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Cesare, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zunino, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dallavalle, S.</span></span> <span> </span><span class="NLM_article-title">Influence of the Adamantyl Moiety on the Activity of Biphenylacrylohydroxamic Acid-Based HDAC Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>79</i></span>,  <span class="NLM_fpage">251</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2014.04.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2014.04.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=24742384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2cXnsFWns78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2014&pages=251-259&author=R.+Cincinelliauthor=L.+Mussoauthor=G.+Gianniniauthor=V.+Zucoauthor=M.+De+Cesareauthor=F.+Zuninoauthor=S.+Dallavalle&title=Influence+of+the+Adamantyl+Moiety+on+the+Activity+of+Biphenylacrylohydroxamic+Acid-Based+HDAC+Inhibitors&doi=10.1016%2Fj.ejmech.2014.04.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors</span></div><div class="casAuthors">Cincinelli, Raffaella; Musso, Loana; Giannini, Giuseppe; Zuco, Valentina; De Cesare, Michelandrea; Zunino, Franco; Dallavalle, Sabrina</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">251-259</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">To investigate the influence of the adamantyl group on the biol. properties of known HDAC inhibitors with a 4-phenylcinnamic skeleton, a series of compds. having the adamantyl moiety in the cap structure were synthesized and compared to the corresponding hydroxamic acids lacking this group.  An unexpected finding was the substantial redn. of inhibitory activity toward the tested enzymes, in particular HDAC6, following the introduction of the adamantyl group.  In spite of the reduced ability to function as HDAC inhibitors, the compds. contg. the adamantyl moiety still retained a good efficacy as antiproliferative and proapoptotic agents.  A selected compd. (2c; ST3056) of this series exhibited an appreciable antitumor activity against the colon carcinoma xenograft HCT116.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzJLw2Q-7h1LVg90H21EOLACvtfcHk0lh3_5q754JBBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXnsFWns78%253D&md5=537039564ff230efc704ba246544cbc0</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2014.04.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2014.04.021%26sid%3Dliteratum%253Aachs%26aulast%3DCincinelli%26aufirst%3DR.%26aulast%3DMusso%26aufirst%3DL.%26aulast%3DGiannini%26aufirst%3DG.%26aulast%3DZuco%26aufirst%3DV.%26aulast%3DDe%2BCesare%26aufirst%3DM.%26aulast%3DZunino%26aufirst%3DF.%26aulast%3DDallavalle%26aufirst%3DS.%26atitle%3DInfluence%2520of%2520the%2520Adamantyl%2520Moiety%2520on%2520the%2520Activity%2520of%2520Biphenylacrylohydroxamic%2520Acid-Based%2520HDAC%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2014%26volume%3D79%26spage%3D251%26epage%3D259%26doi%3D10.1016%2Fj.ejmech.2014.04.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gopalan, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponpandian, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kachhadia, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bharathimohan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vignesh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sivasudar, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Praveen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saranya, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajagopal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajagopal, S.</span></span> <span> </span><span class="NLM_article-title">Discovery of Adamantane Based Highly Potent HDAC Inhibitors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2532</span>– <span class="NLM_lpage">2537</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmcl.2013.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=23538115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3sXks1Sisr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=2532-2537&author=B.+Gopalanauthor=T.+Ponpandianauthor=V.+Kachhadiaauthor=K.+Bharathimohanauthor=R.+Vigneshauthor=V.+Sivasudarauthor=S.+Narayananauthor=B.+Mandarauthor=R.+Praveenauthor=N.+Saranyaauthor=S.+Rajagopalauthor=S.+Rajagopal&title=Discovery+of+Adamantane+Based+Highly+Potent+HDAC+Inhibitors&doi=10.1016%2Fj.bmcl.2013.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of adamantane based highly potent HDAC inhibitors</span></div><div class="casAuthors">Gopalan, Balasubramanian; Ponpandian, Thanasekaran; Kachhadia, Virendra; Bharathimohan, Kuppusamy; Vignesh, Radhakrishnan; Sivasudar, Velaiah; Narayanan, Shridhar; Mandar, Bhonde; Praveen, Rajendran; Saranya, Nithyanandan; Rajagopal, Sriram; Rajagopal, Sridharan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2532-2537</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein, we report the development of highly potent HDAC (histone deacetylases) inhibitors for the treatment of cancer.  A series of adamantane and noradamantane based HDAC inhibitors were designed, synthesized and screened for the inhibitory activity of HDAC.  A no. of compds. exhibited GI50 of 10-100 nM in human HCT116, NCI-H460 and U251 cancer cells, in vitro.  Compd. I displays efficacy in human tumor animal xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNOU_JBIr18bVg90H21EOLACvtfcHk0lh3_5q754JBBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXks1Sisr4%253D&md5=24b3eb5233a6b27e5154713824e74d62</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DGopalan%26aufirst%3DB.%26aulast%3DPonpandian%26aufirst%3DT.%26aulast%3DKachhadia%26aufirst%3DV.%26aulast%3DBharathimohan%26aufirst%3DK.%26aulast%3DVignesh%26aufirst%3DR.%26aulast%3DSivasudar%26aufirst%3DV.%26aulast%3DNarayanan%26aufirst%3DS.%26aulast%3DMandar%26aufirst%3DB.%26aulast%3DPraveen%26aufirst%3DR.%26aulast%3DSaranya%26aufirst%3DN.%26aulast%3DRajagopal%26aufirst%3DS.%26aulast%3DRajagopal%26aufirst%3DS.%26atitle%3DDiscovery%2520of%2520Adamantane%2520Based%2520Highly%2520Potent%2520HDAC%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D2532%26epage%3D2537%26doi%3D10.1016%2Fj.bmcl.2013.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin-Fardon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romieu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, R. R.</span></span> <span> </span><span class="NLM_article-title">Sigma1 (σ<sub>1</sub>) Receptor Antagonists Represent a New Strategy against Cocaine Addiction and Toxicity</span>. <i>Neurosci. Biobehav. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">527</span>, <span class="refDoi"> DOI: 10.1016/S0149-7634(02)00017-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2FS0149-7634%2802%2900017-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=12204195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD38XmsVerurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2002&pages=499-527&author=T.+Mauriceauthor=R.+Martin-Fardonauthor=P.+Romieuauthor=R.+R.+Matsumoto&title=Sigma1+%28%CF%831%29+Receptor+Antagonists+Represent+a+New+Strategy+against+Cocaine+Addiction+and+Toxicity&doi=10.1016%2FS0149-7634%2802%2900017-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma1 (σ1) receptor antagonists represent a new strategy against cocaine addiction and toxicity</span></div><div class="casAuthors">Maurice, Tangui; Martin-Fardon, Remi; Romieu, Pascal; Matsumoto, Rae R.</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience and Biobehavioral Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">499-527</span>CODEN:
                <span class="NLM_cas:coden">NBREDE</span>;
        ISSN:<span class="NLM_cas:issn">0149-7634</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Cocaine is a highly addictive substance abused worldwide.  Its mechanism of action involves initially inhibition of neuronal monoamine transporters in precise brain structures and primarily the dopamine reuptake system located on mesolimbic neurons.  Cocaine rapidly increases the dopaminergic neurotransmission and triggers adaptive changes in numerous neuronal circuits underlying reinforcement, reward, sensitization and the high addictive potential of cocaine.  Current therapeutic strategies focus on counteracting the cocaine effects directly on the dopamine transporter, through post-synaptic D1, D2 or D3 receptors or through the glutamatergic, serotoninergic, opioid or corticotropin-releasing hormone systems.  However, cocaine administration also results in the activation of numerous particular targets.  Among them, the sigma1 (σ1) receptor is involved in several acute or chronic effects of cocaine.  The present review will first bring concise overviews of the present strategies followed to alleviate cocaine addiction and animal models developed to analyze the pharmacol. of cocaine addiction.  Evidence involving activation of the σ1 receptor in the different aspects of cocaine abuse, will then be detailed, following acute, repeated, or overdose administration.  The therapeutic potentials and neuropharmacol. perspectives opened by the use of selective σ1 receptor antagonists in cocaine addiction will finally be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqmpOYpzQ3t7Vg90H21EOLACvtfcHk0lhbexydl8IWBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XmsVerurc%253D&md5=18192324720fbfe288fb39842f370a83</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.1016%2FS0149-7634%2802%2900017-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0149-7634%252802%252900017-9%26sid%3Dliteratum%253Aachs%26aulast%3DMaurice%26aufirst%3DT.%26aulast%3DMartin-Fardon%26aufirst%3DR.%26aulast%3DRomieu%26aufirst%3DP.%26aulast%3DMatsumoto%26aufirst%3DR.%2BR.%26atitle%3DSigma1%2520%2528%25CF%25831%2529%2520Receptor%2520Antagonists%2520Represent%2520a%2520New%2520Strategy%2520against%2520Cocaine%2520Addiction%2520and%2520Toxicity%26jtitle%3DNeurosci.%2520Biobehav.%2520Rev.%26date%3D2002%26volume%3D26%26spage%3D499%26epage%3D527%26doi%3D10.1016%2FS0149-7634%2802%2900017-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weng, T.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, S.-Y. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T.-P.</span></span> <span> </span><span class="NLM_article-title">Roles of Sigma-1 Receptors on Mitochondrial Functions Relevant to Neurodegenerative Diseases</span>. <i>J. Biomed. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">74</span>, <span class="refDoi"> DOI: 10.1186/s12929-017-0380-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1186%2Fs12929-017-0380-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=28917260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVOjsrjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=74&author=T.-Y.+Wengauthor=S.-Y.+A.+Tsaiauthor=T.-P.+Su&title=Roles+of+Sigma-1+Receptors+on+Mitochondrial+Functions+Relevant+to+Neurodegenerative+Diseases&doi=10.1186%2Fs12929-017-0380-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Roles of sigma-1 receptors on mitochondrial functions relevant to neurodegenerative diseases</span></div><div class="casAuthors">Weng, Tzu-Yu; Tsai, Shang-Yi Anne; Su, Tsung-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomedical Science (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">74/1-74/14</span>CODEN:
                <span class="NLM_cas:coden">JBCIEA</span>;
        ISSN:<span class="NLM_cas:issn">1423-0127</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">The sigma-1 receptor (Sig-1R) is a chaperone that resides mainly at the mitochondrion-assocd. endoplasmic reticulum (ER) membrane (called the MAMs) and acts as a dynamic pluripotent modulator in living systems.  At the MAM, the Sig-1R is known to play a role in regulating the Ca2+ signaling between ER and mitochondria and in maintaining the structural integrity of the MAM.  The MAM serves as bridges between ER and mitochondria regulating multiple functions such as Ca2+ transfer, energy exchange, lipid synthesis and transports, and protein folding that are pivotal to cell survival and defense.  Recently, emerging evidences indicate that the MAM is crit. in maintaining neuronal homeostasis.  Thus, given the specific localization of the Sig-1R at the MAM, we highlight and propose that the direct or indirect regulations of the Sig-1R on mitochondrial functions may relate to neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS).  In addn., the promising use of Sig-1R ligands to rescue mitochondrial dysfunction-induced neurodegeneration is addressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqomRZwYzYR6bVg90H21EOLACvtfcHk0lhbexydl8IWBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVOjsrjN&md5=53d2f910e875935072543cfb0b277497</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1186%2Fs12929-017-0380-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12929-017-0380-6%26sid%3Dliteratum%253Aachs%26aulast%3DWeng%26aufirst%3DT.-Y.%26aulast%3DTsai%26aufirst%3DS.-Y.%2BA.%26aulast%3DSu%26aufirst%3DT.-P.%26atitle%3DRoles%2520of%2520Sigma-1%2520Receptors%2520on%2520Mitochondrial%2520Functions%2520Relevant%2520to%2520Neurodegenerative%2520Diseases%26jtitle%3DJ.%2520Biomed.%2520Sci.%26date%3D2017%26volume%3D24%26spage%3D74%26doi%3D10.1186%2Fs12929-017-0380-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glennon, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ablordeppey, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismaiel, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">El-Ashmawy, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howie, K. B.</span></span> <span> </span><span class="NLM_article-title">Structural Features Important for σ<sub>1</sub> Receptor Binding</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1214</span>– <span class="NLM_lpage">1219</span>, <span class="refDoi"> DOI: 10.1021/jm00034a020</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00034a020" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADyaK2cXksV2lsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=1214-1219&author=R.+A.+Glennonauthor=S.+Y.+Ablordeppeyauthor=A.+M.+Ismaielauthor=M.+B.+El-Ashmawyauthor=J.+B.+Fischerauthor=K.+B.+Howie&title=Structural+Features+Important+for+%CF%831+Receptor+Binding&doi=10.1021%2Fjm00034a020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Features Important for σ1 Receptor Binding</span></div><div class="casAuthors">Glennon, Richard A.; Ablordeppey, Seth Y.; Ismaiel, Abd M.; El-Ashmawy, Mahmoud B.; Fischer, James B.; Howie, Kathleen Burke</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1214-19</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Two problems that have hampered σ receptor research are a lack of high-affinity agents and the recent identification of multiple populations of σ receptors (i.e., σ1 and σ2 sites).  Recently, several high-affinity σ ligands have been identified, and the term superpotent σ ligands has been coined to describe agents with Ki values of <1 nM.  It was previously shown that appropriately N-substituted phenylalkylamines bind at σ receptors with high affinity.  The structure-affinity relationships of these phenylalkylamine derivs. for σ1 binding are examd. and some of the first superpotent σ1 ligands described.  A binding model was developed to account for the structural features of the phenylalkylamines that appear to be important for the interaction of these agents with σ1 sites.  Some of the amines were prepd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6nnZHspQ0MLVg90H21EOLACvtfcHk0lhbexydl8IWBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXksV2lsrY%253D&md5=3c9b4ff203d7c304da3779a874837bf5</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1021%2Fjm00034a020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00034a020%26sid%3Dliteratum%253Aachs%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26aulast%3DAblordeppey%26aufirst%3DS.%2BY.%26aulast%3DIsmaiel%26aufirst%3DA.%2BM.%26aulast%3DEl-Ashmawy%26aufirst%3DM.%2BB.%26aulast%3DFischer%26aufirst%3DJ.%2BB.%26aulast%3DHowie%26aufirst%3DK.%2BB.%26atitle%3DStructural%2520Features%2520Important%2520for%2520%25CF%25831%2520Receptor%2520Binding%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26spage%3D1214%26epage%3D1219%26doi%3D10.1021%2Fjm00034a020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span> <span> </span><span class="NLM_article-title">Is the σ<sub>2</sub> Receptor a Histone Binding Protein?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">4153</span>– <span class="NLM_lpage">4158</span>, <span class="refDoi"> DOI: 10.1021/jm0600592</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm0600592" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFentrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=4153-4158&author=N.+A.+Colabufoauthor=F.+Berardiauthor=C.+Abateauthor=M.+Continoauthor=M.+Nisoauthor=R.+Perrone&title=Is+the+%CF%832+Receptor+a+Histone+Binding+Protein%3F&doi=10.1021%2Fjm0600592"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Is the σ2 Receptor a Histone Binding Protein?</span></div><div class="casAuthors">Colabufo, Nicola Antonio; Berardi, Francesco; Abate, Carmen; Contino, Marialessandra; Niso, Mauro; Perrone, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4153-4158</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Starting from the high affinity σ2 receptor ligand 2, (PB28), we synthesized amino deriv. 4 and coupled it to an NHS-ester activated sepharose stationary phase column to elute a crude protein prepd. by lysed human SK-N-SH neuroblastoma cells.  We characterized the SDS-PAGE gel electrophoresis stained bands by MALDI-MS and LC-MS-MS anal.  The MASCOT MS-MS ion search program led to the identification of the protein components.  The six eluted proteins had a mol. wt. ranging from 13 kDa to 26 kDa and were human histone proteins.  A human 40S ribosomal protein S3 (SwissProt accession no.: P23396) was also identified as a comigrated band.  The human histone proteins that were characterized were H3.3A histone (NCBI accession no.: 51859376), H2B histone (NCBI accession no.:1568557), H2A.5 histone (NCBI accession no.: 70686), H1 (NCBI accession no.: 22770677), and H2.1 histone (SwissProt accession no.:P16403).  These results disclosed a dual hypothesis about the σ2 receptor, i.e., that it is formed by histones or that the σ2 ligands also bind histone proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfoEbIIW3bKbVg90H21EOLACvtfcHk0li5KOwoOby91w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFentrY%253D&md5=e9c456f40e43e9bc8203588e6e7662d2</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1021%2Fjm0600592&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0600592%26sid%3Dliteratum%253Aachs%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DContino%26aufirst%3DM.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DPerrone%26aufirst%3DR.%26atitle%3DIs%2520the%2520%25CF%25832%2520Receptor%2520a%2520Histone%2520Binding%2520Protein%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D4153%26epage%3D4158%26doi%3D10.1021%2Fjm0600592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elenewski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azzariti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glennon, R. A.</span></span> <span> </span><span class="NLM_article-title">Interaction of the σ2 Receptor Ligand PB28 with the Human Nucleosome: Computational and Experimental Probes of Interaction with the H2A/H2B Dimer</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">268</span>– <span class="NLM_lpage">273</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200900402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1002%2Fcmdc.200900402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=20077462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtl2ntr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=268-273&author=C.+Abateauthor=J.+Elenewskiauthor=M.+Nisoauthor=F.+Berardiauthor=N.+A.+Colabufoauthor=A.+Azzaritiauthor=R.+Perroneauthor=R.+A.+Glennon&title=Interaction+of+the+%CF%832+Receptor+Ligand+PB28+with+the+Human+Nucleosome%3A+Computational+and+Experimental+Probes+of+Interaction+with+the+H2A%2FH2B+Dimer&doi=10.1002%2Fcmdc.200900402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of the σ2 Receptor Ligand PB28 with the Human Nucleosome: Computational and Experimental Probes of Interaction with the H2A/H2B Dimer</span></div><div class="casAuthors">Abate, Carmen; Elenewski, Justin; Niso, Mauro; Berardi, Francesco; Colabufo, Nicola Antonio; Azzariti, Amalia; Perrone, Roberto; Glennon, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">268-273</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Sigma-2 (σ2) binding sites are an emerging target for anti-neoplastic agents due to the strong apoptotic effect exhibited by σ2 agonists in vitro and the overexpression of these sites in tumor cells.  Nonetheless, no σ2 receptor protein has been identified.  Affinity chromatog. using the high-affinity σ2 ligand PB28 and human SK-N-SH neuroblastoma cells was previously utilized to identify σ2 ligand binding proteins, specifically histones H1, H2A, H2B, and H3.3a.  To rationalize this finding, homol. modeling and automated docking studies were employed to probe intermol. interactions between PB28 and human nucleosomal proteins.  These studies predicted interaction of PB28 with the H2A/H2B dimer at a series of sites previously implicated in chromatin compaction and nucleosomal assembly.  To exptl. verify this prediction, a competitive binding assay was performed on the reconstituted H2A/H2B dimer using [3H]PB28 as radioligand, and an IC50 value of 0.50 nM was detd. for PB28 binding.  In addn., [3H]PB28 was found to accumulate with up to a fivefold excess in nuclear fractions over cytosolic fractions of SK-N-SH and MCF7 cells, indicating that PB28 is capable of entering the nucleus to interact with histone proteins.  In conjunction with computational results, these data suggest that PB28 may exert its cytotoxic effect through direct interaction with nuclear material.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkk6FOeqP6z7Vg90H21EOLACvtfcHk0li5KOwoOby91w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtl2ntr4%253D&md5=34320626eb0e20f03b814697c5ee59b0</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200900402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200900402%26sid%3Dliteratum%253Aachs%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DElenewski%26aufirst%3DJ.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DAzzariti%26aufirst%3DA.%26aulast%3DPerrone%26aufirst%3DR.%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26atitle%3DInteraction%2520of%2520the%2520%25CF%25832%2520Receptor%2520Ligand%2520PB28%2520with%2520the%2520Human%2520Nucleosome%253A%2520Computational%2520and%2520Experimental%2520Probes%2520of%2520Interaction%2520with%2520the%2520H2A%252FH2B%2520Dimer%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26spage%3D268%26epage%3D273%26doi%3D10.1002%2Fcmdc.200900402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothfuss, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangveravong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotchkiss, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Identification of the PGRMC1 Protein Complex as the Putative Sigma-2 Receptor Binding Site</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">380</span>– <span class="NLM_lpage">387</span>, <span class="refDoi"> DOI: 10.1038/ncomms1386</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fncomms1386" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=21730960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BC3MnlvVKgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=380-387&author=J.+Xuauthor=C.+Zengauthor=W.+Chuauthor=F.+Panauthor=J.+M.+Rothfussauthor=F.+Zhangauthor=Z.+Tuauthor=D.+Zhouauthor=D.+Zengauthor=S.+Vangveravongauthor=F.+Johnstonauthor=D.+Spitzerauthor=K.+C.+Changauthor=R.+S.+Hotchkissauthor=W.+G.+Hawkinsauthor=K.+T.+Wheelerauthor=R.+H.+Mach&title=Identification+of+the+PGRMC1+Protein+Complex+as+the+Putative+Sigma-2+Receptor+Binding+Site&doi=10.1038%2Fncomms1386"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site</span></div><div class="casAuthors">Xu Jinbin; Zeng Chenbo; Chu Wenhua; Pan Fenghui; Rothfuss Justin M; Zhang Fanjie; Tu Zhude; Zhou Dong; Zeng Dexing; Vangveravong Suwanna; Johnston Fabian; Spitzer Dirk; Chang Katherine C; Hotchkiss Richard S; Hawkins William G; Wheeler Kenneth T; Mach Robert H</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">380</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The sigma-2 receptor, whose gene remains to be cloned, has been validated as a biomarker for tumour cell proliferation.  Here we report the use of a novel photoaffinity probe, WC-21, to identify the sigma-2 receptor-binding site.  WC-21, a sigma-2 ligand containing both a photoactive azide moiety and a fluorescein isothiocyanate group, irreversibly labels sigma-2 receptors in rat liver; the membrane-bound protein was identified as PGRMC1 (progesterone receptor membrane component 1).  Immunocytochemistry reveals that both PGRMC1 and SW120, a fluorescent sigma-2 receptor ligand, colocalize with molecular markers of the endoplasmic reticulum and mitochondria in HeLa cells.  Overexpression and knockdown of the PGRMC1 protein results in an increase and a decrease in binding of a sigma-2 selective radioligand, respectively.  The identification of the putative sigma-2 receptor-binding site as PGRMC1 should stimulate the development of unique imaging agents and cancer therapeutics that target the sigma-2 receptor/PGRMC1 complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKpNfsa0DIvIJKJbLTgsvCfW6udTcc2ebj9rf67cS-tLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MnlvVKgtQ%253D%253D&md5=46675c07c87eccab091f8a8ec0f12db6</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1038%2Fncomms1386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms1386%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DChu%26aufirst%3DW.%26aulast%3DPan%26aufirst%3DF.%26aulast%3DRothfuss%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DZeng%26aufirst%3DD.%26aulast%3DVangveravong%26aufirst%3DS.%26aulast%3DJohnston%26aufirst%3DF.%26aulast%3DSpitzer%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DK.%2BC.%26aulast%3DHotchkiss%26aufirst%3DR.%2BS.%26aulast%3DHawkins%26aufirst%3DW.%2BG.%26aulast%3DWheeler%26aufirst%3DK.%2BT.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DIdentification%2520of%2520the%2520PGRMC1%2520Protein%2520Complex%2520as%2520the%2520Putative%2520Sigma-2%2520Receptor%2520Binding%2520Site%26jtitle%3DNat.%2520Commun.%26date%3D2011%26volume%3D2%26spage%3D380%26epage%3D387%26doi%3D10.1038%2Fncomms1386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahn, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span> <span> </span><span class="NLM_article-title">Identification of the Gene That Codes for the σ<sub>2</sub> Receptor</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">7160</span>– <span class="NLM_lpage">7165</span>, <span class="refDoi"> DOI: 10.1073/pnas.1705154114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1073%2Fpnas.1705154114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=28559337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovVSisrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=7160-7165&author=A.+Alonauthor=H.+R.+Schmidtauthor=M.+D.+Woodauthor=J.+J.+Sahnauthor=S.+F.+Martinauthor=A.+C.+Kruse&title=Identification+of+the+Gene+That+Codes+for+the+%CF%832+Receptor&doi=10.1073%2Fpnas.1705154114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the gene that codes for the σ2 receptor</span></div><div class="casAuthors">Alon, Assaf; Schmidt, Hayden R.; Wood, Michael D.; Sahn, James J.; Martin, Stephen F.; Kruse, Andrew C.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">7160-7165</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The σ2 receptor is an enigmatic protein that has attracted significant attention because of its involvement in diseases as diverse as cancer and neurol. disorders.  Unlike virtually all other receptors of medical interest, it has eluded mol. cloning since its discovery, and the gene that codes for the receptor remains unknown, precluding the use of modern biol. methods to study its function.  Using a chem. biol. approach, we purified the σ2 receptor from tissue, revealing its identity as TMEM97, an endoplasmic reticulum-resident transmembrane protein that regulates the sterol transporter NPC1.  We show that TMEM97 possesses the full suite of mol. properties that define the σ2 receptor, and we identify Asp29 and Asp56 as essential for ligand recognition.  Cloning the σ2 receptor resolves a longstanding mystery and will enable therapeutic targeting of this potential drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsoAS9Q6KtY7Vg90H21EOLACvtfcHk0lh6kbfHiNzPXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovVSisrw%253D&md5=71d3c246ebe6ac84c33980b97cb9889c</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1705154114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1705154114%26sid%3Dliteratum%253Aachs%26aulast%3DAlon%26aufirst%3DA.%26aulast%3DSchmidt%26aufirst%3DH.%2BR.%26aulast%3DWood%26aufirst%3DM.%2BD.%26aulast%3DSahn%26aufirst%3DJ.%2BJ.%26aulast%3DMartin%26aufirst%3DS.%2BF.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26atitle%3DIdentification%2520of%2520the%2520Gene%2520That%2520Codes%2520for%2520the%2520%25CF%25832%2520Receptor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26spage%3D7160%26epage%3D7165%26doi%3D10.1073%2Fpnas.1705154114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gundlach, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Largent, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, S. H.</span></span> <span> </span><span class="NLM_article-title">Autoradiographic Localization of Sigma Receptor Binding Sites in Guinea Pig and Rat Central Nervous System with (+)<sup>3</sup>H-3-(3-Hydroxyphenyl)-N-(1-Propyl)Piperidine</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1757</span>– <span class="NLM_lpage">1770</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.06-06-01757.1986</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1523%2FJNEUROSCI.06-06-01757.1986" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=3012017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADyaL28Xkslaqt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1986&pages=1757-1770&author=A.+L.+Gundlachauthor=B.+L.+Largentauthor=S.+H.+Snyder&title=Autoradiographic+Localization+of+Sigma+Receptor+Binding+Sites+in+Guinea+Pig+and+Rat+Central+Nervous+System+with+%28%2B%293H-3-%283-Hydroxyphenyl%29-N-%281-Propyl%29Piperidine&doi=10.1523%2FJNEUROSCI.06-06-01757.1986"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Autoradiographic localization of sigma receptor binding sites in guinea pig and rat central nervous system with (+)3H-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine</span></div><div class="casAuthors">Gundlach, Andrew L.; Largent, Brian L.; Snyder, Solomon H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1757-70</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    </div><div class="casAbstract">(+)3H-3-(3-Hydroxyphenyl)-N-(1-propyl)-piperidine ((+)3H-3-PPP)  [103596-12-9] binds with high affinity to brain membranes with a pharmacol. profile consistent with that of sigma receptors.  The distribution of (+)3H-3-PPP binding sites in brain and spinal cord of both guinea pig and rat was detd. by in vitro autoradiog. with binding densities quantitated by computer-assisted densitometry.  (+)3H-3-PPP binding to slide-mounted brain sections is saturable and displays high affinity and a pharmacol. specificity very similar to sites labeled in homogenates.  (+)3H-3-PPP binding sites are heterogeneously distributed.  Highest concns. of binding sites occur in: the spinal cord, particularly the ventral horn and dorsal root ganglia; the pons-medulla, assocd. with the cranial nerve and pontine nuclei and throughout the brain stem reticular formation; the cerebellum, over the Purkinje cell layer; the midbrain, particularly the central gray and red nucleus; and the hippocampus, over the pyramidal cell layer.  Lowest levels are seen in the basal ganglia and parts of the thalamus, whereas all other areas, including hypothalamus and cerebral cortex, exhibit moderate grain densities.  Quinolinic acid-induced lesions of the hippocampus indicate that (+)3H-3-PPP labels hippocampal pyramidal cells and granule cells in the dentate gyrus.  Intrastriatal injection of ibotenic acid markedly reduces (+)3H-3-PPP binding in this area, whereas injection of 6-hydroxydopamine produces a relatively slight decrease.  The distribution of (+)3H-3-PPP binding sites does not correlate with the receptor distribution of any recognized neurotransmitter or neuropeptide, including dopamine.  However, there is a notable similarity between the distribution of (+)3H-3-PPP sites and high-affinity binding sites for psychotomimetic opioids, such as the benzomorphan (+)SKF 10,047.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUK88P9_rGbbVg90H21EOLACvtfcHk0lh6kbfHiNzPXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28Xkslaqt7Y%253D&md5=5364e73d8462bb062298751d3b75c23e</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.06-06-01757.1986&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.06-06-01757.1986%26sid%3Dliteratum%253Aachs%26aulast%3DGundlach%26aufirst%3DA.%2BL.%26aulast%3DLargent%26aufirst%3DB.%2BL.%26aulast%3DSnyder%26aufirst%3DS.%2BH.%26atitle%3DAutoradiographic%2520Localization%2520of%2520Sigma%2520Receptor%2520Binding%2520Sites%2520in%2520Guinea%2520Pig%2520and%2520Rat%2520Central%2520Nervous%2520System%2520with%2520%2528%252B%25293H-3-%25283-Hydroxyphenyl%2529-N-%25281-Propyl%2529Piperidine%26jtitle%3DJ.%2520Neurosci.%26date%3D1986%26volume%3D6%26spage%3D1757%26epage%3D1770%26doi%3D10.1523%2FJNEUROSCI.06-06-01757.1986" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mavlyutov, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epstein, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziskind-Conhaim, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruoho, A. E.</span></span> <span> </span><span class="NLM_article-title">The Sigma-1 Receptor Is Enriched in Postsynaptic Sites of C-Terminals in Mouse Motoneurons. An Anatomical and Behavioral Study</span>. <i>Neuroscience</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>167</i></span>,  <span class="NLM_fpage">247</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1016/j.neuroscience.2010.02.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.neuroscience.2010.02.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=20167253" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksVehsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=167&publication_year=2010&pages=247-255&author=T.+A.+Mavlyutovauthor=M.+L.+Epsteinauthor=K.+A.+Andersenauthor=L.+Ziskind-Conhaimauthor=A.+E.+Ruoho&title=The+Sigma-1+Receptor+Is+Enriched+in+Postsynaptic+Sites+of+C-Terminals+in+Mouse+Motoneurons.+An+Anatomical+and+Behavioral+Study&doi=10.1016%2Fj.neuroscience.2010.02.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">The sigma-1 receptor is enriched in postsynaptic sites of C-terminals in mouse motoneurons. An anatomical and behavioral study</span></div><div class="casAuthors">Mavlyutov, T. A.; Epstein, M. L.; Andersen, K. A.; Ziskind-Conhaim, L.; Ruoho, A. E.</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">167</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">247-255</span>CODEN:
                <span class="NLM_cas:coden">NRSCDN</span>;
        ISSN:<span class="NLM_cas:issn">0306-4522</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The sigma-1 receptor regulates various ion channel activity and possesses protein chaperone function.  Using an antibody against the full sequence of the sigma-1 receptor we detected immunostaining in wild type but not in knockout mice.  The receptor was found primarily in motoneurons localized to the brainstem and spinal cord.  At the subcellular level the receptor is restricted to large cholinergic postsynaptic densities on the soma of motoneurons and is colocalized with the Kv2.1 potassium channel and the muscarinic type 2 cholinergic receptor.  Ultrastructural anal. of the neurons indicates that the immunostained receptor is located close but sep. from the plasma membrane, possibly in subsurface cisternae formed from the endoplasmic reticulum (ER), which are a prominent feature of cholinergic postsynaptic densities.  Behavioral testing on a rotarod revealed that Sigma-1 receptor knockout mice remained on the rotarod for significantly less time (a shorter latency period) compared to the wild type mice.  Together these data indicate that the sigma-1 receptor may play a role in the regulation of motor behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqjsVI80xkvrVg90H21EOLACvtfcHk0lh6kbfHiNzPXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksVehsLk%253D&md5=6517fe58d59ce56b314dc82bb54d4b05</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroscience.2010.02.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroscience.2010.02.022%26sid%3Dliteratum%253Aachs%26aulast%3DMavlyutov%26aufirst%3DT.%2BA.%26aulast%3DEpstein%26aufirst%3DM.%2BL.%26aulast%3DAndersen%26aufirst%3DK.%2BA.%26aulast%3DZiskind-Conhaim%26aufirst%3DL.%26aulast%3DRuoho%26aufirst%3DA.%2BE.%26atitle%3DThe%2520Sigma-1%2520Receptor%2520Is%2520Enriched%2520in%2520Postsynaptic%2520Sites%2520of%2520C-Terminals%2520in%2520Mouse%2520Motoneurons.%2520An%2520Anatomical%2520and%2520Behavioral%2520Study%26jtitle%3DNeuroscience%26date%3D2010%26volume%3D167%26spage%3D247%26epage%3D255%26doi%3D10.1016%2Fj.neuroscience.2010.02.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Al-Saif, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Mohanna, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohlega, S.</span></span> <span> </span><span class="NLM_article-title">A Mutation in Sigma-1 Receptor Causes Juvenile Amyotrophic Lateral Sclerosis</span>. <i>Ann. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">913</span>– <span class="NLM_lpage">919</span>, <span class="refDoi"> DOI: 10.1002/ana.22534</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1002%2Fana.22534" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=21842496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1CqurfI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2011&pages=913-919&author=A.+Al-Saifauthor=F.+Al-Mohannaauthor=S.+Bohlega&title=A+Mutation+in+Sigma-1+Receptor+Causes+Juvenile+Amyotrophic+Lateral+Sclerosis&doi=10.1002%2Fana.22534"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis</span></div><div class="casAuthors">Al-Saif, Amr; Al-Mohanna, Futwan; Bohlega, Saeed</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Neurology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">913-919</span>CODEN:
                <span class="NLM_cas:coden">ANNED3</span>;
        ISSN:<span class="NLM_cas:issn">0364-5134</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Objective: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by loss of motor neurons in the brain and spinal cord, leading to muscle weakness and eventually death from respiratory failure.  ALS is familial in about 10% of cases, with SOD1 mutations accounting for 20% of familial cases.  Here we describe a consanguineous family segregating juvenile ALS in an autosomal recessive pattern and describe the genetic variant responsible for the disorder.  Methods: We performed homozygosity mapping and direct sequencing to detect the genetic variant and tested the effect of this variant on a motor neuron-like cell line model (NSC34) expressing the wild-type or mutant gene.  Results: We identified a shared homozygosity region in affected individuals that spans ∼120kbp on chromosome 9p13.3 contg. 9 RefSeq genes.  Sequencing the SIGMAR1 gene revealed a mutation affecting a highly conserved amino acid located in the transmembrane domain of the encoded protein, sigma-1 receptor.  The mutated protein showed an aberrant subcellular distribution in NSC34 cells.  Furthermore, cells expressing the mutant protein were less resistant to apoptosis induced by endoplasmic reticulum stress.  Interpretation: Sigma-1 receptors are known to have neuroprotective properties, and recently Sigmar1 knockout mice have been described to have motor deficiency.  Our findings emphasize the role of sigma-1 receptors in motor neuron function and disease.  ANN NEUROL 2011;.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBYWm6mJA60LVg90H21EOLACvtfcHk0lhkFIYT5-fFQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1CqurfI&md5=ca3b6746092861e44b37088f3c4f86ea</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=10.1002%2Fana.22534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.22534%26sid%3Dliteratum%253Aachs%26aulast%3DAl-Saif%26aufirst%3DA.%26aulast%3DAl-Mohanna%26aufirst%3DF.%26aulast%3DBohlega%26aufirst%3DS.%26atitle%3DA%2520Mutation%2520in%2520Sigma-1%2520Receptor%2520Causes%2520Juvenile%2520Amyotrophic%2520Lateral%2520Sclerosis%26jtitle%3DAnn.%2520Neurol.%26date%3D2011%26volume%3D70%26spage%3D913%26epage%3D919%26doi%3D10.1002%2Fana.22534" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luty, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwok, J. B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobson-Stone, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loy, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coupland, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlström, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sobow, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tchorzewska, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maruszak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barcikowska, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panegyres, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zekanowski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooks, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blair, I. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mather, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sachdev, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halliday, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schofield, P. R.</span></span> <span> </span><span class="NLM_article-title">Sigma Nonopioid Intracellular Receptor 1 Mutations Cause Frontotemporal Lobar Degeneration-Motor Neuron Disease</span>. <i>Ann. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">639</span>– <span class="NLM_lpage">649</span>, <span class="refDoi"> DOI: 10.1002/ana.22274</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1002%2Fana.22274" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=21031579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFOnsrbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2010&pages=639-649&author=A.+A.+Lutyauthor=J.+B.+J.+Kwokauthor=C.+Dobson-Stoneauthor=C.+T.+Loyauthor=K.+G.+Couplandauthor=H.+Karlstr%C3%B6mauthor=T.+Sobowauthor=J.+Tchorzewskaauthor=A.+Maruszakauthor=M.+Barcikowskaauthor=P.+K.+Panegyresauthor=C.+Zekanowskiauthor=W.+S.+Brooksauthor=K.+L.+Williamsauthor=I.+P.+Blairauthor=K.+A.+Matherauthor=P.+S.+Sachdevauthor=G.+Hallidayauthor=P.+R.+Schofield&title=Sigma+Nonopioid+Intracellular+Receptor+1+Mutations+Cause+Frontotemporal+Lobar+Degeneration-Motor+Neuron+Disease&doi=10.1002%2Fana.22274"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease</span></div><div class="casAuthors">Luty, Agnes A.; Kwok, John B. J.; Dobson-Stone, Carol; Loy, Clement T.; Coupland, Kirsten G.; Karlstrom, Helena; Sobow, Tomasz; Tchorzewska, Joanna; Maruszak, Aleksandra; Barcikowska, Maria; Panegyres, Peter K.; Zekanowski, Cezary; Brooks, William S.; Williams, Kelly L.; Blair, Ian P.; Mather, Karen A.; Sachdev, Perminder S.; Halliday, Glenda M.; Schofield, Peter R.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Neurology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">639-649</span>CODEN:
                <span class="NLM_cas:coden">ANNED3</span>;
        ISSN:<span class="NLM_cas:issn">0364-5134</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Objective: Frontotemporal lobar degeneration (FTLD) is the most common cause of early-onset dementia.  Pathol. ubiquitinated inclusion bodies obsd. in FTLD and motor neuron disease (MND) comprise transactivating response element (TAR) DNA binding protein (TDP-43) and/or fused in sarcoma (FUS) protein.  Our objective was to identify the causative gene in an FTLD-MND pedigree with no mutations in known dementia genes.  Methods: A mutation screen of candidate genes, luciferase assays, and quant. polymerase chain reaction (PCR) was performed to identify the biol. role of the putative mutation.  Neuropathol. characterization of affected individuals and western blot studies of cell lines were performed to identify the pathol. mechanism of the mutation.  Results: We identified a nonpolymorphic mutation (c.672*51G>T) in the 3'-untranslated region (UTR) of the Sigma nonopioid intracellular receptor 1 (SIGMAR1) gene in affected individuals from the FTLD-MND pedigree.  The c.672*51G>T mutation increased gene expression by 1.4-fold, corresponding with a significant 1.5-fold to 2-fold change in the SIGMAR1 transcript or Sigma-1 protein in lymphocyte or brain tissue.  Brains of SIGMAR1 mutation carriers displayed a unique pathol. with cytoplasmic inclusions immunopos. for either TDP-43 or FUS but not Sigma-1.  Overexpression of SIGMAR1 shunted TDP-43 and FUS from the nucleus to the cytoplasm by 2.3-fold and 5.2-fold, resp.  Treatment of cells with Sigma-1 ligands significantly altered translocation of TDP-43 by up to 2-fold.  Interpretation: SIGMAR1 is a causative gene for familial FTLD-MND with a unique neuropathol. that differs from other FTLD and MND cases.  Our findings also suggest Sigma-1 drugs as potential treatments for the TDP-43/FUS proteinopathies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqLlsN4nYXas7Vg90H21EOLACvtfcHk0lhkFIYT5-fFQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFOnsrbM&md5=910ad11aa17d829a5d241efd932e96a6</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1002%2Fana.22274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.22274%26sid%3Dliteratum%253Aachs%26aulast%3DLuty%26aufirst%3DA.%2BA.%26aulast%3DKwok%26aufirst%3DJ.%2BB.%2BJ.%26aulast%3DDobson-Stone%26aufirst%3DC.%26aulast%3DLoy%26aufirst%3DC.%2BT.%26aulast%3DCoupland%26aufirst%3DK.%2BG.%26aulast%3DKarlstr%25C3%25B6m%26aufirst%3DH.%26aulast%3DSobow%26aufirst%3DT.%26aulast%3DTchorzewska%26aufirst%3DJ.%26aulast%3DMaruszak%26aufirst%3DA.%26aulast%3DBarcikowska%26aufirst%3DM.%26aulast%3DPanegyres%26aufirst%3DP.%2BK.%26aulast%3DZekanowski%26aufirst%3DC.%26aulast%3DBrooks%26aufirst%3DW.%2BS.%26aulast%3DWilliams%26aufirst%3DK.%2BL.%26aulast%3DBlair%26aufirst%3DI.%2BP.%26aulast%3DMather%26aufirst%3DK.%2BA.%26aulast%3DSachdev%26aufirst%3DP.%2BS.%26aulast%3DHalliday%26aufirst%3DG.%26aulast%3DSchofield%26aufirst%3DP.%2BR.%26atitle%3DSigma%2520Nonopioid%2520Intracellular%2520Receptor%25201%2520Mutations%2520Cause%2520Frontotemporal%2520Lobar%2520Degeneration-Motor%2520Neuron%2520Disease%26jtitle%3DAnn.%2520Neurol.%26date%3D2010%26volume%3D68%26spage%3D639%26epage%3D649%26doi%3D10.1002%2Fana.22274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mancuso, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliván, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rando, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, X.</span></span> <span> </span><span class="NLM_article-title">Sigma-1R Agonist Improves Motor Function and Motoneuron Survival in ALS Mice</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">814</span>– <span class="NLM_lpage">826</span>, <span class="refDoi"> DOI: 10.1007/s13311-012-0140-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1007%2Fs13311-012-0140-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=22935988" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFOqtbnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=814-826&author=R.+Mancusoauthor=S.+Oliv%C3%A1nauthor=A.+Randoauthor=C.+Casasauthor=R.+Ostaauthor=X.+Navarro&title=Sigma-1R+Agonist+Improves+Motor+Function+and+Motoneuron+Survival+in+ALS+Mice&doi=10.1007%2Fs13311-012-0140-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit156R"><div class="casContent"><span class="casTitleNuber">156</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1R Agonist Improves Motor Function and Motoneuron Survival in ALS Mice</span></div><div class="casAuthors">Mancuso, Renzo; Olivan, Sara; Rando, Amaya; Casas, Caty; Osta, Rosario; Navarro, Xavier</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">814-826</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1878-7479</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Amyotrophic lateral sclerosis is a neurodegenerative disorder characterized by progressive weakness, muscle atrophy, and paralysis due to the loss of upper and lower motoneurons (MNs).  Sigma-1 receptor (sigma-1R) activation promotes neuroprotection after ischemic and traumatic injuries to the central nervous system.  We recently reported that sigma-1R agonist (PRE-084) improves the survival of MNs after root avulsion injury in rats.  Moreover, a mutation of the sigma-1R leading to frontotemporal lobar degeneration/amyotrophic lateral sclerosis (ALS) was recently described in human patients.  In the present study, we analyzed the potential therapeutic effect of the sigma-1R agonist (PRE-084) in the SOD1G93A mouse model of ALS.  Mice were daily administered with PRE-084 (0.25 mg/kg) from 8 to 16 wk of age.  Functional outcome was assessed by electrophysiol. tests and computerized anal. of locomotion.  Histol., immunohistochem. analyses and Western blot of the spinal cord were performed.  PRE-084 administration from 8 wk of age improved the function of MNs, which was manifested by maintenance of the amplitude of muscle action potentials and locomotor behavior, and preserved neuromuscular connections and MNs in the spinal cord.  Moreover, it extended survival in both female and male mice by more than 15 %.  Delayed administration of PRE-084 from 12 wk of age also significantly improved functional outcome and preservation of the MNs.  There was an induction of protein kinase C-specific phosphorylation of the NR1 subunit of the N-methyl-D-aspartate (NMDA) receptor in SOD1G93A animals, and a redn. of the microglial reactivity compared with untreated mice.  PRE-084 exerts a dual therapeutic contribution, modulating NMDA Ca2+ influx to protect MNs, and the microglial reactivity to ameliorate the MN environment.  In conclusion, sigma-1R agonists, such as PRE-084, may be promising candidates for a therapeutical strategy of ALS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo752Zuu4G6tbVg90H21EOLACvtfcHk0lhkFIYT5-fFQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFOqtbnO&md5=d058d70a447dbc778d0bec822a01225b</span></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1007%2Fs13311-012-0140-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13311-012-0140-y%26sid%3Dliteratum%253Aachs%26aulast%3DMancuso%26aufirst%3DR.%26aulast%3DOliv%25C3%25A1n%26aufirst%3DS.%26aulast%3DRando%26aufirst%3DA.%26aulast%3DCasas%26aufirst%3DC.%26aulast%3DOsta%26aufirst%3DR.%26aulast%3DNavarro%26aufirst%3DX.%26atitle%3DSigma-1R%2520Agonist%2520Improves%2520Motor%2520Function%2520and%2520Motoneuron%2520Survival%2520in%2520ALS%2520Mice%26jtitle%3DNeurotherapeutics%26date%3D2012%26volume%3D9%26spage%3D814%26epage%3D826%26doi%3D10.1007%2Fs13311-012-0140-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno-Delgado, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuentes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosell-Vilar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasperini, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Ruiz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medrano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallol, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortés, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casadó, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lluís, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferré, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortiz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canela, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, P. J.</span></span> <span> </span><span class="NLM_article-title">Cocaine Disrupts Histamine H3 Receptor Modulation of Dopamine D1 Receptor Signaling: σ1-D1-H3 Receptor Complexes as Key Targets for Reducing Cocaine’s Effects</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">3545</span>– <span class="NLM_lpage">3558</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.4147-13.2014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1523%2FJNEUROSCI.4147-13.2014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=24599455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2cXkt1ajtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=3545-3558&author=E.+Morenoauthor=D.+Moreno-Delgadoauthor=G.+Navarroauthor=H.+M.+Hoffmannauthor=S.+Fuentesauthor=S.+Rosell-Vilarauthor=P.+Gasperiniauthor=M.+Rodr%C3%ADguez-Ruizauthor=M.+Medranoauthor=J.+Mallolauthor=A.+Cort%C3%A9sauthor=V.+Casad%C3%B3author=C.+Llu%C3%ADsauthor=S.+Ferr%C3%A9author=J.+Ortizauthor=E.+Canelaauthor=P.+J.+McCormick&title=Cocaine+Disrupts+Histamine+H3+Receptor+Modulation+of+Dopamine+D1+Receptor+Signaling%3A+%CF%831-D1-H3+Receptor+Complexes+as+Key+Targets+for+Reducing+Cocaine%E2%80%99s+Effects&doi=10.1523%2FJNEUROSCI.4147-13.2014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Cocaine disrupts histamine H3 receptor modulation of dopamine D1 receptor signaling: σ1-D1-H3 receptor complexes as key targets for reducing cocaine's effects</span></div><div class="casAuthors">Moreno, Estefania; Moreno-Delgado, David; Navarro, Gemma; Hoffmann, Hanne M.; Fuentes, Silvia; Rosell-Vilar, Santi; Gasperini, Paola; Rodriguez-Ruiz, Mar; Medrano, Mireia; Mallol, Josefa; Cortes, Antoni; Casado, Vicent; Lluis, Carme; Ferre, Sergi; Ortiz, Jordi; Canela, Enric; McCormick, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3545-3558</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">The general effects of cocaine are not well understood at the mol. level.  What is known is that the dopamine D1 receptor plays an important role.  Here we show that a key mechanism may be cocaine's blockade of the histamine H3 receptor-mediated inhibition of D1 receptor function.  This blockade requires the σ1 receptor and occurs upon cocaine binding to σ1-D1-H3 receptor complexes.  The cocaine-mediated disruption leaves an uninhibited D1 receptor that activates Gs, freely recruits β-arrestin, increases p-ERK 1/2 levels, and induces cell death when over activated.  Using in vitro assays with transfected cells and in ex vivo expts. using both rats acutely treated or self-administered with cocaine along with mice depleted of σ1 receptor, we show that blockade of σ1 receptor by an antagonist restores the protective H3 receptor-mediated brake on D1 receptor signaling and prevents the cell death from elevated D1 receptor signaling.  These findings suggest that a combination therapy of σ1R antagonists with H3 receptor agonists could serve to reduce some effects of cocaine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_ARavI4E7T7Vg90H21EOLACvtfcHk0ljpG9luHkqrmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXkt1ajtrc%253D&md5=6aea1fdccecd4373e3a36ecea9e5d9dd</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.4147-13.2014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.4147-13.2014%26sid%3Dliteratum%253Aachs%26aulast%3DMoreno%26aufirst%3DE.%26aulast%3DMoreno-Delgado%26aufirst%3DD.%26aulast%3DNavarro%26aufirst%3DG.%26aulast%3DHoffmann%26aufirst%3DH.%2BM.%26aulast%3DFuentes%26aufirst%3DS.%26aulast%3DRosell-Vilar%26aufirst%3DS.%26aulast%3DGasperini%26aufirst%3DP.%26aulast%3DRodr%25C3%25ADguez-Ruiz%26aufirst%3DM.%26aulast%3DMedrano%26aufirst%3DM.%26aulast%3DMallol%26aufirst%3DJ.%26aulast%3DCort%25C3%25A9s%26aufirst%3DA.%26aulast%3DCasad%25C3%25B3%26aufirst%3DV.%26aulast%3DLlu%25C3%25ADs%26aufirst%3DC.%26aulast%3DFerr%25C3%25A9%26aufirst%3DS.%26aulast%3DOrtiz%26aufirst%3DJ.%26aulast%3DCanela%26aufirst%3DE.%26aulast%3DMcCormick%26aufirst%3DP.%2BJ.%26atitle%3DCocaine%2520Disrupts%2520Histamine%2520H3%2520Receptor%2520Modulation%2520of%2520Dopamine%2520D1%2520Receptor%2520Signaling%253A%2520%25CF%25831-D1-H3%2520Receptor%2520Complexes%2520as%2520Key%2520Targets%2520for%2520Reducing%2520Cocaine%25E2%2580%2599s%2520Effects%26jtitle%3DJ.%2520Neurosci.%26date%3D2014%26volume%3D34%26spage%3D3545%26epage%3D3558%26doi%3D10.1523%2FJNEUROSCI.4147-13.2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonaventura, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brugarolas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farré, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguinaga, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallol, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortés, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casadó, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lluís, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canela, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCormick, P. J.</span></span> <span> </span><span class="NLM_article-title">Cocaine Inhibits Dopamine D2 Receptor Signaling via Sigma-1-D2 Receptor Heteromers</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e61245</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0061245</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1371%2Fjournal.pone.0061245" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=23637801" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvFaqs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&author=G.+Navarroauthor=E.+Morenoauthor=J.+Bonaventuraauthor=M.+Brugarolasauthor=D.+Farr%C3%A9author=D.+Aguinagaauthor=J.+Mallolauthor=A.+Cort%C3%A9sauthor=V.+Casad%C3%B3author=C.+Llu%C3%ADsauthor=S.+Ferreauthor=R.+Francoauthor=E.+Canelaauthor=P.+J.+McCormick&title=Cocaine+Inhibits+Dopamine+D2+Receptor+Signaling+via+Sigma-1-D2+Receptor+Heteromers&doi=10.1371%2Fjournal.pone.0061245"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Cocaine inhibits dopamine D2 receptor signaling via sigma-1-D2 receptor heteromers</span></div><div class="casAuthors">Navarro, Gemma; Moreno, Estefania; Bonaventura, Jordi; Brugarolas, Marc; Farre, Daniel; Aguinaga, David; Mallol, Josefa; Cortes, Antoni; Casado, Vicent; Lluis, Carmen; Ferre, Sergi; Franco, Rafael; Canela, Enric; McCormick, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">e61245</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Under normal conditions the brain maintains a delicate balance between inputs of reward seeking controlled by neurons contg. the D1-like family of dopamine receptors and inputs of aversion coming from neurons contg. the D2-like family of dopamine receptors.  Cocaine is able to subvert these balanced inputs by altering the cell signaling of these two pathways such that D1 reward seeking pathway dominates.  Here, we provide an explanation at the cellular and biochem. level how cocaine may achieve this.  Exploring the effect of cocaine on dopamine D2 receptors function, we present evidence of σ1 receptor mol. and functional interaction with dopamine D2 receptors.  Using biophys., biochem. and cell biol. approaches, we discovered that D2 receptors (the long isoform of the D2 receptor) can complex with σ1 receptors, a result that is specific to D2 receptors, as D3 and D4 receptors did not form heteromers.  We demonstrate that the σ1-D2 receptor heteromers consist of higher order oligomers, are found in mouse striatum and that cocaine, by binding to σ1-D2 receptor heteromers, inhibits downstream signaling in both cultured cells and in mouse striatum.  In contrast, in striatum from σ1 knockout animals these complexes are not found and this inhibition is not seen.  Taken together, these data illuminate the mechanism by which the initial exposure to cocaine can inhibit signaling via D2 receptor contg. neurons, destabilizing the delicate signaling balance influencing drug seeking that emanates from the D1 and D2 receptor contg. neurons in the brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR4PjTJlFvzLVg90H21EOLACvtfcHk0ljpG9luHkqrmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvFaqs7g%253D&md5=61bcdce4f07ad8dc8582c3d1b692359d</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0061245&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0061245%26sid%3Dliteratum%253Aachs%26aulast%3DNavarro%26aufirst%3DG.%26aulast%3DMoreno%26aufirst%3DE.%26aulast%3DBonaventura%26aufirst%3DJ.%26aulast%3DBrugarolas%26aufirst%3DM.%26aulast%3DFarr%25C3%25A9%26aufirst%3DD.%26aulast%3DAguinaga%26aufirst%3DD.%26aulast%3DMallol%26aufirst%3DJ.%26aulast%3DCort%25C3%25A9s%26aufirst%3DA.%26aulast%3DCasad%25C3%25B3%26aufirst%3DV.%26aulast%3DLlu%25C3%25ADs%26aufirst%3DC.%26aulast%3DFerre%26aufirst%3DS.%26aulast%3DFranco%26aufirst%3DR.%26aulast%3DCanela%26aufirst%3DE.%26aulast%3DMcCormick%26aufirst%3DP.%2BJ.%26atitle%3DCocaine%2520Inhibits%2520Dopamine%2520D2%2520Receptor%2520Signaling%2520via%2520Sigma-1-D2%2520Receptor%2520Heteromers%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26doi%3D10.1371%2Fjournal.pone.0061245" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzalez-Alvear, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werling, L. L.</span></span> <span> </span><span class="NLM_article-title">Regulation of [<sup>3</sup>H]Dopamine Release from Rat Striatal Slices by Sigma Receptor Ligands</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>271</i></span>,  <span class="NLM_fpage">212</span>– <span class="NLM_lpage">219</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=7965717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADyaK2cXmvFalsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1994&pages=212-219&author=G.+M.+Gonzalez-Alvearauthor=L.+L.+Werling&title=Regulation+of+%5B3H%5DDopamine+Release+from+Rat+Striatal+Slices+by+Sigma+Receptor+Ligands"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation of [3H]dopamine release from rat striatal slices by sigma receptor ligands</span></div><div class="casAuthors">Gonzalez-Alvear, Grace M.; Werling, Linda L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">271</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">212-19</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">Sigma receptors have been located in several areas of the brain that control motor function, including on the dopaminergic projections from substantia nigra to striatum.  In the current study, the regulation of N-methyl-D-aspartate-stimulated [3H]dopamine release from slices of rat striatum by several sigma ligands has been tested.  Both isomers of the benzomorphans SKF10,047 and pentazocine inhibited the stimulated release of dopamine in a concn.-related manner.  All these compds. probably activate sigma and non-sigma receptors, including phencyclidine receptors, over the broad concn. ranges tested.  However, concns. of (+)pentazocine below about 100 nM appear to act solely through sigma receptors.  This phase of inhibition was reversed by the sigma antagonist N-[-2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-[1-pyrimidinyl]-1-piperazine butanol and by the sigma1-selective antagonist (1-(cyclopropylmethyl)-4-2'4''-fluorophenyl)-(2'-oxoethyl)piperidine HBr.  Neither of these antagonists affected stimulated release in the absence of (+)pentazocine.  The synthetic sigma ligands 2-(4-morpholino)ethyl 1-phenylcyclohexane-1-carboxylate hydrochloride, 6-[6-(4-hydroxypiperidinyl)hexoxy]-3-methylflavone hydrochloride and α-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazine butanol enhanced NMDA-stimulated DA release significantly in the presence of (+)pentazocine.  These drugs have affinity at non-sigma receptors as well, and their stimulatory effects may be mediated through these receptors along with nonreceptor mechanisms.  Our findings on the regulation of dopamine support earlier assertions that sigma receptors may be important in the regulation of motor function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocYAAK7ai78rVg90H21EOLACvtfcHk0liFFqkqWwFdSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXmvFalsbY%253D&md5=841e4f47964742ea17263c8c238e6303</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGonzalez-Alvear%26aufirst%3DG.%2BM.%26aulast%3DWerling%26aufirst%3DL.%2BL.%26atitle%3DRegulation%2520of%2520%255B3H%255DDopamine%2520Release%2520from%2520Rat%2520Striatal%2520Slices%2520by%2520Sigma%2520Receptor%2520Ligands%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1994%26volume%3D271%26spage%3D212%26epage%3D219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hong, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiranita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amara, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span> <span> </span><span class="NLM_article-title">The Sigma-1 Receptor Modulates Dopamine Transporter Conformation and Cocaine Binding and May Thereby Potentiate Cocaine Self-Administration in Rats</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>292</i></span>,  <span class="NLM_fpage">11250</span>– <span class="NLM_lpage">11261</span>, <span class="refDoi"> DOI: 10.1074/jbc.M116.774075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1074%2Fjbc.M116.774075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=28495886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFCisL7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=292&publication_year=2017&pages=11250-11261&author=W.+C.+Hongauthor=H.+Yanoauthor=T.+Hiranitaauthor=F.+T.+Chinauthor=C.+R.+McCurdyauthor=T.+P.+Suauthor=S.+G.+Amaraauthor=J.+L.+Katz&title=The+Sigma-1+Receptor+Modulates+Dopamine+Transporter+Conformation+and+Cocaine+Binding+and+May+Thereby+Potentiate+Cocaine+Self-Administration+in+Rats&doi=10.1074%2Fjbc.M116.774075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">The sigma-1 receptor modulates dopamine transporter conformation and cocaine binding and may thereby potentiate cocaine self-administration in rats</span></div><div class="casAuthors">Hong, Weimin Conrad; Yano, Hideaki; Hiranita, Takato; Chin, Frederick T.; McCurdy, Christopher R.; Su, Tsung-Ping; Amara, Susan G.; Katz, Jonathan L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">292</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">11250-11261</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The dopamine transporter (DAT) regulates dopamine (DA) neurotransmission by recapturing DA into the presynaptic terminals and is a principal target of the psychostimulant cocaine.  The sigma-1 receptor (σ1R) is a mol. chaperone, and its ligands have been shown to modulate DA neuronal signaling, although their effects on DAT activity are unclear.  Here, the authors report that the prototypical σ1R agonist (+)-pentazocine potentiated the dose response of cocaine self-administration in rats, consistent with the effects of the σR agonists PRE-084 and DTG (1,3-di-o-tolylguanidine) reported previously.  These behavioral effects appeared to be correlated with functional changes of DAT.  Preincubation with (+)-pentazocine or PRE-084 increased the Bmax values of [3H]WIN35428 binding to DAT in rat striatal synaptosomes and transfected cells.  A specific interaction between σ1R and DAT was detected by co-immunopptn. and bioluminescence resonance energy transfer assays.  Mutational analyses indicated that the transmembrane domain of σ1R likely mediated this interaction.  Furthermore, cysteine accessibility assays showed that σ1R agonist preincubation potentiated cocaine-induced changes in DAT conformation, which were blocked by the specific σ1R antagonist CM304.  Moreover, σ1R ligands had distinct effects on σ1R multimerization.  CM304 increased the proportion of multimeric σ1Rs, whereas (+)-pentazocine increased monomeric σ1Rs.  Together these results support the hypothesis that σ1R agonists promote dissocn. of σ1R multimers into monomers, which then interact with DAT to stabilize an outward-facing DAT conformation and enhance cocaine binding.  The authors propose that this novel mol. mechanism underlies the behavioral potentiation of cocaine self-administration by σ1R agonists in animal models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo9IZLHbohe7rVg90H21EOLACvtfcHk0liFFqkqWwFdSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFCisL7F&md5=5366dbf409e7cbefeb52c79a3198023f</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M116.774075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M116.774075%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DW.%2BC.%26aulast%3DYano%26aufirst%3DH.%26aulast%3DHiranita%26aufirst%3DT.%26aulast%3DChin%26aufirst%3DF.%2BT.%26aulast%3DMcCurdy%26aufirst%3DC.%2BR.%26aulast%3DSu%26aufirst%3DT.%2BP.%26aulast%3DAmara%26aufirst%3DS.%2BG.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26atitle%3DThe%2520Sigma-1%2520Receptor%2520Modulates%2520Dopamine%2520Transporter%2520Conformation%2520and%2520Cocaine%2520Binding%2520and%2520May%2520Thereby%2520Potentiate%2520Cocaine%2520Self-Administration%2520in%2520Rats%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2017%26volume%3D292%26spage%3D11250%26epage%3D11261%26doi%3D10.1074%2Fjbc.M116.774075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Francardo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denis, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayden, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cenci, M. A.</span></span> <span> </span><span class="NLM_article-title">Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson’s Disease</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">465</span>– <span class="NLM_lpage">479</span>, <span class="refDoi"> DOI: 10.1007/s13311-018-00699-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1007%2Fs13311-018-00699-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=30756361" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVyrtL3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2019&pages=465-479&author=V.+Francardoauthor=M.+Gevaauthor=F.+Bezauthor=Q.+Denisauthor=L.+Steinerauthor=M.+R.+Haydenauthor=M.+A.+Cenci&title=Pridopidine+Induces+Functional+Neurorestoration+Via+the+Sigma-1+Receptor+in+a+Mouse+Model+of+Parkinson%E2%80%99s+Disease&doi=10.1007%2Fs13311-018-00699-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson's Disease</span></div><div class="casAuthors">Francardo, Veronica; Geva, Michal; Bez, Francesco; Denis, Quentin; Steiner, Lilach; Hayden, Michael R.; Cenci, M. Angela</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">465-479</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1878-7479</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Pridopidine is a small mol. in clin. development for the treatment of Huntington's disease.  It was recently found to have high binding affinity to the sigma-1 receptor, a chaperone protein involved in cellular defense mechanisms and neuroplasticity.  Here, we have evaluated the neuroprotective and neurorestorative effects of pridopidine in a unilateral 6-hydroxydopamine (6-OHDA) lesion model of parkinsonism in mice.  By 5 wk of daily administration, a low dose of pridopidine (0.3 mg/kg) had significantly improved deficits in forelimb use (cylinder test, stepping test) and abolished the ipsilateral rotational bias typical of hemiparkinsonian animals.  A higher dose of pridopidine (1 mg/kg) significantly improved only the rotational bias, with a trend towards improvement in forelimb use.  The behavioral recovery induced by pridopidine 0.3 mg/kg was accompanied by a significant protection of nigral dopamine cell bodies, an increased dopaminergic fiber d. in the striatum, and striatal upregulation of GDNF, BDNF, and phosphorylated ERK1/2.  The beneficial effects of pridopidine 0.3 mg/kg were absent in 6-OHDA-lesioned mice lacking the sigma-1 receptor.  Pharmacokinetic data confirmed that the ED of pridopidine reached brain concns. sufficient to bind S1R.  These results are the first to show that pridopidine promotes functional neurorestoration in the damaged nigrostriatal system acting via the sigma-1 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrIU8OUezMugrVg90H21EOLACvtfcHk0liFFqkqWwFdSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVyrtL3P&md5=04b464473e75e4ce8aaec9d65bf08231</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1007%2Fs13311-018-00699-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13311-018-00699-9%26sid%3Dliteratum%253Aachs%26aulast%3DFrancardo%26aufirst%3DV.%26aulast%3DGeva%26aufirst%3DM.%26aulast%3DBez%26aufirst%3DF.%26aulast%3DDenis%26aufirst%3DQ.%26aulast%3DSteiner%26aufirst%3DL.%26aulast%3DHayden%26aufirst%3DM.%2BR.%26aulast%3DCenci%26aufirst%3DM.%2BA.%26atitle%3DPridopidine%2520Induces%2520Functional%2520Neurorestoration%2520Via%2520the%2520Sigma-1%2520Receptor%2520in%2520a%2520Mouse%2520Model%2520of%2520Parkinson%25E2%2580%2599s%2520Disease%26jtitle%3DNeurotherapeutics%26date%3D2019%26volume%3D16%26spage%3D465%26epage%3D479%26doi%3D10.1007%2Fs13311-018-00699-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hyrskyluoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulli, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Törnqvist, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korhonen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindholm, D.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 Receptor Agonist PRE084 Is Protective against Mutant Huntingtin-Induced Cell Degeneration: Involvement of Calpastatin and the NF-KB Pathway</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e646</span> <span class="refDoi"> DOI: 10.1038/cddis.2013.170</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fcddis.2013.170" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=23703391" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVykt77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&author=A.+Hyrskyluotoauthor=I.+Pulliauthor=K.+T%C3%B6rnqvistauthor=T.+H.+Hoauthor=L.+Korhonenauthor=D.+Lindholm&title=Sigma-1+Receptor+Agonist+PRE084+Is+Protective+against+Mutant+Huntingtin-Induced+Cell+Degeneration%3A+Involvement+of+Calpastatin+and+the+NF-KB+Pathway&doi=10.1038%2Fcddis.2013.170"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptor agonist PRE084 is protective against mutant huntingtin-induced cell degeneration: involvement of calpastatin and the NF-κB pathway</span></div><div class="casAuthors">Hyrskyluoto, A.; Pulli, I.; Tornqvist, K.; Ho, T. Huu; Korhonen, L.; Lindholm, D.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">May</span>),
    <span class="NLM_cas:pages">e646</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Alterations in mitochondria and increased oxidative stress are assocd. with the disease progression in Huntington's disease (HD).  Endoplasmic reticulum (ER) stress and oxidative damage are linked through the close communication between the ER and mitochondria.  Sigma-1 receptor (Sig-1R) is a chaperone protein in the ER that is involved in ER stress regulation, but little is known about its role in HD or the mechanisms for cell protection.  Here we show that the Sig-1R agonist, PRE084 increases cell survival and counteracts the deleterious effects caused by N-terminal mutant huntingtin proteins in neuronal PC6.3 cells.  Particularly, PRE084 increased the levels of cellular antioxidants by activating the NF-κB pathway that is compromised by the expression of mutant huntingtin proteins.  These results show that the Sig-1R agonist has beneficial effects in models of HD and that compds. affecting the Sig-1R may be promising targets for future drug development in HD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoABRB1xtV29LVg90H21EOLACvtfcHk0lhwkNvDO4auRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVykt77F&md5=987bdc296073218c5acfe69050f288d2</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.1038%2Fcddis.2013.170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddis.2013.170%26sid%3Dliteratum%253Aachs%26aulast%3DHyrskyluoto%26aufirst%3DA.%26aulast%3DPulli%26aufirst%3DI.%26aulast%3DT%25C3%25B6rnqvist%26aufirst%3DK.%26aulast%3DHo%26aufirst%3DT.%2BH.%26aulast%3DKorhonen%26aufirst%3DL.%26aulast%3DLindholm%26aufirst%3DD.%26atitle%3DSigma-1%2520Receptor%2520Agonist%2520PRE084%2520Is%2520Protective%2520against%2520Mutant%2520Huntingtin-Induced%2520Cell%2520Degeneration%253A%2520Involvement%2520of%2520Calpastatin%2520and%2520the%2520NF-KB%2520Pathway%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2013%26volume%3D4%26doi%3D10.1038%2Fcddis.2013.170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith-Dijak, A. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nassrallah, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L. Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayden, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymond, L. A.</span></span> <span> </span><span class="NLM_article-title">Impairment and Restoration of Homeostatic Plasticity in Cultured Cortical Neurons From a Mouse Model of Huntington Disease</span>. <i>Front. Cell. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">209</span>, <span class="refDoi"> DOI: 10.3389/fncel.2019.00209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3389%2Ffncel.2019.00209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=31156395" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhslKms7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=209&author=A.+I.+Smith-Dijakauthor=W.+B.+Nassrallahauthor=L.+Y.+J.+Zhangauthor=M.+Gevaauthor=M.+R.+Haydenauthor=L.+A.+Raymond&title=Impairment+and+Restoration+of+Homeostatic+Plasticity+in+Cultured+Cortical+Neurons+From+a+Mouse+Model+of+Huntington+Disease&doi=10.3389%2Ffncel.2019.00209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Impairment and restoration of homeostatic plasticity in cultured cortical neurons from a mouse model of Huntington disease</span></div><div class="casAuthors">Smith-Dijak, Amy I.; Nassrallah, Wissam B.; Zhang, Lily Y. J.; Geva, Michal; Hayden, Michael R.; Raymond, Lynn A.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Cellular Neuroscience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">209</span>CODEN:
                <span class="NLM_cas:coden">FCNRAH</span>;
        ISSN:<span class="NLM_cas:issn">1662-5102</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Huntington disease (HD) is an inherited neurodegenerative disorder caused by a mutation in the huntingtin gene.  The onset of symptoms is preceded by synaptic dysfunction.  Homeostatic synaptic plasticity (HSP) refers to processes that maintain the stability of networks of neurons, thought to be required to enable new learning and cognitive flexibility.  One type of HSP is synaptic scaling, in which the strength of all of the synapses onto a cell increases or decreases following changes in the cell's level of activity.  Several pathways implicated in synaptic scaling are dysregulated in HD, including brain-derived neurotrophic factor (BDNF) and calcium signaling.  Here, we investigated whether HSP is disrupted in cortical neurons from an HD mouse model.  We treated cultured cortical neurons from wild-type (WT) FVB/N or YAC128 HD mice with tetrodotoxin (TTX) for 48 h to silence action potentials and then recorded miniature excitatory postsynaptic currents.  In WT cultures, these increased in both amplitude and frequency after TTX treatment, and further expts. showed that this was a result of insertion of AMPA receptors and formation of new synapses, resp.  Manipulation of BDNF concn. in the culture medium revealed that BDNF signaling contributed to these changes.  In contrast to WT cortical neurons, YAC128 cultures showed no response to action potential silencing.  Strikingly, we were able to restore the TTX-induced changes in YAC128 cultures by treating them with pridopidine, a drug which enhances BDNF signaling through stimulation of the sigma-1 receptor (S1R), and with the S1R agonist 3-PPP.  These data provide evidence for disruption of HSP in cortical neurons from an HD mouse model that is restored by stimulation of S1R.  Our results suggest a potential new direction for developing therapy to mitigate cognitive deficits in HD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7wLNy01XJ2rVg90H21EOLACvtfcHk0lhwkNvDO4auRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhslKms7g%253D&md5=eb7194d47c11a35696fc5fe416563a28</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.3389%2Ffncel.2019.00209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffncel.2019.00209%26sid%3Dliteratum%253Aachs%26aulast%3DSmith-Dijak%26aufirst%3DA.%2BI.%26aulast%3DNassrallah%26aufirst%3DW.%2BB.%26aulast%3DZhang%26aufirst%3DL.%2BY.%2BJ.%26aulast%3DGeva%26aufirst%3DM.%26aulast%3DHayden%26aufirst%3DM.%2BR.%26aulast%3DRaymond%26aufirst%3DL.%2BA.%26atitle%3DImpairment%2520and%2520Restoration%2520of%2520Homeostatic%2520Plasticity%2520in%2520Cultured%2520Cortical%2520Neurons%2520From%2520a%2520Mouse%2520Model%2520of%2520Huntington%2520Disease%26jtitle%3DFront.%2520Cell.%2520Neurosci.%26date%3D2019%26volume%3D13%26spage%3D209%26doi%3D10.3389%2Ffncel.2019.00209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schreiner, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedskog, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiehager, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ankarcrona, M.</span></span> <span> </span><span class="NLM_article-title">Amyloid-β Peptides Are Generated in Mitochondria-Associated Endoplasmic Reticulum Membranes</span>. <i>J. Alzheimer’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">369</span>– <span class="NLM_lpage">374</span>, <span class="refDoi"> DOI: 10.3233/JAD-132543</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3233%2FJAD-132543" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2014&pages=369-374&author=B.+Schreinerauthor=L.+Hedskogauthor=B.+Wiehagerauthor=M.+Ankarcrona&title=Amyloid-%CE%B2+Peptides+Are+Generated+in+Mitochondria-Associated+Endoplasmic+Reticulum+Membranes&doi=10.3233%2FJAD-132543"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.3233%2FJAD-132543&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-132543%26sid%3Dliteratum%253Aachs%26aulast%3DSchreiner%26aufirst%3DB.%26aulast%3DHedskog%26aufirst%3DL.%26aulast%3DWiehager%26aufirst%3DB.%26aulast%3DAnkarcrona%26aufirst%3DM.%26atitle%3DAmyloid-%25CE%25B2%2520Peptides%2520Are%2520Generated%2520in%2520Mitochondria-Associated%2520Endoplasmic%2520Reticulum%2520Membranes%26jtitle%3DJ.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2014%26volume%3D43%26spage%3D369%26epage%3D374%26doi%3D10.3233%2FJAD-132543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryskamp, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rammes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezprozvanny, I.</span></span> <span> </span><span class="NLM_article-title">Pridopidine Stabilizes Mushroom Spines in Mouse Models of Alzheimer’s Disease by Acting on the Sigma-1 Receptor</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>124</i></span>,  <span class="NLM_fpage">489</span>– <span class="NLM_lpage">504</span>, <span class="refDoi"> DOI: 10.1016/j.nbd.2018.12.022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.nbd.2018.12.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=30594810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntFCrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2019&pages=489-504&author=D.+Ryskampauthor=L.+Wuauthor=J.+Wuauthor=D.+Kimauthor=G.+Rammesauthor=M.+Gevaauthor=M.+Haydenauthor=I.+Bezprozvanny&title=Pridopidine+Stabilizes+Mushroom+Spines+in+Mouse+Models+of+Alzheimer%E2%80%99s+Disease+by+Acting+on+the+Sigma-1+Receptor&doi=10.1016%2Fj.nbd.2018.12.022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Pridopidine stabilizes mushroom spines in mouse models of Alzheimer's disease by acting on the sigma-1 receptor</span></div><div class="casAuthors">Ryskamp, Daniel; Wu, Lili; Wu, Jun; Kim, Dabin; Rammes, Gerhard; Geva, Michal; Hayden, Michael; Bezprozvanny, Ilya</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">489-504</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">There is evidence that cognitive decline in Alzheimer's disease (AD) results from deficiencies in synaptic communication (e.g., loss of mushroom-shaped 'memory spines') and neurodegenerative processes.  This might be treated with sigma-1 receptor (S1R) agonists, which are broadly neuroprotective and modulate synaptic plasticity.  For example, we previously found that the mixed muscarinic/S1R agonist AF710B prevents mushroom spine loss in hippocampal cultures from APP knock-in (APP-KI) and presenilin-1-M146 V knock-in (PS1-KI) mice.  We also found that the "dopaminergic stabilizer" pridopidine (structurally similar to the S1R agonist R(+)-3-PPP), is a high-affinity S1R agonist and is synaptoprotective in a mouse model of Huntington disease.  Here we tested whether pridopidine and R(+)-3-PPP are synaptoprotective in models of AD and whether this requires S1R.  We also examd. the effects of pridopidine on long-term potentiation (LTP), endoplasmic reticulum calcium and neuronal store-operated calcium entry (nSOC) in spines, all of which are dysregulated in AD, contributing to synaptic pathol.  We report here that pridopidine and 3-PPP protect mushroom spines from Aβ42 oligomer toxicity in primary WT hippocampal cultures from mice.  Pridopidine also reversed LTP defects in hippocampal slices resulting from application of Aβ42 oligomers.  Pridopidine and 3-PPP rescued mushroom spines in hippocampal cultures from APP-KI and PS1-KI mice.  S1R knockdown from lenti-viral shRNA expression destabilized WT mushroom spines and prevented the synaptoprotective effects of pridopidine in PS1-KI cultures.  Knockout of PS1/2 destabilized mushroom spines and pridopidine was unable to prevent this.  Pridopidine lowered endoplasmic reticulum calcium levels in WT, PS1-KO, PS1-KI and PS2 KO neurons, but not in PS1/2 KO neurons.  S1R was required for pridopidine to enhance spine nSOC in PS1-KI neurons.  Pridopidine was unable to rescue PS1-KI mushroom spines during pharmacol. or genetic inhibition of nSOC.  Oral pridopidine treatment rescued mushroom spines in vivo in aged PS1-KI-GFP mice.  Pridopidine stabilizes mushroom spines in mouse models of AD and this requires S1R, endoplasmic reticulum calcium leakage through PS1/2 and nSOC.  Thus, pridopidine may be useful to explore for the treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZa0vjyeC-9rVg90H21EOLACvtfcHk0lhwkNvDO4auRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntFCrsg%253D%253D&md5=70e9a25da577b8469533fda8b9316348</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2018.12.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2018.12.022%26sid%3Dliteratum%253Aachs%26aulast%3DRyskamp%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DKim%26aufirst%3DD.%26aulast%3DRammes%26aufirst%3DG.%26aulast%3DGeva%26aufirst%3DM.%26aulast%3DHayden%26aufirst%3DM.%26aulast%3DBezprozvanny%26aufirst%3DI.%26atitle%3DPridopidine%2520Stabilizes%2520Mushroom%2520Spines%2520in%2520Mouse%2520Models%2520of%2520Alzheimer%25E2%2580%2599s%2520Disease%2520by%2520Acting%2520on%2520the%2520Sigma-1%2520Receptor%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2019%26volume%3D124%26spage%3D489%26epage%3D504%26doi%3D10.1016%2Fj.nbd.2018.12.022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryskamp, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geva, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kusko, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grossman, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayden, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezprozvanny, I.</span></span> <span> </span><span class="NLM_article-title">The Sigma-1 Receptor Mediates the Beneficial Effects of Pridopidine in a Mouse Model of Huntington Disease</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">46</span>– <span class="NLM_lpage">59</span>, <span class="refDoi"> DOI: 10.1016/j.nbd.2016.10.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.nbd.2016.10.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=27818324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVKqtb7K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2017&pages=46-59&author=D.+Ryskampauthor=J.+Wuauthor=M.+Gevaauthor=R.+Kuskoauthor=I.+Grossmanauthor=M.+Haydenauthor=I.+Bezprozvanny&title=The+Sigma-1+Receptor+Mediates+the+Beneficial+Effects+of+Pridopidine+in+a+Mouse+Model+of+Huntington+Disease&doi=10.1016%2Fj.nbd.2016.10.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease</span></div><div class="casAuthors">Ryskamp, Daniel; Wu, Jun; Geva, Michal; Kusko, Rebecca; Grossman, Iris; Hayden, Michael; Bezprozvanny, Ilya</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">Part_A</span>),
    <span class="NLM_cas:pages">46-59</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The tri-nucleotide repeat expansion underlying Huntington disease (HD) results in corticostriatal synaptic dysfunction and subsequent neurodegeneration of striatal medium spiny neurons (MSNs).  HD is a devastating autosomal dominant disease with no disease-modifying treatments.  Pridopidine, a postulated "dopamine stabilizer", has been shown to improve motor symptoms in clin. trials of HD.  However, the target(s) and mechanism of action of pridopidine remain to be fully elucidated.  As binding studies identified sigma-1 receptor (S1R) as a high-affinity receptor for pridopidine, we evaluated the relevance of S1R as a therapeutic target of pridopidine in HD.  S1R is an endoplasmic reticulum - (ER) resident transmembrane protein and is regulated by ER calcium homeostasis, which is perturbed in HD.  Consistent with ER calcium dysregulation, we obsd. striatal upregulation of S1R in aged YAC128 transgenic HD mice and HD patients.  We previously demonstrated that dendritic MSN spines are lost in aged corticostriatal co-cultures from YAC128 mice.  We report here that pridopidine and the chem. similar S1R agonist 3-PPP prevent MSN spine loss in aging YAC128 co-cultures.  Spine protection was blocked by neuronal deletion of S1R.  Pridopidine treatment suppressed supranormal ER Ca2 + release, restored ER calcium levels and reduced excessive store-operated calcium (SOC) entry in spines, which may account for its synaptoprotective effects.  Normalization of ER Ca2 + levels by pridopidine was prevented by S1R deletion.  To evaluate long-term effects of pridopidine, we analyzed expression profiles of calcium signaling genes.  Pridopidine elevated striatal expression of calbindin and homer1a, whereas their striatal expression was reduced in aged Q175KI and YAC128 HD mouse models compared to WT.  Pridopidine and 3-PPP are proposed to prevent calcium dysregulation and synaptic loss in a YAC128 corticostriatal co-culture model of HD.  The actions of pridopidine were mediated by S1R and led to normalization of ER Ca2 + release, ER Ca2 + levels and spine SOC entry in YAC128 MSNs.  This is a new potential mechanism of action for pridopidine, highlighting S1R as a potential target for HD therapy.  Upregulation of striatal proteins that regulate calcium, including calbindin and homer1a, upon chronic therapy with pridopidine, may further contribute to long-term beneficial effects of pridopidine in HD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLP9zDH00CBLVg90H21EOLACvtfcHk0lgJ9yz_MC4cFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVKqtb7K&md5=81866000c3f2215fdb8a03f7f69bcff8</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2016.10.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2016.10.006%26sid%3Dliteratum%253Aachs%26aulast%3DRyskamp%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DGeva%26aufirst%3DM.%26aulast%3DKusko%26aufirst%3DR.%26aulast%3DGrossman%26aufirst%3DI.%26aulast%3DHayden%26aufirst%3DM.%26aulast%3DBezprozvanny%26aufirst%3DI.%26atitle%3DThe%2520Sigma-1%2520Receptor%2520Mediates%2520the%2520Beneficial%2520Effects%2520of%2520Pridopidine%2520in%2520a%2520Mouse%2520Model%2520of%2520Huntington%2520Disease%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2017%26volume%3D97%26spage%3D46%26epage%3D59%26doi%3D10.1016%2Fj.nbd.2016.10.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryskamp, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korban, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhemkov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraskovskaya, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezprozvanny, I.</span></span> <span> </span><span class="NLM_article-title">Neuronal Sigma-1 Receptors: Signaling Functions and Protective Roles in Neurodegenerative Diseases</span>. <i>Front. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">862</span>, <span class="refDoi"> DOI: 10.3389/fnins.2019.00862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3389%2Ffnins.2019.00862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=31551669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BB3MnhvVWjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=862&author=D.+A.+Ryskampauthor=S.+Korbanauthor=V.+Zhemkovauthor=N.+Kraskovskayaauthor=I.+Bezprozvanny&title=Neuronal+Sigma-1+Receptors%3A+Signaling+Functions+and+Protective+Roles+in+Neurodegenerative+Diseases&doi=10.3389%2Ffnins.2019.00862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Neuronal Sigma-1 Receptors: Signaling Functions and Protective Roles in Neurodegenerative Diseases</span></div><div class="casAuthors">Ryskamp Daniel A; Zhemkov Vladimir; Bezprozvanny Ilya; Korban Svetlana; Kraskovskaya Nina; Bezprozvanny Ilya</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">862</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">Sigma-1 receptor (S1R) is a multi-functional, ligand-operated protein situated in endoplasmic reticulum (ER) membranes and changes in its function and/or expression have been associated with various neurological disorders including amyotrophic lateral sclerosis/frontotemporal dementia, Alzheimer's (AD) and Huntington's diseases (HD).  S1R agonists are broadly neuroprotective and this is achieved through a diversity of S1R-mediated signaling functions that are generally pro-survival and anti-apoptotic; yet, relatively little is known regarding the exact mechanisms of receptor functioning at the molecular level.  This review summarizes therapeutically relevant mechanisms by which S1R modulates neurophysiology and implements neuroprotective functions in neurodegenerative diseases.  These mechanisms are diverse due to the fact that S1R can bind to and modulate a large range of client proteins, including many ion channels in both ER and plasma membranes.  We summarize the effect of S1R on its interaction partners and consider some of the cell type- and disease-specific aspects of these actions.  Besides direct protein interactions in the endoplasmic reticulum, S1R is likely to function at the cellular/interorganellar level by altering the activity of several plasmalemmal ion channels through control of trafficking, which may help to reduce excitotoxicity.  Moreover, S1R is situated in lipid rafts where it binds cholesterol and regulates lipid and protein trafficking and calcium flux at the mitochondrial-associated membrane (MAM) domain.  This may have important implications for MAM stability and function in neurodegenerative diseases as well as cellular bioenergetics.  We also summarize the structural and biochemical features of S1R proposed to underlie its activity.  In conclusion, S1R is incredibly versatile in its ability to foster neuronal homeostasis in the context of several neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTnXmondofHvmyYR5VtavbzfW6udTcc2ebq0wOKd93lErntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnhvVWjsA%253D%253D&md5=b8a65774a44e82a94e5049247c993883</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2019.00862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2019.00862%26sid%3Dliteratum%253Aachs%26aulast%3DRyskamp%26aufirst%3DD.%2BA.%26aulast%3DKorban%26aufirst%3DS.%26aulast%3DZhemkov%26aufirst%3DV.%26aulast%3DKraskovskaya%26aufirst%3DN.%26aulast%3DBezprozvanny%26aufirst%3DI.%26atitle%3DNeuronal%2520Sigma-1%2520Receptors%253A%2520Signaling%2520Functions%2520and%2520Protective%2520Roles%2520in%2520Neurodegenerative%2520Diseases%26jtitle%3DFront.%2520Neurosci.%26date%3D2019%26volume%3D13%26spage%3D862%26doi%3D10.3389%2Ffnins.2019.00862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Izzo, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staniszewski, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">To, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teich, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saeed, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wostein, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walko, T.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaswani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardius, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syed, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravenscroft, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mozzoni, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silky, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehak, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yurko, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Look, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rishton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safferstein, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johanson, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stopa, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Windisch, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hutter-Paier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shamloo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arancio, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeVine, H.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catalano, S. M.</span></span> <span> </span><span class="NLM_article-title">Alzheimer’s Therapeutics Targeting Amyloid Beta 1–42 Oligomers I: Abeta 42 Oligomer Binding to Specific Neuronal Receptors Is Displaced by Drug Candidates That Improve Cognitive Deficits</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e111898</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0111898</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1371%2Fjournal.pone.0111898" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=25390368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFOnt73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&author=N.+J.+Izzoauthor=A.+Staniszewskiauthor=L.+Toauthor=M.+Faauthor=A.+F.+Teichauthor=F.+Saeedauthor=H.+Wosteinauthor=T.+Walkoauthor=A.+Vaswaniauthor=M.+Wardiusauthor=Z.+Syedauthor=J.+Ravenscroftauthor=K.+Mozzoniauthor=C.+Silkyauthor=C.+Rehakauthor=R.+Yurkoauthor=P.+Finnauthor=G.+Lookauthor=G.+Rishtonauthor=H.+Saffersteinauthor=M.+Millerauthor=C.+Johansonauthor=E.+Stopaauthor=M.+Windischauthor=B.+Hutter-Paierauthor=M.+Shamlooauthor=O.+Arancioauthor=H.+LeVineauthor=S.+M.+Catalano&title=Alzheimer%E2%80%99s+Therapeutics+Targeting+Amyloid+Beta+1%E2%80%9342+Oligomers+I%3A+Abeta+42+Oligomer+Binding+to+Specific+Neuronal+Receptors+Is+Displaced+by+Drug+Candidates+That+Improve+Cognitive+Deficits&doi=10.1371%2Fjournal.pone.0111898"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers I: Abeta 42 oligomer binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits</span></div><div class="casAuthors">Izzo, Nicholas J.; Staniszewski, Agnes; To, Lillian; Fa, Mauro; Teich, Andrew F.; Saeed, Faisal; Wostein, Harrison; Walko, Thomas, III; Vaswani, Anisha; Wardius, Meghan; Syed, Zanobia; Ravenscroft, Jessica; Mozzoni, Kelsie; Silky, Colleen; Rehak, Courtney; Yurko, Raymond; Finn, Patricia; Look, Gary; Rishton, Gilbert; Safferstein, Hank; Miller, Miles; Johanson, Conrad; Stopa, Edward; Windisch, Manfred; Hutter-Paier, Birgit; Shamloo, Mehrdad; Arancio, Ottavio; Le Vine, Harry, III; Catalano, Susan M.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e111898/1-e111898/19, 19 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Synaptic dysfunction and loss caused by age-dependent accumulation of synaptotoxic beta amyloid (Abeta) 1-42 oligomers is proposed to underlie cognitive decline in Alzheimer's disease (AD).  Alterations in membrane trafficking induced by Abeta oligomers mediates redn. in neuronal surface receptor expression that is the basis for inhibition of electrophysiol. measures of synaptic plasticity and thus learning and memory.  We have utilized phenotypic screens in mature, in vitro cultures of rat brain cells to identify small mols. which block or prevent the binding and effects of Abeta oligomers.  Synthetic Abeta oligomers bind saturably to a single site on neuronal synapses and induce deficits in membrane trafficking in neuronal cultures with an EC50 that corresponds to its binding affinity.  The therapeutic lead compds. we have found are pharmacol. antagonists of Abeta oligomers, reducing the binding of Abeta oligomers to neurons in vitro, preventing spine loss in neurons and preventing and treating oligomer-induced deficits in membrane trafficking.  These mols. are highly brain penetrant and prevent and restore cognitive deficits in mouse models of Alzheimer's disease.  Counter-screening these compds. against a broad panel of potential CNS targets revealed they are highly potent and specific ligands of the sigma-2/PGRMC1 receptor.  Brain concns. of the compds. corresponding to greater than 80% receptor occupancy at the sigma-2/PGRMC1 receptor restore cognitive function in transgenic hAPP Swe/Ldn mice.  These studies demonstrate that synthetic and human-derived Abeta oligomers act as pharmacol.-behaved ligands at neuronal receptors - i.e. they exhibit saturable binding to a target, they exert a functional effect related to their binding and their displacement by small mol. antagonists blocks their functional effect.  The first-in-class small mol. receptor antagonists described here restore memory to normal in multiple AD models and sustain improvement long-term, representing a novel mechanism of action for disease-modifying Alzheimer's therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyzEMMs3vvP7Vg90H21EOLACvtfcHk0lgJ9yz_MC4cFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFOnt73I&md5=3672c523a12874998e3696c95ece6a08</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0111898&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0111898%26sid%3Dliteratum%253Aachs%26aulast%3DIzzo%26aufirst%3DN.%2BJ.%26aulast%3DStaniszewski%26aufirst%3DA.%26aulast%3DTo%26aufirst%3DL.%26aulast%3DFa%26aufirst%3DM.%26aulast%3DTeich%26aufirst%3DA.%2BF.%26aulast%3DSaeed%26aufirst%3DF.%26aulast%3DWostein%26aufirst%3DH.%26aulast%3DWalko%26aufirst%3DT.%26aulast%3DVaswani%26aufirst%3DA.%26aulast%3DWardius%26aufirst%3DM.%26aulast%3DSyed%26aufirst%3DZ.%26aulast%3DRavenscroft%26aufirst%3DJ.%26aulast%3DMozzoni%26aufirst%3DK.%26aulast%3DSilky%26aufirst%3DC.%26aulast%3DRehak%26aufirst%3DC.%26aulast%3DYurko%26aufirst%3DR.%26aulast%3DFinn%26aufirst%3DP.%26aulast%3DLook%26aufirst%3DG.%26aulast%3DRishton%26aufirst%3DG.%26aulast%3DSafferstein%26aufirst%3DH.%26aulast%3DMiller%26aufirst%3DM.%26aulast%3DJohanson%26aufirst%3DC.%26aulast%3DStopa%26aufirst%3DE.%26aulast%3DWindisch%26aufirst%3DM.%26aulast%3DHutter-Paier%26aufirst%3DB.%26aulast%3DShamloo%26aufirst%3DM.%26aulast%3DArancio%26aufirst%3DO.%26aulast%3DLeVine%26aufirst%3DH.%26aulast%3DCatalano%26aufirst%3DS.%2BM.%26atitle%3DAlzheimer%25E2%2580%2599s%2520Therapeutics%2520Targeting%2520Amyloid%2520Beta%25201%25E2%2580%259342%2520Oligomers%2520I%253A%2520Abeta%252042%2520Oligomer%2520Binding%2520to%2520Specific%2520Neuronal%2520Receptors%2520Is%2520Displaced%2520by%2520Drug%2520Candidates%2520That%2520Improve%2520Cognitive%2520Deficits%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26doi%3D10.1371%2Fjournal.pone.0111898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Izzo, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirk, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mozzoni, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silky, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rehak, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yurko, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Look, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rishton, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safferstein, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruchaga, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goate, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cahill, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arancio, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craven, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LeVine, H.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spires-Jones, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catalano, S. M.</span></span> <span> </span><span class="NLM_article-title">Alzheimer’s Therapeutics Targeting Amyloid Beta 1-42 Oligomers II: Sigma-2/PGRMC1 Receptors Mediate Abeta 42 Oligomer Binding and Synaptotoxicity</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>, <span class="NLM_elocation-id">e111899</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0111899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1371%2Fjournal.pone.0111899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=25390692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFyht77K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&author=N.+J.+Izzoauthor=J.+Xuauthor=C.+Zengauthor=M.+J.+Kirkauthor=K.+Mozzoniauthor=C.+Silkyauthor=C.+Rehakauthor=R.+Yurkoauthor=G.+Lookauthor=G.+Rishtonauthor=H.+Saffersteinauthor=C.+Cruchagaauthor=A.+Goateauthor=M.+A.+Cahillauthor=O.+Arancioauthor=R.+H.+Machauthor=R.+Cravenauthor=E.+Headauthor=H.+LeVineauthor=T.+Spires-Jonesauthor=S.+M.+Catalano&title=Alzheimer%E2%80%99s+Therapeutics+Targeting+Amyloid+Beta+1-42+Oligomers+II%3A+Sigma-2%2FPGRMC1+Receptors+Mediate+Abeta+42+Oligomer+Binding+and+Synaptotoxicity&doi=10.1371%2Fjournal.pone.0111899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Alzheimer's therapeutics targeting amyloid beta 1-42 oligomers II: sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity</span></div><div class="casAuthors">Izzo, Nicholas J.; Xu, Jinbin; Zeng, Chenbo; Kirk, Molly J.; Mozzoni, Kelsie; Silky, Colleen; Rehak, Courtney; Yurko, Raymond; Look, Gary; Rishton, Gilbert; Safferstein, Hank; Cruchaga, Carlos; Goate, Alison; Cahill, Michael A.; Arancio, Ottavio; Mach, Robert H.; Craven, Rolf; Head, Elizabeth; LeVine, Harry; Spires-Jones, Tara L.; Catalano, Susan M.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e111899/1-e111899/15, 15 pp.</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Amyloid beta (Abeta) 1-42 oligomers accumulate in brains of patients with Mild Cognitive Impairment (MCI) and disrupt synaptic plasticity processes that underlie memory formation.  Synaptic binding of Abeta oligomers to several putative receptor proteins is reported to inhibit long-term potentiation, affect membrane trafficking and induce reversible spine loss in neurons, leading to impaired cognitive performance and ultimately to anterograde amnesia in the early stages of Alzheimer's disease (AD).  We have identified a receptor not previously assocd. with AD that mediates the binding of Abeta oligomers to neurons, and describe novel therapeutic antagonists of this receptor capable of blocking Abeta toxic effects on synapses in vitro and cognitive deficits in vivo.  Knockdown of sigma-2/PGRMC1 (progesterone receptor membrane component 1) protein expression in vitro using siRNA results in a highly correlated redn. in binding of exogenous Abeta oligomers to neurons of more than 90%.  Expression of sigma-2/PGRMC1 is upregulated in vitro by treatment with Abeta oligomers, and is dysregulated in Alzheimer's disease patients' brain compared to age-matched, normal individuals.  Specific, high affinity small mol. receptor antagonists and antibodies raised against specific regions on this receptor can displace synthetic Abeta oligomer binding to synaptic puncta in vitro and displace endogenous human AD patient oligomers from brain tissue sections in a dose-dependent manner.  These receptor antagonists prevent and reverse the effects of Abeta oligomers on membrane trafficking and synapse loss in vitro and cognitive deficits in AD mouse models.  These findings suggest sigma-2/PGRMC1 receptors mediate saturable oligomer binding to synaptic puncta on neurons and that brain penetrant, small mols. can displace endogenous and synthetic oligomers and improve cognitive deficits in AD models.  We propose that sigma-2/PGRMC1 is a key mediator of the pathol. effects of Abeta oligomers in AD and is a tractable target for small mol. disease-modifying therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7DydGr-ZJvbVg90H21EOLACvtfcHk0lhzffmlRfqIRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFyht77K&md5=c6b3cb23c02818632de37efd3b10a6f2</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0111899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0111899%26sid%3Dliteratum%253Aachs%26aulast%3DIzzo%26aufirst%3DN.%2BJ.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DKirk%26aufirst%3DM.%2BJ.%26aulast%3DMozzoni%26aufirst%3DK.%26aulast%3DSilky%26aufirst%3DC.%26aulast%3DRehak%26aufirst%3DC.%26aulast%3DYurko%26aufirst%3DR.%26aulast%3DLook%26aufirst%3DG.%26aulast%3DRishton%26aufirst%3DG.%26aulast%3DSafferstein%26aufirst%3DH.%26aulast%3DCruchaga%26aufirst%3DC.%26aulast%3DGoate%26aufirst%3DA.%26aulast%3DCahill%26aufirst%3DM.%2BA.%26aulast%3DArancio%26aufirst%3DO.%26aulast%3DMach%26aufirst%3DR.%2BH.%26aulast%3DCraven%26aufirst%3DR.%26aulast%3DHead%26aufirst%3DE.%26aulast%3DLeVine%26aufirst%3DH.%26aulast%3DSpires-Jones%26aufirst%3DT.%26aulast%3DCatalano%26aufirst%3DS.%2BM.%26atitle%3DAlzheimer%25E2%2580%2599s%2520Therapeutics%2520Targeting%2520Amyloid%2520Beta%25201-42%2520Oligomers%2520II%253A%2520Sigma-2%252FPGRMC1%2520Receptors%2520Mediate%2520Abeta%252042%2520Oligomer%2520Binding%2520and%2520Synaptotoxicity%26jtitle%3DPLoS%2520One%26date%3D2014%26volume%3D9%26doi%3D10.1371%2Fjournal.pone.0111899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peruzzo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biasutto, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szabò, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leanza, L.</span></span> <span> </span><span class="NLM_article-title">Impact of Intracellular Ion Channels on Cancer Development and Progression</span>. <i>Eur. Biophys. J.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">685</span>– <span class="NLM_lpage">707</span>, <span class="refDoi"> DOI: 10.1007/s00249-016-1143-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1007%2Fs00249-016-1143-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=27289382" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC28XpvV2ntLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2016&pages=685-707&author=R.+Peruzzoauthor=L.+Biasuttoauthor=I.+Szab%C3%B2author=L.+Leanza&title=Impact+of+Intracellular+Ion+Channels+on+Cancer+Development+and+Progression&doi=10.1007%2Fs00249-016-1143-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Impact of intracellular ion channels on cancer development and progression</span></div><div class="casAuthors">Peruzzo, Roberta; Biasutto, Lucia; Szabo, Ildiko; Leanza, Luigi</div><div class="citationInfo"><span class="NLM_cas:title">European Biophysics Journal</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">685-707</span>CODEN:
                <span class="NLM_cas:coden">EBJOE8</span>;
        ISSN:<span class="NLM_cas:issn">0175-7571</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Cancer research is nowadays focused on the identification of possible new targets in order to try to develop new drugs for curing untreatable tumors.  Ion channels have emerged as "oncogenic" proteins, since they have an aberrant expression in cancers compared to normal tissues and contribute to several hallmarks of cancer, such as metabolic re-programming, limitless proliferative potential, apoptosis-resistance, stimulation of neo-angiogenesis as well as cell migration and invasiveness.  In recent years, not only the plasma membrane but also intracellular channels and transporters have arisen as oncol. targets and were proposed to be assocd. with tumorigenesis.  Therefore, the research is currently focusing on understanding the possible role of intracellular ion channels in cancer development and progression on one hand and, on the other, on developing new possible drugs able to modulate the expression and/or activity of these channels.  In a few cases, the efficacy of channel-targeting drugs in reducing tumors has already been demonstrated in vivo in preclin. mouse models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEB4xMw-_W3bVg90H21EOLACvtfcHk0lhzffmlRfqIRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XpvV2ntLw%253D&md5=9b0d1d4a312205381b1a634e913d9901</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1007%2Fs00249-016-1143-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00249-016-1143-0%26sid%3Dliteratum%253Aachs%26aulast%3DPeruzzo%26aufirst%3DR.%26aulast%3DBiasutto%26aufirst%3DL.%26aulast%3DSzab%25C3%25B2%26aufirst%3DI.%26aulast%3DLeanza%26aufirst%3DL.%26atitle%3DImpact%2520of%2520Intracellular%2520Ion%2520Channels%2520on%2520Cancer%2520Development%2520and%2520Progression%26jtitle%3DEur.%2520Biophys.%2520J.%26date%3D2016%26volume%3D45%26spage%3D685%26epage%3D707%26doi%3D10.1007%2Fs00249-016-1143-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crottès, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guizouarn, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borgese, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soriani, O.</span></span> <span> </span><span class="NLM_article-title">The Sigma-1 Receptor: A Regulator of Cancer Cell Electrical Plasticity?</span>. <i>Front. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">175</span>, <span class="refDoi"> DOI: 10.3389/fphys.2013.00175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3389%2Ffphys.2013.00175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=23882221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVOrtr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=175&author=D.+Crott%C3%A8sauthor=H.+Guizouarnauthor=P.+Martinauthor=F.+Borgeseauthor=O.+Soriani&title=The+Sigma-1+Receptor%3A+A+Regulator+of+Cancer+Cell+Electrical+Plasticity%3F&doi=10.3389%2Ffphys.2013.00175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">The sigma-1 receptor: a regulator of cancer cell electrical plasticity?</span></div><div class="casAuthors">Crottes, David; Guizouarn, Helene; Martin, Patrick; Borgese, Franck; Soriani, Olivier</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Membrane Physiology and Membrane Biophysics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">July</span>),
    <span class="NLM_cas:pages">00175, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">FMPMEI</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Originally mistaken as an opioid receptor, the sigma-1 receptor (Sig1R) is a ubiquitous membrane protein that has been involved in many cellular processes.  While the precise function of Sig1R has long remained mysterious, recent studies have shed light on its role and the mol. mechanisms triggered.  Sig1R is in fact a stress-activated chaperone mainly assocd. with the ER-mitochondria interface that can regulate cell survival through the control of calcium homeostasis.  Sig1R functionally regulates ion channels belonging to various mol. families and it has thus been involved in neuronal plasticity and central nervous system diseases.  Interestingly, Sig1R is frequently expressed in tumors but its function in cancer has not been yet clarified.  In this review, we discuss the current understanding of Sig1R.  We suggest herein that Sig1R shapes cancer cell elec. signature upon environmental conditions.  Thus, Sig1R may be used as a novel therapeutic target to specifically abrogate pro-invasive functions of ion channels in cancer tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdYFdskWDj1rVg90H21EOLACvtfcHk0lib5XWdO6SDOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVOrtr%252FL&md5=9dc47ce726d7469990cdd30f149fc9e1</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.3389%2Ffphys.2013.00175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphys.2013.00175%26sid%3Dliteratum%253Aachs%26aulast%3DCrott%25C3%25A8s%26aufirst%3DD.%26aulast%3DGuizouarn%26aufirst%3DH.%26aulast%3DMartin%26aufirst%3DP.%26aulast%3DBorgese%26aufirst%3DF.%26aulast%3DSoriani%26aufirst%3DO.%26atitle%3DThe%2520Sigma-1%2520Receptor%253A%2520A%2520Regulator%2520of%2520Cancer%2520Cell%2520Electrical%2520Plasticity%253F%26jtitle%3DFront.%2520Physiol.%26date%3D2013%26volume%3D4%26spage%3D175%26doi%3D10.3389%2Ffphys.2013.00175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spruce, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTavish, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleyard, M. V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, N. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safrany, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prescott, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nutley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downes, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, S.</span></span> <span> </span><span class="NLM_article-title">Small Molecule Antagonists of the Sigma-1 Receptor Cause Selective Release of the Death Program in Tumor and Self-Reliant Cells and Inhibit Tumor Growth in Vitro and in Vivo</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">4875</span>– <span class="NLM_lpage">4886</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-03-3180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1158%2F0008-5472.CAN-03-3180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=15256458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD2cXls1Omtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=4875-4886&author=B.+A.+Spruceauthor=L.+A.+Campbellauthor=N.+McTavishauthor=M.+A.+Cooperauthor=M.+V.+L.+Appleyardauthor=M.+O%E2%80%99Neillauthor=J.+Howieauthor=J.+Samsonauthor=S.+Wattauthor=K.+Murrayauthor=D.+McLeanauthor=N.+K.+Leslieauthor=S.+T.+Safranyauthor=M.+J.+Fergusonauthor=J.+A.+Petersauthor=A.+R.+Prescottauthor=G.+Boxauthor=A.+Hayesauthor=B.+Nutleyauthor=F.+Raynaudauthor=C.+P.+Downesauthor=J.+J.+Lambertauthor=A.+M.+Thompsonauthor=S.+Eccles&title=Small+Molecule+Antagonists+of+the+Sigma-1+Receptor+Cause+Selective+Release+of+the+Death+Program+in+Tumor+and+Self-Reliant+Cells+and+Inhibit+Tumor+Growth+in+Vitro+and+in+Vivo&doi=10.1158%2F0008-5472.CAN-03-3180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Antagonists of the σ-1 Receptor Cause Selective Release of the Death Program in Tumor and Self-Reliant Cells and Inhibit Tumor Growth in Vitro and in Vivo</span></div><div class="casAuthors">Spruce, Barbara A.; Campbell, Lorna A.; McTavish, Niall; Cooper, Michelle A.; Appleyard, M. Virginia L.; O'Neill, Mary; Howie, Jacqueline; Samson, Jayne; Watt, Stephen; Murray, Karen; McLean, Doris; Leslie, Nick R.; Safrany, Stephen T.; Ferguson, Michelle J.; Peters, John A.; Prescott, Alan R.; Box, Gary; Hayes, Angela; Nutley, Bernard; Raynaud, Florence; Downes, C. Peter; Lambert, Jeremy J.; Thompson, Alastair M.; Eccles, Suzanne</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4875-4886</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The acquisition of resistance to apoptosis, the cell's intrinsic suicide program, is essential for cancers to arise and progress and is a major reason behind treatment failures.  We show in this article that small mol. antagonists of the σ-1 receptor inhibit tumor cell survival to reveal caspase-dependent apoptosis.  σ-Antagonist-mediated caspase activation and cell death are substantially attenuated by the prototypic -1 agonists (+)-SKF10,047 and (+)-pentazocine.  Although several normal cell types such as fibroblasts, epithelial cells, and even σ receptor-rich neurons are resistant to the apoptotic effects of σ antagonists, cells that can promote autocrine survival such as lens epithelial and microvascular endothelial cells are as susceptible as tumor cells.  Cellular susceptibility appears to correlate with differences in σ receptor coupling rather than levels of expression.  In susceptible cells only, σ antagonists evoke a rapid rise in cytosolic calcium that is inhibited by σ-1 agonists.  In at least some tumor cells, σ antagonists cause calcium-dependent activation of phospholipase C and concomitant calcium-independent inhibition of phosphatidylinositol 3'-kinase pathway signaling.  BSystemic administration of σ antagonists significantly inhibits the growth of evolving and established hormone-sensitive and hormone-insensitive mammary carcinoma xenografts, orthotopic prostate tumors, and p53-null lung carcinoma xenografts in immunocompromised mice in the absence of side effects.  Release of a σ receptor-mediated brake on apoptosis may offer a new approach to cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpSCoAyVi6oLVg90H21EOLACvtfcHk0lib5XWdO6SDOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXls1Omtr8%253D&md5=a91eaaa7754714c7113c8107ffedc965</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-03-3180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-03-3180%26sid%3Dliteratum%253Aachs%26aulast%3DSpruce%26aufirst%3DB.%2BA.%26aulast%3DCampbell%26aufirst%3DL.%2BA.%26aulast%3DMcTavish%26aufirst%3DN.%26aulast%3DCooper%26aufirst%3DM.%2BA.%26aulast%3DAppleyard%26aufirst%3DM.%2BV.%2BL.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DM.%26aulast%3DHowie%26aufirst%3DJ.%26aulast%3DSamson%26aufirst%3DJ.%26aulast%3DWatt%26aufirst%3DS.%26aulast%3DMurray%26aufirst%3DK.%26aulast%3DMcLean%26aufirst%3DD.%26aulast%3DLeslie%26aufirst%3DN.%2BK.%26aulast%3DSafrany%26aufirst%3DS.%2BT.%26aulast%3DFerguson%26aufirst%3DM.%2BJ.%26aulast%3DPeters%26aufirst%3DJ.%2BA.%26aulast%3DPrescott%26aufirst%3DA.%2BR.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DNutley%26aufirst%3DB.%26aulast%3DRaynaud%26aufirst%3DF.%26aulast%3DDownes%26aufirst%3DC.%2BP.%26aulast%3DLambert%26aufirst%3DJ.%2BJ.%26aulast%3DThompson%26aufirst%3DA.%2BM.%26aulast%3DEccles%26aufirst%3DS.%26atitle%3DSmall%2520Molecule%2520Antagonists%2520of%2520the%2520Sigma-1%2520Receptor%2520Cause%2520Selective%2520Release%2520of%2520the%2520Death%2520Program%2520in%2520Tumor%2520and%2520Self-Reliant%2520Cells%2520and%2520Inhibit%2520Tumor%2520Growth%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D4875%26epage%3D4886%26doi%3D10.1158%2F0008-5472.CAN-03-3180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gasparre, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassano, G.</span></span> <span> </span><span class="NLM_article-title">The Sigma-1 Receptor Antagonist PB212 Reduces the Ca 2+-Release through the Inositol (1, 4, 5)-Trisphosphate Receptor in SK-N-SH Cells</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>684</i></span>,  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2012.03.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejphar.2012.03.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=22465185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvFynsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=684&publication_year=2012&pages=59-63&author=G.+Gasparreauthor=C.+Abateauthor=F.+Berardiauthor=G.+Cassano&title=The+Sigma-1+Receptor+Antagonist+PB212+Reduces+the+Ca+2%2B-Release+through+the+Inositol+%281%2C+4%2C+5%29-Trisphosphate+Receptor+in+SK-N-SH+Cells&doi=10.1016%2Fj.ejphar.2012.03.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">The sigma-1 receptor antagonist PB212 reduces the Ca2+-release through the inositol (1, 4, 5)-trisphosphate receptor in SK-N-SH cells</span></div><div class="casAuthors">Gasparre, Giuseppe; Abate, Carmen; Berardi, Francesco; Cassano, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">684</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">59-63</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Sigma-1 receptors are specifically located at the endoplasmic reticulum-mitochondrion interface, but upon stimulation by ligands or under prolonged cellular stress, they translocate to other areas of the cell.  Sigma-1 receptors are involved in the regulation of intracellular [Ca2+] by affecting the Ca2+-influx or the release from intracellular stores.  In SK-N-SH cells, we measured the affinity of 4-methyl-1-[4-(6-methoxynaphthalen-1-yl)butyl]piperidine (PB212) at sigma-1 receptor by using a competition binding assay with specific radioligand; we obtained a Ki value = 316 ± 19 nM.  PB212 also showed an antiproliferative effect in SK-N-SH cells (EC50 = 32 ± 4 μM) but had no effect in MCF7 cells, which only express sigma-2 receptor; these findings suggest that PB212 behaves as a sigma-1 receptor antagonist.  We have studied the effect of PB212 on Ca2+ homeostasis of the SK-N-SH cell line with the fluorescent probe Fura-2. 100 μM PB212 induced a Ca2+-efflux from the endoplasmic reticulum through the inositol (1, 4, 5)-trisphosphate (IP3) receptor.  Moreover, [PB212] ranging from 1 to 100 μM reduced the Ca2+-response, triggered by carbachol or bradykinin that engage the phospholipase C/IP3 pathway; such a response is generally increased by sigma-1 receptor agonists.  On the other hand, PB212 did not reduce the Ca2+-response mediated by IP3 in LoVo cells, which do not express neither sigma-1 nor sigma-2 receptors, and in MCF7 cells.  The fact that the activity of the sigma-1 receptor can be exptl. modulated by agonists and antagonists supports the intriguing hypothesis that some endogenous mols., unknown at the moment, modulate the sigma-1 receptor and its cellular targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrO9tdpeuIkCbVg90H21EOLACvtfcHk0lgHqeuYXz1jsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvFynsLw%253D&md5=a6ae6b3b38763757bcf367dc3c99ba71</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2012.03.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2012.03.021%26sid%3Dliteratum%253Aachs%26aulast%3DGasparre%26aufirst%3DG.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DCassano%26aufirst%3DG.%26atitle%3DThe%2520Sigma-1%2520Receptor%2520Antagonist%2520PB212%2520Reduces%2520the%2520Ca%25202%252B-Release%2520through%2520the%2520Inositol%2520%25281%252C%25204%252C%25205%2529-Trisphosphate%2520Receptor%2520in%2520SK-N-SH%2520Cells%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2012%26volume%3D684%26spage%3D59%26epage%3D63%26doi%3D10.1016%2Fj.ejphar.2012.03.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colgan, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Hashimi, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, R. C.</span></span> <span> </span><span class="NLM_article-title">Endoplasmic Reticulum Stress and Lipid Dysregulation</span>. <i>Expert Rev. Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1017/S1462399410001742</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1017%2FS1462399410001742" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2011&pages=1-14&author=S.+M.+Colganauthor=A.+A.+Al-Hashimiauthor=R.+C.+Austin&title=Endoplasmic+Reticulum+Stress+and+Lipid+Dysregulation&doi=10.1017%2FS1462399410001742"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1017%2FS1462399410001742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1017%252FS1462399410001742%26sid%3Dliteratum%253Aachs%26aulast%3DColgan%26aufirst%3DS.%2BM.%26aulast%3DAl-Hashimi%26aufirst%3DA.%2BA.%26aulast%3DAustin%26aufirst%3DR.%2BC.%26atitle%3DEndoplasmic%2520Reticulum%2520Stress%2520and%2520Lipid%2520Dysregulation%26jtitle%3DExpert%2520Rev.%2520Mol.%2520Med.%26date%3D2011%26volume%3D13%26spage%3D1%26epage%3D14%26doi%3D10.1017%2FS1462399410001742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, W. G.</span></span> <span> </span><span class="NLM_article-title">The σ<sub>2</sub> Receptor: A Novel Protein for the Imaging and Treatment of Cancer</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7137</span>– <span class="NLM_lpage">7160</span>, <span class="refDoi"> DOI: 10.1021/jm301545c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301545c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovFWmtr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7137-7160&author=R.+H.+Machauthor=C.+Zengauthor=W.+G.+Hawkins&title=The+%CF%832+Receptor%3A+A+Novel+Protein+for+the+Imaging+and+Treatment+of+Cancer&doi=10.1021%2Fjm301545c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">The σ2 Receptor: A Novel Protein for the Imaging and Treatment of Cancer</span></div><div class="casAuthors">Mach, Robert H.; Zeng, Chenbo; Hawkins, William G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">7137-7160</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The σ2 receptor is an important target for the development of mol. probes in oncol. because of its 10-fold higher d. in proliferating tumor cells compared with that in quiescent tumor cells and because of the observation that σ2 receptor agonists are able to kill tumor cells via apoptotic and nonapoptotic mechanisms.  Although recent evidence indicates that the σ2 receptor binding site is localized within the progesterone receptor membrane component 1 (PGRMC1), most information regarding this protein has been obtained using either radiolabeled or fluorescent receptor-based probes and from biochem. anal. of the effect of σ2 selective ligands on cells grown in culture.  This article reviews the development of σ2 receptor ligands and presents an overview of how they have been used in vitro and in vivo to increase the authors' understanding of the role of the σ2 receptor in cancer and proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWf1ZnaveYT7Vg90H21EOLACvtfcHk0lgHqeuYXz1jsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovFWmtr0%253D&md5=55831988f692d39d423e8cfe7f18240f</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1021%2Fjm301545c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301545c%26sid%3Dliteratum%253Aachs%26aulast%3DMach%26aufirst%3DR.%2BH.%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DHawkins%26aufirst%3DW.%2BG.%26atitle%3DThe%2520%25CF%25832%2520Receptor%253A%2520A%2520Novel%2520Protein%2520for%2520the%2520Imaging%2520and%2520Treatment%2520of%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7137%26epage%3D7160%26doi%3D10.1021%2Fjm301545c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cantonero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camello, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salido, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosado, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redondo, P. C.</span></span> <span> </span><span class="NLM_article-title">NO1, a New Sigma 2 Receptor/TMEM97 Fluorescent Ligand, Downregulates SOCE and Promotes Apoptosis in the Triple Negative Breast Cancer Cell Lines</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">257</span>, <span class="refDoi"> DOI: 10.3390/cancers12020257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.3390%2Fcancers12020257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1Klsb%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=257&author=C.+Cantoneroauthor=P.+J.+Camelloauthor=C.+Abateauthor=F.+Berardiauthor=G.+M.+Salidoauthor=J.+A.+Rosadoauthor=P.+C.+Redondo&title=NO1%2C+a+New+Sigma+2+Receptor%2FTMEM97+Fluorescent+Ligand%2C+Downregulates+SOCE+and+Promotes+Apoptosis+in+the+Triple+Negative+Breast+Cancer+Cell+Lines&doi=10.3390%2Fcancers12020257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">NO1, a new sigma 2 receptor/TMEM97 fluorescent ligand, downregulates SOCE and promotes apoptosis in the triple negative breast cancer cell lines</span></div><div class="casAuthors">Cantonero, Carlos; Camello, Pedro Javier; Abate, Carmen; Berardi, Francesco; Salido, Gines Maria; Rosado, Juan Antonio; Redondo, Pedro C.</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">257</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">(1) Background: The structure of the Sigma 2 receptor/TMEM97 (σ2RTMEM97) has recently been reported. (2, 3) Methods and results: We used genetic and biochem. approaches to identify the mol. mechanism downstream of σ2R/TMEM97.  The novel σ2R/TMEM97 fluorescent ligand, NO1, reduced the proliferation and survival of the triple neg. breast cancer cell lines (TNBC: MDA-MB-231 and MDA-MB-468 cell lines), due to NO1-induced apoptosis.  Greater bioaccumulation and faster uptake of NO1 in MDA-MB-231 cells compared to MCF10A or MCF7 cell lines were also shown.  Accordingly, elevated σ2R/TMEM97 expression was confirmed by Western blotting.  In contrast to NO1, other σ2R/TMEM97 ligands, such as SM21 and PB28, enhanced MDA-MB-231 cell proliferation and migration.  Store-operated calcium entry (SOCE) is crucial for different cancer hallmarks.  Here, we show that NO1, but not other σ2R/TMEM97 ligands, reduced SOCE in MDA-MB-231 cells.  Similarly, TMEM97 silencing in MDA-MB-231 cells also impaired SOCE.  NO1 administration downregulated STIM1-Orai1 interaction, probably by impairing the pos. regulatory effect of σ2R/TMEM97 on STIM1, as we were unable to detect interaction with Orai1. (4) Conclusion: σ2R/TMEM97 is a key protein for the survival of triple neg. breast cancer cells by promoting SOCE; therefore, NO1 may become a good pharmacol. tool to avoid their proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4LjswYuEa77Vg90H21EOLACvtfcHk0lgHqeuYXz1jsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1Klsb%252FP&md5=8410a8bed611defd39251c0d542da069</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.3390%2Fcancers12020257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers12020257%26sid%3Dliteratum%253Aachs%26aulast%3DCantonero%26aufirst%3DC.%26aulast%3DCamello%26aufirst%3DP.%2BJ.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DSalido%26aufirst%3DG.%2BM.%26aulast%3DRosado%26aufirst%3DJ.%2BA.%26aulast%3DRedondo%26aufirst%3DP.%2BC.%26atitle%3DNO1%252C%2520a%2520New%2520Sigma%25202%2520Receptor%252FTMEM97%2520Fluorescent%2520Ligand%252C%2520Downregulates%2520SOCE%2520and%2520Promotes%2520Apoptosis%2520in%2520the%2520Triple%2520Negative%2520Breast%2520Cancer%2520Cell%2520Lines%26jtitle%3DCancers%26date%3D2020%26volume%3D12%26spage%3D257%26doi%3D10.3390%2Fcancers12020257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hafner Ĉesen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repnik, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, B.</span></span> <span> </span><span class="NLM_article-title">Siramesine Triggers Cell Death through Destabilisation of Mitochondria, but Not Lysosomes</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">e818</span>, <span class="refDoi"> DOI: 10.1038/cddis.2013.361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fcddis.2013.361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=24091661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsF2nsb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=e818&author=M.+Hafner+%C4%88esenauthor=U.+Repnikauthor=V.+Turkauthor=B.+Turk&title=Siramesine+Triggers+Cell+Death+through+Destabilisation+of+Mitochondria%2C+but+Not+Lysosomes&doi=10.1038%2Fcddis.2013.361"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">Siramesine triggers cell death through destabilisation of mitochondria, but not lysosomes</span></div><div class="casAuthors">Hafner Cesen, M.; Repnik, U.; Turk, V.; Turk, B.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">Oct.</span>),
    <span class="NLM_cas:pages">e818</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A sigma-2 receptor agonist siramesine has been shown to trigger cell death of cancer cells and to exhibit a potent anticancer activity in vivo.  However, its mechanism of action is still poorly understood.  We show that siramesine can induce rapid cell death in a no. of cell lines at concns. above 20 μM.  In HaCaT cells, cell death was accompanied by caspase activation, rapid loss of mitochondrial membrane potential (MMP), cytochrome c release, cardiolipin peroxidn. and typical apoptotic morphol., whereas in U-87MG cells most apoptotic hallmarks were not notable, although MMP was rapidly lost.  In contrast to the rapid loss of MMP above 20 μM siramesine, a rapid increase in lysosomal pH was obsd. at all concns. tested (5-40 μM); however, it was not accompanied by lysosomal membrane permeabilisation (LMP) and the release of lysosomal enzymes into the cytosol.  Increased lysosomal pH reduced the lysosomal degrdn. potential as indicated by the accumulation of immature forms of cysteine cathepsins.  The lipophilic antioxidant α-tocopherol, but not the hydrophilic antioxidant N-acetyl-cysteine, considerably reduced cell death and destabilization of mitochondrial membranes, but did not prevent the increase in lysosomal pH.  At concns. below 15 μM, siramesine triggered cell death after 2 days or later, which seems to be assocd. with a general metabolic and energy imbalance due to defects in the endocytic pathway, intracellular trafficking and energy prodn., and not by a specific mol. event.  Overall, we show that cell death in siramesine-treated cells is induced by destabilization of mitochondria and is independent of LMP and the release of cathepsins into the cytosol.  Moreover, it is unlikely that siramesine acts exclusively through sigma-2 receptors, but rather through multiple mol. targets inside the cell.  Our findings are therefore of significant importance in designing the next generation of siramesine analogs with high anticancer potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5ykUgq2aIvLVg90H21EOLACvtfcHk0liNpWJFaSmmFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsF2nsb3E&md5=bbc74af055d10a5fd50ba276bb20e10d</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1038%2Fcddis.2013.361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddis.2013.361%26sid%3Dliteratum%253Aachs%26aulast%3DHafner%2B%25C4%2588esen%26aufirst%3DM.%26aulast%3DRepnik%26aufirst%3DU.%26aulast%3DTurk%26aufirst%3DV.%26aulast%3DTurk%26aufirst%3DB.%26atitle%3DSiramesine%2520Triggers%2520Cell%2520Death%2520through%2520Destabilisation%2520of%2520Mitochondria%252C%2520but%2520Not%2520Lysosomes%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2013%26volume%3D4%26spage%3De818%26doi%3D10.1038%2Fcddis.2013.361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pati, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornick, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, W.</span></span> <span> </span><span class="NLM_article-title">Sigma-2 Receptor Agonist Derivatives of 1-Cyclohexyl-4-[3-(5-Methoxy-1,2,3,4-Tetrahydronaphthalen-1-Yl)Propyl]Piperazine (PB28) Induce Cell Death via Mitochondrial Superoxide Production and Caspase Activation in Pancreatic Cancer</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">51</span>, <span class="refDoi"> DOI: 10.1186/s12885-016-3040-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1186%2Fs12885-016-3040-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=28086830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjs12mtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=51&author=M.+L.+Patiauthor=J.+R.+Hornickauthor=M.+Nisoauthor=F.+Berardiauthor=D.+Spitzerauthor=C.+Abateauthor=W.+Hawkins&title=Sigma-2+Receptor+Agonist+Derivatives+of+1-Cyclohexyl-4-%5B3-%285-Methoxy-1%2C2%2C3%2C4-Tetrahydronaphthalen-1-Yl%29Propyl%5DPiperazine+%28PB28%29+Induce+Cell+Death+via+Mitochondrial+Superoxide+Production+and+Caspase+Activation+in+Pancreatic+Cancer&doi=10.1186%2Fs12885-016-3040-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-2 receptor agonist derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4- tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) induce cell death via mitochondrial superoxide production and caspase activation in pancreatic cancer</span></div><div class="casAuthors">Pati, Maria Laura; Hornick, John R.; Niso, Mauro; Berardi, Francesco; Spitzer, Dirk; Abate, Carmen; Hawkins, William</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">51/1-51/12</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Despite considerable efforts by scientific research, pancreatic cancer is the fourth leading cause of cancer related mortalities.  Sigma-2 receptors, which are overexpressed in several tumors, represent promising targets for triggering selective pancreatic cancer cells death.  We selected five differently structured high-affinity sigma-2 ligands (PB28, PB183, PB221, F281 and PB282) to study how they affect the viability of diverse pancreatic cancer cells (human cell lines BxPC3, AsPC1, Mia PaCa-2, and Panc1 and mouse Panc-02, KCKO and KP-02) and how this is reflected in vivo in a tumor model.  Important cytotoxicity was shown by the compds. in the aggressive Panc02 cells, where cytotoxic activity was caspase-3 independent for four of the five compds.  However, both cytotoxicity and caspase-3 activation involved generation of Reactive Oxygen Species (ROS), which could be partially reverted by the lipid antioxidant a-tocopherol, but not by the hydrophilic N-acetylcysteine (NAC) indicating crucial differences in the intracellular sites exposed to oxidative stress induced by sigma-2 receptor ligands.  Importantly, all the compds. strongly increased the prodn. of mitochondrial superoxide radicals except for PB282.  Despite a poor match between in vitro and the in vivo efficacy, daily treatment of C57BL/6 mice bearing Panc02 tumors resulted in promising effects with PB28 and PB282 which were similar compared to the current std.-of-care chemotherapeutic gemcitabine without showing signs of systemic toxicities.  Overall, this study identified differential sensitivities of pancreatic cancer cells to structurally diverse sigma-2 receptor ligands.  Of note, we identified the mitochondrial superoxide pathway as a previously unrecognized sigma-2 receptor-activated process, which encourages further studies on sigma-2 ligand-mediated cancer cell death for the targeted treatment of pancreatic tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokTrvVNhfXn7Vg90H21EOLACvtfcHk0liNpWJFaSmmFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjs12mtbo%253D&md5=f8dce42ee93876e672a4d0705d8dc890</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1186%2Fs12885-016-3040-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-016-3040-4%26sid%3Dliteratum%253Aachs%26aulast%3DPati%26aufirst%3DM.%2BL.%26aulast%3DHornick%26aufirst%3DJ.%2BR.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DSpitzer%26aufirst%3DD.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DHawkins%26aufirst%3DW.%26atitle%3DSigma-2%2520Receptor%2520Agonist%2520Derivatives%2520of%25201-Cyclohexyl-4-%255B3-%25285-Methoxy-1%252C2%252C3%252C4-Tetrahydronaphthalen-1-Yl%2529Propyl%255DPiperazine%2520%2528PB28%2529%2520Induce%2520Cell%2520Death%2520via%2520Mitochondrial%2520Superoxide%2520Production%2520and%2520Caspase%2520Activation%2520in%2520Pancreatic%2520Cancer%26jtitle%3DBMC%2520Cancer%26date%3D2017%26volume%3D17%26spage%3D51%26doi%3D10.1186%2Fs12885-016-3040-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Estrada-Valencia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrera-Arozamena, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viña, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales-García, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Castillo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramos, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Franco, M. I.</span></span> <span> </span><span class="NLM_article-title">New Flavonoid-N, N-Dibenzyl(N-Methyl)Amine Hybrids: Multi-Target-Directed Agents for Alzheimeŕs Disease Endowed with Neurogenic Properties</span>. <i>J. Enzyme Inhib. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">712</span>– <span class="NLM_lpage">727</span>, <span class="refDoi"> DOI: 10.1080/14756366.2019.1581184</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1080%2F14756366.2019.1581184" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=31852270" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1MXksFKisLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2019&pages=712-727&author=M.+Estrada-Valenciaauthor=C.+Herrera-Arozamenaauthor=C.+P%C3%A9rezauthor=D.+Vi%C3%B1aauthor=J.+A.+Morales-Garc%C3%ADaauthor=A.+P%C3%A9rez-Castilloauthor=E.+Ramosauthor=A.+Romeroauthor=E.+Lauriniauthor=S.+Priclauthor=M.+I.+Rodr%C3%ADguez-Franco&title=New+Flavonoid-N%2C+N-Dibenzyl%28N-Methyl%29Amine+Hybrids%3A+Multi-Target-Directed+Agents+for+Alzheime%C5%95s+Disease+Endowed+with+Neurogenic+Properties&doi=10.1080%2F14756366.2019.1581184"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">New flavonoid - N,N-dibenzyl(N-methyl)amine hybrids: Multi-target-directed agents for Alzheimer's disease endowed with neurogenic properties</span></div><div class="casAuthors">Estrada-Valencia, Martin; Herrera-Arozamena, Clara; Perez, Concepcion; Vina, Dolores; Morales-Garcia, Jose A.; Perez-Castillo, Ana; Ramos, Eva; Romero, Alejandro; Laurini, Erik; Pricl, Sabrina; Rodriguez-Franco, Maria Isabel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Enzyme Inhibition and Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">712-727</span>CODEN:
                <span class="NLM_cas:coden">JEIMAZ</span>;
        ISSN:<span class="NLM_cas:issn">1475-6366</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The design of multi-target directed ligands (MTDLs) is a valid approach for obtaining effective drugs for complex pathologies.  MTDLs that combine neuro-repair properties and block the first steps of neurotoxic cascades could be the so long wanted remedies to treat neurodegenerative diseases (NDs).  By linking two privileged scaffolds with well-known activities in ND-targets, the flavonoid and the N,N-dibenzyl(N-methyl)amine (DBMA) fragments, new CNS-permeable flavonoid - DBMA hybrids (-) were obtained.  They were subjected to biol. evaluation in a battery of targets involved in Alzheimer's disease (AD) and other NDs, namely human cholinesterases (hAChE/hBuChE), β-secretase (hBACE-1), monoamine oxidases (hMAO-A/B), lipoxygenase-5 (hLOX-5) and sigma receptors (σ1R/σ2R).  After a funnel-type screening, 6,7-dimethoxychromone - DBMA () was highlighted due to its neurogenic properties and an interesting MTD-profile in hAChE, hLOX-5, hBACE-1 and σ1R.  Mol. dynamic simulations showed the most relevant drug-protein interactions of hybrid , which could synergistically contribute to neuronal regeneration and block neurodegeneration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxvt6TPaP_67Vg90H21EOLACvtfcHk0liNpWJFaSmmFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXksFKisLk%253D&md5=24e4282e83ea909ffd6fd72a74a8e509</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1080%2F14756366.2019.1581184&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14756366.2019.1581184%26sid%3Dliteratum%253Aachs%26aulast%3DEstrada-Valencia%26aufirst%3DM.%26aulast%3DHerrera-Arozamena%26aufirst%3DC.%26aulast%3DP%25C3%25A9rez%26aufirst%3DC.%26aulast%3DVi%25C3%25B1a%26aufirst%3DD.%26aulast%3DMorales-Garc%25C3%25ADa%26aufirst%3DJ.%2BA.%26aulast%3DP%25C3%25A9rez-Castillo%26aufirst%3DA.%26aulast%3DRamos%26aufirst%3DE.%26aulast%3DRomero%26aufirst%3DA.%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DRodr%25C3%25ADguez-Franco%26aufirst%3DM.%2BI.%26atitle%3DNew%2520Flavonoid-N%252C%2520N-Dibenzyl%2528N-Methyl%2529Amine%2520Hybrids%253A%2520Multi-Target-Directed%2520Agents%2520for%2520Alzheime%25C5%2595s%2520Disease%2520Endowed%2520with%2520Neurogenic%2520Properties%26jtitle%3DJ.%2520Enzyme%2520Inhib.%2520Med.%2520Chem.%26date%3D2019%26volume%3D34%26spage%3D712%26epage%3D727%26doi%3D10.1080%2F14756366.2019.1581184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mugnaini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brizzi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligresti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allara, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamponi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacondio, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silva, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corelli, F.</span></span> <span> </span><span class="NLM_article-title">Investigations on the 4-Quinolone-3-Carboxylic Acid Motif. 7. Synthesis and Pharmacological Evaluation of 4-Quinolone-3-Carboxamides and 4-Hydroxy-2-Quinolone-3-Carboxamides as High Affinity Cannabinoid Receptor 2 (CB2R) Ligands with Improved Aqueous Solubility</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1052</span>– <span class="NLM_lpage">1067</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01559</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01559" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC28XmslemsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=1052-1067&author=C.+Mugnainiauthor=A.+Brizziauthor=A.+Ligrestiauthor=M.+Allaraauthor=S.+Lamponiauthor=F.+Vacondioauthor=C.+Silvaauthor=M.+Morauthor=V.+Di+Marzoauthor=F.+Corelli&title=Investigations+on+the+4-Quinolone-3-Carboxylic+Acid+Motif.+7.+Synthesis+and+Pharmacological+Evaluation+of+4-Quinolone-3-Carboxamides+and+4-Hydroxy-2-Quinolone-3-Carboxamides+as+High+Affinity+Cannabinoid+Receptor+2+%28CB2R%29+Ligands+with+Improved+Aqueous+Solubility&doi=10.1021%2Facs.jmedchem.5b01559"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 7. Synthesis and Pharmacological Evaluation of 4-Quinolone-3-carboxamides and 4-Hydroxy-2-quinolone-3-carboxamides as High Affinity Cannabinoid Receptor 2 (CB2R) Ligands with Improved Aqueous Solubility</span></div><div class="casAuthors">Mugnaini, Claudia; Brizzi, Antonella; Ligresti, Alessia; Allara, Marco; Lamponi, Stefania; Vacondio, Federica; Silva, Claudia; Mor, Marco; Di Marzo, Vincenzo; Corelli, Federico</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1052-1067</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">4-Quinolone-3-carboxamide derivs. have long been recognized as potent and selective cannabinoid type-2 receptor (CB2R) ligands.  With the aim to improve their physicochem. properties, basically aq. soly., two different approaches were followed, entailing the substitution of the alkyl chain with a basic replacement or scaffold modification to 4-hydroxy-2-quinolone structure.  According to the first approach, compd. I (R = NMe2) was obtained, showing slightly reduced receptor affinity (Ki = 60 nM) compared to the lead compd. I (R = n-Pr, Ki = 0.8 nM) but greatly enhanced soly. (400-3400 times depending on the pH of the medium).  On the other hand, shifting from 4-quinolone to 4-hydroxy-2-quinolone structure enabled the discovery of a novel class of CB2R ligands, such as II (R1 = 6-i-Pr, and 7-F), characterized by Ki < 1 nM and selectivity index [SI = Ki(CB1R)/Ki(CB2R)] > 1300.  At pH 7.4, compd. II (R1 = 7-F) resulted by 100-fold more sol. than I (R = n-Pr).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovdgV_KOadz7Vg90H21EOLACvtfcHk0lgVe5zLREFeYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmslemsA%253D%253D&md5=303474ea5e8d265bf033c75c89e4ee9c</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01559%26sid%3Dliteratum%253Aachs%26aulast%3DMugnaini%26aufirst%3DC.%26aulast%3DBrizzi%26aufirst%3DA.%26aulast%3DLigresti%26aufirst%3DA.%26aulast%3DAllara%26aufirst%3DM.%26aulast%3DLamponi%26aufirst%3DS.%26aulast%3DVacondio%26aufirst%3DF.%26aulast%3DSilva%26aufirst%3DC.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DCorelli%26aufirst%3DF.%26atitle%3DInvestigations%2520on%2520the%25204-Quinolone-3-Carboxylic%2520Acid%2520Motif.%25207.%2520Synthesis%2520and%2520Pharmacological%2520Evaluation%2520of%25204-Quinolone-3-Carboxamides%2520and%25204-Hydroxy-2-Quinolone-3-Carboxamides%2520as%2520High%2520Affinity%2520Cannabinoid%2520Receptor%25202%2520%2528CB2R%2529%2520Ligands%2520with%2520Improved%2520Aqueous%2520Solubility%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D1052%26epage%3D1067%26doi%3D10.1021%2Facs.jmedchem.5b01559" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weber, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Medicinal Chemistry of σ(1) Receptor Ligands: Pharmacophore Models, Synthesis, Structure Affinity Relationships, and Pharmacological Applications</span>. <i>Handb. Exp. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>244</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">79</span>, <span class="refDoi"> DOI: 10.1007/164_2017_33</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1007%2F164_2017_33" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=28620761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFeitbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=244&publication_year=2017&pages=51-79&author=F.+Weberauthor=B.+W%C3%BCnsch&title=Medicinal+Chemistry+of+%CF%83%281%29+Receptor+Ligands%3A+Pharmacophore+Models%2C+Synthesis%2C+Structure+Affinity+Relationships%2C+and+Pharmacological+Applications&doi=10.1007%2F164_2017_33"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of σ1 receptor ligands: pharmacophore models, synthesis, structure affinity relationships, and pharmacological applications</span></div><div class="casAuthors">Weber, Frauke; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of Experimental Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">244</span>
        (<span class="NLM_cas:issue">Sigma Proteins: Evolution of the Concept of Sigma Receptors</span>),
    <span class="NLM_cas:pages">51-79</span>CODEN:
                <span class="NLM_cas:coden">HEPHD2</span>;
        ISSN:<span class="NLM_cas:issn">1865-0325</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  In the first part of this chapter, it summarize the various pharmacophore models for σ1 receptor ligands.  Common to all of them is a basic amine flanked by two hydrophobic regions, representing the pharmacophoric elements.  The development of computer-based models like the 3D homol. model is described as well as the first crystal structure of the σ1 receptor.  The second part focuses on the synthesis and biol. properties of different σ1 receptor ligands, identified as 1-9.  Monocyclic piperazines 1 and bicyclic piperazines 2 and 3 were developed as cytotoxic compds., thus the IC50 values of cell growth and survival inhibition studies are given for all derivs.  The mechanism of cell survival inhibition, induction of time-dependent apoptosis, of compd. ent-2a is discussed.  Exptl. detd. σ1 affinity shows good correlation with the results from mol. dynamics simulations based on a 3D homol. model.  Spirocyclic compds. 4 and 5 represent well-established σ1 receptor ligands.  The homologous fluoroalkyl derivs. 4 have favorable pharmacol. properties for use as fluorinated PET tracers.  The (S)-configured fluoroethyl substituted compd. (S)-4b is under investigation as PET tracer for imaging of σ1 receptors in the brain of patients affected by major depression.  1,3-Dioxanes 6c and 6d display a very potent σ1 antagonist profile and the racemic 1,3-dioxane 6c has high anti-allodynic activity at low doses.  The arylpropenylamines 7 are very potent σ1 receptor ligands with high σ1/s2 selectivity.  The top compd. 7g acts as an agonist as defined by its ability to potentiate neurite outgrowth at low concns.  Among the morpholinoethoxypyrazoles 8, 8c (known as S1RA) reveals the most promising pharmacokinetic and physicochem. properties.  Due to its good safety profile, 8c is currently being investigated in a phase II clin. trial for the treatment of neuropathic pain.  The most potent ligand 9e of 3,4-dihydro-2(1H)-quinolones 9 shows promising anti-nociceptive activity in the formalin test.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7YQ6_-x_GybVg90H21EOLACvtfcHk0lgVe5zLREFeYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFeitbvM&md5=a86da9cd3be04ca53d9787ad9e73a54b</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1007%2F164_2017_33&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F164_2017_33%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DF.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DMedicinal%2520Chemistry%2520of%2520%25CF%2583%25281%2529%2520Receptor%2520Ligands%253A%2520Pharmacophore%2520Models%252C%2520Synthesis%252C%2520Structure%2520Affinity%2520Relationships%252C%2520and%2520Pharmacological%2520Applications%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2017%26volume%3D244%26spage%3D51%26epage%3D79%26doi%3D10.1007%2F164_2017_33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, L.</span></span> <span> </span><span class="NLM_article-title">Computational Multitarget Drug Design</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">403</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.6b00491</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.6b00491" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFCntr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2017&pages=403-412&author=W.+Zhangauthor=J.+Peiauthor=L.+Lai&title=Computational+Multitarget+Drug+Design&doi=10.1021%2Facs.jcim.6b00491"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Computational Multitarget Drug Design</span></div><div class="casAuthors">Zhang, Weilin; Pei, Jianfeng; Lai, Luhua</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">403-412</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Designing drugs that can simultaneously interact with multiple targets is a promising approach for treating complicated diseases.  Compared to using combinations of single target drugs, multitarget drugs have advantages of higher efficacy, improved safety profile, and simpler administration.  Many in silico methods have been developed to approach different aspects of this polypharmacol.-guided drug design, particularly for drug repurposing and multitarget drug design.  In this review, the authors summarize recent progress in computational multitarget drug design and discuss their advantages and limitations.  Perspectives for future drug development will also be discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-J4p0tdEUR7Vg90H21EOLACvtfcHk0lgVe5zLREFeYw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFCntr8%253D&md5=e00ed6650471d786a04b828a8064f5e9</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.6b00491&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.6b00491%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DPei%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DL.%26atitle%3DComputational%2520Multitarget%2520Drug%2520Design%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2017%26volume%3D57%26spage%3D403%26epage%3D412%26doi%3D10.1021%2Facs.jcim.6b00491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henrick, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakamura, H.</span></span> <span> </span><span class="NLM_article-title">Announcing the Worldwide Protein Data Bank</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">980</span>, <span class="refDoi"> DOI: 10.1038/nsb1203-980</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fnsb1203-980" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD3sXptFOmsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2003&pages=980&author=H.+Bermanauthor=K.+Henrickauthor=H.+Nakamura&title=Announcing+the+Worldwide+Protein+Data+Bank&doi=10.1038%2Fnsb1203-980"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Announcing the worldwide Protein Data Bank</span></div><div class="casAuthors">Berman, Helen; Henrick, Kim; Nakamura, Haruki</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural Biology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">980</span>CODEN:
                <span class="NLM_cas:coden">NSBIEW</span>;
        ISSN:<span class="NLM_cas:issn">1072-8368</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplInmv2AD6cbVg90H21EOLACvtfcHk0liBrjI12QJ1aQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXptFOmsbY%253D&md5=8146ff5fc67f64e31b2f8c475473879c</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1038%2Fnsb1203-980&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb1203-980%26sid%3Dliteratum%253Aachs%26aulast%3DBerman%26aufirst%3DH.%26aulast%3DHenrick%26aufirst%3DK.%26aulast%3DNakamura%26aufirst%3DH.%26atitle%3DAnnouncing%2520the%2520Worldwide%2520Protein%2520Data%2520Bank%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2003%26volume%3D10%26spage%3D980%26doi%3D10.1038%2Fnsb1203-980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gaulton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bellis, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bento, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hersey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Light, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGlinchey, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michalovich, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Lazikani, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overington, J. P.</span></span> <span> </span><span class="NLM_article-title">ChEMBL: A Large-Scale Bioactivity Database for Drug Discovery</span>. <i>Nucleic Acids Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">D1100</span>– <span class="NLM_lpage">D1107</span>, <span class="refDoi"> DOI: 10.1093/nar/gkr777</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1093%2Fnar%2Fgkr777" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=21948594" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs12htbjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2012&pages=D1100-D1107&author=A.+Gaultonauthor=L.+J.+Bellisauthor=A.+P.+Bentoauthor=J.+Chambersauthor=M.+Daviesauthor=A.+Herseyauthor=Y.+Lightauthor=S.+McGlincheyauthor=D.+Michalovichauthor=B.+Al-Lazikaniauthor=J.+P.+Overington&title=ChEMBL%3A+A+Large-Scale+Bioactivity+Database+for+Drug+Discovery&doi=10.1093%2Fnar%2Fgkr777"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">ChEMBL: a large-scale bioactivity database for drug discovery</span></div><div class="casAuthors">Gaulton, Anna; Bellis, Louisa J.; Bento, A. Patricia; Chambers, Jon; Davies, Mark; Hersey, Anne; Light, Yvonne; McGlinchey, Shaun; Michalovich, David; Al-Lazikani, Bissan; Overington, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Nucleic Acids Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">D1</span>),
    <span class="NLM_cas:pages">D1100-D1107</span>CODEN:
                <span class="NLM_cas:coden">NARHAD</span>;
        ISSN:<span class="NLM_cas:issn">0305-1048</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">ChEMBL is an Open Data database contg. binding, functional and ADMET information for a large no. of drug-like bioactive compds.  These data are manually abstracted from the primary published literature on a regular basis, then further curated and standardized to maximize their quality and utility across a wide range of chem. biol. and drug-discovery research problems.  Currently, the database contains 5.4 million bioactivity measurements for more than 1 million compds. and 5200 protein targets.  Access is available through a web-based interface, data downloads and web services at: https://www.ebi.ac.uk/chembldb.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9e9jRENTtubVg90H21EOLACvtfcHk0liBrjI12QJ1aQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs12htbjN&md5=aedf7793e1ca54b6a4fa272ea3ef7d0e</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1093%2Fnar%2Fgkr777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fnar%252Fgkr777%26sid%3Dliteratum%253Aachs%26aulast%3DGaulton%26aufirst%3DA.%26aulast%3DBellis%26aufirst%3DL.%2BJ.%26aulast%3DBento%26aufirst%3DA.%2BP.%26aulast%3DChambers%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DM.%26aulast%3DHersey%26aufirst%3DA.%26aulast%3DLight%26aufirst%3DY.%26aulast%3DMcGlinchey%26aufirst%3DS.%26aulast%3DMichalovich%26aufirst%3DD.%26aulast%3DAl-Lazikani%26aufirst%3DB.%26aulast%3DOverington%26aufirst%3DJ.%2BP.%26atitle%3DChEMBL%253A%2520A%2520Large-Scale%2520Bioactivity%2520Database%2520for%2520Drug%2520Discovery%26jtitle%3DNucleic%2520Acids%2520Res.%26date%3D2012%26volume%3D40%26spage%3DD1100%26epage%3DD1107%26doi%3D10.1093%2Fnar%2Fgkr777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref185"><div class="reference"><strong class="refLabel"><a href="#ref185" class="rightTabRefNumLink">185</a></strong><div class="NLM_citation" id="rightTab-cit185"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campillo, N. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goya, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Páez, J. A.</span></span> <span> </span><span class="NLM_article-title">Homology Models of the Cannabinoid CB1 and CB2 Receptors. A Docking Analysis Study</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">75</span>– <span class="NLM_lpage">83</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2004.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2004.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=15642412" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref185/cit185&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD2MXjtF2jsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2005&pages=75-83&author=C.+Monteroauthor=N.+E.+Campilloauthor=P.+Goyaauthor=J.+A.+P%C3%A1ez&title=Homology+Models+of+the+Cannabinoid+CB1+and+CB2+Receptors.+A+Docking+Analysis+Study&doi=10.1016%2Fj.ejmech.2004.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit185R"><div class="casContent"><span class="casTitleNuber">185</span><div class="casTitle"><span class="NLM_cas:atitle">Homology models of the cannabinoid CB1 and CB2 receptors. A docking analysis study</span></div><div class="casAuthors">Montero, Cristina; Campillo, Nuria Eugenia; Goya, Pilar; Paez, Juan Antonio</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">75-83</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The 3D models of both CB1 and CB2 human receptors have been established by homol. modeling using as template the x-ray structure of bovine Rhodopsin (code pdb: 1F88) a G-protein-coupled receptor (GPCR).  A recursive approach comprising sequence alignment and model building was used to build both models, followed by the refinement of non-conserved regions.  The cannabinoid system has been studied by means of docking techniques, using the 3D models of both CB1 and CB2 and well known ref. inverse agonist/antagonist compds.  An approach based on the flexibility of the structures has been used to model the receptor-ligand complexes.  The structural effects of ligand binding were studied and analyzed on the basis of hydrogen bond interactions, and binding energy calcns.  Potential interaction sites of the receptor were detd. from anal. of the difference accessible surface area (DASA) study of the protein with and without ligand.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoatifSMJvC57Vg90H21EOLACvtfcHk0liBrjI12QJ1aQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXjtF2jsQ%253D%253D&md5=0ef56ee1b6ed33769361b95510e70331</span></div><a href="/servlet/linkout?suffix=cit185&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2004.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2004.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DMontero%26aufirst%3DC.%26aulast%3DCampillo%26aufirst%3DN.%2BE.%26aulast%3DGoya%26aufirst%3DP.%26aulast%3DP%25C3%25A1ez%26aufirst%3DJ.%2BA.%26atitle%3DHomology%2520Models%2520of%2520the%2520Cannabinoid%2520CB1%2520and%2520CB2%2520Receptors.%2520A%2520Docking%2520Analysis%2520Study%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2005%26volume%3D40%26spage%3D75%26epage%3D83%26doi%3D10.1016%2Fj.ejmech.2004.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref186"><div class="reference"><strong class="refLabel"><a href="#ref186" class="rightTabRefNumLink">186</a></strong><div class="NLM_citation" id="rightTab-cit186"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cichero, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ligresti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allarà, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lazzati, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Ursi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marabotti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanesi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spallarossa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranise, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fossa, P.</span></span> <span> </span><span class="NLM_article-title">Homology Modeling in Tandem with 3D-QSAR Analyses: A Computational Approach to Depict the Agonist Binding Site of the Human CB2 Receptor</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">4489</span>– <span class="NLM_lpage">4505</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2011.07.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2011.07.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=21835510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref186/cit186&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtV2rtb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=4489-4505&author=E.+Cicheroauthor=A.+Ligrestiauthor=M.+Allar%C3%A0author=V.+di+Marzoauthor=Z.+Lazzatiauthor=P.+D%E2%80%99Ursiauthor=A.+Marabottiauthor=L.+Milanesiauthor=A.+Spallarossaauthor=P.+Raniseauthor=P.+Fossa&title=Homology+Modeling+in+Tandem+with+3D-QSAR+Analyses%3A+A+Computational+Approach+to+Depict+the+Agonist+Binding+Site+of+the+Human+CB2+Receptor&doi=10.1016%2Fj.ejmech.2011.07.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit186R"><div class="casContent"><span class="casTitleNuber">186</span><div class="casTitle"><span class="NLM_cas:atitle">Homology modeling in tandem with 3D-QSAR analyses: A computational approach to depict the agonist binding site of the human CB2 receptor</span></div><div class="casAuthors">Cichero, Elena; Ligresti, Alessia; Allara, Marco; di Marzo, Vincenzo; Lazzati, Zelda; D'Ursi, Pasqualina; Marabotti, Anna; Milanesi, Luciano; Spallarossa, Andrea; Ranise, Angelo; Fossa, Paola</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4489-4505</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">CB2 receptor belongs to the large family of G-protein coupled receptors (GPCRs) controlling a wide variety of signal transduction.  The recent crystallog. detn. of human β2 adrenoreceptor and its high sequence similarity with human CB2 receptor (hCB2) prompted us to compute a theor. model of hCB2 based also on β2 adrenoreceptor coordinates.  This model has been employed to perform docking and mol. dynamic simulations on WIN-55,212-2 (CB2 agonist commonly used in binding expts.), in order to identify the putative CB2 receptor agonist binding site, followed by mol. docking studies on a series of indol-3-yl-tetramethylcyclopropyl ketone derivs., a novel class of potent CB2 agonists.  Successively, docking-based Comparative Mol. Fields Anal. (CoMFA) and Comparative Mol. Similarity Indexes Anal. (CoMSIA) studies were also performed.  The CoMSIA model resulted to be the more predictive, showing r ncv 2 = 0.96, r cv 2 = 0.713, SEE = 0.193, F = 125.223, and r 2 pred = 0.78.  The obtained 3D-QSAR models allowed us to derive more complete guidelines for the design of new analogs with improved potency so as to synthesize new indoles showing high CB2 affinity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqUOoYxe3QXLVg90H21EOLACvtfcHk0liGHm6G4-mYxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtV2rtb7P&md5=2c1840ef5f091c1472eeccf3dceb471d</span></div><a href="/servlet/linkout?suffix=cit186&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2011.07.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2011.07.023%26sid%3Dliteratum%253Aachs%26aulast%3DCichero%26aufirst%3DE.%26aulast%3DLigresti%26aufirst%3DA.%26aulast%3DAllar%25C3%25A0%26aufirst%3DM.%26aulast%3Ddi%2BMarzo%26aufirst%3DV.%26aulast%3DLazzati%26aufirst%3DZ.%26aulast%3DD%25E2%2580%2599Ursi%26aufirst%3DP.%26aulast%3DMarabotti%26aufirst%3DA.%26aulast%3DMilanesi%26aufirst%3DL.%26aulast%3DSpallarossa%26aufirst%3DA.%26aulast%3DRanise%26aufirst%3DP.%26aulast%3DFossa%26aufirst%3DP.%26atitle%3DHomology%2520Modeling%2520in%2520Tandem%2520with%25203D-QSAR%2520Analyses%253A%2520A%2520Computational%2520Approach%2520to%2520Depict%2520the%2520Agonist%2520Binding%2520Site%2520of%2520the%2520Human%2520CB2%2520Receptor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2011%26volume%3D46%26spage%3D4489%26epage%3D4505%26doi%3D10.1016%2Fj.ejmech.2011.07.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref187"><div class="reference"><strong class="refLabel"><a href="#ref187" class="rightTabRefNumLink">187</a></strong><div class="NLM_citation" id="rightTab-cit187"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tuccinardi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrarini, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortore, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saccomanni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinelli, A.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid CB2/CB1 Selectivity. Receptor Modeling and Automated Docking Analysis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">984</span>– <span class="NLM_lpage">994</span>, <span class="refDoi"> DOI: 10.1021/jm050875u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm050875u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref187/cit187&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD28XksFSmsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=984-994&author=T.+Tuccinardiauthor=P.+L.+Ferrariniauthor=C.+Maneraauthor=G.+Ortoreauthor=G.+Saccomanniauthor=A.+Martinelli&title=Cannabinoid+CB2%2FCB1+Selectivity.+Receptor+Modeling+and+Automated+Docking+Analysis&doi=10.1021%2Fjm050875u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit187R"><div class="casContent"><span class="casTitleNuber">187</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid CB2/CB1 Selectivity. Receptor Modeling and Automated Docking Analysis</span></div><div class="casAuthors">Tuccinardi, Tiziano; Ferrarini, Pier Luigi; Manera, Clementina; Ortore, Gabriella; Saccomanni, Giuseppe; Martinelli, Adriano</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">984-994</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Three-dimensional models of the CB1 and CB2 cannabinoid receptors were constructed by a mol. modeling procedure, using the x-ray structure of bovine rhodopsin as the initial template, and taking into account the available site-directed mutagenesis data.  The cannabinoid system was studied by docking techniques.  An anal. of the interaction of WIN55212-2 with both receptors showed that CB2/CB1 selectivity is mainly detd. by the interaction in the CB2 with the nonconserved residues S3.31 and F5.46, whose importance was suggested by site-directed mutagenesis data.  The authors also carried out an automated docking of several ligands into the CB2 model, using the AUTODOCK 3.0 program; the good correlation obtained between the estd. free energy binding and the exptl. binding data confirmed the authors binding hypothesis and the reliability of the model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY9HJjKUsl_LVg90H21EOLACvtfcHk0liGHm6G4-mYxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XksFSmsg%253D%253D&md5=4e61737ef2abacc73624e15a7748e272</span></div><a href="/servlet/linkout?suffix=cit187&amp;dbid=16384&amp;doi=10.1021%2Fjm050875u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm050875u%26sid%3Dliteratum%253Aachs%26aulast%3DTuccinardi%26aufirst%3DT.%26aulast%3DFerrarini%26aufirst%3DP.%2BL.%26aulast%3DManera%26aufirst%3DC.%26aulast%3DOrtore%26aufirst%3DG.%26aulast%3DSaccomanni%26aufirst%3DG.%26aulast%3DMartinelli%26aufirst%3DA.%26atitle%3DCannabinoid%2520CB2%252FCB1%2520Selectivity.%2520Receptor%2520Modeling%2520and%2520Automated%2520Docking%2520Analysis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D984%26epage%3D994%26doi%3D10.1021%2Fjm050875u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref188"><div class="reference"><strong class="refLabel"><a href="#ref188" class="rightTabRefNumLink">188</a></strong><div class="NLM_citation" id="rightTab-cit188"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hua, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vemuri, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popov, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benchama, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvonok, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Locke, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cinar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffey, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katritch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kunos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makriyannis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevens, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.-J.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of the Human Cannabinoid Receptor CB2</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>176</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">467</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2018.12.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.cell.2018.12.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=30639103" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref188/cit188&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1MXovFKktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=176&publication_year=2019&pages=459-467&author=X.+Liauthor=T.+Huaauthor=K.+Vemuriauthor=J.-H.+Hoauthor=Y.+Wuauthor=L.+Wuauthor=P.+Popovauthor=O.+Benchamaauthor=N.+Zvonokauthor=K.+Lockeauthor=L.+Quauthor=G.+W.+Hanauthor=M.+R.+Iyerauthor=R.+Cinarauthor=N.+J.+Coffeyauthor=J.+Wangauthor=M.+Wuauthor=V.+Katritchauthor=S.+Zhaoauthor=G.+Kunosauthor=L.+M.+Bohnauthor=A.+Makriyannisauthor=R.+C.+Stevensauthor=Z.-J.+Liu&title=Crystal+Structure+of+the+Human+Cannabinoid+Receptor+CB2&doi=10.1016%2Fj.cell.2018.12.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit188R"><div class="casContent"><span class="casTitleNuber">188</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal Structure of the Human Cannabinoid Receptor CB2</span></div><div class="casAuthors">Li, Xiaoting; Hua, Tian; Vemuri, Kiran; Ho, Jo-Hao; Wu, Yiran; Wu, Lijie; Popov, Petr; Benchama, Othman; Zvonok, Nikolai; Locke, K'ara; Qu, Lu; Han, Gye Won; Iyer, Malliga R.; Cinar, Resat; Coffey, Nathan J.; Wang, Jingjing; Wu, Meng; Katritch, Vsevolod; Zhao, Suwen; Kunos, George; Bohn, Laura M.; Makriyannis, Alexandros; Stevens, Raymond C.; Liu, Zhi-Jie</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">176</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">459-467.e13</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The cannabinoid receptor CB2 is predominately expressed in the immune system, and selective modulation of CB2 without the psychoactivity of CB1 has therapeutic potential in inflammatory, fibrotic, and neurodegenerative diseases.  Here, we report the crystal structure of human CB2 in complex with a rationally designed antagonist, AM10257, at 2.8 Å resoln.  The CB2-AM10257 structure reveals a distinctly different binding pose compared with CB1.  However, the extracellular portion of the antagonist-bound CB2 shares a high degree of conformational similarity with the agonist-bound CB1, which led to the discovery of AM10257's unexpected opposing functional profile of CB2 antagonism vs. CB1 agonism.  Further structural anal. using mutagenesis studies and mol. docking revealed the mol. basis of their function and selectivity for CB2 and CB1.  Addnl. analyses of our designed antagonist and agonist pairs provide important insight into the activation mechanism of CB2.  The present findings should facilitate rational drug design toward precise modulation of the endocannabinoid system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFwNUEO0q03LVg90H21EOLACvtfcHk0liGHm6G4-mYxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXovFKktw%253D%253D&md5=90ee72a6dc13b74b84fb6799c3aa0471</span></div><a href="/servlet/linkout?suffix=cit188&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2018.12.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2018.12.011%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DX.%26aulast%3DHua%26aufirst%3DT.%26aulast%3DVemuri%26aufirst%3DK.%26aulast%3DHo%26aufirst%3DJ.-H.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DPopov%26aufirst%3DP.%26aulast%3DBenchama%26aufirst%3DO.%26aulast%3DZvonok%26aufirst%3DN.%26aulast%3DLocke%26aufirst%3DK.%26aulast%3DQu%26aufirst%3DL.%26aulast%3DHan%26aufirst%3DG.%2BW.%26aulast%3DIyer%26aufirst%3DM.%2BR.%26aulast%3DCinar%26aufirst%3DR.%26aulast%3DCoffey%26aufirst%3DN.%2BJ.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DKatritch%26aufirst%3DV.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DKunos%26aufirst%3DG.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26aulast%3DMakriyannis%26aufirst%3DA.%26aulast%3DStevens%26aufirst%3DR.%2BC.%26aulast%3DLiu%26aufirst%3DZ.-J.%26atitle%3DCrystal%2520Structure%2520of%2520the%2520Human%2520Cannabinoid%2520Receptor%2520CB2%26jtitle%3DCell%26date%3D2019%26volume%3D176%26spage%3D459%26epage%3D467%26doi%3D10.1016%2Fj.cell.2018.12.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref189"><div class="reference"><strong class="refLabel"><a href="#ref189" class="rightTabRefNumLink">189</a></strong><div class="NLM_citation" id="rightTab-cit189"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hua, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iliopoulos-Tsoutsouvas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikas, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grim, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benchama, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stahl, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvonok, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makriyannis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.-J.</span></span> <span> </span><span class="NLM_article-title">Activation and Signaling Mechanism Revealed by Cannabinoid Receptor-G(i)Complex Structures</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>180</i></span>,  <span class="NLM_fpage">655</span>– <span class="NLM_lpage">665</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2020.01.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.cell.2020.01.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=32004463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref189/cit189&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFeqtbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2020&pages=655-665&author=T.+Huaauthor=X.+Liauthor=L.+Wuauthor=C.+Iliopoulos-Tsoutsouvasauthor=Y.+Wangauthor=M.+Wuauthor=L.+Shenauthor=C.+A.+Johnstonauthor=S.+P.+Nikasauthor=F.+Songauthor=X.+Songauthor=S.+Yuanauthor=Q.+Sunauthor=Y.+Wuauthor=S.+Jiangauthor=T.+W.+Grimauthor=O.+Benchamaauthor=E.+L.+Stahlauthor=N.+Zvonokauthor=S.+Zhaoauthor=L.+M.+Bohnauthor=A.+Makriyannisauthor=Z.-J.+Liu&title=Activation+and+Signaling+Mechanism+Revealed+by+Cannabinoid+Receptor-G%28i%29Complex+Structures&doi=10.1016%2Fj.cell.2020.01.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit189R"><div class="casContent"><span class="casTitleNuber">189</span><div class="casTitle"><span class="NLM_cas:atitle">Activation and Signaling Mechanism Revealed by Cannabinoid Receptor-Gi Complex Structures</span></div><div class="casAuthors">Hua, Tian; Li, Xiaoting; Wu, Lijie; Iliopoulos-Tsoutsouvas, Christos; Wang, Yuxia; Wu, Meng; Shen, Ling; Johnston, Christina A.; Nikas, Spyros P.; Song, Feng; Song, Xiyong; Yuan, Shuguang; Sun, Qianqian; Wu, Yiran; Jiang, Shan; Grim, Travis W.; Benchama, Othman; Stahl, Edward L.; Zvonok, Nikolai; Zhao, Suwen; Bohn, Laura M.; Makriyannis, Alexandros; Liu, Zhi-Jie</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">655-665.e18</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Human endocannabinoid systems modulate multiple physiol. processes mainly through the activation of cannabinoid receptors CB1 and CB2.  Their high sequence similarity, low agonist selectivity, and lack of activation and G protein-coupling knowledge have hindered the development of therapeutic applications.  Importantly, missing structural information has significantly held back the development of promising CB2-selective agonist drugs for treating inflammatory and neuropathic pain without the psychoactivity of CB1.  Here, we report the cryoelectron microscopy structures of synthetic cannabinoid-bound CB2 and CB1 in complex with Gi, as well as agonist-bound CB2 crystal structure.  Of important scientific and therapeutic benefit, our results reveal a diverse activation and signaling mechanism, the structural basis of CB2-selective agonists design, and the unexpected interaction of cholesterol with CB1, suggestive of its endogenous allosteric modulating role.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgy9tDrt9HArVg90H21EOLACvtfcHk0liA4JlYyJDggw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFeqtbc%253D&md5=b9d4dd05094f3bae76b315a41a11c21b</span></div><a href="/servlet/linkout?suffix=cit189&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2020.01.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2020.01.008%26sid%3Dliteratum%253Aachs%26aulast%3DHua%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DIliopoulos-Tsoutsouvas%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DJohnston%26aufirst%3DC.%2BA.%26aulast%3DNikas%26aufirst%3DS.%2BP.%26aulast%3DSong%26aufirst%3DF.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DYuan%26aufirst%3DS.%26aulast%3DSun%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DS.%26aulast%3DGrim%26aufirst%3DT.%2BW.%26aulast%3DBenchama%26aufirst%3DO.%26aulast%3DStahl%26aufirst%3DE.%2BL.%26aulast%3DZvonok%26aufirst%3DN.%26aulast%3DZhao%26aufirst%3DS.%26aulast%3DBohn%26aufirst%3DL.%2BM.%26aulast%3DMakriyannis%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DZ.-J.%26atitle%3DActivation%2520and%2520Signaling%2520Mechanism%2520Revealed%2520by%2520Cannabinoid%2520Receptor-G%2528i%2529Complex%2520Structures%26jtitle%3DCell%26date%3D2020%26volume%3D180%26spage%3D655%26epage%3D665%26doi%3D10.1016%2Fj.cell.2020.01.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref190"><div class="reference"><strong class="refLabel"><a href="#ref190" class="rightTabRefNumLink">190</a></strong><div class="NLM_citation" id="rightTab-cit190"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bressi, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skene, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melkus, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimshaw, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navre, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gangloff, A. R.</span></span> <span> </span><span class="NLM_article-title">Exploration of the HDAC2 Foot Pocket: Synthesis and SAR of Substituted N-(2-Aminophenyl)Benzamides</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">3142</span>– <span class="NLM_lpage">3145</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.03.091</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmcl.2010.03.091" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=20392638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref190/cit190&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlsFGnsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=3142-3145&author=J.+C.+Bressiauthor=A.+J.+Jenningsauthor=R.+Skeneauthor=Y.+Wuauthor=R.+Melkusauthor=R.+De+Jongauthor=S.+O%E2%80%99Connellauthor=C.+E.+Grimshawauthor=M.+Navreauthor=A.+R.+Gangloff&title=Exploration+of+the+HDAC2+Foot+Pocket%3A+Synthesis+and+SAR+of+Substituted+N-%282-Aminophenyl%29Benzamides&doi=10.1016%2Fj.bmcl.2010.03.091"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit190R"><div class="casContent"><span class="casTitleNuber">190</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides</span></div><div class="casAuthors">Bressi, Jerome C.; Jennings, Andy J.; Skene, Robert; Wu, Yiqin; Melkus, Robert; de Jong, Ron; O'Connell, Shawn; Grimshaw, Charles E.; Navre, Marc; Gangloff, Anthony R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3142-3145</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of N-(2-amino-5-substituted phenyl)benzamides were designed, synthesized and evaluated for their inhibition of HDAC2 and their cytotoxicity in HCT116 cancer cells.  Multiple compds. from this series demonstrated time-dependent binding kinetics that is rationalized using a co-complex crystal structure of HDAC2 and N-(4-aminobiphenyl-3-yl)benzamide I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN0N7gN89VAbVg90H21EOLACvtfcHk0liA4JlYyJDggw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlsFGnsLs%253D&md5=a7cce9bd1fcb1c2d248d2aee0db3ffc7</span></div><a href="/servlet/linkout?suffix=cit190&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.03.091&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.03.091%26sid%3Dliteratum%253Aachs%26aulast%3DBressi%26aufirst%3DJ.%2BC.%26aulast%3DJennings%26aufirst%3DA.%2BJ.%26aulast%3DSkene%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DMelkus%26aufirst%3DR.%26aulast%3DDe%2BJong%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Connell%26aufirst%3DS.%26aulast%3DGrimshaw%26aufirst%3DC.%2BE.%26aulast%3DNavre%26aufirst%3DM.%26aulast%3DGangloff%26aufirst%3DA.%2BR.%26atitle%3DExploration%2520of%2520the%2520HDAC2%2520Foot%2520Pocket%253A%2520Synthesis%2520and%2520SAR%2520of%2520Substituted%2520N-%25282-Aminophenyl%2529Benzamides%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D3142%26epage%3D3145%26doi%3D10.1016%2Fj.bmcl.2010.03.091" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref191"><div class="reference"><strong class="refLabel"><a href="#ref191" class="rightTabRefNumLink">191</a></strong><div class="NLM_citation" id="rightTab-cit191"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weïwer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbacher, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schomburg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinemer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gale, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, W.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reis, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennig, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jefson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fass, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haggarty, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holson, E. B.</span></span> <span> </span><span class="NLM_article-title">Kinetic and Structural Insights into the Binding of Histone Deacetylase 1 and 2 (HDAC1, 2) Inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4008</span>– <span class="NLM_lpage">4015</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.06.040</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmc.2016.06.040" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=27377864" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref191/cit191&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFSgur7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=4008-4015&author=F.+F.+Wagnerauthor=M.+We%C3%AFwerauthor=S.+Steinbacherauthor=A.+Schomburgauthor=P.+Reinemerauthor=J.+P.+Galeauthor=A.+J.+Campbellauthor=S.+L.+Fisherauthor=W.-N.+Zhaoauthor=S.+A.+Reisauthor=K.+M.+Hennigauthor=M.+Thomasauthor=P.+M%C3%BCllerauthor=M.+R.+Jefsonauthor=D.+M.+Fassauthor=S.+J.+Haggartyauthor=Y.+L.+Zhangauthor=E.+B.+Holson&title=Kinetic+and+Structural+Insights+into+the+Binding+of+Histone+Deacetylase+1+and+2+%28HDAC1%2C+2%29+Inhibitors&doi=10.1016%2Fj.bmc.2016.06.040"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit191R"><div class="casContent"><span class="casTitleNuber">191</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetic and structural insights into the binding of histone deacetylase 1 and 2 (HDAC1, 2) inhibitors</span></div><div class="casAuthors">Wagner, Florence F.; Weiwer, Michel; Steinbacher, Stefan; Schomburg, Adrian; Reinemer, Peter; Gale, Jennifer P.; Campbell, Arthur J.; Fisher, Stewart L.; Zhao, Wen-Ning; Reis, Surya A.; Hennig, Krista M.; Thomas, Meryl; Muller, Peter; Jefson, Martin R.; Fass, Daniel M.; Haggarty, Stephen J.; Zhang, Yan-Ling; Holson, Edward B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4008-4015</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The structure-activity and structure-kinetic relationships of a series of novel and selective ortho-aminoanilide inhibitors of histone deacetylases (HDACs) 1 and 2 are described.  Different kinetic and thermodn. selectivity profiles were obtained by varying the moiety occupying an 11 Å channel leading to the Zn2+ catalytic pocket of HDACs 1 and 2, two paralogs with a high degree of structural similarity.  The design of these novel inhibitors was informed by two ligand-bound crystal structures of truncated hHDAC2.  BRD4884 and BRD7232 possess kinetic selectivity for HDAC1 vs. HDAC2.  We demonstrate that the binding kinetics of HDAC inhibitors can be tuned for individual isoforms in order to modulate target residence time while retaining functional activity and increased histone H4K12 and H3K9 acetylation in primary mouse neuronal cell culture assays.  These chromatin modifiers, with tuned binding kinetic profiles, can be used to define the relation between target engagement requirements and the pharmacodynamic response of HDACs in different disease applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQpWplRRVod7Vg90H21EOLACvtfcHk0liA4JlYyJDggw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFSgur7E&md5=bcbe1addb5d30073f345fd77d529dcd4</span></div><a href="/servlet/linkout?suffix=cit191&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.06.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.06.040%26sid%3Dliteratum%253Aachs%26aulast%3DWagner%26aufirst%3DF.%2BF.%26aulast%3DWe%25C3%25AFwer%26aufirst%3DM.%26aulast%3DSteinbacher%26aufirst%3DS.%26aulast%3DSchomburg%26aufirst%3DA.%26aulast%3DReinemer%26aufirst%3DP.%26aulast%3DGale%26aufirst%3DJ.%2BP.%26aulast%3DCampbell%26aufirst%3DA.%2BJ.%26aulast%3DFisher%26aufirst%3DS.%2BL.%26aulast%3DZhao%26aufirst%3DW.-N.%26aulast%3DReis%26aufirst%3DS.%2BA.%26aulast%3DHennig%26aufirst%3DK.%2BM.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DM%25C3%25BCller%26aufirst%3DP.%26aulast%3DJefson%26aufirst%3DM.%2BR.%26aulast%3DFass%26aufirst%3DD.%2BM.%26aulast%3DHaggarty%26aufirst%3DS.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%2BL.%26aulast%3DHolson%26aufirst%3DE.%2BB.%26atitle%3DKinetic%2520and%2520Structural%2520Insights%2520into%2520the%2520Binding%2520of%2520Histone%2520Deacetylase%25201%2520and%25202%2520%2528HDAC1%252C%25202%2529%2520Inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D4008%26epage%3D4015%26doi%3D10.1016%2Fj.bmc.2016.06.040" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref192"><div class="reference"><strong class="refLabel"><a href="#ref192" class="rightTabRefNumLink">192</a></strong><div class="NLM_citation" id="rightTab-cit192"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clausen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolkenberg, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beshore, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duffy, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Myers, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fells, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howell, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnard, R. J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozlowski, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of Ethyl Ketone-Based HDACs 1, 2, and 3 Selective Inhibitors for HIV Latency Reactivation</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">127197</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2020.127197</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmcl.2020.127197" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=32331932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref192/cit192&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnvFeisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2020&pages=127197&author=W.+Yuauthor=J.+Liuauthor=Y.+Yuauthor=V.+Zhangauthor=D.+Clausenauthor=J.+Kellyauthor=S.+Wolkenbergauthor=D.+Beshoreauthor=J.+L.+Duffyauthor=C.+C.+Chungauthor=R.+J.+Myersauthor=D.+L.+Kleinauthor=J.+Fellsauthor=K.+Hollowayauthor=J.+Wuauthor=G.+Wuauthor=B.+J.+Howellauthor=R.+J.+O.+Barnardauthor=J.+Kozlowski&title=Discovery+of+Ethyl+Ketone-Based+HDACs+1%2C+2%2C+and+3+Selective+Inhibitors+for+HIV+Latency+Reactivation&doi=10.1016%2Fj.bmcl.2020.127197"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit192R"><div class="casContent"><span class="casTitleNuber">192</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of ethyl ketone-based HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation</span></div><div class="casAuthors">Yu, Wensheng; Liu, Jian; Yu, Younong; Zhang, Vivian; Clausen, Dane; Kelly, Joseph; Wolkenberg, Scott; Beshore, Douglas; Duffy, Joseph L.; Chang, Christine C.; Myers, Robert W.; Klein, Daniel J.; Fells, James; Holloway, Kate; Wu, Jin; Wu, Guoxin; Howell, Bonnie J.; Barnard, Richard J. O.; Kozlowski, Joseph</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">127197</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel series of Et ketone based HDACs 1, 2, and 3 selective inhibitors have been identified with good enzymic and cellular activity and high selectivity over HDACs 6 and 8.  These inhibitors contain a spirobicyclic group in the amide region.  Compd. 13 stands out as a lead due to its good potency, high selectivity, and reasonable rat and dog PK.  Compds. 33 and 34 show good potency and rat PK profiles as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCRDknBquRfbVg90H21EOLACvtfcHk0liqo5U27ccr2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnvFeisb8%253D&md5=d0fb2e00f70938578cebc54129de8ce9</span></div><a href="/servlet/linkout?suffix=cit192&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2020.127197&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2020.127197%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DV.%26aulast%3DClausen%26aufirst%3DD.%26aulast%3DKelly%26aufirst%3DJ.%26aulast%3DWolkenberg%26aufirst%3DS.%26aulast%3DBeshore%26aufirst%3DD.%26aulast%3DDuffy%26aufirst%3DJ.%2BL.%26aulast%3DChung%26aufirst%3DC.%2BC.%26aulast%3DMyers%26aufirst%3DR.%2BJ.%26aulast%3DKlein%26aufirst%3DD.%2BL.%26aulast%3DFells%26aufirst%3DJ.%26aulast%3DHolloway%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DHowell%26aufirst%3DB.%2BJ.%26aulast%3DBarnard%26aufirst%3DR.%2BJ.%2BO.%26aulast%3DKozlowski%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520Ethyl%2520Ketone-Based%2520HDACs%25201%252C%25202%252C%2520and%25203%2520Selective%2520Inhibitors%2520for%2520HIV%2520Latency%2520Reactivation%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D30%26spage%3D127197%26doi%3D10.1016%2Fj.bmcl.2020.127197" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref193"><div class="reference"><strong class="refLabel"><a href="#ref193" class="rightTabRefNumLink">193</a></strong><div class="NLM_citation" id="rightTab-cit193"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fournier, J.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhurruth-Alcor, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musicki, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aubert, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aurelly, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouix-Peter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouquet, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chantalat, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delorme, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drean, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duvert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleury-Bregeot, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grisendi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hennequin, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isabet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joly, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lafitte, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Millois, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgentin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pascau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piwnica, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rival, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soulet, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thoreau, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomas, L.</span></span> <span> </span><span class="NLM_article-title">Squaramides as Novel Class I and IIB Histone Deacetylase Inhibitors for Topical Treatment of Cutaneous T-Cell Lymphoma</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2985</span>– <span class="NLM_lpage">2992</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.06.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmcl.2018.06.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=30122227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref193/cit193&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1yrsrbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=2985-2992&author=J.-F.+Fournierauthor=Y.+Bhurruth-Alcorauthor=B.+Musickiauthor=J.+Aubertauthor=M.+Aurellyauthor=C.+Bouix-Peterauthor=K.+Bouquetauthor=L.+Chantalatauthor=M.+Delormeauthor=B.+Dreanauthor=G.+Duvertauthor=N.+Fleury-Bregeotauthor=B.+Gauthierauthor=K.+Grisendiauthor=C.+S.+Harrisauthor=L.+F.+Hennequinauthor=T.+Isabetauthor=F.+Jolyauthor=G.+Lafitteauthor=C.+Milloisauthor=R.+Morgentinauthor=J.+Pascauauthor=D.+Piwnicaauthor=Y.+Rivalauthor=C.+Souletauthor=E.+Thoreauauthor=L.+Tomas&title=Squaramides+as+Novel+Class+I+and+IIB+Histone+Deacetylase+Inhibitors+for+Topical+Treatment+of+Cutaneous+T-Cell+Lymphoma&doi=10.1016%2Fj.bmcl.2018.06.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit193R"><div class="casContent"><span class="casTitleNuber">193</span><div class="casTitle"><span class="NLM_cas:atitle">Squaramides as novel class I and IIB histone deacetylase inhibitors for topical treatment of cutaneous t-cell lymphoma</span></div><div class="casAuthors">Fournier, Jean-Francois; Bhurruth-Alcor, Yushma; Musicki, Branislav; Aubert, Jerome; Aurelly, Michele; Bouix-Peter, Claire; Bouquet, Karinne; Chantalat, Laurent; Delorme, Marion; Drean, Benedicte; Duvert, Gwenaelle; Fleury-Bregeot, Nicolas; Gauthier, Blanche; Grisendi, Karine; Harris, Craig S.; Hennequin, Laurent F.; Isabet, Tatiana; Joly, Florence; Lafitte, Guillaume; Millois, Corinne; Morgentin, Remy; Pascau, Jonathan; Piwnica, David; Rival, Yves; Soulet, Catherine; Thoreau, Etienne; Tomas, Loic</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2985-2992</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of squaramide-based hydroxamic acids were designed, synthesized and evaluated against human HDAC enzyme.  Squaramides were found t o be potent in the Hut78 cell line, but initially suffered from low soly.  Leads with improved soly. and metabolic profiles were shown to be class I, IIB and IV selective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8Zi7nKMExXrVg90H21EOLACvtfcHk0liqo5U27ccr2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1yrsrbE&md5=f882594f1146d7d96f3e3860c3199cdb</span></div><a href="/servlet/linkout?suffix=cit193&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.06.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.06.029%26sid%3Dliteratum%253Aachs%26aulast%3DFournier%26aufirst%3DJ.-F.%26aulast%3DBhurruth-Alcor%26aufirst%3DY.%26aulast%3DMusicki%26aufirst%3DB.%26aulast%3DAubert%26aufirst%3DJ.%26aulast%3DAurelly%26aufirst%3DM.%26aulast%3DBouix-Peter%26aufirst%3DC.%26aulast%3DBouquet%26aufirst%3DK.%26aulast%3DChantalat%26aufirst%3DL.%26aulast%3DDelorme%26aufirst%3DM.%26aulast%3DDrean%26aufirst%3DB.%26aulast%3DDuvert%26aufirst%3DG.%26aulast%3DFleury-Bregeot%26aufirst%3DN.%26aulast%3DGauthier%26aufirst%3DB.%26aulast%3DGrisendi%26aufirst%3DK.%26aulast%3DHarris%26aufirst%3DC.%2BS.%26aulast%3DHennequin%26aufirst%3DL.%2BF.%26aulast%3DIsabet%26aufirst%3DT.%26aulast%3DJoly%26aufirst%3DF.%26aulast%3DLafitte%26aufirst%3DG.%26aulast%3DMillois%26aufirst%3DC.%26aulast%3DMorgentin%26aufirst%3DR.%26aulast%3DPascau%26aufirst%3DJ.%26aulast%3DPiwnica%26aufirst%3DD.%26aulast%3DRival%26aufirst%3DY.%26aulast%3DSoulet%26aufirst%3DC.%26aulast%3DThoreau%26aufirst%3DE.%26aulast%3DTomas%26aufirst%3DL.%26atitle%3DSquaramides%2520as%2520Novel%2520Class%2520I%2520and%2520IIB%2520Histone%2520Deacetylase%2520Inhibitors%2520for%2520Topical%2520Treatment%2520of%2520Cutaneous%2520T-Cell%2520Lymphoma%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2018%26volume%3D28%26spage%3D2985%26epage%3D2992%26doi%3D10.1016%2Fj.bmcl.2018.06.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref194"><div class="reference"><strong class="refLabel"><a href="#ref194" class="rightTabRefNumLink">194</a></strong><div class="NLM_citation" id="rightTab-cit194"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lauffer, B. E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mintzer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fong, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukund, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zilberleyb, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flicke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritscher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedorowicz, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunzner, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modrusan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neumann, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koth, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupardus, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaminker, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heise, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steiner, P.</span></span> <span> </span><span class="NLM_article-title">Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span>,  <span class="NLM_fpage">26926</span>– <span class="NLM_lpage">26943</span>, <span class="refDoi"> DOI: 10.1074/jbc.M113.490706</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1074%2Fjbc.M113.490706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=23897821" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref194/cit194&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVClt7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=26926-26943&author=B.+E.+L.+Laufferauthor=R.+Mintzerauthor=R.+Fongauthor=S.+Mukundauthor=C.+Tamauthor=I.+Zilberleybauthor=B.+Flickeauthor=A.+Ritscherauthor=G.+Fedorowiczauthor=R.+Valleroauthor=D.+F.+Ortwineauthor=J.+Gunznerauthor=Z.+Modrusanauthor=L.+Neumannauthor=C.+M.+Kothauthor=P.+J.+Lupardusauthor=J.+S.+Kaminkerauthor=C.+E.+Heiseauthor=P.+Steiner&title=Histone+Deacetylase+%28HDAC%29+Inhibitor+Kinetic+Rate+Constants+Correlate+with+Cellular+Histone+Acetylation+but+Not+Transcription+and+Cell+Viability&doi=10.1074%2Fjbc.M113.490706"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit194R"><div class="casContent"><span class="casTitleNuber">194</span><div class="casTitle"><span class="NLM_cas:atitle">Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability</span></div><div class="casAuthors">Lauffer, Benjamin E. L.; Mintzer, Robert; Fong, Rina; Mukund, Susmith; Tam, Christine; Zilberleyb, Inna; Flicke, Birgit; Ritscher, Allegra; Fedorowicz, Grazyna; Vallero, Roxanne; Ortwine, Daniel F.; Gunzner, Janet; Modrusan, Zora; Neumann, Lars; Koth, Christopher M.; Lupardus, Patrick J.; Kaminker, Joshua S.; Heise, Christopher E.; Steiner, Pascal</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">26926-26943</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are crit. in the control of gene expression, and dysregulation of their activity has been implicated in a broad range of diseases, including cancer, cardiovascular, and neurol. diseases.  HDAC inhibitors (HDACi) employing different zinc chelating functionalities such as hydroxamic acids and benzamides have shown promising results in cancer therapy.  Although it has also been suggested that HDACi with increased isoenzyme selectivity and potency may broaden their clin. utility and minimize side effects, the translation of this idea to the clinic remains to be investigated.  Moreover, a detailed understanding of how HDACi with different pharmacol. properties affect biol. functions in vitro and in vivo is still missing.  Here, we show that a panel of benzamide-contg. HDACi are slow tight-binding inhibitors with long residence times unlike the hydroxamate-contg. HDACi vorinostat and trichostatin-A.  Characterization of changes in H2BK5 and H4K14 acetylation following HDACi treatment in the neuroblastoma cell line SH-SY5Y revealed that the timing and magnitude of histone acetylation mirrored both the assocn. and dissocn. kinetic rates of the inhibitors.  In contrast, cell viability and microarray gene expression anal. indicated that cell death induction and changes in transcriptional regulation do not correlate with the dissocn. kinetic rates of the HDACi.  Therefore, our study suggests that detg. how the selective and kinetic inhibition properties of HDACi affect cell function will help to evaluate their therapeutic utility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2goaOx8CDGbVg90H21EOLACvtfcHk0lhTahmDp0zyFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVClt7jM&md5=af1074c79e8abd932313f4ae13333a98</span></div><a href="/servlet/linkout?suffix=cit194&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M113.490706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M113.490706%26sid%3Dliteratum%253Aachs%26aulast%3DLauffer%26aufirst%3DB.%2BE.%2BL.%26aulast%3DMintzer%26aufirst%3DR.%26aulast%3DFong%26aufirst%3DR.%26aulast%3DMukund%26aufirst%3DS.%26aulast%3DTam%26aufirst%3DC.%26aulast%3DZilberleyb%26aufirst%3DI.%26aulast%3DFlicke%26aufirst%3DB.%26aulast%3DRitscher%26aufirst%3DA.%26aulast%3DFedorowicz%26aufirst%3DG.%26aulast%3DVallero%26aufirst%3DR.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DGunzner%26aufirst%3DJ.%26aulast%3DModrusan%26aufirst%3DZ.%26aulast%3DNeumann%26aufirst%3DL.%26aulast%3DKoth%26aufirst%3DC.%2BM.%26aulast%3DLupardus%26aufirst%3DP.%2BJ.%26aulast%3DKaminker%26aufirst%3DJ.%2BS.%26aulast%3DHeise%26aufirst%3DC.%2BE.%26aulast%3DSteiner%26aufirst%3DP.%26atitle%3DHistone%2520Deacetylase%2520%2528HDAC%2529%2520Inhibitor%2520Kinetic%2520Rate%2520Constants%2520Correlate%2520with%2520Cellular%2520Histone%2520Acetylation%2520but%2520Not%2520Transcription%2520and%2520Cell%2520Viability%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26spage%3D26926%26epage%3D26943%26doi%3D10.1074%2Fjbc.M113.490706" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref195"><div class="reference"><strong class="refLabel"><a href="#ref195" class="rightTabRefNumLink">195</a></strong><div class="NLM_citation" id="rightTab-cit195"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bottomley, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lo Surdo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Giovine, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cirillo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarpelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrigno, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neddermann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Francesco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinkühler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallinari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carfí, A.</span></span> <span> </span><span class="NLM_article-title">Structural and Functional Analysis of the Human HDAC4 Catalytic Domain Reveals a Regulatory Structural Zinc-Binding Domain</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">26694</span>– <span class="NLM_lpage">26704</span>, <span class="refDoi"> DOI: 10.1074/jbc.M803514200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1074%2Fjbc.M803514200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=18614528" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref195/cit195&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtFejtr3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=26694-26704&author=M.+J.+Bottomleyauthor=P.+Lo+Surdoauthor=P.+Di+Giovineauthor=A.+Cirilloauthor=R.+Scarpelliauthor=F.+Ferrignoauthor=P.+Jonesauthor=P.+Neddermannauthor=R.+De+Francescoauthor=C.+Steink%C3%BChlerauthor=P.+Gallinariauthor=A.+Carf%C3%AD&title=Structural+and+Functional+Analysis+of+the+Human+HDAC4+Catalytic+Domain+Reveals+a+Regulatory+Structural+Zinc-Binding+Domain&doi=10.1074%2Fjbc.M803514200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit195R"><div class="casContent"><span class="casTitleNuber">195</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Functional Analysis of the Human HDAC4 Catalytic Domain Reveals a Regulatory Structural Zinc-binding Domain</span></div><div class="casAuthors">Bottomley, Matthew J.; Lo Surdo, Paola; Di Giovine, Paolo; Cirillo, Agostino; Scarpelli, Rita; Ferrigno, Federica; Jones, Philip; Neddermann, Petra; De Francesco, Raffaele; Steinkuehler, Christian; Gallinari, Paola; Carfi, Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">26694-26704</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) regulate chromatin status and gene expression, and their inhibition is of significant therapeutic interest.  To date, no biol. substrate for class IIa HDACs has been identified, and only low activity on acetylated lysines has been demonstrated.  Here, we describe inhibitor-bound and inhibitor-free structures of the histone deacetylase-4 catalytic domain (HDAC4cd) and of an HDAC4cd active site mutant with enhanced enzymic activity toward acetylated lysines.  The structures presented, coupled with activity data, provide the mol. basis for the intrinsically low enzymic activity of class IIa HDACs toward acetylated lysines and reveal active site features that may guide the design of class-specific inhibitors.  In addn., these structures reveal a conformationally flexible structural zinc-binding domain conserved in all class IIa enzymes.  Importantly, either the mutation of residues coordinating the structural zinc ion or the binding of a class IIa selective inhibitor prevented the assocn. of HDAC4 with the N-CoR·HDAC3 repressor complex.  Together, these data suggest a key role of the structural zinc-binding domain in the regulation of class IIa HDAC functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBLYPf6RysNrVg90H21EOLACvtfcHk0lhTahmDp0zyFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtFejtr3O&md5=90431dcb431fe2a6002f82320f0af453</span></div><a href="/servlet/linkout?suffix=cit195&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M803514200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M803514200%26sid%3Dliteratum%253Aachs%26aulast%3DBottomley%26aufirst%3DM.%2BJ.%26aulast%3DLo%2BSurdo%26aufirst%3DP.%26aulast%3DDi%2BGiovine%26aufirst%3DP.%26aulast%3DCirillo%26aufirst%3DA.%26aulast%3DScarpelli%26aufirst%3DR.%26aulast%3DFerrigno%26aufirst%3DF.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DNeddermann%26aufirst%3DP.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26aulast%3DSteink%25C3%25BChler%26aufirst%3DC.%26aulast%3DGallinari%26aufirst%3DP.%26aulast%3DCarf%25C3%25AD%26aufirst%3DA.%26atitle%3DStructural%2520and%2520Functional%2520Analysis%2520of%2520the%2520Human%2520HDAC4%2520Catalytic%2520Domain%2520Reveals%2520a%2520Regulatory%2520Structural%2520Zinc-Binding%2520Domain%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D26694%26epage%3D26704%26doi%3D10.1074%2Fjbc.M803514200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref196"><div class="reference"><strong class="refLabel"><a href="#ref196" class="rightTabRefNumLink">196</a></strong><div class="NLM_citation" id="rightTab-cit196"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luckhurst, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breccia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stott, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aziz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Birch, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bürli, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jarvis, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McAllister, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollack, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saville-Stones, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, C.</span></span> <span> </span><span class="NLM_article-title">Potent, Selective, and CNS-Penetrant Tetrasubstituted Cyclopropane Class IIa Histone Deacetylase (HDAC) Inhibitors</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">34</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00302</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00302" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref196/cit196&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvF2lt7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=34-39&author=C.+A.+Luckhurstauthor=P.+Brecciaauthor=A.+J.+Stottauthor=O.+Azizauthor=H.+L.+Birchauthor=R.+W.+B%C3%BCrliauthor=S.+J.+Hughesauthor=R.+E.+Jarvisauthor=M.+Lamersauthor=P.+M.+Leonardauthor=K.+L.+Matthewsauthor=G.+McAllisterauthor=S.+Pollackauthor=E.+Saville-Stonesauthor=G.+Wishartauthor=D.+Yatesauthor=C.+Dominguez&title=Potent%2C+Selective%2C+and+CNS-Penetrant+Tetrasubstituted+Cyclopropane+Class+IIa+Histone+Deacetylase+%28HDAC%29+Inhibitors&doi=10.1021%2Facsmedchemlett.5b00302"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit196R"><div class="casContent"><span class="casTitleNuber">196</span><div class="casTitle"><span class="NLM_cas:atitle">Potent, Selective, and CNS-Penetrant Tetrasubstituted Cyclopropane Class IIa Histone Deacetylase (HDAC) Inhibitors</span></div><div class="casAuthors">Luckhurst, Christopher A.; Breccia, Perla; Stott, Andrew J.; Aziz, Omar; Birch, Helen L.; Burli, Roland W.; Hughes, Samantha J.; Jarvis, Rebecca E.; Lamers, Marieke; Leonard, Philip M.; Matthews, Kim L.; McAllister, George; Pollack, Scott; Saville-Stones, Elizabeth; Wishart, Grant; Yates, Dawn; Dominguez, Celia</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">34-39</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Potent and selective class IIa HDAC tetrasubstituted cyclopropane hydroxamic acid inhibitors were identified with high oral bioavailability that exhibited good brain and muscle exposure.  Compd. (I) displayed suitable properties for assessment of the impact of class IIa HDAC catalytic site inhibition in preclin. disease models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq01yllqODDNLVg90H21EOLACvtfcHk0liUKdaJFmTMdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvF2lt7vE&md5=dfc4f299bc59bdb7bcf92f7e0bccda0d</span></div><a href="/servlet/linkout?suffix=cit196&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00302&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00302%26sid%3Dliteratum%253Aachs%26aulast%3DLuckhurst%26aufirst%3DC.%2BA.%26aulast%3DBreccia%26aufirst%3DP.%26aulast%3DStott%26aufirst%3DA.%2BJ.%26aulast%3DAziz%26aufirst%3DO.%26aulast%3DBirch%26aufirst%3DH.%2BL.%26aulast%3DB%25C3%25BCrli%26aufirst%3DR.%2BW.%26aulast%3DHughes%26aufirst%3DS.%2BJ.%26aulast%3DJarvis%26aufirst%3DR.%2BE.%26aulast%3DLamers%26aufirst%3DM.%26aulast%3DLeonard%26aufirst%3DP.%2BM.%26aulast%3DMatthews%26aufirst%3DK.%2BL.%26aulast%3DMcAllister%26aufirst%3DG.%26aulast%3DPollack%26aufirst%3DS.%26aulast%3DSaville-Stones%26aufirst%3DE.%26aulast%3DWishart%26aufirst%3DG.%26aulast%3DYates%26aufirst%3DD.%26aulast%3DDominguez%26aufirst%3DC.%26atitle%3DPotent%252C%2520Selective%252C%2520and%2520CNS-Penetrant%2520Tetrasubstituted%2520Cyclopropane%2520Class%2520IIa%2520Histone%2520Deacetylase%2520%2528HDAC%2529%2520Inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D34%26epage%3D39%26doi%3D10.1021%2Facsmedchemlett.5b00302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref197"><div class="reference"><strong class="refLabel"><a href="#ref197" class="rightTabRefNumLink">197</a></strong><div class="NLM_citation" id="rightTab-cit197"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Luckhurst, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aziz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaumont, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bürli, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Breccia, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maillard, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haughan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raphy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stott, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munoz-Sanjuan, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wishart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yates, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, C.</span></span> <span> </span><span class="NLM_article-title">Development and Characterization of a CNS-Penetrant Benzhydryl Hydroxamic Acid Class IIa Histone Deacetylase Inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2018.11.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmcl.2018.11.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=30463802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref197/cit197&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1ChtbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=83-88&author=C.+A.+Luckhurstauthor=O.+Azizauthor=V.+Beaumontauthor=R.+W.+B%C3%BCrliauthor=P.+Brecciaauthor=M.+C.+Maillardauthor=A.+F.+Haughanauthor=M.+Lamersauthor=P.+Leonardauthor=K.+L.+Matthewsauthor=G.+Raphyauthor=A.+J.+Stottauthor=I.+Munoz-Sanjuanauthor=B.+Thomasauthor=M.+Wallauthor=G.+Wishartauthor=D.+Yatesauthor=C.+Dominguez&title=Development+and+Characterization+of+a+CNS-Penetrant+Benzhydryl+Hydroxamic+Acid+Class+IIa+Histone+Deacetylase+Inhibitor&doi=10.1016%2Fj.bmcl.2018.11.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit197R"><div class="casContent"><span class="casTitleNuber">197</span><div class="casTitle"><span class="NLM_cas:atitle">Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitor</span></div><div class="casAuthors">Luckhurst, Christopher A.; Aziz, Omar; Beaumont, Vahri; Burli, Roland W.; Breccia, Perla; Maillard, Michel C.; Haughan, Alan F.; Lamers, Marieke; Leonard, Phil; Matthews, Kim L.; Raphy, Gilles; Stott, Andrew J.; Munoz-Sanjuan, Ignacio; Thomas, Beth; Wall, Michael; Wishart, Grant; Yates, Dawn; Dominguez, Celia</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">83-88</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">We have identified a potent, cell permeable and CNS penetrant class IIa histone deacetylase (HDAC) inhibitor 22(I), with >500-fold selectivity over class I HDACs (1,2,3) and ∼150-fold selectivity over HDAC8 and the class IIb HDAC6 isoform.  Dose escalation pharmacokinetic anal. demonstrated that upon oral administration, compd. 22 can reach exposure levels in mouse plasma, muscle and brain in excess of cellular class IIa HDAC IC50 levels for ∼8 h.  Given the interest in aberrant class IIa HDAC function for a no. of neurodegenerative, neuromuscular, cardiac and oncol. indications, compd. 22 (also known as CHDI-390576) provides a selective and potent compd. to query the role of class IIa HDAC biol., and the impact of class IIa catalytic site occupancy in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYgNfS2AXrN7Vg90H21EOLACvtfcHk0liUKdaJFmTMdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1ChtbbM&md5=8348010d11e3fe0114ca1a2e596206d4</span></div><a href="/servlet/linkout?suffix=cit197&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2018.11.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2018.11.009%26sid%3Dliteratum%253Aachs%26aulast%3DLuckhurst%26aufirst%3DC.%2BA.%26aulast%3DAziz%26aufirst%3DO.%26aulast%3DBeaumont%26aufirst%3DV.%26aulast%3DB%25C3%25BCrli%26aufirst%3DR.%2BW.%26aulast%3DBreccia%26aufirst%3DP.%26aulast%3DMaillard%26aufirst%3DM.%2BC.%26aulast%3DHaughan%26aufirst%3DA.%2BF.%26aulast%3DLamers%26aufirst%3DM.%26aulast%3DLeonard%26aufirst%3DP.%26aulast%3DMatthews%26aufirst%3DK.%2BL.%26aulast%3DRaphy%26aufirst%3DG.%26aulast%3DStott%26aufirst%3DA.%2BJ.%26aulast%3DMunoz-Sanjuan%26aufirst%3DI.%26aulast%3DThomas%26aufirst%3DB.%26aulast%3DWall%26aufirst%3DM.%26aulast%3DWishart%26aufirst%3DG.%26aulast%3DYates%26aufirst%3DD.%26aulast%3DDominguez%26aufirst%3DC.%26atitle%3DDevelopment%2520and%2520Characterization%2520of%2520a%2520CNS-Penetrant%2520Benzhydryl%2520Hydroxamic%2520Acid%2520Class%2520IIa%2520Histone%2520Deacetylase%2520Inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D83%26epage%3D88%26doi%3D10.1016%2Fj.bmcl.2018.11.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref198"><div class="reference"><strong class="refLabel"><a href="#ref198" class="rightTabRefNumLink">198</a></strong><div class="NLM_citation" id="rightTab-cit198"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lobera, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madauss, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pohlhaus, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, Q. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trocha, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baloglu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trump, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hofmann, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray-Thompson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakravorty, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mander, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruidenier, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burkhart, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turunen, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, J. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghosh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nolan, M. A.</span></span> <span> </span><span class="NLM_article-title">Selective Class IIa Histone Deacetylase Inhibition via a Nonchelating Zinc-Binding Group</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">319</span>– <span class="NLM_lpage">325</span>, <span class="refDoi"> DOI: 10.1038/nchembio.1223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fnchembio.1223" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=23524983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref198/cit198&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksVOiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2013&pages=319-325&author=M.+Loberaauthor=K.+P.+Madaussauthor=D.+T.+Pohlhausauthor=Q.+G.+Wrightauthor=M.+Trochaauthor=D.+R.+Schmidtauthor=E.+Balogluauthor=R.+P.+Trumpauthor=M.+S.+Headauthor=G.+A.+Hofmannauthor=M.+Murray-Thompsonauthor=B.+Schwartzauthor=S.+Chakravortyauthor=Z.+Wuauthor=P.+K.+Manderauthor=L.+Kruidenierauthor=R.+A.+Reidauthor=W.+Burkhartauthor=B.+J.+Turunenauthor=J.+X.+Rongauthor=C.+Wagnerauthor=M.+B.+Moyerauthor=C.+Wellsauthor=X.+Hongauthor=J.+T.+Mooreauthor=J.+D.+Williamsauthor=D.+Solerauthor=S.+Ghoshauthor=M.+A.+Nolan&title=Selective+Class+IIa+Histone+Deacetylase+Inhibition+via+a+Nonchelating+Zinc-Binding+Group&doi=10.1038%2Fnchembio.1223"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit198R"><div class="casContent"><span class="casTitleNuber">198</span><div class="casTitle"><span class="NLM_cas:atitle">Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group</span></div><div class="casAuthors">Lobera, Mercedes; Madauss, Kevin P.; Pohlhaus, Denise T.; Wright, Quentin G.; Trocha, Mark; Schmidt, Darby R.; Baloglu, Erkan; Trump, Ryan P.; Head, Martha S.; Hofmann, Glenn A.; Murray-Thompson, Monique; Schwartz, Benjamin; Chakravorty, Subhas; Wu, Zining; Mander, Palwinder K.; Kruidenier, Laurens; Reid, Robert A.; Burkhart, William; Turunen, Brandon J.; Rong, James X.; Wagner, Craig; Moyer, Mary B.; Wells, Carrow; Hong, Xuan; Moore, John T.; Williams, Jon D.; Soler, Dulce; Ghosh, Shomir; Nolan, Michael A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">319-325</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In contrast to studies on class I histone deacetylase (HDAC) inhibitors, the elucidation of the mol. mechanisms and therapeutic potential of class IIa HDACs (HDAC4, HDAC5, HDAC7 and HDAC9) is impaired by the lack of potent and selective chem. probes.  Here we report the discovery of inhibitors that fill this void with an unprecedented metal-binding group, trifluoromethyloxadiazole (TFMO), which circumvents the selectivity and pharmacol. liabilities of hydroxamates.  We confirm direct metal binding of the TFMO through crystallog. approaches and use chemoproteomics to demonstrate the superior selectivity of the TFMO series relative to a hydroxamate-substituted analog.  We further apply these tool compds. to reveal gene regulation dependent on the catalytic active site of class IIa HDACs.  The discovery of these inhibitors challenges the design process for targeting metalloenzymes through a chelating metal-binding group and suggests therapeutic potential for class IIa HDAC enzyme blockers distinct in mechanism and application compared to current HDAC inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpglr3JvlNjhbVg90H21EOLACvtfcHk0liUKdaJFmTMdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksVOiur4%253D&md5=f15a4565213d7a0ec5dc0a0b6032b9ab</span></div><a href="/servlet/linkout?suffix=cit198&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1223%26sid%3Dliteratum%253Aachs%26aulast%3DLobera%26aufirst%3DM.%26aulast%3DMadauss%26aufirst%3DK.%2BP.%26aulast%3DPohlhaus%26aufirst%3DD.%2BT.%26aulast%3DWright%26aufirst%3DQ.%2BG.%26aulast%3DTrocha%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DD.%2BR.%26aulast%3DBaloglu%26aufirst%3DE.%26aulast%3DTrump%26aufirst%3DR.%2BP.%26aulast%3DHead%26aufirst%3DM.%2BS.%26aulast%3DHofmann%26aufirst%3DG.%2BA.%26aulast%3DMurray-Thompson%26aufirst%3DM.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DChakravorty%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DMander%26aufirst%3DP.%2BK.%26aulast%3DKruidenier%26aufirst%3DL.%26aulast%3DReid%26aufirst%3DR.%2BA.%26aulast%3DBurkhart%26aufirst%3DW.%26aulast%3DTurunen%26aufirst%3DB.%2BJ.%26aulast%3DRong%26aufirst%3DJ.%2BX.%26aulast%3DWagner%26aufirst%3DC.%26aulast%3DMoyer%26aufirst%3DM.%2BB.%26aulast%3DWells%26aufirst%3DC.%26aulast%3DHong%26aufirst%3DX.%26aulast%3DMoore%26aufirst%3DJ.%2BT.%26aulast%3DWilliams%26aufirst%3DJ.%2BD.%26aulast%3DSoler%26aufirst%3DD.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DNolan%26aufirst%3DM.%2BA.%26atitle%3DSelective%2520Class%2520IIa%2520Histone%2520Deacetylase%2520Inhibition%2520via%2520a%2520Nonchelating%2520Zinc-Binding%2520Group%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2013%26volume%3D9%26spage%3D319%26epage%3D325%26doi%3D10.1038%2Fnchembio.1223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref199"><div class="reference"><strong class="refLabel"><a href="#ref199" class="rightTabRefNumLink">199</a></strong><div class="NLM_citation" id="rightTab-cit199"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schuetz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allali-Hassani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schapira, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shuen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loppnau, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazitschek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maglathin, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bochkarev, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plotnikov, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vedadi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arrowsmith, C. H.</span></span> <span> </span><span class="NLM_article-title">Human HDAC7 Harbors a Class IIa Histone Deacetylase-Specific Zinc Binding Motif and Cryptic Deacetylase Activity</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>283</i></span>,  <span class="NLM_fpage">11355</span>– <span class="NLM_lpage">11363</span>, <span class="refDoi"> DOI: 10.1074/jbc.M707362200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1074%2Fjbc.M707362200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=18285338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref199/cit199&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD1cXkvVSgtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2008&pages=11355-11363&author=A.+Schuetzauthor=J.+Minauthor=A.+Allali-Hassaniauthor=M.+Schapiraauthor=M.+Shuenauthor=P.+Loppnauauthor=R.+Mazitschekauthor=N.+P.+Kwiatkowskiauthor=T.+A.+Lewisauthor=R.+L.+Maglathinauthor=T.+H.+McLeanauthor=A.+Bochkarevauthor=A.+N.+Plotnikovauthor=M.+Vedadiauthor=C.+H.+Arrowsmith&title=Human+HDAC7+Harbors+a+Class+IIa+Histone+Deacetylase-Specific+Zinc+Binding+Motif+and+Cryptic+Deacetylase+Activity&doi=10.1074%2Fjbc.M707362200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit199R"><div class="casContent"><span class="casTitleNuber">199</span><div class="casTitle"><span class="NLM_cas:atitle">Human HDAC7 Harbors a Class IIa Histone Deacetylase-specific Zinc Binding Motif and Cryptic Deacetylase Activity</span></div><div class="casAuthors">Schuetz, Anja; Min, Jinrong; Allali-Hassani, Abdellah; Schapira, Matthieu; Shuen, Michael; Loppnau, Peter; Mazitschek, Ralph; Kwiatkowski, Nick P.; Lewis, Timothy A.; Maglathin, Rebecca L.; McLean, Thomas H.; Bochkarev, Alexey; Plotnikov, Alexander N.; Vedadi, Masoud; Arrowsmith, Cheryl H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">11355-11363</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) are protein deacetylases that play a role in repression of gene transcription and are emerging targets in cancer therapy.  Here, we characterize the structure and enzymic activity of the catalytic domain of human HDAC7 (cdHDAC7).  Although HDAC7 normally exists as part of a multiprotein complex, we show that cdHDAC7 has a low level of deacetylase activity which can be inhibited by known HDAC inhibitors.  The crystal structures of human cdHDAC7 and its complexes with two hydroxamate inhibitors are the first structures of the catalytic domain of class IIa HDACs and demonstrate significant differences with previously reported class I and class IIb-like HDAC structures.  We show that cdHDAC7 has an addnl. class IIa HDAC-specific zinc binding motif adjacent to the active site which is likely to participate in substrate recognition and protein-protein interaction and may provide a site for modulation of activity.  Furthermore, a different active site topol. results in modified catalytic properties and in an enlarged active site pocket.  Our studies provide mechanistic insights into class IIa HDACs and facilitate the design of specific modulators.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGppuqRJohIAJrVg90H21EOLACvtfcHk0lh4Q0tO6DG5lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXkvVSgtrw%253D&md5=717d5b72b5a08ca7ad1c655fc9af0bec</span></div><a href="/servlet/linkout?suffix=cit199&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M707362200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M707362200%26sid%3Dliteratum%253Aachs%26aulast%3DSchuetz%26aufirst%3DA.%26aulast%3DMin%26aufirst%3DJ.%26aulast%3DAllali-Hassani%26aufirst%3DA.%26aulast%3DSchapira%26aufirst%3DM.%26aulast%3DShuen%26aufirst%3DM.%26aulast%3DLoppnau%26aufirst%3DP.%26aulast%3DMazitschek%26aufirst%3DR.%26aulast%3DKwiatkowski%26aufirst%3DN.%2BP.%26aulast%3DLewis%26aufirst%3DT.%2BA.%26aulast%3DMaglathin%26aufirst%3DR.%2BL.%26aulast%3DMcLean%26aufirst%3DT.%2BH.%26aulast%3DBochkarev%26aufirst%3DA.%26aulast%3DPlotnikov%26aufirst%3DA.%2BN.%26aulast%3DVedadi%26aufirst%3DM.%26aulast%3DArrowsmith%26aufirst%3DC.%2BH.%26atitle%3DHuman%2520HDAC7%2520Harbors%2520a%2520Class%2520IIa%2520Histone%2520Deacetylase-Specific%2520Zinc%2520Binding%2520Motif%2520and%2520Cryptic%2520Deacetylase%2520Activity%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2008%26volume%3D283%26spage%3D11355%26epage%3D11363%26doi%3D10.1074%2Fjbc.M707362200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref200"><div class="reference"><strong class="refLabel"><a href="#ref200" class="rightTabRefNumLink">200</a></strong><div class="NLM_citation" id="rightTab-cit200"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Somoza, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skene, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mol, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ho, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luong, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arvai, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sang, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wynands, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leahy, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougan, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snell, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navre, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knuth, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanson, R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McRee, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tari, L. W.</span></span> <span> </span><span class="NLM_article-title">Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1325</span>– <span class="NLM_lpage">1334</span>, <span class="refDoi"> DOI: 10.1016/j.str.2004.04.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.str.2004.04.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=15242608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref200/cit200&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlsFyrsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=1325-1334&author=J.+R.+Somozaauthor=R.+J.+Skeneauthor=B.+A.+Katzauthor=C.+Molauthor=J.+D.+Hoauthor=A.+J.+Jenningsauthor=C.+Luongauthor=A.+Arvaiauthor=J.+J.+Buggyauthor=E.+Chiauthor=J.+Tangauthor=B.+C.+Sangauthor=E.+Vernerauthor=R.+Wynandsauthor=E.+M.+Leahyauthor=D.+R.+Douganauthor=G.+Snellauthor=M.+Navreauthor=M.+W.+Knuthauthor=R.+V.+Swansonauthor=D.+E.+McReeauthor=L.+W.+Tari&title=Structural+Snapshots+of+Human+HDAC8+Provide+Insights+into+the+Class+I+Histone+Deacetylases&doi=10.1016%2Fj.str.2004.04.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit200R"><div class="casContent"><span class="casTitleNuber">200</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases</span></div><div class="casAuthors">Somoza, John R.; Skene, Robert J.; Katz, Bradley A.; Mol, Clifford; Ho, Joseph D.; Jennings, Andy J.; Luong, Christine; Arvai, Andrew; Buggy, Joseph J.; Chi, Ellen; Tang, Jie; Sang, Bi-Ching; Verner, Erik; Wynands, Robert; Leahy, Ellen M.; Dougan, Douglas R.; Snell, Gyorgy; Navre, Marc; Knuth, Mark W.; Swanson, Ronald V.; McRee, Duncan E.; Tari, Leslie W.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1325-1334</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Modulation of the acetylation state of histones plays a pivotal role in the regulation of gene expression.  Histone deacetylases (HDACs) catalyze the removal of acetyl groups from lysines near the N termini of histones.  This reaction promotes the condensation of chromatin, leading to repression of transcription.  HDAC deregulation has been linked to several types of cancer, suggesting a potential use for HDAC inhibitors in oncol.  Here we describe the first crystal structures of a human HDAC: the structures of human HDAC8 complexed with four structurally diverse hydroxamate inhibitors.  This work sheds light on the catalytic mechanism of the HDACs, and on differences in substrate specificity across the HDAC family.  The structure also suggests how phosphorylation of Ser39 affects HDAC8 activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPLrZup76hGLVg90H21EOLACvtfcHk0lh4Q0tO6DG5lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlsFyrsLc%253D&md5=3f1842802bac2543509a25f5ddbea5f6</span></div><a href="/servlet/linkout?suffix=cit200&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2004.04.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2004.04.012%26sid%3Dliteratum%253Aachs%26aulast%3DSomoza%26aufirst%3DJ.%2BR.%26aulast%3DSkene%26aufirst%3DR.%2BJ.%26aulast%3DKatz%26aufirst%3DB.%2BA.%26aulast%3DMol%26aufirst%3DC.%26aulast%3DHo%26aufirst%3DJ.%2BD.%26aulast%3DJennings%26aufirst%3DA.%2BJ.%26aulast%3DLuong%26aufirst%3DC.%26aulast%3DArvai%26aufirst%3DA.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26aulast%3DChi%26aufirst%3DE.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DSang%26aufirst%3DB.%2BC.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DWynands%26aufirst%3DR.%26aulast%3DLeahy%26aufirst%3DE.%2BM.%26aulast%3DDougan%26aufirst%3DD.%2BR.%26aulast%3DSnell%26aufirst%3DG.%26aulast%3DNavre%26aufirst%3DM.%26aulast%3DKnuth%26aufirst%3DM.%2BW.%26aulast%3DSwanson%26aufirst%3DR.%2BV.%26aulast%3DMcRee%26aufirst%3DD.%2BE.%26aulast%3DTari%26aufirst%3DL.%2BW.%26atitle%3DStructural%2520Snapshots%2520of%2520Human%2520HDAC8%2520Provide%2520Insights%2520into%2520the%2520Class%2520I%2520Histone%2520Deacetylases%26jtitle%3DStructure%26date%3D2004%26volume%3D12%26spage%3D1325%26epage%3D1334%26doi%3D10.1016%2Fj.str.2004.04.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref201"><div class="reference"><strong class="refLabel"><a href="#ref201" class="rightTabRefNumLink">201</a></strong><div class="NLM_citation" id="rightTab-cit201"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Decroos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gullett, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowman, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deardorff, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christianson, D. W.</span></span> <span> </span><span class="NLM_article-title">Biochemical and Structural Characterization of HDAC8 Mutants Associated with Cornelia de Lange Syndrome Spectrum Disorders</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6501</span>– <span class="NLM_lpage">6513</span>, <span class="refDoi"> DOI: 10.1021/acs.biochem.5b00881</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.biochem.5b00881" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref201/cit201&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1yisbzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2015&pages=6501-6513&author=C.+Decroosauthor=N.+H.+Christiansonauthor=L.+E.+Gullettauthor=C.+M.+Bowmanauthor=K.+E.+Christiansonauthor=M.+A.+Deardorffauthor=D.+W.+Christianson&title=Biochemical+and+Structural+Characterization+of+HDAC8+Mutants+Associated+with+Cornelia+de+Lange+Syndrome+Spectrum+Disorders&doi=10.1021%2Facs.biochem.5b00881"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit201R"><div class="casContent"><span class="casTitleNuber">201</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical and Structural Characterization of HDAC8 Mutants Associated with Cornelia de Lange Syndrome Spectrum Disorders</span></div><div class="casAuthors">Decroos, Christophe; Christianson, Nicolas H.; Gullett, Laura E.; Bowman, Christine M.; Christianson, Karen E.; Deardorff, Matthew A.; Christianson, David W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">6501-6513</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cornelia de Lange Syndrome (CdLS) spectrum disorders are characterized by multiple organ system congenital anomalies that result from mutations in genes encoding core cohesin proteins SMC1A, SMC3, and RAD21, or proteins that regulate cohesin function such as NIPBL and HDAC8.  HDAC8 is the Zn2+-dependent SMC3 deacetylase required for cohesin recycling during the cell cycle, and 17 different HDAC8 mutants have been identified to date in children diagnosed with CdLS.  As part of our continuing studies focusing on aberrant HDAC8 function in CdLS, we now report the prepn. and biophys. evaluation of five human HDAC8 mutants: P91L, G117E, H180R, D233G, and G304R.  Addnl., the double mutants D233G-Y306F and P91L-Y306F were prepd. to enable cocrystn. of intact enzyme-substrate complexes.  X-ray crystal structures of G117E, P91L-Y306F, and D233G-Y306F HDAC8 mutants reveal that each CdLS mutation causes structural changes that compromise catalysis and/or thermostability.  For example, the D233G mutation disrupts the D233-K202-S276 hydrogen bond network, which stabilizes key tertiary structure interactions, thereby significantly compromising thermostability.  Mol. dynamics simulations of H180R and G304R HDAC8 mutants suggest that the bulky arginine side chain of each mutant protrudes into the substrate binding site and also causes active site residue Y306 to fluctuate away from the position required for substrate activation and catalysis.  Significantly, the catalytic activities of most mutants can be partially or fully rescued by the activator N-(phenylcarbamothioyl)-benzamide, suggesting that HDAC8 activators may serve as possible leads in the therapeutic management of CdLS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWhipfyECul7Vg90H21EOLACvtfcHk0ljigvfbFZ4bYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1yisbzL&md5=ca96a25665a6266e9d54926b75b5b7a5</span></div><a href="/servlet/linkout?suffix=cit201&amp;dbid=16384&amp;doi=10.1021%2Facs.biochem.5b00881&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.biochem.5b00881%26sid%3Dliteratum%253Aachs%26aulast%3DDecroos%26aufirst%3DC.%26aulast%3DChristianson%26aufirst%3DN.%2BH.%26aulast%3DGullett%26aufirst%3DL.%2BE.%26aulast%3DBowman%26aufirst%3DC.%2BM.%26aulast%3DChristianson%26aufirst%3DK.%2BE.%26aulast%3DDeardorff%26aufirst%3DM.%2BA.%26aulast%3DChristianson%26aufirst%3DD.%2BW.%26atitle%3DBiochemical%2520and%2520Structural%2520Characterization%2520of%2520HDAC8%2520Mutants%2520Associated%2520with%2520Cornelia%2520de%2520Lange%2520Syndrome%2520Spectrum%2520Disorders%26jtitle%3DBiochemistry%26date%3D2015%26volume%3D54%26spage%3D6501%26epage%3D6513%26doi%3D10.1021%2Facs.biochem.5b00881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref202"><div class="reference"><strong class="refLabel"><a href="#ref202" class="rightTabRefNumLink">202</a></strong><div class="NLM_citation" id="rightTab-cit202"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vannini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Volpari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallinari, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carfí, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Francesco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinkühler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marco, S.</span></span> <span> </span><span class="NLM_article-title">Substrate Binding to Histone Deacetylases as Shown by the Crystal Structure of the HDAC8-Substrate Complex</span>. <i>EMBO Rep.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">879</span>– <span class="NLM_lpage">884</span>, <span class="refDoi"> DOI: 10.1038/sj.embor.7401047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fsj.embor.7401047" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=17721440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref202/cit202&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD2sXpvFWks7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=879-884&author=A.+Vanniniauthor=C.+Volpariauthor=P.+Gallinariauthor=P.+Jonesauthor=M.+Mattuauthor=A.+Carf%C3%ADauthor=R.+De+Francescoauthor=C.+Steink%C3%BChlerauthor=S.+Di+Marco&title=Substrate+Binding+to+Histone+Deacetylases+as+Shown+by+the+Crystal+Structure+of+the+HDAC8-Substrate+Complex&doi=10.1038%2Fsj.embor.7401047"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit202R"><div class="casContent"><span class="casTitleNuber">202</span><div class="casTitle"><span class="NLM_cas:atitle">Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex</span></div><div class="casAuthors">Vannini, Alessandro; Volpari, Cinzia; Gallinari, Paola; Jones, Philip; Mattu, Marco; Carfi, Andrea; De Francesco, Raffaele; Steinkuehler, Christian; Di Marco, Stefania</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Reports</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">879-884</span>CODEN:
                <span class="NLM_cas:coden">ERMEAX</span>;
        ISSN:<span class="NLM_cas:issn">1469-221X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Histone deacetylases (HDACs) - an enzyme family that deacetylates histones and non-histone proteins - are implicated in human diseases such as cancer, and the first-generation of HDAC inhibitors are now in clin. trials.  Here, we report the 2.0 Å resoln. crystal structure of a catalytically inactive HDAC8 active-site mutant, Tyr306Phe, bound to an acetylated peptidic substrate.  The structure clarifies the role of active-site residues in the deacetylation reaction and substrate recognition.  Notably, the structure shows the unexpected role of a conserved residue at the active-site rim, Asp101, in positioning the substrate by directly interacting with the peptidic backbone and imposing a constrained cis-conformation.  A similar interaction is obsd. in a new hydroxamate inhibitor-HDAC8 structure that we also solved.  The crucial role of Asp101 in substrate and inhibitor recognition was confirmed by activity and binding assays of wild-type HDAC8 and Asp101Ala, Tyr306Phe and Asp101Ala/Tyr306Phe mutants.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohnS-LTrNkPbVg90H21EOLACvtfcHk0ljigvfbFZ4bYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXpvFWks7Y%253D&md5=1362cac7c0820d5b250b05597fafa7dc</span></div><a href="/servlet/linkout?suffix=cit202&amp;dbid=16384&amp;doi=10.1038%2Fsj.embor.7401047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.embor.7401047%26sid%3Dliteratum%253Aachs%26aulast%3DVannini%26aufirst%3DA.%26aulast%3DVolpari%26aufirst%3DC.%26aulast%3DGallinari%26aufirst%3DP.%26aulast%3DJones%26aufirst%3DP.%26aulast%3DMattu%26aufirst%3DM.%26aulast%3DCarf%25C3%25AD%26aufirst%3DA.%26aulast%3DDe%2BFrancesco%26aufirst%3DR.%26aulast%3DSteink%25C3%25BChler%26aufirst%3DC.%26aulast%3DDi%2BMarco%26aufirst%3DS.%26atitle%3DSubstrate%2520Binding%2520to%2520Histone%2520Deacetylases%2520as%2520Shown%2520by%2520the%2520Crystal%2520Structure%2520of%2520the%2520HDAC8-Substrate%2520Complex%26jtitle%3DEMBO%2520Rep.%26date%3D2007%26volume%3D8%26spage%3D879%26epage%3D884%26doi%3D10.1038%2Fsj.embor.7401047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref203"><div class="reference"><strong class="refLabel"><a href="#ref203" class="rightTabRefNumLink">203</a></strong><div class="NLM_citation" id="rightTab-cit203"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sung, T.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, W.-J.</span></span> <span> </span><span class="NLM_article-title">Novel Class IIa-Selective Histone Deacetylase Inhibitors Discovered Using an in Silico Virtual Screening Approach</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">3228</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-03417-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fs41598-017-03417-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=28607401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref203/cit203&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BC1cnnsF2qsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=3228&author=K.-C.+Hsuauthor=C.-Y.+Liuauthor=T.+E.+Linauthor=J.-H.+Hsiehauthor=T.-Y.+Sungauthor=H.-J.+Tsengauthor=J.-M.+Yangauthor=W.-J.+Huang&title=Novel+Class+IIa-Selective+Histone+Deacetylase+Inhibitors+Discovered+Using+an+in+Silico+Virtual+Screening+Approach&doi=10.1038%2Fs41598-017-03417-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit203R"><div class="casContent"><span class="casTitleNuber">203</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Class IIa-Selective Histone Deacetylase Inhibitors Discovered Using an in Silico Virtual Screening Approach</span></div><div class="casAuthors">Hsu Kai-Cheng; Lin Tony Eight; Liu Chang-Yi; Huang Wei-Jan; Hsieh Jui-Hua; Sung Tzu-Ying; Yang Jinn-Moon; Tseng Hui-Ju; Huang Wei-Jan; Yang Jinn-Moon</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3228</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Histone deacetylases (HDAC) contain eighteen isoforms that can be divided into four classes.  Of these isoform enzymes, class IIa (containing HDAC4, 5, 7 and 9) target unique substrates, some of which are client proteins associated with epigenetic control.  Class IIa HDACs are reportedly associated with some neuronal disorders, making HDACs therapeutic targets for treating neurodegenerative diseases.  Additionally, some reported HDAC inhibitors contain hydroxamate moiety that chelates with zinc ion to become the cofactor of HDAC enzymes.  However, the hydroxamate functional group is shown to cause undesirable effects and has poor pharmacokinetic profile.  This study used in silico virtual screening methodology to identify several nonhydroxamate compounds, obtained from National Cancer Institute database, which potentially inhibited HDAC4.  Comparisons of the enzyme inhibitory activity against a panel of HDAC isoforms revealed these compounds had strong inhibitory activity against class IIa HDACs, but weak inhibitory activity against class I HDACs.  Further analysis revealed that a single residue affects the cavity size between class I and class IIa HDACs, thus contributing to the selectivity of HDAC inhibitors discovered in this study.  The discovery of these inhibitors presents the possibility of developing new therapeutic treatments that can circumvent the problems seen in traditional hydroxamate-based drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRxx_9DBwLcIlQKX3ooHxWjfW6udTcc2ebROt7BEhjTjbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnnsF2qsQ%253D%253D&md5=a7d011c70786e075a3154f31df910435</span></div><a href="/servlet/linkout?suffix=cit203&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-03417-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-03417-1%26sid%3Dliteratum%253Aachs%26aulast%3DHsu%26aufirst%3DK.-C.%26aulast%3DLiu%26aufirst%3DC.-Y.%26aulast%3DLin%26aufirst%3DT.%2BE.%26aulast%3DHsieh%26aufirst%3DJ.-H.%26aulast%3DSung%26aufirst%3DT.-Y.%26aulast%3DTseng%26aufirst%3DH.-J.%26aulast%3DYang%26aufirst%3DJ.-M.%26aulast%3DHuang%26aufirst%3DW.-J.%26atitle%3DNovel%2520Class%2520IIa-Selective%2520Histone%2520Deacetylase%2520Inhibitors%2520Discovered%2520Using%2520an%2520in%2520Silico%2520Virtual%2520Screening%2520Approach%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D3228%26doi%3D10.1038%2Fs41598-017-03417-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref204"><div class="reference"><strong class="refLabel"><a href="#ref204" class="rightTabRefNumLink">204</a></strong><div class="NLM_citation" id="rightTab-cit204"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Q.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, L.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, Y.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, L.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.-X.</span></span> <span> </span><span class="NLM_article-title">Virtual Screening and Experimental Validation of Novel Histone Deacetylase Inhibitors</span>. <i>BMC Pharmacol. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">32</span>, <span class="refDoi"> DOI: 10.1186/s40360-016-0075-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1186%2Fs40360-016-0075-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=27443303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref204/cit204&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkvFWhu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=32&author=Y.-X.+Huangauthor=J.+Zhaoauthor=Q.-H.+Songauthor=L.-H.+Zhengauthor=C.+Fanauthor=T.-T.+Liuauthor=Y.-L.+Baoauthor=L.-G.+Sunauthor=L.-B.+Zhangauthor=Y.-X.+Li&title=Virtual+Screening+and+Experimental+Validation+of+Novel+Histone+Deacetylase+Inhibitors&doi=10.1186%2Fs40360-016-0075-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit204R"><div class="casContent"><span class="casTitleNuber">204</span><div class="casTitle"><span class="NLM_cas:atitle">Virtual screening and experimental validation of novel histone deacetylase inhibitors</span></div><div class="casAuthors">Huang, Yan-xin; Zhao, Jian; Song, Qiu-hang; Zheng, Li-hua; Fan, Cong; Liu, Ting-ting; Bao, Yong-li; Sun, Lu-guo; Zhang, Li-biao; Li, Yu-xin</div><div class="citationInfo"><span class="NLM_cas:title">BMC Pharmacology and Toxicology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">32/1-32/14</span>CODEN:
                <span class="NLM_cas:coden">BPTMAB</span>;
        ISSN:<span class="NLM_cas:issn">2050-6511</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Histone deacetylases (HDACs) are promising therapeutic targets for the treatment of cancer, diabetes and other human diseases.  HDAC inhibitors, as a new class of potential therapeutic agents, have attracted a great deal of interest for both research and clin. applications.  Increasing efforts have been focused on the discovery of HDAC inhibitors and some HDAC inhibitors have been approved for use in cancer therapy.  However, most HDAC inhibitors, including the clin. approved agents, do not selectively inhibit the deacetylase activity of class I and II HDAC is forms, and many suffer from metabolic instability.  This study aims to identify new HDAC inhibitors by using a high-throughput virtual screening approach.  Methods: An integration of in silico virtual screening and in vitro exptl. validation was used to identify novel HDAC inhibitors from a chem. database.  Results: A virtual screening work flow for HDAC inhibitors were created by integrating ligand- and receptor- based virtual screening methods.  Using the virtual screening work flow, 22 hit compds. were selected and further tested via in vitro assays.  Enzyme inhibition assays showed that three of the 22 compds. had HDAC inhibitory properties.  Among these three compds., ZINC12555961 significantly inhibited HDAC activity.  Further in vitro expts. indicated that ZINC12555961 can selectively inhibit proliferation and promote apoptosis of cancer cells.  Conclusions: In summary, our study presents three new and potent HDAC inhibitors and one of these HDAC inhibitors shows anti-proliferative and apoptosis-inducing activity against various cancer cell lines.  These results suggest that the developed virtual screening work flow can provide a useful source of information for the screening and validation of new HDAC inhibitors.  The new-found HDAC inhibitors are worthy to further and more comprehensive investigations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpj4jqNd1ZcS7Vg90H21EOLACvtfcHk0lgEIT0eTD1e8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkvFWhu7w%253D&md5=d0f5e07f0a3180b0149fa5da9c9a0c28</span></div><a href="/servlet/linkout?suffix=cit204&amp;dbid=16384&amp;doi=10.1186%2Fs40360-016-0075-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40360-016-0075-8%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DY.-X.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DSong%26aufirst%3DQ.-H.%26aulast%3DZheng%26aufirst%3DL.-H.%26aulast%3DFan%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DT.-T.%26aulast%3DBao%26aufirst%3DY.-L.%26aulast%3DSun%26aufirst%3DL.-G.%26aulast%3DZhang%26aufirst%3DL.-B.%26aulast%3DLi%26aufirst%3DY.-X.%26atitle%3DVirtual%2520Screening%2520and%2520Experimental%2520Validation%2520of%2520Novel%2520Histone%2520Deacetylase%2520Inhibitors%26jtitle%3DBMC%2520Pharmacol.%2520Toxicol.%26date%3D2016%26volume%3D17%26spage%3D32%26doi%3D10.1186%2Fs40360-016-0075-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref205"><div class="reference"><strong class="refLabel"><a href="#ref205" class="rightTabRefNumLink">205</a></strong><div class="NLM_citation" id="rightTab-cit205"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Halder, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallick, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shikha, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saha, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jha, T.</span></span> <span> </span><span class="NLM_article-title">Design of Dual MMP-2/HDAC-8 Inhibitors by Pharmacophore Mapping, Molecular Docking, Synthesis and Biological Activity</span>. <i>RSC Adv.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">72373</span>– <span class="NLM_lpage">72386</span>, <span class="refDoi"> DOI: 10.1039/C5RA12606A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1039%2FC5RA12606A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref205/cit205&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlCktrvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=72373-72386&author=A.+Halderauthor=S.+Mallickauthor=D.+Shikhaauthor=A.+Sahaauthor=K.+D.+Sahaauthor=T.+Jha&title=Design+of+Dual+MMP-2%2FHDAC-8+Inhibitors+by+Pharmacophore+Mapping%2C+Molecular+Docking%2C+Synthesis+and+Biological+Activity&doi=10.1039%2FC5RA12606A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit205R"><div class="casContent"><span class="casTitleNuber">205</span><div class="casTitle"><span class="NLM_cas:atitle">Design of dual MMP-2/HDAC-8 inhibitors by pharmacophore mapping, molecular docking, synthesis and biological activity</span></div><div class="casAuthors">Halder, Amit K.; Mallick, Sumana; Shikha, Deep; Saha, Achintya; Saha, Krishna D.; Jha, Tarun</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">88</span>),
    <span class="NLM_cas:pages">72373-72386</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Recent analyses have highlighted the promotion of cancer migration and invasion, mediated through HDAC via MMP-2 and MMP-9.  Since both class 1 HDACs and MMP-2/9 are involved in the migration and invasion of cancer, an attempt has been taken to design dual MMP-2/HDAC-8 inhibitors by pharmacophore mapping and mol. docking approaches.  The designed mols. were synthesized and showed a range of inhibitory activity against different MMP subtypes.  Most of these designed compds. were selective towards MMP-2 but less potent against anti-targets like MMP-8, -12, etc.  The highly active MMP-2 inhibitors were also found to be active towards HDAC-8 but less potent against other class 1 HDACs (HDAC-1 and -2).  Mol. dynamics simulations revealed that the designed compds. may be acting through a distinct mechanism of action in the 'acetate ion channel' of HDAC-8.  Some potent dual MMP-2/HDAC-8 inhibitors were further explored for in vitro cellular assays against human lung carcinoma cell line A549.  These analyses revealed that some of these dual inhibitors have considerable anti-migratory and anti-invasive properties.  The work may help to obtain some useful dual inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHr-ImIiRTVLVg90H21EOLACvtfcHk0lgEIT0eTD1e8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlCktrvO&md5=6ea78d3a65d176a1af37c8408dfda5d2</span></div><a href="/servlet/linkout?suffix=cit205&amp;dbid=16384&amp;doi=10.1039%2FC5RA12606A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5RA12606A%26sid%3Dliteratum%253Aachs%26aulast%3DHalder%26aufirst%3DA.%26aulast%3DMallick%26aufirst%3DS.%26aulast%3DShikha%26aufirst%3DD.%26aulast%3DSaha%26aufirst%3DA.%26aulast%3DSaha%26aufirst%3DK.%2BD.%26aulast%3DJha%26aufirst%3DT.%26atitle%3DDesign%2520of%2520Dual%2520MMP-2%252FHDAC-8%2520Inhibitors%2520by%2520Pharmacophore%2520Mapping%252C%2520Molecular%2520Docking%252C%2520Synthesis%2520and%2520Biological%2520Activity%26jtitle%3DRSC%2520Adv.%26date%3D2015%26volume%3D5%26spage%3D72373%26epage%3D72386%26doi%3D10.1039%2FC5RA12606A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref206"><div class="reference"><strong class="refLabel"><a href="#ref206" class="rightTabRefNumLink">206</a></strong><div class="NLM_citation" id="rightTab-cit206"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span> <span> </span><span class="NLM_article-title">Hierarchical Virtual Screening of the Dual MMP-2/HDAC-6 Inhibitors from Natural Products Based on Pharmacophore Models and Molecular Docking</span>. <i>J. Biomol. Struct. Dyn.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">649</span>– <span class="NLM_lpage">670</span>, <span class="refDoi"> DOI: 10.1080/07391102.2018.1434833</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1080%2F07391102.2018.1434833" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=29380672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref206/cit206&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXislSjt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2019&pages=649-670&author=Y.+Wangauthor=L.+Yangauthor=J.+Houauthor=Q.+Zouauthor=Q.+Gaoauthor=W.+Yaoauthor=Q.+Yaoauthor=J.+Zhang&title=Hierarchical+Virtual+Screening+of+the+Dual+MMP-2%2FHDAC-6+Inhibitors+from+Natural+Products+Based+on+Pharmacophore+Models+and+Molecular+Docking&doi=10.1080%2F07391102.2018.1434833"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit206R"><div class="casContent"><span class="casTitleNuber">206</span><div class="casTitle"><span class="NLM_cas:atitle">Hierarchical virtual screening of the dual MMP-2/HDAC-6 inhibitors from natural products based on pharmacophore models and molecular docking</span></div><div class="casAuthors">Wang, Yijun; Yang, Limei; Hou, Jiaying; Zou, Qing; Gao, Qi; Yao, Wenhui; Yao, Qizheng; Zhang, Ji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Structure and Dynamics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">649-670</span>CODEN:
                <span class="NLM_cas:coden">JBSDD6</span>;
        ISSN:<span class="NLM_cas:issn">0739-1102</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">The dual-target inhibitors tend to improve the response rate in treating tumors, comparing with the single-target inhibitors.  Matrix metalloproteinase-2 (MMP-2) and histone deacetylase-6 (HDAC-6) are attractive targets for cancer therapy.  In this study, the hierarchical virtual screening of dual MMP-2/HDAC-6 inhibitors from natural products is investigated.  The pharmacophore model of MMP-2 inhibitors is built based on ligands, but the pharmacophore model of HDAC-6 inhibitors is built based on the exptl. crystal structures of multiple receptor-ligand complexes.  The reliability of these two pharmacophore models is validated subsequently.  The hierarchical virtual screening, combining these two different pharmacophore models of MMP-2 and HDAC-6 inhibitors with mol. docking, is carried out to identify the dual MMP-2/HDAC-6 inhibitors from a database of natural products.  The four potential dual MMP-2/HDAC-6 inhibitors of natural products, STOCK1 N-46177, STOCK1 N-52245, STOCK1 N-55477, and STOCK1 N-69706, are found.  The studies of binding modes show that the screened four natural products can simultaneously well bind with the MMP-2 and HDAC-6 active sites by different kinds of interactions, to inhibit the MMP-2 and HDAC-6 activities.  In addn., the ADMET properties of screened four natural products are assessed.  These found dual MMP-2/HDAC-6 inhibitors of natural products could serve as the lead compds. for designing the new dual MMP-2/HDAC-6 inhibitors having higher biol. activities by carrying out structural modifications and optimizations in the future studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrj-OBmoj28F7Vg90H21EOLACvtfcHk0lgEIT0eTD1e8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXislSjt7c%253D&md5=7fe92585a5c37b548ff3e569c851214f</span></div><a href="/servlet/linkout?suffix=cit206&amp;dbid=16384&amp;doi=10.1080%2F07391102.2018.1434833&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07391102.2018.1434833%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DZou%26aufirst%3DQ.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DYao%26aufirst%3DW.%26aulast%3DYao%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DJ.%26atitle%3DHierarchical%2520Virtual%2520Screening%2520of%2520the%2520Dual%2520MMP-2%252FHDAC-6%2520Inhibitors%2520from%2520Natural%2520Products%2520Based%2520on%2520Pharmacophore%2520Models%2520and%2520Molecular%2520Docking%26jtitle%3DJ.%2520Biomol.%2520Struct.%2520Dyn.%26date%3D2019%26volume%3D37%26spage%3D649%26epage%3D670%26doi%3D10.1080%2F07391102.2018.1434833" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref207"><div class="reference"><strong class="refLabel"><a href="#ref207" class="rightTabRefNumLink">207</a></strong><div class="NLM_citation" id="rightTab-cit207"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurpinar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manglik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span> <span> </span><span class="NLM_article-title">Crystal Structure of the Human σ<sub>1</sub> Receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>532</i></span>,  <span class="NLM_fpage">527</span>– <span class="NLM_lpage">530</span>, <span class="refDoi"> DOI: 10.1038/nature17391</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fnature17391" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=27042935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref207/cit207&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlsl2gt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=532&publication_year=2016&pages=527-530&author=H.+R.+Schmidtauthor=S.+Zhengauthor=E.+Gurpinarauthor=A.+Koehlauthor=A.+Manglikauthor=A.+C.+Kruse&title=Crystal+Structure+of+the+Human+%CF%831+Receptor&doi=10.1038%2Fnature17391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit207R"><div class="casContent"><span class="casTitleNuber">207</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the human σ1 receptor</span></div><div class="casAuthors">Schmidt, Hayden R.; Zheng, Sanduo; Gurpinar, Esin; Koehl, Antoine; Manglik, Aashish; Kruse, Andrew C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">532</span>
        (<span class="NLM_cas:issue">7600</span>),
    <span class="NLM_cas:pages">527-530</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The human σ1 receptor is an enigmatic endoplasmic reticulum (ER)-resident transmembrane protein implicated in a variety of disorders including depression, drug addiction, and neuropathic pain.  Recently, an addnl. connection to amyotrophic lateral sclerosis has emerged from studies of human genetics and mouse models.  Unlike many transmembrane receptors that belong to large, extensively studied families such as G-protein-coupled receptors or ligand-gated ion channels, the σ1 receptor is an evolutionary isolate with no discernible similarity to any other human protein.  Despite its increasingly clear importance in human physiol. and disease, the mol. architecture of the σ1 receptor and its regulation by drug-like compds. remain poorly defined.  Here, the authors report crystal structures of the human σ1 receptor in complex with 2 chem. divergent ligands, PD 144418 and 4-(N-benzylpiperidin-4-yl)-4-iodobenzamide (4-IBP).  The structures revealed a trimeric architecture with a single transmembrane domain in each protomer.  The C-terminal domain of the receptor showed an extensive flat, hydrophobic membrane-proximal surface, suggesting an intimate assocn. with the cytosolic surface of the ER membrane in cells.  This domain included a cupin-like β-barrel with the ligand-binding site buried at its center.  This large, hydrophobic ligand-binding cavity showed remarkable plasticity in ligand recognition, binding the 2 ligands in similar positions despite dissimilar chem. structures.  Taken together, these results revealed the overall architecture, oligomerization state, and mol. basis for ligand recognition by this important but poorly understood protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokQBAf03Pml7Vg90H21EOLACvtfcHk0ljR6v0ipDboyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlsl2gt7o%253D&md5=fb6df7814060fbd05ba41261ad1061f5</span></div><a href="/servlet/linkout?suffix=cit207&amp;dbid=16384&amp;doi=10.1038%2Fnature17391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17391%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DH.%2BR.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DGurpinar%26aufirst%3DE.%26aulast%3DKoehl%26aufirst%3DA.%26aulast%3DManglik%26aufirst%3DA.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26atitle%3DCrystal%2520Structure%2520of%2520the%2520Human%2520%25CF%25831%2520Receptor%26jtitle%3DNature%26date%3D2016%26volume%3D532%26spage%3D527%26epage%3D530%26doi%3D10.1038%2Fnature17391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref208"><div class="reference"><strong class="refLabel"><a href="#ref208" class="rightTabRefNumLink">208</a></strong><div class="NLM_citation" id="rightTab-cit208"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for σ(1) Receptor Ligand Recognition</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">981</span>– <span class="NLM_lpage">987</span>, <span class="refDoi"> DOI: 10.1038/s41594-018-0137-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1038%2Fs41594-018-0137-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=30291362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref208/cit208&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVOjsbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=981-987&author=H.+R.+Schmidtauthor=R.+M.+Betzauthor=R.+O.+Drorauthor=A.+C.+Kruse&title=Structural+Basis+for+%CF%83%281%29+Receptor+Ligand+Recognition&doi=10.1038%2Fs41594-018-0137-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit208R"><div class="casContent"><span class="casTitleNuber">208</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for σ1 receptor ligand recognition</span></div><div class="casAuthors">Schmidt, Hayden R.; Betz, Robin M.; Dror, Ron O.; Kruse, Andrew C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">981-987</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The s1 receptor is a poorly understood membrane protein expressed throughout the human body.  Ligands targeting the s1 receptor are in clin. trials for treatment of Alzheimer's disease, ischemic stroke, and neuropathic pain.  However, relatively little is known regarding the s1 receptor's mol. function.  Here, we present crystal structures of human s1 receptor bound to the antagonists haloperidol and NE-100, and the agonist (+)-pentazocine, at crystallog. resolns. of 3.1 Å, 2.9 Å, and 3.1 Å, resp.  These structures reveal a unique binding pose for the agonist.  The structures and accompanying mol. dynamics (MD) simulations identify agonist-induced structural rearrangements in the receptor.  Addnl., we show that ligand binding to s1 is a multistep process that is rate limited by receptor conformational change.  We used MD simulations to reconstruct a ligand binding pathway involving two major conformational changes.  These data provide a framework for understanding the mol. basis for s1 agonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ2dgVTV70vbVg90H21EOLACvtfcHk0ljR6v0ipDboyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVOjsbvM&md5=d12d12aecbd89684824975977ec03e4b</span></div><a href="/servlet/linkout?suffix=cit208&amp;dbid=16384&amp;doi=10.1038%2Fs41594-018-0137-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41594-018-0137-2%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DH.%2BR.%26aulast%3DBetz%26aufirst%3DR.%2BM.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26atitle%3DStructural%2520Basis%2520for%2520%25CF%2583%25281%2529%2520Receptor%2520Ligand%2520Recognition%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2018%26volume%3D25%26spage%3D981%26epage%3D987%26doi%3D10.1038%2Fs41594-018-0137-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref209"><div class="reference"><strong class="refLabel"><a href="#ref209" class="rightTabRefNumLink">209</a></strong><div class="NLM_citation" id="rightTab-cit209"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greenfield, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span> <span> </span><span class="NLM_article-title">Virtual Screening Identifies Novel High-Affinity σ<sub>1</sub> Receptor Ligands</span>. <i>bioRxiv</i> <span class="NLM_year" style="font-weight: bold;">2019</span>, <span class="refDoi"> DOI: 10.1101/699793</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref209/cit209&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1101%2F699793" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=D.+A.+Greenfieldauthor=H.+R.+Schmidtauthor=P.+Slizauthor=A.+C.+Kruse&title=Virtual+Screening+Identifies+Novel+High-Affinity+%CF%831+Receptor+Ligands&doi=10.1101%2F699793"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit209&amp;dbid=16384&amp;doi=10.1101%2F699793&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1101%252F699793%26sid%3Dliteratum%253Aachs%26aulast%3DGreenfield%26aufirst%3DD.%2BA.%26aulast%3DSchmidt%26aufirst%3DH.%2BR.%26aulast%3DSliz%26aufirst%3DP.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26atitle%3DVirtual%2520Screening%2520Identifies%2520Novel%2520High-Affinity%2520%25CF%25831%2520Receptor%2520Ligands%26jtitle%3DbioRxiv%26date%3D2019%26doi%3D10.1101%2F699793" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref210"><div class="reference"><strong class="refLabel"><a href="#ref210" class="rightTabRefNumLink">210</a></strong><div class="NLM_citation" id="rightTab-cit210"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ehrt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brinkjost, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koch, O.</span></span> <span> </span><span class="NLM_article-title">A Benchmark Driven Guide to Binding Site Comparison: An Exhaustive Evaluation Using Tailor-Made Data Sets (ProSPECCTs)</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>14</i></span>, <span class="NLM_elocation-id">e1006483</span> <span class="refDoi"> DOI: 10.1371/journal.pcbi.1006483</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1371%2Fjournal.pcbi.1006483" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=30408032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref210/cit210&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjsFCkt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2018&author=C.+Ehrtauthor=T.+Brinkjostauthor=O.+Koch&title=A+Benchmark+Driven+Guide+to+Binding+Site+Comparison%3A+An+Exhaustive+Evaluation+Using+Tailor-Made+Data+Sets+%28ProSPECCTs%29&doi=10.1371%2Fjournal.pcbi.1006483"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit210R"><div class="casContent"><span class="casTitleNuber">210</span><div class="casTitle"><span class="NLM_cas:atitle">A benchmark driven guide to binding site comparison: an exhaustive evaluation using tailor-made data sets (ProSPECCTs)</span></div><div class="casAuthors">Ehrt, Christiane; Brinkjost, Tobias; Koch, Oliver</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Computational Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">e1006483/1-e1006483/50</span>CODEN:
                <span class="NLM_cas:coden">PCBLBG</span>;
        ISSN:<span class="NLM_cas:issn">1553-7358</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">The automated comparison of protein-ligand binding sites provides useful insights into yet unexplored site similarities.  Various stages of computational and chem. biol. research can benefit from this knowledge.  The search for putative off-targets and the establishment of polypharmacol. effects by comparing binding sites led to promising results for numerous projects.  Although many cavity comparison methods are available, a comprehensive anal. to guide the choice of a tool for a specific application is wanting.  Moreover, the broad variety of binding site modeling approaches, comparison algorithms, and scoring metrics impedes this choice.  Herein, we aim to elucidate strengths and weaknesses of binding site comparison methodologies.  A detailed benchmark study is the only possibility to rationalize the selection of appropriate tools for different scenarios.  Specific evaluation data sets were developed to shed light on multiple aspects of binding site comparison.  An assembly of all applied benchmark sets (ProSPECCTs-Protein Site Pairs for the Evaluation of Cavity Comparison Tools) is made available for the evaluation and optimization of further and still emerging methods.  The results indicate the importance of such analyses to facilitate the choice of a methodol. that complies with the requirements of a specific scientific challenge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1D8OLhutOVrVg90H21EOLACvtfcHk0ljR6v0ipDboyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjsFCkt7o%253D&md5=1660c344aaaeefb6fde2bd31be55c478</span></div><a href="/servlet/linkout?suffix=cit210&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1006483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1006483%26sid%3Dliteratum%253Aachs%26aulast%3DEhrt%26aufirst%3DC.%26aulast%3DBrinkjost%26aufirst%3DT.%26aulast%3DKoch%26aufirst%3DO.%26atitle%3DA%2520Benchmark%2520Driven%2520Guide%2520to%2520Binding%2520Site%2520Comparison%253A%2520An%2520Exhaustive%2520Evaluation%2520Using%2520Tailor-Made%2520Data%2520Sets%2520%2528ProSPECCTs%2529%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2018%26volume%3D14%26doi%3D10.1371%2Fjournal.pcbi.1006483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref211"><div class="reference"><strong class="refLabel"><a href="#ref211" class="rightTabRefNumLink">211</a></strong><div class="NLM_citation" id="rightTab-cit211"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Duran-Frigola, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siragusa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruppin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barril, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cruciani, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aloy, P.</span></span> <span> </span><span class="NLM_article-title">Detecting Similar Binding Pockets to Enable Systems Polypharmacology</span>. <i>PLoS Comput. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>13</i></span>, <span class="NLM_elocation-id">e1005522</span> <span class="refDoi"> DOI: 10.1371/journal.pcbi.1005522</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1371%2Fjournal.pcbi.1005522" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=28662117" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref211/cit211&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1agurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2017&author=M.+Duran-Frigolaauthor=L.+Siragusaauthor=E.+Ruppinauthor=X.+Barrilauthor=G.+Crucianiauthor=P.+Aloy&title=Detecting+Similar+Binding+Pockets+to+Enable+Systems+Polypharmacology&doi=10.1371%2Fjournal.pcbi.1005522"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit211R"><div class="casContent"><span class="casTitleNuber">211</span><div class="casTitle"><span class="NLM_cas:atitle">Detecting similar binding pockets to enable systems polypharmacology</span></div><div class="casAuthors">Duran-Frigola, Miquel; Siragusa, Lydia; Ruppin, Eytan; Barril, Xavier; Cruciani, Gabriele; Aloy, Patrick</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Computational Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">e1005522/1-e1005522/18</span>CODEN:
                <span class="NLM_cas:coden">PCBLBG</span>;
        ISSN:<span class="NLM_cas:issn">1553-7358</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">In the era of systems biol., multi-target pharmacol. strategies hold promise for tackling disease-related networks.  In this regard, drug promiscuity may be leveraged to interfere with multiple receptors: the so-called polypharmacol. of drugs can be anticipated by analyzing the similarity of binding sites across the proteome.  Here, we perform a pairwise comparison of 90,000 putative binding pockets detected in 3,700 proteins, and find that 23,000 pairs of proteins have at least one similar cavity that could, in principle, accommodate similar ligands.  By inspecting these pairs, we demonstrate how the detection of similar binding sites expands the space of opportunities for the rational design of drug polypharmacol.  Finally, we illustrate how to leverage these opportunities in protein-protein interaction networks related to several therapeutic classes and tumor types, and in a genome-scale metabolic model of leukemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrncR4y_CryxbVg90H21EOLACvtfcHk0ljvUEOkMq-XXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1agurnE&md5=568e97aa21976360c76610cdfd4dbfd7</span></div><a href="/servlet/linkout?suffix=cit211&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pcbi.1005522&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pcbi.1005522%26sid%3Dliteratum%253Aachs%26aulast%3DDuran-Frigola%26aufirst%3DM.%26aulast%3DSiragusa%26aufirst%3DL.%26aulast%3DRuppin%26aufirst%3DE.%26aulast%3DBarril%26aufirst%3DX.%26aulast%3DCruciani%26aufirst%3DG.%26aulast%3DAloy%26aufirst%3DP.%26atitle%3DDetecting%2520Similar%2520Binding%2520Pockets%2520to%2520Enable%2520Systems%2520Polypharmacology%26jtitle%3DPLoS%2520Comput.%2520Biol.%26date%3D2017%26volume%3D13%26doi%3D10.1371%2Fjournal.pcbi.1005522" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref212"><div class="reference"><strong class="refLabel"><a href="#ref212" class="rightTabRefNumLink">212</a></strong><div class="NLM_citation" id="rightTab-cit212"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andersson, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, B. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linusson, A.</span></span> <span> </span><span class="NLM_article-title">Mapping of Ligand-Binding Cavities in Proteins</span>. <i>Proteins: Struct., Funct., Genet.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1408</span>– <span class="NLM_lpage">1422</span>, <span class="refDoi"> DOI: 10.1002/prot.22655</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1002%2Fprot.22655" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=20034113" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref212/cit212&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjt1KksrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2010&pages=1408-1422&author=C.+D.+Anderssonauthor=B.+Y.+Chenauthor=A.+Linusson&title=Mapping+of+Ligand-Binding+Cavities+in+Proteins&doi=10.1002%2Fprot.22655"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit212R"><div class="casContent"><span class="casTitleNuber">212</span><div class="casTitle"><span class="NLM_cas:atitle">Mapping of ligand-binding cavities in proteins</span></div><div class="casAuthors">Andersson, C. David; Chen, Brian Y.; Linusson, Anna</div><div class="citationInfo"><span class="NLM_cas:title">Proteins: Structure, Function, and Bioinformatics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1408-1422</span>CODEN:
                <span class="NLM_cas:coden">PSFBAF</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The complex interactions between proteins and small org. mols. (ligands) are intensively studied because they play key roles in biol. processes and drug activities.  Here, the authors present a novel approach to characterize and map the ligand-binding cavities of proteins without direct geometric comparison of structures, based on Principal Component Anal. of cavity properties (related mainly to size, polarity, and charge).  This approach can provide valuable information on the similarities and dissimilarities, of binding cavities due to mutations, between-species differences and flexibility upon ligand-binding.  The presented results show that information on ligand-binding cavity variations can complement information on protein similarity obtained from sequence comparisons.  The predictive aspect of the method is exemplified by successful predictions of serine proteases that were not included in the model construction.  The presented strategy to compare ligand-binding cavities of related and unrelated proteins has many potential applications within protein and medicinal chem., for example in the characterization and mapping of "orphan structures", selection of protein structures for docking studies in structure-based design, and identification of proteins for selectivity screens in drug design programs.  Proteins 2010. © 2009 Wiley-Liss, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmzqkXA3YhV7Vg90H21EOLACvtfcHk0ljvUEOkMq-XXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjt1KksrY%253D&md5=dab715eea79dd2fbedf04ee9b887f35d</span></div><a href="/servlet/linkout?suffix=cit212&amp;dbid=16384&amp;doi=10.1002%2Fprot.22655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fprot.22655%26sid%3Dliteratum%253Aachs%26aulast%3DAndersson%26aufirst%3DC.%2BD.%26aulast%3DChen%26aufirst%3DB.%2BY.%26aulast%3DLinusson%26aufirst%3DA.%26atitle%3DMapping%2520of%2520Ligand-Binding%2520Cavities%2520in%2520Proteins%26jtitle%3DProteins%253A%2520Struct.%252C%2520Funct.%252C%2520Genet.%26date%3D2010%26volume%3D78%26spage%3D1408%26epage%3D1422%26doi%3D10.1002%2Fprot.22655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref213"><div class="reference"><strong class="refLabel"><a href="#ref213" class="rightTabRefNumLink">213</a></strong><div class="NLM_citation" id="rightTab-cit213"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mangiatordi, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trisciuzzi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alberga, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denora, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacobazzi, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gadaleta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolotti, O.</span></span> <span> </span><span class="NLM_article-title">Novel Chemotypes Targeting Tubulin at the Colchicine Binding Site and Unbiasing P-Glycoprotein</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>139</i></span>,  <span class="NLM_fpage">792</span>– <span class="NLM_lpage">803</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.07.037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2017.07.037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=28863359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref213/cit213&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsVaht7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=139&publication_year=2017&pages=792-803&author=G.+F.+Mangiatordiauthor=D.+Trisciuzziauthor=D.+Albergaauthor=N.+Denoraauthor=R.+M.+Iacobazziauthor=D.+Gadaletaauthor=M.+Cattoauthor=O.+Nicolotti&title=Novel+Chemotypes+Targeting+Tubulin+at+the+Colchicine+Binding+Site+and+Unbiasing+P-Glycoprotein&doi=10.1016%2Fj.ejmech.2017.07.037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit213R"><div class="casContent"><span class="casTitleNuber">213</span><div class="casTitle"><span class="NLM_cas:atitle">Novel chemotypes targeting tubulin at the colchicine binding site and unbiasing P-glycoprotein</span></div><div class="casAuthors">Mangiatordi, Giuseppe Felice; Trisciuzzi, Daniela; Alberga, Domenico; Denora, Nunzio; Iacobazzi, Rosa Maria; Gadaleta, Domenico; Catto, Marco; Nicolotti, Orazio</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">139</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">792-803</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Retrospective validation studies carried out on three benchmark databases contg. a small fraction (that is 2.80%) of known tubulin binders permitted us to develop a computational platform very effective in selecting easier manageable subsets showing by far higher percentages of actives (about 25%).  These studies relied on the hierarchical application of multilayer in silico screenings employing filters implying mol. shape similarity; a structure-based pharmacophore model and mol. docking campaigns.  Building on this validated approach, the authors performed intensive prospective studies to screen a large chem. collection, including up to 3.7 millions of com. compds., to across an unexplored and patent space in the search of novel colchicine binding site inhibitors.  The investigation was successful in identifying a pool of 31 initial hits showing new mol. scaffolds (such as 4,5-dihydro-1H-pyrrolo[3,4-c]pyrazol-6-one and pyrazolo[1,5-a]pyrimidine).  This panel of new hits resulted antiproliferative activity in the low μM range towards MCF-7 human breast cancer, HepG2 human liver cancer, HeLa human ovarian cancer and SHSY5Y human glioblastoma cell lines as well as interesting concn.-dependent inhibition of tubulin polymn. assessed through fluorescence polymn. assays.  Unlike typical tubulin inhibitors, a satisfactorily low sensitivity towards P-gp was also measured in bi-directional transport studies across MDCKII-MDR1 cells for a selected subset of seven compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKxndNEShwSbVg90H21EOLACvtfcHk0ljvUEOkMq-XXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsVaht7rM&md5=eed524fb1b0c29300940c57a9eb51d79</span></div><a href="/servlet/linkout?suffix=cit213&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.07.037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.07.037%26sid%3Dliteratum%253Aachs%26aulast%3DMangiatordi%26aufirst%3DG.%2BF.%26aulast%3DTrisciuzzi%26aufirst%3DD.%26aulast%3DAlberga%26aufirst%3DD.%26aulast%3DDenora%26aufirst%3DN.%26aulast%3DIacobazzi%26aufirst%3DR.%2BM.%26aulast%3DGadaleta%26aufirst%3DD.%26aulast%3DCatto%26aufirst%3DM.%26aulast%3DNicolotti%26aufirst%3DO.%26atitle%3DNovel%2520Chemotypes%2520Targeting%2520Tubulin%2520at%2520the%2520Colchicine%2520Binding%2520Site%2520and%2520Unbiasing%2520P-Glycoprotein%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2017%26volume%3D139%26spage%3D792%26epage%3D803%26doi%3D10.1016%2Fj.ejmech.2017.07.037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref214"><div class="reference"><strong class="refLabel"><a href="#ref214" class="rightTabRefNumLink">214</a></strong><div class="NLM_citation" id="rightTab-cit214"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alberga, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trisciuzzi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montaruli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mangiatordi, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicolotti, O.</span></span> <span> </span><span class="NLM_article-title">A New Approach for Drug Target and Bioactivity Prediction: The Multifingerprint Similarity Search Algorithm (MuSSeL)</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">586</span>– <span class="NLM_lpage">596</span>, <span class="refDoi"> DOI: 10.1021/acs.jcim.8b00698</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jcim.8b00698" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref214/cit214&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlegsLbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2019&pages=586-596&author=D.+Albergaauthor=D.+Trisciuzziauthor=M.+Montaruliauthor=F.+Leonettiauthor=G.+F.+Mangiatordiauthor=O.+Nicolotti&title=A+New+Approach+for+Drug+Target+and+Bioactivity+Prediction%3A+The+Multifingerprint+Similarity+Search+Algorithm+%28MuSSeL%29&doi=10.1021%2Facs.jcim.8b00698"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit214R"><div class="casContent"><span class="casTitleNuber">214</span><div class="casTitle"><span class="NLM_cas:atitle">A New Approach for Drug Target and Bioactivity Prediction: The Multifingerprint Similarity Search Algorithm (MuSSeL)</span></div><div class="casAuthors">Alberga, Domenico; Trisciuzzi, Daniela; Montaruli, Michele; Leonetti, Francesco; Mangiatordi, Giuseppe Felice; Nicolotti, Orazio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">586-596</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We present MuSSeL, a multifingerprint similarity search algorithm, able to predict putative drug targets for a given query small mol. as well as to return a quant. assessment of its bioactivity in terms of Ki or IC50 values.  Predictions are automatically made exploiting a large collection of high quality exptl. bioactivity data available from ChEMBL (version 22.1) combining, in a consensus-like approach, predictions resulting from a similarity search performed using 13 different fingerprint definitions.  Importantly, the herein proposed algorithm is also effective in detecting and handling activity cliffs.  A calibration set including small mols. present in the last updated version of ChEMBL (version 23) was employed to properly tune the algorithm parameters.  Three randomly built external sets were instead challenged for model performances.  The potential use of MuSSeL was also challenged by a prospective exercise for the prediction of five bioactive compds. taken from articles published in the Journal of Medicinal Chem. just few months ago.  The paper emphasizes the importance of implementing multifingerprint consensus strategies to increase the confidence in prediction of similarity search algorithms and provides a fast and easy-to-run tool for drug target and bioactivity prediction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGbAS8w4eqNbVg90H21EOLACvtfcHk0lj2KrHqi5wzUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlegsLbF&md5=96acee376cd68dc164a0f29ee1e3fc4a</span></div><a href="/servlet/linkout?suffix=cit214&amp;dbid=16384&amp;doi=10.1021%2Facs.jcim.8b00698&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jcim.8b00698%26sid%3Dliteratum%253Aachs%26aulast%3DAlberga%26aufirst%3DD.%26aulast%3DTrisciuzzi%26aufirst%3DD.%26aulast%3DMontaruli%26aufirst%3DM.%26aulast%3DLeonetti%26aufirst%3DF.%26aulast%3DMangiatordi%26aufirst%3DG.%2BF.%26aulast%3DNicolotti%26aufirst%3DO.%26atitle%3DA%2520New%2520Approach%2520for%2520Drug%2520Target%2520and%2520Bioactivity%2520Prediction%253A%2520The%2520Multifingerprint%2520Similarity%2520Search%2520Algorithm%2520%2528MuSSeL%2529%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2019%26volume%3D59%26spage%3D586%26epage%3D596%26doi%3D10.1021%2Facs.jcim.8b00698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref215"><div class="reference"><strong class="refLabel"><a href="#ref215" class="rightTabRefNumLink">215</a></strong><div class="NLM_citation" id="rightTab-cit215"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Prado-Prado, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez de la Vega, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uriarte, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ubeira, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chou, K.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González-Díaz, H.</span></span> <span> </span><span class="NLM_article-title">Unified QSAR Approach to Antimicrobials. 4. Multi-Target QSAR Modeling and Comparative Multi-Distance Study of the Giant Components of Antiviral Drug-Drug Complex Networks</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">569</span>– <span class="NLM_lpage">575</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2008.11.075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmc.2008.11.075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=19112024" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref215/cit215&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFerur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=569-575&author=F.+J.+Prado-Pradoauthor=O.+Martinez+de+la+Vegaauthor=E.+Uriarteauthor=F.+M.+Ubeiraauthor=K.-C.+Chouauthor=H.+Gonz%C3%A1lez-D%C3%ADaz&title=Unified+QSAR+Approach+to+Antimicrobials.+4.+Multi-Target+QSAR+Modeling+and+Comparative+Multi-Distance+Study+of+the+Giant+Components+of+Antiviral+Drug-Drug+Complex+Networks&doi=10.1016%2Fj.bmc.2008.11.075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit215R"><div class="casContent"><span class="casTitleNuber">215</span><div class="casTitle"><span class="NLM_cas:atitle">Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks</span></div><div class="casAuthors">Prado-Prado, Francisco J.; de la Vega, Octavio Martinez; Uriarte, Eugenio; Ubeira, Florencio M.; Chou, Kuo-Chen; Gonzalez-Diaz, Humberto</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">569-575</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">One limitation of almost all antiviral Quant. Structure-Activity Relationships (QSAR) models is that they predict the biol. activity of drugs against only one species of virus.  Consequently, the development of multi-tasking QSAR models (mt-QSAR) to predict drugs activity against different species of virus is of the major vitally important.  These mt-QSARs offer also a good opportunity to construct drug-drug Complex Networks (CNs) that can be used to explore large and complex drug-viral species databases.  It is known that in very large CNs we can use the Giant Component (GC) as a representative sub-set of nodes (drugs) and but the drug-drug similarity function selected may strongly dets. the final network obtained.  In the three previous works of the present series we reported mt-QSAR models to predict the antimicrobial activity against different fungi, bacteria or parasite species.  However, including these works, we do not found any report of mt-QSAR models for antivirals drug, or a comparative study of the different GC extd. from drug-drug CNs based on different similarity functions.  In this work, we used Linear Discriminant Anal. (LDA) to fit a mt-QSAR model that classify 600 drugs as active or non-active against the 41 different tested species of virus.  The model correctly classifies 143 of 169 active compds. (specificity = 84.62%) and 119 of 139 non-active compds. (sensitivity = 85.61%) and presents overall training accuracy of 85.1% (262 of 308 cases).  Validation of the model was carried out by means of external predicting series, classifying the model 466 of 514, 90.7% of compds.  In order to illustrate the performance of the model in practice, we develop a virtual screening recognizing the model as active 92.7%, 102 of 110 antivirus compds.  These compds. were never use in training or predicting series.  Next, we obtained and compared the topol. of the CNs and their resp. GCs based on Euclidean, Manhattan, Chebychey, Pearson and other similarity measures.  The GC of the Manhattan network showed the more interesting features for drug-drug similarity search.  We also give the procedure for the construction of Back-Projection Maps for the contribution of each drug sub-structure to the antiviral activity against different species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYSYliyWPcQrVg90H21EOLACvtfcHk0lj2KrHqi5wzUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFerur0%253D&md5=4c617e881fd3709dc3e0a34f453d484b</span></div><a href="/servlet/linkout?suffix=cit215&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2008.11.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2008.11.075%26sid%3Dliteratum%253Aachs%26aulast%3DPrado-Prado%26aufirst%3DF.%2BJ.%26aulast%3DMartinez%2Bde%2Bla%2BVega%26aufirst%3DO.%26aulast%3DUriarte%26aufirst%3DE.%26aulast%3DUbeira%26aufirst%3DF.%2BM.%26aulast%3DChou%26aufirst%3DK.-C.%26aulast%3DGonz%25C3%25A1lez-D%25C3%25ADaz%26aufirst%3DH.%26atitle%3DUnified%2520QSAR%2520Approach%2520to%2520Antimicrobials.%25204.%2520Multi-Target%2520QSAR%2520Modeling%2520and%2520Comparative%2520Multi-Distance%2520Study%2520of%2520the%2520Giant%2520Components%2520of%2520Antiviral%2520Drug-Drug%2520Complex%2520Networks%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D17%26spage%3D569%26epage%3D575%26doi%3D10.1016%2Fj.bmc.2008.11.075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref216"><div class="reference"><strong class="refLabel"><a href="#ref216" class="rightTabRefNumLink">216</a></strong><div class="NLM_citation" id="rightTab-cit216"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iyaguchi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyota, E.</span></span> <span> </span><span class="NLM_article-title">Structural Basis for the Design of Novel Schiff Base Metal Chelate Inhibitors of Trypsin</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">2076</span>– <span class="NLM_lpage">2080</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.02.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmc.2010.02.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=20202854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref216/cit216&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjtVCrsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=2076-2080&author=D.+Iyaguchiauthor=S.+Kawanoauthor=K.+Takadaauthor=E.+Toyota&title=Structural+Basis+for+the+Design+of+Novel+Schiff+Base+Metal+Chelate+Inhibitors+of+Trypsin&doi=10.1016%2Fj.bmc.2010.02.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit216R"><div class="casContent"><span class="casTitleNuber">216</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the design of novel Schiff base metal chelate inhibitors of trypsin</span></div><div class="casAuthors">Iyaguchi, Daisuke; Kawano, Susumu; Takada, Kazuki; Toyota, Eiko</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2076-2080</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The crystal structures of the complexes of bovine trypsin with m-guanidinosalicylidene--alaninato(aqua)copper(II) hydrochloride (inhibitor 1), [N,N'-bis(m-guanidinosalicylidene)ethylenediaminato]copper(II) (inhibitor 2), and [N,N'-bis(m-amidinosalicylidene)ethylenediaminato]copper(II) (inhibitor 4) have been detd.  The guanidine-contg. trypsin-inhibitors (1 and 2) bind to the trypsin active site in a manner similar to that previously reported for amidine-contg. inhibitors, for example, m-amidinosalicylidene--alaninato(aqua)copper(II) hydrochloride (inhibitor 3).  However, the binding mode of the guanidino groups of inhibitors 1 and 2 to Asp189 in the S1 pocket of trypsin was found to be markedly different from that of the amidino group of inhibitor 3.  The present X-ray analyses revealed that the interactions of the metal ion of the inhibitors with the active site residues of trypsin play a crucial role in the binding affinity to the trypsin mol.  These structural information and inhibitory activity data for amidine- and guanidine-contg. Schiff base metal chelate inhibitors provide new avenues for designing novel inhibitors against physiol. important trypsin-like serine proteases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplf37tjGdS_bVg90H21EOLACvtfcHk0lj2KrHqi5wzUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjtVCrsL8%253D&md5=8f692ca71ad1497e66b632e195776da0</span></div><a href="/servlet/linkout?suffix=cit216&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.02.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.02.016%26sid%3Dliteratum%253Aachs%26aulast%3DIyaguchi%26aufirst%3DD.%26aulast%3DKawano%26aufirst%3DS.%26aulast%3DTakada%26aufirst%3DK.%26aulast%3DToyota%26aufirst%3DE.%26atitle%3DStructural%2520Basis%2520for%2520the%2520Design%2520of%2520Novel%2520Schiff%2520Base%2520Metal%2520Chelate%2520Inhibitors%2520of%2520Trypsin%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D2076%26epage%3D2080%26doi%3D10.1016%2Fj.bmc.2010.02.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref217"><div class="reference"><strong class="refLabel"><a href="#ref217" class="rightTabRefNumLink">217</a></strong><div class="NLM_citation" id="rightTab-cit217"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyoda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kodama, H.</span></span> <span> </span><span class="NLM_article-title">The Cell Adhesion and Proliferation Activities of a Peptide Derived from Human Tenascin-C Are Dependent on Two Ile Residues</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">4608</span>– <span class="NLM_lpage">4613</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2012.06.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.bmc.2012.06.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=22776297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref217/cit217&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvFCqtLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=4608-4613&author=R.+Hayashiauthor=S.+Miuraauthor=Y.+Saitoauthor=S.+Osadaauthor=T.+Iyodaauthor=F.+Fukaiauthor=H.+Kodama&title=The+Cell+Adhesion+and+Proliferation+Activities+of+a+Peptide+Derived+from+Human+Tenascin-C+Are+Dependent+on+Two+Ile+Residues&doi=10.1016%2Fj.bmc.2012.06.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit217R"><div class="casContent"><span class="casTitleNuber">217</span><div class="casTitle"><span class="NLM_cas:atitle">The cell adhesion and proliferation activities of a peptide derived from human tenascin-C are dependent on two Ile residues</span></div><div class="casAuthors">Hayashi, Ryo; Miura, Shogo; Saito, Yohei; Osada, Satoshi; Iyoda, Takuya; Fukai, Fumio; Kodama, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">4608-4613</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A tenascin-C derived peptide (TNIIIA2 peptide, 1) stimulated β1 integrin-mediated cell adhesion via binding to syndecan-4.  Ala-substituted peptides were synthesized to understand the structure-activity relationship.  Peptides in which basic amino acids were substituted showed reduced cell adhesion activity, but their proliferation activities were similar to or higher than those mediated by peptide 1.  In contrast, peptides in which the Ile residues of peptide 1 were replaced were inactive, indicating that the Ile residues are crit. for the peptide's activity.  CD anal. suggested that the Ile residues are necessary for the formation of a specific conformation required for binding to syndecan-4.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJY3c2ifSVXrVg90H21EOLACvtfcHk0lgZMhn412BptQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvFCqtLk%253D&md5=5fd3a4ef9184d8baaaf6ea55d4c413a1</span></div><a href="/servlet/linkout?suffix=cit217&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2012.06.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2012.06.036%26sid%3Dliteratum%253Aachs%26aulast%3DHayashi%26aufirst%3DR.%26aulast%3DMiura%26aufirst%3DS.%26aulast%3DSaito%26aufirst%3DY.%26aulast%3DOsada%26aufirst%3DS.%26aulast%3DIyoda%26aufirst%3DT.%26aulast%3DFukai%26aufirst%3DF.%26aulast%3DKodama%26aufirst%3DH.%26atitle%3DThe%2520Cell%2520Adhesion%2520and%2520Proliferation%2520Activities%2520of%2520a%2520Peptide%2520Derived%2520from%2520Human%2520Tenascin-C%2520Are%2520Dependent%2520on%2520Two%2520Ile%2520Residues%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D4608%26epage%3D4613%26doi%3D10.1016%2Fj.bmc.2012.06.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref218"><div class="reference"><strong class="refLabel"><a href="#ref218" class="rightTabRefNumLink">218</a></strong><div class="NLM_citation" id="rightTab-cit218"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abdolmaleki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghasemi, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghasemi, F.</span></span> <span> </span><span class="NLM_article-title">Computer Aided Drug Design for Multi-Target Drug Design: SAR /QSAR, Molecular Docking and Pharmacophore Methods</span>. <i>Curr. Drug Targets</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">556</span>– <span class="NLM_lpage">575</span>, <span class="refDoi"> DOI: 10.2174/1389450117666160101120822</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.2174%2F1389450117666160101120822" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=26721410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref218/cit218&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2sXjs12qt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=556-575&author=A.+Abdolmalekiauthor=J.+B.+Ghasemiauthor=F.+Ghasemi&title=Computer+Aided+Drug+Design+for+Multi-Target+Drug+Design%3A+SAR+%2FQSAR%2C+Molecular+Docking+and+Pharmacophore+Methods&doi=10.2174%2F1389450117666160101120822"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit218R"><div class="casContent"><span class="casTitleNuber">218</span><div class="casTitle"><span class="NLM_cas:atitle">Computer Aided Drug Design for Multi-Target Drug Design: SAR /QSAR, Molecular Docking and Pharmacophore Methods</span></div><div class="casAuthors">Abdolmaleki, Azizeh; Ghasemi, Jahan B.; Ghasemi, Fatemeh</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Targets</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">556-575</span>CODEN:
                <span class="NLM_cas:coden">CDTUAU</span>;
        ISSN:<span class="NLM_cas:issn">1389-4501</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Multi-target drugs against particular multiple targets get better protection, resistance profiles and curative influence by cooperative rules of a key beneficial target with resistance behavior and compensatory elements.  Computational techniques can assist us in the efforts to design novel drugs (ligands) with a preferred bioactivity outline and alternative bioactive mols. at an early stage.  A no. of in silico methods have been explored extensively in order to facilitate the investigation of individual target agents and to propose a selective drug.  A different, progressively more significant field which is used to predict the bioactivity of chem. compds. is the data mining method.  Some of the previously mentioned methods have been investigated for multi-target drug design (MTDD) to find drug leads interact simultaneously with multiple targets.  Several cheminformatics methods and structure-based approaches try to ext. information from units working cooperatively in a biomol. system to fulfill their task.  To dominate the difficulties of the exptl. specification of ligand-target structures, rational methods, namely mol. docking, SAR and QSAR are vital substitutes to obtain knowledge for each structure in at. insight.  These procedures are logically successful for the prediction of binding affinity and have shown promising potential in facilitating MTDD.  Here, we review some of the important features of the multi-target therapeutics discoveries using the computational approach, highlighting the SAR, QSAR, docking and pharmacophore methods to discover interactions between drug-target that could be leveraged for curative benefits.  A summary of each, followed by examples of its applications in drug design has been provided.  Computational efficiency of each method has been represented according to its main strengths and limitations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYCnlSlFtO_rVg90H21EOLACvtfcHk0lgZMhn412BptQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXjs12qt7k%253D&md5=e62d8003ab7cccb962ef00a8e9355adc</span></div><a href="/servlet/linkout?suffix=cit218&amp;dbid=16384&amp;doi=10.2174%2F1389450117666160101120822&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389450117666160101120822%26sid%3Dliteratum%253Aachs%26aulast%3DAbdolmaleki%26aufirst%3DA.%26aulast%3DGhasemi%26aufirst%3DJ.%2BB.%26aulast%3DGhasemi%26aufirst%3DF.%26atitle%3DComputer%2520Aided%2520Drug%2520Design%2520for%2520Multi-Target%2520Drug%2520Design%253A%2520SAR%2520%252FQSAR%252C%2520Molecular%2520Docking%2520and%2520Pharmacophore%2520Methods%26jtitle%3DCurr.%2520Drug%2520Targets%26date%3D2017%26volume%3D18%26spage%3D556%26epage%3D575%26doi%3D10.2174%2F1389450117666160101120822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref219"><div class="reference"><strong class="refLabel"><a href="#ref219" class="rightTabRefNumLink">219</a></strong><div class="NLM_citation" id="rightTab-cit219"><span>Schrödinger Release
2020-2:  <i>Canvas</i>; <span class="NLM_publisher-name">Schrödinger
LLC</span>: <span class="NLM_publisher-loc">New York,
NY</span>. <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Schr%C3%B6dinger+Release%0A2020-2%3A+Canvas%3B+Schr%C3%B6dinger%0ALLC%3A+New+York%2C%0ANY.+2020."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit219&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DCanvas%26pub%3DSchr%25C3%25B6dinger%250ALLC%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref220"><div class="reference"><strong class="refLabel"><a href="#ref220" class="rightTabRefNumLink">220</a></strong><div class="NLM_citation" id="rightTab-cit220"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lill, M. A.</span></span> <span> </span><span class="NLM_article-title">Integrating Structure-Based and Ligand-Based Approaches for Computational Drug Design</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">735</span>– <span class="NLM_lpage">750</span>, <span class="refDoi"> DOI: 10.4155/fmc.11.18</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.4155%2Ffmc.11.18" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=21554079" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref220/cit220&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlvFGisL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2011&pages=735-750&author=G.+L.+Wilsonauthor=M.+A.+Lill&title=Integrating+Structure-Based+and+Ligand-Based+Approaches+for+Computational+Drug+Design&doi=10.4155%2Ffmc.11.18"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit220R"><div class="casContent"><span class="casTitleNuber">220</span><div class="casTitle"><span class="NLM_cas:atitle">Integrating structure-based and ligand-based approaches for computational drug design</span></div><div class="casAuthors">Wilson, Gregory L.; Lill, Markus A.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">735-750</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Methods utilized in computer-aided drug design can be classified into two major categories: structure based and ligand based, using information on the structure of the protein or on the biol. and physicochem. properties of bound ligands, resp.  In recent years there has been a trend towards integrating these two methods in order to enhance the reliability and efficiency of computer-aided drug-design approaches by combining information from both the ligand and the protein.  This trend resulted in a variety of methods that include: pseudoreceptor methods, pharmacophore methods, fingerprint methods and approaches integrating docking with similarity-based methods.  In this article, we will describe the concepts behind each method and selected applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9b-e495CSArVg90H21EOLACvtfcHk0lifVs3JLBjklQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlvFGisL4%253D&md5=ee5d34d69b26accc91c22e1faecc3814</span></div><a href="/servlet/linkout?suffix=cit220&amp;dbid=16384&amp;doi=10.4155%2Ffmc.11.18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.11.18%26sid%3Dliteratum%253Aachs%26aulast%3DWilson%26aufirst%3DG.%2BL.%26aulast%3DLill%26aufirst%3DM.%2BA.%26atitle%3DIntegrating%2520Structure-Based%2520and%2520Ligand-Based%2520Approaches%2520for%2520Computational%2520Drug%2520Design%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2011%26volume%3D3%26spage%3D735%26epage%3D750%26doi%3D10.4155%2Ffmc.11.18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref221"><div class="reference"><strong class="refLabel"><a href="#ref221" class="rightTabRefNumLink">221</a></strong><div class="NLM_citation" id="rightTab-cit221"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Knox, A. J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawlak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golfis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flood, C. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fayne, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meegan, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lloyd, D. G.</span></span> <span> </span><span class="NLM_article-title">Integration of Ligand and Structure-Based Virtual Screening for the Identification of the First Dual Targeting Agent for Heat Shock Protein 90 (Hsp90) and Tubulin</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">2177</span>– <span class="NLM_lpage">2180</span>, <span class="refDoi"> DOI: 10.1021/jm801569z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801569z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref221/cit221&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BD1MXktFGrt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2177-2180&author=A.+J.+S.+Knoxauthor=T.+Priceauthor=M.+Pawlakauthor=G.+Golfisauthor=C.+T.+Floodauthor=D.+Fayneauthor=D.+C.+Williamsauthor=M.+J.+Meeganauthor=D.+G.+Lloyd&title=Integration+of+Ligand+and+Structure-Based+Virtual+Screening+for+the+Identification+of+the+First+Dual+Targeting+Agent+for+Heat+Shock+Protein+90+%28Hsp90%29+and+Tubulin&doi=10.1021%2Fjm801569z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit221R"><div class="casContent"><span class="casTitleNuber">221</span><div class="casTitle"><span class="NLM_cas:atitle">Integration of Ligand and Structure-Based Virtual Screening for the Identification of the First Dual Targeting Agent for Heat Shock Protein 90 (Hsp90) and Tubulin</span></div><div class="casAuthors">Knox, Andrew J. S.; Price, Trevor; Pawlak, Michal; Golfis, Georgia; Flood, Christopher T.; Fayne, Darren; Williams, D. Clive; Meegan, Mary J.; Lloyd, David G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2177-2180</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We describe the discovery of a novel indazole-based scaffold that represents the "first-in-class" dual Hsp90/tubulin binding compd.  Individual known ligands for both targets shared similar 3',4',5'-trimethoxyphenyl cores, and from this it was hypothesized that application of an integrated ligand and structure-based virtual screening (VS) workflow could yield a single scaffold with dual binding affinity.  Following validation of the VS protocol, we successfully identified a novel dual inhibitor, sourced from a com. screening collection of 160 000 compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRptEHjoTCsLVg90H21EOLACvtfcHk0lifVs3JLBjklQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXktFGrt70%253D&md5=c8268f36a0da627404be37696c5afe4b</span></div><a href="/servlet/linkout?suffix=cit221&amp;dbid=16384&amp;doi=10.1021%2Fjm801569z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801569z%26sid%3Dliteratum%253Aachs%26aulast%3DKnox%26aufirst%3DA.%2BJ.%2BS.%26aulast%3DPrice%26aufirst%3DT.%26aulast%3DPawlak%26aufirst%3DM.%26aulast%3DGolfis%26aufirst%3DG.%26aulast%3DFlood%26aufirst%3DC.%2BT.%26aulast%3DFayne%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DD.%2BC.%26aulast%3DMeegan%26aufirst%3DM.%2BJ.%26aulast%3DLloyd%26aufirst%3DD.%2BG.%26atitle%3DIntegration%2520of%2520Ligand%2520and%2520Structure-Based%2520Virtual%2520Screening%2520for%2520the%2520Identification%2520of%2520the%2520First%2520Dual%2520Targeting%2520Agent%2520for%2520Heat%2520Shock%2520Protein%252090%2520%2528Hsp90%2529%2520and%2520Tubulin%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2177%26epage%3D2180%26doi%3D10.1021%2Fjm801569z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref222"><div class="reference"><strong class="refLabel"><a href="#ref222" class="rightTabRefNumLink">222</a></strong><div class="NLM_citation" id="rightTab-cit222"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olivecrona, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaschke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engkvist, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span> <span> </span><span class="NLM_article-title">Molecular De-Novo Design through Deep Reinforcement Learning</span>. <i>J. Cheminf.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">48</span>, <span class="refDoi"> DOI: 10.1186/s13321-017-0235-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1186%2Fs13321-017-0235-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref222/cit222&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADC%252BC1M7mtVKisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=48&author=M.+Olivecronaauthor=T.+Blaschkeauthor=O.+Engkvistauthor=H.+Chen&title=Molecular+De-Novo+Design+through+Deep+Reinforcement+Learning&doi=10.1186%2Fs13321-017-0235-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit222R"><div class="casContent"><span class="casTitleNuber">222</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular de-novo design through deep reinforcement learning</span></div><div class="casAuthors">Olivecrona Marcus; Blaschke Thomas; Engkvist Ola; Chen Hongming</div><div class="citationInfo"><span class="NLM_cas:title">Journal of cheminformatics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48</span>
        ISSN:<span class="NLM_cas:issn">1758-2946</span>.
    </div><div class="casAbstract">This work introduces a method to tune a sequence-based generative model for molecular de novo design that through augmented episodic likelihood can learn to generate structures with certain specified desirable properties.  We demonstrate how this model can execute a range of tasks such as generating analogues to a query structure and generating compounds predicted to be active against a biological target.  As a proof of principle, the model is first trained to generate molecules that do not contain sulphur.  As a second example, the model is trained to generate analogues to the drug Celecoxib, a technique that could be used for scaffold hopping or library expansion starting from a single molecule.  Finally, when tuning the model towards generating compounds predicted to be active against the dopamine receptor type 2, the model generates structures of which more than 95% are predicted to be active, including experimentally confirmed actives that have not been included in either the generative model nor the activity prediction model.  Graphical abstract .</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRyTcZ9MBhh28zK395ZObgVfW6udTcc2eaAfiyeJTWQc7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M7mtVKisg%253D%253D&md5=68f5a1219ef81fbd52a5c8911cacbbfc</span></div><a href="/servlet/linkout?suffix=cit222&amp;dbid=16384&amp;doi=10.1186%2Fs13321-017-0235-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13321-017-0235-x%26sid%3Dliteratum%253Aachs%26aulast%3DOlivecrona%26aufirst%3DM.%26aulast%3DBlaschke%26aufirst%3DT.%26aulast%3DEngkvist%26aufirst%3DO.%26aulast%3DChen%26aufirst%3DH.%26atitle%3DMolecular%2520De-Novo%2520Design%2520through%2520Deep%2520Reinforcement%2520Learning%26jtitle%3DJ.%2520Cheminf.%26date%3D2017%26volume%3D9%26spage%3D48%26doi%3D10.1186%2Fs13321-017-0235-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref223"><div class="reference"><strong class="refLabel"><a href="#ref223" class="rightTabRefNumLink">223</a></strong><div class="NLM_citation" id="rightTab-cit223"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vapnik, V. N.</span></span> <i>Statistical Learning Theory</i>; <span class="NLM_publisher-name">John Wiley & Sons Inc.</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">1998</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1998&author=V.+N.+Vapnik&title=Statistical+Learning+Theory"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit223&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DVapnik%26aufirst%3DV.%2BN.%26btitle%3DStatistical%2520Learning%2520Theory%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%2520Inc%26date%3D1998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref224"><div class="reference"><strong class="refLabel"><a href="#ref224" class="rightTabRefNumLink">224</a></strong><div class="NLM_citation" id="rightTab-cit224"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kingma, D. P.</span>; <span class="NLM_string-name">Welling, M.</span></span> <span> </span><span class="NLM_article-title">Auto-Encoding Variational Bayes</span> <i>arXiv:1312.6114 [stat.ML]</i>, <span class="NLM_year" style="font-weight: bold;">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=D.+P.+Kingma&author=M.+Welling&title=Auto-Encoding+Variational+Bayes"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit224&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKingma%26aufirst%3DD.%2BP.%26atitle%3DAuto-Encoding%2520Variational%2520Bayes%26jtitle%3DarXiv%253A1312.6114%2520%255Bstat.ML%255D%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref225"><div class="reference"><strong class="refLabel"><a href="#ref225" class="rightTabRefNumLink">225</a></strong><div class="NLM_citation" id="rightTab-cit225"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huisman, B. J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, G.</span></span> <span> </span><span class="NLM_article-title">Generative Recurrent Networks for De Novo Drug Design</span>. <i>Mol. Inf.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1700111</span>, <span class="refDoi"> DOI: 10.1002/minf.201700111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref225/cit225&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1002%2Fminf.201700111" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2018&pages=1700111&author=A.+Guptaauthor=A.+T.+M%C3%BCllerauthor=B.+J.+H.+Huismanauthor=J.+A.+Fuchsauthor=P.+Schneiderauthor=G.+Schneider&title=Generative+Recurrent+Networks+for+De+Novo+Drug+Design&doi=10.1002%2Fminf.201700111"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit225&amp;dbid=16384&amp;doi=10.1002%2Fminf.201700111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fminf.201700111%26sid%3Dliteratum%253Aachs%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DM%25C3%25BCller%26aufirst%3DA.%2BT.%26aulast%3DHuisman%26aufirst%3DB.%2BJ.%2BH.%26aulast%3DFuchs%26aufirst%3DJ.%2BA.%26aulast%3DSchneider%26aufirst%3DP.%26aulast%3DSchneider%26aufirst%3DG.%26atitle%3DGenerative%2520Recurrent%2520Networks%2520for%2520De%2520Novo%2520Drug%2520Design%26jtitle%3DMol.%2520Inf.%26date%3D2018%26volume%3D37%26spage%3D1700111%26doi%3D10.1002%2Fminf.201700111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref226"><div class="reference"><strong class="refLabel"><a href="#ref226" class="rightTabRefNumLink">226</a></strong><div class="NLM_citation" id="rightTab-cit226"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hochreiter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidhuber, J.</span></span> <span> </span><span class="NLM_article-title">Long Short-Term Memory</span>. <i>Neural Comput.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1735</span>– <span class="NLM_lpage">1780</span>, <span class="refDoi"> DOI: 10.1162/neco.1997.9.8.1735</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1162%2Fneco.1997.9.8.1735" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=9377276" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref226/cit226&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A280%3ADyaK1c%252FhvVahsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1997&pages=1735-1780&author=S.+Hochreiterauthor=J.+Schmidhuber&title=Long+Short-Term+Memory&doi=10.1162%2Fneco.1997.9.8.1735"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit226R"><div class="casContent"><span class="casTitleNuber">226</span><div class="casTitle"><span class="NLM_cas:atitle">Long short-term memory</span></div><div class="casAuthors">Hochreiter S; Schmidhuber J</div><div class="citationInfo"><span class="NLM_cas:title">Neural computation</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1735-80</span>
        ISSN:<span class="NLM_cas:issn">0899-7667</span>.
    </div><div class="casAbstract">Learning to store information over extended time intervals by recurrent backpropagation takes a very long time, mostly because of insufficient, decaying error backflow.  We briefly review Hochreiter's (1991) analysis of this problem, then address it by introducing a novel, efficient, gradient-based method called long short-term memory (LSTM).  Truncating the gradient where this does not do harm, LSTM can learn to bridge minimal time lags in excess of 1000 discrete-time steps by enforcing constant error flow through constant error carousels within special units.  Multiplicative gate units learn to open and close access to the constant error flow.  LSTM is local in space and time; its computational complexity per time step and weight is O(1).  Our experiments with artificial data involve local, distributed, real-valued, and noisy pattern representations.  In comparisons with real-time recurrent learning, back propagation through time, recurrent cascade correlation, Elman nets, and neural sequence chunking, LSTM leads to many more successful runs, and learns much faster.  LSTM also solves complex, artificial long-time-lag tasks that have never been solved by previous recurrent network algorithms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSijGIiEN1za0PI-fCgwosgfW6udTcc2eYP1G6MkpzFBrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c%252FhvVahsQ%253D%253D&md5=5da426ddc18e5bc1972e520bbcc33bec</span></div><a href="/servlet/linkout?suffix=cit226&amp;dbid=16384&amp;doi=10.1162%2Fneco.1997.9.8.1735&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1162%252Fneco.1997.9.8.1735%26sid%3Dliteratum%253Aachs%26aulast%3DHochreiter%26aufirst%3DS.%26aulast%3DSchmidhuber%26aufirst%3DJ.%26atitle%3DLong%2520Short-Term%2520Memory%26jtitle%3DNeural%2520Comput.%26date%3D1997%26volume%3D9%26spage%3D1735%26epage%3D1780%26doi%3D10.1162%2Fneco.1997.9.8.1735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref227"><div class="reference"><strong class="refLabel"><a href="#ref227" class="rightTabRefNumLink">227</a></strong><div class="NLM_citation" id="rightTab-cit227"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gómez-Bombarelli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duvenaud, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernández-Lobato, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Lengeling, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheberla, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguilera-Iparraguirre, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirzel, T. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, R. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aspuru-Guzik, A.</span></span> <span> </span><span class="NLM_article-title">Automatic Chemical Design Using a Data-Driven Continuous Representation of Molecules</span>. <i>ACS Cent. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">268</span>– <span class="NLM_lpage">276</span>, <span class="refDoi"> DOI: 10.1021/acscentsci.7b00572</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acscentsci.7b00572" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref227/cit227&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1cXntlWquw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2018&pages=268-276&author=R.+G%C3%B3mez-Bombarelliauthor=J.+N.+Weiauthor=D.+Duvenaudauthor=J.+M.+Hern%C3%A1ndez-Lobatoauthor=B.+S%C3%A1nchez-Lengelingauthor=D.+Sheberlaauthor=J.+Aguilera-Iparraguirreauthor=T.+D.+Hirzelauthor=R.+P.+Adamsauthor=A.+Aspuru-Guzik&title=Automatic+Chemical+Design+Using+a+Data-Driven+Continuous+Representation+of+Molecules&doi=10.1021%2Facscentsci.7b00572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit227R"><div class="casContent"><span class="casTitleNuber">227</span><div class="casTitle"><span class="NLM_cas:atitle">Automatic Chemical Design Using a Data-Driven Continuous Representation of Molecules</span></div><div class="casAuthors">Gomez-Bombarelli, Rafael; Wei, Jennifer N.; Duvenaud, David; Hernandez-Lobato, Jose Miguel; Sanchez-Lengeling, Benjamin; Sheberla, Dennis; Aguilera-Iparraguirre, Jorge; Hirzel, Timothy D.; Adams, Ryan P.; Aspuru-Guzik, Alan</div><div class="citationInfo"><span class="NLM_cas:title">ACS Central Science</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">268-276</span>CODEN:
                <span class="NLM_cas:coden">ACSCII</span>;
        ISSN:<span class="NLM_cas:issn">2374-7951</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report a method to convert discrete representations of mols. to and from a multidimensional continuous representation.  This model allows us to generate new mols. for efficient exploration and optimization through open-ended spaces of chem. compds.  A deep neural network was trained on hundreds of thousands of existing chem. structures to construct three coupled functions: an encoder, a decoder, and a predictor.  The encoder converts the discrete representation of a mol. into a real-valued continuous vector, and the decoder converts these continuous vectors back to discrete mol. representations.  The predictor ests. chem. properties from the latent continuous vector representation of the mol.  Continuous representations of mols. allow us to automatically generate novel chem. structures by performing simple operations in the latent space, such as decoding random vectors, perturbing known chem. structures, or interpolating between mols.  Continuous representations also allow the use of powerful gradient-based optimization to efficiently guide the search for optimized functional compds.  We demonstrate our method in the domain of drug-like mols. and also in a set of mols. with fewer that nine heavy atoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXN9RuDQ2cp7Vg90H21EOLACvtfcHk0ljzd0mzvWE_Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXntlWquw%253D%253D&md5=322d9ff569fc9c8831e91d915104d985</span></div><a href="/servlet/linkout?suffix=cit227&amp;dbid=16384&amp;doi=10.1021%2Facscentsci.7b00572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facscentsci.7b00572%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25B3mez-Bombarelli%26aufirst%3DR.%26aulast%3DWei%26aufirst%3DJ.%2BN.%26aulast%3DDuvenaud%26aufirst%3DD.%26aulast%3DHern%25C3%25A1ndez-Lobato%26aufirst%3DJ.%2BM.%26aulast%3DS%25C3%25A1nchez-Lengeling%26aufirst%3DB.%26aulast%3DSheberla%26aufirst%3DD.%26aulast%3DAguilera-Iparraguirre%26aufirst%3DJ.%26aulast%3DHirzel%26aufirst%3DT.%2BD.%26aulast%3DAdams%26aufirst%3DR.%2BP.%26aulast%3DAspuru-Guzik%26aufirst%3DA.%26atitle%3DAutomatic%2520Chemical%2520Design%2520Using%2520a%2520Data-Driven%2520Continuous%2520Representation%2520of%2520Molecules%26jtitle%3DACS%2520Cent.%2520Sci.%26date%3D2018%26volume%3D4%26spage%3D268%26epage%3D276%26doi%3D10.1021%2Facscentsci.7b00572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref228"><div class="reference"><strong class="refLabel"><a href="#ref228" class="rightTabRefNumLink">228</a></strong><div class="NLM_citation" id="rightTab-cit228"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kadurin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nikolenko, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khrabrov, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aliper, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhavoronkov, A.</span></span> <span> </span><span class="NLM_article-title">DruGAN: An Advanced Generative Adversarial Autoencoder Model for de Novo Generation of New Molecules with Desired Molecular Properties in Silico</span>. <i>Mol. Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">3098</span>– <span class="NLM_lpage">3104</span>, <span class="refDoi"> DOI: 10.1021/acs.molpharmaceut.7b00346</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.molpharmaceut.7b00346" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref228/cit228&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFGitbbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2017&pages=3098-3104&author=A.+Kadurinauthor=S.+Nikolenkoauthor=K.+Khrabrovauthor=A.+Aliperauthor=A.+Zhavoronkov&title=DruGAN%3A+An+Advanced+Generative+Adversarial+Autoencoder+Model+for+de+Novo+Generation+of+New+Molecules+with+Desired+Molecular+Properties+in+Silico&doi=10.1021%2Facs.molpharmaceut.7b00346"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit228R"><div class="casContent"><span class="casTitleNuber">228</span><div class="casTitle"><span class="NLM_cas:atitle">druGAN: An Advanced Generative Adversarial Autoencoder Model for de Novo Generation of New Molecules with Desired Molecular Properties in Silico</span></div><div class="casAuthors">Kadurin, Artur; Nikolenko, Sergey; Khrabrov, Kuzma; Aliper, Alex; Zhavoronkov, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3098-3104</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Deep generative adversarial networks (GANs) are the emerging technol. in drug discovery and biomarker development.  In our recent work, we demonstrated a proof-of-concept of implementing deep generative adversarial autoencoder (AAE) to identify new mol. fingerprints with predefined anticancer properties.  Another popular generative model is the variational autoencoder (VAE), which is based on deep neural architectures.  In this work, we developed an advanced AAE model for mol. feature extn. problems, and demonstrated its advantages compared to VAE in terms of (a) adjustability in generating mol. fingerprints; (b) capacity of processing very large mol. data sets; and (c) efficiency in unsupervised pretraining for regression model.  Our results suggest that the proposed AAE model significantly enhances the capacity and efficiency of development of the new mols. with specific anticancer properties using the deep generative models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNg9wvc_4wlrVg90H21EOLACvtfcHk0ljzd0mzvWE_Hw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFGitbbF&md5=6fc20afd4c6a8188e830aa90a7875dd6</span></div><a href="/servlet/linkout?suffix=cit228&amp;dbid=16384&amp;doi=10.1021%2Facs.molpharmaceut.7b00346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.molpharmaceut.7b00346%26sid%3Dliteratum%253Aachs%26aulast%3DKadurin%26aufirst%3DA.%26aulast%3DNikolenko%26aufirst%3DS.%26aulast%3DKhrabrov%26aufirst%3DK.%26aulast%3DAliper%26aufirst%3DA.%26aulast%3DZhavoronkov%26aufirst%3DA.%26atitle%3DDruGAN%253A%2520An%2520Advanced%2520Generative%2520Adversarial%2520Autoencoder%2520Model%2520for%2520de%2520Novo%2520Generation%2520of%2520New%2520Molecules%2520with%2520Desired%2520Molecular%2520Properties%2520in%2520Silico%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2017%26volume%3D14%26spage%3D3098%26epage%3D3104%26doi%3D10.1021%2Facs.molpharmaceut.7b00346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref229"><div class="reference"><strong class="refLabel"><a href="#ref229" class="rightTabRefNumLink">229</a></strong><div class="NLM_citation" id="rightTab-cit229"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Winter, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Montanari, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steffen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briem, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noé, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clevert, D.-A.</span></span> <span> </span><span class="NLM_article-title">Efficient Multi-Objective Molecular Optimization in a Continuous Latent Space</span>. <i>Chem. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">8016</span>– <span class="NLM_lpage">8024</span>, <span class="refDoi"> DOI: 10.1039/C9SC01928F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1039%2FC9SC01928F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=31853357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref229/cit229&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlaltrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=8016-8024&author=R.+Winterauthor=F.+Montanariauthor=A.+Steffenauthor=H.+Briemauthor=F.+No%C3%A9author=D.-A.+Clevert&title=Efficient+Multi-Objective+Molecular+Optimization+in+a+Continuous+Latent+Space&doi=10.1039%2FC9SC01928F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit229R"><div class="casContent"><span class="casTitleNuber">229</span><div class="casTitle"><span class="NLM_cas:atitle">Efficient multi-objective molecular optimization in a continuous latent space</span></div><div class="casAuthors">Winter, Robin; Montanari, Floriane; Steffen, Andreas; Briem, Hans; Noe, Frank; Clevert, Djork-Arne</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">8016-8024</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">One of the main challenges in small mol. drug discovery is finding novel chem. compds. with desirable properties.  In this work, we propose a novel method that combines in silico prediction of mol. properties such as biol. activity or pharmacokinetics with an in silico optimization algorithm, namely Particle Swarm Optimization.  Our method takes a starting compd. as input and proposes new mols. with more desirable (predicted) properties.  It navigates a machine-learned continuous representation of a drug-like chem. space guided by a defined objective function.  The objective function combines multiple in silico prediction models, defined desirability ranges and substructure constraints.  We demonstrate that our proposed method is able to consistently find more desirable mols. for the studied tasks in relatively short time.  We hope that our method can support medicinal chemists in accelerating and improving the lead optimization process.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp1KzYBvH6wCLVg90H21EOLACvtfcHk0liRQF2igJZ5MQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlaltrjO&md5=c63599dc8a30df8f805ce5457ecc053a</span></div><a href="/servlet/linkout?suffix=cit229&amp;dbid=16384&amp;doi=10.1039%2FC9SC01928F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC9SC01928F%26sid%3Dliteratum%253Aachs%26aulast%3DWinter%26aufirst%3DR.%26aulast%3DMontanari%26aufirst%3DF.%26aulast%3DSteffen%26aufirst%3DA.%26aulast%3DBriem%26aufirst%3DH.%26aulast%3DNo%25C3%25A9%26aufirst%3DF.%26aulast%3DClevert%26aufirst%3DD.-A.%26atitle%3DEfficient%2520Multi-Objective%2520Molecular%2520Optimization%2520in%2520a%2520Continuous%2520Latent%2520Space%26jtitle%3DChem.%2520Sci.%26date%3D2019%26volume%3D10%26spage%3D8016%26epage%3D8024%26doi%3D10.1039%2FC9SC01928F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref230"><div class="reference"><strong class="refLabel"><a href="#ref230" class="rightTabRefNumLink">230</a></strong><div class="NLM_citation" id="rightTab-cit230"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span> <span> </span><span class="NLM_article-title">Automated Design and Optimization of Multitarget Schizophrenia Drug Candidates by Deep Learning</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>204</i></span>,  <span class="NLM_fpage">112572</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112572</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=10.1016%2Fj.ejmech.2020.112572" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=32711293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref230/cit230&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVCksbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=2020&pages=112572&author=X.+Tanauthor=X.+Jiangauthor=Y.+Heauthor=F.+Zhongauthor=X.+Liauthor=Z.+Xiongauthor=Z.+Liauthor=X.+Liuauthor=C.+Cuiauthor=Q.+Zhaoauthor=Y.+Xieauthor=F.+Yangauthor=C.+Wuauthor=J.+Shenauthor=M.+Zhengauthor=Z.+Wangauthor=H.+Jiang&title=Automated+Design+and+Optimization+of+Multitarget+Schizophrenia+Drug+Candidates+by+Deep+Learning&doi=10.1016%2Fj.ejmech.2020.112572"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit230R"><div class="casContent"><span class="casTitleNuber">230</span><div class="casTitle"><span class="NLM_cas:atitle">Automated design and optimization of multitarget schizophrenia drug candidates by deep learning</span></div><div class="casAuthors">Tan, Xiaoqin; Jiang, Xiangrui; He, Yang; Zhong, Feisheng; Li, Xutong; Xiong, Zhaoping; Li, Zhaojun; Liu, Xiaohong; Cui, Chen; Zhao, Qingjie; Xie, Yuanchao; Yang, Feipu; Wu, Chunhui; Shen, Jingshan; Zheng, Mingyue; Wang, Zhen; Jiang, Hualiang</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">204</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112572</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Complex neuropsychiatric diseases such as schizophrenia require drugs that can target multiple G protein-coupled receptors (GPCRs) to modulate complex neuropsychiatric functions.  Here, we report an automated system comprising a deep recurrent neural network (RNN) and a multitask deep neural network (MTDNN) to design and optimize multitarget antipsychotic drugs.  The system has successfully generated novel mol. structures with desired multiple target activities, among which high-ranking compd. 3 was synthesized, and demonstrated potent activities against dopamine D2, serotonin 5-HT1A and 5-HT2A receptors.  Hit expansion based on the MTDNN was performed, 6 analogs of compd. 3 were evaluated exptl., among which compd. 8 not only exhibited specific polypharmacol. profiles but also showed antipsychotic effect in animal models with low potential for sedation and catalepsy, highlighting their suitability for further preclin. studies.  The approach can be an efficient tool for designing lead compds. with multitarget profiles to achieve the desired efficacy in the treatment of complex neuropsychiatric diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdRwvxROaCZbVg90H21EOLACvtfcHk0liRQF2igJZ5MQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVCksbnI&md5=dd01837fd3bdbb488e8781cea7d5103b</span></div><a href="/servlet/linkout?suffix=cit230&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112572&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112572%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DY.%26aulast%3DZhong%26aufirst%3DF.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DXiong%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DCui%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DXie%26aufirst%3DY.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DZheng%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DJiang%26aufirst%3DH.%26atitle%3DAutomated%2520Design%2520and%2520Optimization%2520of%2520Multitarget%2520Schizophrenia%2520Drug%2520Candidates%2520by%2520Deep%2520Learning%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2020%26volume%3D204%26spage%3D112572%26doi%3D10.1016%2Fj.ejmech.2020.112572" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZTY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZTY','PDB','5ZTY'); return false;">PDB: 5ZTY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6KPC" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6KPC','PDB','6KPC'); return false;">PDB: 6KPC</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3MAX" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3MAX','PDB','3MAX'); return false;">PDB: 3MAX</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5IX0" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5IX0','PDB','5IX0'); return false;">PDB: 5IX0</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5IWG" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5IWG','PDB','5IWG'); return false;">PDB: 5IWG</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WBZ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WBZ','PDB','6WBZ'); return false;">PDB: 6WBZ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WBW" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6WBW','PDB','6WBW'); return false;">PDB: 6WBW</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6G3O" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6G3O','PDB','6G3O'); return false;">PDB: 6G3O</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LXZ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LXZ','PDB','4LXZ'); return false;">PDB: 4LXZ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LY1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LY1','PDB','4LY1'); return false;">PDB: 4LY1</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VQQ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VQQ','PDB','2VQQ'); return false;">PDB: 2VQQ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VQM" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VQM','PDB','2VQM'); return false;">PDB: 2VQM</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VQJ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2VQJ','PDB','2VQJ'); return false;">PDB: 2VQJ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5A2S" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5A2S','PDB','5A2S'); return false;">PDB: 5A2S</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CBY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CBY','PDB','4CBY'); return false;">PDB: 4CBY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CBT" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4CBT','PDB','4CBT'); return false;">PDB: 4CBT</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FYZ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6FYZ','PDB','6FYZ'); return false;">PDB: 6FYZ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZNR" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZNR','PDB','3ZNR'); return false;">PDB: 3ZNR</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZNS" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3ZNS','PDB','3ZNS'); return false;">PDB: 3ZNS</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3C0Z" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3C0Z','PDB','3C0Z'); return false;">PDB: 3C0Z</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3C10" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3C10','PDB','3C10'); return false;">PDB: 3C10</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1VKG" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1VKG','PDB','1VKG'); return false;">PDB: 1VKG</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T64" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T64','PDB','1T64'); return false;">PDB: 1T64</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5D1B" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5D1B','PDB','5D1B'); return false;">PDB: 5D1B</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T69" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T69','PDB','1T69'); return false;">PDB: 1T69</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T67" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T67','PDB','1T67'); return false;">PDB: 1T67</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2V5X" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2V5X','PDB','2V5X'); return false;">PDB: 2V5X</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HK1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HK1','PDB','5HK1'); return false;">PDB: 5HK1</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HK2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HK2','PDB','5HK2'); return false;">PDB: 5HK2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DJZ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DJZ','PDB','6DJZ'); return false;">PDB: 6DJZ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DK0" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DK0','PDB','6DK0'); return false;">PDB: 6DK0</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DK1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6DK1','PDB','6DK1'); return false;">PDB: 6DK1</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-23%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c01357%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c01357" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677b2721384c23c8","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
